We O
observed O
that O
the O
combined O
administration O
of O
a O
corticosteroid O
drug O
and O
allergen O
extract O
suppressed O
the O
early O
clinical O
and O
immunological O
effects O
of O
SIT O
and O
that O
vitamin O
D O
( O
3 O
) O
prevented O
this O
'adverse O
' O
influence O
of O
steroids O
. O
[]

RESULTS O
CS O
gel O
was O
safe O
with O
no O
reported O
severe O
or O
life-threatening B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AE O
) O
. O
['Adverse-effects']

There O
was O
no O
statistic O
difference O
between O
both O
groups O
( O
p O
= O
0.44 O
) O
. O
[]

Journal-Name:Terapevticheskii O
arkhiv O
[]

Four O
of O
the O
6 O
care-seeking O
behaviors O
judged O
to O
be O
amenable O
to O
promotion O
by O
CHWs O
improved O
more O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area, O
and O
1 O
was O
statistically O
significant O
(treatment O
of O
diarrhea O
with O
ORS O
and O
zinc). O
[]

A O
randomized O
trial O
of O
etoposide O
and O
G-CSF O
with O
or O
without O
rituximab O
for O
PBSC O
mobilization O
in O
B-cell O
non-Hodgkin O
's O
lymphoma O
. O
[]

Lithium O
carbonate O
( O
mean O
dose O
, O
1,166 O
mg/day O
) O
adversely O
affected O
qualitative O
scores O
on O
the O
Porteus O
Maze O
test O
. O
[]

Divergence O
in O
student O
and O
educator O
conceptual O
structures O
during O
auscultation O
training O
. O
[]

Results O
were O
expressed O
in O
incremental O
cost-effectiveness O
ratios O
. O
[]

The O
adoption O
of O
PDS O
in O
other O
subsets O
of O
patients O
, O
i.e. O
, O
obese O
individuals O
, O
is O
to O
be O
questioned O
. O
[]

Generalised O
effects O
of O
music O
therapy O
will O
be O
measured O
using O
standardised O
scales O
completed O
by O
blinded O
assessors O
( O
[]

RESULTS O
No O
significant O
differences O
between O
the O
3 O
groups O
were O
found O
in O
terms O
of O
mental B-outcome ['Life-Impact']
strain I-outcome ['Life-Impact']
, O
concentration-test B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
physical B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
complaints I-outcome ['Life-Impact']
reported O
in O
a O
follow-up O
interview O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Infants O
in O
group O
TF O
had O
significantly O
greater O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
mean O
difference O
41.4 O
( O
95 O
% O
confidence O
interval O
9 O
, O
73.7 O
) O
kcal/kg O
p=0.02 O
; O
weight O
gain O
, O
130 O
( O
CI O
1 O
, O
250 O
) O
g O
p O
= O
0.02 O
; O
head B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
gain I-outcome ['Physiological-Clinical']
, O
mean O
difference O
0.7 O
( O
CI O
0.1 O
, O
1.3 O
) O
cm O
, O
p O
= O
0.04 O
; O
fewer O
episodes O
of O
culture B-outcome ['Physiological-Clinical']
confirmed I-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
, O
mean O
difference O
-0.7 O
( O
-1.3 O
, O
-0.2 O
) O
episodes O
, O
p O
= O
0.04 O
; O
less O
parenteral B-outcome ['Life-Impact']
nutrition I-outcome ['Life-Impact']
, O
mean O
difference O
-11.5 O
( O
CI O
-20 O
, O
-3 O
) O
days O
, O
p O
= O
0 O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
conclusion O
, O
the O
combination O
of O
beclomethasone O
dipropionate O
and O
salmeterol O
improved O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
bronchial B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
earlier O
than O
beclomethasone O
dipropionate O
alone O
, O
while O
nedocromil O
sodium O
improved O
symptoms O
but O
not O
pulmonary O
function O
. O
['Physiological-Clinical', 'Physiological-Clinical']

General O
practitioners O
are O
required O
to O
offer O
regular O
health O
checks O
to O
healthy O
people O
, O
in O
spite O
of O
the O
lack O
of O
scientific O
evidence O
for O
the O
universal O
need O
, O
usefulness O
and O
side O
effects O
of O
such O
an O
intervention O
. O
[]

The O
mean O
reductions O
in O
serum B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
2 O
hours O
after O
PKVP O
and O
on O
postoperative O
day O
1 O
were O
0.52 O
mmol/L O
and O
3.35 O
mmol/L O
, O
respectively O
, O
while O
mean O
reductions O
in O
haemoglobin O
were O
0.36 O
g/dL O
and O
0.24 O
g/dL O
, O
respectively O
. O
['Physiological-Clinical']

The O
area O
under O
the O
curve O
VAS O
and O
VRS B-outcome ['Physiological-Clinical']
scores O
were O
lower O
at O
4 O
, O
6 O
, O
12 O
and O
24 O
h O
in O
Group O
LM O
( O
p O
= O
0.001 O
, O
p O
= O
0.016 O
, O
respectively O
) O
. O
['Physiological-Clinical']

In O
this O
prospective O
randomized O
study O
of O
initial O
chemotherapy O
for O
advanced O
measurable O
metastatic O
large O
bowel O
carcinoma O
, O
the O
response O
rate O
was O
6/32 O
( O
19 O
% O
) O
for O
FU O
+ O
HU O
and O
5/32 O
( O
16 O
% O
) O
for O
MOF-Strep O
; O
the O
estimated O
median O
survival B-outcome ['Mortality']
is O
43 O
weeks O
for O
both O
treatments O
. O
['Mortality']

Thus O
, O
56 O
children O
( O
28 O
in O
each O
group O
) O
completed O
the O
study O
. O
[]

Title: O
When O
color O
helps. O
[]

Journal O
ID: O
8900488 O
[]

Hypoxic O
exercise O
training O
reduces O
senescent B-outcome ['Physiological-Clinical']
T-lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Enrolled O
patients O
received O
trimethoprim-sulfamethoxazole O
( O
n O
= O
85 O
) O
or O
ciprofloxacin O
( O
n O
= O
85 O
) O
for O
10 O
days O
. O
[]

The O
tear B-outcome ['Physiological-Clinical']
film I-outcome ['Physiological-Clinical']
break-up I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
higher O
at O
2 O
weeks O
and O
at O
1 O
month O
in O
group O
A. O
The O
Schirmer O
I O
test O
and O
ocular B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
index O
scores O
were O
also O
better O
in O
group O
A O
for O
up O
to O
2 O
months. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Two O
patients O
in O
the O
placebo O
group O
needed O
antihypertensive O
treatment O
because O
they O
developed O
microalbuminuria B-outcome ['Physiological-Clinical']
and/or O
hypertension B-outcome ['Physiological-Clinical']
, O
but O
no O
patient O
in O
the O
candesartan O
group O
did O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS: O
The O
combination O
of O
data O
sources O
revealed O
four O
themes O
and O
16 O
sub-themes. O
[]

4 O
. O
[]

Complement B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
was O
present O
in O
all O
patients O
studied O
who O
had O
the O
syndrome O
( O
5 O
of O
27 O
) O
but O
also O
in O
many O
patients O
who O
did O
not O
meet O
our O
diagnostic O
criteria O
, O
suggesting O
a O
multifactorial O
cause O
. O
['Physiological-Clinical']

Publication O
date: O
2019/02/20 O
06:00 O
[medline] O
[]

2D-STE O
is O
a O
more O
sensitive O
technique O
to O
evaluate O
subtle O
changes O
in O
LV O
performance O
of O
these O
patients O
. O
[]

The O
primary O
end O
point O
was O
a O
change O
in O
tests O
of O
cardiovascular O
autonomic O
function O
. O
[]

Efficacy O
measures O
were O
tumour B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
at O
weeks O
19 O
and O
52 O
and O
measures O
of O
patients O
' O
acceptability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Verapamil O
, O
although O
primarily O
known O
as O
a O
calcium O
channel O
blocker O
, O
also O
has O
PKC O
inhibitory O
activity O
. O
[]

METHODS O
Fourteen O
preschoolers O
with O
developmental O
disorders O
( O
DD O
, O
n O
= O
14 O
; O
PDD O
, O
n O
= O
12 O
; O
ID O
, O
n O
= O
2 O
) O
underwent O
MPH O
titration O
in O
a O
single-blind O
manner O
followed O
by O
a O
4-week O
double-blind O
crossover O
phase O
. O
[]

All O
drugs O
produced O
a O
drug O
effect O
, O
however O
, O
buspirone O
20 O
mg O
was O
significantly O
less O
liked O
than O
were O
lorazepam O
, O
secobarbital O
, O
or O
buspirone O
10 O
mg O
( O
p O
less O
than O
.05 O
) O
but O
not O
placebo O
. O
[]

Stress O
response B-outcome ['Physiological-Clinical']
was O
assessed O
during O
and O
after O
surgery O
by O
determining O
the O
plasma B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
group O
III O
( O
Mi/Fe O
) O
, O
midazolam O
and O
fentanyl O
were O
used O
for O
induction O
and O
maintenance O
. O
[]

The O
delay O
in O
setting O
up O
the O
infusion O
system O
and O
the O
short O
time O
between O
requesting O
analgesia B-outcome ['Resource-use']
and O
vaginal O
delivery B-outcome ['Physiological-Clinical']
were O
limitations O
with O
self-administration O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Objective: O
To O
determine O
whether O
removing O
co-payment O
barriers O
increases O
P2Y12 B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
persistence I-outcome ['Physiological-Clinical']
and O
lowers O
risk O
of O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
. O
Design, O
Setting, O
and O
Participants: O
Cluster O
randomized O
clinical O
trial O
among O
301 O
hospitals O
enrolling O
adult O
patients O
with O
acute O
MI O
(June O
5, O
2015, O
through O
September O
30, O
2016); O
patients O
were O
followed O
up O
for O
1 O
year O
after O
discharge O
(final O
date O
of O
follow-up O
was O
October O
23, O
2017), O
with O
blinded O
adjudication O
of O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
; O
choice O
of O
P2Y12 O
inhibitor O
was O
per O
clinician O
discretion. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical', 'Mortality']]

We O
evaluated O
the O
additional O
use O
of O
B-type B-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BNP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

A O
total O
of O
79 O
patients O
were O
included O
. O
[]

Title: O
Heart O
Rate O
Variability O
following O
Combined O
Aerobic O
and O
Resistance O
Training O
in O
Sedentary O
Hypertensive O
Women: O
A O
Randomised O
Control O
Trial. O
[]

A O
different O
pattern O
of O
untoward B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
seen O
in O
the O
final O
14 O
weeks O
of O
treatment O
. O
['Adverse-effects']

However O
, O
a O
prospective O
evaluation O
of O
clinical O
benefit O
in O
AGGEC O
patients O
has O
never O
before O
been O
reported O
in O
a O
phase O
III O
setting O
. O
[]

The O
primary O
end O
point O
is O
a O
composite O
of O
incident O
or O
recurrent B-outcome ['Physiological-Clinical']
CVD I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
, O
that O
is O
, O
coronary B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
, O
cerebrovascular B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
in O
the O
intervention O
group O
received O
a O
rechargeable O
, O
powered O
Oral-B? O
oscillating-rotating-pulsating O
toothbrush O
and O
a O
Reach? O
Access? O
Flosser O
that O
has O
a O
toothbrush-like O
handle O
. O
[]

No O
statistically O
significant O
difference O
was O
found O
in O
the O
use O
of O
instrumental B-outcome ['Physiological-Clinical']
vaginal I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
total O
[]

The O
WBC O
count O
in O
P+EN O
group O
was O
significantly O
lower O
than O
that O
in O
PN O
group O
( O
5.9 O
? O
[]

For O
the O
69 O
patients O
in O
each O
group O
who O
completed O
the O
healing O
phase O
of O
the O
trial O
, O
endoscopic O
ulcer O
healing O
was O
almost O
identical O
. O
[]

Prophylactic O
lidocaine O
in O
the O
early O
phase O
of O
suspected O
myocardial O
infarction O
. O
[]

Increasing O
BNP B-outcome ['Physiological-Clinical']
( O
p O
< O
0.0001 O
) O
and O
NT-ANP B-outcome ['Physiological-Clinical']
( O
p O
= O
0.01 O
) O
over O
time O
were O
associated O
with O
a O
concurrent O
decreasing O
EF B-outcome ['Physiological-Clinical']
, O
increasing O
end-diastolic B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EDV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
increasing O
end-systolic B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
ESV O
; O
all O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
concluded O
that O
the O
application O
of O
a O
chlorhexidine O
varnish O
significantly O
improved O
the O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
of O
T O
subjects O
for O
up O
to O
three O
months O
. O
['Physiological-Clinical']

The O
occurrence O
of O
AV B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
in O
the O
atrial O
group O
was O
recorded O
. O
['Physiological-Clinical']

on O
the O
first O
postoperative O
day O
until O
discharge O
. O
[]

However O
, O
they O
did O
not O
report O
the O
relationship O
of O
tobacco B-outcome ['Life-Impact']
using I-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
with O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
study O
also O
seeks O
to O
determine O
the O
acceptability B-outcome ['Life-Impact']
and O
extent O
of O
implementation B-outcome ['Life-Impact']
of O
the O
intervention O
by O
services O
and O
their O
staff O
participating O
in O
the O
study O
. O
['Life-Impact', 'Life-Impact']

Publication O
date: O
2018/12/31 O
06:00 O
[entrez] O
[]

The O
pattern O
of O
remission O
rates O
and O
odds O
ratios O
was O
similar O
when O
patients O
were O
classified O
as O
having O
high O
DWMH O
, O
PVH O
or O
total O
volume O
suggesting O
that O
lesion O
location O
may O
not O
be O
critical O
. O
[]

Patients O
completed O
self-rating O
scales O
on O
pain O
, O
global B-outcome ['Physiological-Clinical']
health B-outcome ['Physiological-Clinical']
, O
mood B-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
coping B-outcome ['Life-Impact']
style I-outcome ['Life-Impact']
, O
health B-outcome ['Physiological-Clinical']
locus B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
control I-outcome ['Life-Impact']
, O
multidimensional B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
spirituality O
, O
sense B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
coherence I-outcome ['Life-Impact']
, O
positive O
states B-outcome ['Life-Impact']
of O
mind B-outcome ['Life-Impact']
, O
and O
social B-outcome ['Life-Impact']
desirability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Changes O
in O
[]

[ O
A O
controlled O
study O
of O
treating O
haemophilia O
A O
on O
an O
out-patient O
basis O
( O
author O
's O
transl O
) O
] O
. O
[]

METHODS O
One O
hundred O
cases O
( O
200 O
eyes O
) O
were O
divided O
into O
treating O
group O
and O
control O
group O
randomly O
according O
to O
using O
and O
not O
using O
Naphcon O
eye O
drops O
before O
Lasik O
surgery O
. O
[]

We O
formulated O
four O
specific O
questions O
: O
( O
1 O
) O
can O
a O
concurrent O
SAS O
shorten O
the O
onset O
of O
automatic O
postural O
responses O
? O
; O
[]

0.3 O
) O
, O
6 O
weeks O
( O
6.3 O
? O
[]

Infants O
' O
eyes O
were O
randomly O
dilated O
twice O
with O
both O
regimens O
within O
a O
2-week O
period O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
22.8 O
and O
8.5 O
months O
after O
initiation O
of O
second-line O
treatment O
for O
the O
platinum-containing O
and O
platinum-free O
regimens O
, O
respectively O
. O
['Mortality']

Complete B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
achieved O
in O
57 O
% O
of O
patients O
receiving O
high-dose O
therapy O
as O
compared O
to O
21 O
% O
of O
patients O
receiving O
standard-dose O
therapy O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Funded O
by O
the O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
; O
TOPCAT O
ClinicalTrials.gov O
number O
, O
NCT00094302 O
. O
) O
. O
[]

OBJECTIVE O
Our O
aim O
was O
to O
evaluate O
the O
hypothesis O
that O
testosterone O
treatment O
and O
a O
nutritional O
supplement O
have O
additive O
benefits O
. O
[]

OBJECTIVE: O
to O
evaluate O
the O
effectiveness O
of O
menthol O
chewing O
gum, O
in O
the O
relief O
of O
the O
intensity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
discomfort B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
the X ['Physiological-Clinical', 'Physiological-Clinical']
surgical X ['Physiological-Clinical', 'Physiological-Clinical']
patient's X ['Physiological-Clinical', 'Physiological-Clinical']
thirst E2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
in O
the O
preoperative O
period. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Improved O
fibrinolysis O
after O
1-year O
treatment O
with O
HMG O
CoA O
reductase O
inhibitors O
in O
patients O
with O
coronary O
heart O
disease O
. O
[]

Central O
5-HT4 O
receptor O
binding O
as O
biomarker O
of O
serotonergic O
tonus O
in O
humans O
: O
a O
[ O
11C O
] O
SB207145 O
PET O
study O
. O
[]

Fondaparinux O
combined O
with O
intermittent O
pneumatic O
compression O
vs. O
intermittent O
pneumatic O
compression O
alone O
for O
prevention O
of O
venous O
thromboembolism O
after O
abdominal O
surgery O
: O
a O
randomized O
, O
double-blind O
comparison O
. O
[]

CONCLUSION O
One-year-long O
complementary O
feeding O
with O
FS O
does O
not O
have O
a O
significantly O
larger O
effect O
than O
LP O
on O
mean O
weight O
gain O
in O
all O
infants O
, O
but O
it O
is O
likely O
to O
boost O
linear B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
in O
the O
most O
disadvantaged O
individuals O
and O
, O
hence O
, O
decrease O
the O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stunting I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Promoting O
question-asking O
in O
school-aged O
children O
with O
autism O
spectrum O
disorders O
: O
effectiveness O
of O
a O
robot O
intervention O
compared O
to O
a O
human-trainer O
intervention O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
after O
injection O
of O
low-dose O
gentamicin O
was O
similar O
to O
that O
of O
control O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
groups O
in O
mean O
age O
, O
anaesthetic B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
perioperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
or O
['Life-Impact', 'Physiological-Clinical']

Eighty O
pregnant O
women O
at O
high O
risk O
of O
giving O
birth O
prematurely O
were O
divided O
randomly O
into O
two O
groups O
. O
[]

OBJECTIVE O
This O
prospective O
randomized O
study O
aims O
at O
evaluation O
and O
comparison O
of O
the O
prophylactic O
effects O
of O
amiodarone O
versus O
digoxin O
and O
metoprolol O
combination O
in O
postcoronary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Restenosis B-outcome ['Physiological-Clinical']
occurred O
in O
27 O
( O
33 O
% O
) O
patients O
, O
and O
was O
significantly O
more O
frequent O
following O
the O
procedures O
for O
rest O
pain O
or O
ulceration O
, O
or O
where O
a O
TBPI B-outcome ['Physiological-Clinical']
increase O
of O
more O
than O
0.15 O
by O
1 O
week O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Low O
doses O
of O
ketazolam O
in O
anxiety B-outcome ['Life-Impact']
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
['Life-Impact']

To O
explore O
how O
to O
improve O
classifications O
, O
univariate O
and O
multivariate O
Cox O
model O
analyses O
were O
carried O
out O
. O
[]

METHODS O
We O
did O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
at O
76 O
centres O
in O
the O
Czech O
Republic O
, O
Germany O
, O
Hungary O
, O
India O
, O
Poland O
, O
Russia O
, O
Ukraine O
, O
Turkey O
, O
and O
the O
UK O
between O
Feb O
15 O
, O
2008 O
, O
and O
May O
14 O
, O
2010 O
. O
[]

There O
was O
some O
evidence O
that O
the O
parent O
training O
group O
made O
more O
progress O
in O
language B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
than O
the O
local O
services O
group O
. O
['Life-Impact']

In O
addition O
we O
investigate O
whether O
there O
is O
an O
increase O
in O
the O
cardiovascular O
metabolism O
in O
persons O
performing O
supervised O
Nordic O
Walking O
compared O
to O
persons O
who O
are O
advised O
to O
stay O
active O
. O
[]

In O
the O
recovery O
ward O
, O
patients O
who O
requested O
analgesia O
were O
allocated O
randomly O
to O
receive O
ketorolac O
30 O
mg O
or O
pethidine O
75 O
mg O
intramuscularly O
. O
[]

Patient O
education O
materials O
did O
not O
enhance O
guideline O
effectiveness O
. O
[]

However O
, O
there O
were O
no O
significant O
differences O
, O
between O
the O
two O
groups O
, O
in O
the O
prevalences O
of O
these O
symptoms O
of O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONTEXT O
The O
Certified O
Safe O
Farm O
( O
CSF O
) O
intervention O
program O
aims O
to O
reduce O
occupational O
injuries O
and O
illnesses O
, O
and O
promote O
wellness O
to O
reduce O
health O
care O
and O
related O
costs O
to O
farmers O
, O
insurers O
, O
and O
other O
stakeholders O
. O
[]

RESULTS O
Fourteen O
patients O
were O
randomised O
to O
receive O
laser O
only O
, O
and O
12 O
to O
receive O
laser O
followed O
by O
brachytherapy O
. O
[]

Changes O
between O
pre- O
and O
post-treatment O
were O
examined O
using O
clinical O
interviews O
as O
well O
as O
child- O
, O
parent- O
and O
teacher-report O
measures O
. O
[]

Recrudescent O
and O
new O
infections O
were O
distinguished O
by O
comparison O
of O
polymorphisms O
in O
merozoite O
surface O
protein O
2 O
( O
MSP2 O
) O
. O
[]

P O
< O
0.001 O
) O
and O
attainment O
of O
sterile O
eyes O
( O
P O
< O
0.001 O
) O
at O
operation O
gained O
by O
patient O
self-administration O
of O
1 O
% O
fusidic O
acid O
four O
times O
daily O
for O
seven O
days O
before O
surgery O
. O
[]

While O
insulin B-outcome ['Resource-use']
remained O
nearly O
constant O
( O
41 O
( O
45 O
; O
38 O
) O
microU/ml O
) O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
dropped O
by O
about O
14 O
% O
and O
reached O
a O
steady O
state O
of O
89 O
( O
134 O
; O
45 O
) O
mg/dl O
. O
['Resource-use', 'Physiological-Clinical']

CONCLUSION O
Patients O
receiving O
higher O
doses O
of O
foscarnet O
have O
slower O
rates O
of O
progression O
and O
therefore O
less O
retinal O
tissue O
damage O
during O
maintenance O
therapy O
. O
[]

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
the O
response O
rate O
, O
the O
duration O
of O
the O
response B-outcome ['Physiological-Clinical']
, O
safety O
, O
and O
the O
quality O
of O
life O
. O
['Mortality', 'Physiological-Clinical']

In O
the O
present O
randomized O
, O
double-blind O
, O
split-face O
, O
comparative O
study O
we O
have O
assessed O
efficacy O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
safety O
of O
a O
base O
cream O
containing O
0.5 O
% O
BAs O
as O
compared O
to O
the O
same O
cream O
without O
these O
active O
ingredients O
in O
the O
treatment O
of O
clinical O
manifestations O
of O
photoaging O
of O
facial O
skin O
. O
['Life-Impact']

BACKGROUND O
CETP O
plays O
an O
important O
role O
in O
HDL O
metabolism O
and O
in O
the O
reverse O
cholesterol O
transport O
pathway O
. O
[]

All O
nifedipine-SR O
doses O
reduced O
supine B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
more O
than O
placebo O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

that O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
and O
Respimat O
2.5 O
?g O
once O
daily O
are O
non-inferior O
to O
HandiHaler O
in O
terms O
of O
all-cause O
mortality O
, O
and O
2 O
) O
. O
[]

CONCLUSIONS O
A O
significant O
association O
exists O
between O
smoking O
and O
a O
diet O
with O
higher O
risks O
of O
atherosclerosis B-outcome ['Physiological-Clinical']
, O
cancer B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
included O
symptoms B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
appetite B-outcome ['Physiological-Clinical']
. O
The O
secondary O
outcomes O
included O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
measured O
by O
the O
MD O
Anderson O
Symptom O
Inventory O
(MDASI) O
score, O
and O
functional B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
as O
evaluated O
by O
the O
Karnofsky O
score. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
has O
not O
been O
reached O
; O
however O
, O
the O
3-year O
survival B-outcome ['Mortality']
rate O
was O
70 O
% O
. O
['Mortality', 'Mortality']

The O
effects O
of O
treatment O
with O
interleukin-1 O
receptor O
antagonist O
on O
the O
inflamed O
synovial O
membrane O
in O
rheumatoid O
arthritis O
. O
[]

The O
most O
salient O
feature O
in O
the O
verum O
group O
was O
a O
drastic O
increase O
in O
the O
absolute O
number O
of O
immunocompetent B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
with O
an O
especially O
pronounced O
effect O
on O
T O
lymphocytes B-outcome ['Physiological-Clinical']
, O
predominantly O
of O
the O
helper/inducer B-outcome ['Physiological-Clinical']
type I-outcome ['Physiological-Clinical']
, O
but O
also O
on O
cytotoxic B-outcome ['Physiological-Clinical']
and O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Planned O
radiotherapy O
was O
the O
same O
in O
both O
groups O
. O
[]

In O
multiple-dose O
bioequivalence O
studies O
, O
it O
is O
possible O
at O
steady O
state O
to O
take O
repeated O
measurements O
of O
pharmacokinetic B-outcome ['Physiological-Clinical']
variables O
, O
such O
as O
area O
under O
the O
curve O
( O
AUC O
) O
and O
the O
maximum O
concentration O
( O
['Physiological-Clinical']

After O
one O
week O
of O
baseline O
assessment O
, O
patients O
were O
randomised O
into O
one O
of O
the O
two O
arms O
of O
the O
study O
. O
[]

TRIAL O
REGISTRATION O
NCT00623090 O
. O
[]

NCX-4016 O
inhibited O
AA-induced B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
as O
well O
as O
serum B-outcome ['Physiological-Clinical']
TXB I-outcome ['Physiological-Clinical']
( O
2 O
) O
and O
platelet B-outcome ['Physiological-Clinical']
TXB I-outcome ['Physiological-Clinical']
( O
2 O
) O
generation B-outcome ['Physiological-Clinical']
induced O
by O
AA O
to O
the O
same O
extent O
as O
aspirin O
( O
not O
significant O
vs. O
aspirin O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
101273946 O
[]

0.1 O
% O
) O
was O
low O
and O
the O
responses O
to O
600 O
ml O
of O
W O
ingestion O
were O
repeatable O
. O
[]

4 O
. O
[]

The O
ESS-1 O
study O
was O
designed O
to O
evaluate O
the O
long-term O
effects O
of O
the O
angiotensin O
converting O
enzyme O
inhibitor O
( O
ACEI O
) O
enalapril O
( O
10 O
mg O
per O
day O
) O
on O
the O
cardio-pulmonary O
system O
in O
patients O
with O
scleroderma O
( O
SSc O
) O
. O
[]

SETTINGS O
The O
trial O
was O
conducted O
at O
a O
private O
CHM O
clinic O
in O
Hove O
( O
U.K. O
) O
and O
at O
a O
National O
Health O
Service O
outpatient O
clinic O
in O
London O
( O
U.K. O
) O
. O
[]

The O
increase O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
was O
statistically O
significant O
( O
p O
< O
0.02 O
) O
in O
placebo-treated O
patients O
at O
12 O
and O
24 O
months O
, O
and O
in O
the O
lovastatin O
group O
after O
24 O
months O
. O
['Physiological-Clinical']

SETTING O
Primary O
health O
care O
, O
Kingston O
, O
Jamaica O
. O
[]

The O
SBAs B-outcome ['Physiological-Clinical']
were O
measured O
by O
the O
microdilution B-outcome ['Physiological-Clinical']
method O
of O
Reller O
and O
Stratton O
( O
L. O
B. O
Reller O
and O
C. O
W. O
Stratton O
, O
J. O
Infect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Despite O
hyperinsulinemia O
, O
blood O
glucose O
was O
kept O
close O
to O
its O
basal O
value O
by O
the O
glucose O
clamp O
technique O
. O
[]

RESULTS O
Rabeprazole B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
lower O
in O
CYP2C19 O
PMs O
than O
in O
EMs O
( O
with O
average O
values O
of O
10.7 O
vs. O
16.8 O
l O
h O
( O
-1 O
) O
in O
PMs O
and O
EMs O
, O
respectively O
) O
, O
resulting O
in O
higher O
plasma O
levels O
in O
the O
former O
group O
. O
['Physiological-Clinical']

Effect O
of O
low-intensity O
back O
exercise O
on O
quality O
of O
life O
and O
back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
in O
patients O
with O
osteoporosis O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

SETTING O
AND O
PARTICIPANTS O
Participants O
included O
87 O
newly O
postmenopausal O
women O
with O
status O
post O
chemotherapy O
, O
recruited O
from O
a O
breast O
cancer O
clinic O
in O
an O
academic O
medical O
center O
. O
[]

General O
anesthesia O
with O
sevoflurane O
was O
induced O
in O
both O
groups O
. O
[]

1 O
, O
heifers O
( O
205 O
+/- O
5 O
kg O
; O
n O
= O
68 O
) O
grazing O
dormant O
native O
pasture O
were O
fed O
0.9 O
kg/d O
( O
as-fed O
basis O
) O
of O
a O
42 O
% O
CP O
supplement O
from O
November O
until O
February O
14 O
. O
[]

PURPOSE O
We O
report O
a O
prospective O
, O
randomized O
comparison O
of O
transperitoneal O
laparoscopic O
adrenalectomy O
( O
TLA O
) O
vs O
retroperitoneal O
laparoscopic O
adrenalectomy O
( O
RLA O
) O
for O
adrenal O
lesions O
with O
long-term O
followup O
. O
[]

Ecological O
referential O
communication O
is O
shown O
to O
be O
an O
appropriate O
paradigm O
for O
studying O
the O
communicative O
process O
and O
its O
products O
and O
could O
be O
used O
to O
develop O
and O
implement O
a O
training O
program O
focused O
on O
those O
skills O
in O
which O
individuals O
with O
ASD O
are O
most O
deficient O
. O
[]

BALF O
levels O
of O
total O
protein B-outcome ['Physiological-Clinical']
, O
neutrophils B-outcome ['Physiological-Clinical']
, O
and O
leukotriene B-outcome ['Physiological-Clinical']
B4 I-outcome ['Physiological-Clinical']
tended O
to O
decrease O
in O
EPA+GLA O
patients O
over O
the O
course O
of O
the O
study O
as O
compared O
with O
control O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
health O
seeking O
behaviour O
outcome O
measure O
included O
knowledge O
regarding O
anaemia O
, O
food O
selection O
ability O
, O
increase O
in O
haemoglobin O
level O
and O
compliance O
to O
iron O
supplementation O
. O
[]

The O
median O
follow-up O
duration O
is O
26 O
months O
. O
[]

Three-year O
overall B-outcome ['Mortality']
actuarial I-outcome ['Mortality']
survivals I-outcome ['Mortality']
in O
the O
two O
treatment O
arms O
, O
however O
, O
were O
68 O
% O
and O
58 O
% O
, O
respectively O
( O
P O
= O
0.38 O
) O
. O
['Mortality']

Group O
A O
received O
Jessner O
's O
solution O
peel O
, O
group O
B O
received O
trichloroacetic O
acid O
peel O
20 O
% O
, O
and O
group O
C O
received O
topical O
hydroquinone O
2 O
% O
and O
kojic O
acid O
. O
[]

No O
differences O
between O
the O
two O
arms O
, O
either O
as O
regards O
the O
duration O
of O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
were O
noted O
in O
the O
group O
with O
more O
than O
one O
invaded O
lymph O
node O
whatever O
the O
number O
of O
invaded O
lymph O
nodes O
. O
['Mortality', 'Mortality']

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
did O
not O
differ O
significantly O
between O
the O
ganitumab O
and O
placebo O
groups O
( O
3?9 O
months O
, O
80 O
% O
CI O
3?6-5?3 O
vs O
5?7 O
months O
, O
4?4-7?4 O
; O
hazard O
ratio O
[ O
HR O
] O
1?17 O
, O
80 O
% O
CI O
0?91-1?50 O
; O
p=0?44 O
) O
. O
['Mortality']

Our O
primary O
aim O
was O
to O
examine O
in O
a O
randomized O
controlled O
setting O
whether O
diets O
enriched O
in O
fatty O
fish O
(FF), O
lean O
fish O
(LF) O
or O
ALA-rich O
camelina O
sativa O
oil O
(CSO) O
differ O
in O
their O
effects O
on O
the O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
response O
of O
selected O
inflammation-related O
genes O
in O
peripheral O
blood O
mononuclear O
cells O
(PBMCs) O
and O
subcutaneous O
adipose O
tissue O
(SAT) O
in O
subjects O
with O
impaired O
fasting O
glucose. O
[['Physiological-Clinical']]

OBJECTIVE O
To O
determine O
whether O
local O
warming O
of O
the O
lower O
arm O
and O
hand O
facilitates O
peripheral B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
cannulation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One-hundred-and-twelve O
subjects O
were O
enrolled O
and O
divided O
into O
two O
groups O
; O
those O
that O
consumed O
MLCT O
oil O
and O
those O
that O
consumed O
long-chain O
triglyceride O
( O
LCT O
) O
oil O
for O
8 O
weeks O
. O
[]

In O
the O
pretreatment O
state O
there O
was O
good O
agreement O
between O
the O
two O
measures O
( O
r2 O
= O
0.96 O
, O
SEE O
0.012 O
g/cm2 O
) O
. O
[]

The O
control O
group O
received O
group O
support O
only O
. O
[]

Following O
individual O
dosing O
of O
100-300 O
mg O
theophylline O
twice O
a O
day O
, O
a O
pharmacokinetic O
profile O
for O
24 O
h O
was O
derived O
after O
seven O
days O
of O
multiple O
dosing O
. O
[]

MATERIAL O
AND O
METHODS O
Data O
from O
246 O
cancer O
patients O
participating O
in O
a O
randomized O
placebo-controlled O
smoking O
cessation O
clinical O
trial O
were O
used O
to O
examine O
baseline O
predictors O
of O
end-of-treatment O
and O
six-month O
postbaseline O
smoking O
cessation O
outcomes O
. O
[]

Changes O
in O
family O
communication O
were O
differentially O
associated O
with O
changes O
in O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
adherence B-outcome ['Life-Impact']
, O
and O
family B-outcome ['Life-Impact']
conflict I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

During O
treatment O
either O
with O
placebo O
or O
oxitropium O
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
clinical B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical']

Journal-Name:Nutrients O
[]

We O
studied O
, O
if O
menses B-outcome ['Physiological-Clinical']
were O
affected O
in O
the O
treatment O
groups O
, O
up O
to O
36 O
months O
after O
randomization O
. O
['Physiological-Clinical']

The O
principal O
analysis O
of O
the O
primary O
endpoint O
was O
done O
on O
the O
intention-to-treat O
cohort O
. O
[]

Although O
the O
overall O
prevalence O
rates O
produced O
by O
self-reports O
and O
urinalysis O
were O
similar O
, O
there O
was O
little O
concordance O
between O
urinalysis B-outcome ['Physiological-Clinical']
positives O
and O
self-report O
positives O
. O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
100 O
women O
( O
mean O
[ O
SD O
] O
age O
, O
52 O
[ O
7 O
] O
years O
; O
height O
, O
154 O
[ O
6 O
] O
cm O
; O
weight O
, O
54 O
[ O
7 O
] O
kg O
) O
were O
included O
in O
the O
study O
. O
[]

However O
, O
the O
absence O
of O
correlations O
between O
EPA O
+ O
DHA O
intakes O
from O
different O
marine O
species O
suggests O
that O
a O
minimum O
EPA O
+ O
DHA O
intake O
is O
necessary O
to O
observe O
a O
relationship O
with O
RBC O
EPA O
+ O
DHA O
concentrations O
. O
[]

The O
goal O
was O
to O
assess O
if O
a O
16-wk O
nutrition O
plus O
CAST O
pilot O
study O
had O
stronger O
effects O
on O
reducing O
adiposity B-outcome ['Physiological-Clinical']
and O
on O
improving O
glucose/insulin B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
compared O
with O
control O
( O
C O
) O
, O
nutrition O
only O
( O
N O
) O
, O
and O
a O
nutrition O
plus O
strength O
training O
( O
N O
+ O
ST O
) O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

TSAb B-outcome ['Physiological-Clinical']
was O
determined O
on O
whole O
serum O
in O
29 O
patients O
before O
and O
at O
the O
end O
of O
treatment O
, O
and O
in O
26 O
patients O
at O
the O
end O
of O
treatment O
only O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
aim O
of O
this O
in O
vitro O
study O
was O
to O
evaluate O
the O
microleakage O
in O
occlusal B-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
, O
after O
preparation O
with O
Er O
: O
YAG O
laser O
and O
compared O
to O
the O
diamond-bur O
conventional O
technique O
. O
['Physiological-Clinical']

Obviously O
, O
onions O
contain O
pharmacologically O
active O
substances O
with O
anti-inflammatory O
and/or O
allergic O
properties O
. O
[]

Especially O
, O
nonresponders O
in O
the O
amantadine O
group O
showed O
significantly O
lower O
deterioration O
of O
depression B-outcome ['Life-Impact']
, O
['Life-Impact']

Prediction O
of O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
in O
patients O
with O
rheumatoid O
arthritis O
: O
comparison O
of O
six O
formulae O
and O
one O
nomogram O
. O
['Physiological-Clinical']

I O
: O
comparison O
of O
placebo O
and O
single O
dose O
of O
human O
synthetic O
secretin O
. O
[]

RESULTS O
Topical O
application O
of O
TGF-beta O
1 O
at O
the O
two O
concentrations O
studied O
had O
no O
significant O
effect O
on O
the O
total O
area O
of O
wounds B-outcome ['Physiological-Clinical']
( O
P O
= O
0.7 O
) O
, O
the O
area O
of O
granulation B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
( O
P O
= O
0.78 O
) O
, O
the O
area O
of O
epithelialisation B-outcome ['Physiological-Clinical']
( O
P O
= O
0.92 O
) O
, O
histological O
assessment O
or O
subjective O
clinical B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
wounds I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
of O
peri-implantitis O
by O
the O
Vector O
system O
. O
[]

Handwarming O
and O
relaxation O
in O
temperature O
feedback O
: O
positive O
placebo O
effects O
. O
[]

Journal-Name: O
Revista O
latino-americana O
de O
enfermagem O
[]

This O
study O
was O
funded O
by O
the O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
and O
the O
National O
Cancer O
Institute O
; O
and O
the O
trial O
was O
registered O
at O
www.clinicaltrials.gov O
as O
# O
NCT00406393 O
. O
[]

The O
principal O
findings O
in O
our O
study O
show O
a O
strong O
correlation O
between O
PGC-1alpha B-outcome ['Physiological-Clinical']
and O
COX5B B-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
and O
between O
PGC-1alpha B-outcome ['Physiological-Clinical']
and O
MT-CO2 B-outcome ['Physiological-Clinical']
( O
p=0.017 O
) O
expression O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Patient-reported O
outcomes O
( O
PRO O
) O
reflect O
the O
functional O
outcomes O
of O
inguinal O
herniorrhaphy O
. O
[]

OBJECTIVES O
To O
estimate O
cost B-outcome ['Resource-use']
and O
outcomes O
of O
the O
Arthritis O
Foundation O
aquatic O
exercise O
classes O
from O
the O
societal O
perspective O
. O
['Resource-use']

2.8 O
) O
were O
significantly O
lower O
than O
those O
in O
control O
group O
( O
8.8 O
? O
[]

RESULTS: O
Patients' O
main B-outcome ['Physiological-Clinical']
curve I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
after O
surgical O
procedure O
regardless O
type O
of O
rod O
was O
48.95+/-11.04 O
(13-75) O
degree. O
[['Physiological-Clinical']]

RESULTS O
The O
rates O
of O
retinitis B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
as O
evaluated O
in O
a O
masked O
fashion O
, O
were O
3.04/person-year O
in O
the O
MSL-109-treated O
group O
and O
3.05/person-year O
in O
the O
placebo-treated O
group O
( O
P=.98 O
; O
Wald O
test O
) O
; O
the O
median O
times O
to O
progression O
were O
67 O
days O
in O
the O
MSL-109-treated O
group O
and O
65 O
days O
in O
the O
placebo-treated O
group O
. O
['Physiological-Clinical']

In O
multivariate O
analysis O
of O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
, O
SPC-prognosis O
[hazard O
ratio O
(HR): O
1.879 O
(1.101-3.205), O
2.399 O
(1.415-4.067), O
p=0.003 O
and O
MSI O
status O
(HR: O
0.363, O
95% O
confidence O
interval: O
0.161-0.820, O
p=0.015) O
were O
independent O
prognostic O
factors O
along O
with O
age, O
Lauren O
classification, O
TNM O
stage, O
and O
chemotherapy. O
[['Physiological-Clinical', 'Mortality']]

The O
overt O
aggression O
scale O
for O
rating O
aggression O
in O
outpatient O
youth O
with O
autistic O
disorder O
: O
preliminary O
findings O
. O
[]

CONCLUSIONS O
Results O
suggest O
the O
need O
for O
careful O
examination O
of O
the O
way O
that O
collaborative O
care O
models O
are O
implemented O
for O
treating O
PTSD O
, O
and O
for O
additional O
supports O
to O
encourage O
primary O
care O
providers O
to O
manage O
PTSD O
. O
[]

Of O
the O
27 O
patients O
who O
received O
room O
temperature O
irrigation O
fluid O
, O
15 O
( O
55.6 O
% O
) O
had O
a O
decrease O
in O
body B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
impairment O
was O
absent O
in O
the O
caffeine O
condition O
. O
[]

EE20/LNG100 O
presented O
reductions O
of O
20 O
% O
and O
42 O
% O
, O
respectively O
, O
but O
without O
statistical O
significance O
. O
[]

Benefit O
of O
FSH O
priming O
of O
women O
with O
PCOS O
to O
the O
in O
vitro O
maturation O
procedure O
and O
the O
outcome O
: O
a O
randomized O
prospective O
study O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
baseline O
status O
of O
knees O
of O
two O
groups O
was O
comparable O
at O
the O
start O
of O
study. O
[]

A O
total O
of O
196 O
patients O
(98 O
per O
group) O
are O
required. O
[]

Neither O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
nor O
survival I-outcome ['Mortality']
in O
these O
subgroups O
was O
significantly O
influenced O
by O
treatment O
. O
['Mortality']

Bacteriologic O
studies O
of O
feces O
and O
colon O
content O
revealed O
no O
significant O
difference O
in O
the O
reduction O
of O
aerobic B-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Forty O
general O
practices O
will O
be O
randomised O
to O
either O
the O
intervention O
group O
or O
the O
control O
group O
. O
[]

The O
area O
under O
the O
ROC B-outcome ['Physiological-Clinical']
curve O
for O
the O
home O
study-derived O
parameters O
was O
between O
0.84 O
and O
0.89 O
, O
compared O
with O
polysomnography O
. O
['Physiological-Clinical']

Pioglitazone O
slowed O
progression O
compared O
with O
glimepiride O
in O
this O
population O
. O
[]

RESULTS O
None O
of O
these O
101 O
patients O
developed O
cervical B-outcome ['Physiological-Clinical']
radiation I-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

A O
clinical O
trial O
using O
prospective O
, O
random O
allocation O
of O
consecutive O
eligible O
patients O
. O
[]

The O
ambulatory O
monitoring O
showed O
that O
lisinopril O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
final O
value O
and O
maintained B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
to O
a O
greater O
degree O
than O
captopril O
throughout O
24-h O
periods O
of O
observation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
101599229 O
[]

Low-dose O
intravenous O
midazolam O
reduces O
etomidate-induced O
myoclonus O
: O
a O
prospective O
, O
randomized O
study O
in O
patients O
undergoing O
elective O
cardioversion O
. O
[]

Data O
were O
analysed O
per O
protocol O
. O
[]

Individuals O
from O
both O
groups O
were O
matched O
based O
on O
their O
primary O
diagnosis O
, O
secondary O
diagnosis O
( O
if O
present O
) O
, O
and O
gender O
. O
[]

The O
P-ASA O
injection O
was O
administered O
, O
utilizing O
the O
Wand O
Plus O
system O
, O
6 O
to O
10 O
mm O
into O
the O
incisive O
canal O
located O
lingual O
to O
the O
central O
incisors O
. O
[]

Male O
students O
( O
N=443 O
) O
were O
randomized O
to O
either O
a O
TC O
or O
TC O
+TSE O
information O
group O
or O
a O
no O
information O
control O
group O
, O
and O
assessed O
at O
three O
time O
points O
. O
[]

Publication O
date: O
2018/11/20 O
00:00 O
[accepted] O
[]

There O
was O
no O
statistical O
difference O
according O
to O
clinical O
stage O
, O
age O
( O
greater O
than O
15 O
or O
less O
than O
15 O
years O
) O
, O
sex O
, O
or O
number O
of O
cycles O
of O
chemotherapy B-outcome ['Resource-use']
( O
six O
or O
three O
) O
. O
['Resource-use']

A O
controlled O
trial O
of O
cisapride O
in O
anorexia O
nervosa O
. O
[]

OBJECTIVE O
To O
determine O
the O
feasibility O
of O
primary B-outcome ['Physiological-Clinical']
care-based I-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
opioid I-outcome ['Physiological-Clinical']
detoxification I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AOD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
using O
two O
protocols O
: O
clonidine O
and O
clonidine O
plus O
naltrexone O
. O
['Physiological-Clinical']

Compared O
with O
before O
treatment O
, O
the O
KPS B-outcome ['Physiological-Clinical']
was O
significantly O
improved O
in O
the O
treatment O
group O
after O
treatment O
, O
while O
it O
significantly O
decreased O
in O
the O
control O
group O
after O
treatment O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
authors O
demonstrated O
that O
total O
and O
conjugated B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
, O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
alanine B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
, O
aspartate B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
and O
cholinesterase B-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
during O
the O
5-days O
observation O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ten O
patients O
, O
5 O
in O
each O
group O
, O
had O
exercise-induced B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
at O
the O
start O
of O
the O
rehabilitation O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
in O
any O
of O
the O
primary O
or O
secondary O
outcomes O
when O
fexofenadine O
was O
added O
to O
treatment O
with O
either O
fluticasone O
propionate-salmeterol O
or O
fluticasone O
propionate O
alone O
. O
[]

A O
reversible O
dose-dependent O
elevation O
in O
adrenocorticotrophic B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
generally O
within O
the O
normal O
reference O
range O
, O
was O
observed O
. O
['Physiological-Clinical']

Blinding O
was O
maintained O
and O
the O
practitioner O
was O
able O
to O
maintain O
meditation B-outcome ['Life-Impact']
for O
both O
tactile O
and O
non-tactile O
LKM O
interventions O
as O
reflected O
in O
significantly O
reduced O
RR B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Twenty O
seven O
patients O
with O
advanced O
colorectal O
cancer O
who O
had O
failed O
at O
least O
2 O
lines O
chemotherapy O
were O
treated O
with O
apatinib O
(500 O
mg/day). O
[]

Participants O
in O
the O
Age-Related O
Eye O
Disease O
Study O
were O
randomly O
assigned O
to O
receive O
daily O
antioxidants O
( O
vitamin O
C O
, O
500 O
mg O
; O
vitamin O
E O
, O
400 O
IU O
; O
beta O
carotene O
, O
15 O
mg O
) O
, O
zinc O
and O
copper O
( O
zinc O
, O
80 O
mg O
; O
cupric O
oxide O
, O
2 O
mg O
) O
, O
antioxidants O
plus O
zinc O
and O
copper O
, O
or O
placebo O
. O
[]

The O
method O
of O
Hills O
and O
Armitage O
was O
used O
, O
reducing O
ethanol O
in O
daily O
alcohol O
consumption O
by O
28 O
ml O
. O
[]

During O
the O
experimental O
phase O
, O
subjects O
were O
asked O
to O
use O
soybean O
oil O
or O
perilla O
oil O
as O
the O
sole O
cooking O
oil O
for O
8 O
mo O
. O
[]

Demographic O
characteristics O
were O
similar O
in O
both O
treatment O
groups O
, O
as O
were O
results O
of O
the O
EORTC O
QOL-30 O
questionnaire O
. O
[]

Positive O
HER2 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels O
were O
found O
in O
19.8 O
% O
( O
55/278 O
) O
. O
['Physiological-Clinical']

A O
randomised O
trial O
comparing O
holmium O
laser O
enucleation O
versus O
transurethral O
resection O
in O
the O
treatment O
of O
prostates O
larger O
than O
40 O
grams O
: O
results O
at O
2 O
years O
. O
[]

Growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
GH-releasing O
hormone O
alone O
or O
combined O
with O
arginine O
in O
patients O
with O
adrenal O
incidentaloma O
: O
evidence O
for O
enhanced O
somatostatinergic O
tone O
. O
['Physiological-Clinical']

Journal O
ID: O
9308586 O
[]

RESULTS: O
The O
obtained O
data O
shows O
the O
significant O
differences O
of O
an O
increase O
in O
highly B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
(HS-Tp) I-outcome ['Physiological-Clinical']
in O
24 O
hours O
after O
PCI O
in O
patients O
with O
no O
admission O
of O
nicorandil O
(117 O
ng/l) O
as O
compared O
with O
the O
nicorandil O
group O
(73 O
ng/l), O
p O
= O
0.04. O
[['Physiological-Clinical']]

APU B-outcome ['Physiological-Clinical']
decreased O
during O
the O
first O
6 O
months O
of O
treatment O
, O
but O
had O
returned O
to O
its O
baseline O
value O
after O
24 O
months O
and O
remained O
unchanged O
throughout O
the O
rest O
of O
the O
study O
. O
['Physiological-Clinical']

The O
evolution O
of O
the O
New O
York O
Heart O
Association O
stage B-outcome ['Physiological-Clinical']
and O
the O
functional B-outcome ['Life-Impact']
signs I-outcome ['Life-Impact']
score O
were O
evaluated O
as O
primary O
efficacy O
criteria O
. O
['Physiological-Clinical', 'Life-Impact']

Using O
a O
sigmoidal O
Emax O
pharmacodynamic O
model O
, O
a O
strong O
relation O
( O
mean O
+/- O
SD O
r2 O
, O
0.78 O
+/- O
0.2 O
) O
was O
observed O
between O
plasma B-outcome ['Physiological-Clinical']
diltiazem I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
percent O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
this O
effect O
was O
only O
found O
in O
higher-functioning O
children O
, O
and O
not O
with O
more O
severely O
impaired O
children O
. O
[]

Title: O
The O
influence O
of O
orlistat, O
metformin O
and O
diet O
on O
serum O
levels O
of O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
in O
obeses O
women O
with O
and O
without O
insulin O
resistance. O
[['Physiological-Clinical']]

PURPOSE O
To O
prospectively O
study O
and O
compare O
the O
effectiveness O
and O
the O
safety O
of O
primary O
deep O
sclerectomy O
with O
and O
without O
the O
use O
of O
mitomycin O
C O
in O
eyes O
with O
open-angle O
glaucoma O
. O
[]

We O
conclude O
that O
pre-operative O
radiotherapy O
is O
at O
least O
as O
effective O
[]

The O
societal O
costs O
were O
high O
, O
but O
no O
significant O
differences O
in O
resource B-outcome ['Resource-use']
use I-outcome ['Resource-use']
or O
in O
total O
['Resource-use']

RESULTS O
At O
12 O
months O
, O
63 O
% O
of O
intervention O
patients O
had O
a O
50 O
% O
or O
greater O
reduction O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
from O
baseline O
as O
assessed O
by O
the O
Patient O
Health O
Questionnaire-9 O
( O
PHQ-9 O
) O
depression B-outcome ['Life-Impact']
scale O
compared O
with O
50 O
% O
of O
EUC O
patients O
( O
odds O
ratio O
[ O
OR O
] O
= O
1.98 O
; O
95 O
% O
CI O
, O
1.16 O
to O
3.38 O
; O
P O
= O
.01 O
) O
. O
['Life-Impact', 'Life-Impact']

RESEARCH O
DESIGN O
AND O
METHODS O
This O
double-blind O
placebo-controlled O
paralleled O
study O
randomized O
302 O
patients O
with O
type O
2 O
diabetes O
( O
mean O
A1C O
8.3 O
% O
) O
on O
metformin O
monotherapy O
( O
mean O
1.5 O
g/day O
) O
to O
receive O
one O
of O
five O
INCB13739 O
doses O
or O
placebo O
once O
daily O
for O
12 O
weeks O
. O
[]

Changes O
in O
spinal O
and/or O
supraspinal O
central O
nervous O
system O
pain O
processing O
due O
to O
visceral O
nociceptive O
input O
play O
an O
important O
role O
in O
this O
pain O
. O
[]

if O
the O
pre-transplant O
C O
( O
2 O
) O
level O
was O
?20 O
ng/mL O
, O
0.1 O
mg/kg O
b.d O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

Data O
was O
analyzed O
by O
repeated O
measures O
analysis O
of O
variance O
(rANOVA) O
and O
chi-squared O
test O
(chi O
test). O
[]

BACKGROUND O
Although O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
are O
better O
tolerated O
than O
tricyclic O
antidepressants O
, O
their O
efficacy O
in O
severe O
depression O
remains O
to O
be O
further O
elucidated O
. O
[]

CONCLUSIONS O
The O
good O
efficacy O
and O
tolerability O
of O
a O
topical O
therapeutic O
preparation O
in O
first O
and O
second O
degree O
hemorrhoids O
have O
been O
convincingly O
demonstrated O
. O
[]

OBJECTIVE O
To O
explore O
the O
short-term O
treatment O
effect O
of O
the O
auditory O
integrative O
training O
on O
autistic O
children O
and O
provide O
them O
with O
clinical O
support O
for O
rehabilitative O
treatment O
. O
[]

Strand B-outcome ['Physiological-Clinical']
breaks I-outcome ['Physiological-Clinical']
decreased O
significantly O
after O
the O
broccoli O
diet O
in O
smokers O
as O
well O
as O
in O
nonsmokers O
( O
-22.2 O
% O
; O
P O
< O
0.0001 O
) O
, O
whereas O
oxidized B-outcome ['Physiological-Clinical']
purines I-outcome ['Physiological-Clinical']
decreased O
significantly O
only O
in O
smokers O
( O
-51.0 O
% O
; O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
D-myo-inositol-1,2,6-trisphosphate O
( O
1,2,6-IP3 O
) O
possesses O
antiinflammatory O
properties O
, O
such O
as O
reduced O
eicosanoid O
synthesis O
and O
inhibition O
of O
inflammation-induced O
edema O
. O
[]

[ O
Comparison O
of O
the O
efficacy/tolerability O
ratio O
of O
cibenzoline O
and O
propafenone O
in O
the O
treatment O
of O
ventricular O
arrhythmia O
] O
. O
[]

The O
setting O
was O
in O
nephrological O
departments O
in O
Italy O
. O
[]

Safety O
and O
efficacy O
of O
oral O
DMSA O
therapy O
for O
children O
with O
autism O
spectrum O
disorders O
: O
part O
B O
- O
behavioral O
results O
. O
[]

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
was O
9.4 O
months O
in O
the O
white O
light O
group O
and O
16.4 O
months O
in O
the O
fluorescence O
group O
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
hematologic I-outcome ['Physiological-Clinical']
response O
rates O
were O
higher O
in O
IFN/HU-treated O
patients O
( O
59 O
vs O
32 O
% O
) O
. O
['Physiological-Clinical']

The O
implications O
of O
these O
findings O
are O
discussed O
. O
[]

For O
both O
groups O
, O
the O
P2 O
and O
N250 O
were O
sensitive O
to O
repetition O
( O
Other O
vs. O
Novels O
) O
and O
personal O
familiarity O
( O
Familiar O
vs. O
Other O
) O
, O
and O
the O
face-N400 O
was O
sensitive O
to O
repetition O
. O
[]

Participants O
in O
both O
groups O
received O
instructions O
and O
demonstration O
on O
the O
use O
of O
the O
devices O
, O
and O
were O
requested O
to O
perform O
the O
respective O
intervention O
twice O
a O
day O
for O
6 O
months O
. O
[]

Fewer O
individuals O
experienced O
side O
effects O
( O
30 O
% O
vs. O
53 O
% O
) O
with O
the O
low-dose O
test O
( O
P O
= O
.0013 O
) O
. O
[]

Cardiovascular O
complications O
to O
treatment O
of O
prostate O
cancer O
with O
estramustine O
phosphate O
( O
Estracyt O
) O
or O
conventional O
estrogen O
. O
[]

Clonidine O
improves O
the O
quality O
of O
spinal B-outcome ['Physiological-Clinical']
bupivacaine I-outcome ['Physiological-Clinical']
and O
ropivacaine B-outcome ['Resource-use']
, O
but O
in O
traditional O
doses O
( O
1-2 O
microg/kg O
) O
it O
produces O
systemic O
side O
effects O
. O
['Physiological-Clinical', 'Resource-use']

For O
all O
statistics O
CLIP O
staging O
system O
had O
a O
better O
prognostic O
ability O
. O
[]

No O
significant O
difference O
( O
all O
P O
values O
> O
0.05 O
) O
was O
found O
in O
baseline O
data O
between O
the O
two O
groups O
. O
[]

The O
24-month O
FFTF B-outcome ['Physiological-Clinical']
rate O
was O
75 O
% O
for O
COPP/ABVD O
and O
84 O
% O
for O
BEACOPP O
pooled O
( O
P O
= O
.034 O
) O
. O
['Physiological-Clinical']

min O
( O
-1 O
) O
) O
. O
[]

The O
2 O
groups O
were O
comparable O
. O
[]

The O
effects O
of O
treatment O
on O
the O
58 O
ABC O
items O
were O
evaluated O
. O
[]

No O
subjects O
developed O
systemic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTIONS O
Patient O
education O
( O
PE O
) O
. O
[]

Initiated O
4 O
months O
after O
hospitalization O
, O
intervention O
groups O
of O
4 O
to O
8 O
women O
met O
for O
a O
total O
of O
20 O
sessions O
that O
were O
spread O
over O
a O
year O
. O
[]

CS O
cannulation O
can O
be O
achieved O
either O
using O
dedicated O
guiding O
catheters O
( O
guiding O
catheter O
alone O
positioning O
strategy O
, O
GCA O
) O
or O
with O
the O
aid O
of O
an O
electrophysiology O
catheter O
advanced O
inside O
the O
guiding O
catheter O
( O
electrophysiology O
catheter O
aided O
positioning O
strategy O
, O
EPA O
) O
. O
[]

Title: O
Comparison O
of O
the O
long-term O
efficacy O
of O
tenofovir O
and O
entecavir O
in O
nucleos(t)ide O
analogue-naive O
HBeAg-positive O
patients O
with O
chronic O
hepatitis O
B: O
A O
large, O
multicentre, O
randomized O
controlled O
trials. O
[]

In O
addition O
, O
ORR O
was O
significantly O
higher O
with O
letrozole O
than O
tamoxifen O
in O
the O
human O
epidermal O
growth O
factor O
receptor O
HER1/HER2+ O
subgroup O
( O
P=0.0004 O
) O
. O
[]

METHOD: O
Thirty O
individuals O
with O
ALS O
(18 O
men O
and O
12 O
women, O
mean O
age O
59 O
years, O
range O
44-74 O
years) O
with O
a O
mean O
score O
of O
26, O
(minimum O
score O
of O
14 O
and O
maximum O
41) O
on O
the O
Revised O
Amyotrophic O
Lateral O
Sclerosis O
Functional O
Rating O
Scale O
(ALSFRS-R) O
and O
30 O
healthy O
controls O
matched O
for O
age O
and O
gender, O
participated. O
[]

The O
major O
dose-limiting B-outcome ['Physiological-Clinical']
toxicity B-outcome ['Adverse-effects']
for O
both O
drugs O
was O
leukopenia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

Rose O
geranium O
( O
Pelargonium O
graveolens O
, O
Geraniaceae O
) O
has O
anti-cancer O
and O
anti-inflammatory O
properties O
, O
and O
promotes O
wound O
healing O
. O
[]

RESULTS O
Sodium O
nitroprusside O
, O
substance O
P O
and O
bradykinin O
produced O
dose-dependent O
increases O
in O
the O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
of O
infused O
forearm O
( O
analysis O
of O
variance O
[ O
ANOVA O
] O
, O
p O
< O
0.001 O
for O
all O
) O
. O
['Physiological-Clinical']

Randomised O
controlled O
trial O
of O
patient O
triggered O
and O
conventional O
fast O
rate O
ventilation O
in O
neonatal O
respiratory O
distress O
syndrome O
. O
[]

SBP B-outcome ['Physiological-Clinical']
( O
175 O
+/- O
3.3 O
vs. O
160 O
+/- O
3.0 O
mm O
Hg O
; O
P O
< O
0.001 O
) O
and O
DBP B-outcome ['Physiological-Clinical']
( O
106 O
+/- O
2.3 O
vs. O
95 O
+/- O
2.0 O
mm O
Hg O
; O
P O
< O
0.001 O
) O
were O
significantly O
reduced O
by O
lisinopril O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
complications O
were O
considered O
minor O
. O
[]

Full B-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
was O
achieved O
in O
93 O
% O
( O
122 O
of O
131 O
) O
. O
['Life-Impact']

The O
cancer B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
rate O
in O
the O
first O
re-biopsy O
after O
the O
diagnosis O
of O
high O
grade O
PIN O
was O
12.9 O
% O
. O
['Physiological-Clinical']

Quantitative O
fit O
tests O
(QNFTs) O
were O
performed O
before O
and O
after O
training O
using O
three O
types O
of O
N95 O
or O
higher O
filter O
respirators O
(cup-type, O
fold-type, O
valve-type). O
[]

SETTING O
The O
study O
was O
performed O
in O
General O
Clinical O
Research O
Centers O
at O
two O
University O
Hospitals O
. O
[]

[ O
Efficacy O
and O
immune B-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
of O
plasma-derived O
hepatitis O
B O
vaccine O
11 O
years O
after O
primary O
immunization O
] O
. O
['Physiological-Clinical']

The O
objectives O
of O
this O
study O
were O
to O
update O
the O
analyses O
of O
each O
individual O
trial O
and O
to O
analyze O
prognostic O
factors O
and O
treatment O
effects O
based O
on O
pooled O
data O
. O
[]

In O
analogy O
, O
a O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
model O
and O
, O
as O
a O
supplement O
, O
a O
best O
case/worst O
case O
analysis O
are O
performed O
for O
further O
statistical O
evaluation O
. O
['Mortality']

We O
found O
significant O
positive O
correlations O
of O
Delta O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
with O
initial O
and O
Delta O
values O
of: O
HOMA-IR B-outcome ['Physiological-Clinical']
, O
triglyceride/high-density B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
visceral B-outcome ['Physiological-Clinical']
adiposity I-outcome ['Physiological-Clinical']
index O
(VAI). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Patients O
who O
were O
identified O
as O
requiring O
pedicled O
flap O
reconstruction O
were O
potential O
candidates O
for O
the O
study O
. O
[]

A O
total O
of O
84 O
evaluable O
women O
provided O
274 O
cycles O
of O
exposure O
in O
the O
LNG/EE O
group O
, O
and O
89 O
women O
provided O
289 O
cycles O
of O
exposure O
in O
the O
NETA/EE O
group O
. O
[]

Yi O
xue O
ban O
= O
Journal O
of O
Central O
South O
University. O
[]

The O
trial O
was O
halted O
after O
an O
interim O
safety O
analysis O
(n=11) O
due O
to O
excess O
grade O
3 O
neutropenia B-outcome ['Physiological-Clinical']
, O
dose B-outcome ['Life-Impact']
reductions I-outcome ['Life-Impact']
and O
treatment B-outcome ['Life-Impact']
delays I-outcome ['Life-Impact']
. O
Grade O
3 O
or O
4 O
neutropenia B-outcome ['Physiological-Clinical']
was O
observed O
in O
64% O
of O
patients. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Indomethacin O
abolished O
the O
prostacyclin B-outcome ['Resource-use']
['Resource-use']

Both O
medications O
were O
well O
tolerated B-outcome ['Life-Impact']
, O
and O
no O
serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
during O
the O
study O
. O
['Life-Impact', 'Adverse-effects']

Scars B-outcome ['Physiological-Clinical']
that O
were O
treated O
with O
garments O
from O
a O
normal O
compression O
class O
did O
score O
significantly O
better O
for O
thickness B-outcome ['Physiological-Clinical']
compared O
to O
the O
low O
compression O
class O
. O
['Physiological-Clinical', 'Physiological-Clinical']

89.1 O
% O
( O
RR O
= O
0.32 O
; O
0.22-0.46 O
) O
, O
( O
P O
< O
0.001 O
) O
. O
[]

In O
conclusion O
cuffed O
, O
tunnelled O
central O
venous O
catheters O
are O
less O
prone O
to O
displacement B-outcome ['Life-Impact']
than O
traditional O
percutaneous O
central O
venous O
catheters O
when O
used O
in O
children O
with O
malignant O
diseases O
. O
['Life-Impact']

MAIN O
OUTCOME O
MEASURES O
Sun B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
promotion I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
of O
primary O
care O
clinicians O
as O
determined O
by O
their O
self O
report O
, O
research O
assistant O
observation O
, O
and O
parent O
interviews O
. O
['Life-Impact']

After O
11 O
months O
of O
prophylaxis O
, O
adult O
male O
subjects O
received O
a O
tetanus-diphtheria O
( O
Td O
) O
vaccination O
. O
[]

AIM O
Anal O
fissures O
are O
associated O
with O
hypertonia O
of O
the O
internal O
anal O
sphincter O
and O
pain O
. O
[]

The O
incidence O
of O
undetectable O
MEP B-outcome ['Physiological-Clinical']
did O
not O
differ O
as O
measured O
in O
both O
groups. O
[['Physiological-Clinical']]

This O
inhibition O
was O
incomplete O
because O
AII O
levels O
increased O
markedly O
when O
captopril O
was O
given O
( O
no O
treatment O
effect O
: O
p O
< O
0.37 O
) O
. O
[]

Although O
the O
reductions O
in O
weight B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
were O
comparable O
in O
IS O
and O
IR O
groups, O
only O
women O
with O
IR O
showed O
a O
significant O
increase O
in O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
concentration O
as O
a O
result O
of O
all O
interventions. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Effect O
of O
TENS O
on O
pain B-outcome ['Physiological-Clinical']
, O
medications B-outcome ['Resource-use']
, O
and O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
following O
coronary O
artery O
bypass O
graft O
surgery O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

A O
precycle B-outcome ['Physiological-Clinical']
risk O
score O
from O
> O
or O
=25 O
to O
< O
40 O
for O
a O
given O
patient O
was O
identified O
as O
being O
the O
optimal O
threshold O
for O
sensitivity O
( O
58.0 O
% O
) O
and O
specificity O
( O
78.7 O
% O
) O
. O
['Physiological-Clinical']

The O
histopathological B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
the O
chemotherapy O
and O
control O
groups O
( O
16 O
specimens O
) O
were O
different O
. O
['Physiological-Clinical']

The O
maximum O
numbers O
of O
repetitions O
in O
each O
station O
was O
12 O
. O
[]

Voice B-outcome ['Physiological-Clinical']
and O
swallowing B-outcome ['Physiological-Clinical']
assessment O
were O
obtained O
by O
using O
the O
Voice B-outcome ['Physiological-Clinical']
Handicap I-outcome ['Physiological-Clinical']
Index-10 O
( O
VHI-10 O
) O
and O
the O
Reflux B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Index O
questionnaires O
( O
RSI O
) O
before O
surgery O
and O
at O
3 O
weeks O
and O
3 O
months O
after O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
multicenter O
study O
on O
the O
use O
of O
pulsed O
low-intensity O
direct O
current O
for O
healing O
chronic B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
decubitus I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
significantly O
greater O
GFR O
increase O
observed O
in O
PR-STENT O
than O
in O
NO-STENT O
at O
univariate O
analysis O
at O
the O
end O
of O
follow-up O
( O
62.5 O
? O
[]

OBJECTIVE O
To O
highlight O
the O
differences O
in O
behaviors O
in O
children O
with O
diagnosis O
of O
Down O
syndrome O
. O
[]

Patients O
were O
assigned O
to O
a O
target O
dose O
of O
losartan O
50 O
mg/day O
and O
captopril O
50 O
mg O
t.i.d. O
, O
as O
tolerated O
. O
[]

No O
statistically O
significant O
difference O
was O
found O
between O
the O
orthoses' O
effects O
on O
pain B-outcome ['Physiological-Clinical']
reduction O
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
(P O
> O
.05). O
[['Physiological-Clinical'], ['Life-Impact']]

RESULTS O
After O
4 O
courses O
of O
treatment O
with O
chemotherapy O
and O
electro-acupuncture O
, O
no O
obvious O
changes O
were O
found O
in O
T O
cell B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
, O
NK B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
humoral B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
and O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
P O
> O
0.05 O
) O
as O
compared O
with O
those O
before O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

p16 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INK4a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
Expression I-outcome ['Physiological-Clinical']
does O
not O
predict O
the O
outcome O
of O
cervical O
intraepithelial O
neoplasia O
grade O
2 O
. O
['Physiological-Clinical']

Reaction O
time O
, O
direct O
recall O
, O
and O
recognition B-outcome ['Life-Impact']
were O
assessed O
. O
['Life-Impact']

RESULTS O
Compliance O
was O
excellent O
, O
with O
7,286 O
questionnaires O
analyzed O
. O
[]

In O
the O
other O
group, O
each O
had O
a O
different O
color. O
[]

CONCLUSIONS: O
Among O
patients O
with O
CAP O
hospitalized O
to O
non-ICU O
wards, O
erythromycin O
use O
was O
associated O
with O
a O
68% O
increased O
risk O
of O
hospital-acquired O
cardiac B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
mainly O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
Levofloxacin B-outcome ['Life-Impact']
and O
moxifloxacin B-outcome ['Life-Impact']
were O
associated O
with O
a O
lower O
risk O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
Although O
our O
study O
does O
not O
fully O
exclude O
confounding O
bias, O
findings O
remained O
largely O
unchanged O
in O
crude, O
adjusted, O
and O
sensitivity O
analyses. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

[ O
Clinical O
observation O
on O
effect O
of O
fuzheng O
yiliu O
granule O
on O
cell O
cycle O
and O
nuclear O
transcription O
factor-kappa O
B O
in O
tissue O
of O
esophageal-gastric O
carcinoma O
] O
. O
[]

CHF O
patients O
with O
clinical O
features O
-- O
with O
( O
156 O
( O
28 O
) O
IU/dl O
) O
and O
without O
( O
152 O
( O
31 O
) O
IU/dl O
) O
LV O
dysfunction O
-- O
also O
had O
higher O
mean O
vWf B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
patients O
with O
asymptomatic O
LV O
dysfunction O
( O
146 O
( O
31 O
) O
IU/dl O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Supplementation O
of O
diets O
with O
increasing O
levels O
of O
RPLM B-outcome ['Physiological-Clinical']
did O
not O
affect O
( O
P O
> O
.10 O
) O
ADG O
or O
carcass O
characteristics O
. O
['Physiological-Clinical']

Hence O
it O
is O
important O
for O
professionals O
to O
consider O
the O
possibility O
of O
a O
dual O
diagnosis O
which O
will O
entitle O
the O
child O
to O
a O
more O
specialized O
and O
effective O
educational O
and O
intervention O
services O
. O
[]

Following O
the O
induction O
of O
general O
anesthesia O
, O
a O
small O
change O
in O
bladder B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

High-dose O
thrombolysis O
led O
to O
better O
rates O
of O
complete B-outcome ['Physiological-Clinical']
recanalization I-outcome ['Physiological-Clinical']
after O
seven O
days O
( O
p O
< O
0.01 O
) O
than O
locoregional O
lysis O
. O
['Physiological-Clinical']

Heart O
rate O
( O
HR O
) O
, O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
pulmonary B-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
measured O
using O
a O
telemetric O
apparatus O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
the O
first O
postoperative O
day O
, O
the O
increase O
in O
the O
mean O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
also O
significantly O
lower O
in O
the O
IP O
patients O
. O
['Physiological-Clinical']

SETTING: O
University O
hospital O
between O
2010 O
and O
2014. O
[]

BACKGROUND O
A O
supplemented O
very-low-protein O
diet O
( O
sVLPD O
) O
seems O
to O
be O
safe O
when O
postponing O
dialysis O
therapy O
. O
[]

Eberconazole O
1 O
% O
cream O
is O
an O
effective O
and O
safe O
alternative O
for O
dermatophytosis O
treatment O
: O
multicenter O
, O
randomized O
, O
double-blind O
, O
comparative O
trial O
with O
miconazole O
2 O
% O
cream O
. O
[]

We O
conclude O
that O
eyes O
undergoing O
a O
vitreous O
operation O
for O
the O
first O
time O
for O
the O
treatment O
of O
proliferative B-outcome ['Physiological-Clinical']
vitreoretinopathy I-outcome ['Physiological-Clinical']
can O
in O
most O
instances O
be O
successfully O
treated O
by O
conventional O
techniques O
without O
the O
need O
for O
relaxing O
retinotomy O
. O
['Physiological-Clinical']

However O
, O
its O
effects O
on O
the O
late O
phase O
remain O
unclear O
. O
[]

Sitting B-outcome ['Life-Impact']
balance I-outcome ['Life-Impact']
( O
measured O
by O
dimension O
B O
of O
the O
Gross O
Motor O
Function O
Measure O
) O
improved O
significantly O
in O
the O
treatment O
group O
( O
effect O
size O
= O
0.36 O
; O
95 O
% O
CI O
0.01-0.71 O
) O
and O
the O
effect O
size O
was O
greater O
in O
the O
severely O
disabled O
group O
( O
effect O
size O
= O
0.80 O
; O
95 O
% O
CI O
0.13-1.47 O
) O
. O
['Life-Impact']

This O
hypothesis O
has O
now O
received O
strong O
support O
and O
is O
currently O
based O
on O
three O
types O
of O
arguments O
: O
( O
1 O
) O
similarity O
between O
autistic O
symptomatology O
and O
abnormal O
behaviors O
induced O
in O
young O
animals O
by O
injections O
of O
exogenous O
opioids O
, O
such O
as O
increasing O
social O
aloofness O
and O
decreasing O
social O
vocalization O
; O
( O
2 O
) O
direct O
biochemical O
evidence O
of O
abnormalities O
of O
peripheral O
endogenous O
opioids O
being O
reported O
in O
autism O
and O
( O
3 O
) O
therapeutic O
effects O
of O
the O
long O
lasting O
opioid O
receptor O
blocking O
agent O
naltrexone O
in O
autism O
. O
[]

in O
14 O
randomized O
patients O
with O
stable O
ischemic O
heart O
disease O
in O
a O
double-blinded O
study O
. O
[]

Resting O
blood O
samples O
were O
collected O
prior O
to O
and O
on O
completion O
of O
each O
diet O
to O
determine O
plasma O
intestinal B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(I-FABP) I-outcome ['Physiological-Clinical']
as O
a O
marker O
of O
acute B-outcome ['Physiological-Clinical']
GI I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
. O
RESULTS: O
Overall O
Irritable B-outcome ['Physiological-Clinical']
Bowel I-outcome ['Physiological-Clinical']
Syndrome-Severity I-outcome ['Physiological-Clinical']
Scoring O
System O
(IBS-SSS) O
score O
significantly O
reduced O
in O
the O
LOWFODMAP O
condition O
from O
81.1 O
+/- O
16.4 O
to O
31.3 O
+/- O
9.2 O
(arbitrary O
units; O
P O
= O
0.004). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
; O
secondary O
end O
points O
included O
6-month O
and O
1-year O
survival B-outcome ['Mortality']
rates O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O
['Mortality', 'Mortality', 'Mortality']

The O
most O
common O
adverse B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
mucocutaneous B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
which O
was O
reported O
in O
65% O
of O
the O
patients O
in O
the O
caplacizumab O
group O
and O
in O
48% O
in O
the O
placebo O
group. O
[['Adverse-effects'], ['Physiological-Clinical']]

The O
study O
is O
registered O
at O
http O
: O
//www.clinicaltrials.gov O
with O
the O
identifier O
NCT00333944 O
. O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS O
Sixty O
chronic O
pancreatitis O
patients O
were O
compared O
to O
15 O
healthy O
controls O
. O
[]

BACKGROUND/AIMS O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
somatostatin O
vs. O
ranitidine O
in O
controlling O
acute B-outcome ['Physiological-Clinical']
non-variceal I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
shortened O
postpartum O
course O
of O
magnesium O
sulphate B-outcome ['Physiological-Clinical']
is O
as O
effective O
as O
the O
standard O
Pritchard O
regimen O
in O
the O
management B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
eclampsia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Continued O
improvement O
in O
pressure-flow B-outcome ['Physiological-Clinical']
parameters O
in O
men O
receiving O
finasteride O
for O
2 O
years O
. O
['Physiological-Clinical']

Demographic O
and O
clinical O
characteristics O
of O
the O
two O
groups O
were O
not O
significantly O
different O
. O
[]

Title: O
Effect O
of O
Medication O
Co-payment O
Vouchers O
on O
P2Y12 B-outcome ['Physiological-Clinical']
Inhibitor I-outcome ['Physiological-Clinical']
Use I-outcome ['Physiological-Clinical']
and O
Major B-outcome ['Physiological-Clinical', 'Mortality']
Adverse I-outcome ['Physiological-Clinical', 'Mortality']
Cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
Events I-outcome ['Physiological-Clinical', 'Mortality']
Among O
Patients O
With O
Myocardial O
Infarction: O
The O
ARTEMIS O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality']]

Early O
morning O
sleep O
deprivation O
( O
patient O
awake O
from O
0200 O
to O
2200 O
hours O
) O
produces O
a O
same-day O
antidepressant B-outcome ['Resource-use']
effect O
in O
approximately O
one-half O
of O
patients O
with O
major O
depression O
. O
['Resource-use']

8.7 O
) O
] O
were O
all O
significantly O
lower O
than O
those O
in O
the O
6 O
( O
th O
) O
weekend O
of O
treatment O
[ O
( O
14.2 O
? O
[]

The O
study O
failed O
to O
show O
significant O
difference O
in O
intelligence B-outcome ['Life-Impact']
quotient I-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
scales O
with O
donepezil O
therapy O
over O
12 O
weeks O
. O
['Life-Impact', 'Life-Impact']

The O
mean O
( O
SE O
) O
exhaled B-outcome ['Physiological-Clinical']
NO I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
31 O
( O
3 O
) O
ppb O
at O
baseline O
, O
39 O
( O
4 O
) O
ppb O
at O
an O
FiO2 O
of O
1.0 O
, O
and O
26 O
( O
3 O
) O
ppb O
at O
an O
FiO2 O
of O
0.1 O
. O
['Physiological-Clinical']

Six O
patients O
dropped O
out O
before O
the O
fifth O
postoperative O
day O
, O
leaving O
79 O
patients O
in O
the O
control O
group O
and O
81 O
patients O
in O
the O
study O
group O
. O
[]

In O
addition, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
recorded O
during O
the O
study O
period. O
[['Adverse-effects']]

METHODS O
AND O
MATERIALS O
Between O
1985 O
and O
1989 O
, O
200 O
patients O
with O
clinical O
Stage O
III O
noninflammatory O
breast O
cancer O
were O
enrolled O
in O
a O
prospective O
study O
investigating O
neoadjuvant O
and O
adjuvant O
chemotherapy O
. O
[]

OBJECTIVE O
Renewed O
insight O
into O
dose-related O
effects O
of O
sertindole O
and O
haloperidol O
was O
sought O
by O
re-analysing O
published O
data O
for O
antipsychotic O
effect O
, O
extrapyramidal O
effect O
, O
and O
patient O
wellbeing O
- O
i.e. O
, O
the O
important O
pharmacopsychometric O
triangle O
domains O
. O
[]

Conclusions: O
CBT-i O
for O
chronic O
insomnia O
is O
effective O
in O
both O
CBT-i O
alone O
and O
combination O
with O
tapered O
hypnotic O
agents. O
[]

in O
moderately O
severe O
reflux O
oesophagitis O
( O
grades O
II-III O
) O
. O
[]

Future O
research O
will O
investigate O
whether O
abnormalities O
in O
these O
mechanisms O
play O
a O
role O
in O
disorders O
of O
diastolic O
function O
. O
[]

This O
study O
therefore O
aimed O
to O
assess O
whether O
a O
short-term O
LOWFODMAP O
diet O
improved O
exercise-related O
GI B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
the O
perceived O
ability B-outcome ['Life-Impact']
to O
exercise O
in O
recreational O
runners. O
[['Physiological-Clinical'], ['Life-Impact']]

There O
was O
no O
relationship O
between O
plasma O
levels O
and O
age O
, O
level O
of O
intellectual O
functioning O
, O
scores O
on O
the O
14 O
selected O
Children O
's O
Psychiatric O
Rating O
Scale O
( O
CPRS O
) O
items O
, O
Clinical O
Global O
Impressions O
, O
Global O
Clinical O
Consensus O
, O
and O
the O
CPRS O
hyperactivity O
factor O
. O
[]

The O
objective O
was O
to O
evaluate O
change O
in O
physical O
activity O
, O
measured O
by O
steps O
per O
day O
and O
minutes O
of O
moderate/vigorous B-outcome ['Life-Impact']
physical O
activity O
. O
['Life-Impact']

In O
the O
treatment O
group O
, O
two O
patients O
died O
in O
the O
early O
weeks O
of O
the O
disease O
. O
[]

BACKGROUND: O
The O
burden O
of O
chronic O
obstructive O
lung O
disease O
(COPD) O
is O
increasing O
in O
women, O
with O
recent O
evidence O
suggesting O
gender O
differences O
in O
disease O
characteristics O
and O
potentially O
in O
treatment O
outcomes. O
[]

CONCLUSION O
This O
study O
demonstrates O
that O
the O
use O
of O
the O
Ligaclip O
to O
close O
lymphatic O
vessels O
may O
reduce O
the O
incidence O
of O
lymphoceles B-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
laparoscopic O
pelvic O
lymphadenectomy O
. O
['Physiological-Clinical']

Twelve O
male O
patients O
with O
stable O
effort O
angina O
and O
without O
previous O
myocardial O
infarction O
were O
studied O
. O
[]

INTRODUCTION O
It O
has O
been O
reported O
in O
an O
open-label O
study O
that O
the O
combination O
of O
alkalinized O
lidocaine O
and O
heparin O
can O
immediately O
relieve O
the O
symptoms O
of O
urinary B-outcome ['Physiological-Clinical']
urgency I-outcome ['Physiological-Clinical']
, O
frequency O
, O
and O
['Physiological-Clinical']

Although O
, O
at O
the O
end O
of O
the O
study O
, O
leptin O
levels O
did O
not O
change O
in O
Ex O
patients O
( O
6.7 O
? O
[]

We O
attempted O
to O
assess O
whether O
retroperitoneal O
partial O
no-closure O
reduces O
the O
incidence O
of O
lymphocyst B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
following O
retroperitoneal O
lymphadenectomy O
. O
['Physiological-Clinical']

They O
were O
randomly O
assigned O
to O
receive O
12 O
mg O
of O
nicorandil O
or O
a O
placebo O
intravenously O
just O
before O
reperfusion O
. O
[]

This O
dose O
was O
then O
maintained O
for O
4 O
weeks O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
degree O
of O
enrichment O
of O
bile O
correlated O
with O
that O
of O
serum O
and O
whether O
either O
of O
these O
measures O
correlated O
with O
improvement O
in O
measures O
of O
liver O
disease O
. O
[]

Peripheral O
intravenous B-outcome ['Life-Impact']
line I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
and O
phlebitis B-outcome ['Physiological-Clinical']
prevention O
in O
patients O
receiving O
intravenous O
antibiotics O
: O
heparin/hydrocortisone O
versus O
in-line O
filters O
. O
['Life-Impact', 'Physiological-Clinical']

Spinal O
2-chloroprocaine O
: O
the O
effect O
of O
added O
clonidine O
. O
[]

RESULTS O
Of O
2,223 O
eligible O
patients O
, O
562 O
( O
25 O
% O
) O
have O
enrolled O
. O
[]

They O
were O
divided O
randomly O
by O
a O
physician O
into O
2 O
groups O
of O
30 O
patients O
each O
for O
5 O
sessions O
of O
active O
treatment O
( O
30 O
mg O
of O
ketorolac O
) O
or O
placebo O
( O
5 O
mL O
of O
normal O
saline O
) O
. O
[]

AIM O
The O
research O
regards O
information O
on O
anesthesia O
to O
patients O
undergoing O
oral O
surgery O
. O
[]

Participants O
had O
colonoscopy O
after O
3 O
years O
of O
follow-up O
. O
[]

For O
85 O
children O
( O
58.2 O
% O
) O
, O
the O
sleeplessness O
was O
attributed O
to O
inappropriate O
sleep O
habits O
. O
[]

Markedly B-outcome ['Physiological-Clinical']
abnormal I-outcome ['Physiological-Clinical']
Fridericia I-outcome ['Physiological-Clinical']
's O
correction B-outcome ['Physiological-Clinical']
of O
QT O
values O
( O
500 O
milliseconds O
or O
greater O
) O
were O
observed O
in O
only O
a O
small O
number O
of O
subjects O
by O
treatment O
group O
, O
that O
is O
2 O
( O
less O
than O
1 O
% O
) O
in O
the O
pooled O
degarelix O
group O
and O
2 O
( O
1 O
% O
) O
in O
the O
leuprolide O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Removing O
bee O
stings O
. O
[]

Because O
oral O
contraceptives O
( O
OCs O
) O
may O
reduce O
the O
active B-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
level O
, O
hormonal O
therapy O
with O
OCs O
has O
been O
used O
successfully O
to O
treat O
patients O
with O
acne O
, O
although O
this O
treatment O
has O
previously O
not O
been O
studied O
in O
placebo-controlled O
trials O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
collected O
at O
the O
start O
and O
end O
of O
the O
experimental O
phase O
for O
fatty O
acid O
analysis O
of O
total O
plasma O
phospholipid O
fraction O
. O
['Physiological-Clinical']

Fentanyl O
( O
15 O
, O
30 O
, O
60 O
micro O
g O
kg-1 O
hour-1 O
) O
or O
remifentanil O
( O
60 O
, O
120 O
, O
240 O
micro O
g O
kg-1 O
hour-1 O
) O
were O
infused O
intravenously O
into O
a O
previously O
cannulated O
tail O
vein O
. O
[]

Long-term O
prospective O
, O
randomized O
, O
controlled O
study O
using O
repetitive O
education O
at O
six-month O
intervals O
and O
monitoring O
for O
adherence O
in O
heart O
failure O
outpatients O
: O
the O
REMADHE O
trial O
. O
[]

Teeth O
were O
submitted O
to O
thermal O
cycling O
and O
immersed O
in O
50 O
% O
silver O
nitrate O
solutions O
for O
8 O
h O
in O
total O
darkness O
. O
[]

Significant O
proportions O
of O
the O
variance O
in O
responsibility B-outcome ['Life-Impact']
, O
struggle B-outcome ['Life-Impact']
, O
and O
cooperation B-outcome ['Life-Impact']
, O
however O
, O
were O
not O
accounted O
for O
by O
therapist O
process O
alone O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Respiratory B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
was O
good O
in O
all O
but O
two O
patients O
. O
['Physiological-Clinical']

Nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
and O
concentration O
of O
sICAM-1 O
in O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
were O
assessed O
before O
and O
on O
the O
last O
day O
of O
each O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS: O
A O
sample O
of O
2262 O
male O
truckers O
registered O
in O
the O
North O
Star O
Alliance O
electronic O
health O
record O
system O
who, O
based O
on O
these O
records, O
were O
not O
testing O
for O
HIV O
regularly O
were O
randomized O
to O
one O
of O
three O
study O
groups O
in O
which O
they O
were O
sent O
text O
messages O
about O
the O
availability O
of O
(1) O
oral O
HIV O
self-test O
kits O
at O
all O
8 O
North O
Star O
Alliance O
Kenya O
clinics O
that O
was O
sent O
three O
times O
(intervention), O
(2) O
HIV O
testing O
in O
general O
(not O
self-testing) O
at O
all O
North O
Star O
Alliance O
clinics O
sent O
three O
times O
(enhanced O
standard O
of O
care O
[SOC]), O
or O
(3) O
HIV O
testing O
in O
general O
(not O
self-testing) O
at O
all O
North O
Star O
Alliance O
clinics O
sent O
one O
time O
(SOC). O
[]

All O
other O
parameters O
of O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
were O
not O
affected O
by O
either O
treatment O
. O
['Life-Impact']

Other O
arrhythmias B-outcome ['Physiological-Clinical']
occurred O
in O
1 O
% O
or O
less O
of O
subjects O
by O
treatment O
group O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
One O
hundred O
seventy-five O
patients O
, O
57.1 O
% O
paroxysmal O
AF O
, O
78.5 O
% O
male O
, O
underwent O
AF O
ablation O
and O
esophagoscopy O
24 O
hours O
thereafter O
. O
[]

Various O
pharmacological O
agents, O
with O
the O
exception O
of O
calcium O
channel O
blockers, O
have O
been O
investigated O
to O
improve O
ET O
outcomes O
by O
reducing O
UC. O
[]

Publication O
date: O
2018/11/20 O
00:00 O
[revised] O
[]

METHODS O
In O
this O
phase O
2b O
, O
double-blind O
, O
multicentre O
trial O
, O
patients O
( O
aged O
18-75 O
years O
) O
with O
, O
or O
with O
high O
risk O
of O
, O
coronary O
heart O
disease O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
dalcetrapib O
600 O
mg/day O
or O
placebo O
for O
24 O
months O
. O
[]

The O
exercise-induced B-outcome ['Life-Impact']
increase O
in O
EGC B-outcome ['Physiological-Clinical']
was O
higher O
during O
the O
HFD O
( O
AUC O
: O
HFD O
, O
1,641 O
+/- O
181 O
micromol/60 O
min O
; O
HCD O
, O
963 O
+/- O
156 O
micromol/60 O
min O
; O
P O
< O
.05 O
) O
and O
was O
associated O
with O
a O
higher O
exercise-induced B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
norepinephrine O
( O
P O
< O
.05 O
) O
and O
epinephrine O
( O
P O
=.056 O
) O
and O
lower O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Normothermic O
patients O
were O
warmed O
to O
36.5-37.0 O
degrees O
C O
after O
an O
initial O
temperature O
decrease O
, O
and O
hypothermic O
patients O
were O
cooled O
to O
35 O
degrees O
C. O
In O
the O
hypothermic O
group O
temperatures O
were O
allowed O
to O
drift O
to O
34.5 O
degrees O
C O
before O
rewarming O
was O
initiated O
. O
[]

INTERVENTIONS O
All O
children O
received O
intensive O
pediatric O
and O
developmental O
surveillance O
. O
[]

OBJECTIVE O
To O
assess O
the O
cost-effectiveness O
of O
clopidogrel O
in O
the O
Canadian O
health O
care O
system O
. O
[]

No O
effect O
of O
beta-carotene O
supplementation O
on O
the O
susceptibility O
of O
low O
density O
lipoprotein O
to O
in O
vitro B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
among O
hypercholesterolaemic O
, O
postmenopausal O
women O
. O
['Physiological-Clinical']

The O
Spearman O
correlation O
coefficients O
for O
pain B-outcome ['Physiological-Clinical']
, O
stiffness B-outcome ['Physiological-Clinical']
and O
function B-outcome ['Life-Impact']
were O
0.88 O
, O
0.77 O
and O
0.87 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Intensive O
physical O
exercise O
may O
cause O
increase O
oxidative O
stress O
and O
muscular O
injury O
in O
elite O
football O
athletes. O
[]

RESULTS O
In O
the O
electrophysiologic-study O
group O
, O
the O
percentage O
of O
patients O
who O
had O
predictions O
of O
drug O
efficacy O
was O
higher O
with O
sotalol O
( O
35 O
percent O
) O
than O
with O
the O
other O
drugs O
( O
16 O
percent O
, O
P O
< O
0.001 O
) O
. O
[]

Fondaparinux O
was O
investigated O
in O
phase O
2 O
studies O
for O
the O
treatment O
of O
acute O
coronary O
syndromes O
, O
including O
acute B-outcome ['Physiological-Clinical']
ST-segment I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PENTALYSE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
unstable B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PENTUA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Equivalence O
Trial O
[]

Immunoenhanced O
enteral O
nutrition O
formulas O
in O
head O
and O
neck O
cancer O
surgery O
: O
a O
prospective O
, O
randomized O
clinical O
trial O
. O
[]

BACKGROUND: O
Head O
to O
head O
trials O
of O
clinical O
outcomes O
of O
sirolimus O
eluting O
polymer O
free O
vs. O
biodegradable O
polymer O
stents O
are O
lacking. O
[]

Journal O
ID: O
7501160 O
[]

METHOD O
The O
study O
was O
a O
between-subjects O
design O
( O
mindfulness O
intervention O
vs O
control O
) O
with O
difference O
between O
number O
of O
most O
and O
least O
chosen O
stimulus O
selections O
on O
an O
over-selectivity O
task O
as O
the O
dependent O
measure O
. O
[]

BACKGROUND O
Some O
evidence O
suggests O
an O
increased O
risk O
of O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
and O
dysrhythmia B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
associated O
with O
beta O
( O
2 O
) O
-agonist O
use O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Diarrhea B-outcome ['Physiological-Clinical']
, O
stomatitis B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
the O
most O
common O
nonhematologic B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
in O
both O
arms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Side-effects B-outcome ['Adverse-effects']
were O
five O
times O
less O
frequent O
in O
SML-treated O
patients O
( O
p O
< O
0.004 O
) O
. O
['Adverse-effects']

In O
addition O
, O
after O
its O
first O
use O
, O
acceptance O
of O
this O
new B-outcome ['Life-Impact']
medium I-outcome ['Life-Impact']
rose O
dramatically O
. O
['Life-Impact']

However O
, O
cellular B-outcome ['Physiological-Clinical']
aspects I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
immunologic I-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
of O
soy-fed O
infants O
have O
not O
been O
studied O
extensively O
. O
['Physiological-Clinical']

A O
controlled O
trial O
after O
upper O
abdominal O
surgery O
. O
[]

Both O
random O
assignment O
and O
large-scale O
geographic O
area O
research O
designs O
were O
used O
. O
[]

In O
Group O
C O
, O
patients O
were O
pretreated O
with O
lidocaine O
1.0 O
mg/kg O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
3.3 O
mg/sec O
. O
[]

0.53 O
kg O
) O
after O
consuming O
the O
solid O
fruits O
and O
vegetables O
whereas O
the O
overweight/obese O
group O
had O
lower O
compensation O
and O
significant O
weight O
gain O
during O
the O
solid O
arm O
( O
46 O
% O
, O
1.77 O
? O
[]

Data O
were O
analyzed O
with O
repeated-measures O
ANOVA O
. O
[]

These O
results O
do O
not O
support O
a O
beneficial O
or O
harmful O
effect O
of O
antioxidants B-outcome ['Resource-use']
or O
zinc B-outcome ['Physiological-Clinical']
and O
copper B-outcome ['Resource-use']
on O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

RESULTS O
Alvimopan O
significantly O
increased O
the O
proportion O
of O
patients O
with O
GI-2 B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
and O
DCO B-outcome ['Physiological-Clinical']
written O
by O
each O
POD O
( O
P O
< O
0.001 O
for O
all O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Title: O
A O
Pilot O
Randomized O
Controlled O
Trial O
of O
Transcutaneous O
Electrical O
Nerve O
Stimulation O
for O
Patients O
With O
Acute O
Tinnitus. O
[]

RESULTS O
1233 O
patients O
were O
randomized O
. O
[]

The O
role O
of O
adjunctive O
exenatide O
therapy O
in O
pediatric O
type O
1 O
diabetes O
. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Patients O
of O
the O
intervention O
group O
were O
more O
likely O
to O
show O
reduction O
in O
body O
mass O
index O
and O
sodium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
to O
stop B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
, O
as O
compared O
with O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

Corrected B-outcome ['Physiological-Clinical']
TIMI I-outcome ['Physiological-Clinical']
frame O
count O
was O
furthermore O
lower O
in O
the O
nicorandil O
group O
( O
21.0+/-9.1 O
versus O
25.1+/-14.1 O
; O
P=0.0009 O
) O
. O
['Physiological-Clinical']

Formation O
of O
ROS O
by O
monocytes O
was O
measured O
by O
gated O
flow O
cytometry O
. O
[]

In O
patients O
receiving O
no O
maintenance O
therapy O
, O
those O
who O
received O
interferon O
alfa-2b O
during O
the O
induction O
phase O
showed O
a O
favourable O
trend O
in O
terms O
of O
incidence O
of O
relapse B-outcome ['Physiological-Clinical']
compared O
to O
those O
who O
had O
received O
chlorambucil O
alone O
. O
['Physiological-Clinical']

Comparison O
of O
comfort B-outcome ['Life-Impact']
and O
local B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
after O
cardiac O
catheterization O
. O
['Life-Impact', 'Adverse-effects']

RESULTS O
At O
baseline O
, O
the O
mean O
intakes O
for O
macronutrients B-outcome ['Physiological-Clinical']
, O
vitamins O
and O
minerals O
exceeded O
Dietary O
Reference O
Intakes O
( O
DRIs O
) O
. O
['Physiological-Clinical']

Compared O
with O
historic O
controls O
, O
the O
ALL-2 O
regimen O
was O
superior O
in O
terms O
of O
incidence O
of O
complete O
remission O
, O
failure O
with O
resistant O
disease O
, O
and O
activity O
in O
patients O
with O
Philadelphia O
chromosome O
( O
Ph O
) O
-positive O
ALL O
. O
[]

Growth O
hormone O
effects O
on O
cortical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
in O
young O
adults O
with O
childhood-onset O
growth O
hormone O
deficiency O
. O
['Physiological-Clinical']

Our O
study O
shows O
that O
use O
of O
a O
small O
dose O
of O
subconjunctival O
5-FU O
provides O
significantly O
lower O
postoperative B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
than O
does O
no O
antimetabolite O
treatment O
. O
['Physiological-Clinical']

There O
were O
22 O
patients O
in O
the O
drug O
treatment O
group O
( O
20.0 O
% O
) O
and O
29 O
patients O
in O
the O
placebo O
group O
( O
24.0 O
% O
) O
with O
opposite-side B-outcome ['Physiological-Clinical']
amputations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SETTING O
Medical O
center O
. O
[]

INTERVENTION O
WB O
exercise O
and O
NWB O
exercise O
groups O
underwent O
an O
8-week O
knee O
extension-flexion O
exercise O
program O
. O
[]

RESULTS O
Mean O
follow-up O
time O
was O
24 O
months O
. O
[]

RESULTS O
A O
repeated O
measures O
analysis O
of O
variance O
indicated O
no O
significant O
differences O
between O
groups O
or O
between O
baseline O
, O
intervention O
, O
and O
withdrawal O
conditions O
. O
[]

Cephalometry B-outcome ['Physiological-Clinical']
with O
and O
without O
a O
chinstrap O
was O
randomly O
performed O
on O
six O
patients O
. O
['Physiological-Clinical']

They O
were O
treated O
for O
20 O
days O
( O
times O
) O
. O
[]

Mean O
gastric B-outcome ['Physiological-Clinical']
endoscopy I-outcome ['Physiological-Clinical']
scores O
at O
Days O
8 O
and O
15 O
were O
significantly O
lower O
in O
the O
risedronate O
group O
than O
in O
the O
alendronate O
group O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

In O
a O
30-day O
study O
, O
we O
compared O
the O
abilities O
of O
four O
different O
treatments O
( O
lithium O
plus O
early O
morning O
sleep O
deprivation O
, O
lithium O
plus O
a O
control O
sleep O
deprivation O
procedure O
, O
and O
desipramine O
with O
either O
of O
the O
two O
sleep O
manipulations O
) O
to O
induce O
a O
rapid O
( O
next-day O
) O
and O
sustained O
antidepressant B-outcome ['Life-Impact']
response I-outcome ['Life-Impact']
in O
16 O
depressed O
patients O
. O
['Life-Impact']

Thirty O
alpacas O
, O
all O
positive O
for O
Chorioptes O
sp O
. O
[]

Among O
men O
with O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
above O
the O
median O
, O
the O
ff O
genotype O
was O
no O
longer O
associated O
with O
risk O
. O
['Physiological-Clinical']

2 O
) O
= O
5.67 O
, O
P O
= O
.02 O
) O
. O
[]

Having O
failed O
to O
respond O
to O
an O
adequate O
antidepressant O
treatment O
course O
predicts O
poorer O
treatment O
outcomes O
in O
patients O
with O
major O
depression O
. O
[]

Confocal O
microscopy O
was O
used O
for O
the O
6-week O
treatment O
group O
to O
examine O
the O
target O
tumor O
area O
at O
each O
interval O
visit O
and O
immediately O
before O
Mohs O
micrographic O
surgery O
. O
[]

FUNDING O
Amgen O
. O
[]

During O
pre- O
and O
post-tests O
, O
submaximal O
exercise O
was O
performed O
on O
a O
stationary O
wheelchair O
ergometer O
at O
fixed O
levels O
of O
power O
output O
. O
[]

A O
meta-analysis O
of O
the O
available O
data O
confirmed O
the O
value O
of O
a O
protective O
ostomy O
for O
patients O
undergoing O
low O
anterior O
resection O
. O
[]

Thus O
it O
was O
concluded O
that O
a O
single O
dose O
of O
cefotiam O
significantly O
reduces O
post-operative B-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
with O
CNS O
metastases O
were O
eligible O
and O
received O
concurrent O
whole-brain O
radiotherapy O
. O
[]

AIMS O
To O
compare O
outcome O
of O
AF O
patients O
with O
effective O
rhythm O
control O
with O
patients O
treated O
with O
rate O
control O
. O
[]

BACKGROUND: O
Transcutaneous O
electrical O
nerve O
stimulation O
(TENS) O
is O
often O
used O
for O
the O
treatment O
of O
low-back O
pain O
(LBP). O
[]

Journal O
ID: O
101521595 O
[]

AIM: O
The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
efficacy O
of O
curcumin O
gel O
as O
local O
drug O
delivery O
post-scaling O
and O
root O
planing O
and O
its O
effect O
on O
clinical O
parameters O
like O
plaque B-outcome ['Physiological-Clinical']
, O
gingival B-outcome ['Physiological-Clinical']
scores, O
pocket B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
(CAL) I-outcome ['Physiological-Clinical']
. O
MATERIALS O
AND O
METHODS: O
Ten O
patients O
with O
two O
sites O
in O
the O
contralateral O
quadrants O
having O
probing O
pocket O
depths O
(PPDs) O
of O
>/=5 O
mm O
were O
selected. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Of O
34 O
patients O
registered O
, O
10 O
patients O
were O
with O
minimal O
disease O
in O
stages O
IIA O
, O
IIIO O
and O
IIIA O
and O
24 O
with O
extensive O
disease O
in O
IIB O
, O
IIIB2 O
and O
IIIC O
. O
[]

Low-intensity O
back-strengthening O
exercise O
was O
effective O
in O
improving O
the O
quality O
of O
life O
and O
back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Researchers O
were O
masked O
to O
allocation, O
but O
participants O
were O
not. O
[]

This O
report O
summarizes O
the O
demographic O
, O
biochemical B-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of O
the O
randomized O
patients O
at O
the O
time O
of O
entry O
into O
the O
trial O
and O
evaluates O
the O
balance O
between O
the O
treatment O
groups O
within O
each O
population O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Similar O
challenge O
vehicle O
recipes O
were O
used O
, O
the O
only O
difference O
being O
the O
lower O
fat O
content O
( O
22.9 O
% O
compared O
with O
31.5 O
% O
) O
. O
[]

CONCLUSIONS O
HFLCS O
application O
on O
enamel O
etched O
with O
37 O
% O
phosphoric O
acid O
did O
not O
affect O
the O
bond O
strength O
values O
and O
the O
bond O
failure O
modes O
of O
metal O
and O
ceramic O
brackets O
bonded O
with O
RMGIC O
. O
[]

Evaluation O
of O
a O
new O
wound O
closure O
device O
for O
linear O
surgical O
incisions O
: O
3M O
Steri-Strip O
S O
Surgical O
Skin O
Closure O
versus O
subcuticular O
closure O
. O
[]

Secretin O
and O
autism O
: O
a O
two-part O
clinical O
investigation O
. O
[]

Airway B-outcome ['Physiological-Clinical']
seal I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
cm O
H O
( O
2 O
) O
O O
) O
for O
LTS O
and O
PLMA O
was O
20 O
+/- O
8.6 O
and O
24.1 O
+/- O
10.8 O
, O
respectively O
( O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Sildenafil O
was O
started O
at O
50 O
mg O
and O
increased O
( O
100 O
mg O
) O
or O
decreased O
( O
25 O
mg O
) O
at O
week O
2 O
if O
necessary O
. O
[]

Further O
investigation O
would O
be O
required O
to O
confirm O
this O
effect O
and O
its O
mechanism O
and O
the O
genotype O
prediction O
of O
effects O
on O
dosing. O
[]

Pathologic O
and O
quantitative O
image O
analyses O
were O
performed O
to O
evaluate O
the O
size O
and O
quality O
of O
the O
obtained O
specimens O
. O
[]

The O
slight O
increase O
in O
local O
recurrence B-outcome ['Physiological-Clinical']
rate O
in O
transfused O
patients O
appears O
to O
be O
related O
to O
complicated O
, O
in O
particular O
rectal O
, O
surgery O
. O
['Physiological-Clinical']

The O
efficacy O
of O
melatonin O
for O
sleep O
problems O
in O
children O
with O
autism O
, O
fragile O
X O
syndrome O
, O
or O
autism O
and O
fragile O
X O
syndrome O
. O
[]

Twenty-two O
maturity-onset O
type O
diabetics O
treated O
with O
oral O
hypoglycaemic O
agents O
entered O
a O
single-blind O
crossover O
study O
using O
placebo O
( O
periods O
A O
and O
C O
, O
2 O
months O
each O
) O
and O
clofibrate O
( O
2 O
g/day O
; O
period O
B O
; O
2 O
months O
) O
. O
[]

Students O
( O
176 O
; O
25.35?1.03 O
years O
, O
63 O
% O
female O
) O
were O
alphabetically O
assigned O
to O
44 O
four-person O
teams O
that O
were O
then O
randomly O
( O
computer-generated O
) O
assigned O
to O
either O
CRM O
intervention O
( O
n=26 O
) O
, O
receiving O
interactive O
video-based O
CRM-training O
, O
or O
to O
control O
intervention O
( O
n=18 O
) O
, O
receiving O
an O
additional O
ALS-training O
. O
[]

Double-blind O
placebo-controlled O
trial O
of O
secretin O
: O
effects O
on O
aberrant B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

AIM O
To O
assess O
the O
effects O
of O
long-term O
peginterferon O
therapy O
and O
disease O
progression O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
and O
sexual O
health O
in O
HALT-C O
patients O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

PURPOSE: O
This O
report O
assesses O
functional B-outcome ['Life-Impact']
mobility I-outcome ['Life-Impact']
in O
children O
with O
neurological O
impairments O
and O
documented O
gross O
motor O
delays, O
before O
and O
after O
receiving O
either O
hippotherapy O
or O
standard O
outpatient O
physical O
therapy O
(PT). O
[['Life-Impact']]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

SESSION O
B O
An O
acupuncture O
needle O
( O
Hwato O
, O
& O
emptyv O
; O
0.30x30 O
mm O
) O
was O
inserted O
perpendicular O
into O
the O
Hegu O
point O
( O
LI O
4 O
) O
in O
the O
middle O
of O
the O
right O
dorsal O
thenar O
muscle O
. O
[]

INTERVENTION O
All O
participants O
received O
usual O
care O
. O
[]

Future O
studies O
investigating O
the O
long-term O
efficacy O
of O
atomoxetine O
in O
children O
and O
adolescents O
with O
ASD O
should O
be O
randomized O
and O
placebo O
controlled O
. O
[]

PURPOSE O
To O
evaluate O
the O
cost B-outcome ['Resource-use']
effectiveness O
of O
CSF B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Prophylaxis O
with O
meropenem O
of O
septic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
acute O
pancreatitis O
: O
a O
randomized O
, O
controlled O
trial O
versus O
imipenem O
. O
['Physiological-Clinical']

Long-term O
growth O
hormone O
treatment O
in O
growth O
hormone O
deficient O
adults O
. O
[]

Muscle O
TCr O
increased O
( O
P O
< O
0.05 O
) O
throughout O
the O
Cr O
trial O
in O
both O
groups O
but O
was O
greater O
( O
P O
< O
0.05 O
) O
in O
VEG O
compared O
with O
NVEG O
, O
at O
days O
1 O
and O
5 O
. O
[]

To O
that O
end O
, O
participants O
completed O
two O
cooperative O
tasks O
with O
a O
confederate O
, O
which O
allowed O
us O
to O
measure O
linguistic B-outcome ['Life-Impact']
alignment I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
confederate I-outcome ['Life-Impact']
in O
terms O
of O
lexical B-outcome ['Life-Impact']
choice I-outcome ['Life-Impact']
, O
syntactic B-outcome ['Life-Impact']
structure O
and O
spatial B-outcome ['Life-Impact']
frame O
of O
reference B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
All O
H. O
pylori O
( O
+ O
) O
patients O
showed O
a O
rapid O
increase O
of O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
with O
a O
mean O
intragastric B-outcome ['Physiological-Clinical']
pH B-outcome ['Physiological-Clinical']
of O
6.7 O
during O
the O
second O
half O
of O
the O
first O
day O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

[ O
The O
effects O
of O
antidepressant O
treatment O
on O
efficacy O
of O
antihypertensive O
therapy O
in O
elderly O
hypertension O
] O
. O
[]

AT O
strain B-outcome ['Physiological-Clinical']
was O
determined O
from O
kinematics O
and O
ultrasound O
images O
of O
medial O
gastrocnemius O
( O
50 O
Hz O
) O
. O
['Physiological-Clinical']

Response O
was O
obtained O
by O
75 O
and O
67 O
% O
of O
patients O
receiving O
MPA O
or O
megestrol O
, O
respectively O
( O
P O
= O
0.5 O
) O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Effects O
of O
omeprazole O
and O
amoxycillin O
on O
the O
human O
oral O
and O
gastrointestinal O
microflora O
in O
patients O
with O
Helicobacter O
pylori O
infection O
. O
[]

PMID: O
31597637 O
[]

Accelerated O
approval O
was O
based O
on O
demonstration O
of O
a O
beneficial O
effect O
on O
progression-free O
survival O
( O
PFS O
) O
. O
[]

METHODS O
A O
single O
blind O
placebo-controlled O
trial O
was O
carried O
out O
for O
two O
years O
in O
220 O
adolescents O
with O
higher O
blood O
pressure O
, O
aged O
18 O
- O
22 O
years O
, O
who O
were O
randomly O
divided O
into O
supplementary O
group O
( O
n O
= O
110 O
) O
and O
control O
group O
( O
n O
= O
110 O
) O
. O
[]

The O
data O
were O
collected O
from O
9 O
clinics O
in O
the O
Netherlands O
, O
Belgium O
, O
Ireland O
, O
the O
United O
Kingdom O
, O
and O
Italy O
. O
[]

RESULTS O
All O
readers O
improved O
analysis O
accuracy O
[]

Although O
grade O
3/4 O
[]

Patients O
responding O
to O
initial O
RTX O
treatment O
could O
receive O
further O
RTX O
courses O
. O
[]

After O
6 O
months O
' O
treatment O
, O
patients O
receiving O
ViviScal O
showed O
a O
mean O
increase O
in O
non-vellus B-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
of O
38 O
% O
compared O
with O
a O
2 O
% O
increase O
in O
the O
fish O
extract O
treatment O
group O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

In O
a O
randomized O
, O
double-masked O
study O
of O
glaucoma O
patients O
, O
over O
60 O
years O
of O
age O
, O
without O
history O
of O
bronchospasm O
and O
who O
were O
using O
timolol O
( O
0.5 O
% O
) O
, O
60 O
patients O
were O
allocated O
to O
betaxolol O
( O
0.5 O
% O
) O
or O
carteolol O
( O
2 O
% O
) O
or O
continued O
timolol O
( O
0.5 O
% O
) O
treatment O
. O
[]

C O
was O
three O
3-weekly O
cycles O
of O
cisplatin/vindesine O
, O
mitomycin/ifosfamide/cisplatin O
, O
mitomycin/vinblastine/cisplatin O
or O
vinorelbine/cisplatin O
. O
[]

Each O
maxillary O
tooth O
's O
mesiodistal O
and O
vestibulo-oral O
width O
was O
measured O
using O
a O
dial O
caliper O
on O
each O
dental O
cast O
. O
[]

Journal-Name:Nutrients O
[]

Low-dose O
growth O
hormone O
treatment O
with O
diet O
restriction O
accelerates B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
exerts O
anabolic O
effect O
and O
improves B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
secretory I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
in O
obese O
adults O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Using O
repeated O
measures O
of O
symptom O
score O
, O
uroflowmetry O
and O
prostate O
specific O
antigen O
in O
the O
clinical O
management O
of O
prostate O
disease O
. O
[]

Differences O
remained O
significant O
( O
p O
< O
0.001 O
) O
through O
week O
12 O
. O
[]

After O
12 O
months O
, O
the O
infants O
in O
the O
experimental O
group O
were O
more O
likely O
to O
be O
fully B-outcome ['Physiological-Clinical']
immunized I-outcome ['Physiological-Clinical']
( O
33 O
% O
) O
than O
the O
infants O
in O
the O
control O
group O
( O
18 O
% O
) O
. O
['Physiological-Clinical']

An O
uncompleted O
randomised O
controlled O
trial O
of O
463 O
women O
. O
[]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

Baseline O
characteristics O
were O
: O
median O
age O
61 O
years O
, O
69 O
% O
male O
, O
48 O
% O
squamous O
cell O
, O
93 O
% O
WHO O
PS O
0-1 O
, O
27 O
% O
stage O
I O
, O
38 O
% O
stage O
II O
, O
and O
34 O
% O
stage O
III O
. O
[]

UICC O
[ O
20 O
] O
stage O
distribution O
of O
patients O
was O
as O
follows O
: O
stage O
IA O
= O
4 O
, O
stage O
IB O
= O
33 O
, O
stage O
IIA O
= O
18 O
, O
stage O
IIB O
= O
38 O
, O
stage O
III O
= O
57 O
, O
stage O
IV O
= O
15 O
. O
[]

Group O
I O
( O
25 O
patients O
) O
received O
capsule O
A O
( O
glibenclamide O
) O
while O
Group O
II O
( O
25 O
patients O
) O
received O
capsule O
B O
( O
gliclazide O
) O
. O
[]

It O
is O
uncertain O
whether O
the O
negative O
finding O
was O
because O
of O
a O
lack O
of O
strength O
of O
the O
interventions O
or O
problems O
detecting O
intervention O
effects O
using O
individual-level O
closed-end O
surveys O
. O
[]

The O
study O
can O
detect O
a O
three-point O
difference O
in O
full-scale O
IQ B-outcome ['Life-Impact']
at O
3-year O
follow-up O
. O
['Life-Impact']

Bilateral O
transversus O
abdominis O
plane O
block O
does O
not O
decrease O
postoperative O
pain O
after O
laparoscopic O
cholecystectomy O
when O
compared O
with O
local O
anesthetic O
infiltration O
of O
trocar O
insertion O
sites O
. O
[]

Safety O
assessment O
included O
vital O
signs O
, O
electrocardiogram O
, O
electroencephalogram O
, O
adverse O
events O
, O
laboratory O
tests O
, O
extrapyramidal O
symptoms O
and O
the O
side O
effects O
. O
[]

In O
two O
thirds O
of O
the O
children O
with O
a O
positive O
response O
to O
risperidone O
at O
eight O
weeks O
( O
23 O
of O
34 O
) O
, O
the O
benefit O
was O
maintained O
at O
six O
months O
. O
[]

Whether O
these O
agents O
work O
by O
inducing O
immunologic O
stimulation O
or O
simply O
a O
nonspecific O
inflammatory O
reaction O
has O
not O
been O
definitively O
demonstrated O
. O
[]

METHODS O
Eight O
hundred O
and O
ninety-one O
patients O
treated O
for O
48 O
weeks O
with O
an O
initial O
ribavirin O
dose O
of O
800 O
or O
1000/1200 O
mg/day O
were O
evaluated O
. O
[]

The O
stone B-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
and O
clearance B-outcome ['Physiological-Clinical']
rates O
were O
the O
two O
end O
points O
for O
evaluation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Therapeutic O
efficacy O
of O
compound O
Xuanju O
capsule O
on O
type O
III O
prostatitis O
] O
. O
[]

Patients O
were O
followed O
for O
12 O
months O
with O
angiographic O
follow-up O
at O
6 O
months O
. O
[]

Long-term O
results O
of O
a O
randomized O
clinical O
trial O
of O
Shouldice O
, O
Lichtenstein O
and O
transabdominal O
preperitoneal O
hernia O
repairs O
. O
[]

DISCUSSION: O
This O
study O
will O
provide O
data O
on O
the O
efficacy O
of O
repeated O
PZQ O
treatment O
on O
the O
clearance O
of O
S.mansoni O
as O
measured O
by O
several O
diagnostic O
techniques. O
[]

Ventricular B-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
responsive I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
amiodarone I-outcome ['Physiological-Clinical']
was O
more O
frequent O
in O
myoblast-treated O
patients O
: O
1 O
( O
placebo O
) O
, O
3 O
( O
low O
dose O
) O
, O
and O
4 O
( O
high O
dose O
) O
. O
['Physiological-Clinical']

Recent O
research O
also O
suggests O
that O
adults O
with O
ASD O
are O
unable O
to O
understand O
their O
own O
mental O
states O
, O
which O
could O
lead O
to O
difficulties O
in O
emotion-regulation O
. O
[]

METHOD: O
A O
prospective O
randomised, O
single O
centre O
parallel O
group O
trial O
comparing O
an O
8-week O
individualised O
multidisciplinary O
intervention O
programme O
(bespoke O
physiotherapy O
and O
occupational O
therapy O
in O
the O
clinical, O
home O
and O
school O
environment) O
with O
current O
standard O
management O
(advice, O
information O
and O
therapy O
referral O
if O
deemed O
necessary). O
[]

The O
use O
of O
?-receptor O
blockers O
in O
peripheral O
arterial O
disease O
is O
controversial O
for O
their O
impact O
on O
vasomotor O
tone O
. O
[]

The O
primary O
and O
secondary O
endpoints, O
excluding O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QoL) I-outcome ['Life-Impact']
, O
have O
been O
published. O
[['Life-Impact']]

Treatment O
response O
was O
not O
correlated O
with O
age O
level O
of O
autistic O
behavior O
, O
or O
full-scale O
IQ O
. O
[]

Calcium B-outcome ['Physiological-Clinical']
solubility I-outcome ['Physiological-Clinical']
and O
absorption O
across O
Caco-2 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
studied O
after O
the O
in O
vitro O
digestion O
of O
the O
diets O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
31 O
patients O
undergoing O
elective O
surgery O
of O
the O
abdominal O
aorta O
were O
subdivided O
at O
random O
into O
3 O
different O
anaesthesia O
groups O
: O
1. O
halothane O
anesthesia O
, O
2. O
neuroleptanalgesia O
( O
NLA O
) O
and O
3. O
thoracic O
EA O
with O
bupivacaine O
( O
0.5 O
% O
) O
in O
combination O
with O
a O
light O
general O
anesthesia O
. O
[]

[ O
Clinical O
observation O
on O
acupuncture O
for O
treatment O
of O
male O
osteoporosis O
] O
. O
[]

These O
diameters O
were O
selected O
because O
they O
simulate O
the O
pressure-flow O
relationships O
of O
adult O
endotracheal O
tubes O
. O
[]

Patients O
were O
treated O
for O
as O
long O
as O
was O
tolerable O
. O
[]

PATIENTS O
A O
total O
of O
67 O
patients O
were O
enrolled O
who O
met O
defined O
criteria O
for O
acute O
lung O
injury/acute O
respiratory O
distress O
syndrome O
. O
[]

Recurrent B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
was O
seen O
significantly O
more O
often O
in O
patients O
receiving O
continuous O
heparin O
therapy O
. O
['Physiological-Clinical']

Students O
were O
assessed O
at O
the O
beginning O
and O
end O
of O
the O
academic O
year O
using O
the O
Differential O
Ability O
Scales O
. O
[]

Secondary O
measures O
included O
assessments O
of O
cocaine B-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
and O
psychiatric B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
At O
1 O
year O
, O
99 O
% O
of O
patients O
( O
89 O
of O
90 O
) O
had O
20/40 O
uncorrected O
vision O
or O
better O
. O
[]

Pretreatment O
leukocytosis O
and O
high O
clinical O
stage O
were O
independent O
adverse O
factors O
in O
a O
Cox O
model O
of O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
but O
the O
effect O
of O
cisplatin O
was O
not O
significant O
. O
['Mortality']

A O
double-blind O
study O
. O
[]

3.6 O
) O
, O
( O
26.2 O
? O
[]

In O
22 O
patients O
plasmapheresis O
in O
combination O
with O
continuous O
venovenous O
hemofiltration O
( O
CVVHF O
) O
was O
administered O
. O
[]

PATIENTS O
AND O
METHODS O
A O
total O
of O
67 O
eyes O
of O
35 O
Behcet O
's O
patients O
with O
chronic O
, O
but O
well-controlled O
uveitis O
, O
and O
CMO O
were O
randomised O
into O
a O
double-masked O
, O
crossover O
trial O
comparing O
the O
effect O
of O
acetazolamide O
vs O
placebo O
. O
[]

We O
conducted O
a O
randomized O
controlled O
trial O
among O
African-American O
patients O
attending O
a O
primary-care O
provider O
visit O
to O
compare O
efficacy O
of O
a O
computer-delivered O
tailored O
intervention O
to O
increase O
colorectal B-outcome ['Resource-use']
cancer I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CRC I-outcome ['Resource-use']
) I-outcome ['Resource-use']
screening I-outcome ['Resource-use']
( O
n O
= O
273 O
) O
with O
non-tailored O
print O
material-an O
American O
Cancer O
Society O
brochure O
on O
CRC O
screening O
( O
n O
= O
283 O
) O
. O
['Resource-use']

RESULTS O
At O
baseline O
, O
46.3 O
% O
of O
1455 O
participants O
screened O
were O
classified O
as O
depression B-outcome ['Life-Impact']
cases O
on O
the O
basis O
of O
their O
score O
on O
the O
Center O
for O
Epidemiological O
Studies O
Depression B-outcome ['Life-Impact']
Scale O
( O
> O
or O
=16 O
) O
or O
the O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Depression B-outcome ['Life-Impact']
Scale O
( O
> O
or O
=8 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
In O
a O
prospective O
, O
randomized O
trial O
, O
balloon O
angioplasty O
was O
compared O
with O
stent O
implantation O
for O
the O
treatment O
of O
chronic O
total O
occlusions O
. O
[]

A O
number O
of O
techniques O
have O
been O
tried O
to O
minimize O
propofol-induced O
pain O
, O
with O
variable O
results O
. O
[]

A O
comparison O
of O
sclerotherapy O
with O
staple O
transection O
of O
the O
esophagus O
for O
the O
emergency O
control O
of O
bleeding B-outcome ['Physiological-Clinical']
from O
esophageal O
varices O
. O
['Physiological-Clinical']

Four O
conditions O
, O
generated O
by O
the O
combinations O
of O
two O
kinds O
of O
stimulus O
delivered O
to O
the O
subjects O
( O
aversive O
or O
nonaversive O
) O
and O
two O
outcomes O
of O
the O
task O
( O
failure O
or O
success O
) O
, O
were O
investigated O
. O
[]

The O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
pass I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
endotracheal I-outcome ['Life-Impact']
tube I-outcome ['Life-Impact']
through I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
nasal I-outcome ['Life-Impact']
cavity I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
nasal I-outcome ['Life-Impact']
passage I-outcome ['Life-Impact']
time B-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
success B-outcome ['Life-Impact']
rate I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
nasal I-outcome ['Life-Impact']
passage I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
nasotracheal I-outcome ['Life-Impact']
tube I-outcome ['Life-Impact']
, O
and O
the O
incidence O
and O
severity O
of O
nasal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
were O
compared O
. O
['Life-Impact', 'Physiological-Clinical']

Measurement O
of O
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic O
acid O
, O
( O
PGE-M O
) O
, O
the O
major O
urinary O
metabolite O
of O
prostaglandin O
E1 O
and O
E2 O
in O
man O
provides O
a O
useful O
indicator O
to O
monitor O
prostaglandin O
biosynthesis O
. O
[]

After O
taking O
take O
135 O
mg O
of O
isoflavones O
daily O
for O
1 O
week O
, O
the O
women O
in O
the O
study O
group O
were O
assigned O
to O
the O
equol-producing O
( O
EP O
) O
or O
the O
non-EP O
group O
according O
to O
the O
presence O
or O
absence O
of O
equol O
in O
their O
urine O
. O
[]

BACKGROUND O
Despite O
concerns O
about O
safety O
in O
children O
, O
fluoroquinolone O
antibiotics O
have O
become O
the O
treatment O
of O
choice O
in O
patients O
with O
multidrug-resistant O
typhoid O
fever O
in O
Vietnam O
. O
[]

Title: O
Randomized O
Controlled O
Trial O
of O
Simulation O
vs. O
Standard O
Training O
for O
Teaching O
Medical O
Students O
High-quality O
Cardiopulmonary O
Resuscitation. O
[]

Effect O
of O
intravenous O
fructose-1,6-diphosphate O
on O
myocardial B-outcome ['Physiological-Clinical']
contractility I-outcome ['Physiological-Clinical']
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
['Physiological-Clinical']

This O
study O
was O
an O
eight-week, O
double-blind, O
randomized, O
parallel-arm, O
and O
placebo-controlled O
trial. O
[]

CONCLUSIONS O
There O
is O
insufficient O
evidence O
to O
indicate O
a O
difference O
in O
language B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
between O
children O
using O
NLFC O
and O
those O
using O
conventional O
amplification O
. O
['Life-Impact']

Hypotension B-outcome ['Physiological-Clinical']
immediately O
after O
administration O
of O
metoclopramide O
was O
observed O
in O
two O
patients O
and O
four O
patients O
given O
ondansetron O
developed O
profound O
systolic O
hypotension O
at O
induction O
of O
anesthesia O
. O
['Physiological-Clinical']

The O
trained O
individuals O
improved O
significantly O
on O
the O
affect B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
, O
but O
not O
on O
any O
other O
measure O
. O
['Life-Impact']

The O
EFS O
for O
those O
who O
achieved O
an O
early O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
than O
for O
those O
who O
did O
not O
. O
['Physiological-Clinical']

There O
were O
78 O
patients O
who O
either O
failed O
to O
achieve O
a O
CR B-outcome ['Physiological-Clinical']
or O
achieved O
a O
CR B-outcome ['Physiological-Clinical']
and O
later O
relapsed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
barbed O
suture O
represents O
an O
innovative O
option O
for O
wound O
closure O
. O
[]

Effectiveness O
of O
education O
for O
gastric O
cancer O
patients O
: O
a O
controlled O
prospective O
trial O
comparing O
interactive O
vs. O
lecture-based O
programs O
. O
[]

A O
single O
experienced O
operator O
, O
blinded O
to O
the O
study O
drug O
, O
subjectively O
determined O
the O
presence O
of O
spasm B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Although O
amantadine O
has O
several O
mechanisms O
of O
action O
, O
the O
NMDA-receptor O
antagonism O
seems O
to O
be O
the O
most O
relevant O
effect O
on O
cortical B-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
randomized O
double-blind O
casein-controlled O
trial O
. O
[]

The O
EC50 B-outcome ['Physiological-Clinical']
in O
the O
2.5 O
and O
5.0 O
microg/kg O
clonidine O
groups O
was O
significantly O
smaller O
than O
that O
in O
the O
Control O
group O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Patients O
of O
the O
IVF+ O
group O
had O
a O
higher O
total O
motile B-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
after O
preparation O
than O
did O
those O
of O
the O
IVF- O
group O
. O
['Physiological-Clinical']

Effect O
of O
the O
motilin O
agonist O
KC O
11458 O
on O
gastric O
emptying O
in O
diabetic O
gastroparesis O
. O
[]

Especially O
for O
patients O
with O
pulmonary O
tuberculosis O
or O
aged O
patients O
with O
primary O
bladder O
tumors O
, O
mitoxantrone O
and O
doxorubicin O
may O
be O
the O
tolerable O
and O
effective O
intravesical O
agents O
. O
[]

RESULTS O
The O
difference O
in O
mean O
( O
95 O
% O
CI O
) O
change O
scores O
( O
final O
minus O
baseline O
) O
between O
treatments O
was O
13.3 O
mm O
( O
-8.6 O
to O
35.2 O
) O
for O
pain O
( O
total O
scale O
500 O
mm O
) O
, O
71.0 O
mm O
( O
-2.4 O
to O
144.5 O
) O
for O
physical O
function O
( O
total O
scale O
1700 O
mm O
) O
, O
and O
4.3 O
mm O
( O
-1.2 O
to O
9.8 O
) O
for O
PGA O
( O
total O
scale O
100 O
mm O
) O
. O
[]

Patients O
were O
randomized O
to O
receive O
G-CSF O
5 O
micro O
g/kg/day O
( O
n=38 O
, O
group O
A O
) O
or O
10 O
micro O
g/kg/day O
( O
n=39 O
, O
group O
B O
) O
from O
day O
+1 O
to O
day O
+30 O
. O
[]

In O
a O
prospective O
double-blind O
clinical O
study O
, O
single-dose O
lumbar O
epidural O
blockade O
was O
instituted O
in O
60 O
healthy O
patients O
undergoing O
lower O
abdominal O
surgery O
. O
[]

However O
, O
there O
is O
no O
report O
of O
a O
prospective O
randomized O
comparison O
of O
different O
techniques O
. O
[]

Group O
3 O
showed O
significant O
hypersensitivity B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
at O
one O
week O
onward O
. O
['Physiological-Clinical']

The O
number O
of O
patients O
with O
both O
gastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
less O
than O
2.5 O
and O
gastric B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
greater O
than O
25 O
ml O
was O
significantly O
higher O
in O
Group O
100 O
compared O
to O
Group O
50 O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
hypothesized O
that O
insulin O
resistance-associated O
hyperinsulinemia O
could O
preferentially O
drive O
endothelin-mediated B-outcome ['Physiological-Clinical']
vasoconstriction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Attitude O
certainty O
has O
been O
the O
subject O
of O
considerable O
attention O
in O
the O
attitudes O
and O
persuasion O
literature O
. O
[]

No O
significant O
variations O
in O
any O
of O
the O
lipid O
parameters O
monitored O
were O
observed O
in O
the O
placebo O
group O
. O
[]

DATA O
COLLECTION/EXTRACTION O
METHODS O
Youth O
surveys O
were O
self-administered O
during O
school O
hours O
. O
[]

Baseline O
characteristics O
were O
well O
balanced O
between O
the O
two O
treatment O
arms O
. O
[]

Multivariate O
analysis O
showed O
local B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
increased O
with O
age O
( O
P=0.0003 O
) O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Between O
January O
1995 O
and O
April O
1996 O
, O
414 O
patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
were O
randomized O
to O
received O
either O
a O
control O
arm O
of O
high-dose O
cisplatin O
( O
100 O
mg/m O
( O
2 O
) O
) O
or O
a O
combination O
of O
paclitaxel O
( O
175 O
mg/m O
( O
2 O
) O
, O
3-hour O
infusion O
) O
and O
cisplatin O
( O
80 O
mg/m O
( O
2 O
) O
) O
every O
21 O
days O
. O
[]

or O
placebo O
for O
two O
weeks O
in O
the O
first O
period O
, O
followed O
by O
one O
week O
washout O
period O
. O
[]

Moreover O
, O
pruritus B-outcome ['Physiological-Clinical']
was O
not O
observed O
after O
discontinuation O
of O
treatment O
from O
day O
15 O
and O
beyond O
in O
the O
pimecrolimus O
group O
, O
whereas O
it O
was O
reported O
in O
most O
patients O
of O
the O
betamethasone O
group O
. O
['Physiological-Clinical']

AIMS O
The O
aim O
was O
to O
explore O
the O
role O
of O
CYP2C19 O
polymorphism O
in O
short-term O
rabeprazole-based O
triple O
therapy O
against O
Helicobacter O
pylori O
infection O
. O
[]

Self-reports O
were O
also O
used O
to O
determine O
adherence O
. O
[]

Multiple O
regression O
analysis O
of O
EPA+DHA O
intake O
and O
RBC O
EPA O
+ O
DHA O
concentration O
indicated O
positive O
and O
significant O
correlations O
for O
oily O
fish O
( O
beta O
= O
0.44 O
, O
95 O
% O
CI O
0.16 O
, O
0.72 O
, O
P O
= O
0.0027 O
) O
, O
total O
fish O
( O
beta O
= O
0.42 O
, O
95 O
% O
CI O
0.19 O
, O
0.64 O
, O
P O
= O
0.0005 O
) O
and O
marine O
food O
products O
( O
beta O
= O
0.42 O
, O
95 O
% O
CI O
0.20 O
, O
0.64 O
, O
P O
= O
0.0003 O
) O
. O
[]

Hitting O
the O
target O
: O
relatively O
easy O
, O
yet O
absolutely O
difficult O
. O
[]

Double O
blind O
cross O
over O
study O
was O
performed O
comparing O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
measuring O
distance O
walked O
on O
a O
6-min B-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
test O
and O
time B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
climb I-outcome ['Life-Impact']
two I-outcome ['Life-Impact']
flights I-outcome ['Life-Impact']
of O
stairs B-outcome ['Life-Impact']
; O
and O
symptoms B-outcome ['Physiological-Clinical']
, O
evaluated O
by O
an O
activity O
of O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
questionnaire O
, O
in O
atrioventricular O
synchronous O
and O
ventricular O
pacing O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Statistical O
significance O
was O
set O
at O
P O
</= O
0.05. O
[]

Serum O
selenium O
concentration O
and O
antioxidant O
activity O
in O
cervical O
cancer O
patients O
before O
and O
after O
treatment O
. O
[]

These O
changes O
in O
interaction O
were O
clinically O
relevant O
. O
[]

Reduction O
in O
the O
number O
of O
lesions B-outcome ['Physiological-Clinical']
was O
similar O
with O
both O
azithromycin O
and O
doxycycline O
treatments O
( O
27 O
+/- O
12 O
and O
30 O
+/- O
12 O
, O
respectively O
) O
in O
both O
groups O
. O
['Physiological-Clinical']

Thus O
, O
greater O
antiarrhythmic B-outcome ['Physiological-Clinical']
efficacy O
can O
be O
achieved O
by O
the O
invasive O
approach O
to O
drug O
selection O
without O
increasing O
total O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
Consecutively O
listed O
candidates O
for O
elective O
bypass O
were O
randomly O
assigned O
to O
either O
off-pump O
or O
on-pump O
techniques O
( O
n O
= O
107 O
) O
. O
[]

Randomised O
participants O
are O
allocated O
to O
receive O
a O
four O
or O
single O
intradermal O
needle O
SWI O
technique O
. O
[]

RESULTS O
Completion O
of O
the O
program O
increased O
blood B-outcome ['Life-Impact']
draw I-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
rates O
from O
85.4 O
% O
to O
96.6 O
% O
( O
odds O
ratio O
= O
4.80 O
; O
95 O
% O
confidence O
interval O
= O
1.12 O
, O
20.59 O
; O
p O
= O
.03 O
) O
. O
['Life-Impact']

CONCLUSIONS O
High O
doses O
of O
beta-endorphin O
induce O
hypotensive O
and O
beneficial O
hormonal O
effects O
in O
humans O
, O
which O
are O
enhanced O
in O
essential O
hypertension O
and O
are O
mediated O
by O
opioid O
receptors O
. O
[]

The O
study O
was O
conducted O
in O
pharmacies O
operated O
by O
the O
Southern O
California O
region O
Kaiser O
Permanente O
Medical O
Care O
Program O
. O
[]

CONCLUSIONS O
COMPASS O
is O
effective O
and O
results O
in O
improved O
educational O
outcomes O
for O
young O
children O
with O
autism O
. O
[]

Epanolol O
, O
a O
selective O
beta O
1-receptor O
blocker O
with O
intrinsic O
sympathomimetic O
activity O
, O
induced O
a O
fall O
in O
intraarterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
8 O
% O
at O
rest O
sitting O
and O
11 O
% O
during O
100 O
W O
bicycle O
exercise O
after O
the O
first O
dose O
of O
200 O
mg O
in O
12 O
patients O
with O
essential O
hypertension O
. O
['Physiological-Clinical']

The O
2-year O
cumulative O
rate O
of O
brain B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
as O
an O
isolated O
first O
site O
of O
relapse B-outcome ['Life-Impact']
was O
45 O
% O
in O
the O
control O
group O
and O
19 O
% O
in O
the O
treatment O
group O
( O
P O
< O
10 O
( O
-6 O
) O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Ciprofloxacin O
and O
rifampicin O
versus O
doxycycline O
and O
rifampicin O
in O
the O
treatment O
of O
brucellosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
, O
parallel O
groups O
design O
with O
fixed O
dose O
was O
used O
, O
with O
random O
assignment O
to O
naltrexone O
or O
placebo O
. O
[]

Patients O
who O
received O
COX-2 O
demonstrated O
improved O
bowel B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
reflected O
by O
more O
bowel O
movements O
on O
postoperative O
day O
2 O
and O
postoperative O
day O
3 O
. O
['Physiological-Clinical']

Two O
groups O
of O
five O
preterm O
infants O
were O
fed O
a O
diet O
containing O
12.5 O
mg/L O
of O
zinc O
and O
either O
0.9 O
mg/L O
or O
2.1 O
mg/L O
of O
copper O
. O
[]

Results O
presented O
here O
suggest O
that O
individuals O
with O
ASD O
achieve O
better O
vocational B-outcome ['Life-Impact']
outcomes O
if O
they O
do O
not O
participate O
in O
sheltered O
workshops O
prior O
to O
enrolling O
in O
supported O
employment O
. O
['Life-Impact']

Also O
, O
EPO O
tended O
to O
enhance O
the O
CPB-induced O
increase O
in O
[]

These O
results O
demonstrate O
that O
guar O
exerts O
its O
cholesterol-lowering O
effect O
in O
addition O
to O
that O
of O
bezafibrate O
. O
[]

RESULTS O
Patients O
became O
significantly O
more O
depressed B-outcome ['Life-Impact']
over O
time O
. O
['Life-Impact']

Nebulized O
bitolterol O
solution O
and O
isoproterenol O
solution O
were O
compared O
when O
used O
on O
a O
regular O
basis O
, O
2.5 O
mg O
three O
times O
a O
day O
for O
1 O
month O
by O
patients O
with O
chronic O
asthma O
. O
[]

Multiple O
raters O
and O
rating O
scales O
were O
employed O
in O
a O
variety O
of O
conditions O
. O
[]

We O
tested O
the O
hypothesis O
that O
gum O
elastic-bougie-guided O
insertion O
of O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
is O
more O
frequently O
successful O
than O
introducer O
tool O
guided O
insertion O
after O
failed O
digital O
insertion O
. O
[]

Although O
lathosterol/TC O
increased O
, O
campesterol/TC O
decreased O
more O
in O
ezetimibe-plus-statin O
. O
[]

HR B-outcome ['Physiological-Clinical']
increased O
. O
['Physiological-Clinical']

The O
median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
time O
was O
approximately O
20 O
months O
and O
the O
median O
overall O
survival O
( O
OS O
) O
time O
was O
approximately O
49 O
months O
. O
['Mortality']

Specifically O
, O
D-dimer B-outcome ['Physiological-Clinical']
levels O
at O
all O
four O
time O
points O
correlated O
with O
patients O
' O
long-term O
outcomes O
. O
['Physiological-Clinical']

The O
best O
overall O
response O
( O
CCR O
+ O
PR O
) O
rate O
was O
71 O
% O
for O
PUVA O
alone O
and O
77 O
% O
for O
the O
combination O
arm O
( O
P O
= O
0?57 O
) O
. O
[]

The O
trial O
was O
complete O
with O
28 O
patients O
randomized O
. O
[]

BACKGROUND O
Combinations O
of O
infero-temporal O
and O
either O
supero-nasal O
( O
'inferior-superior O
' O
) O
or O
medial O
percaruncular O
( O
'inferior-medial O
' O
) O
injections O
are O
popular O
double-injection O
techniques O
for O
establishing O
peribulbar O
block O
analgesia O
. O
[]

The O
current O
study O
assesses O
whether O
COMET O
is O
also O
an O
effective O
intervention O
for O
patients O
with O
depressive O
disorders O
. O
[]

For O
normal O
breathing, O
fit B-outcome ['Physiological-Clinical']
factors I-outcome ['Physiological-Clinical']
before O
and O
after O
training O
were O
121 O
(10-185) O
vs O
192 O
(161-200) O
for O
cup-type, O
200 O
(39-200) O
vs O
200 O
(200-200) O
for O
fold-type, O
and O
85 O
(18-157) O
vs O
173 O
(117-200) O
for O
valve-type. O
[['Physiological-Clinical']]

OBJECTIVE O
To O
compare O
the O
fracture B-outcome ['Physiological-Clinical']
resistances I-outcome ['Physiological-Clinical']
of O
pulpless O
teeth O
restored O
with O
FRC O
( O
Fiber O
Reinforced O
Composite O
) O
posts O
and O
three O
kinds O
of O
resin O
core O
material O
. O
['Physiological-Clinical']

Performance O
tests O
were O
performed O
without O
splint O
. O
[]

The O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
Krug O
et O
al. O
, O
1993 O
) O
was O
used O
, O
adapted O
to O
the O
Portuguese O
language O
by O
Marteleto O
( O
2003 O
) O
. O
['Life-Impact']

We O
aimed O
to O
verify O
whether O
monitoring O
of O
serum B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TMs I-outcome ['Physiological-Clinical']
) O
, O
namely O
carcinoembryonic B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
CA19-9 B-outcome ['Physiological-Clinical']
, O
DUPAN-2 B-outcome ['Physiological-Clinical']
, O
SPan-1 B-outcome ['Physiological-Clinical']
, O
can O
facilitate O
earlier O
confirmation O
of O
treatment O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
persisted O
for O
2 O
years O
, O
with O
a O
mean O
increase O
of O
1.7 O
percentage O
points O
( O
95 O
% O
CI O
, O
0.7 O
to O
2.7 O
) O
versus O
a O
mean O
decrease O
of O
1.2 O
percentage O
points O
( O
95 O
% O
CI O
, O
-1.8 O
to O
-0.5 O
; O
P O
< O
.001 O
) O
in O
the O
hormone O
and O
placebo O
groups O
, O
respectively O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
evaluate O
whether O
and O
to O
what O
extent O
different O
intraoperative O
valve O
orientation O
influence O
feasibility B-outcome ['Life-Impact']
and O
accuracy B-outcome ['Physiological-Clinical']
of O
postoperative O
fluoroscopic O
evaluation O
of O
bileaflet O
prostheses O
. O
['Life-Impact', 'Physiological-Clinical']

There O
was O
a O
paucity O
of O
bacterial O
species O
at O
baseline O
, O
although O
larger O
infants O
had O
more O
bacterial B-outcome ['Physiological-Clinical']
species I-outcome ['Physiological-Clinical']
( O
1.59 O
+/- O
0.13 O
( O
SEM O
) O
vs O
1.11 O
+/- O
0.12 O
; O
P O
< O
0.03 O
) O
and O
higher O
mean O
log B-outcome ['Physiological-Clinical']
colony I-outcome ['Physiological-Clinical']
forming I-outcome ['Physiological-Clinical']
units I-outcome ['Physiological-Clinical']
( O
CFU B-outcome ['Physiological-Clinical']
) O
( O
8.79 O
+/- O
0.43 O
vs O
7.22 O
+/- O
0.63 O
; O
P O
< O
0.05 O
) O
compared O
with O
infants O
weighing O
less O
than O
1500 O
g O
LGG O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
studied O
the O
effect O
of O
warfarin O
plus O
aspirin O
therapy O
( O
WASA O
) O
versus O
aspirin O
therapy O
alone O
( O
ASA O
) O
on O
patient B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
morbidity B-outcome ['Physiological-Clinical']
and O
bypass B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
rates O
in O
a O
randomized O
clinical O
trial O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Symptoms O
of O
depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
among O
the O
partners O
decreased O
substantially O
over O
the O
course O
of O
the O
investigation O
. O
['Life-Impact', 'Life-Impact']

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Patients O
without O
evidence O
of O
mediastinal O
involvement O
did O
not O
have O
mediastinal O
radiotherapy O
. O
[]

Title: O
Effectiveness O
of O
incremental O
vs O
maximum O
bite O
advancement O
during O
Herbst O
appliance O
therapy O
in O
late O
adolescent O
and O
young O
adult O
patients. O
[]

AIMS O
To O
evaluate O
whether O
ketorolac O
eyedrops O
and O
ranibizumab O
intravitreal O
injections O
would O
provide O
additional O
benefit O
over O
ranibizumab O
alone O
in O
the O
treatment O
of O
choroidal O
neovascularisation O
( O
CNV O
) O
. O
[]

RESULTS O
Five O
hundred O
twenty-nine O
patients O
were O
randomised O
( O
58 O
% O
male O
) O
. O
[]

Children O
with O
phenylketonuria O
(PKU) O
follow O
a O
protein O
restricted O
diet O
with O
negligible O
amounts O
of O
docosahexaenoic O
acid O
(DHA). O
[]

Most O
cases O
initially O
experienced O
bleeding B-outcome ['Physiological-Clinical']
in O
the O
first O
3 O
months O
but O
such O
initiation B-outcome ['Physiological-Clinical']
was O
a O
bit O
later O
in O
group O
C. O
Endometrium B-outcome ['Physiological-Clinical']
, O
as O
detected O
by O
B-mode O
ultrasound O
, O
increased O
approximately O
1 O
mm O
in O
HT O
groups O
, O
while O
it O
was O
a O
bit O
thicker O
in O
group O
C. O
Long O
periods O
in O
reproductive O
age O
and O
short O
time O
since O
menopause O
were O
high O
risk O
factors O
for O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Body O
posture O
is O
directly O
related O
to O
PA O
and O
the O
lack O
of O
activity O
affects O
disturbances O
within O
posturometric O
parameters. O
[]

Earlier O
diagnosis O
and O
appropriate O
treatment O
of O
cardiac O
infarction O
may O
improve O
survival O
of O
hip O
fracture O
patients O
. O
[]

The O
remaining O
66 O
patients O
were O
followed O
up O
for O
3-24 O
months O
after O
randomization O
. O
[]

It O
is O
our O
opinion O
that O
, O
in O
the O
future O
, O
laser O
conization O
will O
replace O
cold O
knife O
conization O
. O
[]

Among O
children O
whose O
medications O
were O
stepped O
up O
at O
any O
time O
during O
the O
12-month O
study O
period O
, O
those O
in O
the O
intervention O
group O
experienced O
22.1 O
% O
fewer O
symptom O
days O
and O
37.9 O
% O
fewer O
school O
days O
missed O
. O
[]

Primary O
prevention O
in O
this O
group O
can O
potentially O
reduce O
the O
incidence O
of O
skin O
cancer O
, O
and O
also O
potentiates O
the O
spontaneous O
remission O
of O
existing O
solar O
keratoses O
. O
[]

Effects O
of O
a O
combination O
of O
evening O
primrose O
oil O
( O
gamma O
linolenic O
acid O
) O
and O
fish O
oil O
( O
eicosapentaenoic O
+ O
docahexaenoic O
acid O
) O
versus O
magnesium O
, O
and O
versus O
placebo O
in O
preventing O
pre-eclampsia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Spring-born O
Hereford O
x O
Angus O
heifers O
( O
n O
= O
206 O
) O
were O
used O
to O
determine O
effects O
of O
energy O
supplementation O
programs O
and O
amount O
of O
starch O
in O
the O
diet O
on O
incidence O
of O
puberty B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
pilot O
study O
of O
eyes O
with O
new-onset O
CNV O
. O
[]

RESULTS O
Age O
, O
obesity O
, O
and O
presence O
of O
symptoms O
accompanying O
AF O
were O
inversely O
associated O
with O
baseline O
exercise O
capacity O
, O
but O
these O
factors O
accounted O
for O
only O
10 O
% O
of O
the O
variance O
in O
exercise O
capacity O
. O
[]

CONCLUSIONS O
Long-term O
, O
high-dose O
DHA O
supplementation O
to O
patients O
with O
XLRP O
was O
associated O
with O
limited O
safety O
risks O
in O
this O
4-year O
trial O
. O
[]

Patients O
with O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
had O
a O
statistically O
significantly O
lower O
pregnancy B-outcome ['Physiological-Clinical']
rate O
( O
21.4 O
% O
[ O
9/42 O
] O
vs. O
0 O
[ O
0/18 O
] O
) O
relative O
to O
their O
unaffected O
counterparts O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fifty-three O
rural O
breast O
cancer O
survivors O
were O
randomized O
to O
either O
an O
experimental O
( O
n O
= O
27 O
) O
or O
a O
wait-control O
arm O
( O
n O
= O
26 O
) O
. O
[]

Experimental O
studies O
suggest O
that O
recombinant O
human O
erythropoietin O
( O
EPO O
) O
independent O
of O
its O
erythropoietic O
effect O
may O
be O
used O
clinically O
as O
an O
anti-inflammatory O
drug O
. O
[]

Penetration O
of O
ofloxacin O
and O
ciprofloxacin O
into O
the O
aqueous O
humor O
of O
eyes O
with O
functioning O
filtering O
blebs O
: O
a O
randomized O
trial O
. O
[]

The O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
training I-outcome ['Resource-use']
was O
the O
equivalent O
of O
about O
one O
hour O
of O
nursing O
aide O
time O
per O
patient O
day O
. O
['Resource-use']

Both O
symptom B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
are O
important O
clinical O
treatment O
targets O
. O
['Physiological-Clinical', 'Life-Impact']

Because O
the O
former O
demands O
more O
resources O
, O
we O
advocate O
that O
talc O
slurry O
should O
be O
considered O
as O
the O
procedure O
of O
choice O
in O
the O
treatment O
of O
symptomatic O
malignant O
pleural O
effusion O
in O
patients O
who O
do O
not O
have O
trapped O
lungs O
. O
[]

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

Effect O
of O
diltiazem O
on O
symptomatic O
and O
asymptomatic O
episodes O
of O
ST B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
occurring O
during O
daily O
life O
and O
during O
exercise O
. O
['Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
study O
. O
[]

The O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rates O
were O
32.4 O
% O
and O
28.2 O
% O
respectively O
( O
P O
= O
0.80 O
) O
; O
the O
isolated O
nodal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
rates O
were O
3.0 O
% O
and O
2.6 O
% O
respectively O
( O
P O
= O
0.91 O
) O
; O
all O
INF O
sites O
were O
in O
the O
ipsilateral O
supraclavicular O
fossa O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
in O
safety O
or O
tolerability B-outcome ['Life-Impact']
between O
children O
randomized O
to O
NFV O
+ O
RTV O
+ O
ddI O
versus O
NFV O
+ O
NVP O
+ O
d4T O
were O
identified O
. O
['Life-Impact']

Journal O
ID: O
101265111 O
[]

Journal O
ID: O
100968562 O
[]

For O
the O
positive O
feedback O
condition O
, O
increases O
in O
the O
index O
caused O
an O
increase O
in O
the O
array O
size O
( O
AS O
) O
while O
decreases O
caused O
a O
decrease O
in O
the O
array O
size O
. O
[]

Single-session O
behavioral O
treatment O
of O
earthquake-related O
posttraumatic O
stress O
disorder O
: O
a O
randomized O
waiting O
list O
controlled O
trial O
. O
[]

Subjects O
with O
gastric B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
or O
adverse O
reactions O
had O
lower O
PGE2 O
levels O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
randomised O
non-inferiority O
trial O
carried O
out O
in O
a O
school-based O
clinic O
in O
New O
Zealand O
. O
[]

Comparison O
of O
self-administered O
vaginal O
misoprostol O
versus O
placebo O
for O
cervical O
ripening O
prior O
to O
operative O
hysteroscopy O
using O
a O
sequential O
trial O
design O
. O
[]

At O
day O
45 O
, O
median O
decrease O
in O
retinal O
thickness O
was O
-23.7 O
?m O
. O
[]

Succinate O
sumatriptan O
evaluation O
by O
Doppler O
echocardiography O
in O
patients O
with O
migraine O
. O
[]

BACKGROUND O
Routine O
oral O
calcium O
and O
vitamin O
D O
supplementation O
may O
prevent O
hypocalcemic O
crisis O
, O
but O
its O
efficacy O
has O
not O
been O
studied O
in O
patients O
undergoing O
thyroidectomy O
plus O
central O
neck O
dissection O
( O
CND O
) O
. O
[]

Across O
time O
, O
children O
moved O
across O
diagnostic O
boundaries O
both O
in O
terms O
of O
clinical O
diagnosis O
and O
in O
terms O
of O
instrument O
diagnosis O
on O
the O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Interview-Revised O
( O
ADI-R O
) O
. O
['Life-Impact']

The O
majority O
( O
51 O
% O
) O
of O
these O
participants O
reported O
only O
mild B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

CONCLUSIONS O
The O
interventions O
conducted O
by O
a O
robot O
and O
a O
human O
trainer O
were O
both O
effective O
in O
promoting O
self-initiated O
questions O
in O
children O
with O
ASD O
. O
[]

BACKGROUND O
There O
is O
increasing O
evidence O
that O
dietary O
factors O
may O
play O
a O
role O
in O
the O
production O
, O
metabolism O
, O
and O
bioavailability O
of O
sex O
hormones O
and O
their O
impact O
on O
target O
tissues O
. O
[]

METHODS O
Between O
1994 O
and O
2004 O
, O
we O
retrospectively O
reviewed O
122 O
patients O
with O
rectal O
cancer O
whose O
serum B-outcome ['Physiological-Clinical']
CEA I-outcome ['Physiological-Clinical']
levels O
were O
measured O
on O
the O
preoperative O
day O
and O
postoperative O
days O
7 O
and O
30 O
. O
['Physiological-Clinical']

Incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
comparable O
in O
all O
four O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
the O
midazolam+fentanyl O
groups O
, O
better O
patient B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
surgeon I-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
were O
obtained O
( O
P O
< O
.005 O
) O
, O
verbal O
pain B-outcome ['Physiological-Clinical']
scale O
scores O
were O
significantly O
lower O
( O
P O
< O
.001 O
) O
, O
and O
patients O
needed O
less O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

The O
corresponding O
rates O
between O
weeks O
44 O
and O
80 O
were O
0.10+/-0.25 O
and O
0.03+/-0.28 O
(difference, O
0.07; O
two-sided O
90% O
CI, O
0.03 O
to O
0.10); O
the O
difference O
in O
the O
rate O
of O
progression B-outcome ['Physiological-Clinical']
between O
weeks O
44 O
and O
80 O
did O
not O
meet O
the O
criterion O
for O
noninferiority O
of O
early O
receipt O
of O
levodopa O
to O
delayed O
receipt. O
[['Physiological-Clinical']]

The O
G1 O
presented O
higher O
values O
of O
CRP B-outcome ['Physiological-Clinical']
in O
relation O
to O
the O
G2 O
significantly O
(p O
? O
[['Physiological-Clinical']]

The O
mean O
stretching B-outcome ['Physiological-Clinical']
frequency O
decreased O
from O
3.7 O
to O
1.6 O
times O
a O
week O
in O
both O
groups O
. O
['Physiological-Clinical']

RESULTS O
Risk O
factors O
retained O
in O
the O
model O
included O
poor B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
absolute B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
< O
or O
=2.0 O
x O
10 O
( O
9 O
) O
cells/L O
in O
the O
previous O
cycle O
, O
the O
first O
cycle O
of O
chemotherapy B-outcome ['Resource-use']
, O
DOX O
versus O
PLD O
and O
advanced O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
antidepressant O
effect O
of O
maprotiline O
was O
reflected O
in O
the O
GDS O
. O
[]

A O
57 O
% O
response O
rate O
was O
seen O
in O
the O
combined-modality O
arm O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
43 O
% O
to O
69 O
% O
) O
, O
and O
a O
22 O
% O
response O
rate O
was O
seen O
in O
the O
teniposide-alone O
arm O
( O
95 O
% O
CI O
, O
12 O
% O
to O
34 O
% O
) O
( O
P O
< O
.001 O
) O
. O
[]

Key O
exclusion O
criteria O
included O
diagnosis O
of O
neuromyelitis O
optica O
spectrum O
disorder. O
[]

The O
3 O
year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
77.7 O
% O
and O
79.2 O
% O
for O
cisplatin O
and O
carboplatin O
groups O
, O
respectively O
( O
p=0.9884 O
) O
( O
HR O
0.83 O
, O
95 O
% O
CI O
: O
0.63-1.010 O
) O
. O
['Mortality']

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
and O
homocysteine B-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
metabolites I-outcome ['Physiological-Clinical']
were O
analyzed O
at O
baseline O
and O
after O
12 O
wk O
of O
supplementation O
with O
folic O
acid O
at O
a O
dose O
of O
400 O
microg/d O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Rivaroxaban O
, O
an O
oral O
factor O
Xa O
inhibitor O
, O
may O
provide O
more O
consistent O
and O
predictable O
anticoagulation O
than O
warfarin O
. O
[]

RESULTS: O
Significant O
time O
x O
group O
interactions O
and O
moderate O
to O
high O
effect O
sizes O
were O
found O
for O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
physical B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
bodily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
general B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
, O
vitality B-outcome ['Physiological-Clinical']
, O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Life-Impact']
image I-outcome ['Life-Impact']
, O
and O
upset B-outcome ['Life-Impact']
by O
hair O
loss, O
favoring O
the O
exercise O
group. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

Those O
who O
received O
GLY O
received O
standard O
TPN O
, O
isocaloric O
and O
isonitrogenous O
. O
[]

The O
effects O
of O
candesartan O
on O
diabetes B-outcome ['Physiological-Clinical']
glomerulopathy I-outcome ['Physiological-Clinical']
: O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

The O
difference O
in O
infectious B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
between O
groups O
1 O
and O
3 O
was O
statistically O
highly O
significant O
( O
p O
< O
0.01 O
) O
and O
between O
groups O
2 O
and O
3 O
it O
was O
significant O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

In O
addition O
, O
there O
was O
an O
inverse O
association O
between O
the O
grade O
of O
esthesioneuroblastomas B-outcome ['Physiological-Clinical']
and O
hASH1 O
mRNA O
levels O
. O
['Physiological-Clinical']

The O
primary O
aim O
of O
this O
study O
is O
to O
assess O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
plus O
standard O
wound O
care O
compared O
with O
standard O
wound O
care O
alone O
in O
preventing O
the O
need O
for O
major B-outcome ['Resource-use']
amputation I-outcome ['Resource-use']
in O
patients O
with O
diabetes O
mellitus O
and O
chronic O
ulcers O
of O
the O
lower O
limb O
. O
['Resource-use']

Serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
during O
the O
rhG-CSF O
therapy O
greatly O
exceeded O
endogenous B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
and O
were O
mainly O
due O
to O
the O
presence O
of O
exogenous O
rhG-CSF O
rather O
than O
increased O
levels O
of O
endogenous O
G-CSF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Four O
hundred O
forty-two O
patients O
had O
intermediate-grade O
ML O
, O
221 O
highgrade O
ML O
, O
and O
74 O
unclassified O
ML O
. O
[]

Group O
C O
meningococcal B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
bactericidal B-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
were O
higher O
in O
the O
MenC O
group O
than O
the O
MenPS O
group O
at O
1 O
month O
( O
22.8 O
U/ml O
vs O
4.0 O
U/ml O
, O
p O
< O
0.001 O
, O
and O
87 O
vs O
20 O
, O
p O
< O
0.001 O
, O
respectively O
) O
and O
12 O
months O
( O
6.1 O
U/ml O
vs O
3.0 O
U/ml O
, O
p O
< O
0.001 O
, O
and O
81.3 O
vs O
20.2 O
, O
p O
< O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Dexmedetomidine O
use O
allows O
keeping O
optimal O
type O
of O
haemodynamics O
and O
vegetative O
nervous O
system O
parameters O
on O
first O
day O
of O
postoperative O
period O
. O
[]

Twenty O
four-hour O
urine O
samples O
were O
collected O
for O
6-beta-hydroxycortisol O
measurements O
, O
before O
and O
after O
14 O
days O
of O
ticlopidine O
. O
[]

CONCLUSION O
At O
12 O
months O
, O
exemestane O
was O
associated O
with O
fewer O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
and O
less O
vaginal B-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
than O
tamoxifen O
, O
but O
with O
more O
vaginal B-outcome ['Physiological-Clinical']
dryness I-outcome ['Physiological-Clinical']
, O
bone/muscle B-outcome ['Physiological-Clinical']
aches I-outcome ['Physiological-Clinical']
, O
and O
difficulty B-outcome ['Physiological-Clinical']
sleeping I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effect O
sizes B-outcome ['Physiological-Clinical']
varied O
twofold O
by O
symptom O
category O
, O
largest O
for O
self-injury O
( O
2.11 O
) O
and O
tantrums O
( O
1.95 O
) O
. O
['Physiological-Clinical']

The O
anti-thermal O
hyperalgesia O
and O
anti-mechanical O
allodynia O
may O
be O
partly O
attributable O
to O
the O
decreased O
expression O
of O
HMGB1 O
and O
inhibition O
of O
HMGB1-RAGE O
pathway O
. O
[]

TRIAL O
REGISTRATION O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
ACTRN12610000087055 O
. O
[]

The O
goal O
of O
this O
pilot O
study O
was O
to O
assess O
the O
feasibility O
of O
using O
oral O
N-acetylcysteine O
( O
NAC O
) O
, O
a O
glutamatergic O
modulator O
and O
an O
antioxidant O
, O
in O
the O
treatment O
of O
behavioral O
disturbance O
in O
children O
with O
autism O
. O
[]

Oozing O
and O
need B-outcome ['Resource-use']
for I-outcome ['Resource-use']
pressure I-outcome ['Resource-use']
bandage I-outcome ['Resource-use']
at O
the O
puncture O
site O
were O
observed O
in O
37 O
AS O
patients O
and O
57 O
SC O
patients O
( O
25 O
% O
vs. O
38 O
% O
, O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Resource-use']

Nifedipine O
30 O
mg O
orally O
inhibited O
basal O
acid O
output O
by O
37 O
% O
( O
p O
less O
than O
0.025 O
) O
and O
that O
stimulated O
by O
low O
infusion O
rates O
of O
pentagastrin O
-- O
that O
is O
, O
0.031 O
and O
0.062 O
microgram/kg/h O
by O
44 O
% O
( O
p O
= O
0.05 O
) O
and O
39 O
% O
( O
p O
less O
than O
0.02 O
) O
respectively O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
with O
respect O
to O
any O
of O
the O
measured O
variables O
. O
[]

CONCLUSION O
The O
dose-intensity O
of O
ICE O
chemotherapy O
can O
be O
doubled O
by O
reinfusing O
hematopoietic O
progenitors O
collected O
by O
leukapheresis O
or O
venesection O
and O
stored O
at O
4 O
degrees O
C O
. O
[]

We O
previously O
described O
significant O
reductions O
in O
resting O
energy O
expenditure O
( O
REE O
) O
, O
as O
measured O
by O
indirect O
calorimetry O
, O
over O
the O
course O
of O
HSCT O
. O
[]

Each O
patient O
was O
evaluated O
with O
two O
lead O
configurations O
with O
the O
order O
of O
testing O
randomized O
. O
[]

Fluvoxamine O
as O
effective O
as O
clomipramine O
against O
symptoms O
of O
severe B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
: O
results O
from O
a O
multicentre O
, O
double-blind O
study O
. O
['Life-Impact']

These O
properties O
suggest O
possible O
analgesic B-outcome ['Resource-use']
effects O
. O
['Resource-use']

Intramuscular O
phenobarbitone O
is O
well O
absorbed O
in O
children O
with O
severe O
malaria O
; O
the O
optimum O
prophylactic O
anticonvulsant O
dose O
remains O
to O
be O
determined O
. O
[]

The O
in O
vivo O
effects O
of O
oral O
clarithromycin O
administration O
on O
the O
in O
vivo O
activity O
of O
cytochrome O
P450 O
1A2 O
, O
2C9 O
, O
and O
2D6 O
were O
determined O
. O
[]

METHODS O
The O
current O
study O
aimed O
to O
analyze O
alterations O
in O
microvascular B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
at O
4 O
predefined O
time O
points O
( O
T1-T4 O
) O
during O
on-pump O
CABG O
using O
orthogonal O
polarization O
spectral O
imaging O
. O
['Physiological-Clinical']

Outcome O
measures O
included O
measures O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

A O
highly O
significant O
difference O
for O
bone B-outcome ['Physiological-Clinical']
flap I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
could O
be O
shown O
with O
0.3 O
% O
in O
the O
cefotiam O
group O
versus O
5.1 O
% O
in O
the O
control O
group O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

In O
patients O
given O
GTN O
, O
peak O
TBPI B-outcome ['Physiological-Clinical']
was O
achieved O
by O
1 O
week O
, O
and O
corresponded O
with O
the O
TBPI B-outcome ['Physiological-Clinical']
observed O
immediately O
following O
GTN O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
demonstrate O
that O
a O
local B-outcome ['Resource-use']
injection I-outcome ['Resource-use']
of I-outcome ['Resource-use']
5 I-outcome ['Resource-use']
mg I-outcome ['Resource-use']
tropisetron I-outcome ['Resource-use']
does O
represent O
an O
alternative O
to O
the O
local O
treatment O
with O
corticosteriods O
plus O
local O
anesthetics O
. O
['Resource-use']

All O
eyes O
could O
receive O
treatment O
or O
sham O
as O
often O
as O
every O
4 O
weeks O
. O
[]

Assessments O
pre-treatment O
, O
post-treatment O
, O
and O
after O
6 O
months O
included O
parent O
ratings O
of I-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ASD I-outcome ['Life-Impact']
, O
executive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
tasks O
, O
and O
19-channel O
EEG O
recordings O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
The O
intensity O
of O
LBP B-outcome ['Physiological-Clinical']
decreased O
significantly O
more O
( O
39 O
% O
) O
in O
the O
TG O
than O
in O
CG O
at O
12 O
months O
. O
['Physiological-Clinical']

GII O
and O
GIV O
ewes O
were O
kept O
in O
climatic O
chamber O
at O
40?C O
and O
55 O
% O
RH O
for O
6 O
h O
a O
day O
between O
10:00 O
and O
16:00 O
hours O
to O
induce O
thermal O
stress O
for O
a O
period O
of O
two O
oestrous O
cycles O
. O
[]

Debriefing O
in O
follow-up O
visits O
provided O
participants O
a O
detailed O
review O
of O
all O
consent O
types O
and O
the O
chance O
to O
change O
data O
sharing O
choices O
or O
decline O
genome O
study O
participation O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
assessed O
at O
regular O
intervals O
for O
12 O
hours O
using O
an O
objective O
pain B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
prospective O
, O
fellow-eye O
sham O
controlled O
clinical O
trial O
was O
conducted O
on O
80 O
eyes O
of O
40 O
high-risk O
characteristic O
proliferative O
diabetic O
retinopathy O
type O
II O
diabetics O
. O
[]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

pCR B-outcome ['Resource-use']
was O
achieved O
in O
3 O
patients O
( O
8 O
% O
) O
. O
['Resource-use']

N-butyl O
cyanoacrylate O
embolization O
of O
cerebral O
arteriovenous O
malformations O
: O
results O
of O
a O
prospective O
, O
randomized O
, O
multi-center O
trial O
. O
[]

The O
measurement O
instruments O
were O
the O
visual O
analogue O
scale O
( O
VAS O
) O
and O
the O
aberrant B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
checklist O
( O
ABC O
) O
. O
['Life-Impact']

OBJECTIVE: O
This O
study O
aims O
to O
investigate O
the O
accuracy O
of O
the O
preoperative O
localization B-outcome ['Life-Impact']
of O
small O
nodules O
by O
computerized O
tomography O
(CT)-guided O
placing O
wire O
and O
intrapleural O
fibrin O
glue O
near O
the O
nodules O
at O
3 O
days O
before O
the O
operation. O
[['Life-Impact']]

The O
day O
before O
and O
24 O
h O
after O
the O
allergen O
provocation O
, O
patients O
were O
challenged O
with O
methacholine O
( O
Mth O
) O
( O
until O
FEV1 O
fell O
by O
40 O
% O
) O
and O
blood O
and O
sputum O
samples O
were O
obtained O
. O
[]

The O
average O
number O
of O
dressing B-outcome ['Resource-use']
changes I-outcome ['Resource-use']
performed O
per O
patient O
was O
118.0 O
( O
range O
12-226 O
) O
for O
MWT O
versus O
41 O
( O
6-140 O
) O
for O
NPWT O
( O
P O
= O
.0001 O
) O
. O
['Resource-use']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
were O
monitored O
throughout O
the O
study O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Groups O
had O
similar O
characteristics O
at O
baseline O
. O
[]

Title: O
Acute O
GVHD O
prophylaxis O
plus O
ATLG O
after O
myeloablative O
allogeneic O
haemopoietic O
peripheral O
blood O
stem-cell O
transplantation O
from O
HLA-identical O
siblings O
in O
patients O
with O
acute O
myeloid O
leukaemia O
in O
remission: O
final O
results O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and O
long-term O
outcome O
analysis O
of O
a O
phase O
3 O
randomised O
study. O
[['Life-Impact']]

Functional O
studies O
between O
the O
cross-over O
periods O
showed O
flow-rate B-outcome ['Physiological-Clinical']
values O
close O
to O
normal O
, O
with O
an O
increase O
in O
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
capacity B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Children O
in O
the O
PRN O
group O
had O
higher O
pain B-outcome ['Physiological-Clinical']
intensity O
scores O
compared O
to O
children O
in O
the O
ATC O
group O
, O
both O
at O
rest O
( O
P=0.017 O
) O
and O
with O
swallowing O
( O
P=0.017 O
) O
. O
['Physiological-Clinical']

Group O
1 O
= O
patients O
were O
prehydrated O
with O
isotonic O
lactated O
Ringer O
's O
solution O
at O
7 O
mg/kg O
( O
n O
= O
30 O
) O
; O
Group O
2 O
= O
patients O
were O
given O
prehydration O
with O
3 O
% O
hypertonic O
saline O
at O
7 O
ml/kg O
( O
n O
= O
30 O
) O
. O
[]

There O
is O
a O
paucity O
of O
research O
on O
the O
determinants O
of O
psychological O
distress, O
particularly O
among O
the O
poorest O
girls O
in O
the O
poorest O
communities. O
[]

The O
remainder O
made O
an O
uncomplicated B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

iNOS O
tended O
to O
increase O
mildly O
in O
the O
corpus O
in O
subjects O
with O
adverse O
reactions O
or O
endoscopic O
lesions O
. O
[]

Inhibition O
of O
awake O
sympathetic O
nerve O
activity O
of O
heart O
failure O
patients O
with O
obstructive O
sleep O
apnea O
by O
nocturnal O
continuous O
positive O
airway O
pressure O
. O
[]

SAI O
were O
classified O
as O
lacunar O
infarction O
and O
non-lacunar O
infarction. O
[]

The O
participants O
were O
randomly O
allocated O
to O
two O
groups O
receiving O
the O
drugs O
Novafen O
and O
Ginger. O
[]

In O
patients O
admitted O
to O
the O
hospital O
with O
acute O
HF O
, O
both O
ventricles O
were O
evaluated O
by O
echocardiography O
on O
admission O
, O
at O
discharge O
, O
and O
at O
3 O
months O
. O
[]

METHODS O
Two O
hundred O
sixteen O
male O
and O
female O
CABG O
patients O
were O
assigned O
randomly O
either O
to O
view O
one O
of O
the O
two O
videotapes O
before O
discharge O
from O
the O
hospital O
or O
to O
receive O
only O
the O
standard O
discharge O
preparation O
provided O
by O
the O
hospital O
. O
[]

Gram-positive B-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
were O
isolated O
from O
18 O
patients O
, O
and O
11 O
patients O
were O
cured B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Gastrointestinal O
symptoms O
have O
been O
reported O
in O
association O
with O
myoelectrical O
dysrhythmia O
, O
where O
different O
types O
of O
gastric O
electrical O
activity O
have O
been O
described O
. O
[]

These O
findings O
support O
the O
use O
of O
a O
volume O
of O
infused O
colloid O
solution O
higher O
than O
that O
of O
withdrawn O
blood O
during O
preoperative O
hemodilution O
. O
[]

This O
study O
establishes O
the O
short-term B-outcome ['Physiological-Clinical']
antiproteinuric I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
diclofenac O
. O
['Physiological-Clinical']

A O
direct O
link O
model O
with O
an O
effect O
compartment O
was O
used O
in O
the O
population O
pharmacokinetic-pharmacodynamic O
analysis O
. O
[]

Standard O
rapid-sequence O
intubation O
requires O
a O
nondepolarizing O
blocking O
agent O
before O
succinylcholine O
administration O
. O
[]

Up O
to O
three O
IPL O
or O
Er O
: O
YAG O
treatments O
did O
not O
result O
in O
a O
significant O
improvement O
in O
rhytid O
scores O
. O
[]

STUDY O
DESIGN O
Using O
a O
crossover O
design O
, O
40 O
subjects O
randomly O
received O
, O
in O
a O
double-blind O
manner O
, O
P-ASA O
injections O
of O
1.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
and O
1.4 O
mL O
of O
3 O
% O
mepivacaine O
, O
at O
2 O
separate O
appointments O
. O
[]

In O
addition O
, O
spermiogram B-outcome ['Physiological-Clinical']
, O
testicular B-outcome ['Physiological-Clinical']
enzyme B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
intratesticular B-outcome ['Physiological-Clinical']
steroid B-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
and O
testicular B-outcome ['Physiological-Clinical']
antioxidant I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
were O
estimated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

GM-CSF B-outcome ['Physiological-Clinical']
levels O
were O
measured O
by O
a O
sandwich O
enzyme-linked O
immunosorbent O
assay O
at O
2 O
, O
4 O
, O
6 O
, O
12 O
, O
and O
24 O
hours O
after O
the O
first O
dose O
of O
rhuGM-CSF O
. O
['Physiological-Clinical']

Topical O
tetracaine O
was O
not O
associated O
with O
a O
significant O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
score O
, O
although O
it O
did O
lead O
to O
faster O
recovery B-outcome ['Physiological-Clinical']
times O
. O
['Physiological-Clinical', 'Physiological-Clinical']

of O
isotonic O
saline O
, O
then O
0.15 O
mg/kg O
i.v O
. O
[]

Codeine O
60 O
mg O
was O
significantly O
superior O
to O
placebo O
for O
percent O
SPID O
and O
some O
hourly O
measures O
. O
[]

3 O
adverse O
events O
did O
not O
differ O
between O
MP O
and O
PL O
( O
40 O
of O
93 O
patients O
v O
29 O
of O
97 O
patients O
, O
respectively O
; O
P O
= O
.06 O
) O
. O
[]

RESULTS O
IL-6 O
, O
IL-8 O
levels O
in O
the O
plasma O
and O
BALF O
collected O
at O
T O
( O
2 O
) O
-T O
( O
4 O
) O
increased O
significantly O
as O
compared O
with O
those O
in O
samples O
collected O
at O
T O
( O
1 O
) O
, O
and O
their O
peak O
concentration O
inplasma B-outcome ['Physiological-Clinical']
and O
BALF B-outcome ['Physiological-Clinical']
samples O
were O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
perioperative O
increase O
in O
cortisol B-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
two O
groups O
, O
despite O
the O
differences O
in O
ACTH O
responses O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS O
Forty-eight O
children O
diagnosed O
with O
ASD O
between O
18 O
and O
30 O
months O
of O
age O
were O
randomly O
assigned O
to O
1 O
of O
2 O
groups O
: O
( O
1 O
) O
ESDM O
intervention O
, O
which O
is O
based O
on O
developmental O
and O
applied O
behavioral O
analytic O
principles O
and O
delivered O
by O
trained O
therapists O
and O
parents O
for O
2 O
years O
; O
or O
( O
2 O
) O
referral O
to O
community O
providers O
for O
intervention O
commonly O
available O
in O
the O
community O
. O
[]

The O
rate O
of O
healing B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

0.02 O
, O
p O
< O
0.001 O
) O
. O
[]

Platinum-based O
chemotherapy O
is O
often O
a O
first-line O
treatment O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
analgesia O
activity O
of O
ketorolac O
tromethamine O
10 O
mg O
and O
30 O
mg O
suppositories O
were O
evaluated O
after O
single O
dose O
administration O
by O
assessing O
pain O
intensity O
and O
pain O
relief O
using O
a O
4 O
point O
scale O
( O
VRS O
) O
. O
[]

In O
adjusted O
analyses O
, O
parents O
who O
reported O
that O
their O
child O
had O
ASD O
did O
not O
have O
significantly O
higher O
out-of-pocket B-outcome ['Resource-use']
['Resource-use']

RESULTS O
Analysis O
of O
the O
primary O
outcome O
measures O
found O
no O
statistically O
significant O
difference O
between O
paroxetine O
or O
imipramine O
versus O
placebo O
. O
[]

OBJECTIVE: O
We O
conducted O
this O
study O
to O
compare O
the O
efficacy O
and O
safety O
of O
entecavir O
and O
tenofovir O
in O
the O
treatment O
of O
treatment-naive O
HBV O
e O
antigen O
(HBeAg)-positive O
patients O
with O
chronic O
hepatitis O
B O
(CHB) O
for O
144 O
weeks. O
[]

BACKGROUND O
Limitations O
of O
the O
surgical O
correction O
for O
myopia O
include O
inaccuracy O
, O
instability O
, O
treatment O
of O
the O
central O
optical O
zone O
, O
and O
lack O
of O
reversibility O
. O
[]

All O
measures O
of O
outcome O
were O
worse O
in O
patients O
who O
developed O
fever O
, O
even O
in O
those O
without O
infections B-outcome ['Physiological-Clinical']
or O
who O
were O
World O
Federation O
of O
Neurological O
Surgeons O
grade O
I. O
Logistic O
regression O
analyses O
were O
performed O
to O
adjust O
for O
differences O
in O
preoperative O
factors O
( O
e.g. O
, O
age O
, O
Fisher O
grade O
, O
initial O
neurological O
status O
) O
. O
['Physiological-Clinical']

However O
, O
it O
is O
not O
known O
whether O
oral O
CoQ O
( O
10 O
) O
supplementation O
may O
improve O
cardiocirculatory B-outcome ['Physiological-Clinical']
efficiency O
and O
endothelial O
function B-outcome ['Life-Impact']
in O
patients O
with O
CHF O
. O
['Physiological-Clinical', 'Life-Impact']

Silver O
nanoparticles O
( O
NNPs O
) O
, O
alone O
or O
in O
combination O
with O
the O
bioadhesive O
Gantrez O
S-97 O
, O
have O
demonstrated O
their O
efficacy O
against O
Streptococcus O
mutans O
; O
however O
, O
it O
is O
not O
known O
if O
this O
combination O
changes O
the O
color B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
teeth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mineral O
Trioxide O
Aggregate O
was O
used O
as O
the O
standard O
for O
comparison O
. O
[]

Fecal B-outcome ['Physiological-Clinical']
butyrate I-outcome ['Physiological-Clinical']
levels O
vary O
widely O
among O
individuals O
but O
are O
usually O
increased O
by O
a O
diet O
high O
in O
resistant O
starch O
. O
['Physiological-Clinical']

Secondary O
endpoints O
included O
the O
profile O
of O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
during O
titration O
and O
parathyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
calcium B-outcome ['Physiological-Clinical']
, O
and O
calcium B-outcome ['Physiological-Clinical']
x I-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Ca I-outcome ['Physiological-Clinical']
x I-outcome ['Physiological-Clinical']
P I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
preoperative O
celecoxib O
administration O
in O
alleviating O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
knee O
osteoarthritis O
(OA) O
patients O
undergoing O
total O
knee O
arthroplasty O
(TKA).A O
total O
of O
226 O
knee O
OA O
patients O
underwent O
TKA O
were O
consecutively O
recruited O
and O
randomized O
into O
preoperative O
analgesia O
group O
and O
postoperative O
analgesia O
group O
as O
1:1 O
ratio. O
[['Physiological-Clinical']]

This O
small O
study O
confirms O
that O
this O
combination O
of O
bupivacaine O
and O
clonidine O
provides O
satisfactory B-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
for O
first-stage O
labour O
, O
and O
of O
longer O
duration O
than O
bupivacaine-fentanyl O
. O
['Life-Impact']

For O
patients O
with O
CrCl O
between O
10 O
and O
50 O
ml/min O
, O
the O
levels O
achieved O
were O
low O
and O
these O
patients O
would O
likely O
benefit O
from O
increased O
doses O
. O
[]

METHODS: O
This O
2-arm O
randomized O
controlled O
trial O
(RCT) O
enrolled O
86 O
eligible O
patients O
with O
CUR O
following O
TBI. O
[]

Though O
this O
prolongation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
was O
not O
significant O
in O
the O
bestatin O
group O
compared O
to O
the O
control O
group O
in O
the O
15-49 O
yr O
age O
group O
, O
in O
the O
50-65 O
yr O
age O
group O
it O
was O
significantly O
longer O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Sarpogrelate O
has O
been O
shown O
to O
reduce O
albuminuria O
in O
diabetic O
nephropathy O
. O
[]

albus O
and O
Staph O
. O
[]

Conclusions: O
Resin O
infiltration O
and O
fluoride O
varnish O
are O
clinically O
feasible B-outcome ['Life-Impact']
and O
efficacious O
methods O
for O
the O
treatment O
of O
anterior O
white B-outcome ['Physiological-Clinical']
spot I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
The O
inhibition O
of O
caries O
progression O
by O
resin O
infiltration O
should O
now O
be O
considered O
an O
alternative O
to O
fluoride O
treatment. O
[['Life-Impact'], ['Physiological-Clinical']]

The O
effect O
of O
this O
treatment O
continues O
after O
one O
year O
. O
[]

RESULTS O
ST O
performed O
alone O
, O
or O
in O
conjunction O
with O
aerobic O
exercise O
, O
improved O
maximal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
and O
increased O
total O
lean B-outcome ['Physiological-Clinical']
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
both O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
three O
methods O
of O
evaluation O
showed O
no O
significant O
difference O
between O
Groups O
A O
vs. O
B O
, O
and O
C O
vs. O
D O
, O
while O
statistically O
significant O
differences O
were O
observed O
between O
Groups O
A O
vs. O
C O
, O
A O
vs. O
D O
, O
B O
vs. O
C O
and O
B O
vs. O
D. O
Based O
on O
the O
results O
of O
this O
study O
, O
the O
size O
of O
occlusal O
access O
significantly O
affected O
the O
efficacy O
of O
demineralized B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Therefore O
, O
85 O
HCC O
patients O
after O
transcatheter O
arterial O
chemoembolization O
and O
radiofrequency O
ablation O
therapy O
were O
randomized O
to O
immunotherapy O
group O
and O
no O
adjuvant O
therapy O
group O
. O
[]

UNLABELLED O
Bone O
, O
muscle O
, O
and O
fat O
may O
affect O
gait O
and O
balance O
in O
older O
adults O
. O
[]

Lidocaine O
and O
bupivacaine O
mixtures O
for O
epidural O
blockade O
. O
[]

TENS O
for O
the O
treatment O
of O
writer O
's O
cramp O
dystonia O
: O
a O
randomized O
, O
placebo-controlled O
study O
. O
[]

In O
patients O
with O
episodic O
migraine, O
>/=50% O
response O
was O
maintained O
in O
41.5 O
and O
41.1% O
of O
galcanezumab-treated O
patients O
(120 O
mg O
and O
240 O
mg, O
respectively) O
for O
>/=3 O
consecutive O
months O
(until O
patient's O
endpoint) O
and O
19.0 O
and O
20.5%, O
respectively, O
for O
6 O
consecutive O
months O
and O
was O
significantly O
greater O
than O
the O
21.4 O
and O
8.0% O
of O
placebo-treated O
patients O
at O
>/=3 O
and O
6 O
months O
consecutively O
(P O
< O
0.001). O
[]

CONCLUSION O
A O
larger O
study O
investigating O
the O
same O
hypothesis O
is O
warranted O
to O
detect O
difference O
in O
the O
effects O
of O
these O
treatments O
strategies O
. O
[]

The O
statistic O
analysis O
pointed O
out O
differences O
only O
in O
Group O
1 O
for O
the O
variables O
percentage O
of O
communicative B-outcome ['Life-Impact']
space I-outcome ['Life-Impact']
used O
and O
use O
of O
the O
mediating O
object O
. O
['Life-Impact']

The O
primary O
outcome O
is O
change O
in O
providers O
' O
tobacco O
treatment O
practices O
and O
the O
secondary O
outcomes O
are O
cost O
per O
quit O
, O
use O
of O
tobacco O
cessation O
treatments O
, O
quit O
attempts O
, O
and O
smoking O
abstinence O
. O
[]

We O
examined O
possible O
associations O
between O
a O
broad O
spectrum O
of O
circulating O
biomarkers O
of O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
risk O
of O
fibroadenomas O
. O
['Life-Impact']

METHODS O
Two O
hundred O
seven O
consecutive O
coronary O
artery O
bypass O
patients O
( O
mean O
age O
62 O
+/- O
11 O
years O
) O
were O
randomized O
to O
receive O
sotalol O
alone O
( O
80 O
mg O
twice O
daily O
for O
5 O
days O
starting O
from O
the O
morning O
of O
the O
first O
postoperative O
day O
) O
( O
group O
S O
) O
, O
magnesium O
alone O
( O
1.5 O
g O
daily O
for O
6 O
days O
starting O
in O
the O
operating O
room O
just O
before O
cardiopulmonary O
bypass O
) O
( O
group O
M O
) O
, O
both O
pharmacologic O
agents O
at O
the O
same O
dosages O
( O
group O
S+M O
) O
, O
or O
no O
antiarrhythmic O
agents O
( O
group O
CTR O
) O
. O
[]

Also O
, O
there O
were O
no O
significant O
differences O
in O
LDL B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
after O
in O
vitro O
enrichment O
of O
LDL O
with O
RRR-AT O
and O
all-rac-AT O
. O
['Physiological-Clinical']

All O
rural O
primary O
schools O
(n O
= O
164) O
in O
the O
county O
were O
invited O
to O
participate. O
[]

Metabolic O
and O
ventilatory O
responses O
during O
very O
low O
level O
exercise O
. O
[]

CONCLUSIONS O
Despite O
advances O
in O
interventional O
techniques O
, O
diabetes O
remains O
a O
significant O
independent O
predictor O
of O
adverse O
events O
in O
the O
intermediate O
term O
after O
PCI O
. O
[]

OBJECTIVE O
We O
investigated O
, O
in O
humans O
, O
the O
relation O
between O
past O
use O
of O
ecstasy O
and O
cognitive O
performance O
as O
well O
as O
serotonergic O
function O
. O
[]

Induction O
was O
with O
8 O
% O
sevoflurane O
, O
60 O
% O
nitrous O
oxide O
( O
N2O O
) O
, O
40 O
% O
oxygen O
at O
a O
flow O
rate O
of O
8 O
L O
x O
min O
( O
-1 O
) O
through O
a O
Mapleson O
C O
circuit O
. O
[]

The O
participants O
performed O
a O
2000-m O
test O
on O
a O
rowing O
ergometer O
at O
the O
beginning O
(1st O
examination) O
and O
at O
the O
end O
of O
the O
supplementation O
period O
(2nd O
examination). O
[]

Four O
infants O
had O
consent O
withdrawn O
or O
unconfirmed, O
leaving O
1098 O
infants O
in O
the O
lactoferrin O
group O
and O
1101 O
in O
the O
sucrose O
group. O
[]

Using O
baby O
books O
to O
increase O
new B-outcome ['Life-Impact']
mothers I-outcome ['Life-Impact']
' O
safety O
practices B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Among O
the O
postmenopausal O
patients O
there O
were O
no O
substantial O
differences O
in O
terms O
of O
recurrence-free B-outcome ['Mortality']
or I-outcome ['Mortality']
overall I-outcome ['Mortality']
survival I-outcome ['Mortality']
between O
the O
treatment O
groups O
. O
['Mortality']

There O
was O
a O
significant O
linear O
trend O
x O
group O
interaction O
on O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions- O
Improvement O
( O
CGI-I O
) O
and O
50 O
% O
on O
olanzapine O
versus O
20 O
% O
on O
placebo O
were O
responders O
. O
['Physiological-Clinical']

In O
the O
intent-to-treat O
sample O
, O
which O
is O
perhaps O
more O
clinically O
relevant O
, O
only O
haloperidol O
proved O
superior O
to O
baseline O
on O
a O
global O
measure O
of O
autistic B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
, O
as O
well O
as O
specific O
measures O
for O
irritability B-outcome ['Life-Impact']
and O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
mean O
[]

The O
present O
study O
evaluated O
5-year O
survival O
and O
cancer O
recurrence O
among O
512 O
patients O
with O
gastrointestinal O
cancer O
included O
in O
the O
TACTIC O
study O
. O
[]

It O
could O
be O
a O
new O
modality O
in O
the O
drug O
therapy O
of O
alcoholism O
, O
not O
involving O
an O
antabuse O
effect O
, O
an O
antidepressant O
action O
, O
or O
conditioning O
. O
[]

Progress O
was O
measured O
by O
patient O
's O
assessment O
on O
pain O
at O
rest B-outcome ['Life-Impact']
and O
on O
movement B-outcome ['Physiological-Clinical']
and O
by O
physician O
's O
assessment O
on O
functional O
impairment O
. O
['Life-Impact', 'Physiological-Clinical']

Only O
one O
subject O
had O
documented O
clinical B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Utility O
of O
the O
bladder O
flap O
at O
cesarean O
delivery O
: O
a O
randomized O
controlled O
trial O
. O
[]

Relative O
increases O
in O
[]

Whereas O
subjects O
with O
white-coat O
hypertension O
should O
not O
be O
treated O
with O
antihypertensive O
agents O
, O
they O
must O
be O
followed O
and O
managed O
through O
non-pharmacologic O
means O
. O
[]

Most O
had O
used O
heroin O
by O
injection O
. O
[]

The O
Coping O
Cat O
program O
for O
children O
with O
anxiety O
and O
autism O
spectrum O
disorder O
: O
a O
pilot O
randomized O
controlled O
trial O
. O
[]

Mean O
confidence B-outcome ['Life-Impact']
scores O
and O
additional O
imaging O
recommendations O
were O
compared O
between O
CT O
and O
DSA O
groups O
in O
an O
intention-to-diagnose-and-treat O
analysis O
. O
['Life-Impact']

BACKGROUND: O
The O
increasing O
multidrug O
resistance O
among O
gram-negative O
uropathogens O
necessitates O
new O
treatments O
for O
serious O
infections. O
[]

This O
12-week O
, O
randomized O
, O
double-blind O
, O
forced-titration O
study O
compared O
the O
efficacy O
of O
3 O
angiotensin O
receptor O
blockers O
. O
[]

Journal O
ID: O
2985248R O
[]

CONCLUSION O
CS O
gel O
applied O
to O
the O
penis O
was O
well O
tolerated B-outcome ['Life-Impact']
in O
this O
HIV-positive O
male O
population O
. O
['Life-Impact']

RESULTS: O
Forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
(FVC) I-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
(MVV) I-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
, O
and O
self-reported O
health B-outcome ['Physiological-Clinical']
status O
were O
significantly O
increased O
(P O
< O
.05) O
in O
the O
group O
receiving O
joint O
Baduanjin O
and O
CBT O
intervention O
at O
3 O
months O
and O
6 O
months, O
as O
compared O
to O
the O
Baduanjin O
only O
group O
or O
the O
CBT O
only O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

vessel O
wall O
without O
any O
signs O
of O
atherosclerotic O
disease O
) O
. O
[]

Those O
analyzing O
liver B-outcome ['Physiological-Clinical']
and O
kidney B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
blinded O
to O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Loxiglumide O
significantly O
reduced O
the O
number O
of O
[]

AIM O
To O
compare O
the O
effects O
of O
single O
doses O
of O
three O
oral O
medications O
on O
postoperative O
pain B-outcome ['Physiological-Clinical']
following O
instrumentation O
of O
root O
canals O
in O
teeth O
with O
irreversible O
pulpitis O
. O
['Physiological-Clinical']

Future O
trials O
in O
HCL O
must O
be O
aware O
of O
the O
risk O
of O
second B-outcome ['Physiological-Clinical']
malignancies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS O
Preoperative O
patient O
characteristics O
and O
operative O
parameters O
were O
similar O
in O
three O
groups O
. O
[]

We O
explored O
the O
possibility O
that O
a O
simple O
and O
single O
test O
could O
replace O
the O
modified O
Mallampati O
score O
for O
either O
a O
difficult O
or O
an O
unaccomplished O
tracheal B-outcome ['Physiological-Clinical']
intubation I-outcome ['Physiological-Clinical']
in O
an O
impending B-outcome ['Physiological-Clinical']
hypoxic I-outcome ['Physiological-Clinical']
patient O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Synthetic O
intakes O
> O
151-410 O
microg/d O
in O
these O
women O
produced O
little O
additional O
benefit O
in O
terms O
of O
maximizing O
RBC O
content O
. O
[]

All O
but O
six O
of O
the O
women O
continued O
to O
breast-feed O
for O
> O
or O
= O
12 O
mo O
. O
[]

Our O
results O
suggest O
that O
a O
HIIT O
training O
program O
with O
TRX O
have O
benefits O
in O
BMI B-outcome ['Physiological-Clinical']
, O
handgrip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
gait B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
older O
adults. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

There O
was O
no O
difference O
between O
the O
groups O
in O
the O
percentage O
of O
infants B-outcome ['Physiological-Clinical']
who I-outcome ['Physiological-Clinical']
avoided I-outcome ['Physiological-Clinical']
transfusions I-outcome ['Physiological-Clinical']
altogether I-outcome ['Physiological-Clinical']
( O
12 O
% O
in O
the O
liberal-transfusion O
group O
versus O
10 O
% O
in O
the O
restrictive-transfusion O
group O
) O
. O
['Physiological-Clinical']

Compliance O
with O
the O
requirement O
to O
record O
details O
of O
the O
healthcare O
services O
during O
the O
year-long O
study O
was O
high O
. O
[]

CONCLUSION O
( O
S O
) O
A O
flexible O
protocol O
of O
0.25 O
mg O
of O
cetrorelix O
for O
IUI O
cycles O
appears O
to O
suppress O
the O
rate O
of O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
during O
ovarian O
stimulation O
with O
letrozole O
and O
gonadotropins O
. O
['Physiological-Clinical']

Severe B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
life-threatening I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
in O
44 O
percent O
and O
20 O
percent O
, O
respectively O
, O
of O
the O
patients O
who O
received O
combined O
therapy O
, O
as O
compared O
with O
25 O
percent O
and O
3 O
percent O
of O
those O
treated O
with O
radiation O
alone O
. O
['Adverse-effects']

Immunogenicity B-outcome ['Physiological-Clinical']
and O
safety O
were O
evaluated O
for O
up O
to O
10 O
months O
. O
['Physiological-Clinical']

Personality O
( O
16-PF O
and O
IIQ O
) O
, O
quality O
of O
life O
( O
FLIC O
) O
, O
and O
depression B-outcome ['Life-Impact']
( O
BDI O
) O
scores O
were O
the O
endpoints O
for O
this O
study O
, O
and O
the O
questionnaires O
were O
completed O
by O
the O
patients O
at O
diagnosis O
, O
and O
up O
to O
9 O
months O
after O
diagnosis O
. O
['Life-Impact']

DESIGN O
A O
randomized O
, O
double-blind O
, O
phase O
III O
clinical O
trial O
. O
[]

Ambulatory B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP I-outcome ['Physiological-Clinical']
after O
3 O
months O
of O
aspirin O
treatment O
were O
similar O
to O
baseline O
: O
deltaSBP O
-0.5 O
mmHg O
( O
95 O
% O
confidence O
intervals O
[ O
CI O
] O
from O
-1.9 O
to O
+2.9 O
mm O
Hg O
) O
and O
deltaDBP O
-1.1 O
mm O
Hg O
( O
95 O
% O
CI O
from O
-2.5 O
to O
+0.3 O
mm O
Hg O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
ability O
to O
predict O
the O
effect O
of O
anthelmintic O
treatment O
on O
milk O
production O
depends O
on O
the O
level O
of O
parasitism O
quantified O
by O
an O
ELISA O
measuring O
milk B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against O
O. O
ostertagi O
, O
and O
reported O
as O
optical B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ODRs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
DJQ O
showed O
efficiency O
synergism O
and O
toxicity O
reducing O
effects O
, O
but O
with O
no O
effect O
on O
the O
hematopoietic O
function O
of O
the O
bone O
marrow O
. O
[]

CONCLUSIONS O
Although O
the O
overall O
mood O
profiles O
were O
similar O
for O
the O
users O
of O
any O
of O
the O
standard O
malaria O
chemoprophylaxis O
regimens O
, O
we O
found O
that O
women O
using O
mefloquine O
showed O
more O
fatigue O
and O
confusion O
than O
men O
and O
that O
younger O
persons O
aged O
less O
than O
34 O
years O
, O
regardless O
of O
chemoprophylaxis O
used O
, O
reported O
more O
tension O
and O
fatigue O
than O
their O
older O
counterparts O
. O
[]

There O
were O
three O
measurement O
periods O
: O
prior O
to O
randomization O
( O
Time O
1 O
) O
and O
at O
5 O
and O
9 O
months O
post O
enrollment O
( O
Times O
2 O
and O
3 O
) O
. O
[]

7.89 O
vs O
0.81 O
? O
[]

In O
addition O
to O
quantifying O
falls B-outcome ['Life-Impact']
, O
we O
shall O
measure O
mobility B-outcome ['Life-Impact']
, O
activity B-outcome ['Life-Impact']
limitations I-outcome ['Life-Impact']
and O
quality O
of O
life O
as O
secondary O
outcomes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Due O
to O
dyspnea O
and O
fatigue O
, O
patients O
with O
chronic O
heart O
failure O
( O
CHF O
) O
are O
often O
restricted O
in O
the O
performance O
of O
everyday O
activities O
, O
which O
gradually O
may O
lead O
to O
hypoactivity O
. O
[]

Salient O
contours O
within O
this O
complex O
background O
were O
formed O
by O
colinear O
alignment O
of O
nearby O
segments O
. O
[]

Bifidobacterium B-outcome ['Physiological-Clinical']
longum I-outcome ['Physiological-Clinical']
was O
the O
most O
frequently O
detected O
species O
in O
breast-milk O
. O
['Physiological-Clinical']

This O
trial O
initiates O
the O
effort O
to O
establish O
weight O
loss O
support O
for O
overweight O
or O
obese O
breast O
cancer O
survivors O
as O
a O
new O
standard O
of O
clinical O
care O
. O
[]

BACKGROUND O
This O
study O
tried O
to O
resolve O
whether O
glucagon O
is O
a O
better O
premedication O
for O
endoscopic O
retrograde O
cholangiopancreatography O
( O
ERCP O
) O
. O
[]

Dose-limiting B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
consisting O
of O
febrile B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
in O
some O
patients O
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
nonproductive B-outcome ['Physiological-Clinical']
cough I-outcome ['Physiological-Clinical']
, O
was O
observed O
at O
a O
dose O
level O
of O
30 O
micrograms/kg O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Practical O
experiences O
from O
the O
Oslo O
Study O
. O
[]

RESULTS O
Women O
treated O
with O
pravastatin O
had O
a O
risk O
reduction O
of O
43 O
% O
for O
the O
primary O
end O
point O
( O
p O
= O
0.035 O
) O
, O
46 O
% O
for O
combined O
coronary O
events O
( O
p O
= O
0.001 O
) O
, O
48 O
% O
for O
PTCA O
( O
p O
= O
0.025 O
) O
, O
40 O
% O
for O
CABG O
( O
p O
= O
0.14 O
) O
and O
56 O
% O
for O
stroke O
( O
p O
= O
0.07 O
) O
. O
[]

Title: O
[Nursing O
intervention O
for O
respiratory O
function O
exercise O
in O
patients O
with O
silicosis O
complicated O
by O
stable O
chronic O
obstructive O
pulmonary O
disease]. O
[]

An O
open O
label O
maintenance O
study O
. O
[]

All O
procedures O
started O
between O
8 O
and O
10 O
AM O
, O
and O
operating O
room O
( O
OR O
) O
temperature O
was O
maintained O
between O
21 O
degrees O
and O
23 O
degrees O
C O
, O
with O
relative O
humidity O
ranging O
between O
40 O
% O
and O
45 O
% O
. O
[]

METHODS O
Seventeen O
subjects O
were O
randomized O
into O
control O
( O
n O
= O
9 O
) O
and O
HBOT O
treatment O
( O
n O
= O
8 O
) O
arms O
. O
[]

RESULTS O
Most O
female O
heroin O
addicts O
were O
young O
and O
single O
, O
with O
a O
low O
education O
level O
. O
[]

min O
( O
-1 O
) O
or O
an O
AT O
of O
11 O
to O
14 O
mL O
? O
[]

Single O
dose O
of O
intraoperative O
amiodarone O
may O
be O
used O
to O
decrease O
postoperative O
arrhythmia O
in O
open O
heart O
surgery O
. O
[]

RESULTS O
Patients O
( O
n O
= O
48 O
) O
enrolled O
at O
the O
beginning O
of O
our O
study O
had O
significantly O
increased O
osteocalcin B-outcome ['Physiological-Clinical']
levels O
( O
3.45 O
+/- O
0.93 O
-- O
> O
4.42 O
+/- O
1.39 O
ng/ml O
p O
< O
0.02 O
) O
after O
one O
year O
if O
inflammatory B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
decreased O
( O
> O
or O
= O
1 O
SD O
: O
erythrocyte B-outcome ['Physiological-Clinical']
sedimentation I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ESR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
26.4 O
mm/h O
, O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CRP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
3.8 O
mg/dl O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Ten O
healthy O
adult O
volunteers O
participated O
in O
a O
controlled O
cross-over O
experiment O
. O
[]

All O
sheep O
were O
exposed O
to O
natural O
sub-clinical O
helminthosis O
challenge O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
between O
propranolol- O
and O
placebo-treated O
groups O
. O
['Physiological-Clinical']

Nonanimal O
stabilized O
hyaluronic O
acid O
has O
reduced O
potential O
for O
immunogenicity O
and O
hypersensitivity O
and O
may O
provide O
a O
more O
durable O
aesthetic O
result O
. O
[]

To O
reduce O
the O
lidocaine-induced O
side O
effects O
, O
we O
evaluated O
the O
MEG-X O
formation O
after O
0.5 O
and O
1 O
mg/kg O
lidocaine O
intravenously O
in O
subjects O
with O
normal O
( O
n O
= O
5 O
) O
and O
severely O
impaired O
liver O
function O
( O
n O
= O
7 O
) O
( O
study O
I O
) O
. O
[]

Endoscopy O
and O
evaluator-blind O
assessments O
of O
the O
esophageal O
, O
gastric O
, O
and O
duodenal O
mucosa O
were O
performed O
at O
baseline O
and O
on O
Days O
8 O
and O
15 O
. O
[]

Randomization O
was O
made O
at O
the O
time O
of O
diagnosis O
with O
223 O
assigned O
to O
continuing O
CHOP O
and O
234 O
to O
3 O
cycles O
of O
CHOP O
followed O
by O
a O
BEAM O
( O
carmustine O
, O
etoposide O
, O
cytarabine O
, O
melphalan O
) O
autograft O
. O
[]

Risperidone O
[ O
mean O
dose O
( O
+/- O
SD O
) O
: O
1.37 O
mg/day O
( O
0.7 O
) O
] O
resulted O
in O
significantly O
greater O
reduction O
from O
baseline O
to O
endpoint O
in O
ABC-I O
versus O
placebo O
[ O
mean O
change O
( O
+/- O
SD O
) O
: O
-13.4 O
( O
1.5 O
) O
vs. O
-7.2 O
( O
1.4 O
) O
, O
P O
< O
0.05 O
; O
ES=-0.7 O
] O
. O
[]

A O
total O
of O
98.4 O
% O
of O
patients O
( O
63/64 O
) O
experienced O
a O
reduction O
in O
the O
frequency O
of O
angina B-outcome ['Physiological-Clinical']
attacks/week O
and O
91 O
% O
of O
patients O
( O
58/64 O
) O
had O
angina B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
reduced O
to O
< O
or O
= O
2/week O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eight O
hours O
after O
the O
start O
of O
the O
loading O
dose O
infusion O
, O
the O
first O
maintenance O
dose O
( O
120 O
mg O
) O
was O
administered O
over O
60 O
minutes O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Fifty-one O
children O
( O
age O
range O
2-18 O
years O
) O
who O
did O
not O
respond O
to O
sleep O
hygiene O
intervention O
were O
enrolled O
. O
[]

Transmission O
was O
almost O
interrupted O
in O
two O
communities O
treated O
with O
combined O
therapy O
. O
[]

35.3 O
cm/cm? O
in O
MECC O
group O
; O
P O
= O
.034 O
) O
. O
[]

The O
children O
were O
taught O
how O
to O
see O
objects O
in O
context O
by O
reinforcing O
attention O
to O
pivotal O
contextual O
information O
. O
[]

Randomized O
phase O
II O
trial O
of O
high-dose O
4'-epi-doxorubicin O
+ O
cyclophosphamide O
versus O
high-dose O
4'-epi-doxorubicin O
+ O
cisplatin O
in O
previously O
untreated O
patients O
with O
extensive O
small O
cell O
lung O
cancer O
. O
[]

Guided O
imagery O
appeared O
to O
have O
potential O
as O
a O
useful O
nursing O
modality O
for O
chronic O
pain O
sufferers O
. O
[]

RESULTS O
Using O
an O
intent-to-treat O
approach O
, O
findings O
replicated O
earlier O
results O
with O
a O
very O
large O
effect O
size O
( O
d O
= O
1.41 O
) O
for O
the O
FF O
group O
and O
a O
large O
effect O
size O
( O
d O
= O
1.12 O
) O
for O
the O
WEB O
group O
relative O
to O
the O
PBO O
group O
. O
[]

RESULTS O
No O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
either O
group O
. O
['Adverse-effects']

RESULTS O
The O
MCIC B-outcome ['Physiological-Clinical']
of O
the O
PI-NRS O
ranged O
from O
3.5 O
to O
4.7 O
points O
in O
( O
sub O
) O
acute O
patients O
and O
2.5 O
to O
4.5 O
points O
in O
chronic O
patients O
with O
low O
back O
pain O
. O
['Physiological-Clinical']

METHOD O
Thirty-eight O
patients O
received O
baseline O
MRIs O
as O
part O
of O
a O
larger O
12-week O
, O
randomized O
clinical O
trial O
comparing O
sertraline O
and O
nortriptyline O
in O
the O
treatment O
of O
late-life O
depression O
. O
[]

CONCLUSIONS O
Administration O
of O
low-dose O
clonidine O
in O
patients O
undergoing O
noncardiac O
surgery O
did O
not O
reduce O
the O
rate O
of O
the O
composite O
outcome O
of O
death B-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
; O
it O
did O
, O
however O
, O
increase O
the O
risk O
of O
clinically B-outcome ['Physiological-Clinical']
important I-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
and O
nonfatal B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
. O
( O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
clinical B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
score O
also O
showed O
significant O
improvement O
in O
the O
MgSO4 O
group O
1 O
, O
2 O
, O
3 O
and O
11 O
hours O
after O
stopping O
the O
infusion O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Patients O
with O
normal O
levels O
, O
except O
CA72-4 O
, O
also O
had O
more O
clinical O
responses O
( O
PR+SD4 O
) O
than O
patients O
with O
elevated O
values O
. O
[]

The O
peak O
ELISPOT O
response O
occurred O
?2 O
weeks O
after O
each O
ZV O
dose O
. O
[]

A O
curve O
was O
observed O
after O
2.5 O
h O
treatment O
between O
the O
2 O
groups O
( O
P=0.001 O
) O
. O
[]

Of O
44 O
patients O
in O
the O
CRT O
group O
, O
12 O
( O
28 O
% O
) O
had O
had O
bowel O
obstruction O
compared O
with O
5 O
of O
33 O
( O
15 O
% O
) O
in O
the O
RT O
group O
( O
p O
= O
0.27 O
) O
. O
[]

Inhibition O
of O
epidural B-outcome ['Physiological-Clinical']
morphine-induced I-outcome ['Physiological-Clinical']
pruritus I-outcome ['Physiological-Clinical']
by O
intravenous O
droperidol O
. O
['Physiological-Clinical']

Nineteen O
incidents O
of O
PCP O
and O
13 O
deaths B-outcome ['Mortality']
, O
of O
which O
one O
was O
related O
to O
an O
acute O
episode O
of O
PCP O
, O
were O
noted O
in O
the O
control O
group O
. O
['Mortality']

FINDINGS O
183 O
( O
61 O
% O
) O
of O
316 O
participants O
were O
diagnosed O
with O
at O
least O
one O
episode O
of O
uncomplicated O
malaria O
. O
[]

OBJECTIVE O
To O
determine O
the O
extent O
to O
which O
the O
estrogen-induced O
changes O
in O
lipids O
and O
markers O
of O
carbohydrate O
metabolism O
explain O
the O
beneficial O
effect O
of O
estrogen O
therapy O
on O
the O
progression O
of O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

The O
patients O
were O
divided O
into O
two O
groups O
( O
20 O
in O
each O
) O
. O
[]

The O
skin O
microvessels O
' O
vasodilatory O
reserve O
was O
assessed O
with O
a O
heat O
challenge O
at O
the O
end O
of O
the O
protocol O
. O
[]

RESULTS O
The O
6-month O
follow-up O
rate O
was O
97 O
% O
in O
both O
groups O
. O
[]

The O
primary O
end O
point O
was O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

The O
patients O
in O
the O
NES O
group O
received O
NES O
intervention, O
while O
the O
subjects O
in O
the O
sham O
group O
underwent O
sham O
NES. O
[]

Laser O
conization O
versus O
cold O
knife O
conization O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
whether O
untreated O
ruptures O
are O
associated O
with O
changes O
over O
time O
in O
magnetic O
resonance O
imaging O
findings O
, O
serologic O
markers O
, O
or O
self-reported O
breast O
symptoms O
. O
[]

Local B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
such O
as O
swelling B-outcome ['Physiological-Clinical']
and O
redness B-outcome ['Physiological-Clinical']
were O
observed O
in O
2 O
% O
( O
8/399 O
) O
to O
2.3 O
% O
( O
9/385 O
) O
of O
the O
acellular O
vaccine O
recipients O
as O
against O
31 O
% O
( O
122/394 O
) O
in O
the O
whole-cell O
vaccine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
This O
study O
was O
designed O
as O
within-subject O
, O
quasi-experimental O
research O
. O
[]

Results O
were O
similar O
for O
all O
(mild/moderate/severe) O
exacerbations B-outcome ['Physiological-Clinical']
. O
Improvements O
in O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Physiological-Clinical']
status O
and O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
use I-outcome ['Resource-use']
with O
IND/GLY O
vs O
SFC O
were O
comparable O
between O
men O
and O
women. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

Between O
December O
1983 O
and O
December O
1988 O
, O
we O
conducted O
two O
trials O
simultaneously O
: O
one O
aimed O
at O
patients O
without O
HBV O
markers O
and O
the O
second O
at O
patients O
with O
HBV O
markers O
. O
[]

RESULTS O
All O
the O
patients O
were O
followed O
up O
, O
and O
the O
duration O
ranged O
from O
12 O
to O
30 O
months O
, O
with O
an O
average O
of O
15.6 O
months O
. O
[]

CONCLUSION O
In O
comparison O
to O
electrosurgical O
resection O
during O
hysteroscopic O
polypectomy O
, O
morcellation O
was O
significantly O
quicker O
, O
less O
painful B-outcome ['Physiological-Clinical']
, O
more O
acceptable B-outcome ['Life-Impact']
to O
women O
, O
and O
more O
likely O
to O
completely B-outcome ['Physiological-Clinical']
remove I-outcome ['Physiological-Clinical']
endometrial I-outcome ['Physiological-Clinical']
polyps I-outcome ['Physiological-Clinical']
compared O
with O
electrosurgical O
resection O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Laryngoscopy O
and O
tracheal O
intubation O
may O
provoke O
changes O
of O
cardiac B-outcome ['Physiological-Clinical']
repolarisation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Left O
ventricular O
( O
LV O
) O
hypertrophy O
is O
known O
to O
be O
an O
independent O
risk O
factor O
for O
cardiac O
death O
, O
but O
its O
significance O
in O
non-Q-wave O
acute O
myocardial O
infarction O
( O
AMI O
) O
has O
not O
been O
assessed O
previously O
. O
[]

The O
best O
results O
are O
obtained O
by O
integration O
with O
wall O
motion O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
feasibility O
and O
anti-inflammatory B-outcome ['Physiological-Clinical']
effects O
of O
100-125 O
ppm O
CO O
inhalation O
in O
patients O
with O
stable O
COPD O
. O
['Physiological-Clinical']

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India. O
[]

The O
findings O
of O
this O
study O
suggest O
that O
sibutramine O
treatment O
promotes O
thermogenesis B-outcome ['Physiological-Clinical']
, O
thus O
facilitating O
weight O
loss B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Treatment O
with O
sevoflurane O
before O
coronary O
occlusion O
seem O
effective O
in O
reducing O
functional B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
due O
to O
ischemia O
. O
['Physiological-Clinical']

For O
those O
who O
reported O
more O
alcohol O
consequences O
at O
baseline O
, O
the O
alcohol O
intervention O
resulted O
in O
significantly O
less O
alcohol O
use O
and O
fewer O
heavy B-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
at O
follow-up O
, O
while O
no O
difference O
was O
observed O
between O
intervention O
conditions O
for O
those O
with O
few O
baseline O
consequences O
. O
['Life-Impact']

METHODS O
This O
14-day O
, O
multicenter O
, O
randomized O
, O
double-blind O
study O
was O
conducted O
during O
the O
Texas O
mountain O
cedar O
season O
. O
[]

A O
total O
of O
2771 O
pregnant O
women O
with O
gestational O
age O
estimated O
by O
ultrasound O
measurement O
of O
the O
fetal O
biparietal O
diameter O
( O
BPD O
) O
before O
the O
22nd O
week O
of O
gestation O
were O
re-examined O
by O
ultrasound O
in O
the O
32nd O
and O
37th O
week O
of O
pregnancy O
at O
which O
time O
the O
fetal O
BPD O
and O
abdominal O
diameter O
( O
AD O
) O
were O
measured O
. O
[]

Within O
24 O
h O
after O
operation, O
the O
sufentanil B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
in O
group O
D[(35.86+/-8.65)mug]was O
significantly O
less O
than O
that O
in O
group O
C[(59.53+/-15.26) O
mug, O
t=7.061, O
P<0.05], O
and O
the O
number O
of O
patient O
controlled O
analgesia B-outcome ['Resource-use']
pressing O
in O
group O
D(2.15+/-1.38) O
was O
obviously O
less O
than O
that O
in O
group O
C(5.85+/-2.16, O
t=4.971, O
P<0.05). O
[['Resource-use'], ['Resource-use']]

Throughout O
the O
study O
smokers O
were O
more O
likely O
to O
dropout O
than O
non-smokers O
. O
[]

Both O
drugs O
were O
associated O
with O
the O
topical O
application O
of O
povidone O
iodine O
. O
[]

Age O
, O
FIGO O
stage O
, O
histologic O
grade O
, O
and O
residual O
disease O
all O
exerted O
a O
significant O
effect O
on O
survival O
time O
. O
[]

However O
, O
all O
patients O
had O
a O
unilateral O
uptake O
of O
the O
tracer O
on O
the O
side O
of O
the O
mass O
with O
suppression O
of O
the O
contralateral O
normal O
adrenal O
gland O
. O
[]

BACKGROUND O
The O
problem O
of O
ghostwriting O
in O
corporate-sponsored O
clinical O
trials O
is O
of O
concern O
to O
medicine O
, O
bioethics O
, O
and O
government O
agencies O
. O
[]

METHODS O
Sixty-six O
subjects O
were O
randomised O
to O
SFC O
or O
FP/M O
for O
12 O
weeks O
. O
[]

Clinicaltrials.gov O
NCT01702974. O
[]

Infants O
of O
dexamethasone-treated O
dams O
had O
significantly O
lower O
incidence O
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HMD I-outcome ['Physiological-Clinical']
than O
did O
infants O
of O
control O
animals O
( O
50 O
versus O
92 O
% O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

It O
is O
also O
associated O
with O
ritualistic O
and O
stereotypical O
behaviour O
. O
[]

The O
combination O
of O
infusion O
5 O
FU O
and O
methyl-CCNU O
achieved O
responses B-outcome ['Physiological-Clinical']
in O
9 O
% O
and O
5 O
% O
of O
stomach O
and O
pancreatic O
tumors O
, O
respectively O
. O
['Physiological-Clinical']

METHOD O
A O
randomized O
clinical O
trial O
that O
included O
a O
convenience O
sample O
of O
first O
time O
CABG O
patients O
. O
[]

The O
IT O
group O
demonstrated O
significant O
improvements O
with O
medium O
to O
large O
effect O
sizes O
in O
their O
responsiveness B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
diversity I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
after O
the O
intervention O
with O
maintenance O
of O
these O
skills O
1 O
year O
post-intervention O
. O
['Life-Impact']

All O
patients O
in O
both O
groups O
that O
completed O
COMET O
were O
contacted O
3 O
and O
6 O
months O
later O
to O
assess O
whether O
the O
effects O
of O
COMET O
had O
remained O
stable O
. O
[]

Paracervical O
anesthesia O
for O
outpatient B-outcome ['Resource-use']
hysteroscopy I-outcome ['Resource-use']
. O
['Resource-use']

OBJECTIVES O
Palpitations O
can O
generate O
feelings O
of O
anxiety B-outcome ['Life-Impact']
and O
decrease O
quality O
of O
life O
( O
QoL B-outcome ['Life-Impact']
) O
due O
to O
fear O
of O
a O
cardiac O
abnormality O
. O
['Life-Impact', 'Life-Impact']

In O
the O
initial O
2 O
weeks O
of O
active O
drug O
listlessness O
, O
food B-outcome ['Life-Impact']
refusal I-outcome ['Life-Impact']
, O
and O
stomach B-outcome ['Physiological-Clinical']
upset I-outcome ['Physiological-Clinical']
were O
frequently O
seen O
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Recent O
studies O
have O
suggested O
that O
exposure O
to O
air O
pollutants O
may O
enhance O
the O
airway O
responsiveness O
of O
susceptible O
individuals O
to O
inhaled O
allergen O
. O
[]

All O
the O
patients O
were O
evaluated O
for O
toxicity B-outcome ['Adverse-effects']
and O
survival B-outcome ['Mortality']
according O
to O
the O
as-treated O
principle O
. O
['Adverse-effects', 'Mortality']

Effect O
of O
perception O
of O
mechanical O
loading O
on O
human B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
regulation O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effect O
of O
budesonide O
Turbuhaler O
400 O
microg/day O
with O
budesonide O
aqua O
256 O
microg/day O
in O
the O
treatment O
of O
seasonal O
allergic O
rhinitis O
( O
SAR O
) O
. O
[]

OBJECTIVE O
To O
identify O
factors O
associated O
with O
completion O
of O
care O
among O
foreign-born O
adolescents O
treated O
for O
latent O
tuberculosis O
infection O
( O
LTBI O
) O
. O
[]

Of O
the O
62 O
patients O
who O
entered O
the O
study O
, O
51 O
were O
considered O
evaluable O
( O
24 O
with O
adjuvant O
hormone O
therapy O
and O
27 O
with O
no O
further O
treatment O
) O
. O
[]

The O
population-based O
program O
provides O
primarily O
telephonic O
patient O
education O
and O
monitoring O
services O
. O
[]

CONCLUSION O
The O
results O
suggest O
that O
the O
combination O
of O
topiramate O
with O
risperidone O
may O
be O
superior O
to O
risperidone O
monotherapy O
for O
children O
with O
autistic O
disorder O
. O
[]

Seventeen O
individuals O
had O
approximal O
surfaces O
with O
consistently O
high O
or O
consistently O
low O
S. O
mutans B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Each O
treatment O
lasted O
4 O
weeks O
with O
2 O
weeks O
of O
washout O
in O
between O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

OBJECTIVES O
To O
evaluate O
the O
effectiveness O
of O
a O
back O
support O
plus O
education O
versus O
education O
alone O
in O
promoting O
recovery O
from O
a O
work-related O
low O
back O
disorder O
( O
WR-LBD O
) O
while O
simultaneously O
considering O
personal O
, O
health O
, O
and O
occupational O
factors O
and O
the O
impact O
of O
occupational O
factors O
on O
recovery O
. O
[]

The O
median O
duration B-outcome ['Mortality']
of I-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
ANLL O
patients O
was O
significantly O
longer O
( O
P O
= O
0.004 O
) O
than O
that O
of O
ALL O
patients O
treated O
on O
Regimens O
I O
and O
II O
combined O
. O
['Mortality']

Educational O
intervention O
for O
altering O
water-sanitation O
behavior O
to O
reduce O
childhood O
diarrhea B-outcome ['Physiological-Clinical']
in O
urban O
Bangladesh O
: O
impact O
on O
nutritional O
status O
. O
['Physiological-Clinical']

It O
is O
unclear O
whether O
ACEi O
provide O
additional O
benefit O
when O
added O
to O
a O
standard O
exercise O
training O
program O
. O
[]

Immunogenicity B-outcome ['Physiological-Clinical']
was O
measured O
by O
specific O
IgG O
( O
Mite O
) O
and O
IgG4 O
( O
Mite O
) O
, O
by O
antibody-blocking O
properties O
on O
basophil O
activation O
, O
and O
by O
the O
T O
cell O
subset O
transcription O
factors O
Foxp3 O
, O
T-bet O
, O
and O
GATA-3 O
. O
['Physiological-Clinical']

Cost-effectiveness O
of O
clozapine O
compared O
with O
conventional O
antipsychotic O
medication O
for O
patients O
in O
state O
hospitals O
. O
[]

The O
efficacy O
was O
evaluated O
in O
two O
groups O
. O
[]

We O
conclude O
that O
in O
our O
open O
label O
pilot O
study O
, O
the O
antihypertensive O
activity O
of O
valsartan O
is O
not O
significantly O
attenuated O
by O
supplemented O
salt O
diet O
in O
hypertensive O
African O
Americans O
. O
[]

A O
total O
of O
17 O
patients O
were O
entered O
, O
eight O
in O
group O
A O
and O
nine O
in O
group O
B O
. O
[]

These O
results O
have O
implications O
for O
the O
design O
and O
evaluation O
of O
behavioral O
intervention O
studies O
. O
[]

DNA O
was O
extracted O
from O
all O
swabs O
and O
HSV-1 O
DNA O
copy O
numbers O
were O
determined O
. O
[]

INTERVENTIONS O
Neurosurgical O
patients O
' O
hands O
and O
forearms O
were O
covered O
for O
15 O
minutes O
with O
a O
carbon O
fibre O
heating O
mitt O
. O
[]

Substance O
use O
relapse O
rates O
are O
often O
high O
in O
the O
first O
months O
after O
discharge O
from O
inpatient O
substance O
abuse O
treatment O
, O
and O
patient B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
aftercare I-outcome ['Life-Impact']
plans O
is O
often O
low O
. O
['Life-Impact']

This O
study O
assessed O
the O
diagnostic B-outcome ['Life-Impact']
accuracy O
of O
coronary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
evaluation O
obtained O
by O
three O
readers O
at O
different O
levels O
of O
training O
or O
at O
different O
points O
of O
the O
learning O
curve O
proposed O
by O
the O
international O
guidelines O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
To O
observe O
the O
efficacy O
of O
encephalopathy O
therapeutic O
tongue O
acupoint O
apparatus O
( O
ETTAA O
) O
in O
the O
treatment O
of O
autism O
. O
[]

On O
sheath O
removal O
, O
hemostasis O
was O
obtained O
using O
the O
TR O
band O
with O
a O
plethysmography-guided O
patent O
hemostasis O
technique O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Change O
in O
the O
clinical O
symptom B-outcome ['Physiological-Clinical']
score O
( O
consisting O
of O
the O
subscores O
redness B-outcome ['Physiological-Clinical']
, O
swelling B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
secretion B-outcome ['Physiological-Clinical']
) O
and O
of O
the O
visual O
analogue O
scale O
( O
VAS O
) O
rating O
for O
pain B-outcome ['Physiological-Clinical']
from O
Visit O
1 O
( O
Day O
1 O
) O
to O
Visit O
2 O
( O
Day O
4 O
+/- O
1 O
) O
, O
patient O
's O
assessment O
of O
efficacy O
at O
Visit O
3 O
( O
Day O
10 O
+/- O
2 O
) O
, O
and O
the O
frequency O
and O
type O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
subsequent O
dose O
of O
spinal O
bupivacaine O
was O
determined O
by O
the O
improved O
up-down O
allocation O
method. O
[]

PATIENTS O
AND O
METHODS O
Of O
462 O
patients O
with O
disseminated O
disease O
, O
49 O
( O
10.6 O
% O
) O
had O
CNS O
disease O
at O
diagnosis O
( O
CNS+ O
) O
. O
[]

Clinical O
variables O
, O
including O
stomatitis B-outcome ['Physiological-Clinical']
, O
and O
laboratory O
parameters O
, O
such O
as O
CD4 O
( O
+ O
) O
and O
CD8 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
FeLV I-outcome ['Physiological-Clinical']
p I-outcome ['Physiological-Clinical']
27 I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
were O
recorded O
throughout O
the O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
difference O
in O
the O
prevalence O
of O
PONV O
was O
found O
between O
patients O
receiving O
propofol O
and O
those O
receiving O
droperidol O
, O
and O
propofol O
and O
droperidol O
were O
associated O
with O
significantly O
lower O
prevalences O
of O
PONV O
compared O
with O
metoclopramide O
( O
P O
= O
0.022 O
and O
P O
= O
0.043 O
, O
respectively O
) O
. O
[]

Patients O
were O
eligible O
for O
treatment O
with O
the O
alternate O
therapy O
at O
third O
line O
. O
[]

BACKGROUND O
Whiplash-associated O
disorder O
( O
or O
whiplash O
) O
is O
a O
common O
condition O
incurring O
considerable O
expense O
in O
social O
and O
economic O
terms O
. O
[]

Patients O
in O
the O
MVPF O
film O
group O
also O
reported O
significantly O
less O
difficulty O
in O
wound B-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
and O
in O
dressing B-outcome ['Life-Impact']
interference I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

At O
a O
cut-off O
of O
26 O
, O
the O
AQ-J B-outcome ['Physiological-Clinical']
had O
satisfactory B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
, O
specificity O
, O
and O
negative O
predictive O
value O
, O
but O
it O
had O
low O
positive O
predictive O
value O
( O
0.24 O
) O
possibly O
due O
to O
the O
facts O
that O
the O
25 O
mild O
HPDD O
patients O
scored O
lower O
and O
the O
controls O
scored O
higher O
on O
the O
AQ-J O
than O
British O
counterparts O
on O
the O
AQ O
. O
['Physiological-Clinical', 'Life-Impact']

40 O
subjects O
participated O
in O
this O
parallel O
, O
randomized O
, O
double O
blind O
, O
prospective O
longitudinal O
clinical O
study O
following O
active O
peridontal O
therapy O
. O
[]

AIM O
This O
study O
investigated O
whether O
pre- O
and O
postmenopausal O
women O
with O
sexual O
arousal O
disorder O
are O
less O
genitally O
responsive O
to O
visual O
sexual O
stimuli O
than O
pre- O
and O
postmenopausal O
women O
without O
sexual O
problems O
. O
[]

We O
compared O
the O
incidence O
and O
frequency O
of O
hypotension B-outcome ['Physiological-Clinical']
and O
vasopressor B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
after O
spinal O
anesthesia O
and O
no O
prehydration O
with O
crystalloid O
and O
colloid O
prehydration O
in O
elderly O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Methylphenidate B-outcome ['Life-Impact']
dosing I-outcome ['Life-Impact']
was O
significantly O
higher O
in O
individuals O
on O
L-methylfolate O
over O
time O
(chi O
= O
7.35, O
P O
= O
0.007). O
[['Life-Impact']]

The O
overall O
approach O
includes O
providing O
universal O
access O
to O
diagnosis O
and O
treatment O
of O
malaria, O
and O
sustainable O
preventive O
measures, O
including O
vector O
control. O
[]

The O
subjective O
improvement O
in O
various O
degrees O
and O
the O
shrinkage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
in O
the O
X-ray O
films O
were O
present O
in O
5/25 O
cases O
who O
received O
preoperative O
chemotherapy O
. O
['Physiological-Clinical']

The O
first O
group O
( O
n O
= O
49 O
) O
received O
ketoconazole O
( O
400 O
mg O
daily O
) O
till O
correction O
of O
metabolic O
syndrome O
followed O
by O
clomiphene O
( O
100 O
mg/day O
) O
; O
the O
second O
group O
( O
n O
= O
48 O
) O
receiving O
clomiphene O
without O
ketoconazole O
pretreatment O
. O
[]

Methods O
in O
situ O
are O
recently O
available O
to O
study O
separately O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
of O
dental B-outcome ['Physiological-Clinical']
tissues I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
above O
findings O
demonstrated O
that O
root O
planning O
is O
effective O
in O
the O
treatment O
of O
furcation O
involvement O
and O
that O
the O
effects O
are O
enhanced O
by O
the O
local O
administration O
of O
TC O
films O
. O
[]

The O
use O
of O
a O
PSA-D O
threshold O
value O
of O
0 O
. O
[]

Parent O
expansions O
of O
child O
verbal O
utterances O
predicted O
spoken B-outcome ['Life-Impact']
vocabulary I-outcome ['Life-Impact']
after O
controlling O
for O
child O
talkativeness O
. O
['Life-Impact']

The O
animals O
in O
group O
1 O
( O
RDN0 O
) O
were O
fed O
with O
ad O
libitum O
FMS O
. O
[]

SETTING O
Kanta-Hame O
Central O
Hospital O
, O
a O
district O
referral O
center O
in O
Finland O
. O
[]

Journal O
ID: O
101307187 O
[]

The O
QLQ-C30 O
incorporates O
five O
functional O
scales O
, O
three O
symptom O
scales O
, O
a O
global O
health O
and O
quality-of O
life O
scale O
and O
some O
single O
symptom O
measures O
. O
['Life-Impact']

METHODS: O
In O
2 O
similarly O
designed O
studies O
of O
patients O
with O
episodic O
migraine O
(6 O
months) O
and O
1 O
study O
of O
patients O
with O
chronic O
migraine O
(3 O
months), O
patients O
randomized O
in O
a O
1:1:2 O
ratio O
received O
a O
subcutaneous O
injection O
of O
galcanezumab O
120 O
mg/month O
(after O
an O
initial O
loading O
dose O
of O
240 O
mg) O
or O
240 O
mg/month O
or O
placebo. O
[]

An O
excess O
of O
renal O
AEs O
and O
acute-phase O
reactions O
occurred O
with O
zoledronic O
acid O
; O
hypocalcemia O
occurred O
more O
frequently O
with O
denosumab O
. O
[]

On O
day O
28, O
mean O
cry B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
fuss B-outcome ['Life-Impact', 'Life-Impact']
time E1-outcome ['Life-Impact', 'Life-Impact']
became O
statistically O
different: O
142 O
(89) O
vs. O
199 O
(72), O
respectively O
(p O
< O
0.05). O
[['Life-Impact', 'Life-Impact']]

The O
administration O
of O
NMES O
or O
sham O
NMES, O
as O
intervention, O
was O
performed O
for O
an O
8-week O
period O
treatment, O
and O
4-week O
period O
follow-up. O
[]

STUDY O
OBJECTIVE O
To O
investigate O
the O
effect O
of O
simultaneously O
administered O
didanosine O
( O
ddI O
) O
on O
the O
absorption O
of O
a O
single O
dose O
of O
itraconazole O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
the O
proportion O
of O
[]

Intravesical O
treatment O
with O
adriamycin O
has O
been O
extensively O
employed O
in O
the O
last O
decade O
. O
[]

Change O
in O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
( O
peak O
VO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) O
and O
quality O
of O
life O
( O
secondary O
) O
. O
['Life-Impact', 'Physiological-Clinical']

At O
all O
doses O
up O
to O
600 O
mg O
, O
Ro O
15-1788 O
demonstrated O
none O
of O
the O
classical O
behavioural B-outcome ['Life-Impact']
effects O
of O
the O
benzodiazepines O
. O
['Life-Impact']

Evaluation O
of O
electrofunctional O
data O
following O
argon-laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
. O
[]

METHODS O
AND O
MATERIALS O
The O
prospective O
study O
included O
112 O
patients O
with O
advanced O
larynx O
cancer O
after O
radical O
surgical O
treatment O
. O
[]

A O
further O
randomised O
study O
of O
marimastat O
in O
these O
patients O
is O
warranted O
. O
[]

METHODS: O
Cross-sectional O
survey O
of O
1191 O
low O
caste O
girls O
in O
two O
districts O
in O
north O
Karnataka, O
conducted O
as O
part O
of O
a O
cluster O
randomised-control O
trial. O
[]

INTERVENTIONS O
Assignment O
in O
a O
1 O
: O
1 O
ratio O
to O
a O
diagnostic O
strategy O
including O
point-of-care O
measurement O
of O
BNP O
( O
n O
= O
163 O
) O
or O
standard O
assessment O
without O
BNP O
( O
n O
= O
160 O
) O
. O
[]

Both O
groups O
of O
animals O
received O
individual O
supportive O
treatment O
consisting O
of O
adjusted O
diet O
and O
electrolyte O
solution O
. O
[]

CONCLUSION O
RFA O
took O
longer O
to O
perform O
but O
resulted O
in O
a O
significantly O
better O
early O
outcome O
than O
conventional O
surgery O
in O
suitable O
patients O
with O
great O
saphenous O
varicose O
veins O
. O
[]

Ninety O
nine O
patients O
( O
group O
A O
) O
were O
randomized O
to O
receive O
paclitaxel O
175 O
mg/m2 O
in O
three-hour O
infusion O
plus O
carboplatin O
dosed O
to O
an O
area O
under O
the O
concentration-time O
curve O
of O
6 O
every O
3 O
weeks O
and O
99 O
( O
group O
B O
) O
to O
receive O
the O
same O
regimen O
with O
paclitaxel O
increased O
to O
225 O
mg/m2 O
. O
[]

Neuroimaging O
studies O
have O
shown O
the O
engagement O
of O
the O
left O
dorsolateral O
prefrontal O
cortex O
( O
DLPFC O
) O
in O
executive O
functioning O
, O
and O
more O
specifically O
during O
selective O
attention O
. O
[]

At O
the O
end O
of O
the O
follow-up O
, O
an O
investigation O
of O
the O
immune B-outcome ['Physiological-Clinical']
status O
was O
done O
, O
and O
compared O
with O
that O
of O
a O
healthy O
control-group O
. O
['Physiological-Clinical']

Differences O
between O
two O
groups O
each O
time O
showed O
no O
statistical O
significance O
(p O
> O
0.05). O
[]

CONCLUSIONS O
This O
is O
the O
first O
ASD O
randomized O
trial O
involving O
toddlers O
to O
identify O
an O
active O
ingredient O
for O
enhancing O
socially O
engaged O
imitation O
. O
[]

Elevated B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
counts O
, O
elevated B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
counts O
, O
and O
a O
high O
neutrophil-lymphocyte B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
were O
significant O
independent O
predictors O
for O
shorter O
OS O
in O
a O
model O
with O
established O
prognostic O
factors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Aberrant O
Behavior O
Checklist-Community O
Version O
( O
ABC-CV O
) O
and O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
( O
CGI O
) O
scale O
were O
used O
as O
outcome O
variables O
. O
['Life-Impact', 'Physiological-Clinical']

This O
study O
is O
registered O
, O
number O
ISRCTN78390996 O
. O
[]

Data O
suggest O
that O
inflammation O
can O
contribute O
to O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
although O
the O
converse O
remains O
untested O
. O
['Life-Impact']

The O
therapeutic O
benefits O
of O
LOWFODMAP O
diets O
in O
recreational O
and O
trained O
athletes O
during O
sustained O
training O
periods O
warrants O
further O
investigation. O
[]

The O
less O
favourable O
improvement O
in O
periodontal O
function O
of O
postsplint O
or O
nonsplint O
teeth O
seemed O
to O
be O
due O
to O
the O
loss O
of O
BRG B-outcome ['Physiological-Clinical']
material I-outcome ['Physiological-Clinical']
caused O
by O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Spectral O
analysis O
was O
performed O
on O
the O
all-night O
records O
( O
1-min O
epochs O
) O
, O
and O
the O
relative O
power O
of O
six O
frequency O
bands O
calculated O
. O
[]

From O
a O
previously O
reported O
5-year O
screening O
programme O
of O
6,956 O
47-49-year-old O
Malm? O
males O
, O
a O
series O
of O
41 O
subjects O
with O
early-stage O
Type O
2 O
( O
non-insulin-dependent O
) O
diabetes O
mellitus O
and O
181 O
subjects O
with O
impaired O
glucose O
tolerance O
were O
selected O
for O
prospective O
study O
and O
to O
test O
the O
feasibility O
aspect O
of O
long-term O
intervention O
with O
an O
emphasis O
on O
life-style O
changes O
. O
[]

Funded O
by O
the O
National O
Cancer O
Institute O
and O
others; O
ClinicalTrials.gov O
number, O
NCT02066181 O
.). O
[]

METHODS O
We O
used O
a O
prospective O
study O
that O
utilized O
the O
Short-Form O
36 O
Survey O
at O
baseline O
presentation O
and O
at O
a O
mean O
time O
of O
3 O
years O
post-functional O
endoscopic O
sinus O
surgery O
to O
assess O
the O
general O
health O
status O
of O
patients O
who O
presented O
for O
their O
initial O
visitfrom O
1996 O
to O
1998 O
. O
[]

A O
single O
prophylactic O
intraoperative O
dose O
of O
intravenous O
amiodarone O
decreased O
post B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
arrhythmia I-outcome ['Physiological-Clinical']
in O
this O
study O
in O
comparison O
to O
the O
control O
group O
. O
['Physiological-Clinical']

It O
is O
devoid O
of O
any O
behavioural O
activity O
in O
animals O
, O
except O
at O
very O
high O
doses O
. O
[]

Tolerability B-outcome ['Life-Impact']
was O
good O
, O
except O
in O
1 O
patient O
on O
placebo O
, O
who O
was O
withdrawn O
from O
the O
study O
because O
of O
severe B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
study O
was O
designed O
as O
a O
large O
simple O
trial O
with O
a O
large O
number O
of O
centers O
( O
302 O
) O
in O
the O
United O
States O
and O
Canada O
, O
many O
of O
which O
were O
inexperienced O
in O
research O
. O
[]

Seventy-one O
alcohol-dependent O
subjects O
were O
detoxified O
and O
subsequently O
randomised O
into O
two O
groups O
, O
receiving O
50 O
mg O
of O
NAL O
or O
150-450 O
mg O
of O
PRE O
. O
[]

The O
experimental O
groups O
performed O
either O
endurance O
or O
resistance O
training O
3 O
days O
a O
week O
for O
12 O
weeks O
. O
[]

The O
analysis O
of O
individual O
target O
symptoms O
and O
the O
parents O
' O
treatment O
preferences O
substantiated O
the O
beneficial O
effects O
of O
ORG O
2766 O
. O
[]

The O
superficial O
needle O
insertion O
into O
the O
skin O
overlaying O
the O
right O
thenar O
muscle O
caused O
a O
pronounced O
balanced O
increase O
in O
both O
the O
sympathetic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
parasympathetic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
post O
stimulation O
period O
of O
60 O
min O
( O
P O
< O
0.01 O
) O
while O
no O
changes O
were O
observed O
during O
the O
stimulation O
period O
. O
['Physiological-Clinical']

A O
total O
of O
108 O
volunteers O
undergoing O
an O
elective O
surgical O
procedure O
were O
randomly O
given O
a O
single O
2-g O
intravenous O
prophylactic O
dose O
of O
either O
a O
cephalosporin O
or O
mezlocillin O
. O
[]

Pedantic O
speaking O
style O
differentiates O
Asperger O
syndrome O
from O
high-functioning O
autism O
. O
[]

OBJECTIVE O
To O
describe O
the O
clinical O
characteristics O
and O
survival O
experience O
of O
a O
prospectively O
followed O
up O
group O
of O
patients O
with O
small O
choroidal O
melanoma O
. O
[]

CONCLUSIONS O
In O
patients O
with O
high-risk O
resected O
melanoma O
, O
HDI O
is O
effective O
adjuvant O
therapy O
with O
strong O
evidence O
for O
improved O
RFS B-outcome ['Mortality']
and O
evidence O
for O
moderate O
improvement O
in O
OS B-outcome ['Mortality']
based O
on O
two O
prospective O
randomized O
studies O
but O
not O
the O
pooled O
analysis O
. O
['Mortality', 'Mortality']

The O
changes O
of O
scores O
of O
IQ B-outcome ['Life-Impact']
were O
determined O
with O
Gesell O
and O
WPPSI O
or O
WISC-R O
. O
['Life-Impact']

The O
study O
participants O
were O
divided O
randomly O
into O
two O
groups: O
the O
supplemented O
group O
ingested O
caffeine O
before O
exercise O
(GCAF), O
while O
the O
control O
group O
was O
given O
a O
placebo O
(GCON). O
[]

Complete B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cords I-outcome ['Physiological-Clinical']
was O
present O
in O
all O
but O
two O
patients O
, O
one O
in O
each O
group O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
investigation O
was O
to O
determine O
the O
effect O
of O
unexpected O
forward O
perturbations O
( O
FP O
) O
during O
gait O
on O
lower O
extremity B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
mechanics I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
Electromyographic I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EMG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
in O
healthy O
adults O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fewer O
patients O
in O
the O
experimental O
arm O
reported O
both O
pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
at O
20 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ClinicalTrials.gov O
number O
, O
NCT00479375 O
[ O
ClinicalTrials.gov O
] O
. O
) O
. O
[]

These O
results O
are O
discussed O
in O
relation O
to O
the O
effects O
of O
frustration O
. O
[]

Lactational B-outcome ['Physiological-Clinical']
amenorrhea I-outcome ['Physiological-Clinical']
( O
LA O
) O
is O
associated O
with O
postpartum O
infertility O
and O
is O
known O
to O
be O
related O
to O
breast-feeding O
frequency O
and O
duration O
, O
but O
the O
exact O
role O
of O
complementary O
feeding O
of O
the O
infant O
has O
not O
been O
clearly O
defined O
. O
['Physiological-Clinical']

Differences O
in O
treatment O
efficacy O
were O
assessed O
by O
ANCOVA O
. O
[]

They O
were O
followed O
for O
another O
8 O
weeks O
before O
retesting O
hs-CRP O
and O
TA O
. O
[]

Two O
of O
42 O
patients O
who O
underwent O
resection O
and O
had O
been O
treated O
with O
n-BCA O
experienced O
[]

The O
control O
group O
consisted O
of O
patients O
who O
received O
no O
specific O
training O
. O
[]

The O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stomatitis I-outcome ['Physiological-Clinical']
and O
mucositis B-outcome ['Physiological-Clinical']
was O
0.6 O
% O
in O
the O
mitoxantrone O
group O
and O
8.4 O
% O
in O
the O
doxorubicin O
group O
( O
P O
= O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS: O
Once-daily O
plazomicin O
was O
noninferior O
to O
meropenem O
for O
the O
treatment O
of O
complicated O
UTIs O
and O
acute O
pyelonephritis O
caused O
by O
Enterobacteriaceae, O
including O
multidrug-resistant O
strains. O
( O
[]

There O
was O
a O
correspondence O
in O
6 O
of O
the O
7 O
patients O
with O
positive O
reaction O
in O
aR O
between O
both O
methods O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
that O
MCT O
oil O
can O
be O
incorporated O
into O
a O
weight O
loss O
program O
without O
fear O
of O
adversely O
affecting O
metabolic O
risk O
factors O
. O
[]

OBJECTIVE O
To O
assess O
the O
effect O
of O
a O
nutritional O
supplement O
containing O
vitamin O
E O
, O
selenium O
, O
vitamin O
C O
and O
coenzyme O
Q10 O
on O
changes O
in O
serum O
levels O
of O
PSA O
in O
patients O
with O
hormonally O
untreated O
carcinoma O
of O
the O
prostate O
and O
rising O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
current O
analysis O
showed O
that O
fulvestrant O
was O
similar O
to O
anastrozole O
with O
respect O
to O
overall O
survival O
in O
the O
second-line O
treatment O
of O
postmenopausal O
women O
with O
advanced O
breast O
carcinoma O
. O
[]

Patients O
were O
induced O
with O
midazolam O
0.1 O
mg/kg O
, O
fentanyl O
5 O
?g/kg O
, O
propofol O
1-1.5 O
mg/kg O
, O
and O
suxamethonium O
1.5 O
mg/kg O
. O
[]

CONCLUSIONS O
Trophic O
feeding O
improves O
clinical O
outcome O
in O
ill O
preterm O
infants O
requiring O
parenteral O
nutrition O
. O
[]

Thus O
, O
increased O
plasma B-outcome ['Physiological-Clinical']
tyrosine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
low-birth-weight O
infants O
are O
related O
directly O
both O
to O
the O
quantity O
and O
to O
the O
quality O
of O
the O
protein O
in O
their O
diets O
. O
['Physiological-Clinical']

METHODS O
We O
randomly O
assigned O
60 O
patients O
attending O
for O
ECV O
of O
persistent O
AF O
to O
a O
transesophageal O
or O
a O
transthoracic O
approach O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND O
Blocking O
the O
renin-angiotensin O
system O
( O
RAS O
) O
with O
angiotensin O
receptor O
blockers O
or O
angiotensin-converting O
enzyme O
inhibitors O
protects O
against O
renal O
injury O
in O
patients O
with O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

= O
1.68 O
, O
P O
= O
0.002 O
; O
F O
= O
8.21 O
, O
d.f O
. O
[]

METHODS O
We O
studied O
433 O
patients O
( O
36.0 O
% O
women O
) O
from O
the O
M-HART O
treatment O
group O
who O
received O
two O
home O
visits O
after O
achieving O
a O
high O
psychological O
distress O
score O
( O
ie O
, O
> O
or O
=5 O
) O
on O
the O
General O
Health O
Questionnaire O
( O
GHQ O
) O
. O
[]

The O
difference O
in O
time O
to O
relapse O
between O
aripiprazole O
and O
placebo O
was O
not O
statistically O
significant O
( O
P O
= O
.097 O
) O
. O
[]

PARTICIPANTS O
Participants O
were O
195 O
Veterans O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials O
identifier O
: O
NCT01195025 O
. O
[]

The O
present O
study O
examined O
the O
emotional B-outcome ['Life-Impact']
reactivity I-outcome ['Life-Impact']
of O
persons O
with O
heightened O
borderline O
personality O
( O
BP O
) O
features O
to O
social O
rejection O
and O
negative O
evaluation O
in O
the O
laboratory O
. O
['Life-Impact']

A O
value O
of O
P O
less O
than O
.05 O
was O
considered O
statistically O
significant O
. O
[]

Polycystic O
ovary O
syndrome O
and O
cardiovascular O
risk O
in O
young O
patients O
treated O
with O
drospirenone-ethinylestradiol O
or O
contraceptive O
vaginal O
ring O
. O
[]

The O
loss O
of O
HBsAg B-outcome ['Physiological-Clinical']
in O
addition O
to O
HBeAg B-outcome ['Physiological-Clinical']
and O
hepatitis B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
was O
more O
likely O
to O
occur O
in O
patients O
with O
chronic O
infection O
of O
less O
than O
2 O
years O
duration O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Measurements O
were O
repeated O
3 O
times O
for O
each O
specimen O
. O
[]

CONCLUSION O
[]

Children O
with O
no O
GI O
problems O
are O
unaffected O
by O
either O
secretin O
or O
placebo O
. O
[]

This O
study O
was O
designed O
to O
determine O
the O
effects O
of O
ascorbic O
acid O
supplementation O
on O
circulating O
biomarkers O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
following O
a O
single O
bout O
of O
exercise. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
therapy O
was O
either O
active O
40 O
KHz O
ultrasound O
delivered O
by O
a O
saline O
mist O
or O
a O
sham O
device O
which O
delivered O
a O
saline O
mist O
without O
the O
use O
of O
ultrasound O
. O
[]

The O
efficacy O
was O
assessed O
by O
serial O
Holter B-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Trainees O
put O
emphasis O
on O
the O
development O
of O
their O
personal O
relationship O
with O
the O
client O
. O
[]

Journal-Name:BMC O
public O
health O
[]

OBJECTIVE O
To O
compare O
the O
outcomes O
of O
an O
adapted O
pilot O
Changing O
Childbirth O
initiative O
providing O
continuity O
of O
care O
by O
a O
group O
of O
known O
midwives O
with O
traditional O
maternity O
care O
. O
[]

PATIENTS O
The O
study O
population O
consisted O
of O
head O
injured O
, O
blunt O
trauma O
adult O
patients O
with O
a O
Glasgow O
Coma O
Scale O
of O
lower O
than O
9 O
. O
[]

Recent O
anecdotal O
reports O
have O
touted O
the O
gastrointestinal O
( O
GI O
) O
hormone O
secretin O
as O
a O
treatment O
modality O
for O
autism O
, O
though O
there O
is O
little O
clinical O
evidence O
or O
literature O
to O
support O
its O
viability O
. O
[]

The O
VARS O
of O
EQ-5D O
also O
disclosed O
significant O
changes O
from O
day O
2 O
( O
17 O
, O
P O
< O
0.01 O
) O
. O
[]

Types O
of O
chronic O
pain O
included O
back O
( O
214 O
; O
45.6 O
% O
) O
, O
arthritic O
( O
145 O
; O
30.9 O
% O
) O
, O
other O
musculoskeletal O
( O
65 O
; O
13.9 O
% O
) O
, O
cancer O
( O
6 O
; O
1.3 O
% O
) O
, O
diabetic O
neuropathic O
( O
3 O
; O
0.6 O
% O
) O
, O
postherpetic O
neuralgic O
( O
5 O
; O
1.1 O
% O
) O
, O
other O
neurologic O
( O
21 O
; O
4.5 O
% O
) O
, O
and O
other O
unclassified O
chronic O
pain O
( O
10 O
; O
2.1 O
% O
) O
. O
[]

Multiple O
Cox-regression O
analyses O
yielded O
the O
presence O
of O
subthreshold O
symptoms O
of O
depression B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
at O
baseline O
, O
the O
premorbid O
level O
of O
mobility O
, O
and O
a O
history O
of O
( O
treated O
) O
depression B-outcome ['Life-Impact']
as O
risk O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Acute B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
resulted O
in O
maternal B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
, O
hyperinsulinemia B-outcome ['Physiological-Clinical']
, O
and O
an O
increase O
in O
the O
blood O
lactate I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
investigation O
assesses O
the O
validity O
of O
the O
Lactate O
Minimum O
Test O
( O
LMT O
) O
, O
which O
consists O
of O
inducing O
lactic O
acidosis O
through O
a O
VO2peak O
test O
, O
followed O
by O
an O
eight-minute O
walking O
recovery O
and O
an O
incremental O
exercise O
test O
, O
to O
determine O
if O
the O
running O
velocity O
associated O
with O
the O
minimum O
lactate O
value O
predicts O
the O
MLSS O
velocity O
. O
[]

RESULTS O
There O
was O
a O
significant O
decrease O
in O
overall O
scores O
of O
stress O
levels O
for O
participants O
over O
the O
course O
of O
the O
study O
and O
there O
was O
a O
significant O
increase O
in O
the O
four O
factors O
of O
quality O
of O
life O
that O
were O
measured O
( O
satisfaction B-outcome ['Life-Impact']
, O
independence O
, O
competence B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
) O
as O
well O
as O
the O
total O
score O
for O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
from O
baseline O
to O
the O
end O
of O
the O
intervention O
12 O
months O
later O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

No O
significant O
changes O
were O
observed O
in O
either O
the O
sympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Postoperative O
magnesium O
sulphate O
infusion O
reduces O
analgesic O
requirements O
in O
spinal O
anaesthesia O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Circulating B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
GH B-outcome ['Physiological-Clinical']
, O
IGF-I B-outcome ['Physiological-Clinical']
, O
bioavailable B-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
, O
IGF-binding B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
IGFBP B-outcome ['Physiological-Clinical']
) O
-1 O
, O
IGFBP-3 B-outcome ['Physiological-Clinical']
, O
and O
acid-labile B-outcome ['Physiological-Clinical']
subunit O
were O
analyzed O
upon O
admission O
and O
d O
3 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Breast O
cancer O
is O
the O
most O
common O
invasive O
cancer O
among O
women O
in O
developed O
countries O
. O
[]

Infant B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
negatively O
correlated O
with O
cigarettes O
smoked O
per O
day O
( O
r O
= O
-0.29 O
, O
P O
< O
.01 O
) O
and O
expired O
carbon O
monoxide O
( O
r O
= O
-0.39 O
, O
( O
P O
< O
.001 O
) O
at O
delivery O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
will O
provide O
the O
clearest O
evidence O
to O
date O
about O
the O
value O
of O
yoga O
as O
a O
therapeutic O
option O
for O
treating O
chronic B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
if O
the O
results O
are O
positive O
, O
will O
help O
focus O
future O
, O
more O
in-depth O
, O
research O
on O
the O
most O
promising O
potential O
mechanisms O
of O
action O
identified O
by O
this O
study O
. O
['Physiological-Clinical']

Simulation O
has O
been O
shown O
in O
similar O
settings O
to O
enhance O
performance O
and O
knowledge. O
[]

Title: O
Reduction O
of O
postendodontic O
pain B-outcome ['Physiological-Clinical']
after O
one-visit O
root O
canal O
treatment O
using O
three O
irrigating O
regimens O
with O
different O
temperature. O
[['Physiological-Clinical']]

Publication O
Type: O
Journal O
Article O
[]

Aims O
included O
evaluating O
the O
acceptability O
of O
the O
program O
and O
gathering O
preliminary O
evidence O
on O
efficacy O
. O
[]

Risperidone-treated O
subjects O
also O
exhibited O
significantly O
greater O
decreases O
on O
the O
other O
4 O
subscales O
of O
the O
ABC O
; O
on O
the O
conduct O
problem O
, O
insecure/anxious B-outcome ['Life-Impact']
, O
hyperactive B-outcome ['Life-Impact']
, O
and O
overly B-outcome ['Life-Impact']
sensitive I-outcome ['Life-Impact']
subscales O
of O
the O
Nisonger O
Child O
Behavior O
Rating O
Form O
( O
parent O
version O
) O
; O
and O
on O
the O
Visual O
Analog O
Scale O
of O
the O
most O
troublesome O
symptom O
. O
['Life-Impact']

The O
TP53 B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
has O
been O
analysed O
at O
the O
DNA O
level O
in O
tumours O
from O
45 O
ovarian O
cancer O
patients O
randomized O
to O
treatment O
with O
paclitaxel O
and O
cisplatin O
or O
cyclophosphamide O
and O
cisplatin O
. O
['Physiological-Clinical']

The O
primary O
objective O
of O
this O
study O
was O
to O
compare O
the O
12-h O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
of O
S O
( O
+ O
) O
-ibuprofen O
following O
administration O
of O
single O
doses O
of O
ibuprofen O
arginate O
( O
600 O
mg O
) O
and O
dexibuprofen O
( O
400 O
mg O
) O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
226 O
patients O
were O
evaluable O
for O
response O
. O
[]

Comparison O
of O
antihypertensives O
after O
coronary O
artery O
surgery O
. O
[]

Patients O
suffering O
from O
moderate O
to O
severe O
pain O
following O
surgery O
were O
monitored O
for O
up O
to O
8 O
hours O
. O
[]

A O
total O
of O
40 O
highly O
functioning O
men O
with O
ASD O
participated O
and O
were O
randomized O
in O
the O
trial O
. O
[]

Title: O
Remote O
ischemic O
preconditioning O
for O
prevention O
of O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
-Insights O
from O
an O
Indian O
study. O
[['Physiological-Clinical']]

The O
addition O
of O
inflammatory O
markers O
improves O
the O
discriminatory O
value O
of O
the O
prognostic O
classification O
as O
compared O
with O
established O
factors O
alone O
( O
C-statistic O
0.673 O
vs O
0.654 O
, O
P=0.002 O
for O
the O
difference O
) O
, O
with O
25.8 O
% O
( O
P=0.004 O
) O
of O
patients O
more O
appropriately O
classified O
using O
the O
new O
classification O
. O
[]

Third O
, O
the O
curriculum O
is O
briefly O
described O
, O
and O
finally O
, O
the O
role O
of O
the O
students O
and O
community O
in O
the O
video O
production O
is O
described O
. O
[]

A O
double-blind O
study O
of O
terfenadine O
and O
placebo O
in O
110 O
patients O
suffering O
from O
hay O
fever O
( O
confirmed O
by O
skin O
tests O
) O
was O
conducted O
. O
[]

Mean O
( O
+/-SD O
) O
age O
was O
70 O
( O
+/-13 O
) O
years O
. O
[]

The O
different O
effects O
on O
serum O
lipoprotein O
( O
a O
) O
[ O
Lp O
( O
a O
) O
] O
levels O
by O
administering O
estrogens O
at O
different O
times O
of O
the O
day O
( O
8 O
a.m. O
and O
8 O
p.m. O
) O
were O
evaluated O
in O
twenty-four O
post-menopausal O
women O
. O
[]

Adult O
inpatients O
who O
had O
received O
warfarin O
sodium O
10 O
mg O
daily O
for O
less O
than O
three O
days O
were O
eligible O
for O
the O
study O
. O
[]

METHODS: O
The O
BabyGel O
pilot O
was O
a O
cluster O
randomised O
trial O
that O
assessed O
the O
post-partum O
use O
of O
alcohol-based O
hand O
rub O
(ABHR) O
to O
prevent O
neonatal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
Mbale, O
Uganda. O
[['Physiological-Clinical']]

METHODS O
We O
studied O
the O
effects O
of O
nicotine O
in O
nonsmoking O
adults O
( O
6 O
male O
, O
5 O
female O
; O
ages O
23-36 O
years O
) O
using O
a O
double-blind O
, O
randomized O
, O
cross-over O
study O
. O
[]

FINDINGS: O
Between O
Feb O
28, O
2013, O
and O
April O
12, O
2018, O
71 O
patients O
were O
enrolled. O
[]

Atypical O
neuroleptics O
, O
including O
olanzapine O
, O
may O
have O
less O
risk O
for O
dyskinesia O
, O
but O
their O
efficacy O
in O
autistic O
disorder O
is O
not O
established O
. O
[]

A O
2-week O
baseline O
period O
in O
which O
patients O
maintained O
their O
current O
antianginal O
therapy O
was O
followed O
by O
a O
10-week O
treatment O
period O
with O
5-10 O
mg O
of O
amlodipine/day O
. O
[]

Electronic O
address: O
cedar@stanford.edu. O
[]

AIMS O
To O
examine O
the O
effect O
of O
a O
single O
dose O
of O
human O
synthetic O
secretin O
( O
HSS O
) O
on O
behaviour O
and O
communication O
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
using O
an O
objective O
measure O
of O
communication O
and O
social O
reciprocity O
and O
standardised O
rating O
scales O
. O
[]

The O
effectiveness O
of O
Bosinji, O
one O
of O
the O
herbal O
medicines O
used O
for O
low O
back O
pain O
and O
radiating O
pain O
in O
patient O
with O
LHIVD, O
has O
been O
reported O
in O
several O
studies; O
however, O
little O
clinical O
evidence O
is O
available O
owing O
to O
the O
methodological O
limitations O
in O
previous O
studies. O
[]

A O
secondary O
purpose O
was O
to O
test O
the O
effects O
of O
a O
post-diagnosis O
nursing O
intervention O
on O
parents O
' O
reports O
of O
stress B-outcome ['Life-Impact']
, O
impact O
of O
event O
( O
diagnosis O
) O
, O
and O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
services I-outcome ['Life-Impact']
after O
a O
child O
is O
newly O
diagnosed O
with O
ASD O
. O
['Life-Impact', 'Life-Impact']

Treatment O
Treatment O
was O
considered O
successful O
only O
if O
spontaneous O
chest B-outcome ['Physiological-Clinical']
pains I-outcome ['Physiological-Clinical']
disappeared O
completely O
. O
['Physiological-Clinical']

Paraesthesia O
during O
regional O
anaesthesia O
is O
an O
unpleasant O
sensation O
for O
patients O
and O
, O
more O
importantly O
, O
in O
some O
cases O
it O
is O
related O
to O
neurological O
injury O
. O
[]

OBJECTIVE O
To O
investigate O
the O
free O
radicals O
( O
FR O
) O
generation O
after O
ischaemic O
preconditioning O
and O
cardiopulmonary O
bypass O
and O
during O
reperfusion O
in O
CABG O
patients O
, O
and O
the O
role O
of O
ischaemic O
preconditioning O
. O
[]

Allergic O
children O
have O
a O
different O
fecal O
microflora O
, O
with O
less O
lactobacilli O
and O
bifidobacteria O
. O
[]

In O
the O
trimethoprim-sulfamethoxazole O
arm O
, O
7 O
of O
17 O
women O
( O
41 O
% O
) O
with O
a O
trimethoprim-sulfamethoxazole-nonsusceptible O
isolate O
had O
a O
clinical O
cure O
compared O
with O
84 O
% O
of O
women O
with O
a O
trimethoprim-sulfamethoxazole-susceptible O
isolate O
( O
P O
< O
.001 O
) O
. O
[]

The O
increase O
in O
the O
number O
of O
decayed B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
filled I-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
after O
one O
year O
was O
significantly O
lower O
in O
the O
experimental O
groups O
than O
in O
the O
control O
group O
. O
['Physiological-Clinical']

There O
was O
no O
statistically O
significant O
difference O
of O
plaque O
regression O
between O
the O
2 O
groups O
( O
p O
= O
0.96 O
) O
. O
[]

Values O
are O
given O
as O
median O
( O
range O
) O
or O
n O
( O
% O
) O
. O
( O
[]

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

They O
were O
both O
perfectly O
homogeneous O
. O
[]

The O
Studies O
of O
Ocular O
Complications O
of O
AIDS O
Research O
Group O
. O
[]

Group O
VI O
was O
filled O
with O
gutta-percha O
and O
without O
sealer O
to O
serve O
as O
a O
control O
. O
[]

RESULTS: O
There O
were O
significant O
increases O
in O
the O
scores O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
dimensions O
in O
the O
experimental O
group O
after O
the O
intervention O
(p</=0.05). O
[['Life-Impact']]

There O
was O
no O
effect O
on O
the O
peak O
oxygen O
consumption O
, O
exercise O
time O
, O
ventilation O
to O
carbon O
dioxide O
slope O
, O
or O
anaerobic O
threshold O
. O
[]

There O
is O
preliminary O
evidence O
of O
disturbed O
serotoninergic O
neurotransmission O
in O
such O
cases O
. O
[]

A O
hot B-outcome ['Physiological-Clinical']
flash I-outcome ['Physiological-Clinical']
score O
was O
calculated O
at O
each O
time O
point O
. O
['Physiological-Clinical']

Mean O
( O
range O
) O
Hb B-outcome ['Physiological-Clinical']
levels O
were O
11.35 O
( O
8.96-14.22 O
) O
g/dL O
and O
11.54 O
( O
8.74-13.84 O
) O
g/dL O
for O
patients O
receiving O
epoetin O
zeta O
and O
epoetin O
alfa O
, O
respectively O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
[ O
test-reference O
] O
: O
0.09-0.28 O
g/dL O
, O
within O
the O
predefined O
equivalence O
range O
of O
+/-0.6 O
g/dL O
) O
. O
['Physiological-Clinical']

Circulating B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
and O
glucagon B-outcome ['Physiological-Clinical']
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Efficacy O
of O
wrist O
working O
splints O
in O
patients O
with O
rheumatoid O
arthritis O
: O
a O
randomized O
controlled O
study O
. O
[]

In O
the O
early O
postoperative O
period O
, O
hypothermic O
patients O
had O
abnormally O
high B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
compared O
with O
the O
normothermic B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
5 O
min O
of O
baseline O
recording O
, O
acupuncture O
was O
applied O
to O
PC4 O
and O
a O
control O
site O
in O
proximity O
to O
PC4 O
for O
10 O
min O
and O
scanning O
was O
performed O
for O
60 O
min O
after O
acupuncture O
stimulation O
. O
[]

Journal O
ID: O
100968547 O
[]

The O
new O
DSM-5 O
diagnostic O
criteria O
for O
autism O
spectrum O
disorders O
( O
ASDs O
) O
include O
sensory O
disturbances O
in O
addition O
to O
the O
well-established O
language O
, O
communication O
, O
and O
social O
deficits O
. O
[]

For O
instrumentation O
prior O
to O
each O
treatment O
, O
each O
dog O
was O
anesthetized O
with O
isoflurane O
. O
[]

We O
randomly O
grouped O
the O
61 O
patients O
into O
control O
group O
( O
group O
C O
) O
, O
block O
group O
( O
group O
B O
) O
and O
dexketoprofen-block O
group O
( O
group O
DB O
) O
. O
[]

Counselling O
of O
postnatal O
depression O
: O
a O
controlled O
study O
on O
a O
population O
based O
Swedish O
sample O
. O
[]

CAC B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
35 O
vs. O
24 O
% O
, O
p O
= O
0.94 O
) O
and O
bone B-outcome ['Physiological-Clinical']
histological I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
at O
baseline O
and O
12 O
months O
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
single O
blind O
study O
was O
to O
evaluate O
effect O
of O
gluten O
and O
casein-free O
diet O
for O
children O
with O
autistic O
syndromes O
and O
urinary O
peptide O
abnormalities O
. O
[]

Conclusions: O
Tretinoin O
0.05% O
lotion O
was O
significantly O
more O
effective O
than O
its O
vehicle O
in O
achieving O
treatment B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
and O
reducing O
inflammatory O
and O
noninflammatory O
acne O
lesions B-outcome ['Physiological-Clinical']
in O
a O
Hispanic O
population. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

ST-segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
was O
defined O
as O
an O
average O
value O
below O
-1.00 O
mm O
. O
['Physiological-Clinical']

Parenting B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
in O
the O
infant O
aphakia O
treatment O
study O
. O
['Life-Impact']

Predicting O
completion O
of O
treatment O
among O
foreign-born O
adolescents O
treated O
for O
latent O
tuberculosis O
infection O
in O
Los O
Angeles O
. O
[]

Efficacy O
was O
assessed O
by O
facial B-outcome ['Physiological-Clinical']
acne I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
counts O
, O
an O
investigator O
's O
global B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
, O
a O
subject O
's O
self-assessment O
, O
and O
an O
analysis O
of O
within-cycle O
variation O
( O
cycle O
6 O
) O
in O
lesion B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Primary O
outcomes O
were O
fatigue B-outcome ['Physiological-Clinical']
( O
measured O
by O
Chalder O
fatigue B-outcome ['Physiological-Clinical']
questionnaire O
score O
) O
and O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
( O
measured O
by O
short O
form-36 O
subscale O
score O
) O
up O
to O
52 O
weeks O
after O
randomisation O
, O
and O
safety O
was O
assessed O
primarily O
by O
recording O
all O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
including O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Adverse-effects', 'Adverse-effects']

Of O
all O
participants O
who O
established O
abstinence O
and O
then O
relapsed O
, O
DT+ O
participants O
relapsed O
later O
and O
were O
more O
likely O
to O
reestablish B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
. O
['Life-Impact']

Patients O
received O
premedication O
and O
opioids O
consistent O
with O
institutional O
practice O
, O
and O
inhalation O
agents O
were O
titrated O
to O
effect O
during O
anesthetic O
maintenance O
. O
[]

CONCLUSION O
Among O
the O
children O
studied O
here O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
IMV O
and O
SIMV+PS O
in O
terms O
of O
time O
on O
MV O
, O
duration O
of O
weaning O
or O
time O
spent O
in O
the O
PICU O
. O
[]

CONCLUSION O
Thermal O
welding O
tonsillectomy O
procedure O
provides O
sufficient O
hemostasis B-outcome ['Physiological-Clinical']
, O
lower O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
quick O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
normal I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Youth O
reported O
on O
their O
emotional O
health O
( O
positive O
affect O
, O
life O
satisfaction O
, O
depression O
, O
anxiety O
) O
and O
social-emotional O
and O
character O
development O
. O
[]

As O
compared O
with O
placebo O
, O
secretin O
treatment O
was O
not O
associated O
with O
significant O
improvements O
in O
any O
of O
the O
outcome O
measures O
. O
[]

MAIN O
OUTCOME O
MEASURES: O
The O
primary O
outcome O
measure O
was O
a O
composite O
of O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
perinatal I-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
: O
perinatal B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
Apgar B-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
<4, O
impaired B-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
, O
asphyxia B-outcome ['Physiological-Clinical']
, O
seizures B-outcome ['Physiological-Clinical']
, O
assisted B-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
, O
septicaemia B-outcome ['Physiological-Clinical']
, O
meningitis B-outcome ['Physiological-Clinical']
, O
bronchopulmonary B-outcome ['Physiological-Clinical']
dysplasia I-outcome ['Physiological-Clinical']
, O
intraventricular B-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
, O
periventricular B-outcome ['Physiological-Clinical']
leukomalacia I-outcome ['Physiological-Clinical']
, O
or O
necrotising B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
. O
Secondary O
outcomes O
were O
two O
composite O
measures O
of O
severe B-outcome ['Physiological-Clinical']
maternal I-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
and O
spontaneous B-outcome ['Physiological-Clinical']
labour I-outcome ['Physiological-Clinical']
and O
birth O
. O
RESULTS: O
Between O
1 O
February O
2015 O
and O
29 O
February O
2016, O
60 O
midwifery O
practices O
enrolled O
13 O
520 O
women O
in O
mid-pregnancy O
(mean O
22.8 O
(SD O
2.4) O
weeks' O
gestation). O
[['Adverse-effects'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Protocol-driven O
costs O
were O
excluded O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
clarify O
the O
role O
of O
microembolization O
in O
the O
genesis O
of O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
['Physiological-Clinical']

We O
studied O
the O
effect O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
ACE O
inhibitor O
) O
in O
a O
double-blind O
placebo-controlled O
study O
, O
on O
eight O
volunteers O
undergoing O
physical O
stress O
on O
an O
ergometric O
bicycle O
. O
[]

EL O
and O
ES O
had O
similar O
cost/variceal O
rebleeding O
prevented O
( O
$ O
28,678 O
vs. O
$ O
29,093 O
) O
and O
cost/survival O
( O
$ O
27,313 O
vs. O
$ O
23,804 O
) O
. O
['Mortality', 'Resource-use']

The O
stages O
of O
change O
construct O
has O
been O
applied O
to O
healthful O
dietary O
behavior O
in O
cross-sectional O
studies O
. O
[]

Cycles O
were O
repeated O
every O
3 O
weeks O
. O
[]

On O
follow-up O
, O
the O
sevelamer O
group O
had O
higher O
levels O
of O
intact B-outcome ['Physiological-Clinical']
parathyroid I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
498 O
+/- O
352 O
vs. O
326 O
+/- O
236 O
pg/ml O
, O
p O
= O
0.017 O
) O
, O
bone B-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
( O
38 O
+/- O
24 O
vs. O
28 O
+/- O
15 O
U/l O
, O
p O
= O
0.03 O
) O
and O
deoxypyridinoline B-outcome ['Physiological-Clinical']
( O
135 O
+/- O
107 O
vs. O
89 O
+/- O
71 O
nmol/l O
, O
p O
= O
0.03 O
) O
and O
lower B-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
74 O
+/- O
21 O
vs. O
91 O
+/- O
28 O
mg/dl O
, O
p O
= O
0.015 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Uterine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
mean O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
uterine B-outcome ['Physiological-Clinical']
weight O
, O
drop O
in O
hemoglobin B-outcome ['Physiological-Clinical']
, O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
conversions B-outcome ['Resource-use']
to I-outcome ['Resource-use']
laparotomy I-outcome ['Resource-use']
, O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
recorded O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Resource-use']

After O
12 O
weeks O
a O
greater O
proportion O
of O
patients O
taking O
lisinopril O
was O
controlled O
( O
sitting O
diastolic O
blood O
pressure O
below O
95 O
mm O
Hg O
) O
than O
in O
those O
taking O
nifedipine O
. O
[]

BACKGROUND O
Intravenous O
cangrelor O
, O
a O
rapid-acting O
, O
reversible O
adenosine O
diphosphate O
( O
ADP O
) O
receptor O
antagonist O
, O
might O
reduce O
ischemic O
events O
during O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

Results O
of O
the O
Erectile O
Dysfunction O
and O
Statins O
Trial O
[ O
ISRCTN66772971 O
] O
. O
[]

A O
high O
remission B-outcome ['Physiological-Clinical']
rate O
was O
observed O
in O
subjects O
with O
a O
history O
of O
no O
prior O
treatment O
or O
inadequate O
treatment O
who O
were O
treated O
with O
a O
combination O
of O
olanzapine O
and O
sertraline O
. O
['Physiological-Clinical']

Clinical O
periodontal O
measurements O
and O
data O
regarding O
patients O
' O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
( O
perceived B-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
gums I-outcome ['Physiological-Clinical']
, O
gingival B-outcome ['Physiological-Clinical']
recession I-outcome ['Physiological-Clinical']
, O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
, O
packing B-outcome ['Life-Impact']
foods I-outcome ['Life-Impact']
, O
aesthetics B-outcome ['Life-Impact']
, O
bad B-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
, O
and O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
) O
were O
collected O
at O
baseline O
and O
3 O
months O
after O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
difference O
is O
probably O
due O
to O
the O
reduction O
of O
wave B-outcome ['Physiological-Clinical']
reflection I-outcome ['Physiological-Clinical']
caused O
by O
enalapril O
. O
['Physiological-Clinical']

PURPOSE O
Minority O
patients O
with O
cancer O
experience O
worse O
control O
of O
their O
pain O
than O
do O
their O
white O
counterparts O
. O
[]

Fine O
texture O
analysis O
with O
either O
a O
conventional O
instrument O
or O
a O
laparoscopic O
instrument O
was O
superior O
to O
direct O
palpation O
( O
p O
< O
0.05 O
) O
. O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

Another O
1 O
patient O
( O
A O
) O
was O
dead B-outcome ['Mortality']
of O
ileus O
. O
['Mortality']

Moreover O
, O
adding O
a O
low O
dose O
of O
HCTZ O
appears O
to O
be O
the O
most O
effective O
strategy O
in O
enhancing O
the O
antihypertensive O
activity O
of O
this O
angiotensin O
II O
receptor O
blocker O
in O
contrast O
to O
either O
doubling O
the O
dose O
or O
adding O
an O
angiotensin O
converting O
enzyme O
inhibitor O
. O
[]

Following O
the O
study, O
5 O
focus O
group O
discussions O
(FGDs) O
were O
conducted O
consisting O
of O
6-8 O
purposively O
sampled O
participants O
from O
intervention O
villages. O
[]

OBJECTIVES O
Childhood O
asthma O
is O
a O
growing O
public O
health O
concern O
in O
low-income O
urban O
communities O
. O
[]

A O
double O
blind O
randomized O
study O
of O
oral O
clodronate O
in O
the O
treatment O
of O
bone O
metastases O
from O
tumors O
poorly O
responsive O
to O
chemotherapy O
. O
[]

The O
constitutive O
enzymes O
( O
COX-1 O
and O
eNOS O
) O
did O
not O
change O
after O
treatment O
. O
[]

The O
primary O
outcome O
was O
the O
between-group O
difference O
in O
the O
mean O
change O
from O
baseline O
to O
week O
80 O
in O
the O
total O
score O
on O
the O
Unified O
Parkinson's B-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Rating O
Scale O
(UPDRS; O
scores O
range O
from O
0 O
to O
176, O
with O
higher O
scores O
signifying O
more O
severe O
disease). O
[['Physiological-Clinical']]

The O
median O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
for O
tamoxifen O
( O
20 O
months O
) O
was O
longer O
than O
that O
for O
surgical O
oophorectomy O
( O
7 O
months O
) O
, O
but O
this O
did O
not O
achieve O
statistical O
significance O
( O
P O
= O
.056 O
) O
. O
['Physiological-Clinical']

In O
the O
zoledronic O
acid O
group O
, O
bone O
marrow O
was O
not O
collected O
from O
one O
patient O
because O
of O
disease O
progression O
, O
one O
patient O
was O
taken O
off O
study O
because O
of O
severe O
diarrhoea O
, O
and O
two O
patients O
had O
not O
consented O
at O
the O
time O
of O
surgery O
. O
[]

Efficacy O
was O
evaluated O
using O
the O
caregiver-rated O
Aberrant O
Behavior O
Checklist O
Irritability O
subscale O
( O
primary O
efficacy O
measure O
) O
and O
the O
clinician-rated O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impressions-Improvement O
score O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

There O
were O
no O
statistically O
significant O
differences O
in O
mortality B-outcome ['Mortality']
( O
4 O
% O
in O
telemedicine O
and O
11 O
% O
in O
telephone O
) O
or O
rates O
of O
intracerebral B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
4 O
% O
in O
telemedicine O
and O
0 O
% O
in O
telephone O
) O
. O
['Mortality', 'Physiological-Clinical']

One O
patient O
on O
propranolol O
was O
withdrawn O
from O
the O
trial O
because O
of O
poor O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
suspected B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
pectoris I-outcome ['Physiological-Clinical']
after O
5 O
weeks O
on O
active O
medication O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
screen O
for O
bacterial O
vaginosis O
( O
BV O
) O
and O
to O
investigate O
the O
effect O
of O
treatment O
with O
vaginal O
clindamycin O
in O
order O
to O
observe O
the O
effect O
on O
late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
prior I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
37 I-outcome ['Physiological-Clinical']
completed I-outcome ['Physiological-Clinical']
weeks I-outcome ['Physiological-Clinical']
( O
primary O
outcome O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
On O
each O
POD O
analyzed O
, O
alvimopan O
significantly O
increased O
the O
proportion O
of O
patients O
who O
achieved O
GI-2 B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
and O
DCO O
written O
versus O
placebo O
and O
was O
associated O
with O
relatively O
low O
NNTs O
. O
['Physiological-Clinical']

RESULTS: O
Truckers O
in O
the O
intervention O
group O
were O
significantly O
more O
likely O
to O
test B-outcome ['Life-Impact']
for O
HIV O
compared O
to O
those O
in O
the O
enhanced O
SOC O
(OR O
= O
2.7, O
p O
= O
0.009). O
[['Life-Impact']]

CONCLUSIONS O
The O
P-ASA O
injection O
of O
1.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
or O
3 O
% O
mepivacaine O
, O
administered O
with O
the O
Wand O
Plus O
, O
has O
the O
potential O
to O
be O
a O
painful O
injection O
. O
[]

These O
results O
reveal O
that O
6 O
mg O
of O
astaxanthin O
per O
day O
from O
a O
H. O
pluvialis O
algal O
extract O
can O
be O
safely O
consumed O
by O
healthy O
adults O
. O
[]

RESULTS O
Groups O
1 O
and O
2 O
showed O
significant O
hypersensitivity B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
over O
baseline O
at O
all O
time O
points O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
any O
of O
these O
study O
measures O
among O
the O
three O
treatment O
conditions O
( O
P O
> O
0.1 O
for O
all O
) O
. O
[]

The O
primary O
outcomes O
were O
success B-outcome ['Life-Impact']
rate O
and O
procedure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
The O
secondary O
outcome O
was O
a O
subjective O
measure O
of O
the O
similarity O
of O
the O
simulator O
to O
the O
porcine O
larynx. O
[['Life-Impact'], ['Life-Impact']]

It O
was O
therefore O
sought O
to O
determine O
whether O
regular O
intake O
of O
lime O
juice O
will O
ameliorate O
crisis O
, O
especially O
recurrent B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thus O
, O
these O
pilot O
data O
emphasize O
the O
need O
for O
further O
research O
and O
implementation O
of O
classroom-based O
interventions O
targeting O
[]

Measurements O
by O
spring-weighted O
scales O
were O
taken O
to O
assess O
the O
efficiency O
of O
each O
splint O
design O
in O
the O
reduction O
of O
hypertonus B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
degree O
of O
injured O
vertebra B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
, O
VAS O
score, O
and O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI) O
score O
were O
significantly O
improved O
in O
both O
groups O
at O
immediate O
after O
operation O
and O
last O
follow-up O
( O
P<0.05). O
[['Physiological-Clinical'], ['Life-Impact']]

People O
without O
and O
with O
diabetes O
who O
are O
at O
high O
risk O
for O
cardiovascular B-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
are O
also O
at O
risk O
for O
a O
progressive O
rise O
in O
albuminuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Concerning O
parameters O
of O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
first O
ICTP O
as O
marker O
of O
bone B-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
showed O
a O
significant O
increase O
, O
later O
on O
the O
marker O
of O
bone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
increased O
as O
well O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
the O
subjective O
workload B-outcome ['Life-Impact']
assessment O
technique O
( O
SWAT O
) O
has O
been O
widely O
used O
, O
it O
has O
two O
main O
problems O
: O
it O
is O
not O
very O
sensitive O
for O
low O
mental O
workloads O
and O
it O
requires O
a O
time-consuming O
card O
sorting O
pretask O
procedure O
. O
['Life-Impact']

The O
patients O
in O
the O
ozone O
therapy O
group O
were O
treated O
with O
basic O
treatments O
plus O
ozone O
therapy O
system O
. O
[]

The O
findings O
indicated O
support O
for O
the O
use O
of O
chronic O
aerobic O
exercise O
as O
a O
strategy O
for O
improved O
coping O
with O
acute O
stress O
. O
[]

Heartburn O
, O
retrosternal O
pain O
and O
belching O
improved O
significantly O
better O
with O
lansoprazole O
than O
with O
ranitidine O
, O
as O
did O
the O
patient-rated O
overall O
symptom O
severity O
. O
[]

Percutaneous O
tracheostomy O
in O
critically O
ill O
patients O
: O
a O
prospective O
, O
randomized O
comparison O
of O
two O
techniques O
. O
[]

Severe O
enteropathy O
among O
patients O
with O
stage O
II/III O
colon O
cancer O
treated O
on O
a O
randomized O
trial O
of O
bolus O
5-fluorouracil/leucovorin O
plus O
or O
minus O
oxaliplatin O
: O
a O
prospective O
analysis O
. O
[]

RESULTS O
Mean O
intakes B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
calcium I-outcome ['Life-Impact']
during O
the O
intervention O
were O
742.4 O
+/- O
321.5 O
, O
1026.4 O
+/- O
311.3 O
, O
and O
1131.29 O
+/- O
337.2 O
mg/d O
for O
the O
control O
, O
medium-dairy O
, O
and O
high-dairy O
groups O
, O
respectively O
( O
P O
< O
0.0001 O
) O
. O
['Life-Impact']

Fifty-four O
heparin-resistant O
patients O
were O
randomized O
. O
[]

Complete B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
observed O
in O
six O
of O
ten O
sites O
treated O
with O
Re-PUVA O
, O
two O
of O
ten O
with O
Re O
, O
and O
one O
of O
ten O
sites O
with O
PUVA O
within O
12 O
weeks O
. O
['Physiological-Clinical']

RESULTS O
Parents O
in O
the O
parent O
+ O
therapist O
group O
demonstrated O
greater O
use O
of O
EMT B-outcome ['Physiological-Clinical']
strategies I-outcome ['Physiological-Clinical']
at O
home O
than O
untrained O
parents O
in O
the O
therapist-only O
group O
, O
and O
these O
effects O
maintained O
over O
time O
. O
['Physiological-Clinical']

Parent-based O
sleep O
education O
, O
delivered O
in O
relatively O
few O
sessions O
, O
was O
associated O
with O
improved O
sleep O
onset O
delay O
in O
children O
with O
ASD O
. O
[]

At O
baseline O
, O
the O
resting O
and O
stimulated O
salivary O
flow O
rates O
( O
g/5min O
) O
were O
significantly O
greater O
in O
the O
control O
group O
than O
in O
the O
study O
group O
( O
p O
< O
0.05 O
) O
. O
[]

At O
week O
18 O
, O
WHO O
functional O
class O
was O
improved O
or O
maintained O
in O
more O
patients O
receiving O
sitaxsentan O
100 O
mg O
than O
placebo O
( O
P O
= O
0.038 O
) O
; O
0 O
% O
versus O
12 O
% O
of O
patients O
deteriorated O
, O
respectively O
. O
[]

RESULTS O
Twenty O
patients O
were O
assigned O
to O
the O
resection O
group O
and O
22 O
to O
the O
radiochemotherapy O
group O
. O
[]

Children O
's O
age O
, O
sex O
, O
ethnicity O
, O
and O
height O
and O
weight O
( O
used O
to O
calculate O
BMI O
) O
were O
collected O
between O
August O
2001 O
and O
May O
2004 O
. O
[]

CONCLUSIONS O
Hexaminolevulinate O
fluorescence O
cystoscopy O
significantly O
improves O
long-term O
bladder O
cancer O
time O
to O
recurrence O
with O
a O
trend O
toward O
improved O
bladder O
preservation O
. O
[]

No O
benefit O
of O
preoperative O
enteral O
feeding O
on O
QOL B-outcome ['Life-Impact']
could O
be O
demonstrated O
6 O
months O
after O
surgery O
. O
['Life-Impact']

This O
study O
was O
undertaken O
to O
compare O
the O
recovery O
and O
discharge B-outcome ['Resource-use']
times O
of O
outpatients O
undergoing O
procedures O
greater O
than O
2 O
hours O
in O
length O
. O
['Physiological-Clinical', 'Resource-use']

In O
the O
risperidone O
group O
, O
12 O
of O
19 O
children O
showed O
improvement O
in O
the O
total O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
score O
and O
17 O
of O
19 O
children O
in O
the O
Children B-outcome ['Physiological-Clinical']
's O
Global B-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Scale O
score O
compared O
with O
0 O
of O
20 O
children O
for O
the O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
score O
and O
2 O
of O
20 O
children O
for O
the O
Children B-outcome ['Physiological-Clinical']
's O
Global B-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Scale O
score O
in O
the O
placebo O
group O
( O
P O
< O
.001 O
and O
P O
= O
.035 O
, O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

These O
data O
show O
that O
a O
wider O
variety O
of O
dental O
procedures O
than O
was O
previously O
documented O
cause O
bacteremia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BP B-outcome ['Physiological-Clinical']
became O
['Physiological-Clinical']

During O
the O
pentoxifylline O
treatment O
period O
, O
in O
contrast O
with O
the O
control O
period O
, O
nine O
men O
were O
able O
to O
reestablish B-outcome ['Life-Impact']
coital I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
and O
three O
had O
no O
improvement O
. O
['Life-Impact']

The O
influence O
of O
penbutolol O
and O
placebo O
on O
blood O
sugar O
levels O
and O
insulin O
consumption O
in O
the O
glucose-controlled O
insulin O
infusion O
system O
( O
artificial O
endocrine O
pancreas O
) O
. O
[]

After O
lymph O
node O
excision O
, O
patients O
without O
any O
detectable O
metastases O
were O
randomly O
assigned O
to O
receive O
either O
TIL O
plus O
interleukin-2 O
( O
IL-2 O
) O
for O
2 O
months O
, O
or O
IL-2 O
only O
. O
[]

[ O
Intra-arterial O
chemotherapy O
in O
advanced O
ovarian O
cancers O
. O
[]

LIMITATIONS O
The O
study O
did O
not O
contain O
a O
group O
treated O
with O
a O
topical O
corticosteroid O
alone O
. O
[]

A O
prospective O
, O
randomized O
study O
] O
. O
[]

BACKGROUND O
Angiotensin-converting O
enzyme O
inhibitors O
provide O
hemodynamic O
and O
symptomatic O
benefit O
and O
are O
associated O
with O
improved O
survival O
in O
patients O
with O
congestive O
heart O
failure O
. O
[]

The O
relative O
risks O
of O
0.67 O
and O
0.74 O
were O
clinically O
similar O
and O
the O
difference O
between O
them O
did O
not O
reach O
statistical O
significance O
. O
[]

Abnormal O
spatial B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
body I-outcome ['Life-Impact']
postures I-outcome ['Life-Impact']
in O
children O
with O
autism O
often O
interfere O
with O
visual O
abilities O
to O
attend O
tasks O
and O
social O
interactions O
. O
['Life-Impact']

Journal-Name:The O
western O
journal O
of O
emergency O
medicine O
[]

A O
cluster O
randomized O
controlled O
trial O
was O
conducted O
to O
evaluate O
the O
effectiveness O
of O
household B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
local I-outcome ['Life-Impact']
media I-outcome ['Life-Impact']
in O
the O
increasing O
demand O
for O
fee-based O
As O
testing O
. O
['Life-Impact']

Eleven O
chronic O
renal O
failure O
patients O
and O
11 O
matched O
controls O
, O
received O
growth O
hormone O
GHRH O
( O
1 O
microgram/kg O
iv O
) O
or O
TRH O
( O
400 O
microgram O
iv O
) O
on O
separate O
occasions O
, O
immediately O
before O
undergoing O
hemodialysis O
. O
[]

INTERVENTIONS O
Transoesophageal O
Tissue O
Doppler O
echocardiographic O
examination O
of O
myocardial O
systolic O
and O
early O
diastolic O
velocities O
in O
both O
groups O
basally O
and O
60 O
s O
after O
coronary O
occlusion O
by O
the O
surgeon O
. O
[]

colchicine O
. O
[]

Between O
March O
2001 O
and O
November O
2001 O
, O
87 O
patients O
with O
99 O
lesions O
were O
enrolled O
in O
this O
study O
and O
were O
treated O
with O
12 O
and O
16 O
mm O
long O
iridium-oxide O
coated O
Lunar O
stents O
. O
[]

Group O
P O
received O
the O
placebo O
( O
0.9 O
% O
normal O
saline O
2 O
ml O
) O
and O
Group O
D O
received O
10 O
mg O
dexamethasone O
intravenously O
right O
before O
the O
induction O
of O
anesthesia O
. O
[]

There O
was O
no O
significant O
difference O
in O
[]

To O
determine O
the O
efficacy O
and O
safety O
of O
endoscopic O
sclerotherapy O
and O
ligation O
, O
the O
2 O
methods O
were O
compared O
in O
a O
randomized O
control O
trial O
in O
49 O
children O
with O
extrahepatic O
portal O
venous O
obstruction O
who O
had O
proven O
bleeding O
from O
esophageal O
varices O
. O
[]

Intra-group O
comparisons O
also O
failed O
to O
show O
any O
differences O
between O
baseline O
and O
14-day O
P2Y B-outcome ['Physiological-Clinical']
( O
12 O
) O
reactivity B-outcome ['Physiological-Clinical']
index O
['Physiological-Clinical', 'Physiological-Clinical']

These O
interactions O
can O
cascade O
over O
larger O
distances O
provided O
the O
spacing O
of O
stimulus O
elements O
is O
kept O
within O
a O
limited O
range O
. O
[]

RESULTS O
All O
three O
groups O
had O
a O
spike O
in O
cost O
associated O
with O
the O
index O
clinic O
visit O
. O
[]

PATIENTS O
120 O
ASA O
physical O
status O
1 O
and O
2 O
patients O
undergoing O
elective O
orthopedic O
surgeries O
. O
[]

Patients O
were O
randomly O
assigned O
to O
undergo O
transthoracic O
open O
esophagectomy O
(open O
procedure) O
or O
hybrid O
minimally O
invasive O
esophagectomy O
(hybrid O
procedure). O
[]

Conclusion: O
Berberine O
improves O
diabetic O
kidney O
disease O
by O
reducing O
urine O
albumin/creatine B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
and O
serum O
cystatin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
in O
T2DM O
patients, O
and O
it O
was O
safe. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:Japanese O
journal O
of O
clinical O
oncology O
[]

Deliberate O
mild O
intraoperative O
hypothermia O
for O
craniotomy O
. O
[]

Assuming O
that O
bronchial B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
could O
be O
an O
indirect O
measurement O
of O
airway O
inflammation O
, O
overtreatment O
of O
asthma O
in O
relationship O
with O
the O
classification O
of O
asthma O
severity O
of O
the O
International O
Guidelines O
could O
improve O
both O
airway O
inflammation O
and O
the O
prognosis O
of O
airway O
obstruction O
. O
['Physiological-Clinical']

Helicobacter O
pylori O
and O
gastric O
cancer O
: O
current O
status O
of O
the O
Austrain O
Czech O
German O
gastric O
cancer O
prevention O
trial O
( O
PRISMA O
Study O
) O
. O
[]

OBJECTIVE O
To O
test O
the O
effectiveness O
of O
interventions O
intended O
to O
increase O
rates O
of O
regular B-outcome ['Life-Impact']
breast I-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
, O
according O
to O
recommended O
guidelines O
. O
['Life-Impact']

RESULTS O
Assessment O
of O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
parents O
' O
behavioral B-outcome ['Life-Impact']
assessments O
revealed O
no O
significant O
differences O
between O
the O
treatment O
and O
placebo O
groups O
. O
['Life-Impact', 'Life-Impact']

RESULTS: O
With O
a O
median O
follow-up O
of O
27.2 O
months, O
the O
2-year O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
rate O
was O
81% O
(95% O
confidence O
interval O
[CI], O
69 O
to O
96) O
in O
the O
sorafenib O
group O
and O
36% O
(95% O
CI, O
22 O
to O
57) O
in O
the O
placebo O
group O
(hazard O
ratio O
for O
progression B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
, O
0.13; O
95% O
CI, O
0.05 O
to O
0.31; O
P<0.001). O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Mortality']]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
an O
oral O
formulation O
of O
cetirizine O
5 O
mg O
with O
sustained-release O
pseudoephedrine O
( O
PSE O
) O
120 O
mg O
relative O
to O
placebo O
in O
patients O
with O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
antibody B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
either O
influenza O
A O
or O
B O
in O
64 O
patients O
who O
received O
GM-CSF O
at O
vaccination O
, O
compared O
with O
the O
53 O
who O
did O
not O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

These O
results O
suggest O
that O
end-to-side O
neurorrhaphy O
can O
induce O
the O
functional O
collateral O
sprouting O
of O
both O
motor O
and O
sensory O
axons O
in O
the O
peripheral O
nerve O
. O
[]

No O
side-effects B-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

At O
week O
84 O
, O
HBV B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
rates O
of O
acute B-outcome ['Physiological-Clinical']
kidney I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
gastrointestinal B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
indicated O
that O
Skp2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
closely O
associated O
with O
tumor O
progression O
and O
represented O
an O
independent O
marker O
for O
prognosis O
of O
LSCC O
. O
['Physiological-Clinical']

3 O
) O
Eleven O
children O
had O
later O
onset O
, O
atypical B-outcome ['Physiological-Clinical']
absences I-outcome ['Physiological-Clinical']
, O
tonic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
, O
and O
no O
myoclonus O
, O
or O
vibratory O
tonic O
seizures O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Among O
202 O
patients O
who O
received O
ketorolac O
and O
417 O
who O
did O
not O
, O
ketorolac O
use O
was O
associated O
with O
decreased O
pneumonia B-outcome ['Physiological-Clinical']
( O
odds O
ratio O
, O
.14 O
; O
95 O
% O
confidence O
interval O
, O
.04 O
to O
.46 O
) O
and O
increased O
ventilator-free B-outcome ['Resource-use']
days I-outcome ['Resource-use']
( O
difference O
, O
1.8 O
days O
; O
95 O
% O
confidence O
interval O
, O
1.1 O
to O
2.5 O
) O
and O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit-free I-outcome ['Resource-use']
days I-outcome ['Resource-use']
( O
difference O
, O
2.1 O
days O
; O
95 O
% O
confidence O
interval O
, O
1.3 O
to O
3.0 O
) O
within O
30 O
days O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

MATERIAL O
AND O
METHOD O
In O
this O
prospective O
, O
randomized O
controlled O
study O
, O
61 O
ASA O
physical O
status O
I-III O
patients O
scheduled O
for O
elective O
unilateral O
total O
knee O
arthroplasty O
( O
TKA O
) O
under O
spinal O
anesthesia O
( O
SA O
) O
participated O
. O
[]

Linezolid O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
the O
frequency O
of O
drug-related B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
between O
the O
linezolid O
and O
placebo O
groups O
. O
['Life-Impact', 'Adverse-effects']

Differences O
in O
complications O
( O
choroidal O
detachment O
, O
hyphema O
, O
leakage O
) O
seen O
between O
the O
two O
groups O
were O
statistically O
nonsignificant O
. O
[]

RESULTS O
Overall O
10-year O
survival B-outcome ['Mortality']
was O
47.1 O
% O
for O
the O
immunochemotherapy O
group O
( O
P O
< O
0.037 O
vs O
FAM O
and O
P O
< O
0.0006 O
vs O
control O
) O
, O
30 O
% O
for O
the O
chemotherapy O
group O
( O
vs O
control O
, O
NS O
) O
, O
and O
15.2 O
% O
for O
the O
control O
group O
. O
['Mortality']

OBJECTIVE O
To O
examine O
the O
effect O
of O
ulinastatin O
( O
UTI O
) O
on O
the O
inflammatory B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
induced O
by O
oesophagectomy O
. O
['Physiological-Clinical']

PATIENTS O
83 O
patients O
with O
osteoarthritis O
of O
the O
knee O
who O
were O
randomly O
assigned O
to O
receive O
treatment O
( O
n O
= O
42 O
; O
15 O
men O
and O
27 O
women O
[ O
mean O
age O
, O
60 O
+/- O
11 O
years O
] O
) O
or O
placebo O
( O
n O
= O
41 O
; O
19 O
men O
and O
22 O
women O
[ O
mean O
age O
, O
62 O
+/- O
10 O
years O
] O
) O
. O
[]

0.05). O
[]

Title: O
Effectiveness O
and O
cost-effectiveness O
of O
a O
loyalty O
scheme O
for O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
behaviour O
change O
maintenance: O
results O
from O
a O
cluster O
randomised O
controlled O
trial. O
[['Life-Impact']]

Fifteen O
males O
with O
angiographic O
evidence O
of O
coronary O
heart O
disease O
and O
stable O
, O
exercise-induced O
angina O
pectoris O
were O
given O
placebo O
or O
isosorbide O
dinitrate O
( O
ISDN O
) O
in O
a O
dialy O
dose O
of O
30 O
mg O
, O
120 O
mg O
, O
240 O
mg O
and O
480 O
mg O
in O
a O
randomized O
single-blind O
trial O
. O
[]

Group O
A O
patients O
( O
n O
: O
9 O
) O
received O
the O
pill O
at O
8 O
a.m. O
, O
and O
group O
B O
patients O
( O
n O
: O
12 O
) O
received O
the O
pill O
at O
8 O
p.m O
. O
[]

What O
is O
the O
place O
of O
plasma O
exchanges O
( O
PE O
) O
in O
the O
treatment O
of O
systemic O
vasculitis O
? O
[]

RESULTS O
In O
total O
, O
313 O
patients O
were O
randomized O
to O
receive O
epoetin O
zeta O
( O
n O
= O
155 O
) O
or O
epoetin O
alfa O
( O
n O
= O
158 O
) O
; O
146 O
and O
145 O
patients O
( O
respectively O
) O
switched O
treatment O
after O
12 O
weeks O
. O
[]

Randomized O
controlled O
trial O
evaluating O
the O
clinical O
benefit O
of O
montelukast O
for O
treating O
spring B-outcome ['Physiological-Clinical']
seasonal I-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

21 O
mm O
. O
[]

Although O
SILS O
is O
technically O
even O
more O
challenging O
than O
conventional O
laparoscopy O
, O
published O
data O
of O
first O
clinical O
series O
seem O
to O
demonstrate O
the O
feasibility O
of O
these O
approaches O
. O
[]

Heparin O
caused O
less O
attenuation O
of O
a O
challenge O
with O
adenosine O
and O
probably O
does O
not O
affect O
mast O
cell O
degranulation O
. O
[]

UNLABELLED O
There O
are O
few O
data O
concerning O
changes O
in O
lung O
function O
and O
respiratory O
symptoms O
in O
smokers O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
weeks O
to O
months O
after O
quitting O
smoking O
. O
[]

European O
Cancer O
Prevention O
Organisation O
Study O
Group O
. O
[]

Blood O
samples O
were O
taken O
immediately O
before, O
immediately O
after O
and O
30 O
min O
post-exercise O
to O
determine O
plasma O
albumin B-outcome ['Physiological-Clinical']
, O
total O
protein B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
markers. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Under O
VCV O
mode, O
the O
levels O
of O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
were O
increased O
with O
the O
increase O
in O
atomized O
oxygen O
flow, O
and O
there O
was O
significant O
difference O
at O
9 O
L/min O
as O
compared O
with O
those O
before O
atomization O
[ O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(cmH2O): O
29.44+/-4.58 O
vs. O
24.39+/-4.64, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
896.26+/-24.91 O
vs. O
497.61+/-8.67, O
both O
P O
< O
0.05]. O
There O
was O
no O
significant O
change O
in O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
no O
significant O
difference O
at O
9 O
L/min O
of O
atomized O
oxygen O
flow O
as O
compared O
with O
that O
before O
atomization O
(mL: O
494.67+/-3.07 O
vs. O
492.61+/-6.05, O
P O
> O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

There O
was O
no O
significant O
difference O
between O
groups O
in O
the O
median O
cumulative O
time O
with O
mean O
arterial O
pressure O
below O
60 O
mm O
Hg O
(7 O
vs O
7 O
minutes; O
difference, O
0.0 O
[95% O
CI, O
-1.7 O
to O
1.7]). O
[]

The O
patients O
were O
assigned O
at O
random O
to O
one O
of O
the O
following O
treatments O
: O
1 O
) O
Defibrotide O
at O
a O
dose O
of O
400 O
mg O
b.i.d O
. O
[]

During O
the O
fifth O
and O
sixth O
cycles O
of O
combination O
therapy O
94 O
% O
of O
cycles O
were O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
flushing I-outcome ['Physiological-Clinical']
( O
vs. O
31 O
% O
for O
control O
, O
P O
< O
0.01 O
) O
, O
64 O
% O
of O
cycles O
were O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
spotting I-outcome ['Physiological-Clinical']
not O
requiring B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
( O
control O
75 O
% O
) O
, O
96 O
% O
of O
cycles O
were O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
vaginal I-outcome ['Physiological-Clinical']
bleeding B-outcome ['Physiological-Clinical']
( O
control O
100 O
% O
) O
, O
endometrial O
biopsy O
showed O
inactive B-outcome ['Physiological-Clinical']
endometrium I-outcome ['Physiological-Clinical']
in O
nine O
of O
the O
10 O
subjects O
re-biopsied O
, O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Defibrillation B-outcome ['Physiological-Clinical']
efficacy O
decreases O
with O
increasing O
VF O
duration O
using O
biphasic O
waveforms O
in O
humans O
. O
['Physiological-Clinical']

One O
limitation O
of O
the O
various O
versions O
of O
the O
LPFST O
is O
that O
they O
are O
carried O
out O
using O
a O
constant O
level O
of O
low-pass O
filtering O
( O
e.g O
. O
[]

Primary O
deep O
sclerectomy O
versus O
primary O
deep O
sclerectomy O
with O
the O
use O
of O
mitomycin O
C O
in O
primary O
open-angle O
glaucoma O
. O
[]

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O
[]

No O
significant O
differences O
emerged O
between O
the O
TMI O
and O
the O
IMZ O
group O
. O
[]

17 O
mg/dl O
; O
p O
= O
0.001 O
) O
. O
[]

Both O
drugs O
, O
administered O
in O
a O
dose O
of O
one O
suppository O
twice O
a O
day O
for O
7 O
days O
, O
showed O
marked O
anti-inflammatory B-outcome ['Physiological-Clinical']
, O
analgesic B-outcome ['Resource-use']
and O
antipyretic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
produced O
a O
significant O
, O
progressive O
improvement O
in O
the O
typical O
symptoms O
of O
the O
inflammatory B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
up O
to O
their O
complete O
remission O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Results: O
Participant O
retention O
was O
100% O
at O
6 O
months. O
[]

Clinical O
trials O
in O
chronic O
schizophrenic O
patients O
have O
shown O
trends O
in O
favor O
of O
risperidone O
in O
the O
control O
of O
negative O
symptoms B-outcome ['Life-Impact']
compared O
with O
haloperidol O
, O
perphenazine O
or O
zuclopenthixol O
, O
but O
the O
differences O
were O
not O
consistently O
statistically O
significant O
. O
['Life-Impact']

2 O
) O
( O
1 O
) O
= O
3.750 O
, O
P O
= O
0.05 O
] O
. O
[]

Patients O
, O
investigators O
, O
study O
monitors O
, O
and O
the O
sponsor O
staff O
were O
masked O
to O
treatment O
allocation O
. O
[]

RESULTS O
Topical O
capsaicin O
caused O
> O
50 O
% O
reduction O
of O
arterial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
absence O
of O
attack O
in O
17/23 O
patients O
, O
as O
opposed O
to O
two O
with O
vaseline O
. O
['Physiological-Clinical']

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
were O
found O
by O
analysis O
of O
variance O
to O
be O
significantly O
lower O
( O
2.6-4.8 O
and O
2.2-3.0 O
mm O
Hg O
, O
respectively O
) O
than O
those O
in O
the O
control O
group O
during O
experimental O
period O
2 O
for O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
experimental O
period O
1 O
for O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
contrast O
early O
discharge O
versus O
attempted O
full O
nutritional O
rehabilitation O
in O
hospital O
of O
children O
suffering O
from O
severe O
protein-energy O
malnutrition O
( O
PEM O
) O
. O
[]

Improved O
responsiveness O
of O
PCOS O
patients O
to O
clomiphene O
after O
CYP17a O
inhibitor O
. O
[]

The O
group O
receiving O
bevacizumab O
had O
better O
BCVA B-outcome ['Physiological-Clinical']
and O
lower O
CMT B-outcome ['Physiological-Clinical']
values O
at O
all O
time O
points O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
tidal O
volumes O
obtained O
by O
one-handed O
and O
two-handed O
ventilation O
techniques O
. O
[]

An O
increase O
in O
response O
rate O
for O
patients O
with O
measurable O
disease O
, O
of O
borderline O
statistical O
significance O
( O
P O
= O
0.088 O
, O
P O
for O
trend O
= O
0.018 O
) O
, O
from O
42 O
% O
in O
the O
CEF O
group O
to O
69 O
% O
in O
the O
CEF O
+ O
GM-CSF O
group O
, O
was O
observed O
. O
[]

On O
day O
16 O
, O
a O
higher O
mean O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
a O
lower O
proportion O
of O
patients O
with O
severe O
( O
< O
500/microL O
) O
neutropenia B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
clinical O
trial O
of O
cutting O
balloon O
angioplasty O
versus O
high-pressure O
balloon O
angioplasty O
in O
hemodialysis O
arteriovenous O
fistula O
stenoses O
resistant O
to O
conventional O
balloon O
angioplasty O
. O
[]

Eight O
spots O
were O
equally O
distributed O
at O
a O
distance O
of O
500 O
microm O
from O
one O
another O
over O
the O
anterior O
trabeculum O
. O
[]

Journal-Name:Journal O
of O
athletic O
training O
[]

[ O
Study O
on O
safety O
and O
immunogenicity O
of O
oral O
poliomyelitis O
attenuated O
live O
vaccine O
( O
human O
diploid O
cell O
) O
] O
. O
[]

Elbow B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
also O
induced O
involuntary O
changes O
in O
the O
intrinsic B-outcome ['Physiological-Clinical']
thumb I-outcome ['Physiological-Clinical']
flexor I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
( O
44.6 O
% O
increase O
under O
30 O
% O
elbow O
extensor O
activation O
; O
p O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Prophylactic O
administration O
of O
amantadine O
in O
doses O
of O
100 O
mg. O
twice O
a O
day O
offered O
statistically O
significant O
protection O
against O
influenza B-outcome ['Physiological-Clinical']
A2 I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
a O
double-blind O
field O
trial O
involving O
391 O
medical O
student O
volunteers O
during O
the O
influenza O
A2 O
Hong O
Kong O
epidemic O
in O
Helsinki O
in O
the O
winter O
of O
1969 O
. O
['Physiological-Clinical']

Six O
subjects O
( O
86 O
% O
) O
completed O
the O
study O
; O
one O
was O
removed O
due O
to O
the O
development O
of O
a O
rash O
. O
[]

OBJECTIVE O
Symptoms O
of O
depression O
and O
anxiety O
are O
commonly O
comorbid O
with O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
. O
[]

INTERVENTION O
The O
nutrition O
goals O
for O
women O
randomly O
assigned O
to O
the O
low-fat O
intervention O
were O
to O
reduce O
total O
fat O
intake O
to O
20 O
% O
or O
less O
of O
energy O
from O
fat O
and O
to O
consume O
5 O
or O
more O
fruit/vegetable O
servings O
daily O
and O
6 O
or O
more O
grain O
servings O
daily O
. O
[]

MATERIALS O
AND O
METHODS: O
In O
this O
blinded O
randomized O
trial, O
70 O
patients O
were O
assigned O
to O
receive O
four O
500mg O
capsules O
of O
green O
tea O
or O
starch O
as O
placebo O
daily O
for O
three O
days O
along O
with O
trimethoprim-sulfamethoxazole. O
[]

degree O
C-1 O
. O
[]

Overall O
response O
[]

BACKGROUND O
Infants O
fed O
a O
soy O
protein O
isolate-based O
formula O
have O
immunization B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
similar O
to O
breast-fed O
infants O
. O
['Physiological-Clinical']

Statistical O
analysis O
was O
done O
by O
the O
Mann-Whitney O
test O
, O
with O
P O
less O
than O
0.05 O
considered O
significant O
. O
[]

Effect O
of O
simvastatin O
on O
hemostasis O
in O
patients O
with O
isolated O
hypertriglyceridemia O
. O
[]

Journal-Name:Medicine O
[]

A O
total O
of O
1918 O
patients O
were O
screened O
for O
participation O
; O
1214 O
were O
recruited O
. O
[]

METHODS O
Prospectively O
enrolled O
patients O
with O
rectal O
cancer O
from O
October O
2007 O
to O
October O
2008 O
. O
[]

BACKGROUND: O
Tafenoquine, O
a O
single-dose O
therapy O
for O
Plasmodium O
vivax O
malaria, O
has O
been O
associated O
with O
relapse O
prevention O
through O
the O
clearance O
of O
P. O
vivax O
parasitemia O
and O
hypnozoites, O
termed O
"radical O
cure." O
[]

Double-blind O
placebo-controlled O
administration O
of O
fluoxetine O
in O
restricting- O
and O
restricting-purging-type O
anorexia O
nervosa O
. O
[]

Four O
patients O
achieved O
partial O
responses O
and O
17 O
had O
stable O
disease O
, O
lasting O
> O
3 O
months O
in O
14 O
patients O
. O
[]

Covariates O
included O
age O
, O
race O
, O
treatment O
arm O
, O
history O
of O
prostatectomy O
, O
nodal O
involvement O
, O
Gleason O
score O
, O
clinical O
stage O
, O
and O
BMI O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
postoperative B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
patients O
during O
the O
first O
and O
second O
days O
postsurgery O
. O
['Physiological-Clinical']

CONCLUSION O
Mizolastine O
( O
10 O
mg O
daily O
) O
is O
confirmed O
as O
an O
[]

Journal O
ID: O
8008349 O
[]

Cronassial O
, O
a O
mixture O
of O
four O
naturally O
occurring O
gangliosides O
, O
was O
administered O
in O
a O
randomized O
double-blind O
test O
to O
evaluate O
whether O
this O
agent O
could O
prevent O
vincristine-induced O
neuropathy O
. O
[]

Both O
the O
anesthesiologists O
and O
the O
recovery O
room O
nurses O
rated O
remifentanil O
better O
with O
respect O
to O
level O
of O
consciousness B-outcome ['Life-Impact']
. O
['Life-Impact']

Sustained O
benefit O
of O
continuous O
glucose O
monitoring O
on O
A1C O
, O
glucose O
profiles O
, O
and O
hypoglycemia O
in O
adults O
with O
type O
1 O
diabetes O
. O
[]

We O
aim O
to O
recruit O
319 O
women O
presenting O
at O
term O
, O
seeking O
analgesia O
for O
continuous O
severe O
lower O
back O
pain O
during O
labour O
. O
[]

Toxicities B-outcome ['Adverse-effects']
were O
graded O
according O
to O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
( O
NCI-CTC O
) O
system O
. O
['Adverse-effects']

METHODS O
Fundamental O
or O
harmonic O
MCE O
was O
performed O
with O
continuous O
or O
triggered O
imaging O
in O
203 O
patients O
with O
a O
previous O
MI O
using O
bolus O
doses O
of O
a O
perfluorocarbon-filled O
contrast O
agent O
( O
NC100100 O
) O
. O
[]

In O
hospitals O
that O
lack O
an O
efficient O
obstetric O
triage O
system O
, O
it O
is O
very O
difficult O
to O
regulate O
patient O
flow O
and O
wait O
times O
. O
[]

TRIAL O
REGISTRATION: O
WISDOM O
(ClinicalTrials.gov O
number, O
NCT00975195 O
). O
[]

Diclofenac O
did O
not O
significantly O
increase O
creatinine B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Calibration O
chi-square O
was O
acceptable O
for O
all O
models O
. O
[]

They O
were O
randomized O
to O
receive O
a O
periprostatic O
nerve O
block O
or O
no O
anesthesia O
. O
[]

Intravenous O
sodium O
valproate O
versus O
diazepam O
infusion O
for O
the O
control O
of O
refractory O
status O
epilepticus O
in O
children O
: O
a O
randomized O
controlled O
trial O
. O
[]

Journal O
ID: O
100968562 O
[]

Sample O
size O
was O
based O
on O
80 O
% O
power O
to O
reject O
the O
null O
hypothesis O
that O
the O
cost/QALY O
gained O
would O
not O
exceed O
$ O
50,000 O
. O
['Resource-use']

Controlled O
study O
on O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
of O
propionyl-L-carnitine O
in O
patients O
with O
congestive O
heart O
failure O
. O
['Physiological-Clinical']

Age-related B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
two O
Haemophilus O
influenzae O
type O
b O
vaccines O
. O
['Physiological-Clinical']

PATIENTS O
50 O
pediatric O
patients O
( O
18 O
girls O
, O
32 O
boys O
) O
, O
aged O
4 O
months O
to O
15 O
years O
, O
undergoing O
elective O
repair O
of O
congenital O
heart O
disease O
. O
[]

PTK2 O
expression O
may O
be O
a O
useful O
biomarker O
for O
patient O
selection O
in O
future O
trials O
. O
[]

EXPERIMENTAL O
DESIGN O
prospective O
, O
randomized O
study O
. O
[]

Women O
aged O
50 O
to O
80 O
years O
received O
raloxifene O
for O
96 O
weeks O
and O
were O
then O
randomized O
to O
continue O
raloxifene O
( O
group O
1 O
, O
n=20 O
) O
or O
placebo O
( O
group O
2 O
, O
n=20 O
) O
for O
a O
further O
96 O
weeks O
. O
[]

Risperidone O
and O
haloperidol O
treatments O
were O
applied O
with O
a O
once O
daily O
dosage O
regimen O
as O
0.01-0.08 O
mg/kg/day O
. O
[]

However O
, O
the O
hazard O
ratio O
and O
95 O
% O
confidence O
intervals O
are O
consistent O
with O
the O
previously O
reported O
meta-analysis O
and O
two O
large O
recently O
reported O
trials O
, O
which O
suggest O
a O
small O
survival O
benefit O
with O
cisplatin-based O
chemotherapy O
. O
[]

This O
study O
demonstrates O
the O
importance O
of O
conducting O
rigorous O
trials O
in O
children O
with O
autism O
and O
casts O
doubt O
on O
one O
GI O
mechanism O
presumed O
to O
exert O
etiological O
and/or O
symptomatic O
effects O
in O
this O
population O
. O
[]

Overall O
the O
mean O
postoperative B-outcome ['Physiological-Clinical']
Snore I-outcome ['Physiological-Clinical']
Index O
( O
SI O
) O
was O
less O
than O
the O
preoperative O
SI O
( O
P O
< O
0.0001 O
) O
, O
the O
average O
difference O
being O
78.2 O
snores/h O
. O
['Physiological-Clinical']

RESULTS O
The O
overall O
breastfeeding B-outcome ['Physiological-Clinical']
rate O
at O
8-12 O
weeks O
postpartum O
was O
67 O
% O
. O
['Physiological-Clinical']

Three O
cases O
of O
catheter B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
, O
two O
in O
the O
tunnelled O
group O
and O
one O
in O
the O
conventional O
group O
, O
were O
registered O
. O
['Physiological-Clinical']

Hence O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
relative O
effects O
of O
RRR-AT O
and O
all-rac-AT O
on O
plasma O
antioxidant O
levels O
and O
LDL O
oxidation O
in O
healthy O
persons O
in O
a O
dose-response O
study O
. O
[]

Performance O
on O
a O
cancellation O
task O
( O
number O
of O
correct B-outcome ['Life-Impact']
detections I-outcome ['Life-Impact']
) O
and O
a O
verbal B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
( O
word B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
) O
was O
better O
on O
risperidone O
than O
on O
placebo O
( O
without O
correction O
for O
multiplicity O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

No O
statistical O
difference O
in O
mortality B-outcome ['Mortality']
rate O
was O
seen O
among O
the O
3 O
fluid O
resuscitation O
groups O
. O
['Mortality']

Antiarrhythmic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
neoton O
manifested O
on O
MI O
day O
2 O
. O
['Physiological-Clinical']

DESIGN O
This O
randomized O
double-blind O
phase O
I O
study O
assessed O
the O
safety O
and O
acceptability B-outcome ['Life-Impact']
of O
seven O
consecutive O
daily O
doses O
of O
CS O
versus O
KY O
Jelly O
in O
36 O
HIV-positive O
men O
. O
['Life-Impact']

The O
influence O
of O
nonhandicapped O
peers O
on O
the O
social B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
of O
children O
with O
a O
pervasive O
development O
disorder O
. O
['Life-Impact']

The O
differences O
in O
the O
percentage O
changes O
of O
the O
FEV1 B-outcome ['Physiological-Clinical']
and O
FVC B-outcome ['Physiological-Clinical']
in O
the O
iopamidol O
and O
the O
sodium O
iothalamate O
groups O
were O
not O
statistically O
significant O
( O
P O
greater O
than O
0.5 O
and O
P O
greater O
than O
0.1 O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pimecrolimus O
cream O
and O
Tacrolimus O
ointment O
in O
the O
treatment O
of O
atopic B-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
: O
a O
pilot O
study O
on O
patient O
preference O
. O
['Physiological-Clinical']

CONCLUSIONS O
As O
compared O
with O
CABG O
, O
an O
initial O
strategy O
of O
PTCA O
did O
not O
significantly O
compromise O
five-year O
survival B-outcome ['Mortality']
in O
patients O
with O
multivessel O
disease O
, O
although O
subsequent B-outcome ['Resource-use']
revascularization I-outcome ['Resource-use']
was O
required O
more O
often O
with O
this O
strategy O
. O
['Mortality', 'Resource-use']

Eighteen O
patients O
were O
eventually O
treated O
with O
pentostatin O
and O
ten O
with O
2-chlorodeoxyadenosine O
( O
2-CdA O
) O
. O
[]

Survival B-outcome ['Mortality']
was O
poor O
in O
both O
groups O
and O
not O
significantly O
different O
. O
['Mortality']

CONCLUSIONS O
These O
results O
indicate O
that O
E-PEG O
was O
safe O
, O
tolerable B-outcome ['Life-Impact']
and O
speedy O
when O
compared O
ordinary O
pull-method O
PEG O
. O
['Life-Impact']

A O
prospective O
study O
in O
high-risk O
patients O
. O
[]

Thirty-three O
patients O
with O
II O
type O
mixed O
essential O
cryoglobulinemia O
( O
MEC O
) O
were O
randomized O
into O
two O
groups O
: O
one O
to O
receive O
combined O
therapy O
including O
prednisone O
plus O
interferon O
, O
the O
other O
to O
receive O
prednisone O
therapy O
. O
[]

Citrated B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
was O
obtained O
before O
and O
after O
1 O
and O
2 O
weeks O
of O
exercise O
: O
tPA B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
was O
assessed O
by O
a O
10 O
min O
venous O
occlusion O
( O
VO O
) O
test O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
A O
structured O
, O
multicomponent O
skills O
training O
intervention O
that O
targeted O
CG O
self-care O
behaviors O
as O
one O
of O
five O
target O
areas O
, O
improved O
self-reported B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
and O
decreased O
burden B-outcome ['Life-Impact']
and O
bother O
in O
racially O
and O
ethnically O
diverse O
CGs O
of O
people O
with O
dementia O
. O
['Life-Impact', 'Life-Impact']

rHCNTF O
was O
safe O
and O
tolerated B-outcome ['Life-Impact']
within O
acceptable O
limits O
when O
administered O
to O
patients O
with O
ALS O
in O
this O
study O
at O
doses O
of O
up O
to O
30 O
micrograms/kg O
3 O
times O
a O
week O
for O
2 O
weeks O
. O
['Life-Impact']

The O
effects O
of O
epinephrine-free O
and O
epinephrine-containing O
local O
anesthetic O
solutions O
on O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
investigated O
in O
20 O
patients O
undergoing O
oral O
surgery O
with O
intravenous O
midazolam O
sedation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Eighty O
postmenopausal O
women O
with O
osteoporosis O
were O
randomly O
assigned O
to O
a O
control O
group O
( O
n O
= O
38 O
) O
or O
an O
exercise O
group O
( O
n O
= O
42 O
) O
. O
[]

Possibilities O
include O
sustained O
attention O
to O
the O
affected O
limb O
, O
in O
which O
case O
the O
order O
of O
MIP O
components O
would O
not O
alter O
the O
effect O
, O
and O
sequential O
activation O
of O
cortical O
motor O
networks O
, O
in O
which O
case O
it O
would O
. O
[]

Smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
rates O
were O
statistically O
significantly O
better O
in O
the O
smokeless O
tobacco O
group O
than O
in O
the O
control O
group O
during O
the O
first O
7 O
weeks O
. O
['Life-Impact']

OBJECTIVE O
The O
objective O
was O
to O
evaluate O
parallel B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
physician I-outcome ['Life-Impact']
computer-mediated I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
training I-outcome ['Life-Impact']
on O
participants O
' O
report O
of O
skill O
use O
and O
patient O
satisfaction O
. O
['Life-Impact']

BACKGROUND: O
Acute O
bacterial O
skin O
and O
skin-structure O
infections O
are O
associated O
with O
substantial O
morbidity O
and O
health O
care O
costs. O
[]

Seventy-three O
eligible O
patients O
were O
assigned O
to O
treatment O
with O
cytarabine O
and O
infusional O
daunorubicin O
with O
or O
without O
intravenous O
CsA O
. O
[]

Major O
outcome O
was O
resolution B-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
at O
72 O
h. O
Total O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Reappraisal O
enhanced O
memory O
for O
educational B-outcome ['Life-Impact']
details I-outcome ['Life-Impact']
relative O
to O
no O
instructions O
. O
['Life-Impact']

RESULTS O
Both O
groups O
showed O
a O
reduction O
in O
DSH B-outcome ['Physiological-Clinical']
and O
hospitalizations B-outcome ['Resource-use']
, O
but O
there O
were O
no O
significant O
differences O
in O
DSH O
, O
hospital B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
or O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
hospital O
between O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use']

The O
pre- O
, O
intra- O
and O
postoperative O
relevant O
data O
of O
all O
selected O
patients O
were O
analyzed O
. O
[]

Human O
motor O
responses O
to O
simultaneous O
aversive O
stimulation O
and O
failure O
on O
a O
valued O
task O
. O
[]

The O
epinephrine-containing O
local O
anesthetic O
significantly O
reduced O
the O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
concentration O
10 O
min O
after O
injection B-outcome ['Physiological-Clinical']
, O
by O
0.16 O
+/- O
0.20 O
mmol/L O
( O
mean O
+/- O
SD O
) O
, O
and O
increased O
the O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
at O
10 O
, O
20 O
, O
and O
30 O
min O
( O
by O
0.46 O
+/- O
0.37 O
, O
0.63 O
+/- O
0.45 O
, O
and O
0.56 O
+/- O
0.28 O
mmol/L O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
changes O
in O
serum B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
from O
3 O
to O
6 O
mo O
were O
positively O
related O
to O
changes O
in O
the O
ratio O
of O
total O
to O
HDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
= O
0.041 O
) O
and O
in O
fasting O
( O
P O
= O
0.013 O
) O
and O
postprandial B-outcome ['Physiological-Clinical']
( O
P B-outcome ['Physiological-Clinical']
= O
0.016 O
) O
triacylglycerols B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

IP O
resulted O
in O
a O
complete O
recovery O
of O
the O
mean O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
index O
( O
SVI O
) O
after O
the O
operation O
. O
['Physiological-Clinical']

Falls B-outcome ['Life-Impact']
and O
mobility B-outcome ['Life-Impact']
in O
Parkinson O
's O
disease O
: O
protocol O
for O
a O
randomised O
controlled O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

INTERVENTION O
Following O
random O
assignment O
to O
one O
of O
the O
treatment O
groups O
, O
subjects O
received O
active O
medication O
or O
placebo O
for O
8 O
weeks O
in O
combination O
with O
cognitive O
behavioral O
counseling O
. O
[]

We O
found O
pronounced O
synergy O
between O
each O
nucleoside O
and O
the O
alkylator O
but O
even O
more O
enhanced O
cytotoxic O
synergy O
when O
the O
nucleoside O
analogs O
were O
combined O
prior O
to O
exposing O
the O
cells O
to O
Bu O
. O
[]

The O
mean O
age O
of O
the O
patients O
was O
14.9 O
years O
and O
the O
mean O
follow-up O
was O
24 O
months. O
[]

Asthma O
: O
communication O
between O
hospital O
and O
general O
practitioners O
. O
[]

On O
the O
basis O
of O
all O
patients O
treated O
, O
the O
rate O
of O
H. O
pylori O
eradication O
was O
significantly O
higher O
for O
triple O
therapy O
20/23 O
cases O
, O
87.0 O
% O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
0.664-0.972 O
) O
than O
for O
dual O
therapy O
13/25 O
, O
52.0 O
% O
; O
0.313-0.722 O
; O
P O
< O
0.05 O
) O
. O
[]

Using O
single-subject O
research O
analysis O
and O
medication O
given O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
cross-over O
design O
, O
4 O
of O
9 O
children O
randomized O
( O
44 O
% O
) O
had O
evidence O
of O
behavioral B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
. O
['Life-Impact']

After O
5 O
years O
of O
median O
follow-up O
, O
the O
cumulative O
incidence O
of O
IBR B-outcome ['Physiological-Clinical']
was O
2.5 O
% O
in O
the O
surgery-only O
arm O
and O
0.7 O
% O
in O
the O
surgery O
plus O
RT O
arm O
. O
['Physiological-Clinical']

It O
is O
concluded O
that O
the O
myocardial O
protection O
during O
ischemia O
was O
sufficient O
to O
prevent O
significant O
reductions O
of O
myocardial B-outcome ['Physiological-Clinical']
ATP I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
irrespective O
of O
supplementation O
with O
CP O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
then O
controlled O
after O
5 O
, O
10 O
, O
15 O
, O
20 O
, O
30 O
, O
45 O
, O
60 O
, O
120 O
min O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
three-year O
clinical O
outcomes O
between O
sirolimus-versus O
paclitaxel-eluting O
stents O
in O
diabetic O
patients O
: O
prospective O
randomized O
multicenter O
trial O
. O
[]

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
IFN-alpha O
administered O
as O
an O
adjuvant O
of O
HBV O
vaccine O
in O
healthy O
unvaccinated O
individuals O
. O
[]

The O
cardiovascular O
( O
CV O
) O
responses O
to O
meal O
ingestion O
and O
orthostasis O
are O
well O
established O
. O
[]

Only O
those O
patients O
who O
received O
prenatal O
care O
at O
the O
Central O
Maternity O
Hospital O
for O
Luanda O
were O
included O
in O
the O
study O
. O
[]

The O
main O
outcome O
was O
completion B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
CRC I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
. O
['Life-Impact']

Eighteen O
patients O
completed O
1-year O
and O
7.5-year O
follow-up O
. O
[]

Studies O
of O
the O
effect O
of O
vascular O
volume O
and O
intraperitoneal O
pressure O
on O
renal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hepatic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
At O
six O
centers O
, O
71 O
angiographers O
each O
reviewed O
a O
set O
of O
100 O
angiographic O
sequences O
. O
[]

In O
this O
study O
, O
both O
iobitridol O
and O
iopromide O
provided O
excellent O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
and O
a O
low O
rate O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Free B-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
decreased O
in O
53.85 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
37.5 O
% O
of O
women O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Pre-transplant O
pharmacokinetic O
profiling O
and O
tacrolimus B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
post-transplant I-outcome ['Resource-use']
. O
['Resource-use']

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
efficacy O
and O
safety O
of O
apatinib O
in O
patients O
with O
advanced O
colorectal O
cancer O
for O
whom O
at O
least O
two O
lines O
of O
prior O
chemotherapy O
had O
failed. O
[]

Exemestane O
for O
breast-cancer O
prevention O
in O
postmenopausal O
women O
. O
[]

Three O
weeks O
later O
, O
the O
participants O
returned O
and O
the O
protocol O
was O
repeated O
on O
the O
contralateral O
limb O
, O
using O
the O
opposite O
intervention O
( O
HVPC O
or O
placebo O
) O
. O
[]

Noninfiltrative O
anesthesia O
for O
transrectal O
prostate O
biopsy O
: O
a O
randomized O
prospective O
study O
comparing O
lidocaine-prilocaine O
cream O
and O
lidocaine-ketorolac O
gel O
. O
[]

Patterns O
of O
management O
of O
atrial O
fibrillation O
complicating O
coronary O
artery O
bypass O
grafting O
: O
Results O
from O
the O
PRoject O
of O
Ex-vivo O
Vein O
graft O
ENgineering O
via O
Transfection O
IV O
( O
PREVENT-IV O
) O
Trial O
. O
[]

Secondary O
endpoints O
included O
other O
MRI O
measures O
and O
clinical O
endpoints O
. O
[]

In O
this O
study O
, O
87 O
volunteers O
who O
wanted O
to O
quit O
cigarette O
smoking O
were O
assigned O
randomly O
to O
the O
experimental O
hypnosis O
group O
, O
the O
comparison O
relaxation O
group O
, O
and O
the O
waiting O
list O
control O
group O
. O
[]

The O
objective O
of O
this O
open-label O
, O
multiple-dose O
, O
controlled O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
argatroban O
in O
patients O
undergoing O
elective O
PCI O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

SETTING O
Rural O
Malawi O
. O
[]

To O
assess O
blinding O
, O
subjects O
were O
asked O
after O
the O
interventions O
what O
the O
practitioner O
was O
doing O
during O
each O
period O
( O
reading O
, O
touch O
, O
or O
something O
else O
) O
. O
[]

Accelerated O
production B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
material I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
phospholipids I-outcome ['Physiological-Clinical']
in O
infants O
from O
dexamethasone-treated O
dams O
was O
indicated O
by O
increases O
in O
total O
lung B-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
( O
84.5 O
+/- O
8.1 O
mg/g O
dry O
lung O
versus O
75.1 O
+/- O
9.9 O
, O
p O
less O
than O
0.025 O
) O
, O
alveolar B-outcome ['Physiological-Clinical']
lavage I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
( O
5.65 O
+/- O
3.33 O
mg/g O
dry O
lung O
versus O
3.01 O
+/- O
1.84 O
, O
p O
less O
than O
0.05 O
) O
, O
and O
alveolar B-outcome ['Physiological-Clinical']
lavage I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
disaturated I-outcome ['Physiological-Clinical']
phosphatidylcholine I-outcome ['Physiological-Clinical']
( O
DPC B-outcome ['Physiological-Clinical']
) O
( O
2.47 O
+/- O
1.84 O
mg/g O
dry O
lung O
versus O
1.06 O
+/- O
1.05 O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Proparacaine O
use O
significantly O
lowered O
mean O
PIPP O
scores O
( O
P=0.027 O
) O
and O
delta O
scores O
( O
P=0.013 O
) O
at O
1 O
min O
after O
examination O
, O
but O
there O
was O
no O
difference O
at O
5 O
min O
after O
examination O
. O
[]

Participants O
who O
underwent O
SCTG+CAF+EMD O
application O
were O
identified O
as O
the O
test O
group O
(n O
= O
19) O
and O
those O
who O
underwent O
SCTG+CAF O
as O
control O
group O
(n O
= O
19). O
[]

Using O
the O
Quality O
Adjusted O
Life O
Year O
outcome, O
the O
intervention O
was O
not O
cost O
effective O
from O
an O
NHS/PSS O
perspective. O
[]

Between O
5 O
and O
25 O
min O
after O
morphine O
administration O
, O
pain B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
the O
IV O
group O
was O
significantly O
improved O
compared O
with O
the O
IM O
group O
. O
['Physiological-Clinical']

However O
, O
a O
trend O
toward O
a O
higher O
rate O
of O
permanent B-outcome ['Life-Impact']
discontinuation I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
study I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
was O
noted O
among O
children O
assigned O
to O
NFV O
+ O
NVP O
+ O
d4T O
compared O
with O
NFV O
+ O
RTV O
+ O
ddI O
[ O
7 O
of O
20 O
( O
35 O
% O
) O
versus O
2 O
of O
21 O
( O
10 O
% O
) O
; O
P O
= O
0.12 O
] O
. O
['Life-Impact']

10 O
( O
p O
= O
0.04 O
) O
. O
[]

This O
study O
examined O
children O
's O
ratings O
of O
attitudes B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
toward O
a O
peer O
presented O
with O
or O
without O
autistic O
behaviors O
. O
['Life-Impact']

METHODS: O
We O
randomly O
assigned O
493 O
patients O
with O
resected O
pancreatic O
ductal O
adenocarcinoma O
to O
receive O
a O
modified O
FOLFIRINOX O
regimen O
(oxaliplatin O
[85 O
mg O
per O
square O
meter O
of O
body-surface O
area], O
irinotecan O
[180 O
mg O
per O
square O
meter, O
reduced O
to O
150 O
mg O
per O
square O
meter O
after O
a O
protocol-specified O
safety O
analysis], O
leucovorin O
[400 O
mg O
per O
square O
meter], O
and O
fluorouracil O
[2400 O
mg O
per O
square O
meter O
every O
2 O
weeks) O
or O
gemcitabine O
(1000 O
mg O
per O
square O
meter O
on O
days O
1, O
8, O
and O
15 O
every O
4 O
weeks) O
for O
24 O
weeks. O
[]

Marker O
changes O
at O
2 O
and O
4 O
months O
showed O
a O
highly O
significant O
correlation O
with O
the O
UICC O
assessed O
response O
at O
3 O
and O
6 O
months O
( O
P O
< O
0.001 O
) O
; O
sensitivity O
100 O
% O
, O
specificity O
87 O
% O
; O
positive O
predictive O
value O
85 O
% O
; O
negative O
predictive O
value O
100 O
% O
. O
[]

Postprandial O
increases O
in O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
and O
C-peptide B-outcome ['Physiological-Clinical']
were O
consistently O
lower O
in O
the O
acarbose-treated O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Deliberate B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
in O
patients O
with O
intracranial O
arteriovenous O
malformations O
: O
esmolol O
compared O
with O
isoflurane O
and O
sodium O
nitroprusside O
. O
['Physiological-Clinical']

Bipolar O
transurethral O
resection O
of O
the O
prostate O
causes O
less O
bleeding O
than O
the O
monopolar O
technique O
: O
a O
single-centre O
randomized O
trial O
of O
202 O
patients O
. O
[]

There O
were O
no O
significant O
differences O
between O
initial O
and O
final O
results O
in O
either O
group O
in O
terms O
of O
BMI O
, O
WHR O
or O
waist O
circumference O
. O
[]

In O
the O
sheep O
model O
, O
it O
was O
clearly O
shown O
that O
the O
release O
of O
bupivacaine O
from O
microspheres O
was O
controlled O
and O
prolonged O
despite O
the O
largest O
dose O
of O
bupivacaine O
used O
( O
500 O
mg O
; O
n O
= O
4 O
) O
. O
[]

Parecoxib O
( O
40 O
mg O
) O
was O
given O
in O
all O
the O
patients O
immediately O
before O
the O
operation O
, O
and O
the O
mixture O
( O
4-5 O
ml O
) O
of O
lidocaine O
and O
ropivacaine O
was O
administered O
into O
the O
3 O
intercostal O
spaces O
upper O
and O
lower O
to O
the O
incision O
before O
chest O
closure O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

For O
a O
comparison O
of O
propranolol O
and O
nadolol O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
clinical O
effects O
, O
20 O
newly O
diagnosed O
patients O
with O
thyrotoxicosis O
were O
randomly O
selected O
to O
receive O
as O
sole O
therapy O
, O
either O
propranolol O
, O
40 O
mg O
every O
6 O
hours O
for O
14 O
days O
, O
or O
nadolol O
, O
80 O
mg O
each O
morning O
for O
14 O
days O
. O
['Physiological-Clinical']

The O
subjects O
were O
randomly O
assigned O
to O
the O
high O
dose, O
low O
dose, O
or O
placebo O
group O
(each O
group: O
n O
= O
21). O
[]

In O
Study O
1 O
, O
each O
of O
the O
following O
explanations O
was O
unrelated O
to O
persistence B-outcome ['Life-Impact']
: O
public O
commitment O
, O
self-consistency O
, O
and O
unique O
causal O
risk O
models O
. O
['Life-Impact']

FUNDING: O
University O
of O
Texas O
MD O
Anderson O
Cancer O
Center O
and O
National O
Cancer O
Institute O
Specialized O
Programs O
of O
Research O
Excellence. O
[]

Outcome O
measures O
included O
histologic B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
biopsies I-outcome ['Physiological-Clinical']
and O
assessment O
of I-outcome ['Physiological-Clinical']
serologic B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IBD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
fecal B-outcome ['Physiological-Clinical']
calprotectin O
levels O
, O
and O
polymorphisms O
in O
immune-related B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Analyze O
the O
relationship O
between O
tobacco B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
and O
intake O
of O
macro O
and O
micronutrients B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

REVAMP O
comprised O
two O
phases O
: O
1 O
) O
a O
12-week O
open-label O
antidepressant O
trial O
and O
2 O
) O
, O
a O
subsequent O
phase O
, O
in O
which O
phase O
1 O
non-remitters O
( O
N O
= O
491 O
) O
were O
randomized O
to O
either O
receive O
an O
ongoing O
medication O
algorithm O
alone O
, O
medication O
plus O
cognitive O
behavioral O
analysis O
system O
of O
psychotherapy O
, O
or O
medication O
plus O
brief O
supportive O
psychotherapy O
. O
[]

Immunogenicity O
was O
evaluated O
using O
VZV O
interferon-gamma O
( O
IFN-? O
) O
enzyme-linked O
immunospot O
( O
ELISPOT O
) O
assay O
and O
VZV O
glycoprotein O
enzyme-linked O
immunosorbent O
antibody O
( O
gpELISA O
) O
assay O
. O
[]

CT O
had O
a O
lower O
confidence B-outcome ['Life-Impact']
score O
than O
did O
DSA O
( O
7.2 O
vs O
8.2 O
, O
P O
< O
.001 O
) O
. O
['Life-Impact']

Similarly O
, O
a O
greater O
proportion O
of O
the O
CBZ O
600 O
group O
required O
a O
change O
in O
dose O
, O
47 O
% O
versus O
20 O
% O
( O
LTG O
100 O
) O
and O
17 O
% O
( O
LTG O
200 O
) O
or O
withdrew O
completely O
due O
to O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
, O
10.3 O
% O
versus O
4.3 O
% O
( O
LTG O
100 O
) O
and O
4.5 O
% O
( O
LTG O
200 O
) O
. O
['Adverse-effects']

After O
three-month O
drug O
therapy O
, O
the O
serum B-outcome ['Physiological-Clinical']
EMAb I-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Physiological-Clinical']
rate O
was O
obviously O
higher O
in O
the O
test O
group O
than O
in O
the O
control O
group O
( O
44.44 O
% O
vs O
15.62 O
% O
) O
, O
showing O
statistical O
difference O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Baseline O
values O
were O
compared O
with O
data O
collected O
during O
the O
treatment O
period O
. O
[]

4 O
) O
No O
synchronous O
or O
metachronous O
double O
cancer O
. O
[]

The O
mean O
difference O
was O
more O
significant O
when O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
per O
gm O
. O
['Physiological-Clinical']

BEACOPP O
, O
a O
new O
dose-escalated O
and O
accelerated O
regimen O
, O
is O
at O
least O
as O
effective O
as O
COPP/ABVD O
in O
patients O
with O
advanced-stage O
Hodgkin O
's O
lymphoma O
: O
interim O
report O
from O
a O
trial O
of O
the O
German O
Hodgkin O
's O
Lymphoma O
Study O
Group O
. O
[]

The O
days B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in I-outcome ['Resource-use']
NICU I-outcome ['Resource-use']
was O
shorter O
in O
intensive O
insulin O
control O
group O
than O
that O
in O
conventional O
therapy O
group O
[ O
4.2 O
days O
vs. O
5.6 O
days O
( O
medians O
) O
P O
< O
0.05 O
] O
. O
['Resource-use']

METHODS O
Diagnosed O
hypertensive O
patients O
were O
enrolled O
in O
this O
RCT O
and O
randomized O
to O
one O
of O
two O
study O
groups O
: O
( O
1 O
) O
the O
intervention O
condition O
-- O
Web-based O
hypertension O
feedback O
, O
based O
on O
the O
individual O
patient O
's O
self-report O
of O
health O
variables O
and O
previous O
BP O
measurements O
, O
to O
prompt O
them O
to O
ask O
questions O
during O
their O
next O
physician O
's O
visit O
about O
hypertension O
care O
( O
2 O
) O
the O
control O
condition O
-- O
Web-based O
preventive O
health O
feedback O
, O
based O
on O
the O
individual O
's O
self-report O
of O
receiving O
preventive O
care O
( O
e.g. O
, O
pap O
testing O
) O
, O
to O
prompt O
them O
to O
ask O
questions O
during O
their O
next O
physician O
's O
visit O
about O
preventive O
care O
. O
[]

Forty-one O
patients O
had O
active O
leukemia O
at O
the O
time O
of O
transplant O
, O
and O
35 O
achieved O
CR O
( O
85 O
% O
) O
. O
[]

The O
safety O
of O
whey O
protein O
concentrate O
derived O
from O
the O
milk O
of O
cows O
immunized O
against O
Clostridium O
difficile O
. O
[]

Tests O
of O
upright B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
included O
: O
timed B-outcome ['Physiological-Clinical']
up I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
go I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TUG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
sharpened B-outcome ['Physiological-Clinical']
Romberg I-outcome ['Physiological-Clinical']
, O
360-degree B-outcome ['Physiological-Clinical']
turns I-outcome ['Physiological-Clinical']
, O
25-foot B-outcome ['Physiological-Clinical']
walk I-outcome ['Physiological-Clinical']
, O
and O
computerized B-outcome ['Physiological-Clinical']
platform I-outcome ['Physiological-Clinical']
posturography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
A O
randomized O
, O
placebo-controlled O
trial O
in O
which O
patients O
received O
either O
usual O
care O
by O
a O
general O
practitioner O
( O
information O
and O
analgesics O
) O
, O
or O
placebo O
physiotherapy O
given O
by O
a O
physiotherapist O
, O
or O
exercise O
therapy O
given O
by O
a O
physiotherapist O
. O
[]

Among O
participants O
with O
1-year O
abstinence, O
those O
in O
the O
e-cigarette O
group O
were O
more O
likely O
than O
those O
in O
the O
nicotine-replacement O
group O
to O
use B-outcome ['Life-Impact']
their O
assigned O
product O
at O
52 O
weeks O
(80% O
[63 O
of O
79 O
participants O
vs. O
9% O
[4 O
of O
44 O
participants]). O
[['Life-Impact']]

We O
studied O
the O
effects O
of O
a O
single O
dose O
of O
fenoterol O
on O
the O
relationship O
between O
inspiratory O
effort O
sensation O
( O
IES O
) O
and O
inspiratory O
muscle O
fatigue O
induced O
by O
inspiratory O
threshold O
loading O
in O
healthy O
subjects O
. O
[]

In O
some O
regions O
, O
these O
effects O
may O
be O
related O
to O
the O
receptor O
( O
target O
) O
density O
. O
[]

In O
conclusion O
, O
intra-arterial O
and O
intravenous O
heparin O
administration O
provide O
comparable O
efficacy O
in O
preventing O
RAO O
, O
favoring O
a O
probable O
systemically O
mediated O
mechanism O
of O
action O
, O
rather O
than O
a O
local O
effect O
. O
[]

On O
the O
basis O
of O
the O
presence O
and O
dose O
intensity O
of O
the O
included O
agents O
, O
we O
hypothesised O
that O
PELF O
would O
be O
superior O
to O
FAMTX O
. O
[]

The O
median O
time O
to O
documentation O
of O
conversion B-outcome ['Life-Impact']
was O
51 O
mo O
. O
['Life-Impact']

Eradication B-outcome ['Physiological-Clinical']
of O
H. O
pylori B-outcome ['Physiological-Clinical']
in O
the O
omeprazole-amoxycillin B-outcome ['Resource-use']
group O
was O
50 O
% O
and O
in O
the O
omeprazole O
placebo O
group O
0 O
% O
four O
weeks O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

However O
, O
the O
success B-outcome ['Physiological-Clinical']
rate O
at O
24 O
hours O
was O
significantly O
higher O
in O
the O
vaginal O
group O
( O
85 O
% O
) O
compared O
with O
the O
sublingual O
group O
( O
64 O
% O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Both O
the O
potassium O
titanyl O
phosphate O
and O
the O
bipolar O
radiofrequency O
techniques O
were O
safe O
and O
easy B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
for O
tonsillectomy O
, O
with O
reduced O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
complication B-outcome ['Adverse-effects']
rates O
and O
better O
post-operative O
general O
patient O
condition O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Adverse-effects']

According O
to O
our O
results O
, O
long-duration O
low-intensity O
general O
warm-up O
seems O
be O
appropriately O
to O
improve O
1RM O
performance O
in O
strength-trained O
individuals O
. O
[]

Secondary O
outcomes O
were O
mean O
BP B-outcome ['Physiological-Clinical']
and O
TC B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Most O
subjects O
were O
vitD(3) O
deficient O
at O
enrolment, O
but O
a O
gradual O
and O
significant O
improvement O
of O
vitD(3) B-outcome ['Physiological-Clinical']
status O
was O
demonstrated O
in O
the O
vitD(3) O
+ O
PBA O
group O
compared O
with O
placebo O
(p O
< O
0.0001) O
from O
week O
0 O
to O
16 O
(median O
37.5 O
versus O
115.5 O
nmol/L). O
[['Physiological-Clinical']]

The O
6-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
EFS O
) O
was O
85 O
% O
+/- O
2 O
% O
for O
dexamethasone O
and O
77 O
% O
+/- O
2 O
% O
for O
prednisone O
( O
P O
=.002 O
) O
. O
['Mortality']

Flosequinan O
evoked O
a O
significant O
increase O
in O
maximal B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
with O
a O
four-point O
scale O
: O
0 O
= O
no O
pain O
, O
1 O
= O
mild O
pain O
, O
2 O
= O
moderate O
pain O
, O
and O
3 O
= O
severe O
pain O
at O
the O
time O
of O
propofol O
injection O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
study O
aimed O
to O
( O
1 O
) O
investigate O
whether O
provision O
of O
a O
home-based O
program O
in O
addition O
to O
a O
center-based O
program O
improves O
development O
in O
young O
children O
with O
disabilities O
and O
coping O
abilities O
of O
their O
families O
and O
( O
2 O
) O
describe O
the O
characteristics O
of O
children O
and O
families O
who O
benefit O
most O
from O
the O
intervention O
. O
[]

A O
total O
of O
45 O
menopausal O
participants O
were O
recruited O
in O
this O
study. O
[]

In O
one O
study O
arm O
, O
patients O
with O
bulimia O
nervosa O
were O
treated O
with O
150 O
mg O
Spironolactone O
per O
day O
; O
in O
the O
other O
arm O
, O
patients O
received O
a O
placebo O
for O
a O
total O
of O
8 O
weeks O
. O
[]

Journal-Name:BMC O
public O
health O
[]

RESULTS O
Significant O
differences O
( O
P O
< O
0.05 O
) O
with O
initial O
values O
were O
found O
after O
a O
2 O
mm O
marginal O
bone O
removal O
( O
Osstell/Periotest O
) O
; O
for O
a O
peri-apical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
, O
after O
removal O
of O
5 O
mm O
( O
Osstell O
) O
or O
8 O
mm O
( O
Periotest O
) O
; O
for O
a O
6-mm-long O
dehiscence O
, O
after O
removal O
up O
to O
180 O
degrees O
of O
the O
implant O
perimeter O
( O
Osstell/Periotest O
) O
; O
for O
a O
3-mm-wide O
dehiscence O
, O
after O
removal O
of O
10 O
mm O
( O
Osstell O
) O
or O
6 O
mm O
( O
Periotest O
) O
. O
['Physiological-Clinical']

METHODS O
Fifteen O
atopic O
asthmatics O
were O
randomized O
in O
double-blind O
, O
cross-over O
fashion O
to O
receive O
for O
1 O
week O
either O
levocetirizine O
5 O
mg O
or O
placebo O
. O
[]

The O
incidence O
of O
pertussis O
in O
the O
vaccine O
groups O
and O
prevalence O
of O
pertussis O
in O
children O
under O
5 O
years O
of O
age O
in O
the O
study O
area O
were O
also O
determined O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
20.3 O
and O
14.9 O
months O
for O
HART O
and O
qdRT O
, O
respectively O
( O
P O
= O
.28 O
) O
. O
['Mortality']

DESIGN O
This O
was O
a O
prospective O
, O
randomized O
, O
placebo-controlled O
trial O
in O
21 O
patients O
aged O
35 O
+/- O
11 O
y O
( O
x O
+/- O
SD O
) O
with O
burns O
on O
45 O
+/- O
21 O
% O
of O
their O
body O
surface O
area O
. O
[]

Analyses O
were O
based O
on O
the O
intent-to-treat O
population O
. O
[]

Elevated O
concentration O
of O
placental O
growth O
factor O
( O
PlGF O
) O
and O
long O
term O
risk O
in O
patients O
with O
acute O
coronary O
syndrome O
in O
the O
PROVE O
IT-TIMI O
22 O
trial O
. O
[]

The O
Dutch O
Gastric O
Cancer O
Group O
( O
DGCG O
) O
. O
[]

The O
total O
incidence O
of O
PONV B-outcome ['Physiological-Clinical']
in O
the O
desflurane-only O
group O
was O
80 O
% O
( O
P O
< O
0.01 O
) O
, O
compared O
to O
40 O
% O
and O
20 O
% O
in O
the O
desflurane O
group O
receiving O
ondansetron O
and O
the O
propofol O
group O
, O
respectively O
. O
['Physiological-Clinical']

RESULTS: O
Over O
17 O
months, O
53 O
patients O
were O
assessed O
for O
eligibility O
and O
36 O
(68%) O
were O
randomised O
(47% O
male; O
mean O
age O
36.9 O
[SD O
11.2 O
years); O
13 O
to O
HIIT, O
12 O
to O
MICT, O
and O
11 O
to O
control. O
[]

Families O
were O
recruited O
through O
schools O
and O
community O
centers O
and O
were O
included O
if O
there O
was O
1 O
child O
in O
Grades O
1-3 O
at O
moderate O
to O
high O
risk O
for O
skin O
cancer O
. O
[]

Alinidine O
increased O
both O
total O
exercise O
duration O
from O
246.7 O
+/- O
120.7 O
to O
346.6 O
+/- O
114.1 O
s O
( O
p O
less O
than O
0.05 O
) O
and O
time O
to O
0.1-mV O
ST O
segment O
depression O
from O
98.3 O
+/- O
53 O
to O
187.2 O
+/- O
105 O
s O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Fenfluramine O
may O
have O
a O
limited O
place O
in O
the O
management O
of O
some O
patients O
with O
autistic O
disorder O
. O
[]

METHODS O
Randomly O
selected O
medical O
records O
were O
reviewed O
for O
248 O
African O
American O
, O
30 O
Hispanic O
, O
and O
235 O
white O
or O
other-race O
patients O
undergoing O
above- O
or O
below-knee O
amputation O
between O
1995 O
and O
2003 O
at O
three O
Chicago O
teaching O
hospitals O
. O
[]

DESIGN O
A O
randomized O
controlled O
trial O
. O
[]

During O
the O
initial O
, O
medication-free O
exercise O
all O
patients O
had O
increased O
pulmonary B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
wedge I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAWP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
31.4 O
+/- O
5.56 O
mmHg O
( O
mean O
+/- O
SD O
) O
, O
showing O
impaired O
left O
ventricular O
function O
, O
while O
mean O
arterial B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
( O
MAP O
) O
rose O
from O
112 O
+/- O
16.3 O
mmHg O
at O
rest O
to O
141 O
+/- O
15.9 O
mmHg O
during O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
reduction O
in O
total B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
(TC) I-outcome ['Physiological-Clinical']
, O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(LDL-C) I-outcome ['Physiological-Clinical']
and O
non-high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(HDL-C) I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
DR O
group, O
whereas O
mean O
reduction O
in O
triglycerides B-outcome ['Physiological-Clinical']
(TG) I-outcome ['Physiological-Clinical']
and O
increase O
in O
non-high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein-cholesterol I-outcome ['Physiological-Clinical']
(HDL-C) I-outcome ['Physiological-Clinical']
was O
similar O
in O
both O
the O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Both O
groups O
were O
treated O
with O
insulin O
infusion O
to O
maintain O
normoglycemia O
after O
leaving O
NICU O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
chronic O
cigarette O
smoking O
, O
acute O
nicotine O
administration O
, O
and O
OC O
use O
on O
cardiovascular B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Active O
treatment O
programs O
for O
patients O
with O
chronic O
low O
back O
pain O
: O
a O
prospective O
, O
randomized O
, O
observer-blinded O
study O
. O
[]

As O
compared O
with O
the O
placebo O
group, O
women O
who O
received O
zoledronate O
had O
a O
lower O
risk O
of O
nonvertebral B-outcome ['Physiological-Clinical']
fragility I-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
(hazard O
ratio, O
0.66; O
P=0.001), O
symptomatic B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
(hazard O
ratio, O
0.73; O
P=0.003), O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
(odds O
ratio, O
0.45; O
P=0.002), O
and O
height B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(P<0.001). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND O
Immunisation O
against O
influenza O
is O
an O
effective O
intervention O
that O
reduces O
serologically O
confirmed O
cases O
by O
between O
60 O
% O
and O
70 O
% O
. O
[]

The O
quality O
of O
the O
motor O
process O
of O
an O
eye O
movement O
is O
known O
as O
saccade O
metrics O
. O
[]

STUDY O
DESIGN O
Fifty-five O
children O
with O
cancer O
and O
eight O
children O
given O
total O
parenteral O
nutrition O
by O
the O
surgery O
or O
nutrition O
support O
services O
were O
randomly O
assigned O
to O
receive O
a O
heparin O
CVC O
flush O
solution O
( O
n O
= O
31 O
) O
or O
a O
heparin-vancomycin O
CVC O
flush O
solution O
( O
n O
= O
32 O
) O
. O
[]

Effect O
of O
acebutolol O
on O
left O
ventricular O
performance O
. O
[]

The O
efficacy O
and O
safety O
of O
tamsulone-FS O
was O
comparable O
to O
those O
of O
omnik O
. O
[]

Treatment O
effects O
were O
determined O
by O
analysing O
cumulative O
probability O
of O
cure O
by O
testing O
Cox O
proportional O
hazards O
models O
and O
relative O
risk O
( O
RR O
) O
. O
[]

Using O
a O
set O
of O
objective O
diagnostic O
criteria O
, O
we O
saw O
a O
significant O
difference O
in O
the O
incidence O
of O
the O
syndrome B-outcome ['Physiological-Clinical']
between O
corticosteroid- O
( O
0 O
of O
21 O
) O
and O
placebo-treated O
patients O
( O
9 O
of O
41 O
) O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Both O
groups O
were O
similar O
regarding O
age O
( O
p O
= O
0.06 O
, O
Mann-Whitney O
test O
) O
. O
[]

T O
Diabetes O
Management O
Self-Efficacy B-outcome ['Life-Impact']
Scale O
was O
completed O
at O
baseline O
6-month O
and O
12-month. O
[['Life-Impact']]

OBJECTIVE O
To O
explore O
the O
effect O
of O
antidepressant O
treatment O
on O
antihypertensive O
therapy O
of O
senile O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
this O
open-label O
, O
multicenter O
, O
phase O
II O
study O
, O
eligible O
patients O
( O
N O
= O
112 O
) O
were O
randomized O
2:1 O
to O
lapatinib O
plus O
vinorelbine O
[ O
( O
N O
= O
75 O
) O
1,250 O
mg O
orally O
once O
daily O
( O
QD O
) O
continuously O
plus O
20 O
mg/m O
( O
2 O
) O
/day O
intravenously O
] O
or O
lapatinib O
plus O
capecitabine O
[ O
( O
N O
= O
37 O
) O
1,250 O
mg O
orally O
QD O
continuously O
plus O
2,000 O
mg/m O
( O
2 O
) O
/day O
orally O
, O
2 O
doses O
] O
. O
[]

Treatment O
of O
acute O
otitis O
media O
in O
children O
under O
2 O
years O
of O
age O
. O
[]

RESULTS: O
Both O
groups O
heat B-outcome ['Physiological-Clinical']
acclimated I-outcome ['Physiological-Clinical']
similarly O
(p>0.05) O
evidenced O
by O
lower O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
thermoregulatory, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
physiological, B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
perceptual B-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
responses E1-outcome ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']
( O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
thermal B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
) O
Pre O
HA O
vs. O
Post O
HA O
(p</=0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Resident B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
was O
measured O
by O
a O
70-item O
examination O
. O
['Life-Impact']

Culturally O
and O
linguistically O
appropriate O
interventions O
are O
necessary O
to O
increase O
hepatitis B-outcome ['Life-Impact']
B I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
serologic B-outcome ['Physiological-Clinical']
testing O
, O
and O
vaccination B-outcome ['Resource-use']
among O
Cambodian O
Americans O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

Peripheral B-outcome ['Physiological-Clinical']
natural I-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NK I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
LAK B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
were O
augmented O
in O
all O
patients O
and O
total O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
increased O
during O
IS-IL-2 O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Split-face O
comparison O
of O
the O
erbium O
micropeel O
with O
intense O
pulsed O
light O
. O
[]

Complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
enlarged I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
within O
168 O
h O
was O
associated O
with O
a O
sensitive O
response O
to O
each O
treatment O
. O
['Physiological-Clinical']

Milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
of O
dairy O
cows O
fed O
wet O
corn O
gluten O
feed O
during O
the O
dry O
period O
and O
lactation O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
satisfaction B-outcome ['Life-Impact']
rate O
and O
the O
effectiveness O
of O
transcervical O
hysteroscopic O
endometrial O
resection O
and O
thermal O
destruction O
of O
the O
endometrium O
in O
the O
treatment O
of O
menorrhagia O
. O
['Life-Impact']

Symptoms O
were O
reassessed O
at O
the O
end O
of O
each O
month O
. O
[]

Forty-five O
children O
and O
their O
parents O
were O
randomly O
assigned O
to O
either O
intervention O
or O
wait-list O
control O
conditions O
. O
[]

The O
study O
also O
examines O
the O
cost O
effectiveness O
of O
this O
therapy O
in O
this O
setting O
through O
examination O
of O
health O
care O
service O
utilisation O
across O
groups O
during O
the O
first O
3 O
months. O
[]

Considering O
growth O
over O
all O
3 O
measurement O
periods O
, O
an O
exploratory O
analysis O
showed O
that O
growth O
rate O
of O
the O
number O
of O
different B-outcome ['Life-Impact']
nonimitative I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
was O
faster B-outcome ['Physiological-Clinical']
in O
the O
PECS O
group O
than O
in O
the O
RPMT O
group O
for O
children O
who O
began O
treatment O
with O
relatively O
high O
object O
exploration O
. O
['Life-Impact', 'Physiological-Clinical']

Primary O
non-resectable O
liver O
malignancies O
show O
the O
best O
results O
after O
chemoembolisation O
( O
Frankfurt O
method O
) O
. O
[]

The O
ApoA-I O
Synthesis O
Stimulation O
and O
Intravascular O
Ultrasound O
for O
Coronary O
Atheroma O
Regression O
Evaluation O
( O
ASSURE O
, O
NCT01067820 O
) O
study O
aims O
to O
evaluate O
the O
effect O
of O
RVX-208 O
on O
plaque O
burden O
. O
[]

AIMS O
This O
study O
assessed O
off-the-shelf O
VR O
for O
( O
1 O
) O
its O
effect O
on O
reducing O
acute O
pain O
intensity O
during O
adolescent O
burn O
wound O
care O
, O
and O
( O
2 O
) O
its O
clinical O
utility O
in O
a O
busy O
hospital O
setting O
. O
[]

PURPOSE O
We O
evaluated O
the O
efficacy O
and O
safety O
of O
silodosin O
for O
treatment O
of O
benign O
prostatic O
hyperplasia O
symptoms O
in O
2 O
randomized O
, O
placebo O
controlled O
, O
phase O
3 O
studies O
. O
[]

PRA O
, O
AII O
, O
ALD O
, O
renal O
blood O
flow O
and O
damage O
to O
renal O
function O
of O
the O
two O
groups O
before O
treatment O
and O
20 O
days O
after O
treatment O
were O
compared O
. O
[]

The O
effects O
of O
consuming O
a O
liquid O
formula O
containing O
either O
fish O
oil O
enriched O
in O
omega-3 O
fatty O
acids O
or O
vegetable O
oil O
enriched O
in O
oleic O
acid O
was O
evaluated O
in O
20 O
male O
subjects O
randomly O
allocated O
into O
two O
groups O
over O
a O
42-d O
period O
. O
[]

Therefore, O
denosumab O
possibly O
regulates O
noggin B-outcome ['Physiological-Clinical']
and O
favours O
bone O
turnover O
in O
TDT O
patients O
with O
osteoporosis O
through O
a O
novel O
mechanism O
of O
action. O
[['Physiological-Clinical']]

The O
respective O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
85 O
% O
, O
74 O
% O
, O
55 O
% O
and O
84 O
% O
, O
71 O
% O
, O
40 O
% O
( O
P O
= O
0.64 O
) O
. O
['Mortality']

The O
caries-preventive O
effects O
of O
two O
toothpastes O
were O
tested O
in O
a O
3-year O
clinical O
trial O
involving O
1319 O
children O
aged O
11-13 O
years O
. O
['Physiological-Clinical']

Among O
them O
, O
86 O
% O
were O
successfully O
eradicated B-outcome ['Physiological-Clinical']
by O
the O
tinidazole O
, O
tetracycline O
, O
bismuth O
and O
rabeprazole O
therapy O
. O
['Physiological-Clinical']

More O
patients O
in O
the O
intervention O
group O
had O
returned B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
at O
T O
( O
2 O
) O
( O
P O
< O
0.001 O
) O
and O
did O
so O
more O
quickly O
( O
P O
< O
0.01 O
) O
. O
['Life-Impact']

Rationale O
and O
study O
design O
of O
the O
increase O
of O
vagal O
tone O
in O
heart O
failure O
study O
: O
INOVATE-HF O
. O
[]

It O
may O
also O
shorten O
the O
operative O
time O
since O
tissue O
is O
resected O
instead O
of O
just O
vaporized O
. O
[]

Noradrenergic O
moderation O
of O
working O
memory O
impairments O
in O
adults O
with O
autism O
spectrum O
disorder O
. O
[]

We O
aimed O
to O
assess O
the O
effect O
of O
nitazoxanide-a O
new O
broad-spectrum O
antiparasitic O
drug-on O
morbidity B-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
Zambian O
children O
with O
diarrhoea O
due O
to O
Cryptosporidium O
parvum O
. O
['Physiological-Clinical', 'Mortality']

CONCLUSIONS O
Oral O
magnesium O
supplementation O
improves O
the O
metabolic O
profile O
and O
blood O
pressure O
of O
MONW O
individuals O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

The O
self-reported B-outcome ['Life-Impact']
alcohol I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
was O
56.1 O
+/- O
3.6 O
( O
SEM O
) O
ml/day O
during O
the O
usual O
alcohol O
drinking O
period O
and O
26.1 O
+/- O
3.0 O
ml/day O
during O
the O
period O
of O
reduced O
alcohol O
consumption O
. O
['Life-Impact']

STUDY O
DESIGN O
A O
prospective O
study O
was O
performed O
. O
[]

[ O
Supplementary O
treatment O
with O
Esberitox O
of O
female O
patients O
undergoing O
curative O
adjuvant O
irradiation O
following O
breast O
cancer O
] O
. O
[]

Before O
and O
after O
the O
program O
, O
all O
subjects O
participated O
in O
DTI O
scans O
. O
[]

Among O
patients O
with O
BRAF O
wild-type O
cancer O
, O
IFL O
conferred O
no O
suggestion O
of O
benefit O
beyond O
FU/LV O
alone O
( O
multivariate O
HR O
= O
1.02 O
; O
95 O
% O
CI O
: O
0.72-1.46 O
) O
. O
[]

BACKGROUND O
As O
renin-angiotensin O
system O
( O
RAS O
) O
activity O
may O
affect O
the O
severity O
of O
oxidative O
stress O
and O
inflammatory O
markers O
, O
we O
assessed O
the O
effects O
of O
enalapril O
( O
E O
) O
and/or O
losartan O
( O
L O
) O
on O
these O
markers O
in O
renal O
transplant O
recipients O
with O
RAS O
polymorphisms O
. O
[]

The O
chi O
independent O
test O
or O
2-tailed O
paired O
t O
test O
were O
performed O
for O
statistical O
analysis. O
[]

The O
mean O
age O
of O
enrolled O
subjects O
was O
51 O
years O
old O
[range: O
22 O
to O
76]. O
The O
majority O
was O
male O
(90%). O
[]

SETTING O
Participant O
enrolment O
and O
baseline O
assessments O
were O
conducted O
remotely O
online O
via O
the O
study O
website O
, O
with O
the O
advice O
reports O
presented O
by O
the O
same O
website O
. O
[]

CONCLUSIONS O
Although O
the O
patients O
in O
the O
levosimendan O
group O
were O
alive O
for O
more O
days O
and O
thus O
at O
risk O
of O
hospitalisation B-outcome ['Resource-use']
for O
longer O
, O
there O
was O
no O
increase O
in O
hospitalisation B-outcome ['Resource-use']
or O
hospitalisation B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
with O
levosimendan O
treatment O
. O
['Resource-use', 'Resource-use', 'Resource-use']

Each O
subject O
underwent O
an O
initial O
isoglycemic/hyperinsulinemic O
clamp O
after O
1-wk O
dietary O
control O
and O
a O
second O
clamp O
after O
completing O
the O
study O
. O
[]

Levofloxacin O
was O
effective O
therapy O
for O
9 O
of O
15 O
( O
60 O
% O
) O
patients O
. O
[]

The O
current O
study O
has O
been O
designed O
to O
compare O
the O
classical O
mono O
chemotherapy O
docetaxel O
with O
a O
docetaxel O
cisplatin O
doublet O
. O
[]

Subjects O
also O
had O
significant O
reductions O
in O
RR B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
and O
['Physiological-Clinical']

Although O
capable O
of O
inducing O
an O
anabolic O
state O
after O
surgery O
, O
parenteral O
nutrition O
, O
including O
glucose O
, O
leads O
to O
hyperglycemia O
. O
[]

Constant O
score O
for O
function B-outcome ['Life-Impact']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
using O
SF-36], O
simple O
shoulder O
test O
(SST) O
and O
the O
Disabilities B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
the Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
Arm I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
Shoulder I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact']
Hand S3-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact']
(DASH) O
score O
were O
also O
calculated O
at O
six, O
12 O
and O
24 O
weeks O
of O
follow-up. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact', 'Life-Impact', 'Life-Impact']]

The O
effect O
of O
zidovudine O
and O
didanosine O
on O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
of O
neopterin O
was O
studied O
in O
12 O
patients O
with O
human O
immunodeficiency O
virus O
type-1 O
( O
HIV-1 O
) O
infection O
3-12 O
months O
after O
initiation O
of O
antiretroviral O
therapy O
. O
[]

However O
, O
little O
is O
known O
about O
the O
effect O
of O
azelnidipine O
on O
the O
AGE-RAGE B-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

No O
patients O
complained O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

We O
found O
no O
evidence O
that O
the O
proportion O
of O
patients O
with O
events O
increased O
as O
the O
number O
of O
injections B-outcome ['Resource-use']
increased O
. O
['Resource-use']

Participants O
were O
randomly O
assigned O
to O
one O
of O
three O
experimental O
consent O
documents O
( O
traditional O
, O
n O
= O
110 O
; O
binary O
, O
n O
= O
103 O
; O
and O
tiered O
, O
n O
= O
110 O
) O
. O
[]

Wakings B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
night I-outcome ['Physiological-Clinical']
were O
0.35 O
( O
95 O
% O
CI O
0.18-0.53 O
) O
baseline O
, O
0.26 O
( O
95 O
% O
CI O
0.20-0.34 O
) O
with O
placebo O
and O
0.08 O
( O
95 O
% O
CI O
0.04-0.12 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

METHODS O
In O
all O
, O
153 O
individuals O
were O
randomized O
to O
receive O
the O
decision O
aid O
or O
a O
control O
pamphlet O
at O
the O
end O
of O
their O
first O
genetic O
counseling O
consultation O
. O
[]

Data O
obtained O
by O
such O
analyses O
allow O
simulation O
of O
the O
dilution O
of O
the O
plasma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
during O
infusion O
of O
the O
solution O
at O
different O
rates O
. O
['Physiological-Clinical']

Title: O
A O
Randomized O
Trial O
of O
Lymphadenectomy O
in O
Patients O
with O
Advanced O
Ovarian O
Neoplasms. O
[]

A O
parent-mediated O
intervention O
to O
increase O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
child B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
children O
with O
ASD O
: O
a O
randomized O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

Mean O
compression B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
was O
0.724 O
(95% O
CI O
[0.699-0.751]) O
for O
SIM O
group O
and O
0.679 O
(95% O
CI O
[0.655-0.702]) O
for O
STD, O
p=0.01. O
[['Physiological-Clinical']]

Accompanying O
this O
improved O
survival O
, O
the O
ID O
Group O
also O
had O
greater O
white B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
a O
greater O
number O
of O
T O
cells B-outcome ['Physiological-Clinical']
, O
and O
a O
more O
dramatic B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
to O
the O
extracted O
cell O
wall O
polysaccharide O
of O
hemolytic O
streptococcus O
Su-strain O
( O
Su-PS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Amla O
extract O
(500 O
mg) O
or O
a O
matching O
placebo O
capsule O
was O
administered O
twice O
daily O
for O
12 O
weeks O
to O
the O
respective O
group O
of O
patients. O
[]

There O
were O
no O
significant O
changes O
in O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
after O
HSS O
or O
saline O
placebo O
. O
['Physiological-Clinical']

The O
MOONLIGHT O
( O
Multicenter O
Objective O
ObservatioNal O
Lunar O
Iridiumoxide O
intimal O
GrowtH O
Trial O
) O
study O
was O
carried O
out O
to O
evaluate O
the O
immediate O
outcome O
and O
long-term O
angiographic O
success O
after O
implantation O
of O
Lunar O
stents O
. O
[]

Responses O
were O
evaluated O
in O
164 O
patients O
. O
[]

CONCLUSIONS O
In O
patients O
with O
recurrent O
duodenal O
ulcer O
, O
eradication B-outcome ['Physiological-Clinical']
of O
H. O
pylori O
by O
a O
regimen O
that O
does O
not O
have O
any O
direct O
action O
on O
the O
mucosa O
is O
followed O
by O
a O
marked O
reduction O
in O
the O
rate O
of O
recurrence O
, O
suggesting O
a O
causal O
role O
for O
H. O
pylori O
in O
recurrent O
duodenal O
ulcer O
. O
['Physiological-Clinical']

Finally O
, O
69 O
% O
of O
parents O
in O
the O
enriched O
group O
and O
31 O
% O
of O
parents O
in O
the O
control O
group O
reported O
improvement O
in O
their O
child O
over O
the O
6-month O
study O
. O
[]

These O
patients O
were O
allocated O
to O
one O
of O
two O
groups O
by O
drawing O
lots O
: O
IMV O
group O
( O
IMVG O
; O
n O
= O
35 O
) O
and O
SIMV+PS O
group O
( O
SIMVG O
; O
n O
= O
35 O
) O
. O
[]

BACKGROUND: O
Delayed-release O
dimethyl O
fumarate O
(DMF) O
has O
demonstrated O
efficacy O
and O
a O
favorable O
benefit-risk O
profile O
in O
phase O
2 O
and O
3 O
studies O
that O
enrolled O
predominantly O
white O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
(RRMS). O
[]

We O
approached O
families O
affected O
by O
melanoma O
for O
possible O
participation O
in O
a O
randomized O
controlled O
trial O
of O
a O
web-based O
communication O
and O
support O
intervention O
. O
[]

14.4 O
vs. O
73.1 O
? O
[]

In O
man O
, O
however O
, O
routine O
pre-transplantation O
blood O
transfusions O
have O
recently O
become O
controversial O
, O
principally O
because O
of O
the O
adverse O
effect O
of O
transfusion-induced O
sensitisation O
on O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
rates O
. O
['Life-Impact']

BACKGROUND O
We O
examined O
the O
sustained O
efficacy O
of O
a O
group-based O
cognitive-behavioural O
stress O
management O
( O
CBSM O
) O
intervention O
in O
comparison O
to O
a O
modified O
wait-list O
control O
condition O
on O
measures O
of O
mood B-outcome ['Life-Impact']
, O
coping B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
in O
mildly O
symptomatic O
HIV-positive O
homosexual O
and O
bisexual O
men O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
Since O
the O
results O
were O
essentially O
identical O
between O
the O
techniques O
, O
it O
seems O
that O
[]

Peer O
and O
adolescent O
substance O
use O
are O
highly O
correlated O
, O
but O
this O
relationship O
is O
not O
fully O
understood O
. O
[]

The O
gastrointestinal O
dysfunction O
score O
in O
P+EN O
, O
EN O
, O
PN O
groups O
14 O
days O
after O
nutritional O
intervention O
was O
0.28 O
? O
[]

Parents O
also O
completed O
4-day O
sun O
exposure O
and O
protection O
diaries O
for O
their O
child O
and O
themselves O
. O
[]

The O
outcome O
was O
measured O
by O
using O
Conners O
abbreviated O
parent O
and O
teacher O
questionnaires O
and O
by O
determining O
the O
number O
of O
daily O
performance O
tasks O
completed O
by O
the O
child O
at O
school O
. O
[]

Inclusion O
criteria O
were O
: O
1 O
) O
pain O
raising O
suspicion O
of O
ACS O
and O
2 O
) O
pain O
score O
?4 O
. O
[]

Improvements O
were O
unrelated O
to O
changes O
in O
the O
physiological O
parameters O
measured O
. O
[]

46 O
upper O
and O
lower O
molars O
with O
furcation O
grade O
II O
involvement O
were O
selected O
from O
16 O
patients O
with O
periodontal O
disease O
. O
[]

CONCLUSIONS O
A O
brief O
course O
of O
oral O
dexamethasone O
( O
4 O
days O
) O
was O
significantly O
more O
effective O
than O
placebo O
within O
14 O
days O
for O
the O
treatment O
of O
depression O
in O
a O
randomized O
, O
double-blind O
study O
of O
depressed O
outpatients O
. O
[]

We O
conclude O
that O
, O
for O
cardiovascular O
and O
cardiorespiratory O
adaptations O
in O
athletes O
, O
strength O
and O
endurance O
training O
are O
compatible O
and O
that O
exercise O
timing O
and O
sequence O
significantly O
influence O
training O
adaptations O
, O
complimenting O
our O
previous O
similar O
conclusions O
for O
strength B-outcome ['Physiological-Clinical']
, O
muscle B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Study O
drugs O
were O
administered O
for O
three O
months O
in O
both O
groups O
. O
[]

RESULTS O
Death B-outcome ['Mortality']
or O
neurological B-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
at O
day O
10 O
was O
associated O
, O
both O
in O
unadjusted O
and O
adjusted O
analyses O
, O
with O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
adjusted O
OR O
, O
1.02 O
; O
95 O
% O
CI O
, O
1.01-1.03 O
) O
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
OR O
, O
1.02 O
; O
95 O
% O
CI O
, O
1.01-1.04 O
) O
, O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
OR O
, O
1.02 O
; O
95 O
% O
CI O
, O
1.01-1.03 O
) O
, O
and O
BP B-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
( O
OR O
, O
1.03 O
; O
95 O
% O
CI O
, O
1.01-1.05 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Five O
children O
showed O
clinical O
improvement O
in O
standard O
scores O
: O
two O
after O
HSS O
and O
three O
after O
placebo O
. O
[]

Sodium O
cromoglycate O
was O
superior O
to O
placebo O
in O
improving O
breathlessness B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.001 O
) O
, O
breathlessness B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.05 O
) O
and O
the O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.001 O
) O
, O
and O
also O
in O
improving O
the O
morning O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow O
rate O
value O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES: O
To O
determine O
if O
intermittent O
exercise-heat O
exposures O
(IHE) O
every O
fifth O
day O
sustain O
heat B-outcome ['Physiological-Clinical']
acclimation I-outcome ['Physiological-Clinical']
(HA) I-outcome ['Physiological-Clinical']
adaptations O
25 O
days O
after O
initial O
HA. O
[['Physiological-Clinical']]

The O
pressure O
profile O
and O
VO2 O
were O
not O
modified O
by O
ACE O
inhibitor O
. O
[]

BACKGROUND O
Interventions O
for O
pervasive O
developmental O
disorders O
( O
PDD O
) O
aim O
to O
alleviate O
symptoms O
and O
improve O
functioning O
. O
[]

Butyrate B-outcome ['Physiological-Clinical']
levels O
increased O
in O
response O
to O
RS O
in O
most O
individuals O
but O
often O
decreased O
when O
entry O
levels O
were O
high O
. O
['Physiological-Clinical']

The O
authors O
explain O
the O
objectives O
and O
the O
structure O
of O
a O
programme O
evolved O
for O
the O
methodic O
study O
of O
advanced O
breast O
cancers O
which O
they O
have O
worked O
out O
and O
carried O
out O
in O
cooperation O
with O
the O
departments O
of O
medicine O
in O
eight O
French O
anticancer O
centres O
. O
[]

Patients O
were O
randomized O
to O
receive O
a O
clear O
liquid O
diet O
and O
the O
PEG O
4L O
regimen O
( O
106 O
patients O
) O
or O
the O
low O
residue O
test O
meals O
and O
the O
PEG O
4L O
regimen O
( O
TM-PEG O
4L O
, O
108 O
patients O
) O
. O
[]

DISCUSSION O
In O
this O
study O
, O
an O
American O
model O
to O
enhance O
care O
for O
patients O
with O
a O
depressive O
disorder O
, O
the O
collaborative O
care O
model O
, O
will O
be O
evaluated O
for O
effectiveness O
in O
the O
primary O
care O
setting O
. O
[]

Studies O
evaluating O
fondaparinux O
for O
the O
treatment O
of O
VTE O
are O
part O
of O
the O
large O
MATISSE O
clinical O
program O
( O
MATISSE O
DVT O
and O
MATISSE O
PE O
) O
. O
[]

Modest O
visceral O
fat O
gain O
causes O
endothelial O
dysfunction O
in O
healthy O
humans O
. O
[]

ACL-implantation O
remains O
our O
method O
of O
choice O
for O
secondary O
implantation O
in O
patients O
with O
an O
intact O
iris O
diaphragm O
. O
[]

We O
studied O
the O
antiproteinuric B-outcome ['Physiological-Clinical']
effect O
of O
such O
a O
treatment O
in O
a O
double-blind O
study O
. O
['Physiological-Clinical']

Gamma O
aminobutyric O
acid O
( O
GABA O
) O
-mediated O
synapses O
and O
the O
oscillations O
they O
orchestrate O
are O
altered O
in O
autism O
. O
[]

Baseline O
characteristics O
of O
participants O
in O
the O
Appropriate O
Blood O
Pressure O
Control O
in O
Diabetes O
trial O
. O
[]

Anatomical O
benefit O
from O
ranibizumab O
treatment O
of O
predominantly O
classic O
neovascular O
age-related O
macular O
degeneration O
in O
the O
2-year O
anchor O
study O
. O
[]

In O
2 O
separate O
phases O
, O
women O
who O
met O
triage O
criteria O
were O
randomly O
assigned O
to O
either O
the O
triage O
room O
or O
the O
standard O
care O
labor O
room O
. O
[]

OBJECTIVES O
To O
assess O
the O
efficacy O
of O
an O
adjuvant O
PDL O
treatment O
when O
combined O
with O
a O
proven O
topical O
treatment O
[ O
fixed-combination O
clindamycin O
1 O
% O
-benzoyl O
peroxide O
5 O
% O
hydrating O
gel O
( O
C/BPO O
) O
] O
. O
[]

OBJECTIVE O
To O
compare O
elastic O
stable O
intramedullary O
nailing O
( O
ESIN O
) O
with O
nonoperative O
treatment O
of O
fully O
displaced O
midshaft O
clavicular O
fractures O
in O
adults O
. O
[]

Indications O
included O
chronic O
tonsillitis O
and O
obstructive O
sleep O
apnea O
syndrome O
. O
[]

In O
2 O
randomized O
controlled O
trials O
(RCTs) O
of O
stressed O
community O
adults, O
mindfulness O
skills O
were O
dismantled O
into O
2 O
structurally O
equivalent O
interventions: O
(a) O
training O
in O
both O
monitoring O
and O
acceptance O
(Monitor O
+ O
Accept) O
and O
(b) O
training O
in O
monitoring O
only O
(Monitor O
Only) O
without O
acceptance O
training. O
[]

The O
study O
recruited O
successive O
patients O
with O
unresectable O
grade O
I/II O
head O
and O
neck O
cancer O
who O
were O
not O
suitable O
for O
irradiation O
treatment O
( O
T O
any O
N3 O
or O
T4 O
N2C O
) O
, O
metastatic O
or O
previously O
irradiated O
. O
[]

METHODS O
AND O
RESULTS O
Sixteen O
patients O
who O
had O
chronic O
mitral O
regurgitation O
due O
to O
myxomatous O
degeneration O
were O
randomized O
to O
preservation O
( O
Pres O
group O
, O
n O
= O
8 O
) O
or O
no O
preservation O
( O
No O
Pres O
group O
, O
n O
= O
8 O
) O
of O
the O
chordae O
tendineae O
and O
papillary O
muscles O
during O
mitral O
valve O
replacement O
. O
[]

Disease B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
side O
effects O
were O
compared O
using O
Fisher O
's O
exact O
test O
. O
['Physiological-Clinical']

No O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
any O
treatment O
group O
. O
['Adverse-effects']

The O
trial O
's O
final O
sample O
was O
composed O
of O
521 O
current O
smokers O
. O
[]

There O
was O
no O
significant O
difference O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
groups O
and O
no O
side O
effects O
occurred O
. O
['Physiological-Clinical']

The O
antihypertensive O
effects O
of O
the O
oral O
converting O
enzyme O
inhibitor O
captopril O
and O
of O
propranolol O
were O
evaluated O
in O
a O
single-blind O
trial O
of O
12 O
weeks O
in O
19 O
ambulatory O
men O
with O
moderated O
essential O
hypertension O
( O
supine B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
DPB I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
, O
100 O
to O
120 O
mm O
Hg O
after O
receiving O
placebo O
for O
two O
weeks O
) O
whose O
sodium O
intake O
was O
unrestricted O
. O
['Physiological-Clinical']

Enrolled O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
a O
computer-generated O
schedule O
to O
follow O
either O
a O
standard O
diagnostic O
strategy O
( O
based O
on O
culture O
and O
histology O
) O
or O
a O
biomarker-based O
diagnostic O
strategy O
( O
aspergillus O
galactomannan O
and O
PCR O
) O
to O
direct O
treatment O
with O
antifungal O
drugs O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
a O
2-dimensional O
, O
handheld O
ultrasound O
device O
and O
a O
newly O
developed O
ultrasound O
volume O
scanner O
( O
based O
on O
bladder O
scan O
technology O
) O
with O
computed O
tomography O
( O
CT O
) O
for O
diagnosing O
AAA O
. O
[]

Analysis O
of O
trends O
demonstrated O
increasing O
( O
but O
not O
statistically O
significant O
) O
confidence B-outcome ['Life-Impact']
in O
CT O
and O
stable O
['Life-Impact']

METHODS O
Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
vWf B-outcome ['Physiological-Clinical']
and O
sP-sel B-outcome ['Physiological-Clinical']
were O
measured O
by O
enzyme O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
in O
1321 O
participants O
in O
the O
SPAF O
III O
study O
and O
related O
to O
the O
presence O
and O
onset O
of O
clinical O
CHF O
, O
as O
well O
as O
echocardiographic O
findings O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Lactated O
Ringer O
's O
solution O
( O
4 O
degrees O
C O
) O
was O
infused O
via O
a O
central O
venous O
catheter O
over O
a O
period O
of O
approximately O
2 O
h O
to O
decrease O
tympanic B-outcome ['Physiological-Clinical']
membrane I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
by O
approximately O
1.5 O
degrees O
C O
h O
( O
-1 O
) O
. O
['Physiological-Clinical']

Significant O
diastolic B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Isoflurane O
was O
administered O
according O
to O
predetermined O
hemodynamic O
criteria O
. O
[]

FINDINGS O
Mechanical O
efficiency O
increased O
and O
metabolic B-outcome ['Physiological-Clinical']
cost I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
experimental O
group O
compared O
to O
the O
control O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
authors O
examine O
whether O
an O
innovative O
family O
economic O
empowerment O
intervention O
addresses O
mental O
health O
functioning O
of O
AIDS-affected O
children O
in O
communities O
heavily O
impacted O
by O
HIV/AIDS O
in O
Uganda O
. O
[]

The O
same O
evaluation O
was O
used O
18 O
to O
30 O
months O
postoperatively O
to O
estimate O
the O
results O
of O
our O
treatment. O
[]

Patients O
also O
received O
consolidation O
, O
maintenance O
therapy O
, O
and O
central O
nervous O
system O
prophylaxis O
. O
[]

The O
effect O
of O
increasing O
the O
doses O
of O
morphine O
and O
of O
droperidol O
. O
[]

In O
our O
adjusted O
multivariable O
regression O
models, O
SPOC O
scores O
at O
6 O
weeks O
post-surgery O
accounted O
for O
10% O
of O
the O
variation O
in O
short O
form-12 O
physical B-outcome ['Life-Impact']
component O
summary O
scores O
and O
14% O
of O
short O
form-12 O
mental B-outcome ['Life-Impact']
component O
summary O
scores O
at O
1 O
yr. O
[['Life-Impact'], ['Life-Impact']]

However O
, O
a O
50 O
% O
reduction O
of O
the O
median O
daily B-outcome ['Life-Impact']
ICS I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
was O
observed O
in O
the O
control O
group O
. O
['Life-Impact']

The O
difference O
in O
the O
number O
of O
occlusions B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

The O
two O
groups O
were O
comparable O
regarding O
age O
and O
sex O
distribution O
. O
[]

A O
double-blind O
placebo O
controlled O
trial O
of O
piracetam O
added O
to O
risperidone O
in O
patients O
with O
autistic O
disorder O
. O
[]

UNLABELLED O
The O
aim O
of O
our O
study O
is O
to O
evaluate O
the O
safety O
, O
efficacy O
and O
also O
the O
maximum O
duration O
of O
effect O
of O
the O
pleural B-outcome ['Physiological-Clinical']
tent I-outcome ['Physiological-Clinical']
in O
reducing O
the O
incidence O
of O
air O
leak O
after O
upper O
lobectomy O
. O
['Physiological-Clinical']

For O
the O
representative O
of O
the O
municipality O
the O
possible O
economical O
gain O
of O
the O
project O
was O
in O
focus. O
[]

The O
renin-angiotensin O
system O
played O
a O
part O
in O
maintenance O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
only O
with O
severe O
salt O
restriction O
and O
in O
a O
small O
proportion O
of O
cases O
. O
['Physiological-Clinical']

RESULTS O
Treatment O
sides O
had O
greater O
decrease O
in O
lesion B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
than O
observation O
sides O
of O
face O
at O
weeks O
2 O
( O
P O
< O
.001 O
) O
and O
5 O
( O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

The O
improved O
side-effect O
profile O
of O
the O
wax-matrix O
form O
of O
niacin O
was O
particularly O
notable O
. O
[]

BACKGROUND: O
Mothers O
of O
preterm O
infants O
often O
have O
symptoms O
of O
anxiety O
and O
depression, O
recognized O
as O
risk O
factors O
for O
the O
development O
of O
cardiovascular O
diseases O
and O
associated O
with O
low O
rates O
of O
heart O
rate O
variability O
(HRV). O
[]

A O
blinded O
, O
randomized O
and O
controlled O
clinical O
trial O
was O
developed O
in O
a O
paediatric O
hospital O
located O
on O
northeast O
of O
Brazil O
with O
42 O
asthmatic O
children O
aged O
? O
[]

Cardiac O
failure O
: O
symptoms O
and O
functional O
status O
. O
[]

58 O
% O
of O
the O
patients O
opted O
to O
continuetreatment B-outcome ['Life-Impact']
with O
lansoprazole O
, O
compared O
with O
only O
25 O
% O
in O
the O
case O
of O
esomeprazole O
. O
['Life-Impact']

Of O
40 O
subjects O
, O
23 O
( O
57.5 O
% O
) O
responded O
fully O
( O
50 O
% O
decrease O
in O
Aberrant O
Behavior O
Checklist-Community O
Irritability I-outcome ['Life-Impact']
subscale O
score O
) O
, O
while O
35 O
subjects O
( O
87.5 O
% O
) O
showed O
a O
25 O
% O
decrease O
. O
['Life-Impact']

Plasma B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
analyzed O
using O
a O
sensitive O
modification O
of O
radioreceptor O
assay O
. O
['Physiological-Clinical']

METHODS O
We O
compared O
total O
BMD B-outcome ['Physiological-Clinical']
changes O
over O
96 O
weeks O
in O
106 O
ART-naive O
HIV-infected O
subjects O
who O
were O
randomized O
to O
receive O
efavirenz O
( O
EFV O
) O
+ O
zidovudine/lamivudine O
( O
n O
= O
32 O
) O
or O
lopinavir/ritonavir O
( O
LPV/r O
) O
+ O
zidovudine/lamivudine O
induction O
( O
n O
= O
74 O
) O
for O
24-48 O
weeks O
followed O
by O
LPV/r O
monotherapy O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Efficacy O
outcomes O
24 O
weeks O
after O
each O
course O
were O
calculated O
relative O
to O
first O
RTX O
pretreatment O
baseline O
. O
[]

The O
study O
included O
60 O
patients O
with O
A O
degree O
of O
ERD O
, O
consistently O
received O
in-patient O
treatment O
in O
the O
Municipal O
KGVV O
, O
mean O
age O
79.0 O
+/- O
6.8 O
years O
. O
[]

Integrated O
CE O
produced O
discernibly O
larger O
gains O
than O
serial O
CE O
or O
a O
trend O
for O
four O
of O
six O
training O
adaptations O
. O
[]

After O
baseline O
screening O
, O
subjects O
with O
FXS O
( O
n O
= O
49 O
) O
underwent O
a O
1-week O
placebo O
lead-in O
and O
then O
were O
randomized O
to O
study O
drug O
or O
placebo O
for O
a O
4-week O
period O
. O
[]

RESULTS O
Evaluation O
of O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
on O
days O
2 O
, O
5 O
, O
8 O
and O
14 O
+/- O
1 O
showed O
best O
results O
for O
the O
polyurethane O
and O
hydrocolloid O
plasters O
. O
['Physiological-Clinical']

HYPOTHESIS O
There O
will O
be O
a O
detectable O
increase O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
using O
preoperative O
( O
PRE O
) O
as O
opposed O
to O
perioperative O
( O
PERI O
) O
chemotherapy O
in O
resectable O
StageI-II O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
['Mortality']

METHODS: O
A O
total O
of O
320 O
treatment-naive O
HBeAg-positive O
CHB O
patients O
who O
received O
randomly O
a O
single O
regimen O
of O
either O
entecavir O
capsule O
(ETV) O
(n O
= O
160) O
or O
tenofovir O
disoproxil O
fumarate O
capsule O
(TDF) O
(n O
= O
160) O
for O
144 O
weeks O
were O
consecutively O
enrolled O
from O
14 O
tertiary O
hospitals O
or O
university O
hospitals O
in O
China O
between O
January O
2012 O
and O
December O
2014. O
[]

Mean O
postvaccination B-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
were O
compared O
for O
subjects O
with O
and O
without O
confirmed O
influenza O
illness O
by O
study O
and O
in O
pooled O
analyses O
. O
['Physiological-Clinical']

Reversal O
of O
skeletal O
effects O
of O
endocrine O
treatments O
in O
the O
Intergroup O
Exemestane O
Study O
. O
[]

While O
the O
efficacy O
index O
of O
the O
two O
drugs O
was O
similar O
( O
approximately O
60 O
% O
) O
, O
they O
differed O
greatly O
in O
their O
profile O
of O
side-effects B-outcome ['Adverse-effects']
. O
['Adverse-effects']

OBJECTIVE O
To O
compare O
the O
efficacy O
( O
maintenance O
of O
remission B-outcome ['Physiological-Clinical']
) O
, O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
cyclosporin O
( O
CsA O
) O
with O
those O
of O
cyclophosphamide O
in O
patients O
with O
steroid-dependent O
or O
frequently O
relapsing O
nephrotic O
syndrome O
( O
NS O
) O
. O
['Physiological-Clinical', 'Life-Impact']

in O
J O
Child O
Psychol O
Psychiatry O
50:224-234 O
, O
2009 O
) O
, O
children O
's O
daily O
living O
skills O
and O
related O
parental B-outcome ['Life-Impact']
intrusiveness I-outcome ['Life-Impact']
were O
assessed O
. O
['Life-Impact']

CONCLUSIONS O
Caffeine O
was O
efficacious O
in O
overcoming O
sleep B-outcome ['Physiological-Clinical']
inertia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
presence O
of O
leakage B-outcome ['Physiological-Clinical']
( O
settings O
II O
and O
III O
) O
, O
the O
attempt O
to O
compensate O
for O
leak O
was O
only O
evident O
during O
pressure-limited O
NPPV O
, O
since O
inspiratory B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
delivered O
by O
the O
ventilator O
increased O
from O
726+/-129 O
( O
setting O
I O
) O
to O
1104+/-164 O
( O
setting O
II O
) O
, O
and O
to O
1257+/-166 O
( O
setting O
III O
) O
ml O
during O
pressure-limited O
NPPV O
, O
respectively O
( O
all O
p O
< O
0.001 O
) O
; O
however O
, O
they O
remained O
stable O
during O
volume-limited O
NPPV O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tacrolimus/sirolimus O
vs O
tacrolimus/methotrexate O
as O
GVHD O
prophylaxis O
after O
matched O
, O
related O
donor O
allogeneic O
HCT O
. O
[]

Bu O
as O
pretransplant O
conditioning O
is O
safe O
in O
high-risk O
myeloid O
leukemia O
patients O
; O
( O
2 O
) O
clofarabine O
is O
sufficiently O
immunosuppressive O
to O
support O
allo-SCT O
in O
myeloid O
leukemia O
; O
and O
( O
3 O
) O
the O
median O
OS O
of O
23 O
months O
in O
this O
high-risk O
patient O
population O
is O
encouraging O
. O
[]

Title: O
Baseline O
characteristics O
associated O
with O
early O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
gains O
after O
ranibizumab O
treatment O
for O
retinal O
vein O
occlusion. O
[['Physiological-Clinical']]

Comparative O
study O
of O
actinic O
keratosis O
treatment O
with O
3 O
% O
diclofenac O
sodium O
and O
5 O
% O
5-fluorouracil O
. O
[]

Physicians O
who O
viewed O
the O
seminars O
were O
significantly O
more O
likely O
to O
recommend B-outcome ['Life-Impact']
guideline-consistent I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
to O
patients O
in O
the O
vignettes O
. O
['Life-Impact']

Problems O
with O
potency O
of O
CX516 O
in O
other O
studies O
have O
suggested O
dosing O
may O
have O
been O
inadequate O
for O
therapeutic O
effect O
and O
thus O
it O
remains O
unclear O
whether O
modulation O
of O
AMPA-mediated O
neurotransmission O
is O
a O
viable B-outcome ['Life-Impact']
therapeutic I-outcome ['Life-Impact']
strategy I-outcome ['Life-Impact']
for O
the O
treatment O
of O
FXS O
. O
['Life-Impact']

Fluorescein O
angiography O
was O
performed O
at O
baseline O
and O
at O
weeks O
6 O
and O
16 O
, O
and O
proliferative O
diabetic O
retinopathy O
regression O
was O
evaluated O
in O
a O
masked O
fashion O
. O
[]

METHODS O
We O
randomly O
allocated O
healthy O
children O
aged O
6 O
months O
to O
5 O
years O
to O
receive O
25 O
mg/kg O
sulfadoxine O
and O
1.25 O
mg/kg O
pyrimethamine O
plus O
either O
placebo O
, O
25 O
mg/kg O
amodiaquine O
, O
or O
12 O
mg/kg O
artesunate O
. O
[]

Retention O
needles O
on O
the O
head O
with O
simultaneous O
behavior O
training O
was O
applied O
for O
the O
trial O
group O
. O
[]

RESULTS O
At O
6 O
months O
, O
the O
RVCAL B-outcome ['Physiological-Clinical']
gains O
of O
the O
control O
and O
test O
group O
were O
0.39 O
+/- O
1.00 O
and O
0.54 O
+/- O
0.95 O
mm O
, O
while O
the O
RHCAL B-outcome ['Physiological-Clinical']
gains O
were O
1.21 O
+/- O
2.28 O
and O
1.36 O
+/- O
1.26 O
mm O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Grade O
0-I O
and O
II-III O
[]

1 O
capsule O
on O
morphology B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
motility I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
in O
patients O
with O
oligospermia O
] O
. O
['Physiological-Clinical']

However O
, O
the O
uremic O
patients O
did O
not O
show O
the O
habitual O
post-peak O
fall O
, O
remaining O
GH B-outcome ['Physiological-Clinical']
levels O
over O
10 O
micrograms/l O
till O
the O
end O
of O
the O
test O
. O
['Physiological-Clinical']

Bilastine O
was O
characterized O
by O
two-compartmental O
kinetics O
with O
a O
rapid-absorption O
phase O
( O
first-order O
absorption O
rate O
constant O
= O
1.50 O
h O
( O
-1 O
) O
) O
, O
plasma B-outcome ['Physiological-Clinical']
peak O
concentrations B-outcome ['Physiological-Clinical']
were O
observed O
at O
1 O
hour O
following O
administration O
and O
the O
maximal O
response O
was O
observed O
at O
approximately O
4 O
hours O
or O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
combine O
two O
in O
situ O
protocols O
to O
study O
the O
interplay O
between O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
of O
enamel B-outcome ['Physiological-Clinical']
and O
dentine B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
HDL-cholesterol B-outcome ['Physiological-Clinical']
, O
LDL-cholesterol B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
protein B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
the O
number O
of O
podocytes B-outcome ['Physiological-Clinical']
were O
measured O
before O
treatment O
and O
at O
3 O
and O
6 O
months O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Eliminating O
the O
causes O
of O
pain O
has O
a O
clear O
advantage O
over O
symptomatic O
treatment O
using O
analgetics O
, O
a O
fact O
worth O
a O
good O
consideration O
especially O
with O
the O
post-operative O
sojourn O
at O
the O
hospital O
becoming O
shorter O
and O
shorter O
. O
[]

22 O
patients O
treated O
with O
basic O
therapy O
were O
as O
a O
control O
group O
. O
[]

Maximal O
LORETA O
source O
strength O
did O
not O
differ O
from O
controls O
. O
[]

The O
findings O
suggest O
that O
in O
the O
presence O
of O
overt B-outcome ['Life-Impact']
emotional I-outcome ['Life-Impact']
disturbance I-outcome ['Life-Impact']
, O
of O
new B-outcome ['Physiological-Clinical']
psychological I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
psychophysiological I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
preceding I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
by O
up O
to O
a O
year O
, O
and O
of O
high O
motivation B-outcome ['Life-Impact']
for O
it O
, O
brief O
psychiatric O
treatment O
improves O
the O
outcome O
in O
eczema B-outcome ['Physiological-Clinical']
( O
the O
proportion O
clear O
at O
18 O
months O
was O
about O
doubled O
) O
, O
whereas O
in O
their O
absence O
such O
treatment O
may O
worsen O
it O
, O
especially O
in O
the O
short O
term O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Title: O
A O
high-fidelity O
simulator O
for O
needle O
cricothyroidotomy O
training O
is O
not O
associated O
with O
increased O
proficiency B-outcome ['Life-Impact']
compared O
with O
conventional O
simulators: O
A O
randomized O
controlled O
study. O
[['Life-Impact']]

The O
non-responders O
underwent O
the O
subsequent O
instillation O
of O
the O
other O
intravesical O
therapy O
alternately O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
homeostasis I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
hemostasic B-outcome ['Physiological-Clinical']
variables O
were O
assessed O
at O
baseline O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Two O
hundred O
children O
were O
randomized O
to O
receive O
S. O
boulardii O
in O
a O
granulated O
form O
in O
a O
daily O
dose O
of O
250 O
mg O
( O
S. O
boulardii O
group O
) O
or O
placebo O
( O
placebo O
group O
) O
for O
5 O
d. O
Clinical O
and O
demographic O
characteristics O
on O
admission O
were O
similar O
between O
the O
study O
groups O
. O
[]

This O
was O
more O
pronounced O
in O
those O
patients O
who O
were O
treated O
for O
the O
initial O
2 O
weeks O
with O
indomethacin O
plus O
placebo O
( O
and O
subsequently O
with O
cilazapril O
in O
addition O
) O
than O
in O
the O
subjects O
who O
first O
received O
cilazapril O
plus O
placebo O
and O
then O
the O
combination O
. O
[]

In O
the O
second O
study O
we O
used O
a O
naturalistic O
follow-up O
design O
. O
[]

METHODS O
500 O
mg O
of O
sacharose O
ferric O
oxide O
( O
Venofer O
) O
was O
intravenously O
administered O
in O
two O
days O
regimen O
to O
50 O
women O
with O
clinical O
and O
lab O
signs O
of O
postpartal O
anemia O
. O
[]

In O
both O
cases O
, O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
showed O
no O
significant O
differences O
. O
['Physiological-Clinical']

A O
randomized O
, O
placebo-controlled O
trial O
of O
controlled O
release O
melatonin O
treatment O
of O
delayed O
sleep O
phase O
syndrome O
and O
impaired O
sleep O
maintenance O
in O
children O
with O
neurodevelopmental O
disabilities O
. O
[]

Journal O
ID: O
8610224 O
[]

However O
, O
the O
effects O
on O
residualized O
gains O
in O
parental B-outcome ['Life-Impact']
responsivity I-outcome ['Life-Impact']
from O
Time O
1 O
to O
both O
Times O
2 O
and O
3 O
yielded O
noteworthy O
effect O
sizes O
( O
Glass O
's O
? O
['Life-Impact']

In O
the O
montelukast/levocetirizine O
arm O
, O
montelukast O
decreased O
nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
more O
significantly O
than O
levocetirizine O
, O
whereas O
in O
reduction O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
all O
active O
treatment O
options O
were O
equally O
effective O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:BMC O
ophthalmology O
[]

Mixed-effects O
modelling O
showed O
that O
a O
decrease O
in O
patients O
' O
anxiety O
was O
linked O
with O
screening O
questions O
( O
P O
= O
0.045 O
) O
, O
physicians O
' O
satisfaction B-outcome ['Life-Impact']
about O
support O
given O
( O
P O
= O
0.004 O
) O
and O
with O
patients O
' O
distress O
( O
P O
< O
0.001 O
) O
. O
['Life-Impact']

Fasciculations B-outcome ['Physiological-Clinical']
were O
recorded O
using O
a O
graded O
visual O
scale O
. O
['Physiological-Clinical']

METHODS O
This O
study O
was O
performed O
for O
190 O
patients O
with O
DU O
. O
[]

To O
investigate O
the O
underlying O
causal O
mechanisms O
, O
we O
conducted O
a O
randomized O
clinical O
trial O
of O
an O
experimental O
intervention O
( O
Focused O
Playtime O
Intervention O
, O
FPI O
) O
that O
aims O
to O
enhance O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
( O
N O
= O
70 O
) O
. O
['Life-Impact']

Exemestane O
patients O
reported O
more O
bone/muscle B-outcome ['Physiological-Clinical']
aches I-outcome ['Physiological-Clinical']
( O
P O
< O
.0001 O
) O
, O
vaginal B-outcome ['Physiological-Clinical']
dryness I-outcome ['Physiological-Clinical']
( O
P O
= O
.0004 O
) O
, O
and O
difficulty B-outcome ['Physiological-Clinical']
sleeping I-outcome ['Physiological-Clinical']
( O
P O
= O
.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
( O
?SEM O
) O
was O
significantly O
lower O
( O
1.75 O
? O
['Physiological-Clinical']

Comparisons O
between O
synchronisation O
and O
continuation O
showed O
a O
pattern O
in O
keeping O
with O
prior O
neuroimaging O
studies O
of O
paced O
finger O
tapping O
. O
[]

Erythrocyte B-outcome ['Physiological-Clinical']
deformability I-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
cyclosporin-treated O
patients O
and O
returned O
to O
normal O
values O
after O
supplementation O
of O
either O
oil O
. O
['Physiological-Clinical']

In O
summary O
, O
the O
irritative B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
obstructive I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
caused O
by O
benign B-outcome ['Physiological-Clinical']
prostatic I-outcome ['Physiological-Clinical']
hypertrophy I-outcome ['Physiological-Clinical']
were O
decreased O
and O
urodynamic B-outcome ['Physiological-Clinical']
studies I-outcome ['Physiological-Clinical']
were O
markedly O
improved O
by O
the O
alpha O
1-blocker O
, O
YM617 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
determine O
the O
effect O
of O
parent O
education O
on O
adaptive B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
cognitive/language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
of O
young O
children O
with O
autistic O
disorder O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

HRQOL B-outcome ['Life-Impact']
improved O
in O
both O
groups O
throughout O
the O
study O
, O
with O
an O
overall O
mean O
increment O
in O
the O
EuroQoL O
visual O
analog O
scale O
( O
EQ B-outcome ['Physiological-Clinical']
VAS O
) O
of O
9.2 O
at O
12 O
months O
( O
P O
< O
0.01 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Diltiazem O
, O
a O
calcium O
channel O
blocker O
, O
has O
been O
shown O
to O
be O
safe O
and O
effective O
in O
the O
treatment O
of O
patients O
in O
atrial O
fibrillation O
and/or O
atrial O
flutter O
. O
[]

Primary O
outcome O
measures O
are O
the O
20-item O
Toronto O
Alexithymia O
Scale O
, O
the O
Coping O
Inventory O
for O
Stressful O
Situations O
, O
the O
Motion O
Picture O
Mind-Reading O
task O
, O
and O
an O
ASD O
questionnaire O
. O
[]

7.07 O
?g/L O
vs. O
48.00 O
? O
[]

The O
interventions O
were O
either O
a O
commercially O
available O
weighted O
blanket O
or O
otherwise O
identical O
usual O
weight O
blanket O
( O
control O
) O
, O
introduced O
at O
bedtime O
; O
each O
was O
used O
for O
a O
2-week O
period O
before O
crossover O
to O
the O
other O
blanket O
. O
[]

The O
injecting O
physician O
assessed O
severity O
of O
pain B-outcome ['Physiological-Clinical']
and O
ease B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
injection I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

PRINCIPAL O
FINDINGS O
Survey O
results O
showed O
that O
mobilization B-outcome ['Life-Impact']
increased O
to O
the O
same O
degree O
in O
both O
intervention O
and O
control O
neighborhoods O
with O
no O
evidence O
of O
an O
overall O
intervention O
effect O
. O
['Life-Impact']

OBJECTIVE O
To O
study O
the O
effect O
of O
adapalene O
gel O
comparing O
the O
treatment O
with O
adapalene O
gel O
and O
2 O
% O
ketoconazole O
cream O
in O
pityriasis O
versicolor O
. O
[]

Each O
communicative O
act O
is O
scored O
according O
to O
its O
form O
, O
function O
, O
role O
and O
complexity O
. O
[]

DESIGN O
The O
study O
was O
a O
two-arm O
, O
parallel O
randomized O
clinical O
trial O
. O
[]

Forty O
times O
less O
erythema B-outcome ['Physiological-Clinical']
and O
15 O
times O
less O
induration B-outcome ['Physiological-Clinical']
were O
found O
with O
polymerized O
ragweed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
patients O
without O
kidney O
disease O
, O
BNP O
testing O
significantly O
reduced O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
( O
from O
9.5 O
days O
to O
2.5 O
days O
) O
( O
P= O
0.003 O
) O
and O
total O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
( O
from O
7184 O
dollars O
to O
4151 O
dollars O
) O
( O
P= O
0.004 O
) O
. O
['Physiological-Clinical', 'Resource-use']

Finally O
, O
ACE O
inhibitor O
resulted O
in O
decreased O
GFR B-outcome ['Physiological-Clinical']
( O
p O
= O
115 O
+/- O
5.8 O
ml/mn-1 O
, O
C O
= O
91.1 O
+/- O
4 O
, O
p O
< O
0.05 O
) O
with O
exercise O
without O
modification O
of O
MA O
. O
['Physiological-Clinical']

Acute O
effects O
of O
decaffeinated O
coffee O
and O
the O
major O
coffee O
components O
chlorogenic O
acid O
and O
trigonelline O
on O
glucose B-outcome ['Physiological-Clinical']
tolerance O
. O
['Physiological-Clinical']

Two O
of O
these O
4 O
patients O
had O
right B-outcome ['Physiological-Clinical']
bundle-branch I-outcome ['Physiological-Clinical']
block B-outcome ['Physiological-Clinical']
at O
pacemaker O
implantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Analyses O
revealed O
that O
clients O
receiving O
psychotherapy O
under O
conditions O
of O
heightened O
therapist O
disclosure O
not O
only O
reported O
lower O
levels O
of O
symptom O
distress O
but O
also O
liked B-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
therapist I-outcome ['Life-Impact']
more O
. O
['Life-Impact']

Predictor O
variables O
were O
coded O
as O
0 O
or O
1 O
to O
represent O
absence O
or O
presence O
, O
respectively O
, O
of O
each O
condition O
and O
were O
included O
as O
fixed O
effects O
. O
[]

Generally O
we O
have O
very O
good O
treatment O
results O
. O
[]

Vitamin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
levels O
were O
measured O
at O
the O
end O
of O
the O
study O
, O
and O
the O
placebo O
group O
had O
levels O
that O
were O
significantly O
below O
average O
for O
typical O
children O
, O
whereas O
the O
supplement O
group O
had O
near-average O
levels O
. O
['Physiological-Clinical']

Potassium O
titanyl O
phosphate O
laser O
resulted O
in O
reduced O
operative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
immediate B-outcome ['Physiological-Clinical']
post-operative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
compared O
with O
the O
bipolar O
radiofrequency O
technique O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
MATERIALS O
Between O
1995 O
and O
1996 O
, O
100 O
patients O
were O
randomized O
to O
receive O
a O
prophylactic O
therapy O
for O
prevention O
of O
heterotopic O
ossification O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
are O
common O
after O
recovery O
from O
anesthesia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS: O
Ecabet O
sodium O
had O
a O
preventive O
effect O
on O
low-dose O
aspirin-induced O
small O
intestinal O
mucosal O
injury O
in O
the O
upper O
part O
of O
the O
small O
intestine. O
[]

Internet-based O
searches O
represent O
a O
potentially O
useful O
approach O
to O
tracing O
subjects O
in O
epidemiologic O
studies O
. O
[]

Patients O
who O
received O
caplacizumab O
needed O
less O
plasma B-outcome ['Resource-use']
exchange I-outcome ['Resource-use']
and O
had O
a O
shorter O
hospitalization B-outcome ['Resource-use']
than O
those O
who O
received O
placebo. O
[['Resource-use'], ['Resource-use']]

Journal O
ID: O
8303003 O
[]

METHODS O
Forty-one O
adolescents O
( O
11-17 O
years O
) O
participated O
in O
this O
prospective O
randomized O
controlled O
trial O
. O
[]

METHODS: O
From O
October O
2015 O
to O
December O
2017, O
a O
total O
of O
79 O
patients, O
who O
received O
preoperative O
localization O
of O
small O
pulmonary O
nodules O
and O
surgical O
treatment O
in O
the O
Department O
of O
Thoracic O
Surgery O
of O
Hohhot O
First O
Hospital, O
were O
enrolled O
into O
this O
study. O
[]

Effect O
of O
two O
monophasic O
oral O
contraceptives O
containing O
gestodene O
or O
desogestrel O
on O
serum O
lipoprotein O
lipid O
levels O
. O
[]

Complications O
related O
to O
the O
ablation O
procedure O
occurred O
in O
two O
patients O
; O
no O
deaths B-outcome ['Mortality']
occurred O
within O
30 O
days O
after O
ablation O
. O
['Mortality']

Owner B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
scores O
at O
day O
14 O
( O
p=0.01 O
) O
and O
day O
42 O
( O
p=0.002 O
) O
were O
significantly O
improved O
compared O
to O
pre-treatment O
scores O
for O
the O
meloxicam O
group O
. O
['Physiological-Clinical']

BACKGROUND: O
Maintenance O
therapy O
following O
autologous O
stem O
cell O
transplantation O
(ASCT) O
can O
delay O
disease O
progression O
and O
prolong O
survival O
in O
patients O
with O
multiple O
myeloma. O
[]

Fulvestrant O
versus O
anastrozole O
for O
the O
treatment O
of O
advanced O
breast O
carcinoma O
: O
a O
prospectively O
planned O
combined O
survival O
analysis O
of O
two O
multicenter O
trials O
. O
[]

Significant O
treatment O
effects O
were O
found O
for O
blind-rated O
perceptions O
of O
conversational B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
, O
for O
parent-reported O
measures O
of O
pragmatic B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
and O
for O
teacher-reported O
ratings O
of O
classroom B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

In O
addition O
six O
of O
eight O
conventional O
catheters O
were O
accidentally O
removed O
whereas O
all O
catheters O
in O
the O
tunnelled O
group O
had O
to O
be O
removed O
via O
a O
small O
incision O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
two O
arms O
for O
the O
end O
points O
of O
local B-outcome ['Physiological-Clinical']
relapse-free I-outcome ['Physiological-Clinical']
rate O
( O
p O
= O
0.91 O
) O
, O
regional B-outcome ['Physiological-Clinical']
relapse-free I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
p O
= O
0.17 O
, O
adjusted O
) O
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
p O
= O
0.86 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Additional O
arterial O
or O
vein O
grafts O
were O
used O
as O
indicated. O
[]

RESULTS O
Baseline O
systolic O
BP O
and O
GFR O
values O
were O
not O
different O
between O
groups O
. O
[]

By O
24 O
h O
postoperatively O
in O
both O
groups O
, O
IL-1beta B-outcome ['Physiological-Clinical']
had O
decreased O
significantly O
( O
p O
< O
0.05 O
) O
, O
whereas O
IFN-gamma B-outcome ['Physiological-Clinical']
had O
increased O
significantly O
( O
p O
< O
0.05 O
) O
compared O
with O
the O
end O
of O
anaesthesia O
and O
surgery O
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Within O
the O
limitations O
of O
this O
study O
and O
in O
comparison O
to O
untreated O
control O
teeth O
, O
Linkmax O
treatment O
resulted O
in O
a O
significant O
reduction O
in O
tooth B-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
over O
1 O
week O
( O
P=.02 O
) O
, O
whereas O
RelyX O
ARC O
did O
not O
( O
P=.066 O
) O
. O
['Physiological-Clinical']

The O
occurrence O
of O
bleeding B-outcome ['Physiological-Clinical']
and/or O
spotting B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
cycles O
2 O
and O
3 O
in O
the O
LNG/EE O
group O
( O
41.7 O
% O
and O
34.8 O
% O
, O
respectively O
) O
compared O
with O
the O
NETA/EE O
group O
( O
62.3 O
% O
and O
56.3 O
% O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Prenatal O
depression O
predicts O
postpartum O
maternal O
attachment O
in O
low-income O
Latina O
mothers O
with O
infants O
. O
[]

mean O
circular O
resultant O
( O
MCR O
) O
, O
expiration/inspiration O
( O
E/I O
) O
ratio O
] O
. O
[]

The O
patients O
inhaled O
hydrogen O
gas O
for O
3 O
h/day O
at O
their O
own O
homes O
and O
received O
chemotherapy O
at O
the O
Tamana O
Regional O
Health O
Medical O
Center O
(Tamana, O
Kumamoto, O
Japan). O
[]

Cite O
this O
article: O
Bone O
Joint O
J O
2019;101-B:340-347 O
[]

The O
secondary O
outcome O
was O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
For O
the O
safety O
assessment, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
during O
the O
study O
period. O
[['Physiological-Clinical'], ['Adverse-effects']]

PURPOSE O
The O
accuracy O
of O
the O
clinical O
neurosensory O
test O
to O
diagnose O
trigeminal O
nerve O
injuries O
has O
never O
been O
statistically O
evaluated O
. O
[]

However O
, O
little O
is O
known O
about O
how O
neuronal O
activity O
in O
visual O
cortex O
represents O
second-order B-outcome ['Physiological-Clinical']
modulations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Compared O
with O
TAH O
, O
LAVH O
has O
advantages O
in O
removing O
uteri O
weighing O
< O
or O
= O
500 O
g O
, O
with O
comparable O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
less O
post-operative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
shorter O
recovery B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
( O
SD O
) O
time O
taken O
for O
complete O
healing O
with O
combination O
treatment O
[ O
1.9 O
( O
0.6 O
) O
weeks O
] O
was O
significantly O
shorter O
than O
that O
with O
minoxidil O
alone O
( O
3.1 O
[ O
1.7 O
] O
weeks O
; O
p=0.001 O
) O
or O
with O
lignocaine O
alone O
( O
3.3 O
[ O
0.8 O
] O
weeks O
; O
p=0.002 O
) O
. O
[]

Hexetidine O
( O
'Oraldene O
' O
) O
: O
a O
report O
on O
its O
antibacterial B-outcome ['Physiological-Clinical']
and O
antifungal B-outcome ['Physiological-Clinical']
properties O
on O
the O
oral O
flora O
in O
healthy O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Small O
needle-knife O
comprehensive O
therapy O
can O
significantly O
improve O
pain B-outcome ['Physiological-Clinical']
and O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
in O
the O
chronic O
nonspecific O
low O
back O
pain O
patient O
, O
with O
a O
stable O
long-term O
therapeutic O
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
investigate O
the O
effect O
of O
adjunctive O
mitomycin O
C O
on O
primary O
glaucoma O
triple O
procedure O
in O
patients O
with O
primary O
open-angle O
glaucoma O
with O
and O
without O
one O
or O
more O
of O
the O
prognostic O
factors O
for O
filtration O
failure O
of O
primary O
glaucoma O
triple O
procedure O
. O
[]

PATIENTS O
AND O
METHODS O
Forty-eight O
patients O
were O
randomized O
to O
receive O
: O
FA O
( O
25 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
followed O
by O
5-FU O
( O
750 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
arm O
A O
; O
or O
FA O
( O
25 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
followed O
by O
5-FU O
( O
750 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
plus O
IFO O
( O
2,000 O
mg/m2 O
in O
1000 O
mL O
5 O
% O
dextrose O
in O
a O
2-hr O
infusion O
, O
days O
1 O
to O
3 O
) O
, O
arm O
B. O
Mesna O
was O
added O
during O
and O
after O
IFO O
to O
prevent O
hemorrhagic O
cystitis O
. O
[]

METHODS O
In O
a O
double-blinded O
, O
placebo-controlled O
study O
we O
randomized O
1223 O
mothers O
with O
infants O
at O
high O
risk O
for O
allergy O
to O
receive O
a O
probiotic O
mixture O
( O
2 O
lactobacilli O
, O
bifidobacteria O
, O
and O
propionibacteria O
) O
or O
placebo O
during O
the O
last O
month O
of O
pregnancy O
and O
their O
infants O
to O
receive O
it O
from O
birth O
until O
age O
6 O
months O
. O
[]

A O
non-significant O
decrease O
in O
30-day O
mortality B-outcome ['Mortality']
was O
observed O
in O
favour O
of O
the O
pre-hospital O
group O
( O
13 O
% O
: O
P O
= O
0.08 O
) O
, O
whereas O
the O
decrease O
in O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
observed O
, O
also O
in O
favour O
of O
the O
pre-hospital O
group O
, O
was O
on O
the O
borderline O
of O
significance O
( O
16 O
% O
; O
P O
= O
0.049 O
) O
. O
['Mortality', 'Mortality']

We O
investigated O
whether O
parents O
of O
young O
children O
on O
the O
autism O
spectrum O
could O
learn O
and O
implement O
the O
specific O
categories O
of O
verbal O
responsiveness O
that O
have O
been O
suggested O
to O
facilitate O
language O
development O
. O
[]

The O
third O
group O
of O
patients O
underwent O
acute O
salt O
loading O
. O
[]

Interim O
analysis O
of O
a O
randomized, O
double O
blinded, O
placebo-controlled O
trial. O
[]

Folate O
and O
arsenic O
metabolism O
: O
a O
double-blind O
, O
placebo-controlled O
folic O
acid-supplementation O
trial O
in O
Bangladesh O
. O
[]

In O
addition O
, O
the O
conditioned O
pain O
modulation O
response O
to O
cold O
pressor O
task O
was O
determined O
. O
[]

Blood O
samples O
were O
collected O
at O
0.5-4 O
hours O
( O
peak O
samples O
group O
, O
n O
= O
47 O
) O
and O
at O
22-24 O
hours O
( O
trough O
samples O
group O
, O
n O
= O
84 O
) O
after O
dose O
. O
[]

With O
increasing O
Na O
intake O
, O
T1/2 B-outcome ['Physiological-Clinical']
increased O
in O
both O
whites O
and O
blacks O
; O
at O
the O
400 O
mmol/d O
intake O
, O
the O
T1/2 O
for O
whites O
was O
2.88 O
days O
and O
for O
blacks O
was O
5.81 O
days O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Within O
the O
simvastatin O
group O
, O
a O
reduction O
in O
prothrombin B-outcome ['Physiological-Clinical']
F1+2 I-outcome ['Physiological-Clinical']
was O
observed O
( O
P=.038 O
) O
. O
['Physiological-Clinical']

The O
addition O
of O
rhTPO O
to O
G-CSF O
increased O
median O
CD34+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
yield/pheresis I-outcome ['Physiological-Clinical']
in O
cohorts O
in O
which O
rhTPO O
was O
started O
before O
day O
5 O
, O
with O
higher O
yields O
in O
groups O
2 O
( O
2.67 O
x O
10 O
( O
6 O
) O
/kg O
) O
and O
groups O
3 O
and O
4 O
( O
3.10 O
x O
10 O
( O
6 O
) O
/kg O
) O
than O
in O
group O
1 O
( O
1.86 O
x O
10 O
( O
6 O
) O
/kg O
) O
or O
group O
5 O
( O
1.65 O
x O
10 O
( O
6 O
) O
/kg O
) O
( O
P=.006 O
across O
groups O
) O
. O
['Physiological-Clinical']

METHODS O
Subjects O
were O
healthy O
volunteers O
who O
were O
told O
the O
study O
was O
evaluating O
the O
effect O
of O
time O
and O
touch O
on O
the O
autonomic O
nervous O
system O
. O
[]

An O
independent O
test O
set O
was O
derived O
from O
282 O
pretreatment O
specimens O
from O
CLL8 O
, O
a O
study O
of O
FC O
or O
R-FC O
in O
treatment-na?ve O
patients O
. O
[]

Twenty-seven O
minutes O
after O
drug O
instillation O
subjects O
were O
challenged O
with O
allergen O
. O
[]

Comparison O
of O
nitinol O
tipless O
stone O
baskets O
in O
an O
in O
vitro B-outcome ['Physiological-Clinical']
caliceal O
model O
. O
['Physiological-Clinical']

We O
assessed O
a O
composite O
primary O
endpoint O
of O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
platelet O
recovery O
(CRp) O
, O
and O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
haematological O
recovery O
(CRi) O
achieved O
at O
any O
time O
and O
assessed O
by O
intention O
to O
treat. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

FINDINGS O
Annual O
occupational O
injury B-outcome ['Resource-use']
and I-outcome ['Resource-use']
illness I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
per O
farmer O
paid O
by O
insurers O
were O
45 O
% O
lower O
in O
the O
intervention O
cohort O
( O
$ O
183 O
) O
than O
in O
the O
control O
cohort O
( O
$ O
332 O
) O
. O
['Resource-use']

Effects O
of O
remaxol O
vs O
placebo O
on O
the O
functional B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
affected O
liver O
are O
discussed O
. O
['Life-Impact']

CONCLUSIONS O
The O
use O
of O
periprocedural O
cangrelor O
during O
PCI O
was O
not O
superior O
to O
placebo O
in O
reducing O
the O
primary O
end O
point O
. O
[]

PATIENTS O
35 O
patients O
with O
chronic O
stable O
coronary O
artery O
disease O
. O
[]

Patients O
receiving O
the O
high-dose O
pralidoxime O
regimen O
required O
less O
atropine B-outcome ['Physiological-Clinical']
during O
the O
first O
24 O
h O
than O
controls O
( O
median O
6 O
mg O
vs O
30 O
mg O
; O
difference O
24 O
mg O
[ O
95 O
% O
CI O
24-26 O
, O
p O
< O
0.0001 O
] O
) O
. O
['Physiological-Clinical']

Force O
measurements O
were O
obtained O
by O
a O
hydraulic O
dynamometer O
immediately O
before O
and O
after O
each O
intervention O
at O
the O
same O
period O
before O
training O
up O
to O
3 O
weeks O
with O
at O
least O
36 O
hours O
between O
interventions O
. O
[]

GNCC B-outcome ['Physiological-Clinical']
was O
associated O
with O
an O
iron O
profile O
similar O
to O
that O
of O
iron O
deficiency O
. O
['Physiological-Clinical']

36 O
consecutive O
patients O
with O
non-metastatic O
breast O
cancer O
assigned O
to O
surgery O
and O
systemic O
chemotherapy O
were O
randomised O
to O
receive O
either O
psychological O
intervention O
( O
weekly O
cognitive O
individual O
psychotherapy O
and O
bimonthly O
family O
counselling O
) O
or O
standard O
follow-up O
. O
[]

However O
, O
current O
standard O
consent O
forms O
may O
not O
accomplish O
their O
intended O
purpose O
due O
to O
the O
variety O
of O
patient O
literacy O
and O
experiences O
and O
, O
in O
the O
dental O
school O
setting O
, O
the O
developing O
competence O
of O
students O
. O
[]

RESULTS O
The O
complete B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
showed O
neither O
in O
the O
basic O
measurement O
( O
aR O
0,38 O
+/- O
0,14 O
kPa/l/s O
; O
IOS O
0,38 O
+/- O
0,11 O
kPa/l/s O
) O
nor O
in O
the O
control O
solution O
( O
aR O
0,38 O
+/- O
0,14 O
; O
IOS O
0,39 O
+/- O
0,14 O
) O
nor O
after O
application O
of O
the O
allergenic O
solution O
( O
15 O
min O
: O
aR O
0,69 O
+/- O
0,27 O
; O
IOS O
0,77 O
+/- O
0,42 O
; O
30 O
min O
: O
aR O
0,65 O
+/- O
0,29 O
; O
IOS O
0,6 O
+/- O
0,38 O
) O
a O
significant O
difference O
between O
the O
two O
methods O
. O
['Physiological-Clinical']

Omeprazole O
significantly O
decreased O
aspirin-induced B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
, O
Wilcoxon O
signed-rank O
test O
) O
. O
['Physiological-Clinical']

Only O
one O
case O
of O
secondary B-outcome ['Physiological-Clinical']
post-tonsillectomy I-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
was O
recorded O
, O
in O
the O
potassium O
titanyl O
phosphate O
laser O
group O
( O
2.5 O
per O
cent O
) O
, O
managed O
conservatively O
. O
['Physiological-Clinical']

Parietal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
duodenal O
ulcer O
patients O
after O
short-term O
treatment O
with O
cimetidine O
and O
antacids O
. O
['Physiological-Clinical']

All O
canals O
were O
cleaned O
and O
shaped O
with O
Reciproc O
instruments, O
and O
were O
used O
with O
a O
micro O
motor O
(VDW, O
Munich O
Germany). O
[]

RESULTS O
A O
total O
of O
170 O
participants O
( O
n O
= O
86 O
perindopril O
, O
n O
= O
84 O
placebo O
) O
were O
randomized O
. O
[]

Implants O
with O
reported O
mechanical O
and/or O
mucosal O
problems O
or O
placed O
more O
apically O
in O
relation O
to O
the O
adjacent O
teeth O
did O
not O
present O
more O
bone O
loss O
as O
compared O
with O
implants O
with O
no O
problems O
or O
placed O
more O
coronally O
, O
respectively O
( O
p O
> O
.05 O
) O
. O
[]

The O
erythropoietic O
stimulus O
of O
phlebotomy O
for O
autologous O
blood O
donations O
is O
often O
not O
efficient O
enough O
to O
guarantee O
a O
constant O
haematocrit B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
effect O
of O
a O
classroom-based O
activity O
break O
on O
in-school B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
levels O
of O
primary O
school O
children O
. O
['Life-Impact']

Until O
now O
, O
radiotherapy O
was O
considered O
the O
treatment O
of O
choice O
in O
this O
clinical O
setting O
of O
patients O
. O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
54.4 O
months O
in O
the O
modified-FOLFIRINOX O
group O
and O
35.0 O
months O
in O
the O
gemcitabine O
group O
(stratified O
hazard O
ratio O
for O
death B-outcome ['Mortality']
, O
0.64; O
95% O
CI, O
0.48 O
to O
0.86; O
P=0.003). O
[['Mortality'], ['Mortality']]

This O
study O
sought O
to O
test O
the O
clinical B-outcome ['Physiological-Clinical']
effectiveness O
of O
PD O
pharmacotherapy O
embedded O
in O
a O
disease O
management O
framework O
of O
collaborative O
care O
( O
CC O
) O
. O
['Physiological-Clinical']

RESULTS O
Intention-to-treat O
analysis O
revealed O
significant O
differences O
( O
P O
< O
0.05 O
) O
in O
the O
respective O
eradication B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
LOAD I-outcome ['Physiological-Clinical']
therapies I-outcome ['Physiological-Clinical']
( O
88.9 O
% O
( O
80/90 O
) O
LOAD-10 O
, O
90 O
% O
( O
81/90 O
) O
LOAD-7 O
, O
89.4 O
% O
( O
161/180 O
) O
for O
combined O
LOAD O
) O
compared O
with O
those O
receiving O
LAC B-outcome ['Physiological-Clinical']
, O
73.3 O
% O
( O
66/90 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Analgesic B-outcome ['Resource-use']
efficacy O
of O
caudal O
block O
versus O
diclofenac O
suppository O
and O
local O
anesthetic O
infiltration O
following O
pediatric O
laparoscopy O
. O
['Resource-use']

Risperidone O
in O
the O
treatment O
of O
disruptive O
behavioral O
symptoms O
in O
children O
with O
autistic O
and O
other O
pervasive O
developmental O
disorders O
. O
[]

Date O
of O
registration: O
September O
2009. O
[]

RESULTS O
The O
treatment O
with O
MET O
was O
well O
tolerated O
. O
[]

Severe O
pancreatitis O
patients O
showed O
lower O
pain B-outcome ['Physiological-Clinical']
thresholds I-outcome ['Physiological-Clinical']
than O
moderate O
pancreatitis O
patients O
or O
healthy O
volunteers O
. O
['Physiological-Clinical']

Ponezumab O
was O
well O
tolerated O
with O
no O
drug-attributed O
serious O
adverse O
events O
. O
[]

In O
conclusion O
, O
administration O
of O
RG-CMH O
to O
patients O
receiving O
chemotherapy/radiotherapy O
may O
have O
the O
capacity O
to O
delay O
, O
or O
ease O
, O
the O
reduction O
in O
levels O
of O
leucocytes O
and O
neutrophils O
that O
are O
experienced O
by O
patients O
during O
cancer O
treatment O
. O
[]

Although O
the O
mean O
endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
lower O
in O
the O
verum O
group O
after O
1 O
week O
( O
paromomycin O
, O
8.0 O
+/- O
1.9 O
pg/ml O
; O
placebo O
, O
14.6 O
+/- O
3.5 O
pg/ml O
; O
p O
> O
0.05 O
) O
, O
paromomycin O
treatment O
had O
no O
significant O
effect O
on O
endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
or O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
during O
the O
4-week O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
participating O
in O
an O
intensive O
skill O
development O
program O
, O
pharmacists O
performed O
in O
an O
interdisciplinary O
team O
in O
a O
rural O
clinic O
. O
[]

There O
was O
no O
difference O
in O
FPPA O
(knee O
valgus O
angle) O
between O
groups O
(15, O
0.63-377.99). O
[]

Other O
measures O
of O
chorea B-outcome ['Physiological-Clinical']
( O
UHDRS O
chorea B-outcome ['Physiological-Clinical']
score O
, O
video O
ratings O
) O
showed O
no O
improvement O
. O
['Physiological-Clinical']

BACKGROUND O
Although O
percutaneous O
endoscopic O
gastrostomy O
( O
PEG O
) O
has O
become O
popular O
for O
patients O
with O
swallowing O
disorders O
as O
a O
nutrition O
support O
or O
a O
decompressant O
of O
gastrointestine O
, O
perioperative O
complications O
associated O
with O
PEG O
have O
not O
decreased O
, O
especially O
peristomal O
infections O
. O
[]

Injections O
of O
rtPA O
were O
then O
given O
through O
hematoma O
catheter O
every O
8 O
h O
, O
up O
to O
9 O
doses O
, O
or O
until O
a O
clot-reduction O
endpoint O
. O
[]

More O
active O
regimens O
than O
FAMTX O
are O
required O
for O
future O
randomised O
trials O
. O
[]

Clinical O
and O
experimental O
studies O
suggest O
that O
it O
has O
good O
short-term O
and O
long-term O
effects O
on O
both O
human O
and O
animal B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Forty O
patients O
with O
esophageal O
cancer O
( O
without O
serious O
hypertension O
, O
heart O
disease O
, O
or O
respiratory O
function O
impairment O
, O
including O
34 O
men O
and O
6 O
women O
aged O
46 O
to O
70 O
years O
) O
scheduled O
for O
oesophagectomy O
via O
left O
thoracotomy O
were O
randomly O
divided O
into O
control O
group O
( O
n=20 O
) O
and O
UTI O
group O
( O
n=20 O
) O
. O
[]

In O
the O
control O
group O
, O
there O
were O
no O
significant O
changes O
in O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P=0.89 O
) O
or O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.70 O
) O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Life-Impact']

No O
correlations O
were O
seen O
between O
the O
GHQ O
scores O
and O
fT3 O
( O
b O
: O
0.318 O
, O
P O
= O
0.275 O
) O
, O
rT O
( O
3 O
) O
( O
b O
: O
0.095 O
, O
P O
= O
0.95 O
) O
, O
rT O
( O
3 O
) O
to O
fT4 O
ratio O
( O
b O
: O
71.83 O
, O
P O
= O
0.09 O
) O
or O
fT3 O
to O
rT O
( O
3 O
) O
ratio O
( O
b O
: O
0.05 O
, O
P O
= O
0.32 O
) O
. O
[]

Anhedonia B-outcome ['Life-Impact']
was O
defined O
to O
be O
present O
if O
the O
participants O
reported O
having O
suffered O
a O
major O
loss O
of O
interest O
during O
the O
previous O
month O
. O
['Life-Impact']

A O
majority O
of O
the O
men O
encountered O
a O
variety O
of O
barriers O
including O
economic O
, O
social O
, O
and O
lifestyle O
obstacles O
to O
adequate O
BP O
care O
and O
control O
, O
including O
no O
current B-outcome ['Physiological-Clinical']
HBP I-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
( O
49 O
% O
) O
, O
risk O
of O
alcoholism B-outcome ['Life-Impact']
( O
62 O
% O
) O
, O
use O
of O
illicit B-outcome ['Life-Impact']
drugs I-outcome ['Life-Impact']
( O
45 O
% O
) O
, O
social B-outcome ['Life-Impact']
isolation I-outcome ['Life-Impact']
( O
47 O
% O
) O
, O
unemployment B-outcome ['Life-Impact']
( O
40 O
% O
) O
, O
and O
lack O
of O
health B-outcome ['Life-Impact']
insurance I-outcome ['Life-Impact']
( O
51 O
% O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
registration O
can O
be O
found O
at O
the O
following O
URL: O
https://clinicaltrials.gov/ct2/show/NCT01838668. O
[]

In O
addition O
, O
a O
regression O
analysis O
was O
conducted O
to O
determine O
whether O
changes O
in O
social O
interaction O
skills O
were O
associated O
with O
language O
development O
. O
[]

The O
pregnancy B-outcome ['Physiological-Clinical']
rate O
within O
one O
year O
after O
laparoscopic O
surgery O
were O
compared O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Compared O
to O
IVO O
, O
exposure O
of O
germinal-vesicle O
oocytes O
for O
a O
maturation O
period O
of O
30 O
hours O
did O
not O
increase O
aneuploidy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
secondary O
goal O
was O
to O
assess O
the O
predictors O
of O
arterial B-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
in O
this O
large O
group O
of O
patients O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
authors O
conclude O
that O
both O
methods O
were O
safe O
, O
but O
the O
stapled O
technique O
resulted O
in O
more O
stricture B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
side-effects B-outcome ['Adverse-effects']
were O
mild O
and O
tolerable O
. O
['Adverse-effects']

The O
Doppler O
study O
showed O
a O
similarly O
favorable O
hemodynamic B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
regardless O
of O
valve O
orientation O
. O
['Physiological-Clinical']

PURPOSE O
To O
assess O
any O
changes O
in O
the O
Functional O
Communicative O
Profile O
( O
FCP O
) O
and O
in O
the O
Social O
Cognitive O
Performance O
( O
SCP O
) O
of O
children O
with O
Autism O
Spectrum O
Disorders O
, O
based O
on O
two O
short O
periods O
of O
intervention O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
also O
significantly O
greater O
in O
overweight O
patients O
subjected O
to O
OA O
than O
in O
patients O
of O
normal O
weight O
after O
4 O
weeks O
; O
the O
clinical O
significance O
may O
, O
however O
, O
be O
of O
less O
importance O
since O
the O
values O
are O
low O
( O
0.26 O
vs O
0.09 O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Study O
outcomes O
were O
assessed O
at O
baseline O
and O
at O
16 O
and O
32 O
weeks O
after O
randomization O
. O
[]

PARTICIPANTS O
Twenty O
eyes O
of O
20 O
consecutive O
patients O
( O
spherical O
equivalent O
[ O
SE O
] O
, O
-2.01+/-1.36 O
diopters O
[ O
D O
] O
) O
treated O
with O
wavefront-guided O
Zyoptix O
Ablation O
Refinement O
software O
( O
ZAR O
) O
LASIK O
and O
20 O
eyes O
of O
20 O
consecutive O
patients O
( O
SE O
, O
-1.81+/-1.21 O
D O
) O
treated O
with O
standard O
Planoscan O
LASIK O
, O
both O
for O
residual O
refractive O
error O
enhancement O
. O
[]

Long-term O
effects O
. O
[]

BACKGROUND O
No O
standard O
treatment O
for O
locally O
advanced O
pancreatic O
cancer O
( O
LAPC O
) O
is O
defined O
. O
[]

A O
placebo O
controlled O
study O
. O
[]

To O
determine O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
junctional I-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
JET I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
a O
modern O
cohort O
of O
pediatric O
patients O
, O
evaluate O
possible O
risk O
factors B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
JET I-outcome ['Physiological-Clinical']
, O
and O
examine O
the O
effects O
of O
JET O
on O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

PARTICIPANTS O
84 O
elementary O
school O
children O
, O
mean O
age O
6.8 O
years O
. O
[]

During O
the O
ovarian O
stimulation O
regimen O
, O
the O
patients O
were O
submitted O
to O
hormonal O
( O
oestradiol O
and O
growth O
hormone O
) O
, O
ultrasonographic O
( O
follicular O
number O
and O
diameter O
, O
endometrial O
thickness O
) O
and O
Doppler O
( O
uterine O
and O
perifollicular O
arteries O
) O
evaluations O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
short-term O
efficacy O
and O
safety O
of O
aripiprazole O
in O
the O
treatment O
of O
irritability O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

Evaluation O
of O
oral O
beclomethasone O
dipropionate O
for O
prevention O
of O
acute O
graft-versus-host O
disease O
. O
[]

Outpatient O
management O
of O
asthma O
with O
regular O
nebulized O
beta O
agonists O
: O
comparison O
of O
bitolterol O
mesylate O
and O
isoproterenol O
. O
[]

The O
prevalences O
of O
clinical B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
['Adverse-effects']

DESIGN O
Multicentric O
, O
randomized O
, O
single-blind O
, O
parallel-group O
clinical O
trial O
. O
[]

Journal-Name:Lancet O
(London, O
England) O
[]

Scores O
of O
left-colon B-outcome ['Physiological-Clinical']
cleansing I-outcome ['Physiological-Clinical']
for O
flexible O
sigmoidoscopy O
were O
equally O
high O
for O
the O
three O
methods O
. O
['Physiological-Clinical']

For O
up O
to O
1 O
year O
they O
continued O
on O
Z O
infusions O
every O
3-4 O
weeks O
, O
while O
their O
renal O
safety O
was O
monitored O
. O
[]

Title: O
"We O
find O
what O
we O
look O
for, O
and O
we O
look O
for O
what O
we O
know": O
factors O
interacting O
with O
a O
mental O
health O
training O
program O
to O
influence O
its O
expected O
outcomes O
in O
Tunisia. O
[]

RESULTS O
Cuffed O
tubes O
selected O
by O
our O
formula O
were O
appropriate O
for O
99 O
% O
of O
patients O
. O
[]

Cumulative O
5-FU B-outcome ['Physiological-Clinical']
dose B-outcome ['Life-Impact']
was O
higher O
with O
combined O
therapy O
( O
P O
< O
0.001 O
) O
: O
more O
patients O
receiving O
monotherapy O
discontinued O
treatment O
because O
of O
['Physiological-Clinical', 'Life-Impact']

For O
example O
, O
the O
mean O
increase O
in O
[]

Nine O
patients O
with O
chronic O
renal O
anemia O
on O
maintenance O
hemodialysis O
were O
enrolled O
in O
rHu-EPO O
treatment O
trial O
. O
[]

With O
a O
relative O
dose O
intensity O
of O
paclitaxel O
0.94 O
in O
both O
groups O
, O
neurotoxicity B-outcome ['Physiological-Clinical']
( O
P O
= O
0.025 O
) O
and O
leucopenia B-outcome ['Physiological-Clinical']
( O
P O
= O
0.038 O
) O
were O
more O
pronounced O
in O
group O
B O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Both O
treatments O
were O
well O
tolerated O
. O
[]

METHODS O
Two O
hundred O
twenty-five O
consecutive O
patients O
with O
sick O
sinus O
syndrome O
and O
intact O
AV O
conduction O
were O
randomized O
to O
undergo O
single-chamber O
atrial O
pacing O
( O
110 O
patients O
) O
or O
single-chamber O
ventricular O
pacing O
( O
115 O
patients O
) O
. O
[]

Marked O
interpatient O
differences O
within O
each O
dose O
arm O
were O
greater O
than O
differences O
between O
arms O
. O
[]

The O
co-primary O
endpoints O
at O
12 O
months O
were O
patient/graft B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
a O
composite O
renal B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
endpoint O
( O
percent O
with O
a O
measured O
glomerular O
filtration O
rate O
( O
mGFR O
) O
< O
60 O
mL/min/1.73 O
m O
( O
2 O
) O
at O
Month O
12 O
or O
a O
decrease O
in O
mGFR O
> O
or O
=10 O
mL/min/1.73 O
m O
( O
2 O
) O
Month O
3-Month O
12 O
) O
and O
the O
incidence O
of O
acute B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

A O
sample O
of O
14 O
high-functioning O
adults O
with O
ASD O
and O
a O
demographically-matched O
comparison O
group O
of O
13 O
typically O
developing O
individuals O
participated O
. O
[]

Hormone O
therapy O
consisted O
of O
gestonorone O
caproate O
( O
17 O
alpha-hydroxy-19-norpregn-4-en O
3 O
, O
20 O
dione O
caproate O
) O
administered O
i.m O
. O
[]

Here O
, O
the O
screw/neck O
angle O
deviation O
has O
had O
the O
strongest O
significance O
for O
prediction O
of O
fixation O
failure O
. O
[]

Effects O
of O
dietary O
pyridoxine O
on O
haemato-immunological B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
of O
Labeo O
rohita O
fingerlings O
reared O
at O
higher O
water O
temperature O
. O
['Physiological-Clinical']

Stimuli O
were O
presented O
via O
headphones O
and O
consisted O
of O
common O
facts O
( O
Group O
A O
, O
29 O
patients O
) O
, O
or O
familiar O
or O
unfamiliar O
full O
names O
of O
fictitious O
people O
( O
GRoup O
B O
, O
29 O
patients O
) O
. O
[]

TRIAL O
REGISTRATION: O
Current O
Controlled O
Trials O
ChiCTR-INR-16008863 O
(Date O
of O
registration: O
20 O
July O
2016). O
[]

Fewer O
nefazodone-treated O
than O
placebo-treated O
patients O
discontinued O
owing O
to O
lack O
of O
efficacy O
. O
[]

Dysfunctional O
attitudes O
as O
a O
moderator O
of O
pharmacotherapy O
and O
psychotherapy O
for O
chronic O
depression O
. O
[]

The O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
lowest O
in O
the O
ketazolam O
group O
. O
['Adverse-effects']

This O
corresponded O
to O
4 O
, O
8 O
, O
or O
12 O
kcal/kg O
per O
week O
( O
KKW O
) O
of O
energy O
expenditure O
. O
[]

Different O
prognostic O
factors O
and O
SLN O
tumor O
burden O
were O
recorded O
. O
[]

The O
calculation O
of O
total O
AUC O
also O
involves O
prolonged O
sampling O
, O
adding O
to O
the O
cost O
and O
risks O
associated O
with O
bioequivalence O
studies O
. O
[]

Measurements O
of O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
and O
visual B-outcome ['Physiological-Clinical']
fields I-outcome ['Physiological-Clinical']
were O
performed O
throughout O
the O
five O
years O
, O
with O
the O
clinician O
masked O
to O
the O
treatment O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
concomitant O
reduction O
of O
the O
urinary O
excretion O
of O
PGE-M O
( O
68 O
to O
85 O
% O
decrease O
) O
and O
prostaglandin O
E O
( O
73 O
to O
100 O
% O
decrease O
) O
after O
indomethacin O
treatment O
in O
each O
case O
( O
n=8 O
) O
is O
evidence O
that O
a O
diminished O
urinary O
PGE-M O
output O
reflects O
a O
decrease O
in O
prostaglandin O
E O
biosynthesis O
. O
[]

However O
, O
overall O
survival O
was O
worse O
in O
the O
the O
ganitumab O
group O
than O
in O
the O
placebo O
group O
( O
HR O
1?78 O
, O
80 O
% O
CI O
1?27-2?50 O
; O
p=0?025 O
) O
. O
[]

The O
18 O
: O
2/18 O
: O
1 O
ratio O
decreased O
significantly O
in O
all O
the O
lipid O
esters O
analyzed O
. O
[]

In O
recent O
years, O
enamel O
matrix O
derivatives O
(EMDs) O
have O
been O
used O
for O
their O
regenerative O
potential O
in O
periodontics. O
[]

5 O
. O
[]

After O
1 O
year O
of O
treatment O
, O
lumbar B-outcome ['Physiological-Clinical']
and O
total O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
decreased I-outcome ['Physiological-Clinical']
significantly O
in O
patients O
treated O
only O
with O
calcium O
and O
cholecalciferol O
( O
group O
A O
) O
, O
whereas O
it O
did O
not O
change O
significantly O
at O
any O
skeletal O
site O
in O
patients O
treated O
also O
with O
neridronate O
( O
group O
B O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
first O
Stroke O
Prevention O
in O
Atrial O
Fibrillation O
( O
SPAF-I O
) O
study O
, O
direct O
comparison O
of O
warfarin O
with O
aspirin O
was O
limited O
by O
the O
small O
number O
of O
thromboembolic O
events O
. O
[]

Journal O
ID: O
0372541 O
[]

Cockroach B-outcome ['Life-Impact']
infestation I-outcome ['Life-Impact']
in O
the O
past O
3 O
months O
was O
reported O
by O
23.4 O
% O
of O
caregivers O
, O
while O
57.1 O
% O
were O
unaware O
of O
the O
association O
of O
roaches B-outcome ['Life-Impact']
and O
asthma B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Journal-Name:Respiratory O
research O
[]

Of O
these O
, O
109 O
( O
71.2 O
% O
) O
completed O
the O
first O
questionnaire O
1 O
week O
after O
consultation O
, O
whereas O
95 O
( O
62.1 O
% O
) O
completed O
the O
6-month O
follow-up O
questionnaire O
. O
[]

Since O
treatment O
decisions O
are O
often O
made O
or O
modified O
at O
the O
first O
outpatient O
clinic O
visit O
, O
this O
study O
was O
designed O
to O
evaluate O
the O
importance O
of O
post-hospital O
data O
on O
mortality O
prediction O
after O
a O
first O
myocardial O
infarction O
( O
MI O
) O
. O
[]

9.2 O
years O
with O
angiographically O
diagnosed O
unilateral O
RAS O
( O
? O
[]

The O
median O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
longer O
in O
medical O
patients O
than O
in O
surgical O
patients O
( O
6.1 O
vs. O
2.4 O
weeks O
in O
Group O
1 O
[ O
P O
less O
than O
0.001 O
] O
and O
5.0 O
vs. O
3.1 O
weeks O
in O
Group O
2 O
[ O
P O
less O
than O
0.01 O
] O
) O
. O
['Resource-use']

METHODS O
Thirteen O
healthy O
human O
volunteers O
( O
6 O
men O
and O
7 O
women O
, O
aged O
20-28 O
years O
) O
were O
included O
in O
the O
study O
. O
[]

METHODS O
At O
surgery O
, O
an O
intraocular O
lens O
( O
IOL O
) O
was O
implanted O
or O
children O
were O
left O
aphakic O
, O
treated O
with O
contact O
lens O
( O
CL O
) O
. O
[]

The O
introduction O
of O
prostanoid O
therapy O
has O
revolutionized O
the O
treatment O
of O
pulmonary O
arterial O
hypertension O
( O
PAH O
) O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
a O
catheterization O
duration O
of O
2 O
weeks O
increased O
the O
risk O
of O
nosocomial B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
when O
compared O
with O
a O
1-week O
duration O
. O
['Physiological-Clinical']

BACKGROUND O
5-Fluorouracil O
( O
5-FU O
) O
, O
doxorubicin O
and O
methotrexate O
( O
FAMTX O
) O
and O
cisplatin O
, O
epirubicin O
, O
leucovorin O
and O
5-FU O
( O
PELF O
) O
have O
both O
been O
reported O
to O
be O
superior O
to O
the O
combination O
5-FU O
, O
doxorubicin O
and O
mitomycin O
C O
( O
FAM O
) O
in O
advanced O
gastric O
carcinoma O
. O
[]

This O
was O
particularly O
evident O
over O
the O
first O
2 O
years O
among O
those O
not O
on O
vitamin O
A O
prior O
to O
entry O
( O
test O
for O
trend O
, O
P O
=.003 O
) O
. O
[]

CONCLUSION: O
In O
second-line O
treatment O
for O
metastatic O
colorectal O
cancer, O
mFOLFOX6 O
or O
FOLFIRI O
with O
erlotinib O
in O
a O
sequence-dependent O
fashion O
is O
not O
feasible O
despite O
potential O
promising O
activity. O
[]

Twelve O
patients O
( O
group O
1 O
) O
received O
dexamethasone O
and O
12 O
( O
group O
2 O
) O
did O
not O
. O
[]

RESULTS O
The O
administration O
of O
penicillin O
did O
not O
significantly O
( O
P O
> O
.05 O
) O
reduce O
pain B-outcome ['Physiological-Clinical']
, O
percussion B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
or O
the O
number O
of O
['Physiological-Clinical', 'Physiological-Clinical']

The O
findings O
provide O
new O
insights O
on O
the O
effects O
and O
mechanisms O
of O
a O
MBI O
on O
aMCI O
symptoms. O
[]

Montelukast O
was O
significantly O
more O
effective O
than O
placebo O
( O
P O
= O
0.003 O
) O
in O
improving O
the O
daytime B-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
score O
( O
difference O
in O
least O
square O
means O
, O
-0.09 O
; O
95 O
% O
confidence O
interval O
, O
-0.16 O
, O
-0.03 O
) O
averaged O
over O
2 O
weeks O
of O
therapy O
. O
['Physiological-Clinical']

At O
52 O
weeks O
, O
patients O
receiving O
the O
implant O
with O
the O
postulated O
biomechanical O
advantage O
achieved O
116 O
% O
of O
the O
power O
output B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

CONCLUSIONS O
Administration O
of O
L-arginine O
and O
citrulline O
to O
patients O
with O
HFpEF O
improved O
right O
ventricular O
function O
by O
increasing O
right O
ventricular O
ejection O
fraction O
, O
and O
probably O
decreasing O
systolic O
pulmonary O
artery O
pressure O
. O
[]

This O
three-dimensional O
stability O
was O
related O
to O
tendon O
structure O
in O
previous O
studies O
. O
[]

Because O
the O
process O
for O
learning O
new O
or O
unfamiliar O
stimuli O
( O
elaboration O
) O
in O
particular O
may O
be O
impaired O
under O
general O
anesthesia O
, O
more O
memory O
priming O
was O
expected O
for O
familiar O
than O
for O
unfamiliar O
material O
. O
[]

CONCLUSIONS O
Single-dose O
tranexamic O
acid O
did O
not O
give O
effective O
results O
. O
[]

The O
participants O
consumed O
the O
probiotic O
during O
3 O
months O
. O
[]

Similar O
changes O
were O
observed O
in O
some O
slight O
or O
more O
serious O
unintentional O
injuries B-outcome ['Physiological-Clinical']
(P=0.030). O
[['Physiological-Clinical']]

However O
, O
PVP O
use O
led O
to O
more O
favorable O
evolution O
of O
fluorescein-staining B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
punctuations I-outcome ['Physiological-Clinical']
( O
P O
= O
0.028 O
) O
. O
['Physiological-Clinical']

GOALS O
OF O
WORK O
We O
set O
out O
to O
assess O
the O
preference O
of O
patients O
with O
common O
cancers O
involving O
bone O
receiving O
intravenous O
bisphosphonate O
therapy O
for O
either O
pamidronate O
( O
P O
) O
or O
zoledronic O
acid O
( O
Z O
) O
and O
their O
preference O
for O
the O
location O
of O
the O
infusion O
( O
clinic O
or O
home O
) O
. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
either O
prazosin O
( O
n O
= O
15 O
) O
or O
captopril O
( O
n O
= O
16 O
) O
. O
[]

Decreases O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
occurred O
with O
both O
doses O
of O
saralasin O
and O
even O
with O
suppression O
of O
the O
renin-angiotensin O
axis O
. O
['Physiological-Clinical']

Over O
twice O
as O
many O
patients O
on O
ginseng O
perceived O
a O
benefit O
and O
were O
satisfied B-outcome ['Life-Impact']
with O
treatment O
over O
those O
on O
placebo O
. O
['Life-Impact']

Over O
the O
trial O
duration O
, O
no O
significant O
differences O
between O
DHA O
and O
placebo O
groups O
were O
found O
for O
vitamin O
A O
, O
vitamin O
E O
, O
platelet O
aggregation O
, O
antioxidant O
activity O
, O
lipoprotein O
cholesterol O
, O
or O
oxidized O
LDL O
levels O
( O
all O
P O
> O
0.14 O
) O
. O
[]

Lower O
extremity B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
blockade B-outcome ['Physiological-Clinical']
was O
increased O
with O
clonidine O
( O
return O
to O
baseline O
Bromage O
score O
: O
65 O
+/- O
13 O
min O
versus O
79 O
+/- O
19 O
min O
, O
P O
= O
0.004 O
; O
return O
to O
90 O
% O
gastrocnemius B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
: O
P O
= O
0.003 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
had O
improved O
function B-outcome ['Life-Impact']
and O
regained B-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
assessors O
were O
masked O
as O
to O
group O
allocation. O
[]

Retroinfusion-supported O
stenting O
in O
high-risk O
patients O
for O
percutaneous O
intervention O
and O
bypass O
surgery O
: O
results O
of O
the O
prospective O
randomized O
myoprotect O
I O
study O
. O
[]

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
investigate O
whether O
hydrotalcite O
was O
comparable O
to O
esomeprazole O
, O
a O
proton O
pump O
inhibitor O
, O
in O
on-demand O
therapy O
for O
non-erosive O
reflux O
disease O
( O
NERD O
) O
. O
[]

Vascular O
endothelial O
growth O
factor O
A O
( O
VEGF-A O
) O
and O
vascular O
endothelial O
growth O
factor O
receptor O
2 O
( O
VEGFR2 O
) O
are O
the O
key O
factors O
mediating O
neo-vascularization O
. O
[]

Between O
January O
1996 O
and O
February O
1998 O
, O
259 O
men O
with O
prostate O
cancer O
underwent O
radical O
retropubic O
prostatectomy O
and O
bilateral O
pelvic O
node O
dissection O
in O
the O
26 O
centres O
participating O
in O
the O
Italian O
randomised O
prospective O
PROSIT O
study O
. O
[]

Multicenter O
randomized O
controlled O
trial O
of O
the O
management O
of O
unresectable O
malignant O
mesothelioma O
proposed O
by O
the O
British O
Thoracic O
Society O
and O
the O
British O
Medical O
Research O
Council O
. O
[]

Participants O
were O
drawn O
from O
a O
randomized-controlled-treatment O
trial O
that O
examined O
the O
effects O
of O
targeted O
interventions O
on O
the O
social B-outcome ['Life-Impact']
networks I-outcome ['Life-Impact']
of O
60 O
elementary-aged O
children O
with O
ASD O
. O
['Life-Impact']

Secondary O
outcomes O
included O
3 O
months O
of O
seizure B-outcome ['Physiological-Clinical']
freedom I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
6-month I-outcome ['Physiological-Clinical']
follow-up I-outcome ['Physiological-Clinical']
, O
measures O
of O
psychosocial B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
health B-outcome ['Resource-use']
service I-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
and O
employment B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact']

Microfilarial B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
had O
decreased O
1 O
year O
after O
treatment O
in O
all O
14 O
communities O
; O
this O
decrease O
was O
significantly O
higher O
in O
communities O
given O
combined O
therapy O
than O
in O
those O
given O
diethylcarbamazine O
alone O
( O
mean O
decreases O
57.5 O
% O
and O
30.6 O
% O
, O
respectively O
; O
p O
= O
0.0013 O
) O
. O
['Physiological-Clinical']

METHODS O
Simplified O
Disease O
Activity O
Index O
( O
SDAI O
) O
scores O
, O
Clinical O
Disease O
Activity O
Index O
( O
CDAI O
) O
scores O
, O
and O
the O
Disease O
Activity O
Score O
in O
28 O
joints O
( O
DAS28 O
) O
were O
calculated O
using O
data O
from O
tocilizumab O
trials O
in O
patients O
with O
RA O
in O
whom O
disease O
had O
remained O
active O
despite O
treatment O
with O
disease-modifying O
antirheumatic O
drugs O
. O
[]

Journal O
ID: O
0255562 O
[]

8-oxo-dG B-outcome ['Physiological-Clinical']
is O
significantly O
higher O
( O
up O
to O
about O
threefold O
) O
in O
lymphocyte O
DNA O
from O
men O
in O
Ireland O
and O
the O
U.K. O
Oxidative B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
is O
not O
significantly O
affected O
by O
carotenoid O
supplementation O
; O
nor O
is O
there O
any O
association O
with O
mean O
baseline O
levels O
of O
antioxidants B-outcome ['Physiological-Clinical']
, O
which O
are O
generally O
similar O
in O
the O
five O
countries O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Different O
methods O
and O
propofol O
formulations O
have O
been O
used O
to O
decrease O
propofol B-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
but O
it O
remains O
an O
unresolved O
problem O
. O
['Physiological-Clinical']

Mean O
clearance O
, O
half-life O
and O
volume O
of O
distribution O
were O
similar O
irrespective O
of O
dose O
for O
both O
the O
oral O
and O
intravenous O
routes O
. O
[]

CONCLUSIONS O
Chlorogenic O
acid O
and O
trigonelline O
reduced O
early O
glucose B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
during O
an O
OGTT O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
issue O
of O
clinical O
understaging O
and O
of O
resection O
limit O
positivity O
have O
led O
to O
the O
development O
of O
novel O
management O
practices O
, O
including O
neoadjuvant O
hormonal O
therapy O
( O
NHT O
) O
. O
[]

Current O
management O
is O
delivered O
by O
a O
multidisciplinary O
team, O
but O
evidence O
of O
effectiveness O
is O
limited. O
[]

The O
study O
included O
93 O
patients O
. O
[]

Preoperatively, O
all O
patients O
were O
evaluated O
clinically O
( O
Kujala O
score O
questionnaire]) O
and O
radiologically. O
[]

Although O
AmB O
in O
lipid B-outcome ['Physiological-Clinical']
emulsion I-outcome ['Physiological-Clinical']
is O
apparently O
cleared O
faster O
and O
distributes O
more O
widely O
than O
AmB B-outcome ['Physiological-Clinical']
in O
['Physiological-Clinical', 'Physiological-Clinical']

Time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
recurrence I-outcome ['Life-Impact']
of O
any O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
was O
significantly O
longer O
with O
paliperidone O
ER O
than O
placebo O
( O
p=0.017 O
; O
based O
on O
weighted O
Z-test O
at O
0.0198 O
significance O
level O
; O
hazard O
ratio O
[ O
placebo O
: O
paliperidone O
ER O
; O
unweighted O
95 O
% O
confidence O
interval O
] O
: O
1.43 O
[ O
1.03 O
; O
1.98 O
] O
) O
; O
the O
difference O
was O
significant O
for O
preventing O
['Life-Impact', 'Life-Impact']

METHODS: O
This O
study O
was O
part O
of O
an O
effectiveness O
and O
process O
evaluation O
including O
24 O
intervention O
and O
27 O
control O
classes. O
[]

Determinants O
of O
post-intervention O
serum O
retinol O
concentration O
included O
baseline O
serum O
retinol O
concentration O
, O
caregiver O
's O
education O
, O
receipt O
of O
high-dose O
vitamin O
A O
capsule O
, O
interaction O
between O
consumption O
of O
vitamin O
A-fortified O
cooking O
oil O
and O
of O
other O
vitamin O
A-rich O
foods O
, O
and O
between O
households O
purchasing O
cooking O
oil O
and O
food O
expenditure O
. O
[]

Individual O
concentrations O
in O
serum O
versus O
time O
data O
were O
evaluated O
by O
linear O
regression O
analysis O
. O
[]

Dialectical O
behaviour O
therapy O
( O
DBT O
) O
has O
been O
reported O
to O
be O
effective O
in O
reducing O
DSH O
and O
hospitalization O
. O
[]

All O
patients O
received O
cyclophosphamide O
750 O
mg/m(2) O
and O
doxorubicin O
50 O
mg/m(2) O
on O
day O
1 O
of O
each O
cycle O
intravenously O
and O
prednisone O
100 O
mg O
once O
daily O
on O
days O
1 O
to O
5 O
of O
each O
cycle O
orally, O
followed O
by O
either O
brentuximab O
vedotin O
1.8 O
mg/kg O
and O
a O
placebo O
form O
of O
vincristine O
intravenously O
(A+CHP O
group) O
or O
vincristine O
1.4 O
mg/m(2) O
and O
a O
placebo O
form O
of O
brentuximab O
vedotin O
intravenously O
(CHOP O
group) O
on O
day O
1 O
of O
each O
cycle. O
[]

RESULTS O
Fifty-four O
children O
completed O
the O
assessments O
12 O
months O
after O
conclusion O
of O
the O
intervention O
. O
[]

The O
current O
study O
examined O
youth O
substance O
involvement O
over O
4 O
years O
( O
using O
five O
waves O
of O
data O
collection O
) O
following O
treatment O
for O
alcohol O
and O
drug O
abuse O
. O
[]

Journal O
ID: O
0255562 O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
average O
percentage O
changes O
of O
total O
[]

UTC O
categorises O
four O
different O
echotypes B-outcome ['Physiological-Clinical']
that O
represent O
( O
I O
) O
highly O
stable B-outcome ['Physiological-Clinical']
; O
( O
II O
) O
medium O
stable O
; O
( O
III O
) O
highly O
variable B-outcome ['Physiological-Clinical']
and O
( O
IV O
) O
constantly O
low O
intensity O
and O
variable O
distribution O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Identification O
, O
course O
, O
and O
treatment O
of O
depression O
after O
admission O
for O
a O
cardiac O
condition O
: O
rationale O
and O
patient O
characteristics O
for O
the O
Identifying O
Depression O
As O
a O
Comorbid O
Condition O
( O
IDACC O
) O
project O
. O
[]

It O
is O
suggested O
that O
the O
mechanisms O
underlying O
opioid-immune O
interactions O
are O
altered O
in O
this O
population O
of O
autistic O
children O
and O
that O
an O
immunological O
screening O
may O
have O
prognostic O
value O
for O
the O
pharmacological O
therapy O
with O
opiate O
antagonists O
. O
[]

0.4 O
vs. O
6.8 O
? O
[]

Serial O
blood O
samples O
were O
collected O
up O
to O
12 O
h O
on O
days O
6 O
and O
12 O
following O
the O
administration O
of O
the O
morning O
dose O
. O
[]

DESIGN O
Multicentre O
randomised O
controlled O
trial O
. O
[]

34.1 O
ng/L O
, O
67.8 O
? O
[]

The O
changes O
of O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
before O
and O
after O
the O
three O
groups O
were O
compared, O
and O
the O
changes O
of O
serum O
SOD O
and O
MDA O
were O
detected O
by O
immunoenzyme-linked O
adsorption O
for O
comparative O
analysis. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Iron O
intake O
and O
iron O
nutritional O
status O
of O
infants O
fed O
iron-fortified O
beikost O
with O
meat O
. O
[]

A O
cognitive-behavioral O
intervention O
for O
emotion O
regulation O
in O
adults O
with O
high-functioning O
autism O
spectrum O
disorders O
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
[]

After O
3 O
months O
, O
similar O
anti-anginal O
efficacy O
was O
observed O
between O
the O
trimetazidine O
( O
n O
= O
71 O
) O
and O
propranolol O
( O
n O
= O
78 O
) O
groups O
. O
['Physiological-Clinical']

In O
each O
patient O
a O
euglycaemic O
glucose O
clamp O
with O
simultaneous O
indirect O
calorimetry O
allowed O
us O
to O
determine O
whole B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
disposal I-outcome ['Physiological-Clinical']
and O
substrate B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Dopexamine O
has O
been O
shown O
to O
reduce O
both O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
in O
major O
surgery O
when O
it O
is O
used O
as O
part O
of O
a O
protocol O
to O
increase O
oxygen O
delivery O
in O
the O
perioperative O
period O
. O
['Mortality', 'Physiological-Clinical']

Retinal B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
were O
measured O
with O
a O
retinal O
vessel O
analyzer O
, O
and O
retinal B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
speed I-outcome ['Physiological-Clinical']
was O
assessed O
by O
bi-directional O
laser O
Doppler O
velocimetry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Epidural O
block O
was O
performed O
with O
75 O
microg O
clonidine O
( O
n O
= O
20 O
) O
or O
50 O
microg O
fentanyl O
( O
n O
= O
21 O
) O
combined O
with O
0.125 O
% O
bupivacaine O
( O
10 O
mL O
) O
. O
[]

RESULTS O
The O
technique O
of O
alginate O
compared O
with O
antacids O
provided O
significantly O
more O
complete O
and O
earlier O
effect O
on O
the O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
, O
regurgitation B-outcome ['Physiological-Clinical']
, O
chronic B-outcome ['Physiological-Clinical']
cough I-outcome ['Physiological-Clinical']
, O
sore B-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
carbohydrate O
substitutes O
fructose O
, O
sorbitol O
and O
xylitol O
are O
gaining O
more O
and O
more O
importance O
in O
the O
production O
of O
dietary O
food O
. O
[]

SETTING O
Five O
community-based O
research O
facilities O
. O
[]

During O
a O
mean O
follow-up O
period O
of O
1.8 O
years O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
two O
groups O
included O
death B-outcome ['Mortality']
( O
4.3 O
percent O
in O
the O
aspirin O
group O
vs. O
9.7 O
percent O
in O
the O
warfarin O
group O
; O
hazard O
ratio O
for O
aspirin O
relative O
to O
warfarin O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.23 O
to O
0.90 O
; O
P=0.02 O
) O
, O
major B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
3.2 O
percent O
vs. O
8.3 O
percent O
, O
respectively O
; O
hazard O
ratio O
, O
0.39 O
; O
95 O
percent O
confidence O
interval O
, O
0.18 O
to O
0.84 O
; O
P=0.01 O
) O
, O
and O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
or O
sudden B-outcome ['Mortality']
death I-outcome ['Mortality']
( O
2.9 O
percent O
vs. O
7.3 O
percent O
, O
respectively O
; O
hazard O
ratio O
, O
0.40 O
; O
95 O
percent O
confidence O
interval O
, O
0.18 O
to O
0.91 O
; O
P=0.02 O
) O
. O
['Adverse-effects', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Together O
with O
a O
visual O
analog O
scale O
( O
VAS O
, O
range O
0-100 O
) O
on O
overall B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
the O
questionnaire O
was O
applied O
in O
210 O
RA O
patients O
who O
participated O
in O
a O
randomized O
trial O
comparing O
3 O
types O
of O
multidisciplinary O
care O
. O
['Life-Impact']

Primary O
outcomes O
were O
death O
, O
CHF B-outcome ['Resource-use']
hospitalisation I-outcome ['Resource-use']
and O
length O
of O
hospital O
stay O
. O
['Resource-use']

OBJECTIVES: O
To O
compare O
the O
effect O
of O
toric O
versus O
spherical O
soft O
contact O
lenses O
on O
objective O
measures O
of O
visual B-outcome ['Physiological-Clinical']
performance O
using O
visual O
acuity O
and O
electromyography O
of O
the O
orbicularis O
oculi O
muscle. O
[['Physiological-Clinical']]

Perioperative O
antibiotics O
decrease O
surgical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SWI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
trauma O
patients O
requiring O
abdominal O
exploration O
. O
['Physiological-Clinical']

RESULTS O
Large O
and O
stable O
pre-post O
effect O
sizes O
were O
found O
for O
both O
treatment O
conditions O
in O
the O
study O
( O
d O
= O
1.06-1.24 O
on O
the O
Yale-Brown O
Obsessive B-outcome ['Life-Impact']
Compulsive I-outcome ['Life-Impact']
Scale O
) O
. O
['Life-Impact']

Short- O
and O
long-term O
wound B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
were O
not O
improved O
with O
NPWT. O
[['Physiological-Clinical']]

CONCLUSION O
( O
1 O
) O
Serum O
level O
of O
sCD44v6 O
could O
be O
taken O
as O
the O
criterion O
for O
evaluating O
the O
development O
and O
prognosis O
of O
gastric B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
therapeutic O
target O
for O
anti-metastasis O
treatment O
; O
( O
2 O
) O
Serum O
level O
of O
sCD44v6 O
is O
related O
to O
some O
extent O
with O
TCM O
type O
of O
blood B-outcome ['Physiological-Clinical']
stasis I-outcome ['Physiological-Clinical']
and O
Pi-deficiency B-outcome ['Physiological-Clinical']
; O
( O
3 O
) O
WTC O
combined O
with O
chemotherapy O
could O
further O
inhibit O
the O
expression O
of O
serum B-outcome ['Physiological-Clinical']
sCD44v6 I-outcome ['Physiological-Clinical']
in O
gastric O
carcinoma O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIMS O
Testing O
the O
effectiveness O
of O
a O
topical O
combination O
preparation O
containing O
standardized O
leech O
extract O
, O
polidocanol O
and O
allantoin O
. O
[]

This O
may O
partially O
explain O
the O
protective O
effect O
of O
D53 O
immunostimulant O
against O
respiratory B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Deceased-donor O
kidney O
transplant O
patients O
at O
protocol-specified O
risk O
of O
DGF O
were O
randomized O
to O
start O
everolimus O
on O
day O
1 O
( O
immediate O
everolimus O
, O
IE O
; O
n O
= O
65 O
) O
or O
week O
5 O
( O
delayed O
everolimus O
, O
DE O
; O
n O
= O
74 O
) O
. O
[]

Losartan O
vs. O
amlodipine O
treatment O
in O
elderly O
oncologic O
hypertensive O
patients O
: O
a O
randomized O
clinical O
trial O
. O
[]

CONCLUSIONS O
Salbutamol O
was O
shown O
to O
be O
effective O
and O
safe O
in O
the O
treatment O
of O
acute O
bronchiolitis O
. O
[]

Two O
open-label O
, O
controlled O
, O
multicenter O
, O
intergroup O
, O
international O
, O
randomized O
phase O
III O
studies O
were O
submitted O
-- O
one O
conducted O
by O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer B-outcome ['Physiological-Clinical']
( O
n O
= O
946 O
) O
and O
the O
other O
by O
the O
Southwest O
Oncology O
Group O
( O
n O
= O
746 O
) O
. O
['Physiological-Clinical']

Retrospectively O
registered O
14th O
October O
2016. O
[]

Operator O
and O
subject O
questionnaires O
were O
completed O
immediately O
after O
treatment O
to O
determine O
ease O
of O
the O
scaling O
procedure O
. O
[]

SETTING O
Primary O
contact O
, O
college O
out-patient O
clinic O
. O
[]

Mycological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
at O
4 O
weeks O
was O
33 O
% O
for O
ketoconazole O
and O
29 O
% O
for O
griseofulvin O
, O
and O
at O
8 O
weeks O
was O
53 O
% O
and O
57 O
% O
respectively O
. O
['Physiological-Clinical']

Stentless O
( O
Freestyle O
, O
Toronto O
, O
n O
= O
106 O
) O
or O
conventional O
biological O
aortic O
valves O
( O
Carpentier-Edwards O
, O
n O
= O
74 O
) O
were O
evaluated O
prospectively O
. O
[]

The O
Candidas O
were O
cultured O
. O
[]

Where O
practical O
, O
later O
infusions O
were O
given O
at O
home O
( O
rather O
than O
in O
the O
clinic O
) O
and O
patients O
questioned O
on O
their O
preferred O
infusion O
location O
. O
[]

The O
effects O
of O
moderate O
to O
vigorous B-outcome ['Physiological-Clinical']
aerobic O
exercise O
on O
the O
sleep O
need O
of O
sedentary O
young O
adults O
. O
['Physiological-Clinical']

Journal-Name:PLoS O
neglected O
tropical O
diseases O
[]

Parameters O
studied O
were O
body O
weight O
, O
oestrus O
incidences O
, O
plasma O
oestradiol O
17-? O
, O
plasma O
progesterone O
, O
conception O
rate O
, O
gestation O
period O
, O
lambing O
rate O
, O
and O
birth O
weight O
of O
lambs O
. O
[]

Residential O
school O
children O
( O
N O
= O
18 O
) O
were O
randomly O
assigned O
to O
either O
ascorbate-ascorbate-placebo O
treatment O
order O
group O
or O
ascorbate-placebo-ascorbate O
treatment O
order O
group O
. O
[]

Isoflurane O
and O
propofol O
for O
long-term O
sedation O
in O
the O
intensive O
care O
unit O
. O
[]

RESULTS O
At O
12-month O
follow-up O
, O
seven O
( O
35 O
% O
) O
patients O
who O
underwent O
optical O
urethrotomy O
and O
21 O
( O
70 O
% O
) O
in O
the O
VLASU O
group O
did O
not O
require O
repetition O
of O
the O
procedure O
. O
[]

In O
the O
treated O
group O
, O
the O
percentage O
of O
G0/G1 B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
significantly O
increased O
and O
that O
of O
S O
stage B-outcome ['Physiological-Clinical']
significantly O
decreased O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjective O
effects O
of O
the O
drugs O
were O
monitored O
using O
the O
Profile O
of O
Mood B-outcome ['Life-Impact']
States O
( O
POMS O
) O
and O
a O
shortened O
version O
of O
the O
Addiction B-outcome ['Life-Impact']
Research O
Center O
Inventory O
( O
ARCI B-outcome ['Physiological-Clinical']
) O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
therapies O
included O
hydroxyzine O
with O
or O
without O
doxepin O
at O
night O
, O
pentoxifylline O
, O
indomethacin O
and O
topical O
moisturization O
with O
medium-strength O
topical O
steroids O
. O
[]

Monitoring O
included O
ECG B-outcome ['Resource-use']
, O
blood O
pressure O
, O
respiratory O
rate O
, O
oxygen O
saturation O
and O
sedation B-outcome ['Life-Impact']
score O
. O
['Resource-use', 'Life-Impact']

Asthma O
among O
children O
and O
adolescents, O
its O
relations O
with O
physical O
activity O
(PA) O
and O
PA O
relations O
with O
body O
posture O
were O
and O
are O
still O
being O
investigated. O
[]

This O
investigation O
was O
conducted O
to O
determine O
if O
pyridostigmine O
affects O
various O
physiological O
and O
biophysical O
parameters O
of O
human O
temperature O
regulation O
in O
subjects O
wearing O
CW O
protective O
clothing O
. O
[]

However O
, O
levels O
between O
0.5 O
and O
1 O
microg/ml O
( O
within O
the O
IC50 O
of O
most O
cytomegalovirus O
isolates O
) O
could O
be O
achieved O
with O
tolerable O
oral O
doses O
. O
[]

RESULT O
( O
S O
) O
Both O
treatments O
improved O
hirsutism B-outcome ['Physiological-Clinical']
, O
hyperandrogenemia B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
we O
sought O
to O
evaluate O
the O
implicit O
ability O
to O
perceive O
the O
temporal O
outcome O
of O
different O
movements O
in O
a O
group O
of O
patients O
with O
writer O
's O
cramp O
. O
[]

Impact O
of O
vitamin O
D O
supplementation O
on O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
African O
Americans O
: O
results O
of O
a O
four-arm O
, O
randomized O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
between O
the O
groups O
in O
terms O
of O
total O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
P O
= O
0.55 O
) O
. O
['Adverse-effects']

Major O
Outcome O
Measure O
: O
We O
measured O
insulin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
response O
to O
iv B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
and O
arginine B-outcome ['Physiological-Clinical']
before O
and O
after O
treatment O
and O
after O
drug O
washout O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

RESULTS O
At O
enrollment O
, O
minority O
patients O
had O
significantly O
more O
pain B-outcome ['Physiological-Clinical']
than O
their O
white O
counterparts O
( O
6.0 O
vs O
5.0 O
, O
P O
= O
0.05 O
) O
. O
['Physiological-Clinical']

Changes O
in O
continuously O
recorded O
'Finapres O
' O
finger B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
ten O
normotensive O
and O
seven O
hypertensive O
subjects O
induced O
by O
self-inflation O
of O
the O
cuff O
or O
just O
wearing O
the O
inflated O
cuff O
were O
studied O
. O
['Physiological-Clinical']

EXPERIMENTAL O
DESIGN O
Irinotecan O
was O
given O
orally O
in O
fasted O
patients O
once O
daily O
for O
5 O
consecutive O
days O
and O
repeated O
every O
3 O
weeks O
. O
[]

Nevertheless O
, O
GI O
symptoms O
should O
be O
monitored O
in O
all O
patients O
taking O
high O
dose O
DHA O
especially O
those O
with O
personal O
or O
family O
history O
of O
GI O
disturbances O
. O
( O
[]

REACH O
patients O
with O
higher O
pretreatment O
protein O
tyrosine O
kinase O
2 O
( O
PTK2 O
) O
messenger O
RNA O
levels O
derived O
greater O
benefit O
from O
R-FC O
, O
with O
significant O
improvements O
in O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
independent O
of O
known O
prognostic O
factors O
in O
a O
multivariate O
model O
. O
['Mortality']

Patients O
receiving O
tamoxifen O
had O
significantly O
more O
vaginal B-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
Patients O
who O
have O
hypertension O
and O
are O
scheduled O
for O
PCI O
will O
be O
enrolled O
. O
[]

1.59 O
years O
, O
respectively O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
soy O
isoflavones O
on O
menopausal O
symptoms O
in O
women O
who O
do O
and O
who O
do O
not O
produce O
equol O
, O
a O
daidzein O
metabolite O
. O
[]

Secondary O
end O
points O
were O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
blood B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
at O
day O
+120 O
, O
and O
survival B-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

Cox O
proportional O
hazard O
ratio O
estimates O
for O
selected O
baseline O
covariates O
showed O
a O
significantly O
increased O
risk O
of O
cardiovascular O
events O
by O
age O
( O
p=0.0459 O
) O
and O
systolic O
blood O
pressure O
( O
p=0.0061 O
) O
. O
[]

METHODS O
A O
randomized O
, O
placebo-controlled O
, O
dose-escalation O
trial O
with O
five O
cohorts O
( O
N7-GP O
dose O
of O
12.5-100 O
?g O
kg O
( O
-1 O
) O
) O
was O
performed O
. O
[]

The O
incidences O
of O
any O
Common O
Terminology O
Criteria O
for O
Adverse B-outcome ['Adverse-effects']
Events I-outcome ['Adverse-effects']
grade O
3 O
and O
4 O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs B-outcome ['Adverse-effects']
) O
were O
87 O
% O
and O
72 O
% O
in O
the O
panitumumab O
and O
control O
groups O
, O
respectively O
. O
['Adverse-effects', 'Adverse-effects', 'Adverse-effects']

Accuracy O
and O
feasibility O
of O
contrast O
echocardiography O
for O
detection O
of O
perfusion O
defects O
in O
routine O
practice O
: O
comparison O
with O
wall O
motion O
and O
technetium-99m O
sestamibi O
single-photon O
emission O
computed O
tomography O
. O
[]

CONCLUSION: O
This O
is O
the O
first O
randomised O
controlled O
trial O
to O
compare O
a O
structured O
multidisciplinary, O
multisite O
intervention O
with O
standard O
care O
in O
symptomatic O
childhood O
hypermobility. O
[]

All O
groups O
perceived O
the O
instruction O
as O
effective. O
[]

In O
Stratum O
II O
, O
16 O
of O
29 O
( O
55 O
% O
) O
patients O
receiving O
CRT O
+ O
ITC O
experienced O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
: O
3 O
deaths O
during O
continuous O
complete O
remission O
( O
CCR O
) O
and O
13 O
relapses B-outcome ['Physiological-Clinical']
( O
2 O
CNS O
, O
1 O
CNS O
+ O
BM O
, O
1 O
BM O
+ O
testes O
, O
and O
2 O
testes O
) O
as O
compared O
with O
only O
5 O
relapses B-outcome ['Physiological-Clinical']
in O
20 O
( O
25 O
% O
) O
patients O
on O
CSpRT O
( O
1 O
CNS O
, O
1 O
CNS O
+ O
BM O
, O
1 O
BM O
, O
and O
2 O
testes O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
active O
treatment O
groups O
all O
resulted O
in O
improvements O
across O
all O
outcome O
measures O
, O
with O
moderate-to-large O
effect O
sizes O
from O
baseline O
to O
a O
12-week O
assessment O
. O
[]

BACKGROUND O
Proponents O
of O
single-incision O
laparoscopic O
surgery O
( O
SILS O
) O
claim O
patients O
have O
less O
pain O
, O
faster O
recovery O
, O
and O
better O
long-term O
cosmetic O
results O
than O
patients O
who O
undergo O
multiport O
laparoscopy O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
among O
treatments O
. O
['Adverse-effects']

RESULTS O
The O
percentage O
of O
patients O
with O
endoscopically-verified B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
on O
lansoprazole O
than O
on O
ranitidine O
both O
after O
4 O
weeks O
( O
79 O
% O
vs. O
42 O
% O
) O
and O
8 O
weeks O
( O
91 O
% O
vs. O
66 O
% O
) O
, O
though O
smoking O
had O
a O
negative O
impact O
on O
oesophagitis O
healing O
with O
lansoprazole O
. O
['Physiological-Clinical']

ET O
vs. O
BMV O
) O
. O
[]

Safety O
and O
acceptability O
of O
cellulose O
sulfate O
as O
a O
vaginal O
microbicide O
in O
HIV-infected O
women O
. O
[]

Skillful O
laser O
ablation O
can O
remove O
any O
volume O
of O
human O
papillomavirus-associated O
vulvar O
disease O
but O
can O
not O
prevent O
reactivation O
of O
the O
surrounding O
latent O
viral O
reservoir O
during O
postoperative O
healing O
. O
[]

BACKGROUND O
Both O
standard O
and O
low-dose O
allergen O
provocations O
are O
an O
established O
tool O
in O
asthma O
research O
to O
improve O
our O
understanding O
of O
the O
pathophysiological O
mechanism O
of O
allergic O
asthma O
. O
[]

The O
response B-outcome ['Physiological-Clinical']
rate O
was O
18%. O
[['Physiological-Clinical']]

Effects O
of O
ezetimibe O
, O
a O
new O
cholesterol O
absorption O
inhibitor O
, O
on O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
patients O
with O
primary O
hypercholesterolemia O
. O
['Physiological-Clinical']

The O
independent O
beneficial O
effect O
of O
treatment O
with O
primary O
PTCA O
rather O
than O
tPA O
in O
anterior O
wall O
AMI O
was O
confirmed O
by O
multivariate O
analysis O
and O
interaction O
testing O
. O
[]

Cardiovascular O
reactivity O
to O
psychological O
stress O
may O
be O
one O
mechanism O
for O
the O
enhanced O
risk O
, O
but O
the O
small O
number O
of O
studies O
examining O
whether O
OC O
users O
who O
smoke O
have O
greater O
reactivity B-outcome ['Physiological-Clinical']
have O
produced O
mixed O
results O
. O
['Physiological-Clinical']

MPA O
: O
in O
this O
group O
, O
89 O
% O
of O
responders O
still O
showed O
a O
benefit O
at O
week O
24 O
, O
compared O
with O
45 O
% O
in O
the O
megestrol O
group O
( O
P O
= O
0.03 O
) O
. O
[]

Of O
24 O
children O
randomized O
to O
the O
CBT O
arm O
, O
18 O
( O
75 O
% O
) O
were O
treatment O
responders O
, O
versus O
only O
3 O
of O
21 O
children O
( O
14 O
% O
) O
in O
the O
TAU O
arm O
. O
[]

Training O
of O
physicians O
, O
nurses O
and O
dietitians O
included O
preparation O
of O
operating O
manual O
and O
videos O
, O
interactive O
sessions O
, O
and O
evaluation O
of O
local O
facilities O
and O
resources O
. O
[]

The O
relation O
of O
pacing O
rate O
to O
physiologic O
variables O
of O
metabolic O
demand O
was O
examined O
in O
10 O
consecutive O
patients O
with O
a O
minute O
ventilation-sensing O
, O
rate-modulating O
ventricular O
pacemaker O
implanted O
for O
complete O
heart O
block O
. O
[]

Patients O
had O
received O
epoetin O
for O
> O
or O
= O
3 O
months O
upon O
study O
entry O
and O
had O
achieved O
a O
target O
Hb O
level O
of O
10.5-12.5 O
g/dL O
with O
a O
stable O
epoetin O
dose O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
for O
postoperative O
pain O
relief O
after O
total O
knee O
arthroplasty O
. O
[]

METHODS O
The O
study O
was O
carried O
out O
in O
middle-income O
students O
in O
two O
residential O
schools O
that O
catered O
to O
children O
from O
a O
semi-urban O
population O
near O
Hyderabad O
, O
India O
. O
[]

DESIGN O
AND O
METHODS O
The O
HERA O
study O
( O
Hyperium O
Effect O
on O
the O
sympathetic O
Reflex O
activation O
and O
Adrenaline O
) O
is O
a O
randomised O
, O
double-blind O
, O
6-week O
cross-over O
trial O
, O
with O
a O
1-week O
placebo O
run-in O
period O
, O
two O
2-week O
active O
treatment O
intervals O
( O
rilmenidine O
1 O
mg O
bid O
, O
placebo O
) O
and O
intervening O
one O
week O
placebo O
wash-out O
. O
[]

Lithium O
plus O
early O
morning O
sleep O
deprivation O
produced O
a O
quicker O
response O
than O
lithium O
with O
the O
control O
sleep O
deprivation O
, O
and O
the O
response O
was O
sustained O
for O
at O
least O
30 O
days O
. O
[]

BACKGROUND O
Non-pharmacological O
treatment O
( O
NPT O
) O
is O
a O
useful O
treatment O
option O
in O
the O
management O
of O
hip B-outcome ['Physiological-Clinical']
or O
knee B-outcome ['Physiological-Clinical']
osteoarthritis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

MLSS O
is O
an O
excellent O
tool O
for O
assessing O
fitness O
level O
, O
predicting O
endurance O
performance O
, O
and O
designing O
training O
programs O
. O
[]

Small O
but O
important O
errors O
in O
cardiovascular O
risk O
calculation O
by O
practice O
nurses O
: O
a O
cross-sectional O
study O
in O
randomised O
trial O
setting O
. O
[]

They O
exposed O
seven O
healthy O
young O
men O
on O
alternate O
days O
to O
acid O
or O
control O
equiosmolar O
NaCl O
aerosol O
during O
40 O
min O
of O
resting O
ventilation O
and O
20 O
min O
of O
exercise O
; O
the O
latter O
was O
sufficiently O
intense O
to O
induce O
oronasal B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
reocclusion B-outcome ['Physiological-Clinical']
rates O
were O
7.3 O
% O
and O
8.2 O
% O
, O
respectively O
( O
P O
= O
1.00 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Severe O
neurological O
involvement O
in O
systemic O
lupus O
erythematosus O
( O
NPSLE O
) O
is O
one O
of O
the O
most O
dreadful O
complications O
of O
the O
disease O
. O
[]

Postprandial B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
with O
oral B-outcome ['Physiological-Clinical']
estrogen B-outcome ['Physiological-Clinical']
treatment O
, O
both O
before O
( O
P O
< O
0.05 O
) O
and O
during O
( O
P O
< O
0.05 O
) O
GH O
administration O
, O
compared O
with O
transdermal O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
101090220 O
[]

Rate O
of O
healing B-outcome ['Physiological-Clinical']
of O
the I-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
defects B-outcome ['Physiological-Clinical']
were O
measured O
as O
percentage O
decrease O
from O
the O
baseline O
parameter O
at O
each O
subsequent O
follow O
up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
intermittent O
or O
continuous O
methotrexate O
plus O
6-mercaptopurine O
in O
regimens O
for O
standard-risk O
acute O
lymphoblastic O
leukemia O
in O
childhood O
( O
JCCLSG-S811 O
) O
. O
[]

Montelukast O
treatment O
of O
moderate O
to O
severe O
atopic O
dermatitis O
in O
adults O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Including O
clinical O
factors O
improved O
the O
predictive O
power O
of O
all O
models O
significantly O
. O
[]

Once-daily O
versus O
twice-daily O
intravenous O
administration O
of O
vancomycin O
for O
infections O
in O
hospitalized O
patients O
. O
[]

The O
incidence O
of O
local O
hematoma O
was O
2.3 O
% O
and O
3.7 O
% O
in O
the O
2,000- O
and O
5,000-IU O
groups O
, O
respectively O
( O
p O
= O
0.42 O
) O
. O
[]

Tolfenamic O
acid O
is O
a O
potent O
inhibitor O
of O
prostaglandin O
biosynthesis O
, O
which O
has O
been O
proved O
effective O
in O
the O
treatment O
of O
acute B-outcome ['Physiological-Clinical']
migraine I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
mean O
percentage O
decrease O
of O
AMH B-outcome ['Physiological-Clinical']
levels O
in O
the O
BC O
group O
and O
LS O
group O
at O
3- O
, O
6- O
, O
and O
12-month O
follow-up O
. O
['Physiological-Clinical']

While O
both O
techniques O
were O
associated O
with O
an O
increase O
in O
bladder O
compliance O
, O
statistical O
significance O
was O
demonstrated O
only O
in O
the O
spinal O
anesthesia O
treatment O
group O
. O
[]

In O
a O
double-blind O
placebo-controlled O
crossover O
trial O
, O
14 O
autistic O
children O
were O
treated O
with O
the O
neuropeptide O
ORG O
2766 O
, O
a O
synthetic O
analog O
of O
adrenocorticotrophic O
hormone O
( O
ACTH O
) O
( O
4-9 O
) O
. O
[]

CONCLUSION: O
In O
patients O
undergoing O
primary O
cementless O
THA, O
using O
a O
posterior O
approach, O
who O
are O
treated O
with O
rivaroxaban O
for O
thromboembolic O
prophylaxis, O
short- O
and O
long-TXA O
IV O
protocols O
are O
significantly O
more O
effective O
than O
placebo O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL), O
without O
any O
thromboembolic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
Non-inferiority O
of O
a O
short- O
versus O
a O
long-TXA O
protocol O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL) O
was O
supported O
in O
a O
secondary O
analysis. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE O
To O
observe O
the O
therapeutic O
effect O
of O
probucol O
on O
serum O
malondialdehyde O
( O
MDA O
) O
and O
superoxide O
dismutase O
( O
SOD O
) O
in O
patients O
with O
primary O
hypertension O
. O
[]

Pre- O
and O
postsupplementation O
, O
UVR O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
compare O
pharmacokinetics O
and O
pharmacokinetic-pharmacodynamic O
( O
PK-PD O
) O
relationship O
of O
rocuronium O
in O
children O
anesthetized O
with O
nitrous O
oxide O
( O
N2O O
) O
and O
fentanyl O
or O
with O
N2O O
and O
sevoflurane O
. O
[]

In B-outcome ['Physiological-Clinical']
stent I-outcome ['Physiological-Clinical']
re-stenosis I-outcome ['Physiological-Clinical']
was O
found O
in O
7 O
of O
85(8.2%) O
in O
the O
polymer-free O
group O
vs. O
6 O
of O
98(6.12%) O
in O
the O
biodegradable O
polymer O
group. O
[['Physiological-Clinical']]

Theory-driven O
intervention O
improves O
calcium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
osteoporosis B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
and O
self-efficacy B-outcome ['Life-Impact']
in O
community-dwelling O
older O
Black O
adults O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Inadequate O
discharge O
planning O
following O
inpatient O
stays O
is O
a O
major O
issue O
in O
the O
provision O
of O
a O
high O
standard B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
for O
patients O
who O
receive O
psychiatric O
treatment O
. O
['Life-Impact']

TRIAL O
REGISTRATION O
UMIN O
Clinical O
Trials O
Registry O
000007942 O
. O
[]

METHODS O
Thirteen O
emmetropic O
subjects O
were O
randomly O
fitted O
with O
two O
different O
tinted O
Nike O
Maxsight O
( O
Bausch O
& O
Lomb O
, O
Rochester O
, O
NY O
, O
USA O
) O
CL O
in O
one O
eye O
, O
while O
the O
contralateral O
eye O
was O
fitted O
with O
a O
clear O
lens O
made O
of O
the O
same O
material O
( O
Optima O
38 O
, O
Bausch O
& O
Lomb O
) O
. O
[]

METHODS O
Sixty-eight O
patients O
with O
unresectable O
HCC O
were O
randomized O
into O
2 O
age O
, O
tumor O
size O
, O
TNM O
stages O
, O
and O
liver O
function O
grade-matched O
groups O
: O
TACE O
group O
( O
n=30 O
) O
undergoing O
TACE O
and O
TACE+HIFU O
group O
( O
n=38 O
) O
undergoing O
2-3 O
weeks O
after O
TACE O
. O
[]

= O
1 O
, O
P O
= O
0.045 O
respectively O
) O
. O
[]

RESULTS O
As O
previously O
published O
, O
the O
intent-to-treat O
( O
ITT O
) O
clearance O
rate O
was O
50 O
% O
( O
54/109 O
) O
in O
the O
imiquimod-treated O
group O
and O
11 O
% O
( O
11/100 O
) O
in O
the O
vehicle-treated O
group O
( O
P O
< O
0.0001 O
) O
. O
[]

CONCLUSIONS O
Small-diameter O
hysteroscopy O
with O
bipolar O
electrode O
for O
the O
incision O
of O
uterine O
septum O
is O
as O
effective O
as O
resectoscopy O
with O
unipolar O
electrode O
regarding O
reproductive O
outcome O
and O
is O
associated O
with O
shorter O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
lower O
complication B-outcome ['Adverse-effects']
rate O
. O
['Life-Impact', 'Adverse-effects']

CONCLUSION O
YDJ O
played O
a O
role O
in O
clearing O
HR-HPV O
infection O
and O
reversing O
the O
cervical B-outcome ['Physiological-Clinical']
precancerous I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
possibly O
through O
down-regulating O
the O
mRNA O
expression O
of O
hTERT O
and O
lowering O
the O
telomerase O
activation O
. O
['Physiological-Clinical']

Outpatients O
were O
excluded O
due O
to O
difficulties O
in O
obtaining O
sufficient O
clinical O
information O
. O
[]

RESULTS O
Groups O
were O
well O
matched O
for O
birthweight O
, O
gestation O
and O
CRIB O
scores O
. O
[]

No O
major B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effect O
was O
observed O
. O
['Adverse-effects']

Publication O
date: O
2019/01/31 O
06:00 O
[entrez] O
[]

Current O
evidence O
on O
the O
effectiveness O
of O
patient O
reminders O
for O
all O
types O
of O
immunisation O
programmes O
is O
largely O
based O
on O
North O
American O
studies O
. O
[]

Ten O
male O
subjects O
with O
untreated O
type O
2 O
diabetes O
were O
given O
, O
in O
random O
sequence O
, O
50 O
g O
protein O
in O
the O
form O
of O
very O
lean O
beef O
or O
only O
water O
at O
0800 O
h O
and O
studied O
over O
the O
subsequent O
8 O
h. O
Protein O
ingestion O
resulted O
in O
an O
increase O
in O
circulating B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
glucagon B-outcome ['Physiological-Clinical']
, O
alpha B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
and O
urea B-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
, O
and O
triglycerides B-outcome ['Physiological-Clinical']
; O
a O
decrease O
in O
nonesterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
; O
and O
a O
modest O
increase O
in O
respiratory B-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
30-month O
longitudinal O
study O
of O
the O
effects O
of O
some O
oral O
hygiene O
measures O
on O
Streptococcus B-outcome ['Physiological-Clinical']
mutans I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
approximal I-outcome ['Physiological-Clinical']
dental I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTIONS O
Standard O
sensory O
integration O
therapy O
( O
SI O
) O
was O
compared O
to O
the O
SI O
with O
TTM O
treatments O
. O
[]

Vilazodone O
had O
no O
significant O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
PR B-outcome ['Physiological-Clinical']
, O
or O
QRS B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Weighted O
blankets O
and O
sleep O
in O
autistic O
children O
-- O
a O
randomized O
controlled O
trial O
. O
[]

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

Patients O
in O
Group O
D O
also O
requested O
less O
rescue O
anti-emetic O
( O
17 O
% O
) O
than O
those O
in O
Group O
P O
( O
30 O
% O
, O
p O
< O
0.05 O
) O
. O
[]

Crown O
lengthening O
with O
a O
2.0 O
mm O
apical O
extended O
ferrule O
resulted O
in O
reduced O
fracture B-outcome ['Physiological-Clinical']
strengths I-outcome ['Physiological-Clinical']
for O
endodontically-treated O
teeth O
restored O
using O
two O
dowel-core O
systems O
and O
cast O
metal O
crowns O
. O
['Physiological-Clinical']

DISCUSSION O
Because O
this O
study O
is O
expected O
to O
yield O
evidence O
regarding O
the O
selection O
of O
antipsychotics O
for O
facilitating O
the O
recovery O
of O
social O
activity O
in O
patients O
with O
schizophrenia O
, O
it O
is O
considered O
highly O
valuable O
to O
perform O
this O
effectiveness O
study O
under O
ordinary O
healthcare O
setting O
in O
Japan O
. O
[]

OBJECTIVE: O
To O
observe O
the O
effect O
of O
Ronghuang O
granule O
on O
serum O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
in O
non-dialysis O
patients O
with O
chronic O
kidney O
disease-mineral O
and O
bone O
disorder O
(CKD-MBD) O
and O
kidney O
deficiency O
and O
damp O
heat O
syndrome. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

All O
practices O
participated O
in O
4 O
sessions O
of O
training O
, O
including O
didactic O
lectures O
and O
office O
flow O
modification O
workshops O
. O
[]

BACKGROUND O
The O
use O
of O
warfarin O
reduces O
the O
rate O
of O
ischemic B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
in O
patients O
with O
atrial O
fibrillation O
but O
requires O
frequent O
monitoring O
and O
dose O
adjustment O
. O
['Physiological-Clinical']

Patients O
with O
and O
without O
LV O
hypertrophy O
did O
not O
differ O
significantly O
in O
acute O
mortality B-outcome ['Mortality']
during O
hospitalization B-outcome ['Resource-use']
, O
progression B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
waves I-outcome ['Physiological-Clinical']
, O
reinfarction O
by O
CK-MB B-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
or O
angina B-outcome ['Physiological-Clinical']
associated O
with O
transient O
electrocardiographic O
changes O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Stability O
, O
tipping O
and O
relapse O
of O
bone-borne O
versus O
tooth-borne O
surgically O
assisted O
rapid O
maxillary O
expansion O
; O
a O
prospective O
randomized O
patient O
trial O
. O
[]

The O
intervention O
featured O
a O
group-based O
cognitive-behavioral O
weight O
loss O
program O
with O
telephone O
counseling O
and O
tailored O
newsletters O
to O
support O
initial O
weight O
loss O
and O
subsequent O
maintenance O
, O
with O
the O
goal O
of O
7 O
% O
weight O
loss O
at O
two O
years O
. O
[]

Total O
intramuscular O
analgesic O
requirements O
in O
the O
first O
24 O
hours O
, O
time O
to O
satisfactory O
transfer O
to O
oral O
analgesia O
, O
antiemetic O
requirements O
and O
length O
of O
stay B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
postoperatively I-outcome ['Resource-use']
were O
noted O
. O
['Resource-use']

The O
most O
significant O
toxicity B-outcome ['Adverse-effects']
associated O
with O
chemotherapy O
was O
doxorubicin-induced B-outcome ['Physiological-Clinical']
cardiomyopathy I-outcome ['Physiological-Clinical']
, O
which O
resulted O
in O
clinically O
apparent O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
five O
patients O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
infants O
were O
divided O
into O
three O
groups O
: O
Group O
A O
and O
B O
received O
a O
dose O
of O
1.6 O
x O
10 O
( O
8 O
) O
cells O
of O
B. O
breve O
supplement O
twice O
a O
day O
, O
commencing O
either O
from O
several O
hours O
after O
birth O
( O
group O
A O
) O
or O
24 O
h O
after O
birth O
( O
group O
B O
) O
. O
[]

More O
active O
capsacinoids O
might O
be O
tried O
in O
the O
future O
and O
could O
provide O
a O
new O
method O
for O
treating O
migraine O
attacks O
. O
[]

RESULTS O
Comparing O
baseline O
to O
6-month O
results O
, O
both O
groups O
showed O
statistically O
significant O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
( O
PD B-outcome ['Physiological-Clinical']
) O
, O
horizontal O
clinical O
attachment O
level O
( O
CAL-h O
) O
gain O
, O
and O
increase O
in O
gingival B-outcome ['Physiological-Clinical']
recession I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
open-label O
T3 O
was O
administered O
to O
68 O
high-risk O
patients O
undergoing O
open O
heart O
surgery O
. O
[]

METHODS O
Eighty-five O
cases O
with O
chronic O
severe O
hepatitis O
were O
randomly O
divided O
into O
ozone O
therapy O
group O
( O
43 O
cases O
) O
and O
control O
group O
( O
42 O
cases O
) O
. O
[]

Naltrexone O
reduced O
hyperactivity B-outcome ['Life-Impact']
and O
had O
no O
effect O
on O
discrimination B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
in O
the O
laboratory O
. O
['Life-Impact', 'Life-Impact']

In O
the O
GHB O
group O
, O
AWS B-outcome ['Physiological-Clinical']
score O
dropped O
from O
6.6 O
+/- O
2.6 O
to O
1.8 O
+/- O
2.1 O
( O
p O
< O
.01 O
) O
, O
while O
in O
the O
CLO O
group O
, O
the O
score O
dropped O
from O
6 O
+/- O
2.5 O
to O
4.1 O
+/- O
2.4 O
( O
n. O
s. O
) O
. O
['Physiological-Clinical']

The O
present O
study O
demonstrated O
that O
the O
IL-6R B-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
levels O
in O
skeletal O
muscle O
are O
increased O
in O
response O
to O
acute O
exercise O
, O
a O
response O
that O
is O
very O
well O
conserved O
, O
being O
affected O
by O
neither O
training B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
nor O
intramuscular B-outcome ['Physiological-Clinical']
glycogen I-outcome ['Physiological-Clinical']
levels O
, O
as O
opposed O
to O
IL-6 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
By O
year O
4 O
, O
supplementation O
elevated O
plasma O
and O
red O
blood O
cell-DHA O
4.4- O
and O
3.6-fold O
, O
respectively O
, O
compared O
with O
the O
placebo O
group O
( O
P O
< O
0.00001 O
) O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
use O
inhibition O
of O
wheal O
and O
flare O
formation O
after O
2-mu O
g O
intradermal O
histamine O
injections O
as O
a O
measure O
of O
the O
antihistamine O
effect O
of O
repeated O
doses O
of O
mizolastine O
. O
[]

The O
relationship O
of O
changes O
in O
EORTC O
QLQ-C30 O
scores O
to O
ratings O
on O
the O
Subjective O
Significance O
Questionnaire O
in O
men O
with O
localized O
prostate O
cancer O
. O
[]

Patients O
were O
randomised O
to O
receive O
treatment O
with O
a O
4-week O
cycle O
of O
subcutaneous O
low O
doses O
IL-2 O
+ O
IFN O
in O
months O
1 O
, O
3 O
and O
5 O
, O
and O
then O
every O
3 O
months O
until O
the O
first O
documented O
disease O
progression O
( O
arm O
A O
, O
suspension O
) O
, O
or O
the O
same O
regimen O
, O
with O
chronic O
maintenance O
of O
immunotherapy O
, O
regardless O
of O
tumour O
response O
, O
until O
death O
or O
intolerable O
toxicity O
( O
arm O
B O
, O
maintenance O
) O
. O
[]

There O
were O
four O
cases O
of O
posttransplant B-outcome ['Physiological-Clinical']
lymphoproliferative O
disorder B-outcome ['Physiological-Clinical']
( O
PTLD O
) O
from O
the O
beginning O
of O
the O
LTE O
to O
year O
5 O
( O
n O
= O
3 O
LI O
; O
n O
= O
1 O
CsA O
) O
; O
two O
of O
three O
PTLD O
cases O
in O
the O
LI O
group O
were O
in O
patients O
who O
were O
seronegative O
for O
Epstein-Barr O
virus O
( O
EBV O
( O
- O
) O
) O
at O
transplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
description O
of O
the O
clinical O
characteristics O
at O
baseline O
of O
patients O
recruited O
into O
the O
Carvedilol O
or O
Metoprolol O
European O
Trial O
( O
COMET O
) O
. O
[]

10 O
adolescent O
or O
adult O
subjects O
with O
high-functioning O
autism O
or O
Asperger-syndrome O
were O
included O
in O
the O
investigation O
. O
[]

The O
primary O
endpoint O
was O
clinical B-outcome ['Physiological-Clinical']
response O
on O
day O
7 O
after O
the O
start O
of O
treatment O
. O
['Physiological-Clinical']

rhinorrhea O
and O
itching O
. O
[]

The O
lowest O
SaO2 B-outcome ['Physiological-Clinical']
after O
resuming O
ventilation O
and O
the O
time O
from O
that O
nadir O
to O
an O
SaO2 O
of O
97 O
% O
were O
also O
recorded O
. O
['Physiological-Clinical']

Post-operative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
return O
to O
activity O
show O
statistically O
significant O
differences O
. O
['Life-Impact', 'Resource-use']

Median O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
48.2 O
months O
(95% O
CI O
35.2-not O
evaluable) O
in O
the O
A+CHP O
group O
and O
20.8 O
months O
(12.7-47.6) O
in O
the O
CHOP O
group O
(hazard O
ratio O
0.71 O
[95% O
CI O
0.54-0.93], O
p=0.0110). O
[['Physiological-Clinical', 'Mortality']]

The O
inflammatory O
actions O
of O
synthetic O
C16:0 O
and O
C18:0 O
platelet O
activating O
factor O
( O
PAF O
) O
homologues O
, O
both O
alone O
and O
in O
combination O
, O
have O
been O
compared O
in O
an O
in O
vitro O
human O
neutrophil O
chemokinesis O
assay O
and O
by O
intradermal O
injection O
in O
human O
skin O
. O
[]

At O
the O
end O
of O
the O
study O
period O
there O
were O
no O
differences O
between O
those O
patients O
receiving O
tetracycline O
and O
those O
receiving O
placebo O
. O
[]

PURPOSE O
The O
aim O
of O
this O
study O
was O
to O
determine O
if O
local O
injection O
of O
bupivacaine O
after O
hemorrhoidal O
banding O
causes O
a O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
and O
in O
the O
incidence O
of O
associated O
symptoms B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Substance B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
and O
the O
number O
of O
substance B-outcome ['Life-Impact']
using O
friends O
increased O
in O
linear O
fashion O
from O
T1 O
to O
T5 O
. O
['Life-Impact', 'Life-Impact']

Exclusion O
criteria O
were O
diabetic O
ketoacidosis O
, O
severe O
hepatic O
failure O
or O
hepatic O
resection O
, O
pancreatitis O
, O
glucose O
of O
less O
than O
2.2 O
mmol/L O
on O
admission O
to O
hospital O
, O
insulin O
infusion O
on O
admission O
to O
ICU O
, O
planned O
withdrawal O
of O
life O
support O
, O
and O
inability O
to O
obtain O
informed O
consent O
. O
[]

Comparative O
efficacy O
of O
oral O
erythromycin O
versus O
oral O
tetracycline O
in O
the O
treatment O
of O
acne B-outcome ['Physiological-Clinical']
vulgaris I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
parents O
of O
consecutive O
children O
with O
autism O
( O
2 O
( O
1/2 O
) O
-5 O
years O
old O
) O
from O
the O
autism O
assessment O
services O
for O
the O
intervention O
regions O
were O
then O
randomly O
allocated O
to O
either O
a O
20-week O
manual-based O
parent O
education O
and O
behavior O
management O
intervention O
( O
n O
= O
35 O
) O
or O
a O
manual-based O
parent O
education O
and O
counseling O
intervention O
( O
n O
= O
35 O
) O
. O
[]

In O
Rickard O
, O
Lau O
, O
and O
Pashler O
's O
( O
2008 O
) O
investigation O
of O
the O
lag O
effect O
on O
memory-based B-outcome ['Life-Impact']
automaticity I-outcome ['Life-Impact']
, O
response O
times O
were O
faster O
and O
proportion O
of O
trials O
retrieved O
was O
higher O
at O
the O
end O
of O
practice O
for O
short O
lag O
items O
than O
for O
long O
lag O
items O
. O
['Life-Impact']

METHODS O
We O
performed O
a O
4-week O
randomized O
controlled O
trial O
among O
33 O
RA O
patients O
with O
wrist O
arthritis O
. O
[]

The O
patients O
were O
randomized O
into O
one O
of O
three O
programs O
: O
group O
1 O
-- O
a O
full-time O
, O
intensive O
3-week O
multidisciplinary O
program O
, O
including O
active O
physical O
and O
ergonomic O
training O
and O
psychological O
pain O
management O
, O
followed O
by O
1 O
day O
weekly O
for O
the O
subsequent O
3 O
weeks O
; O
group O
2 O
-- O
active O
physical O
training O
, O
twice O
a O
week O
for O
6 O
weeks O
, O
for O
a O
total O
of O
24h O
; O
group O
3 O
-- O
psychological O
pain O
management O
combined O
with O
active O
physical O
training O
, O
twice O
a O
week O
for O
6 O
weeks O
, O
also O
for O
a O
total O
of O
24h O
. O
[]

This O
study O
was O
carried O
out O
to O
compare O
patient O
safety O
and O
analgesic B-outcome ['Resource-use']
efficacy O
of O
a O
single O
and O
high O
dose O
of O
morphine O
given O
IM O
or O
IV O
for O
post-operative O
pain O
management O
. O
['Resource-use']

The O
treated O
patients O
had O
a O
logMAR B-outcome ['Physiological-Clinical']
vision I-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
of O
0.02 O
+/- O
0.213 O
, O
and O
the O
placebo O
patients O
had O
a O
vision B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
of O
0.02 O
+/- O
0.20 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Exercise O
intolerance O
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
results O
from O
a O
complex O
interaction O
between O
central O
( O
ventilatory O
) O
and O
peripheral O
( O
limb O
muscles O
) O
components O
of O
exercise O
limitation O
. O
[]

Comparison O
with O
computed O
tomography O
of O
two O
ultrasound O
devices O
for O
diagnosis O
of O
abdominal O
aortic O
aneurysm O
. O
[]

In O
addition O
, O
multiple O
assessments O
of O
insulin O
sensitivity O
were O
conducted O
. O
[]

In O
a O
randomized O
, O
2-group O
clinical O
study O
, O
acupuncture O
was O
used O
for O
the O
relief O
of O
menopausal B-outcome ['Physiological-Clinical']
hot I-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
, O
and O
mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

No O
evidence O
of O
new O
microhemorrhage O
, O
vasogenic O
edema O
, O
or O
meningoencephalitis B-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

Journal-Name:Cornea O
[]

Release B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
but O
not O
of O
prolactin B-outcome ['Physiological-Clinical']
after O
dexfenfluramine O
administration O
was O
significantly O
reduced O
in O
both O
groups O
of O
ecstasy O
users O
compared O
with O
the O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
by O
visual O
analogue O
scale O
( O
VAS O
) O
and O
the O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
was O
determined O
before O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Internal O
limiting O
membrane O
delamination O
vs O
posterior O
hyaloid O
removal O
. O
[]

The O
efficacy O
of O
low O
pressure O
, O
high O
pressure O
and O
passive O
drainage O
systems O
have O
been O
compared O
after O
cholecystectomy O
. O
[]

CM O
was O
also O
significantly O
superior O
to O
EC O
during O
the O
first O
attack O
for O
complete B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
( O
20 O
vs. O
8 O
% O
, O
p O
= O
0.006 O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
42 O
vs. O
63 O
% O
, O
p O
= O
0 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
article O
reports O
the O
psychometric O
properties O
of O
two O
scales O
for O
rating O
positive O
and O
negative O
schizophrenic O
signs O
and O
symptoms O
. O
[]

Minocycline O
safety O
and O
tolerability B-outcome ['Life-Impact']
in O
Huntington O
disease O
. O
['Life-Impact']

PATIENTS O
Ninety-five O
patients O
from O
southwestern O
iowa O
and O
southeastern O
Nebraska O
were O
enrolled O
, O
of O
whom O
88 O
were O
considered O
eligible O
for O
comparison O
( O
by O
continuing O
through O
week O
2 O
of O
the O
study O
) O
. O
[]

Energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
amount B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
carbohydrate I-outcome ['Life-Impact']
ingested I-outcome ['Life-Impact']
by O
both O
groups O
diminished O
over O
the O
trial O
, O
whereas O
the O
consumption O
of O
protein B-outcome ['Physiological-Clinical']
and O
fibre B-outcome ['Life-Impact']
increased O
and O
lipid O
ingestion O
remained O
unchanged O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

In O
Exp O
. O
[]

The O
AS O
skin O
test O
and O
intradermal O
histamine-induced O
wheal O
and O
flare O
reaction O
were O
performed O
at O
baseline O
( O
without O
AH O
) O
, O
after O
8 O
and O
16 O
weeks O
( O
under O
AH O
treatment O
) O
. O
[]

Her O
pregnancy O
ended O
with O
stillbirth B-outcome ['Mortality']
. O
['Mortality']

METHODS O
Randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Of O
the O
nine O
TSCS O
scales O
, O
the O
improvement O
on O
the O
Moral-Ethical O
scale O
was O
significantly O
greater O
in O
the O
PALS O
group O
. O
[]

IMg2+ O
values O
correlated O
with O
TMg O
values O
in O
both O
hemodialysis O
( O
r O
= O
0.93 O
; O
p O
< O
0.0001 O
) O
and O
CAPD O
( O
r O
= O
0.92 O
; O
p O
< O
0.0001 O
) O
patients O
did O
not O
correlate O
with O
age O
, O
time O
on O
dialysis O
, O
weight O
, O
fasting O
cholesterol O
or O
triglyceride O
, O
albumin O
, O
blood O
urea O
nitrogen O
( O
BUN O
) O
, O
creatinine O
, O
hematocrit O
, O
phosphate O
, O
or O
PTH O
values O
. O
( O
[]

10.9 O
ng/L O
vs. O
132.1 O
? O
[]

The O
proportions O
of O
depressed B-outcome ['Life-Impact']
( O
p O
< O
0.01 O
) O
and O
anxious B-outcome ['Life-Impact']
( O
p=0.04 O
) O
patients O
were O
also O
smaller O
in O
the O
group O
who O
were O
operated O
on O
. O
['Life-Impact', 'Life-Impact']

Various O
parameters O
such O
as O
Karnofsky O
performance B-outcome ['Physiological-Clinical']
status O
, O
pain O
score O
( O
measured O
by O
a O
visual-analogue O
scale O
) O
and O
analgesic B-outcome ['Resource-use']
requirement O
were O
recorded O
at O
monthly O
intervals O
. O
['Physiological-Clinical', 'Resource-use']

During O
the O
break O
between O
sets O
, O
the O
participants O
either O
rested O
( O
control O
[ O
CON O
] O
) O
or O
completed O
a O
static O
stretching O
protocol O
( O
static O
stretch O
[ O
SS O
] O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
clinical O
efficacy O
of O
treating O
knee O
osteoarthritis O
( O
KOA O
, O
Bi O
syndrome O
of O
knee O
) O
by O
massage O
combined O
Chinese O
materia O
medica O
( O
CMM O
) O
footbath O
fumigation O
and O
washing O
, O
and O
to O
observe O
the O
changes O
of O
the O
Lysholm O
knee B-outcome ['Physiological-Clinical']
score O
( O
LKSS O
) O
. O
['Physiological-Clinical']

The O
need O
for O
research O
to O
develop O
algorithms O
that O
allow O
one O
to O
select O
the O
best O
combination O
of O
medical O
and O
behavioral O
interventions O
for O
specific O
illnesses O
and O
contexts O
is O
noted O
. O
[]

CONCLUSION O
In O
our O
study O
, O
both O
concomitant O
and O
sequential O
therapy O
, O
but O
not O
hybrid O
therapy O
, O
reached O
high O
eradication B-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
scores O
with O
intramuscular O
ketorolac O
compared O
with O
placebo O
. O
['Physiological-Clinical']

Overall O
survival B-outcome ['Mortality']
was O
greater O
with O
the O
implantable O
defibrillator O
, O
with O
unadjusted O
estimates O
of O
89.3 O
percent O
, O
as O
compared O
with O
82.3 O
percent O
in O
the O
antiarrhythmic-drug O
group O
at O
one O
year O
, O
81.6 O
percent O
versus O
74.7 O
percent O
at O
two O
years O
, O
and O
75.4 O
percent O
versus O
64.1 O
percent O
at O
three O
years O
( O
P O
< O
0.02 O
) O
. O
['Mortality']

BACKGROUND O
Rebound O
acid O
hypersecretion O
might O
occur O
after O
treatment O
with O
proton O
pump O
inhibitors O
. O
[]

Cytology B-outcome ['Physiological-Clinical']
( O
at O
a O
cutoff O
of O
atypical O
squamous O
cells O
of O
undetermined O
significance O
or O
greater O
) O
detected O
76 O
% O
of O
cases O
among O
both O
treated O
and O
untreated O
women O
. O
['Physiological-Clinical']

Seventy-eight O
patients O
were O
randomized O
( O
Evr O
n O
= O
52 O
; O
CsA O
n O
= O
26 O
) O
. O
[]

No O
modification O
was O
found O
in O
nonresponders O
. O
[]

METHODS O
Patients O
with O
stage O
I/II O
melanoma O
, O
consecutively O
submitted O
to O
a O
SLN O
procedure O
by O
the O
same O
surgeon O
from O
2000 O
to O
2006 O
, O
were O
evaluated O
. O
[]

INTERVENTIONS O
PDT O
with O
the O
Ciaglia O
technique O
using O
the O
Ciaglia O
PDT O
introducer O
set O
and O
the O
Griggs O
technique O
using O
a O
Griggs O
PDT O
kit O
and O
guidewire O
dilating O
forceps O
. O
[]

METHOD O
In O
this O
relatively O
long-term O
study O
of O
risperidone O
efficacy O
and O
safety O
for O
aggression O
and O
self-injury O
in O
children O
, O
adolescents O
, O
and O
adults O
with O
MR O
and O
PDDs O
, O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
was O
measured O
in O
a O
21-subject O
subset O
during O
the O
course O
of O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

Studies O
have O
shown O
that O
live O
, O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
is O
efficacious O
in O
children O
. O
[]

A O
total O
of O
149 O
children O
and O
adolescents O
5 O
to O
17 O
years O
of O
age O
( O
mean O
[ O
SD O
] O
age O
, O
9.4 O
[ O
3.1 O
] O
years O
) O
from O
6 O
academic O
centers O
were O
randomly O
assigned O
to O
citalopram O
( O
n O
= O
73 O
) O
or O
placebo O
( O
n O
= O
76 O
) O
. O
[]

CONCLUSION O
In O
MBC O
, O
longer O
epirubicin-based O
regimens O
are O
better O
in O
terms O
of O
response O
duration O
and O
TTP B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
applied O
TCA O
to O
the O
preseptal O
skin O
of O
10 O
patients O
48 O
h O
before O
standard O
upper-eyelid O
blepharoplasty O
. O
[]

The O
patients O
and O
partners O
were O
re-evaluated O
8 O
weeks O
after O
the O
treatment O
. O
[]

RESULTS: O
A O
protocol-defined O
decrease O
in O
the O
hemoglobin B-outcome ['Physiological-Clinical']
level O
occurred O
in O
4 O
of O
166 O
patients O
(2.4%; O
95% O
confidence O
interval O
[CI], O
0.9 O
to O
6.0) O
in O
the O
tafenoquine O
group O
and O
in O
1 O
of O
85 O
patients O
(1.2%; O
95% O
CI, O
0.2 O
to O
6.4) O
in O
the O
primaquine O
group, O
for O
a O
between-group O
difference O
of O
1.2 O
percentage O
points O
(95% O
CI, O
-4.2 O
to O
5.0). O
[['Physiological-Clinical']]

There O
were O
no O
significant O
demographic O
differences O
between O
the O
2 O
groups O
. O
[]

We O
investigated O
the O
feasibility O
of O
two O
intermediate O
dose-dense O
FEC O
regimens O
. O
[]

BACKGROUND O
Reductions O
in O
serum O
magnesium O
have O
been O
postulated O
to O
play O
a O
role O
in O
promoting O
arrhythmias O
and O
to O
have O
an O
adverse O
impact O
on O
survival O
in O
congestive O
heart O
failure O
, O
although O
support O
for O
this O
postulate O
is O
lacking O
. O
[]

CONCLUSIONS O
A O
postoperative O
, O
fixed-dose O
enoxaparin O
regimen O
is O
more O
effective O
than O
adjusted-dose O
warfarin O
in O
preventing O
deep O
venous O
thrombosis O
after O
knee O
arthroplasty O
. O
[]

0.78 O
hours O
and O
2.25 O
? O
[]

The O
remaining O
participants O
were O
told O
that O
the O
person O
watching O
was O
just O
observing O
the O
procedure O
( O
no O
motivation O
condition O
) O
. O
[]

CONCLUSION O
Results O
for O
PFS B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
favor O
combination O
of O
bevacizumab O
with O
either O
chemotherapy O
or O
erlotinib O
over O
chemotherapy O
alone O
in O
the O
second-line O
setting O
. O
['Mortality', 'Mortality']

It O
has O
been O
shown O
previously O
that O
alopecia O
areata O
can O
be O
treated O
with O
dinitrochlorobenzene O
( O
DNCB O
) O
and O
other O
contact O
allergens O
. O
[]

Variables O
indicating O
the O
quality O
of O
life O
of O
the O
two O
groups O
were O
compared O
. O
[]

Bacterial B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
considered O
life-threatening O
or O
fatal O
) O
occurred O
in O
17 O
children O
with O
ALL O
and O
in O
7 O
with O
ANLL O
. O
['Physiological-Clinical']

Argon O
laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
-- O
results O
in O
black O
Jamaican O
population O
. O
[]

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred. O
[['Adverse-effects']]

Results O
of O
the O
present O
study O
demonstrate O
a O
potent O
and O
long-lasting O
analgesic O
effect O
of O
1,2,6-IP3 O
, O
possibly O
related O
to O
its O
antiinflammatory O
properties O
. O
[]

Randomized O
evaluation O
of O
octreotide O
vs O
prochlorperazine O
for O
ED O
treatment O
of O
migraine B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Hypertensive O
patients O
were O
randomly O
assigned O
to O
receive O
5 O
mg O
of O
enalapril O
( O
n O
= O
50 O
) O
or O
10 O
mg O
of O
lisinopril O
( O
n O
= O
47 O
) O
daily O
. O
[]

The O
main O
outcome O
measures O
were O
1-y O
changes O
in O
body O
weight O
( O
in O
kg O
) O
and O
fat O
mass O
( O
in O
kg O
) O
. O
[]

CONCLUSIONS O
With O
regard O
to O
gait O
kinematics O
in O
the O
early O
postoperative O
period O
( O
three O
months O
) O
, O
the O
present O
study O
showed O
no O
significant O
benefit O
for O
patients O
who O
underwent O
a O
total O
hip O
arthroplasty O
through O
a O
minimally O
invasive O
Watson-Jones O
approach O
in O
comparison O
with O
those O
who O
were O
managed O
with O
a O
standard O
transgluteal O
approach O
. O
[]

Though O
cardiorespiratory O
exercise O
training O
increases O
HRV O
, O
little O
is O
known O
regarding O
the O
exercise O
dose O
necessary O
to O
promote O
this O
improvement O
. O
[]

Publication O
date: O
2019/01/22 O
06:00 O
[medline] O
[]

Virtual O
reality O
for O
acute O
pain O
reduction O
in O
adolescents O
undergoing O
burn O
wound O
care O
: O
a O
prospective O
randomized O
controlled O
trial O
. O
[]

When O
compared O
with O
the O
no-treatment O
group O
, O
the O
combined-treatment O
group O
had O
significantly O
fewer O
subjects O
admitted B-outcome ['Resource-use']
to I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
( O
0 O
compared O
with O
5 O
, O
P O
= O
0.03 O
) O
, O
fewer O
days B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
( O
0 O
compared O
with O
74 O
, O
P O
= O
0.041 O
) O
, O
and O
a O
longer O
time O
to O
hospital O
admission O
( O
P O
= O
0.017 O
) O
. O
['Resource-use', 'Resource-use']

Can O
a O
questionnaire O
predict O
vitamin O
D O
status B-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
? O
['Physiological-Clinical']

UNLABELLED O
Many O
cancer O
patients O
continue O
to O
smoke O
postdiagnosis O
, O
which O
is O
associated O
with O
poorer O
clinical O
outcomes O
. O
[]

The O
characteristics O
of O
the O
contrast O
media O
enhancement O
argue O
for O
an O
active O
concomitant O
process O
of O
destruction O
and O
regeneration O
. O
[]

The O
addition O
of O
bioactive O
glass O
improved O
the O
biocompatibility O
of O
glass O
ionomer O
cement O
to O
fibroblasts O
better O
than O
addition O
of O
collagen O
. O
[]

Cumulative O
opioid B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
after O
48 O
hours O
were O
similar O
between O
the O
groups. O
[['Resource-use']]

AIM O
To O
determine O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
PHX1149 O
, O
a O
novel O
dipeptidyl O
peptidase-4 O
( O
DPP4 O
) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
. O
['Life-Impact']

To O
compare O
the O
safety O
and O
efficacy O
of O
a O
topical O
diclofenac O
solution O
versus O
oral O
diclofenac O
in O
relieving O
the O
symptoms O
of O
primary O
osteoarthritis O
( O
OA O
) O
of O
the O
knee O
, O
in O
a O
randomized O
, O
double-blind O
, O
double-dummy O
equivalence O
trial O
. O
[]

Preventing O
disability B-outcome ['Life-Impact']
and O
managing B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
in O
frail O
older O
adults O
: O
a O
randomized O
trial O
of O
a O
community-based O
partnership O
with O
primary O
care O
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
The O
pain O
in O
sickle O
cell O
anemia O
( O
SCA O
) O
is O
often O
triggered O
by O
dehydration O
, O
acidosis O
, O
and O
fever O
that O
are O
usually O
due O
to O
malaria O
. O
[]

Median O
back B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
leg I-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
varied O
between O
17 O
and O
23 O
mm O
( O
VAS O
) O
, O
and O
the O
Million O
and O
Oswestry B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
varied O
between O
14 O
and O
23 O
points O
2 O
months O
postoperatively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
impact O
of O
a O
parent O
education O
and O
behavior O
management O
intervention O
( O
PEBM O
) O
on O
the O
mental O
health O
and O
adjustment O
of O
parents O
with O
preschool O
children O
with O
autism O
. O
[]

The O
results O
were O
related O
to O
the O
capsulorhexis O
position O
, O
which O
was O
assessed O
with O
a O
retroillumination O
photograph O
. O
[]

Depression O
and O
inflammation O
are O
common O
among O
cancer O
patients O
. O
[]

RESULTS O
Data O
analysis O
showed O
sustained O
, O
statistically O
significant O
improvements O
in O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
measured I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
gingival I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
( O
GBI B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
PI I-outcome ['Physiological-Clinical']
) O
comparing O
users O
and O
non-users O
of O
toothbrushes O
and O
dentifrice O
in O
the O
original O
study O
( O
PI O
: O
p O
= O
0.04 O
; O
GBI O
: O
p O
= O
0.03 O
) O
and O
sustained B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
toothbrushes I-outcome ['Life-Impact']
and O
dentifrice B-outcome ['Resource-use']
by O
60 O
% O
of O
the O
subjects O
at O
follow-up O
one O
year O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

Overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
rates O
at O
6 O
months O
follow-up O
were O
similar O
in O
the O
2 O
groups O
( O
61 O
of O
117 O
, O
52.1 O
% O
vs. O
62 O
of O
116 O
, O
53.4 O
% O
; O
P=0.8 O
) O
. O
['Mortality']

Verapamil O
's O
beneficial O
effect O
appeared O
to O
be O
related O
, O
in O
part O
, O
to O
a O
10 O
% O
reduction O
of O
the O
rate-pressure O
product O
at O
rest O
( O
p O
less O
than O
0.05 O
) O
and O
a O
12 O
% O
reduction O
during O
submaximal O
exercise O
( O
p O
less O
than O
0.001 O
) O
. O
[]

CONCLUSIONS O
EE30/LNG150 O
decreased O
plasma O
androgen O
levels O
, O
but O
there O
was O
no O
impairment O
in O
sexual O
desire O
, O
on O
the O
other O
hand O
, O
sexual O
desire O
score O
increased O
with O
EE20/LNG100 O
formulation O
. O
[]

We O
conducted O
a O
randomized O
, O
controlled O
, O
pilot-study O
to O
evaluate O
the O
need O
for O
diverting B-outcome ['Physiological-Clinical']
ileostomy I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
low O
anterior O
resection O
[ O
NCT00457327 O
] O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
thyroid O
hormone O
excess O
and O
deficiency O
on O
TAFI O
levels O
and O
function O
. O
[]

Double-blind O
, O
placebo-controlled O
study O
of O
azelastine O
and O
fluticasone O
in O
a O
single O
nasal O
spray O
delivery O
device O
. O
[]

Retrobulbar O
anesthesia O
consisted O
of O
a O
2.5 O
ml O
injection O
of O
a O
1:1 O
mixture O
of O
2 O
% O
lidocaine O
without O
epinephrine O
and O
0.5 O
% O
bupivacaine O
. O
[]

This O
method O
is O
better O
than O
taking O
Alendronate O
. O
[]

METHODS: O
The O
study O
was O
conducted O
in O
96 O
sub-village O
units O
(balozis) O
in O
the O
Kongwa O
district O
of O
Tanzania O
which O
were O
predicted O
from O
prior O
prevalence O
surveys O
to O
have O
TF O
between O
5 O
and O
9.9%. O
[]

Both O
groups O
decreased O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
E O
% O
( O
energy O
percent O
) O
fat O
and O
increased O
E B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
fiber B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
but O
there O
was O
no O
differences O
between O
the O
groups O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Wheelchair O
skills O
training O
to O
improve O
confidence B-outcome ['Life-Impact']
with O
using O
a O
manual O
wheelchair O
among O
older O
adults O
: O
a O
pilot O
study O
. O
['Life-Impact']

BACKGROUND O
During O
cancer O
treatment O
children O
have O
reduced O
contact O
with O
their O
social O
network O
of O
friends O
, O
and O
have O
limited O
participation O
in O
education O
, O
sports O
, O
and O
leisure O
activities O
. O
[]

Overall B-outcome ['Physiological-Clinical']
tooth I-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
( O
including O
all O
tooth O
groups O
) O
in O
patients O
with O
palatally-displaced O
canines O
was O
significantly O
less O
than O
that O
in O
the O
control O
group O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
, O
sustained B-outcome ['Physiological-Clinical']
virologic I-outcome ['Physiological-Clinical']
response O
( O
SVR O
) O
, O
was O
defined O
as O
a O
reduction O
in O
hepatitis B-outcome ['Physiological-Clinical']
B B-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
deoxyribonucleic I-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HBV I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
> O
or=2 O
log10 O
copies/mL O
and O
HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
< O
20,000 O
copies/mL O
at O
24 O
wk O
of O
follow-up O
( O
week O
84 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
gains O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
were O
associated O
with O
treatment O
, O
a O
mediation O
analysis O
did O
not O
support O
imitation O
as O
the O
mechanism O
of O
action O
. O
['Life-Impact']

The O
effect O
of O
a O
single O
dose O
of O
1,000 O
mg O
of O
levetiracetam O
on O
essential O
tremor O
was O
investigated O
in O
24 O
patients O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Qualitative O
interviews O
are O
conducted O
with O
referring O
and O
non-referring O
health O
care O
professionals O
( O
malignant O
disease O
protocol O
only O
) O
. O
[]

CONCLUSION O
Irrespective O
of O
the O
preexercise O
meal O
, O
cycling O
TT O
performance O
of O
approximately O
30 O
min O
was O
not O
improved O
after O
PSE O
supplementation O
. O
[]

RESULTS O
Compared O
with O
usual O
care O
, O
peer O
counseling O
reduced O
smoking O
( O
-9.1 O
versus O
-4.5 O
cigarettes O
daily O
, O
P O
=.03 O
) O
, O
but O
did O
not O
affect O
absolute O
quit B-outcome ['Life-Impact']
rates O
( O
24 O
% O
versus O
21 O
% O
) O
at O
36 O
weeks O
' O
gestation O
. O
['Life-Impact']

DESIGN O
Prospective O
randomized O
study O
( O
Canadian O
Task O
Force O
classification O
I O
) O
. O
[]

1.43 O
mg/L O
and O
1.03 O
h O
( O
0.75-2.50 O
) O
, O
respectively O
. O
[]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

The O
pharmacologic O
effects O
of O
lorazepam O
( O
2 O
mg O
) O
, O
buspirone O
( O
20 O
mg O
, O
10 O
mg O
) O
, O
secobarbital O
( O
100 O
mg O
) O
, O
and O
placebo O
were O
compared O
in O
15 O
male O
, O
experienced O
, O
intermittent O
nontherapeutic O
drug O
users O
. O
[]

The O
intervention O
started O
at O
the O
first O
week O
of O
life O
and O
involved O
8 O
weeks O
of O
daily O
passive O
extension O
and O
flexion O
range-of-motion O
exercise O
of O
the O
upper O
and O
lower O
extremities O
. O
[]

Can O
patient O
coaching O
reduce O
racial/ethnic O
disparities O
in O
cancer O
pain O
control O
? O
[]

These O
data O
support O
the O
prophylactic O
value O
of O
corticosteroid O
treatment O
in O
patients O
at O
high O
risk O
for O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
particularly O
if O
several O
unfavorable O
predictors O
are O
present O
. O
['Physiological-Clinical']

End-treatment B-outcome ['Physiological-Clinical']
TSAb I-outcome ['Physiological-Clinical']
values O
, O
when O
low O
( O
less O
than O
350 O
% O
) O
or O
negative O
did O
not O
correlate O
with O
later O
evolution O
: O
in O
these O
39 O
patients O
, O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
41 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
recurrence B-outcome ['Physiological-Clinical']
rate O
was O
3.2 O
% O
both O
in O
1 O
year O
and O
2 O
years O
later O
in O
the O
former O
group-one O
consisting O
of O
31 O
patients O
with O
H. O
pylori O
eradicated O
, O
while O
the O
recurrence B-outcome ['Physiological-Clinical']
rate O
was O
57.1 O
% O
in O
1 O
year O
and O
78.6 O
% O
in O
2 O
years O
later O
, O
in O
the O
latter O
group-the O
other O
of O
42 O
patients O
with O
H. O
pylori O
not O
eradicated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

lack O
of O
comparison O
groups O
in O
research O
designs O
and O
longitudinal O
follow-up O
data O
) O
. O
[]

Falls B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
without I-outcome ['Life-Impact']
loss I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
consciousness I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
were O
reduced O
by O
two-thirds O
: O
controls O
reported O
669 O
falls O
( O
mean O
9.3 O
; O
range O
0 O
to O
89 O
) O
, O
and O
paced O
patients O
216 O
falls O
( O
mean O
4.1 O
; O
range O
0 O
to O
29 O
) O
. O
['Life-Impact']

Allelic B-outcome ['Physiological-Clinical']
imbalance I-outcome ['Physiological-Clinical']
in O
the O
clonal O
evolution O
of O
prostate O
carcinoma O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
compare O
defibrillation O
thresholds O
with O
lead O
systems O
consisting O
of O
an O
active O
left O
pectoral O
electrode O
and O
either O
single O
or O
dual O
transvenous O
coils O
. O
[]

Classes O
in O
each O
grade O
were O
randomized O
to O
receive O
a O
micronutrient-enriched O
beverage O
or O
a O
placebo O
without O
added O
micronutrients O
. O
[]

This O
report O
is O
an O
analysis O
of O
the O
morbidity B-outcome ['Physiological-Clinical']
in O
the O
bladder O
and O
bowel O
observed O
in O
a O
randomized O
trial O
of O
d O
( O
15 O
) O
+Be O
neutrons O
versus O
megavoltage O
photons O
in O
the O
treatment O
of O
bladder O
cancer O
. O
['Physiological-Clinical']

II O
. O
[]

Large O
bleeding O
gastric O
varices O
in O
20 O
heparinized O
dogs O
were O
randomized O
to O
endoscopic O
injection O
treatment O
with O
one O
of O
the O
following O
agents O
: O
cyanoacrylate O
; O
a O
1:1:1 O
mixture O
of O
sodium O
tetradecyl O
sulfate O
3 O
% O
, O
ethanol O
98 O
% O
, O
and O
normal O
saline O
solution O
; O
ethanolamine O
oleate O
5 O
% O
; O
sodium O
morrhuate O
5 O
% O
; O
sodium O
tetradecyl O
sulfate O
1.5 O
% O
; O
polidocanol O
1 O
% O
; O
normal O
saline O
solution O
with O
epinephrine O
1:10,000 O
; O
or O
normal O
saline O
solution O
( O
control O
) O
. O
[]

Therefore O
, O
it O
is O
probable O
that O
these O
changes O
are O
membrane-related O
. O
[]

An O
international O
multi-clinic O
study O
comparing O
the O
therapeutic O
efficacy O
of O
colloidal O
bismuth O
subcitrate O
coated O
tablets O
with O
chewing O
tablets O
in O
the O
treatment O
of O
duodenal O
ulceration O
. O
[]

We O
examined O
the O
effect O
of O
CEE O
alone O
on O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
a O
subsample O
of O
the O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
clinical O
trial O
participants O
. O
['Physiological-Clinical']

Publication O
Type: O
Comparative O
Study, O
Journal O
Article, O
Multicenter O
Study, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

CONCLUSIONS O
Titanoreine O
can O
effectively O
relieve B-outcome ['Physiological-Clinical']
the O
early O
postoperative O
symptoms O
after O
PPH O
. O
['Physiological-Clinical']

Whereas O
Group O
I O
patients O
did O
not O
receive O
a O
dopexamine O
infusion O
. O
[]

All O
reactions O
resolved O
without O
incident O
. O
[]

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
measured O
from O
the O
date O
of O
randomization O
to O
the O
date O
of O
recurrence O
or O
death O
, O
whichever O
occurred O
first O
. O
['Mortality', 'Mortality']

However O
, O
by O
2 O
weeks O
the O
conventional O
group O
reported O
significantly O
higher O
pain B-outcome ['Physiological-Clinical']
scores O
particularly O
on O
passing O
stool O
. O
['Physiological-Clinical']

For O
these O
reasons O
, O
PTCA O
therapy O
of O
acute O
MI O
should O
not O
be O
routinely O
performed O
with O
adjunctive O
intravenous O
streptokinase O
therapy O
. O
[]

A O
sample O
was O
selected O
of O
85 O
children O
with O
LD O
, O
with O
age O
range O
between O
8 O
years O
and O
10 O
years O
( O
age O
, O
M=111.02 O
, O
SD=9.6 O
) O
, O
whose O
spelling O
performance O
was O
two O
years O
below O
grade O
level O
. O
[]

Objective: O
To O
investigate O
the O
efficacy O
of O
cognitive-behavioral O
therapy O
for O
insomnia O
(CBT-i) O
or O
combination O
with O
tapered O
hypnotic O
agents. O
[]

2 O
. O
[]

58 O
participants O
aged O
11-16 O
years-old O
were O
randomly O
assigned O
to O
either O
an O
immediate O
treatment O
or O
waitlist O
comparison O
group O
. O
[]

Five O
experiments O
tested O
the O
idea O
that O
instructing O
a O
witness O
to O
close O
their O
eyes O
during O
retrieval O
might O
increase O
retrieval B-outcome ['Life-Impact']
success I-outcome ['Life-Impact']
. O
['Life-Impact']

Do O
catheter O
washouts O
extend O
patency B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
long-term O
indwelling B-outcome ['Physiological-Clinical']
urethral O
catheters O
? O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
compared O
side-effect B-outcome ['Adverse-effects']
profiles O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Adverse-effects', 'Life-Impact']

CONCLUSION O
The O
results O
suggest O
that O
12 O
g O
RDN O
kg?? O
DOMI O
or O
19 O
g O
RDN O
kg?? O
DOMR O
may O
be O
adequate O
for O
optimum O
MPS O
, O
NCE O
and O
digestibility O
of O
nutrients O
in O
sheep O
fed O
on O
an O
FMS-based O
diet O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

CONCLUSION O
In O
our O
study O
, O
the O
H2O2 O
mouth O
rinse O
does O
not O
provide O
a O
better O
analgesic B-outcome ['Resource-use']
effect O
than O
the O
water O
rinse O
for O
post-tonsillectomy B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Pregabalin O
versus O
naltrexone O
in O
alcohol O
dependence O
: O
a O
randomised O
, O
double-blind O
, O
comparison O
trial O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
whether O
the O
magnitude O
of O
implicit O
racial O
bias O
predicts O
physician O
recommendation O
of O
TKR O
for O
black O
and O
white O
patients O
with O
OA O
and O
to O
assess O
the O
effectiveness O
of O
a O
web-based O
instrument O
as O
an O
intervention O
to O
decrease O
the O
effect O
of O
implicit O
racial O
bias O
on O
physician O
recommendation O
of O
TKR O
. O
[]

BACKGROUND O
Whether O
early O
detection O
and O
treatment O
of O
prostate O
cancer O
( O
PCa O
) O
will O
reduce O
disease-related B-outcome ['Mortality']
mortality I-outcome ['Mortality']
remains O
uncertain O
. O
['Mortality']

Unchanged B-outcome ['Physiological-Clinical']
rate, O
transfer B-outcome ['Physiological-Clinical']
rate O
of O
patients, O
rate O
of O
impaired B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
, O
turn B-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
rate O
and O
other O
biochemical O
indicators O
of O
patients O
and O
people O
with O
impaired O
glucose O
tolerance O
from O
control O
group O
and O
intervention O
group O
were O
analyzed, O
to O
evaluate O
the O
intervention O
effects O
of O
peer O
support O
education O
mode. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Measures O
included O
changes O
in O
professionally O
completed O
Childhood O
Autism O
Rating O
Scale O
( O
CARS O
) O
, O
hand B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
testing O
, O
and O
modified O
clinical B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
impression I-outcome ['Physiological-Clinical']
( O
CGI O
) O
forms O
; O
parent O
completed O
Autism B-outcome ['Life-Impact']
Treatment O
Evaluation O
Checklist O
( O
ATEC O
) O
, O
treatment O
adherence B-outcome ['Life-Impact']
measurement O
( O
TAM O
) O
, O
frequency O
and O
intensity O
of O
side O
effect O
rating O
( O
FISER O
) O
/global O
rating O
of O
side O
effect O
burden B-outcome ['Physiological-Clinical']
( O
GRSEB B-outcome ['Physiological-Clinical']
) O
/patient O
report O
of O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
PRISE B-outcome ['Physiological-Clinical']
) O
forms B-outcome ['Physiological-Clinical']
; O
and O
lab O
testing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
clinical O
trial O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
in O
a O
prospective O
trial O
AV O
conduction O
during O
the O
long-term O
follow-up O
of O
patients O
with O
sick O
sinus O
syndrome O
. O
[]

Patients O
who O
completed O
the O
flexibility O
programme O
were O
invited O
to O
cross O
over O
to O
the O
exercise O
programme O
afterwards O
. O
[]

Two O
courses O
of O
consolidation O
therapy O
were O
followed O
by O
continuation O
therapy O
or O
hematopoietic O
stem O
cell O
transplantation O
. O
[]

By O
five O
years O
after O
study O
entry O
, O
8 O
percent O
of O
the O
patients O
assigned O
to O
CABG O
had O
undergone O
additional O
revascularization B-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
, O
as O
compared O
with O
54 O
percent O
of O
those O
assigned O
to O
PTCA O
; O
69 O
percent O
of O
those O
assigned O
to O
PTCA O
did O
not O
subsequently O
undergo O
CABG O
. O
['Resource-use']

The O
effect O
of O
different O
aprotinin O
applications O
on O
hemostatic O
changes O
and O
blood O
product O
requirements O
in O
orthotopic O
liver O
transplantation O
was O
investigated O
in O
a O
prospective O
, O
open O
, O
and O
randomized O
study O
. O
[]

The O
high-dose O
challenge O
model O
is O
suitable O
only O
in O
an O
attenuated O
form O
in O
diseased O
volunteers O
for O
proof-of-concept O
studies O
and O
in O
clinical O
settings O
to O
reduce O
the O
risk O
of O
severe O
asthma O
exacerbations O
. O
[]

BACKGROUND O
Recently O
, O
amlodipine O
maleate O
was O
developed O
and O
tested O
in O
preclinical O
and O
Phase O
I O
clinical O
trials O
in O
Korea O
. O
[]

No O
differences O
were O
detected O
in O
surgical B-outcome ['Life-Impact']
resection I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
number O
of O
patients O
who O
required O
transfusion B-outcome ['Resource-use']
, O
volume O
and O
number O
of O
transfusion B-outcome ['Resource-use']
units I-outcome ['Resource-use']
, O
or O
type O
and O
volume O
of O
fluid B-outcome ['Physiological-Clinical']
replacement I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Resource-use', 'Resource-use', 'Physiological-Clinical']

BACKGROUND O
The O
value O
of O
pancreatoduodenectomy O
( O
PD O
) O
with O
extended O
lymphadenectomy O
for O
pancreatic O
cancer O
has O
been O
evaluated O
by O
many O
retrospective O
studies O
and O
3 O
randomized O
controlled O
trials O
( O
RCT O
) O
. O
[]

A O
drawback O
to O
this O
therapeutic O
approach O
is O
the O
relatively O
long O
and O
complex O
management O
of O
the O
induction O
phase O
. O
[]

The O
Breathlessness O
Intervention O
Service O
( O
BIS O
) O
seeks O
to O
improve O
the O
care O
of O
breathless B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
with O
advanced O
disease O
( O
regardless O
of O
cause O
) O
through O
the O
use O
of O
evidence-based O
practice O
and O
working O
with O
other O
healthcare O
providers O
. O
['Physiological-Clinical']

No O
statistically O
significant O
differences O
in O
survival B-outcome ['Mortality']
parameters O
were O
observed O
. O
['Mortality']

Analysis O
will O
be O
by O
intention-to-treat O
. O
[]

During O
the O
placebo O
control O
period O
, O
serum B-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
, O
LBM B-outcome ['Physiological-Clinical']
, O
and O
TBW B-outcome ['Physiological-Clinical']
increased O
( O
P O
< O
0.001 O
) O
, O
whereas O
BF B-outcome ['Physiological-Clinical']
decreased O
( O
P O
< O
0.001 O
) O
and O
serum B-outcome ['Physiological-Clinical']
GHBP I-outcome ['Physiological-Clinical']
was O
unchanged O
in O
the O
group O
treated O
with O
GH O
compared O
with O
the O
patients O
treated O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
hazard O
ratio O
for O
the O
risk O
of O
recurrence B-outcome ['Physiological-Clinical']
was O
0.30 O
(95% O
CI, O
0.22 O
to O
0.40) O
with O
tafenoquine O
as O
compared O
with O
placebo O
(P<0.001) O
and O
0.26 O
(95% O
CI, O
0.18 O
to O
0.39) O
with O
primaquine O
as O
compared O
with O
placebo O
(P<0.001). O
[['Physiological-Clinical']]

GHRH-induced O
GH O
peak O
in O
uremics O
( O
22.7 O
+/- O
5.2 O
micrograms/l O
) O
was O
not O
different O
from O
that O
obtained O
in O
control O
subjects O
( O
16.0 O
+/- O
4.3 O
micrograms/l O
) O
. O
[]

To O
ensure O
accurate O
comparisons O
between O
consecutive O
cardiac O
output O
measurements O
, O
the O
researchers O
recommend O
that O
the O
position O
in O
which O
the O
cardiac O
output O
measurements O
are O
performed O
be O
documented O
and O
the O
cardiac O
output O
measurements O
be O
conducted O
in O
a O
uniform O
position O
. O
[]

RESULTS O
The O
total O
effective O
rate O
in O
the O
treated O
group O
reached O
92 O
% O
, O
it O
was O
shown O
that O
SXN O
could O
improve O
the O
iron O
metabolism O
, O
increase O
levels O
of O
Fe O
, O
TS O
, O
SF O
and O
reduce O
levels O
of O
TIBC O
, O
Tf O
, O
sTfR O
, O
it O
has O
obvious O
effect O
in O
promoting O
erythrocyte O
generation O
and O
could O
promote O
formation O
of O
leucocytes O
and O
platelets O
. O
[]

Therefore O
, O
we O
were O
interested O
in O
determining O
whether O
this O
also O
was O
the O
case O
in O
people O
with O
type O
2 O
diabetes O
. O
[]

RESULTS: O
In O
the O
modified O
intention-to-treat O
population, O
omadacycline O
(316 O
patients) O
was O
noninferior O
to O
linezolid O
(311 O
patients) O
with O
respect O
to O
early O
clinical O
response O
(rate O
of O
response, O
84.8% O
and O
85.5%, O
respectively; O
difference, O
-0.7 O
percentage O
points; O
95% O
confidence O
interval O
[CI], O
-6.3 O
to O
4.9). O
[]

Raters O
' O
[]

The O
trial O
was O
designed O
to O
assess O
the O
impact O
of O
the O
Asha-Life O
intervention O
engaging O
with O
an O
HIV-trained O
village O
woman O
, O
Asha O
( O
Accredited O
Social O
Health O
Activist O
) O
, O
to O
participate O
in O
the O
care O
of O
women O
living O
with O
AIDS O
( O
WLA O
) O
, O
along O
with O
other O
health O
care O
providers O
compared O
to O
a O
Usual O
Care O
group O
. O
[]

In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
low-dose O
dopexamine O
on O
morbidity O
after O
major O
abdominal O
surgery O
in O
patients O
who O
were O
at O
increased O
risk O
by O
virtue O
of O
a O
reduced O
AT O
. O
[]

OBJECTIVE: O
To O
observe O
the O
clinical O
efficacy O
of O
dopamine O
modulator O
methylphenidate O
(MPH) O
of O
extended-release O
formulations O
(MPH-ER) O
augmentation O
of O
ongoing O
fluvoxamine O
treatment O
in O
refractory O
obsessive-compulsive O
disorder O
(OCD) O
and O
its O
effects O
on O
patient's O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
Methods: O
A O
pilot O
randomized, O
placebo-controlled, O
and O
double-blind O
trial O
was O
conducted O
at O
an O
outpatient, O
single-center O
academic O
setting. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical']]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

After O
0.5 O
week O
( O
range O
3 O
to O
4 O
days O
) O
of O
treatment O
patients O
receiving O
silodosin O
vs O
placebo O
achieved O
significant O
improvement O
in O
total O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom B-outcome ['Physiological-Clinical']
Score O
( O
difference O
-1.9 O
, O
p O
< O
0.0001 O
) O
and O
irritative B-outcome ['Physiological-Clinical']
( O
-0.5 O
, O
p O
= O
0.0002 O
) O
and O
obstructive B-outcome ['Physiological-Clinical']
( O
-1.4 O
, O
p O
< O
0.0001 O
) O
subscores O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
was O
developed O
through O
a O
dynamic O
and O
iterative O
process O
that O
involved O
extensive O
development O
activities O
, O
focus O
groups O
with O
the O
target O
population O
to O
pilot O
individual O
activities O
and O
intervention O
sessions O
, O
and O
later O
, O
pilot O
testing O
of O
the O
entire O
intervention O
. O
[]

At O
6 O
months O
, O
study O
outcomes O
included O
days O
of O
alcohol B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
measured O
using O
the O
time-line O
follow-back O
method O
. O
['Life-Impact']

Effectiveness O
of O
a O
national O
quality O
improvement O
programme O
to O
improve O
survival O
after O
emergency O
abdominal O
surgery O
(EPOCH): O
a O
stepped-wedge O
cluster-randomised O
trial. O
[]

Subjects O
who O
were O
H B-outcome ['Physiological-Clinical']
pylori B-outcome ['Physiological-Clinical']
negative O
had O
14.8 O
% O
more O
regression O
and O
13.7 O
% O
less O
progression B-outcome ['Physiological-Clinical']
than O
patients O
who O
were O
positive O
at O
12 O
years O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

4 O
) O
The O
patients O
whose O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
reduced O
significantly O
( O
< O
or= O
50 O
beats O
per O
minute O
) O
in O
the O
diltiazem O
group O
were O
more O
than O
in O
the O
nitroglycerin O
group O
[ O
8 O
( O
7.7 O
% O
) O
vs O
0 O
( O
0 O
% O
) O
, O
P O
< O
0.01 O
] O
. O
['Physiological-Clinical']

Nausea B-outcome ['Physiological-Clinical']
scores O
at O
the O
24th O
postoperative O
hour O
were O
significantly O
lower O
in O
the O
OSTAP O
group O
compared O
with O
the O
Sham O
group O
CONCLUSION:: O
We O
concluded O
that O
bilateral O
US-guided O
OSTAP O
blocks O
reduced O
24th O
hour O
tramadol B-outcome ['Resource-use']
requirements O
and O
VAS O
scores O
after O
laparoscopic O
hysterectomy. O
[['Physiological-Clinical'], ['Resource-use']]

CONCLUSIONS O
We O
advocate O
that O
to O
maintain O
optimal B-outcome ['Physiological-Clinical']
lens I-outcome ['Physiological-Clinical']
integrity I-outcome ['Physiological-Clinical']
and O
ocular B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
RGP O
lenses O
used O
for O
extended O
wear O
should O
be O
replaced O
every O
3 O
to O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Moderate/severe O
PFOA O
was O
associated O
with O
lower O
knee B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
( O
mean O
? O
['Physiological-Clinical']

Mean O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
['Physiological-Clinical']

Patients O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
and O
8 O
weeks O
after O
starting O
medication O
. O
[]

Of O
1016 O
patients O
( O
45 O
percent O
of O
whom O
had O
ventricular O
fibrillation O
, O
and O
55 O
percent O
ventricular O
tachycardia O
) O
, O
507 O
were O
randomly O
assigned O
to O
treatment O
with O
implantable O
cardioverter-defibrillators O
and O
509 O
to O
antiarrhythmic-drug O
therapy O
. O
[]

In O
addition O
, O
CRP O
, O
plasma O
renin O
activity O
, O
plasma O
aldosterone O
, O
and O
traditional O
risk O
factors O
were O
assessed O
. O
[]

Sensitivity O
to O
musical O
structure O
in O
the O
human O
brain O
. O
[]

The O
GH O
response O
to O
low-dose O
bolus O
growth O
hormone-releasing O
hormone O
( O
GHRH O
( O
1-29 O
) O
NH2 O
) O
is O
attenuated O
in O
patients O
with O
longstanding O
post-irradiation O
GH O
insufficiency O
. O
[]

Results O
were O
not O
materially O
affected O
by O
adjustment O
for O
basline O
values O
or O
changes O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

dal-PLAQUE O
is O
the O
first O
multicentre O
study O
using O
novel O
non-invasive O
multimodality O
imaging O
to O
assess O
structural O
and O
inflammatory O
indices O
of O
atherosclerosis O
as O
primary O
endpoints O
. O
[]

The O
present O
study O
investigated O
the O
effects O
of O
oral O
ENT O
administration O
on O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
in O
subjects O
with O
a O
preference O
for O
a O
high-fat O
diet O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Somatization O
, O
anxiety O
, O
and O
depression O
were O
also O
measured O
. O
[]

The O
pathogens O
were O
Haemophilus O
influenzae O
type O
b O
( O
54 O
cases O
) O
, O
streptococci O
( O
9 O
cases O
) O
, O
meningococci O
( O
9 O
cases O
) O
, O
and O
unknown O
( O
6 O
cases O
) O
. O
[]

Spectra O
were O
measured O
( O
a O
) O
before O
and O
( O
b O
) O
after O
surface O
preparation O
, O
( O
c O
) O
immediately O
before O
and O
( O
d O
) O
after O
laser O
irradiation O
at O
630 O
nm O
. O
[]

Epirubicin-based O
chemotherapy O
in O
metastatic O
breast O
cancer O
patients O
: O
role O
of O
dose-intensity O
and O
duration O
of O
treatment O
. O
[]

36 O
months O
. O
[]

Of O
63 O
patients O
undergoing O
deep O
anterior O
resection O
of O
the O
rectum O
, O
39 O
patients O
received O
a O
straight O
colo-anal O
anastomosis O
( O
CAA O
) O
, O
24 O
additionally O
had O
a O
colon-j-pouch O
( O
CPA O
) O
constructed O
. O
[]

INTERVENTIONS O
Problem-solving O
education O
is O
a O
brief O
, O
cognitive O
intervention O
delivered O
in O
six O
30-minute O
individualized O
sessions O
by O
existing O
staff O
( O
early O
intervention O
programs O
) O
or O
research O
staff O
without O
formal O
mental O
health O
training O
( O
autism O
clinic O
) O
. O
[]

Findings O
may O
also O
be O
used O
by O
decision-makers O
interested O
in O
implementing O
the O
mhGAP-IG O
training O
in O
other O
LMICs. O
[]

Patients O
in O
Group O
2 O
( O
n=72 O
) O
received O
totally O
1200 O
mg O
intravenous/24 O
h O
amiodarone O
which O
the O
300 O
mg O
- O
bolus O
dose/1 O
h O
was O
given O
as O
soon O
as O
the O
operation O
had O
been O
finished O
. O
[]

The O
purpose O
of O
this O
investigation O
was O
to O
conduct O
a O
human O
safety O
study O
with O
a O
Haematococcus O
pluvialis O
algal O
extract O
with O
high O
levels O
of O
astaxanthin O
. O
[]

Children O
were O
assessed O
at O
the O
end O
of O
a O
two-week O
placebo-baseline O
period O
and O
again O
after O
four O
weeks O
of O
treatment O
. O
[]

Twelve O
normotensive O
white O
and O
12 O
normotensive O
black O
men O
were O
given O
10 O
, O
200 O
, O
and O
400 O
mmol/d O
Na O
as O
the O
chloride O
salt O
for O
7 O
days O
in O
random O
order O
. O
[]

Conservative O
surgery O
with O
and O
without O
radiotherapy O
in O
elderly O
patients O
with O
early-stage O
breast O
cancer O
: O
a O
prospective O
randomised O
multicentre O
trial O
. O
[]

METHODS O
Sixty O
wives O
completed O
measures O
prior O
to O
random O
assignment O
to O
either O
the O
psychoeducational O
group O
intervention O
or O
a O
no-treatment O
control O
group O
, O
and O
1 O
month O
after O
completion O
of O
the O
group O
. O
[]

RESULTS O
Proteinuria B-outcome ['Physiological-Clinical']
was O
positively O
correlated O
with O
circulating B-outcome ['Physiological-Clinical']
AGE O
and O
sRAGE O
levels O
in O
our O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
and O
investigators O
were O
masked O
to O
treatment O
. O
[]

APC O
was O
also O
used O
to O
measure O
the O
effects O
of O
treatment O
on O
hepatic B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

5-FU/FA O
. O
[]

A O
convenience O
sample O
of O
140 O
patients O
presenting O
with O
acute O
bronchitis O
were O
tested O
for O
M O
pneumoniae O
, O
91 O
of O
whom O
were O
treated O
with O
either O
erythromycin O
250 O
mg O
four O
times O
daily O
for O
10 O
days O
or O
an O
identical-appearing O
placebo O
. O
[]

Results O
on O
word-learning B-outcome ['Life-Impact']
tests O
and O
Sternberg O
Memory B-outcome ['Life-Impact']
Scanning I-outcome ['Life-Impact']
Tests O
were O
not O
significantly O
impaired O
. O
['Life-Impact', 'Life-Impact']

Self-reported O
life-time O
medical O
diagnosis O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
or O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
antidepressants I-outcome ['Resource-use']
was O
considered O
as O
outcome. O
[['Physiological-Clinical', 'Life-Impact'], ['Resource-use']]

This O
prospective O
randomized O
, O
double-blinded O
, O
dose-response O
study O
examined O
the O
anesthetic O
and O
recovery O
profiles O
of O
60- O
and O
80-mg O
doses O
of O
preservative-free O
plain O
mepivacaine O
for O
ambulatory O
spinal O
anesthesia O
. O
[]

This O
study O
shows O
final B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
60 O
girls O
with O
Turner O
syndrome O
treated O
in O
a O
randomized O
dose-response O
trial O
, O
combining O
GH O
treatment O
with O
low O
dose O
estrogens O
at O
a O
relatively O
young O
age O
. O
['Physiological-Clinical']

Since O
left O
heart O
failure O
may O
be O
associated O
with O
pulmonary O
hypertension O
out O
of O
proportion O
to O
left O
heart O
disease O
, O
sildenafil O
may O
have O
beneficial O
effect O
in O
such O
patients O
. O
[]

Take O
a O
walk O
in O
the O
park O
? O
[]

Contrast O
reduction O
was O
maintained O
in O
the O
rotational O
angiography O
group O
compared O
to O
the O
conventional O
technique O
( O
A O
vs O
B O
, O
335.1 O
[ O
192.1 O
] O
vs O
238.5 O
[ O
114.4 O
] O
mL O
; O
P=.02 O
) O
. O
[]

RESULTS O
Infants O
nursed O
with O
a O
postural O
support O
roll O
and O
a O
postural O
support O
nappy O
demonstrated O
improved O
hip B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
to O
term O
equivalent O
age O
compared O
with O
infants O
nursed O
with O
either O
a O
postural O
support O
roll O
only O
, O
or O
a O
postural O
support O
nappy O
only O
. O
['Physiological-Clinical']

Thus O
the O
rise O
in O
pressure B-outcome ['Physiological-Clinical']
was O
related O
to O
the O
muscular O
activity O
required O
for O
cuff O
inflation O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

6 O
. O
[]

Systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SVR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
unaltered O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
VAS O
scores O
and O
recognition O
thresholds O
for O
four O
basic O
tastes B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
before O
treatment. O
[['Physiological-Clinical']]

The O
risk O
of O
SSI B-outcome ['Physiological-Clinical']
was O
39 O
% O
lower O
in O
the O
80 O
% O
FIO2 O
group O
( O
relative O
risk O
[ O
RR O
] O
, O
0.61 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.38-0.98 O
) O
vs O
the O
30 O
% O
FIO2 O
group O
. O
['Physiological-Clinical']

These O
were O
used O
to O
compare O
trained O
( O
T.S O
. O
) O
[]

Frusemide O
administration O
at O
the O
midpoint O
of O
each O
study O
limb O
resulted O
in O
each O
case O
in O
a O
prompt O
15 O
to O
20 O
fold O
increase O
in O
natriuresis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Parenteral O
troxerutin O
and O
carbazochrome O
combination O
in O
the O
treatment O
of O
post-hemorrhoidectomy O
status O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
phase O
IV O
study O
. O
[]

We O
compared O
the O
effects O
of O
one O
vs O
two O
daily O
bouts O
of O
walking O
on O
aerobic B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
changes O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
either O
fructose-1,6-diphosphate O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Uncuffed O
tubes O
selected O
by O
Cole O
's O
formula O
were O
appropriate O
for O
77 O
% O
of O
patients O
( O
P O
< O
0.001 O
) O
. O
[]

Title: O
Effect O
of O
a O
short-term O
low O
fermentable O
oligiosaccharide, O
disaccharide, O
monosaccharide O
and O
polyol O
(FODMAP) O
diet O
on O
exercise-related O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

However O
, O
a O
measure O
of O
rate O
of O
non-verbal B-outcome ['Life-Impact']
communicative I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
taken O
from O
an O
interactive O
play-based O
assessment O
at O
age O
2 O
was O
significantly O
associated O
with O
language B-outcome ['Life-Impact']
, O
communication B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
outcomes I-outcome ['Life-Impact']
at O
age O
7 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Statistical O
analyses O
were O
performed O
using O
2-tailed O
McNemar O
tests O
, O
Pearson O
chi-square O
tests O
, O
and O
Student O
's O
t-tests O
; O
P O
< O
0.05 O
was O
considered O
statistically O
significant O
. O
[]

A O
slight O
interactive O
effect O
was O
observed O
in O
arithmetic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
( O
p O
less O
than O
.05 O
) O
. O
['Life-Impact']

All O
had O
been O
paced O
for O
complete O
or O
Mobitz O
II O
heart O
block O
. O
[]

Mu-power O
increased O
at O
frontal O
and O
central O
sensors O
during O
movement O
observation O
. O
[]

Results O
held O
across O
formats O
and O
suggest O
that O
parent O
management O
training O
can O
provide O
an O
[]

[ O
Propofol O
infusion O
for O
the O
maintenance O
of O
short-term O
anesthesia B-outcome ['Resource-use']
] O
. O
['Resource-use']

In O
these O
patients O
with O
normal O
or O
near-normal O
resting O
left O
ventricular O
function O
, O
neither O
drug O
induced O
depression O
of O
left O
ventricular O
function O
. O
[]

The O
average O
hourly O
incidence O
of O
ventricular B-outcome ['Physiological-Clinical']
premature I-outcome ['Physiological-Clinical']
contractions I-outcome ['Physiological-Clinical']
was O
22 O
with O
placebo O
and O
25 O
with O
hydrochlorothiazide O
. O
['Physiological-Clinical']

As O
calcium O
acquired O
during O
adolescence O
is O
essential O
to O
maximize O
peak O
bone O
mass O
and O
to O
prevent O
osteoporosis O
, O
possible O
long-term O
effects O
of O
excessive O
MRP O
intake O
during O
this O
period O
warrant O
attention O
. O
[]

Allergic O
conjunctivitis O
( O
AC O
) O
affects O
an O
estimated O
20 O
% O
of O
the O
population O
in O
the O
Western O
world O
, O
with O
a O
large O
fraction O
suffering O
due O
to O
seasonal O
or O
perennial O
allergen O
exposures O
. O
[]

RESULTS O
The O
age O
of O
the O
patients O
and O
the O
severity O
of O
their O
burns O
did O
not O
differ O
significantly O
between O
the O
groups O
. O
[]

MATERIAL O
AND O
METHODS O
The O
hypersensitive O
root O
surfaces O
of O
selected O
teeth O
were O
randomized O
to O
receive O
1 O
of O
3 O
treatments O
: O
coating O
with O
a O
self-etching O
adhesive O
( O
Linkmax O
) O
and O
its O
respective O
cement O
, O
coating O
with O
a O
conventionally O
etched O
adhesive O
( O
RelyX O
ARC O
) O
and O
its O
cement O
, O
or O
no O
treatment O
( O
negative O
control O
) O
. O
[]

Nitrous O
oxide O
does O
not O
increase O
the O
incidence O
of O
nausea O
and O
vomiting O
after O
isoflurane O
anesthesia O
. O
[]

After O
6 O
months O
all O
patients O
received O
GH O
. O
[]

Patients O
in O
group O
A O
received O
2 O
weeks O
of O
daily O
GM-CSF O
, O
at O
which O
time O
zidovudine O
was O
restarted O
if O
the O
ANC O
was O
greater O
than O
1,000/microL O
; O
if O
the O
ANC O
was O
less O
than O
1,000/microL O
, O
the O
dose O
of O
GM-CSF O
was O
increased O
to O
3.0 O
micrograms/kg O
, O
and O
at O
2-week O
intervals O
either O
zidovudine O
was O
restarted O
or O
the O
dose O
of O
GM-CSF O
was O
increased O
to O
5 O
micrograms/kg O
and O
then O
10 O
micrograms/kg O
, O
to O
maintain O
the O
ANC O
greater O
than O
1,000/microL O
. O
[]

Effects O
of O
Thai O
traditional O
massage O
on O
autistic O
children O
's O
behavior O
. O
[]

Forty-six O
children O
were O
included O
. O
[]

A O
six-session O
higher-functioning O
autism O
anti-stigma O
program O
incorporating O
descriptive O
, O
explanatory O
and O
directive O
information O
was O
delivered O
to O
adolescent O
boys O
and O
the O
impact O
upon O
knowledge B-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
and O
behavioural B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
towards O
peers O
with O
autism O
was O
evaluated O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

High-sensitivity O
C-reactive O
protein O
( O
hs-CRP O
) O
and O
total O
antioxidant O
( O
TA O
) O
inflammatory O
and O
antioxidative O
markers O
were O
measured O
after O
2 O
months O
. O
[]

Three O
undertook O
the O
pilot O
study O
, O
33 O
were O
allocated O
to O
three O
groups O
: O
no O
screening O
( O
control O
) O
, O
screening O
followed O
by O
intensive O
treatment O
( O
IT O
) O
and O
screening O
plus O
routine O
care O
( O
RC O
) O
in O
an O
unbalanced O
( O
1:3:3 O
) O
randomisation O
. O
[]

Effect O
of O
intravenous O
dezocine O
on O
fentanyl-induced O
cough B-outcome ['Physiological-Clinical']
during O
general O
anesthesia O
induction O
: O
a O
double-blinded O
, O
prospective O
, O
randomized O
, O
controlled O
trial O
. O
['Physiological-Clinical']

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O
[]

Perceived O
exercise B-outcome ['Physiological-Clinical']
frequency O
(z O
= O
2.309, O
P O
= O
0.02) O
and O
intensity O
(z O
= O
2.687, O
P O
= O
0.007) O
was O
significantly O
improved O
following O
a O
short-term O
LOWFODMAP O
approach O
compared O
to O
HIGHFODMAP. O
[['Physiological-Clinical']]

CONCLUSION O
WP-IMRT O
is O
associated O
with O
significantly O
less O
toxicity O
compared O
with O
WP-CRT O
and O
has O
a O
comparable O
clinical O
outcome O
. O
[]

The O
differences O
between O
the O
preoperative O
and O
postoperative O
changes O
were O
found O
statistically O
significant, O
but O
not O
different O
between O
the O
2 O
techniques O
at O
any O
given O
time O
studied. O
[]

In O
this O
new O
analysis O
of O
the O
Anandron O
European O
Study O
, O
independent O
prognostic O
factors O
have O
been O
evaluated O
in O
order O
to O
identify O
those O
which O
could O
influence O
the O
study O
outcome O
and O
the O
impact O
of O
the O
treatment O
. O
[]

Both O
T2W O
and O
T2*W O
MRI O
show O
reduced O
interobserver O
variability O
and O
improved O
accuracy O
compared O
to O
CT, O
this O
was O
statistically O
significant O
for O
T2*W O
imaging O
compared O
to O
CT O
across O
all O
four O
comparison O
metrics. O
[]

Each O
slice O
was O
immersed O
into O
photo O
developing O
solution O
and O
was O
photographed O
, O
and O
microleakage B-outcome ['Physiological-Clinical']
was O
scored O
from O
0 O
to O
7 O
, O
by O
three O
calibrated O
examiners O
. O
['Physiological-Clinical']

This O
study O
conducted O
further O
analysis O
of O
the O
Pirarubicin O
Monotherapy O
Study O
Group O
cohort O
, O
focusing O
on O
intravesical O
seeding O
of O
cancer O
cells O
. O
[]

STUDY O
OBJECTIVE O
To O
compare O
the O
intraoperative O
conditions O
and O
postoperative O
recovery O
of O
patients O
following O
the O
use O
of O
either O
propofol-nitrous O
oxide O
( O
N2O O
) O
or O
enflurane-N2O O
for O
maintenance O
of O
outpatient O
anesthesia O
. O
[]

MATERIALS O
AND O
METHODS O
Between O
December O
1997 O
and O
November O
1999 O
, O
57 O
consecutive O
eligible O
patients O
with O
surgical O
adrenal O
disease O
were O
prospectively O
randomized O
to O
undergo O
TLA O
( O
25 O
) O
or O
RLA O
( O
32 O
) O
. O
[]

However O
, O
3-port O
patients O
reported O
better O
physical O
attractiveness O
( O
4.0 O
? O
[]

A O
significant O
increase O
of O
initial O
claudication O
distance O
was O
found O
in O
the O
nebivolol O
group O
. O
[]

Analyses O
were O
by O
intention O
to O
treat O
. O
[]

Clinically O
relevant O
improvement O
of O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
5-aminolevulinic O
acid O
induced O
fluorescence O
diagnosis O
in O
patients O
with O
superficial O
bladder O
tumors O
. O
['Mortality']

Ovulation O
was O
randomly O
triggered O
( O
hCG O
5000 O
IU O
, O
IM O
) O
when O
the O
leading O
follicle O
diameter O
ranged O
between O
either O
16.0 O
and O
16.9 O
mm O
( O
Early O
hCG O
group O
, O
n=227 O
) O
or O
18.0 O
and O
18.9 O
mm O
( O
Late O
hCG O
group O
, O
n=207 O
) O
and O
IUI O
was O
performed O
approximately O
36 O
h O
later O
. O
[]

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
crossover O
study O
, O
6 O
months O
of O
octreotide O
( O
40 O
mg O
every O
28 O
days O
) O
therapy O
limited O
kidney O
volume O
growth O
more O
effectively O
than O
placebo O
in O
12 O
patients O
with O
ADPKD O
. O
[]

Parents O
and O
caregivers O
of O
children O
6 O
to O
40 O
months O
age O
group O
in O
intervention O
villages O
received O
intensive O
education O
on O
hand O
hygiene. O
[]

Effect O
of O
perioperative O
parecoxib O
on O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
local B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
factors O
PGE2 O
and O
IL-6 O
for O
total O
knee O
arthroplasty O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Impact O
of O
dronedarone O
on O
hospitalization B-outcome ['Resource-use']
burden I-outcome ['Resource-use']
in O
patients O
with O
atrial O
fibrillation O
: O
results O
from O
the O
ATHENA O
study O
. O
['Resource-use']

PATIENTS O
AND O
METHODS O
Sixty-one O
patients O
were O
randomised O
to O
either O
HoLEP O
or O
TURP O
. O
[]

Phase O
1 O
was O
from O
19 O
to O
58 O
wk O
, O
and O
phase O
2 O
was O
from O
59 O
to O
68 O
wk O
. O
[]

Especially O
important O
is O
the O
fact O
that O
the O
thalamus O
is O
activated O
by O
nicotine O
. O
[]

Parents O
were O
taught O
the O
same O
3 O
infant-handling O
techniques O
after O
random O
assignment O
to O
the O
(1) O
direct, O
(2) O
video, O
or O
(3) O
written-pictorial O
instructional O
groups. O
[]

The O
risk O
was O
most O
reduced O
among O
children O
under O
3 O
years O
of O
age O
( O
6 O
to O
11 O
months O
-- O
relative O
risk O
, O
0.28 O
; O
95 O
percent O
confidence O
interval O
, O
0.09 O
to O
0.85 O
; O
12 O
to O
35 O
months O
-- O
relative O
risk O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.26 O
to O
0.81 O
) O
and O
among O
those O
who O
were O
chronically O
undernourished O
, O
as O
manifested O
by O
stunting O
( O
relative O
risk O
, O
0.11 O
; O
95 O
percent O
confidence O
interval O
, O
0.03 O
to O
0.36 O
) O
. O
[]

FUNDING O
Australian O
National O
Health O
and O
Medical O
Research O
Council O
, O
Cancer O
Council O
New O
South O
Wales O
, O
Pfizer O
, O
Merck O
, O
Gilead O
Sciences O
. O
[]

After O
12 O
months O
, O
a O
significant O
reduction O
in O
HbA1c B-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
nateglinide O
group O
, O
whereas O
a O
significant O
increase O
of O
HbA1c B-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
untreated O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
variables O
were O
direct O
and O
indirect B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
treatment O
and O
PD B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

The O
seven-day O
course O
of O
metronidazole O
was O
superior O
to O
the O
single-dose O
regimen O
in O
the O
percentage O
of O
patients O
with O
clue O
cells O
and O
the O
percentage O
of O
patients O
with O
a O
positive O
sniff O
test O
at O
the O
first O
follow-up O
visit O
; O
however O
, O
differences O
in O
the O
initial B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
assessed I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
and O
Gram-stained B-outcome ['Physiological-Clinical']
smear I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
were O
not O
statistically O
significant O
between O
the O
two O
patient O
treatment O
regimens O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
interim O
results O
of O
the O
ongoing O
Finnish O
Diabetes O
Prevention O
Study O
demonstrate O
the O
efficacy O
and O
[]

Clinical O
trial O
of O
tooth B-outcome ['Physiological-Clinical']
whitening I-outcome ['Physiological-Clinical']
with O
6 O
% O
hydrogen O
peroxide O
whitening O
strips O
and O
two O
whitening O
dentifrices O
. O
['Physiological-Clinical']

CONCLUSION O
Enteral O
nutrition O
improves O
QOL B-outcome ['Life-Impact']
of O
severely O
malnourished O
head O
and O
neck O
cancer O
patients O
in O
the O
period O
preceding O
surgery O
. O
['Life-Impact']

Ventilatory O
function O
during O
urography O
: O
a O
comparison O
of O
iopamidol O
and O
sodium O
iothalamate O
. O
[]

Palo O
Alto, O
CA, O
USA. O
[]

Two O
breasts O
with O
smooth O
prostheses O
were O
contracted O
after O
6 O
months O
( O
Baker O
III O
or O
IV O
) O
. O
[]

The O
primary O
outcome O
variable O
for O
the O
trial O
was O
dichotomized O
Glasgow O
Outcome O
Scale O
( O
good O
outcome O
versus O
all O
others O
) O
. O
[]

METHOD O
Forty O
children O
( O
7-11 O
years O
old O
) O
were O
randomly O
assigned O
to O
16 O
sessions O
of O
CBT O
or O
a O
3-month O
waitlist O
( O
36 O
completed O
treatment O
or O
waitlist O
) O
. O
[]

On O
day O
4 O
, O
the O
effects O
of O
diphenhydramine O
did O
not O
reach O
significance O
. O
[]

OBJECTIVE O
Weight O
gain O
is O
common O
for O
individuals O
with O
serious O
mental O
illness O
( O
SMI O
) O
receiving O
antipsychotic O
drug O
therapy O
. O
[]

Of O
the O
47 O
complete O
responders O
, O
7 O
, O
or O
14.9 O
% O
, O
have O
relapsed O
, O
with O
the O
median O
duration O
of O
remission O
of O
44+ O
months O
. O
[]

The O
results O
indicated O
that O
short-term O
treatment O
with O
the O
alkaloid O
improved O
memory B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
. O
['Life-Impact']

AIM O
The O
aim O
of O
this O
study O
was O
to O
examine O
the O
pharmacokinetics O
of O
donepezil O
HCl O
and O
digoxin O
separately O
, O
and O
in O
combination O
, O
following O
administration O
of O
single O
oral O
doses O
. O
[]

CONSLUSIONS: O
Kangfuxin O
liquid O
combined O
with O
Garlicin O
Capsules O
can O
improve O
the O
therapeutic O
effect O
of O
ROU O
and O
repair B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
damaged I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
in O
children, O
increasing O
the O
immune O
function O
of O
children. O
[['Physiological-Clinical']]

Folic O
acid-based O
supplementation O
is O
not O
beneficial O
and O
may O
even O
be O
harmful O
in O
the O
secondary O
prevention O
of O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
with O
unstable O
angina O
and O
non-ST-elevation O
myocardial O
infarction O
. O
['Physiological-Clinical']

Experience O
and O
perception O
of O
bodily O
symptoms O
therefore O
play O
an O
important O
role O
in O
social O
anxiety O
. O
[]

Before O
treatment O
, O
TSAb B-outcome ['Physiological-Clinical']
ranging O
from O
170 O
to O
1529 O
% O
was O
present O
in O
28/29 O
patients O
and O
reached O
significantly O
low O
levels O
at O
the O
end O
of O
treatment O
whatever O
its O
duration O
. O
['Physiological-Clinical']

Temporal O
expectation O
in O
focal O
hand O
dystonia O
. O
[]

Duration O
of O
chronic B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scale O
modified O
for O
pervasive O
developmental O
disorders O
. O
[]

Bestatin O
is O
shown O
to O
be O
a O
clinically O
useful O
drug O
for O
immunotherapy O
of O
adult O
ANLL O
, O
since O
it O
has O
prolonged O
survival B-outcome ['Mortality']
and O
remission B-outcome ['Physiological-Clinical']
especially O
in O
elderly O
patients O
, O
with O
few O
side-effects B-outcome ['Adverse-effects']
. O
['Mortality', 'Physiological-Clinical', 'Adverse-effects']

10?/L O
, O
6.3 O
? O
[]

RESULTS O
Of O
the O
469 O
patients O
, O
255 O
( O
54.4 O
% O
) O
were O
female O
and O
214 O
( O
45.6 O
% O
) O
were O
male O
. O
[]

OBJECTIVE O
To O
study O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
the O
laparoscopic O
surgery O
in O
combination O
of O
Quyu O
Jiedu O
Recipe O
( O
QYJDR O
) O
on O
endometriosis O
( O
EMs O
) O
-related O
infertility O
patients O
. O
['Physiological-Clinical']

Surgery O
of O
aphakic O
retinal O
detachment O
. O
[]

Subsequently O
, O
the O
group O
A O
specimens O
were O
immediately O
brushed O
( O
40 O
strokes O
) O
, O
and O
the O
others O
were O
brushed O
after O
the O
following O
times O
: O
B O
, O
20 O
min O
; O
C O
, O
40 O
min O
; O
and O
D O
, O
60 O
min O
. O
[]

Randomized O
clinical O
trial O
of O
hydrocodone/acetaminophen O
versus O
codeine/acetaminophen O
in O
the O
treatment O
of O
acute O
extremity O
pain O
after O
emergency O
department O
discharge O
. O
[]

Patients O
given O
neoton O
in O
acute O
period O
of O
MI O
had O
no O
increase O
in O
the O
end B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
in O
the O
course O
of O
the O
first O
months O
after O
MI O
onset O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Bednet B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
among O
the O
560 O
households O
in O
the O
study O
, O
increased O
from O
6 O
to O
91 O
% O
after O
6 O
months O
. O
['Life-Impact']

Title: O
Music-instruction O
intervention O
for O
treatment O
of O
post-traumatic O
stress O
disorder: O
a O
randomized O
pilot O
study. O
[]

Only O
one O
patient O
( O
FEC O
( O
90 O
) O
) O
experienced O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
vomiting B-outcome ['Physiological-Clinical']
and O
throat B-outcome ['Physiological-Clinical']
oedema I-outcome ['Physiological-Clinical']
) O
. O
['Adverse-effects', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Eight O
hundred O
and O
three O
patients O
with O
representative O
pretreatment O
tissue O
samples O
from O
the O
randomized O
DAHANCA O
6 O
and O
7 O
study O
of O
5 O
vs. O
6 O
fx/wk O
of O
radiotherapy O
. O
[]

Journal-Name:Nigerian O
journal O
of O
clinical O
practice O
[]

Standardised O
photographs O
of O
each O
wart O
were O
taken O
before O
, O
during O
( O
week O
7 O
) O
and O
after O
treatment O
( O
weeks O
14 O
and O
18 O
) O
. O
[]

CIU O
patients O
with O
treatment O
failure O
under O
fexofenadine O
at O
180 O
mg O
q.d O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

[ O
Clinical O
study O
on O
retarding B-outcome ['Physiological-Clinical']
aging I-outcome ['Physiological-Clinical']
effect O
of O
tongbu O
recipe O
to O
traditional O
Chinese O
medicine O
] O
. O
['Physiological-Clinical']

The O
incidence O
of O
proximal O
deep-vein O
thrombosis O
as O
assessed O
by O
Doppler O
ultrasonography O
was O
23 O
% O
in O
the O
control O
group O
and O
0 O
% O
in O
those O
using O
the O
device O
( O
p O
less O
than O
0.01 O
) O
. O
[]

INTERPRETATION O
AND O
CONCLUSIONS O
Both O
schemes O
of O
chemotherapy O
followed O
by O
radiotherapy O
produce O
high O
percentages O
of O
CR B-outcome ['Physiological-Clinical']
, O
low O
risk O
of O
relapse B-outcome ['Physiological-Clinical']
and O
an O
['Physiological-Clinical', 'Physiological-Clinical']

Radiation-induced O
brachial O
plexopathy O
: O
neurological O
follow-up O
in O
161 O
recurrence-free O
breast O
cancer O
patients O
. O
[]

In O
part O
A O
of O
the O
trial, O
patients O
without O
recent O
porphyria O
attacks O
(i.e., O
no O
attacks O
in O
the O
6 O
months O
before O
baseline) O
were O
randomly O
assigned O
to O
receive O
a O
single O
subcutaneous O
injection O
of O
one O
of O
five O
ascending O
doses O
of O
givosiran O
(0.035, O
0.10, O
0.35, O
1.0, O
or O
2.5 O
mg O
per O
kilogram O
of O
body O
weight) O
or O
placebo. O
[]

PURPOSE O
Increased O
growth O
factor O
signaling O
may O
contribute O
to O
tamoxifen O
resistance O
. O
[]

CRP B-outcome ['Physiological-Clinical']
results O
followed O
a O
similar O
pattern O
but O
were O
delayed O
by O
1 O
day O
. O
['Physiological-Clinical']

that O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
is O
superior O
to O
HandiHaler O
in O
terms O
of O
time O
to O
first O
exacerbation O
. O
[]

These O
sponsorships O
provide O
visibility O
for O
Healthway O
and O
positive O
health O
messages O
. O
[]

Acute O
and O
short-term O
effects O
of O
secondhand O
smoke O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
cytokine B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
3.8 O
years O
of O
median O
follow-up O
, O
for O
the O
primary O
end O
point O
, O
recurrence-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
( O
RFS B-outcome ['Mortality']
) O
, O
risk O
was O
reduced O
by O
18 O
% O
( O
hazard O
rate O
= O
0.82 O
; O
P O
= O
.01 O
) O
in O
the O
PEG-IFN-alpha-2b O
arm O
compared O
with O
observation O
. O
['Physiological-Clinical', 'Mortality', 'Mortality']

Chemoradiotherapy O
with O
concurrent O
gemcitabine O
and O
cisplatin O
with O
or O
without O
sequential O
chemotherapy O
with O
gemcitabine/cisplatin O
vs O
chemoradiotherapy O
with O
concurrent O
5-fluorouracil O
in O
patients O
with O
locally O
advanced O
pancreatic O
cancer O
-- O
a O
multi-centre O
randomised O
phase O
II O
study O
. O
[]

Until O
data O
from O
such O
studies O
are O
available O
, O
women O
planning O
a O
pregnancy O
should O
continue O
to O
consume O
a O
daily O
folic O
acid O
supplement O
of O
400 O
microg O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Endoscopic O
ligation O
, O
a O
new O
form O
of O
endoscopic O
treatment O
for O
bleeding O
varices O
, O
has O
been O
shown O
to O
be O
superior O
to O
sclerotherapy O
in O
adult O
patients O
with O
cirrhosis O
. O
[]

PURPOSE O
Nasopharyngeal O
carcinoma O
( O
NPC O
) O
is O
a O
radiosensitive O
and O
chemosensitive O
tumor O
. O
[]

Consecutive O
post-menopausal O
women O
aged O
50 O
years O
to O
86 O
years O
starting O
treatment O
with O
raloxifene O
according O
to O
daily O
practice O
were O
enrolled O
from O
126 O
primary O
care O
offices O
in O
Spain O
. O
[]

No O
routine O
laboratory O
or O
physical O
findings O
reliably O
predicted O
the O
development O
of O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
except O
petechial B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
, O
which O
occurred O
only O
in O
5 O
placebo-treated O
patients O
who O
developed O
the O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Alfentanil O
was O
used O
as O
a O
comparator O
drug O
. O
[]

We O
performed O
cardiac O
magnetic O
resonance O
imaging O
and O
echocardiography O
and O
measured O
the O
ECV B-outcome ['Physiological-Clinical']
in O
42 O
patients O
treated O
with O
anthracyclines O
. O
['Physiological-Clinical']

The O
remission B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
improvisational O
music O
therapy O
on O
joint O
attention O
behaviors O
in O
pre-school O
children O
with O
autism O
. O
[]

The O
measurements O
were O
comparative O
study O
of O
the O
number O
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
using O
3 O
various O
dosages O
of O
intravenous O
gammaglobulins O
, O
each O
given O
monthly O
for O
M O
least O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
288 O
events O
in O
which O
the O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
exceeded O
a O
predetermined O
trigger O
value O
were O
observed O
. O
['Physiological-Clinical']

Comparison O
of O
the O
effectiveness O
of O
oral O
diazepam O
and O
midazolam O
for O
the O
sedation B-outcome ['Physiological-Clinical']
of O
autistic O
patients O
during O
dental O
treatment O
. O
['Physiological-Clinical']

The O
exon O
12 O
genotype O
was O
not O
associated O
with O
sex O
or O
age O
. O
[]

These O
values O
were O
reversed O
when O
compared O
with O
Groups O
1 O
and O
2 O
when O
sodium O
ascorbate O
was O
used O
. O
[]

Chronic O
RAO O
occurred O
in O
3.2 O
% O
, O
( O
n O
= O
8 O
) O
of O
the O
intravenous O
group O
compared O
to O
4 O
% O
( O
n O
= O
10 O
) O
of O
the O
intra-arterial O
group O
. O
[]

CONCLUSIONS O
In O
this O
study O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
aripiprazole O
and O
placebo O
in O
time O
to O
relapse O
during O
maintenance O
therapy O
. O
[]

RESULTS O
For O
the O
204 O
patients O
evaluable O
for O
response O
assessment O
, O
the O
response O
rates O
were O
48.6 O
% O
for O
GP1 O
, O
52.2 O
% O
for O
GP2 O
, O
and O
52.3 O
% O
for O
GD O
. O
[]

There O
were O
no O
significant O
changes O
in O
the O
control O
group O
. O
[]

There O
was O
no O
difference O
in O
survival B-outcome ['Mortality']
, O
cause-specific B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
pattern O
of O
relapse B-outcome ['Physiological-Clinical']
between O
both O
groups O
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

BACKGROUND O
A O
recently O
identified O
germline O
mutation O
G84E O
in O
HOXB13 O
was O
shown O
to O
increase O
the O
risk O
of O
prostate O
cancer O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
incidence O
of O
first-dose O
hypotension O
with O
quinapril O
in O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

Previous O
studies O
of O
home-based O
pulmonary O
rehabilitation O
in O
COPD O
have O
demonstrated O
improvement O
in O
exercise O
capacity O
and O
quality O
of O
life O
, O
but O
not O
all O
elements O
of O
the O
program O
were O
conducted O
in O
the O
home O
environment O
. O
[]

The O
stratum O
corneum O
was O
painlessly O
ablated O
with O
a O
low-fluence O
Er O
: O
YAG O
laser O
on O
half O
of O
the O
face O
, O
then O
the O
whole O
face O
was O
covered O
with O
ELA-Max O
cream O
for O
60 O
minutes O
. O
[]

Previous O
research O
supports O
that O
children O
with O
autism O
show O
deficits O
in O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
, O
as O
well O
as O
deficits O
in O
its O
elementary O
components O
: O
abstraction B-outcome ['Life-Impact']
and O
cognitive B-outcome ['Life-Impact']
flexibility I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Effects O
of O
telmisartan O
and O
enalapril O
on O
renoprotection O
in O
patients O
with O
mild O
to O
moderate O
chronic O
kidney O
disease O
. O
[]

Effect O
of O
home-based O
nursing O
pulmonary O
rehabilitation O
on O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
: O
a O
randomised O
clinical O
trial O
. O
[]

Thirty-seven O
children O
between O
3 O
and O
11 O
years O
of O
age O
with O
a O
diagnosis O
of O
autism O
and/or O
pervasive O
developmental O
disorder O
were O
gender O
and O
age O
matched O
and O
randomly O
assigned O
to O
receive O
either O
placebo O
or O
dimethylglycine O
for O
4 O
weeks O
. O
[]

Efficacy O
of O
chlorhexidine O
gluconate O
use O
in O
the O
prevention O
of O
perirectal O
infections O
in O
patients O
with O
acute O
leukemia O
. O
[]

As O
a O
comparison O
control, O
26 O
advanced O
colorectal O
cancer O
patients O
with O
comparable O
clinical O
baseline O
characteristics O
including O
age, O
sex, O
Eastern O
Cooperative O
Oncology O
Group O
(ECOG) O
score, O
pathological O
type, O
carcinoembryonic O
antigen O
(CEA) O
level, O
tumor O
location, O
number O
and O
location(s) O
of O
metastasis, O
and O
previous O
chemotherapies O
were O
subject O
to O
observation. O
[]

The O
primary O
outcome O
measure O
was O
mycological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
the O
target O
toenail B-outcome ['Physiological-Clinical']
at O
18 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
two O
years O
, O
control O
heifers O
( O
n O
= O
46 O
) O
grazed O
pasture O
and O
received O
0.9 O
kg O
of O
SBM O
supplement/d O
; O
LS O
( O
n O
= O
46 O
) O
heifers O
were O
self-fed O
a O
distiller O
's O
grain O
and O
soybean O
hull-based O
diet O
in O
drylot O
; O
and O
HS O
heifers O
( O
n O
= O
46 O
) O
were O
limited-fed O
a O
corn-based O
diet O
in O
drylot O
. O
[]

LIMITATIONS O
The O
unblinded O
nature O
of O
the O
study O
, O
exclusion O
of O
patients O
with O
diabetes O
, O
and O
incomplete O
enrollment O
. O
[]

Eight-week O
treatment O
phases O
were O
completed O
for O
both O
a O
placebo O
and O
L-carnitine O
. O
[]

Subjects O
were O
treated O
with O
a O
capsule O
containing O
either O
centrally O
acting O
nicotine O
blocker O
, O
mecamylamine O
( O
10 O
mg O
) O
, O
or O
placebo O
. O
[]

However O
, O
among O
patients O
with O
serious O
comorbidities O
( O
Charlson O
score O
> O
4 O
) O
, O
[]

The O
secondary O
objective O
was O
to O
investigate O
the O
postinduction O
levels O
of O
serum O
neurohormones B-outcome ['Physiological-Clinical']
in O
an O
attempt O
to O
explain O
the O
mechanisms O
involved. O
[['Physiological-Clinical']]

Moreover O
, O
it O
suggests O
a O
close O
relationship O
between O
the O
ability O
of O
listeners O
to O
perform O
frequency O
discrimination O
of O
simple O
tones O
and O
spectral-shape O
discrimination O
of O
two-tone O
complexes O
. O
[]

The O
pharmacokinetics O
for O
NVP O
, O
RTV O
and O
d4T O
were O
similar O
to O
those O
of O
previously O
reported O
data O
. O
[]

METHODS O
In O
a O
double-blind O
fashion O
, O
40 O
patients O
( O
ASA O
physical O
status O
III-IV O
) O
scheduled O
for O
elective O
cardioversion O
were O
randomly O
assigned O
to O
receive O
either O
0.015 O
mg/kg O
midazolam O
or O
placebo O
90 O
s O
before O
the O
injection O
of O
0.3 O
mg/kg O
etomidate O
. O
[]

PURPOSE O
To O
study O
the O
efficacy O
of O
indirect O
diode O
laser O
photocoagulation O
and O
cryotherapy O
in O
prethreshold B-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prematurity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ROP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
The O
authors O
compared O
continuous O
epidural O
infusion O
( O
CEI O
) O
with O
continuous O
femoral O
nerve O
block O
( O
CFNB O
) O
regarding O
the O
postoperative B-outcome ['Physiological-Clinical']
analgesic I-outcome ['Physiological-Clinical']
efficacy O
, O
side O
effects O
, O
postoperative B-outcome ['Physiological-Clinical']
knee I-outcome ['Physiological-Clinical']
rehabilitation I-outcome ['Physiological-Clinical']
, O
and O
hospital B-outcome ['Resource-use']
length I-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( I-outcome ['Resource-use']
LOS I-outcome ['Resource-use']
) I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

CONCLUSIONS: O
These O
findings O
call O
into O
question O
the O
validity O
of O
the O
self-affirmation O
manipulation, O
which O
is O
purported O
to O
reduce O
defensive B-outcome ['Life-Impact']
reactions I-outcome ['Life-Impact']
to O
threatening O
warnings. O
[['Life-Impact']]

We O
conclude O
there O
is O
no O
difference O
between O
OG O
( O
using O
local O
anesthesia O
) O
and O
PEG O
with O
regard O
to O
morbidity B-outcome ['Physiological-Clinical']
, O
mortality B-outcome ['Mortality']
, O
or O
tube B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Mortality', 'Life-Impact']

Journal-Name:Einstein O
(Sao O
Paulo, O
Brazil) O
[]

OBJECTIVE O
The O
purpose O
of O
this O
prospective O
, O
randomized O
, O
double-blind O
study O
was O
to O
determine O
the O
effect O
of O
penicillin O
on O
pain O
in O
untreated O
teeth O
diagnosed O
with O
irreversible O
pulpitis O
. O
[]

IOPs B-outcome ['Physiological-Clinical']
were O
measured O
at O
3 O
, O
6 O
, O
9 O
, O
and O
24 O
hours O
postoperatively O
. O
['Physiological-Clinical']

Linagliptin O
exhibits O
non-linear O
pharmacokinetics O
( O
PK O
) O
due O
to O
saturable O
binding O
to O
plasma O
and O
tissue O
DPP-4 O
. O
[]

We O
provide O
evidence O
that O
low-dose O
CY O
not O
only O
depletes O
patients O
' O
Treg O
cells O
and O
enhances O
function O
of O
HPV-specific B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
NK B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
the O
periphery O
, O
but O
also O
ameliorates O
the O
immune B-outcome ['Physiological-Clinical']
milieu I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
, O
leading O
to O
the O
elimination O
of O
remnant O
viruses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Randomized O
trial O
of O
intensive O
early O
intervention O
for O
children O
with O
pervasive O
developmental O
disorder O
. O
[]

Standard O
PN O
does O
not O
improve O
antioxidant O
status O
compared O
with O
administration O
of O
micronutrients O
alone O
. O
[]

METHODS O
Thirty-five O
children O
with O
> O
or O
=40 O
% O
total O
body O
surface O
area O
burns O
were O
randomized O
to O
receive O
either O
placebo O
or O
oxandrolone O
( O
0.1 O
mg/kg O
by O
mouth O
twice O
daily O
) O
from O
postoperative O
day O
5 O
to O
1 O
year O
postburn O
. O
[]

Journal-Name:Zhonghua O
nei O
ke O
za O
zhi O
[]

Gastric O
biopsies O
were O
obtained O
at O
baseline O
, O
and O
at O
3 O
, O
6 O
, O
and O
12 O
years O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
consecutively O
collected O
for O
analysis O
of O
lymphocyte O
subpopulations O
using O
an O
indirect O
immunofluorescence O
( O
IF O
) O
method O
, O
and O
hepatitis O
B O
virus O
( O
HBV O
) O
DNA O
was O
quantified O
by O
a O
chemiluminescent O
, O
molecular-hybridization O
assay O
. O
['Physiological-Clinical']

Medication O
adherence B-outcome ['Life-Impact']
and O
occurrence O
of O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
( O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
readmission B-outcome ['Resource-use']
, O
emergency B-outcome ['Resource-use']
department I-outcome ['Resource-use']
visits I-outcome ['Resource-use']
, O
and O
death B-outcome ['Mortality']
) O
were O
assessed O
at O
the O
follow-up O
visit, O
30 O
days O
after O
discharge. O
[['Life-Impact'], ['Adverse-effects'], ['Adverse-effects'], ['Resource-use'], ['Resource-use'], ['Mortality']]

Noggin B-outcome ['Physiological-Clinical']
was O
measured, O
for O
the O
first O
time O
in O
thalassemia O
patients, O
at O
baseline O
and O
at O
12 O
months, O
using O
a O
recently O
developed O
high O
sensitivity O
fluorescent O
immunoassay. O
[['Physiological-Clinical']]

METHOD O
Patients O
were O
withdrawn O
from O
antidepressants O
and O
sedative/hypnotics O
, O
and O
then O
randomized O
to O
receive O
4.5 O
, O
6 O
, O
or O
9 O
g O
SXB O
or O
placebo O
nightly O
for O
8 O
weeks O
. O
[]

No O
significant O
differences O
between O
the O
two O
treatment O
groups O
were O
observed O
for O
the O
coagulation B-outcome ['Resource-use']
products I-outcome ['Resource-use']
prothrombin B-outcome ['Physiological-Clinical']
fragment O
1+2 O
or O
thrombin-antithrombin B-outcome ['Physiological-Clinical']
complex I-outcome ['Physiological-Clinical']
or O
for O
D-dimer B-outcome ['Physiological-Clinical']
, O
although O
there O
were O
significant O
decreases O
in O
the O
levels O
within O
the O
hormone O
replacement O
therapy O
group O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
A O
cohort O
of O
youth O
( O
N O
= O
162 O
, O
60 O
% O
male O
) O
treated O
during O
adolescence O
( O
mean O
age O
= O
16 O
years O
) O
was O
followed O
into O
young O
adulthood O
, O
a O
period O
associated O
with O
stabilization O
of O
alcohol O
use O
patterns O
and O
elevated O
risk O
for O
life O
problems O
secondary O
to O
both O
alcohol O
and O
drug O
use O
. O
[]

There O
was O
a O
statistically O
significant O
positive O
relationship O
found O
between O
the O
sensory B-outcome ['Physiological-Clinical']
impairment B-outcome ['Life-Impact']
score O
and O
the O
['Physiological-Clinical', 'Life-Impact']

One O
hundred O
and O
twenty O
four O
randomly O
selected O
patients O
with O
DBU O
were O
included O
in O
this O
prospective O
study O
. O
[]

Journal-Name:Zhonghua O
wei O
zhong O
bing O
ji O
jiu O
yi O
xue O
[]

Improvement O
in O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
was O
dramatic O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
urinary B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
was O
markedly O
higher O
and O
['Physiological-Clinical']

This O
may O
enhance O
the O
effects O
of O
endothelin O
, O
as O
these O
patients O
also O
had O
elevated O
endothelin O
levels O
. O
[]

Blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
and O
glucagon B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
rose O
post-operatively O
whether O
or O
not O
insulin O
was O
given O
, O
but O
the O
increment O
in O
insulin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
when O
insulin O
was O
given O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
CTnI B-outcome ['Physiological-Clinical']
level O
was O
statistically O
significantly O
lower O
in O
the O
IP O
group O
( O
p O
= O
0.043 O
) O
, O
and O
IP O
patients O
tended O
to O
have O
a O
smaller O
CK-MB B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
after O
surgery O
( O
not O
significant O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
two O
combined O
spinal O
epidural O
anaesthesia O
techniques O
: O
the O
needle-through-needle O
technique O
and O
the O
double O
segment O
technique O
in O
this O
respect O
. O
[]

bolus O
followed O
by O
continuous O
i.v O
. O
[]

F1+2 O
increased O
0.15 O
nmol/L O
after O
the O
combined O
vaccination O
; O
an O
increase O
in O
response O
to O
the O
influenza B-outcome ['Physiological-Clinical']
vaccination I-outcome ['Physiological-Clinical']
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

During O
recovery O
, O
4E-BP1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
increased O
in O
both O
experiments O
( O
P O
< O
0.01 O
) O
, O
and O
tended O
to O
be O
higher O
in O
the O
CHO+PRO O
test O
( O
P O
= O
0.08 O
) O
. O
['Physiological-Clinical']

Both O
regimens O
were O
started O
after O
surgery O
. O
[]

These O
results O
confirm O
that O
relative-direction O
judgments O
do O
not O
require O
information O
about O
eye O
position O
. O
[]

Thirty-two O
extracted O
mandibular O
first O
premolars O
were O
sectioned O
perpendicular O
to O
the O
long O
axis O
at O
a O
point O
1.0 O
mm O
occlusal O
to O
the O
buccal O
cementoenamel O
junction O
. O
[]

There O
was O
a O
main O
effect O
of O
stimulus O
temperature O
on O
pain O
ratings O
, O
but O
no O
main O
effect O
of O
condition O
( O
p O
= O
0.32 O
) O
, O
nor O
a O
condition O
x O
temperature O
interaction O
( O
p O
= O
0.31 O
) O
. O
[]

There O
was O
no O
significant O
difference O
in O
caries B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
the O
three O
groups O
. O
['Physiological-Clinical']

Timolol O
reduced O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
at O
both O
administration O
times O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2019/03/01 O
06:00 O
[medline] O
[]

METHODS O
The O
authors O
conducted O
a O
multicenter O
, O
prospective O
, O
randomized O
trial O
of O
the O
ALL-2 O
regimen O
compared O
with O
a O
standard O
4-drug O
induction O
( O
the O
L-20 O
regimen O
) O
. O
[]

The O
e-cigarette O
group O
reported O
greater O
declines O
in O
the O
incidence O
of O
cough B-outcome ['Physiological-Clinical']
and O
phlegm B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
from O
baseline O
to O
52 O
weeks O
than O
did O
the O
nicotine-replacement O
group O
(relative O
risk O
for O
cough, O
0.8; O
95% O
CI, O
0.6 O
to O
0.9; O
relative O
risk O
for O
phlegm, O
0.7; O
95% O
CI, O
0.6 O
to O
0.9). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
subjects O
( O
n O
= O
45 O
) O
were O
randomized O
into O
three O
groups O
without O
regard O
to O
age O
, O
sex O
, O
or O
race O
. O
[]

None O
of O
the O
children O
had O
[]

The O
absence O
of O
efficacy O
may O
relate O
to O
an O
effect O
of O
hyperglycaemia O
. O
[]

The O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
for O
those O
assigned O
to O
trimethoprim-sulfamethoxazole O
( O
P O
= O
0.017 O
) O
. O
['Physiological-Clinical']

Thirteen O
experienced O
male O
weightlifters O
taking O
high-protein O
diets O
and O
regular O
exercise O
took O
part O
in O
a O
double-blind O
crossover O
trial O
of O
methandienone O
10 O
or O
25 O
mg/day O
to O
seeif O
the O
drug O
improved O
athletic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

Translucency B-outcome ['Physiological-Clinical']
of O
zirconia O
copings O
was O
significantly O
lower O
( O
P=.001 O
) O
than O
that O
of O
the O
lithium O
disilicate O
glass-ceramic O
control O
. O
['Physiological-Clinical']

Risperidone O
elevates O
prolactin B-outcome ['Physiological-Clinical']
more O
than O
other O
atypical O
antipsychotic O
medications O
. O
['Physiological-Clinical']

A O
trend O
is O
developing O
for O
greater O
reduction O
of O
depressive B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
in O
the O
group O
treated O
with O
self-disclosure O
. O
['Life-Impact']

INTERVENTION O
All O
patients O
were O
surgically O
treated O
in O
the O
ENT O
Department O
, O
University O
of O
Siena O
Medical O
School O
. O
[]

Patients O
receiving O
BCT O
and O
50Gy O
whole O
breast O
irradiation O
were O
randomized O
to O
no O
boost O
and O
16Gy O
boost O
( O
N=5318 O
) O
. O
[]

CONCLUSION O
A O
quality O
improvement O
intervention O
that O
can O
be O
widely O
disseminated O
by O
using O
Internet-based O
information O
technology O
significantly O
improved O
the O
quality O
of O
ADHD O
care O
in O
community-based O
pediatric O
settings O
. O
[]

In O
order O
to O
evaluate O
any O
beneficial O
effect O
of O
such O
an O
administration O
, O
a O
group O
of O
patients O
with O
recurrent O
gastric O
cancer O
was O
studied O
. O
[]

Elevated B-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
predicted O
the O
need O
for O
insulin O
therapy O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
The O
study O
was O
a O
controlled O
clinical O
trial O
at O
two O
tertiary O
care O
centres O
of O
patients O
with O
SLE O
according O
to O
the O
ACR O
criteria O
, O
with O
incident O
( O
no O
more O
than O
15 O
days O
) O
onset O
of O
severe O
NP O
manifestations O
such O
as O
seizures O
, O
optic O
neuritis O
, O
peripheral O
or O
cranial O
neuropathy O
, O
coma O
, O
brainstem O
disease O
, O
or O
transverse O
myelitis O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
controlled O
, O
masked O
clinical O
trial O
for O
one O
year O
in O
southern O
India O
involving O
15,419 O
preschool-age O
children O
who O
received O
either O
8.7 O
mumol O
( O
8333 O
IU O
) O
of O
vitamin O
A O
and O
46 O
mumol O
( O
20 O
mg O
) O
of O
vitamin O
E O
( O
the O
treated O
group O
) O
or O
vitamin O
E O
alone O
( O
the O
control O
group O
) O
. O
[]

c O
) O
Pain B-outcome ['Physiological-Clinical']
in O
the O
two O
treatment O
groups O
. O
['Physiological-Clinical']

The O
diets O
did O
not O
differ O
in O
sodium O
content O
( O
approximately O
3 O
g/day O
) O
. O
[]

Data O
on O
oxygenation B-outcome ['Physiological-Clinical']
and O
ventilation B-outcome ['Physiological-Clinical']
were O
recorded O
at O
admission O
and O
at O
the O
start O
of O
weaning O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Hemodynamic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
were O
performed O
at O
established O
times O
during O
the O
infusion O
protocols O
. O
['Physiological-Clinical']

SETTING O
The O
studies O
were O
conducted O
at O
the O
Boston O
VA O
Healthcare O
System O
and O
the O
Boston O
University O
School O
of O
Medicine O
Medication O
Development O
Research O
Unit O
( O
MDRU O
) O
. O
[]

Repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
are O
a O
core O
symptom O
domain O
in O
autism O
that O
has O
been O
linked O
to O
alterations O
in O
the O
serotonin O
system O
. O
['Life-Impact']

This O
outcome O
was O
assessed O
by O
an O
independent O
data O
review O
committee O
from O
which O
the O
study O
allocations O
were O
masked O
. O
[]

The O
absolute O
bioavailability B-outcome ['Physiological-Clinical']
of O
the O
tablet O
product O
was O
82 O
% O
, O
which O
is O
in O
agreement O
with O
published O
data O
for O
other O
oral O
dosage O
forms O
of O
methylprednisolone O
. O
['Physiological-Clinical']

The O
skin O
sites O
were O
then O
treated O
epidermally O
with O
45 O
% O
alcohol/onion O
extract O
and O
45 O
% O
ethanol O
under O
occlusion O
. O
[]

Our O
results O
replicated O
Izuma B-outcome ['Physiological-Clinical']
et O
al O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
the O
PostureJac O
( O
SomatoCentric O
Systems O
, O
Inc. O
, O
Toronto O
, O
Ontario O
, O
Canada O
) O
, O
a O
posture O
support O
and O
exercise O
jacket O
, O
was O
effective O
in O
enhancing O
deep B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS: O
Once-monthly O
injections O
of O
givosiran O
in O
patients O
who O
had O
recurrent O
porphyria B-outcome ['Physiological-Clinical']
attacks O
resulted O
in O
mainly O
low-grade O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
reductions O
in O
induced O
ALAS1 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels, O
nearly O
normalized O
levels O
of O
the O
neurotoxic O
intermediates O
delta B-outcome ['Physiological-Clinical']
aminolevulinic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
porphobilinogen B-outcome ['Physiological-Clinical']
, O
and O
a O
lower O
attack B-outcome ['Physiological-Clinical']
rate O
than O
that O
observed O
with O
placebo. O
( O
[['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

PURPOSE O
The O
aim O
of O
this O
study O
was O
to O
compare O
recovery O
for O
oral O
surgery O
patients O
given O
a O
deep O
sedation O
regimen O
of O
midazolam O
, O
propofol O
, O
and O
remifentanil O
with O
a O
standard O
control O
of O
fentanyl O
in O
place O
of O
remifentanil O
. O
[]

Cardiovascular O
safety O
and O
gastrointestinal B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
etoricoxib O
vs O
diclofenac O
in O
a O
randomized O
controlled O
clinical O
trial O
( O
The O
MEDAL O
study O
) O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
DHA O
supplementation O
increased O
the O
DHA B-outcome ['Physiological-Clinical']
concentration O
in O
plasma B-outcome ['Physiological-Clinical']
by O
76 O
% O
( O
P O
< O
0.0001 O
) O
and O
the O
proportion O
in O
erythrocyte B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
by O
58 O
% O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
8 O
months O
of O
follow-up O
, O
there O
were O
statistically O
significant O
differences O
in O
favor O
of O
pharmaceutical O
care O
in O
the O
proportions O
of O
patients O
who O
achieved O
therapeutic O
goals O
for O
BP B-outcome ['Physiological-Clinical']
( O
52.5 O
% O
vs. O
43.0 O
% O
, O
P=0.017 O
) O
, O
TC B-outcome ['Physiological-Clinical']
( O
56.5 O
% O
vs. O
44.1 O
% O
, O
P=0.001 O
) O
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
( O
37.1 O
% O
vs. O
21.8 O
% O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

As O
predicted, O
across O
2 O
RCTs, O
Monitor O
+ O
Accept O
training O
increased O
positive B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
compared O
with O
both O
Monitor O
Only O
and O
control O
groups. O
[['Life-Impact']]

SETTING O
A O
specialized O
outpatient O
dermatology O
clinic O
within O
a O
state-funded O
hospital O
in O
Germany O
. O
[]

Studies O
performed O
on O
airway O
smooth O
muscle O
in O
vitro O
have O
indicated O
that O
salmeterol O
is O
a O
partial O
agonist O
on O
the O
beta2-receptor O
in O
comparison O
to O
formoterol O
. O
[]

The O
cumulative O
rate O
of O
HIV O
transmission O
at O
6 O
weeks O
was O
3?3 O
% O
( O
95 O
% O
CI O
1?9-5?6 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
5?0 O
% O
( O
3?3-7?7 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
, O
and O
at O
12 O
months O
was O
5?4 O
% O
( O
3?6-8?1 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
9?5 O
% O
( O
7?0-12?9 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
( O
p=0?029 O
) O
. O
[]

The O
single-item O
Uniscale O
, O
a O
global O
QOL B-outcome ['Life-Impact']
instrument O
, O
found O
comparable O
scores O
. O
['Life-Impact']

Self-reported O
ratings O
of O
the O
strength B-outcome ['Physiological-Clinical']
of O
the O
gum O
were O
significantly O
diminished O
by O
mecamylamine O
pretreatment O
. O
['Physiological-Clinical']

Thirty O
patients O
undergoing O
elective O
cholecystectomy O
were O
allocated O
randomly O
to O
receive O
an O
infusion O
of O
morphine O
or O
an O
infusion O
of O
placebo O
( O
control O
group O
) O
for O
24 O
hours O
. O
[]

Benefits O
of O
adding O
fluticasone O
propionate/salmeterol O
to O
tiotropium O
in O
moderate O
to O
severe O
COPD O
. O
[]

At O
week O
24 O
, O
the O
medication O
was O
gradually O
withdrawn O
to O
determine O
whether O
subjects O
in O
the O
combined O
treatment O
group O
could O
be O
managed O
on O
a O
lower O
dose O
or O
off O
medication O
without O
relapse O
. O
[]

Risk O
factors O
for O
smoking O
at O
both O
endpoints O
in O
the O
combined O
sample O
included O
treatment O
with O
tailored O
mailings O
, O
female O
gender O
, O
younger O
age O
, O
higher O
levels O
of O
tobacco O
dependence O
, O
shorter O
previous O
quit O
attempts O
, O
previous O
use O
of O
nicotine O
replacement O
therapy O
, O
and O
report O
of O
current O
depressive O
symptoms O
or O
lifetime O
depression O
. O
[]

OBJECTIVE O
To O
explore O
the O
efficacy O
of O
KGQG O
and O
its O
therapeutic O
mechanisms O
in O
chronic O
hepatitis O
B O
patients O
with O
liver O
fibrosis O
. O
[]

METHOD O
Each O
treatment O
was O
delivered O
to O
children O
for O
a O
maximum O
total O
of O
24 O
hr O
over O
a O
6-month O
period O
. O
[]

The O
glucose B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Resource-use']
area O
under O
the O
curve O
after O
the O
diabetes O
specific O
formula O
compared O
to O
the O
standard O
formula O
were O
significantly O
lower O
. O
['Physiological-Clinical', 'Resource-use']

Transoral O
robotic O
surgery O
( O
TORS O
) O
has O
emerged O
as O
a O
promising O
alternative O
treatment O
, O
with O
preliminary O
case O
series O
demonstrating O
encouraging O
oncologic O
, O
functional O
, O
and O
quality O
of O
life O
( O
QOL O
) O
outcomes O
. O
[]

Caregivers O
in O
control O
and O
counseling O
groups O
whose O
relatives O
entered O
a O
nursing O
home O
improved O
their O
psychosocial B-outcome ['Life-Impact']
adjustment I-outcome ['Life-Impact']
23 O
% O
on O
average O
whereas O
those O
continuing O
to O
live O
in O
the O
community O
decreased O
by O
8 O
% O
. O
['Life-Impact']

The O
drug O
combination O
and O
administration O
periods O
in O
the O
PPI O
group O
were O
LPZ O
30 O
mg O
, O
CAM O
400 O
mg O
, O
MTZ O
500 O
mg O
( O
LCM O
group O
) O
. O
[]

Cycles O
were O
repeated O
every O
3 O
weeks O
for O
four O
cycles O
. O
[]

We O
tested O
the O
efficacy O
, O
tolerability O
and O
pharmacokinetics O
of O
2 O
combination O
therapies O
containing O
an O
NRTI O
, O
protease O
inhibitors O
+/- O
a O
nonnucleoside O
reverse O
transcription O
inhibitor O
( O
NNRTI O
) O
. O
[]

The O
role O
of O
pre-operative O
short-term O
pulmonary O
rehabilitation O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
who O
undergo O
coronary O
artery O
bypass O
graft O
surgery O
has O
been O
assessed O
for O
the O
first O
time O
prospectively O
. O
[]

Blood O
samples O
were O
drawn O
before O
and O
every O
30 O
min O
up O
to O
180 O
min O
after O
the O
meals O
. O
[]

Acute O
and O
long-term O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
in O
children O
with O
autism O
. O
['Life-Impact']

The O
most O
successful B-outcome ['Physiological-Clinical']
method O
was O
to O
leave O
the O
laryngoscope O
in O
the O
mouth O
and O
rotate O
the O
tube O
to O
-90 O
degrees O
. O
['Physiological-Clinical']

NNRTI O
versus O
PI O
hazard O
ratios O
( O
HRs O
) O
for O
the O
composite O
endpoint O
, O
for O
AIDS B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
, O
for O
death B-outcome ['Mortality']
, O
and O
for O
virological B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
1.02 O
( O
95 O
% O
CI O
0.79-1.31 O
) O
, O
1.07 O
( O
0.80-1.41 O
) O
, O
0.95 O
( O
0.66-1.37 O
) O
, O
and O
0.66 O
( O
0.56-0.78 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Mortality', 'Mortality', 'Physiological-Clinical']

Relocating O
away O
from O
family O
and O
country O
for O
treatment, O
adjusting O
to O
life O
with O
a O
chronic O
condition O
and O
time O
lost O
to O
dialysis O
cause O
grief O
and O
sadness O
which O
have O
immense O
impact O
on O
quality O
of O
life O
and O
challenges O
treatment O
adherence. O
[]

CONCLUSION O
At O
12-year O
median O
follow-up O
, O
there O
still O
was O
no O
survival O
difference O
in O
those O
patients O
treated O
prophylactically O
to O
the O
pelvic O
nodes O
and O
prostatic O
bed O
vs. O
the O
prostatic O
bed O
alone O
. O
[]

Short-term O
aerobic O
exercise O
training O
in O
obese O
humans O
with O
type O
2 O
diabetes O
mellitus O
improves O
whole-body O
insulin O
sensitivity O
through O
gains O
in O
peripheral O
, O
not O
hepatic O
insulin O
sensitivity O
. O
[]

This O
study O
has O
2 O
parts O
. O
[]

METHODS O
We O
randomly O
assigned O
2079 O
men O
and O
women O
who O
were O
35 O
years O
of O
age O
or O
older O
and O
who O
had O
had O
one O
or O
more O
histologically O
confirmed O
colorectal O
adenomas O
removed O
within O
six O
months O
before O
randomization O
to O
one O
of O
two O
groups O
: O
an O
intervention O
group O
given O
intensive O
counseling O
and O
assigned O
to O
follow O
a O
diet O
that O
was O
low O
in O
fat O
( O
20 O
percent O
of O
total O
calories O
) O
and O
high O
in O
fiber O
( O
18 O
g O
of O
dietary O
fiber O
per O
1000 O
kcal O
) O
and O
fruits O
and O
vegetables O
( O
3.5 O
servings O
per O
1000 O
kcal O
) O
, O
and O
a O
control O
group O
given O
a O
standard O
brochure O
on O
healthy O
eating O
and O
assigned O
to O
follow O
their O
usual O
diet O
. O
[]

CONCLUSIONS O
Breast-milk O
contains O
significant O
numbers O
of O
bifidobacteria O
and O
the O
maternal O
allergic O
status O
further O
deranges O
the O
counts O
of O
bifidobacteria O
in O
breast-milk O
. O
[]

The O
results O
of O
a O
multicenter O
, O
randomized O
trial O
on O
the O
effect O
of O
intravenous O
administration O
of O
gamma O
globulin O
( O
IVGG O
) O
plus O
aspirin O
versus O
aspirin O
alone O
upon O
coronary O
aneurysm O
formation O
show O
a O
decrease O
in O
coronary B-outcome ['Physiological-Clinical']
aneurysm I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
from O
the O
usual O
20 O
% O
-30 O
% O
to O
3 O
% O
. O
['Physiological-Clinical']

Group O
cognitive O
behavior O
therapy O
for O
children O
with O
high-functioning O
autism O
spectrum O
disorders O
and O
anxiety O
: O
a O
randomized O
trial O
. O
[]

Three O
hundred O
adult O
patients O
were O
enrolled O
in O
this O
study O
. O
[]

MIP B-outcome ['Physiological-Clinical']
was O
the O
primary O
outcome O
. O
['Physiological-Clinical']

The O
effects O
of O
a O
specific O
warm-up O
have O
already O
been O
acknowledged O
in O
improving O
performance O
. O
[]

Most O
frequent O
grade O
3/4 O
adverse O
events O
were O
neutropenia O
( O
37 O
% O
) O
, O
fatigue O
( O
33 O
% O
) O
and O
hypertension O
( O
30 O
% O
) O
. O
[]

RESULTS O
Fifty-eight O
patients O
( O
72.5 O
% O
) O
were O
positive O
for O
hepatitis O
B O
surface O
antibody O
, O
and O
HBV O
DNA O
was O
undetectable O
in O
50 O
patients O
( O
62.5 O
% O
) O
. O
[]

Such O
embolic O
signals O
are O
common O
after O
carotid O
endarterectomy O
, O
and O
their O
frequency O
predicts O
risk O
of O
stroke O
recurrence O
. O
[]

CONCLUSION: O
The O
findings O
of O
this O
study O
showed O
that O
BZSF O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
may O
be O
not O
superior O
to O
the O
ceftriaxone O
alone O
for O
Chinese O
female O
patients O
with O
uncomplicated O
gonorrhea O
after O
10 O
days O
treatment. O
[]

Data O
from O
eligible O
nonrandomized O
patients O
were O
analyzed O
separately O
. O
[]

Time O
to O
fi O
rst O
PCA O
demand O
was O
longer O
, O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
values O
were O
lower O
and O
satisfaction O
scores O
were O
higher O
in O
group O
DB O
than O
in O
the O
other O
two O
groups O
( O
p O
< O
0.05 O
) O
. O
['Resource-use']

The O
incidence O
of O
side O
effects O
was O
low O
in O
our O
study O
. O
[]

Australian O
adults O
(N O
= O
1132) O
aged O
18-24 O
years O
were O
recruited O
via O
a O
national O
online O
panel. O
[]

The O
left O
ventricular O
mass O
index O
( O
LVMI O
) O
was O
calculated O
from O
two-dimensional O
M-mode O
echocardiography O
. O
[]

Plaque O
indices O
have O
largely O
been O
developed O
for O
buccal O
and O
lingual O
tooth O
surfaces O
. O
[]

METHODS O
Sixty-four O
participating O
schools O
were O
assigned O
to O
study O
and O
control O
groups O
using O
a O
stratified O
, O
blocked O
randomisation O
technique O
. O
[]

Echis O
carinatus O
is O
the O
most O
important O
cause O
of O
morbidity O
and O
mortality O
from O
snake O
bite O
in O
Nigeria O
and O
in O
many O
other O
parts O
of O
the O
world O
. O
[]

Patients O
with O
poor O
initial O
performance O
status O
or O
liver O
involvement O
had O
significantly O
lower O
response O
rates O
and O
reduced O
survival B-outcome ['Mortality']
. O
['Mortality']

DESIGN O
Prospective O
clinical O
trial O
. O
[]

14.7 O
% O
with O
and O
without O
music O
, O
respectively O
; O
p O
? O
[]

Laryngeal O
preservation O
with O
induction O
chemotherapy O
for O
hypopharyngeal O
squamous O
cell O
carcinoma O
: O
10-year O
results O
of O
EORTC O
trial O
24891 O
. O
[]

Stratification O
was O
made O
by O
gross O
motor O
function O
classification O
system O
levels O
, O
and O
allocation O
was O
concealed O
. O
[]

The O
findings O
thus O
support O
previous O
conclusions O
that O
early O
discharge O
from O
hospital O
after O
uncomplicated O
MI O
is O
not O
associated O
with O
greater O
risk O
for O
the O
patient O
than O
later O
discharge O
. O
[]

A O
prospective O
, O
randomized O
, O
controlled O
study O
on O
cefotiam O
. O
[]

CONCLUSIONS O
Esomeprazole O
, O
at O
daily O
doses O
of O
40 O
mg O
or O
20 O
mg O
, O
is O
effective O
and O
safe O
for O
the O
treatment O
of O
chronic B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
in O
patients O
without O
erosive O
oesophagitis O
. O
['Physiological-Clinical']

Unlike O
intracoronary O
brachytherapy O
, O
there O
was O
no O
evidence O
of O
negative O
edge O
effects O
, O
unhealed B-outcome ['Physiological-Clinical']
dissections I-outcome ['Physiological-Clinical']
, O
or I-outcome ['Physiological-Clinical']
late I-outcome ['Physiological-Clinical']
stent-vessel I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

METHODS O
186 O
patients O
received O
either O
indomethacin O
3 O
times O
daily O
, O
or O
rofecoxib O
twice O
, O
and O
1 O
placebo O
, O
daily O
for O
7 O
days O
. O
[]

Granisetron O
at O
both O
doses O
also O
was O
superior O
to O
the O
control O
for O
the O
prevention O
of O
nausea B-outcome ['Physiological-Clinical']
over O
the O
24-h O
study O
period O
( O
nausea B-outcome ['Physiological-Clinical']
visual O
analog O
scales O
at O
24-h O
postsurgery O
: O
49 O
mm O
, O
17 O
mm O
, O
and O
18 O
mm O
in O
the O
control O
, O
granisetron O
20 O
micrograms/kg O
, O
and O
granisetron O
40 O
micrograms/kg O
groups O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
To O
analyze O
to O
what O
extent O
the O
percentage O
of O
suspicious O
digital O
rectal O
examination O
( O
DRE O
) O
findings O
vary O
between O
examiners O
and O
to O
what O
extent O
the O
percentage O
of O
prostate O
cancers O
( O
PCs O
) O
detected O
in O
men O
with O
these O
suspicious O
findings O
varies O
between O
examiners O
. O
[]

RESULTS O
Groups O
were O
comparable O
at O
baseline O
in O
age O
, O
sex O
, O
tumor O
type O
, O
weight O
loss O
, O
and O
performance O
status O
. O
[]

Pheasant O
chicks O
( O
approximately O
1 O
day-old O
; O
n O
= O
160 O
) O
were O
randomly O
blocked O
by O
sex O
into O
four O
treatment O
groups O
and O
given O
their O
respective O
diets O
continuously O
for O
6 O
wk O
. O
[]

The O
mean O
operative B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
: O
63+/-7.6 O
, O
54+/-6.7 O
and O
75+/-8.4 O
min O
( O
TPL O
vs O
EPL O
P O
< O
0.001 O
; O
EPL O
vs O
LPL O
P O
< O
0.001 O
; O
TPL O
vs O
LPL O
P O
< O
0.001 O
) O
for O
TPL O
, O
EPL O
and O
LPL O
respectively O
. O
['Life-Impact']

In O
addition O
, O
the O
experimental O
group O
showed O
enhanced O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
anterior O
cingulate O
cortex O
, O
a O
region O
that O
mediates O
self-control O
, O
whereas O
the O
PMR O
group O
did O
not O
. O
['Physiological-Clinical']

Tamsulosin O
at O
both O
dosages O
was O
well O
tolerated B-outcome ['Life-Impact']
as O
maintenance O
therapy O
. O
['Life-Impact']

The O
purpose O
of O
the O
study O
described O
was O
to O
evaluate O
the O
effectiveness O
of O
a O
cognitive O
behavioural O
intervention O
for O
anger O
management O
with O
children O
diagnosed O
with O
Asperger O
syndrome O
. O
[]

Treatment O
did O
not O
improve O
liver O
blood O
tests O
nor O
histological O
appearances O
of O
the O
liver O
, O
but O
there O
was O
a O
trend O
towards O
reduction O
of O
serum B-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Erythropoietin B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
was O
approximately O
ten O
times O
greater O
for O
IV O
dosing O
than O
for O
subcutaneous O
dosing O
. O
['Physiological-Clinical']

BACKGROUND O
Combining O
maintenance O
medications O
with O
different O
mechanisms O
of O
action O
may O
improve O
outcomes O
in O
COPD O
. O
[]

Comparison O
of O
single- O
and O
dual-coil O
active O
pectoral O
defibrillation O
lead O
systems O
. O
[]

In O
group O
1 O
( O
risedronate O
plus O
calcium/vitamin O
D-treated O
patients O
) O
, O
serum O
levels O
of O
RANKL O
and O
IL-1beta O
significantly O
decreased O
and O
the O
level O
of O
osteoprotegerin B-outcome ['Physiological-Clinical']
significantly O
increased O
after O
three O
and O
6 O
months O
, O
but O
no O
significant O
difference O
was O
found O
in O
TNF-alpha B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
analyzed O
data O
from O
a O
completed O
clinical O
trial O
that O
randomized O
100 O
patients O
to O
12 O
weeks O
of O
tai O
chi O
classes O
or O
to O
time-matched O
education O
control O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
the O
prostacyclin O
analogue O
iloprost O
was O
studied O
during O
a O
2 O
week O
treatment O
and O
6 O
month O
follow-up O
period O
in O
103 O
patients O
with O
ischaemic O
ulcers O
who O
were O
randomised O
to O
receive O
active O
treatment O
or O
placebo O
. O
['Physiological-Clinical']

Patients O
were O
assessed O
objectively O
( O
employing O
National O
Prostate O
Cancer O
Project O
criteria O
) O
and O
subjectively O
( O
using O
a O
numerical O
scoring O
scheme O
) O
. O
[]

At O
week O
8 O
compared O
with O
week O
4 O
, O
the O
concentration O
of O
P B-outcome ['Physiological-Clinical']
increased O
from O
5.7+/-1.4 O
to O
6.4+/-1.7 O
mg/dL O
in O
group O
A O
, O
and O
decreased O
significantly O
in O
groups O
B O
and O
C O
, O
and O
in O
group O
B O
compared O
with O
groups O
A O
and O
C O
; O
groups O
A O
and O
C O
had O
similar O
concentrations O
at O
week O
8 O
. O
['Physiological-Clinical']

Three O
groups O
of O
subjects O
were O
tested O
: O
i O
) O
a O
group O
of O
40-55-year-old O
subjects O
( O
AGE O
group O
; O
N O
= O
11 O
) O
who O
were O
tested O
in O
the O
morning O
, O
ii O
) O
a O
group O
of O
21-35-year-old O
subjects O
( O
CTL O
group O
; O
N O
= O
12 O
) O
who O
were O
also O
tested O
in O
the O
morning O
, O
and O
iii O
) O
a O
group O
of O
21-35-year-olds O
who O
were O
tested O
in O
the O
late O
afternoon O
( O
AFT O
group O
; O
N O
= O
13 O
) O
. O
[]

Furthermore, O
there O
were O
no O
statistically O
significant O
differences O
between O
all O
measured O
variables O
for O
the O
EG O
and O
the O
CG O
at O
the O
final O
assessment. O
[]

The O
effect O
assessed O
at O
the O
end O
of O
supplementation O
showed O
that O
the O
intervention O
was O
beneficial O
. O
[]

PATIENTS O
AND O
DESIGN O
In O
a O
double-blinded O
setup O
, O
90 O
patients O
( O
78 O
women O
; O
median O
age O
, O
52 O
yr O
; O
range O
, O
22-83 O
) O
with O
a O
nontoxic O
nodular O
goiter O
( O
median O
size O
, O
63 O
ml O
; O
range O
, O
25-379 O
ml O
) O
were O
randomized O
to O
either O
0.1 O
mg O
rhTSH O
( O
n=60 O
) O
followed O
by O
a O
thyroid O
dose O
of O
50 O
Gy O
or O
placebo O
followed O
by O
100 O
Gy O
( O
n=30 O
) O
. O
[]

Fourteen O
patients O
( O
4.7 O
% O
) O
temporarily O
discontinued O
prasugrel O
( O
average O
6.5 O
days O
) O
mainly O
because O
of O
surgical O
procedures O
. O
[]

Rates O
of O
infection B-outcome ['Physiological-Clinical']
, O
dehiscence B-outcome ['Physiological-Clinical']
, O
and O
other O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
did O
not O
significantly O
differ O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

FINDINGS O
107 O
patients O
were O
included O
in O
the O
ITT O
population O
( O
ablation O
group O
, O
n=52 O
; O
control O
group O
, O
n=55 O
) O
. O
[]

INTERPRETATION O
ASI O
gave O
significant O
clinical O
benefit O
in O
surgically O
resected O
patients O
with O
stage O
II O
colon O
cancer O
. O
[]

With O
oral O
administration O
of O
the O
drug O
over O
a O
period O
of O
one O
week O
antiischemic B-outcome ['Physiological-Clinical']
effects O
could O
also O
be O
documented O
with O
Holter B-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
as O
well O
as O
during O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
were O
distinguished O
by O
the O
absence O
( O
group O
I O
) O
or O
presence O
( O
group O
II O
) O
of O
supplementation O
with O
0.25 O
mg O
of O
cetrorelix O
. O
[]

A O
comparative O
efficacy O
and O
safety O
study O
of O
clarithromycin O
, O
roxithromycin O
and O
erythromycin O
stearate O
in O
mild O
pneumonia O
. O
[]

Clinical O
outcomes O
measured O
included O
total O
energy O
intake O
and O
growth B-outcome ['Physiological-Clinical']
over O
the O
first O
six O
postnatal O
weeks O
, O
sepsis B-outcome ['Physiological-Clinical']
incidence I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
milk B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
, O
duration O
of O
respiratory B-outcome ['Resource-use']
support I-outcome ['Resource-use']
, O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
complication B-outcome ['Adverse-effects']
incidence O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Adverse-effects']

There O
was O
no O
difference O
in O
the O
incidence O
of O
pruritus B-outcome ['Physiological-Clinical']
between O
use O
of O
2 O
mg O
and O
4 O
mg O
morphine O
. O
['Physiological-Clinical']

Twenty-three O
patients O
in O
the O
control O
group O
were O
asked O
to O
perform O
self-shoulder O
stretching O
exercise O
. O
[]

Fourteen O
children O
( O
12 O
infantile O
autism O
full O
syndrome O
present O
, O
2 O
atypical O
pervasive O
developmental O
disorder O
) O
between O
5 O
and O
13 O
years O
of O
age O
participated O
in O
a O
double-blind O
placebo-controlled O
cross-over O
trial O
. O
[]

hemoglobin O
per O
gm O
. O
[]

RESULTS O
The O
questionnaire O
was O
returned O
by O
174 O
patients O
( O
83 O
% O
) O
. O
[]

There O
was O
a O
significant O
difference O
in O
the O
rates O
for O
successful B-outcome ['Life-Impact']
first-time I-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
in O
those O
patients O
with O
tube O
orientation O
of O
-90 O
degrees O
( O
with O
the O
bevel O
facing O
posteriorly O
) O
as O
compared O
with O
a O
tube O
orientation O
of O
0 O
degrees O
( O
the O
normal O
orientation O
with O
the O
bevel O
facing O
left O
) O
. O
['Life-Impact']

The O
Dong O
Nai O
Pediatric O
Center O
Typhoid O
Study O
Group O
. O
[]

This O
study O
was O
proposed O
to O
investigate O
the O
effect O
of O
donor-site O
bone O
loss O
on O
the O
strength O
of O
the O
radius O
under O
torsional O
( O
rotational O
) O
loading O
. O
[]

m(-2) O
and O
0.42 O
+/- O
0.40 O
degrees O
C, O
respectively, O
before O
exercise. O
[]

Telephone O
( O
n=14 O
) O
and O
videophone O
( O
n=14 O
) O
interactions O
were O
audio O
taped O
and O
analyzed O
using O
the O
Roter O
Interaction O
Analysis O
System O
. O
[]

Journal-Name:BMC O
infectious O
diseases O
[]

CONCLUSION: O
CART O
showed O
significant O
improvement O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
(HRV) I-outcome ['Physiological-Clinical']
parameters O
indicating O
vagal O
dominance O
in O
middle-aged O
hypertensive O
women. O
[['Physiological-Clinical']]

The O
duration O
of O
each O
level O
of O
embolic O
phenomena O
( O
zero O
, O
moderate O
, O
severe O
) O
was O
used O
to O
determine O
total O
embolic O
load O
with O
various O
steps O
( O
fracture O
manipulation O
, O
proximal O
portal O
opening O
, O
reaming O
, O
and O
nail O
passage O
) O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
whether O
cerivastatin O
, O
a O
newly O
developed O
, O
potent O
synthetic O
statin O
, O
affects O
proteinuria O
and O
urinary O
podocyte O
excretion O
in O
patients O
with O
chronic O
glomerulonephritis O
( O
CGN O
) O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
detect O
a O
difference O
in O
knowledge B-outcome ['Life-Impact']
gain O
between O
students O
receiving O
structured O
versus O
student-directed O
learning O
for O
the O
two-week O
Child O
Health O
outpatient O
module O
. O
['Life-Impact']

There O
is O
a O
need O
for O
culturally O
sensitive O
family O
treatments O
offered O
by O
nurses O
. O
[]

In O
children O
on O
lamotrigine O
, O
the O
drug O
was O
titrated O
upward O
over O
8 O
weeks O
to O
reach O
a O
mean O
maintenance O
dose O
of O
5.0 O
mg/kg O
per O
day O
. O
[]

The O
bone O
mass O
measurements O
of O
46 O
patients O
participating O
in O
a O
current O
trial O
of O
therapy O
for O
osteoporosis O
were O
reviewed O
. O
[]

UNLABELLED O
Growth O
hormone O
( O
GH O
) O
treatment O
in O
young O
adults O
with O
childhood-onset O
GH O
deficiency O
has O
beneficial O
effects O
on O
bone B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Physiological O
responses O
, O
such O
as O
water B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
surface B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Amantadine-sulfate O
has O
been O
used O
for O
several O
decades O
to O
treat O
acute O
influenza O
A O
, O
Parkinson O
's O
disease O
( O
PD O
) O
, O
and O
acute O
or O
chronic O
drug-induced O
dyskinesia O
. O
[]

One O
of O
the O
objectives O
of O
Childrens O
Cancer O
Study O
Group O
( O
CCSG O
) O
study O
141 O
( O
CCG-141 O
) O
was O
to O
determine O
the O
frequency O
of O
occult B-outcome ['Physiological-Clinical']
testicular I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
3 O
years O
of O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
DFS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
to O
retreat O
boys O
with O
occult O
TL O
to O
prolong O
their O
subsequent O
DFS O
. O
['Physiological-Clinical', 'Mortality']

The O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
benefits O
of O
treating O
the O
donor O
liver O
with O
Simvastatin O
compared O
with O
the O
standard O
transplant O
procedure. O
[]

The O
secondary O
objective O
is O
to O
determine O
equivalency O
of O
the O
effects O
of O
a O
calcium O
channel O
blocker O
( O
nisoldipine O
) O
and O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
enalapril O
) O
as O
a O
first-line O
antihypertensive O
agent O
in O
the O
prevention O
and/or O
progression O
of O
these O
diabetic O
vascular O
complications O
. O
[]

BACKGROUND O
The O
role O
of O
oximes O
for O
the O
treatment O
of O
organophosphorus O
pesticide O
poisoning O
has O
not O
been O
conclusively O
established O
. O
[]

Sequential O
alternate O
administration O
of O
tamoxifen O
and O
medroxyprogesterone O
acetate O
in O
advanced O
breast O
cancer O
: O
clinical-biological O
randomized O
study O
. O
[]

Time B-outcome ['Resource-use']
spent I-outcome ['Resource-use']
in I-outcome ['Resource-use']
the I-outcome ['Resource-use']
neonatal I-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
did O
not O
differ O
between O
groups O
. O
['Resource-use']

RESULTS O
Symptomatic O
tendons O
showed O
less O
pixels O
in O
echo-types O
I O
and O
II O
than O
asymptomatic O
tendons O
( O
51.5 O
% O
vs O
76.6 O
% O
, O
p O
< O
0.001 O
) O
, O
thus O
less O
three-dimensional O
stability O
of O
the O
echo B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Publication O
date: O
['2019/10/16 O
06:00' O
[]

In O
addition O
, O
melatonin O
enhanced O
the O
activation O
in O
the O
left B-outcome ['Physiological-Clinical']
parahippocampus I-outcome ['Physiological-Clinical']
in O
an O
autobiographic O
memory O
task O
. O
['Physiological-Clinical']

Esomeprazole O
resolves O
chronic B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
in O
patients O
without O
erosive O
oesophagitis O
. O
['Physiological-Clinical']

Seventy-five O
patients O
with O
an O
abdominal O
trauma O
index O
( O
ATI O
) O
greater O
than O
15 O
and O
less O
than O
40 O
were O
randomized O
at O
initial O
laparotomy O
to O
receive O
either O
TEN O
( O
Vivonex O
TEN O
) O
or O
TPN O
( O
Freamine O
HBC O
6.9 O
% O
and O
Trophamine O
6 O
% O
) O
; O
both O
regimens O
contained O
2.5 O
% O
fat O
, O
33 O
% O
branched O
chain O
amino O
acids O
, O
and O
had O
a O
calorie O
to O
nitrogen O
ratio O
of O
150:1 O
. O
[]

For O
14 O
days O
, O
patients O
recorded O
pain O
levels O
twice O
daily O
using O
a O
visual O
analogue O
scale O
. O
[]

A O
Bifidobacterium-predominant O
flora O
was O
formed O
at O
an O
average O
of O
2 O
weeks O
after O
birth O
in O
group O
A O
and O
at O
an O
average O
of O
4 O
weeks O
after O
birth O
in O
group O
B O
, O
while O
no O
Bifidobacterium O
was O
isolated O
in O
eight O
out O
of O
10 O
infants O
in O
group O
C O
during O
the O
observation O
period O
of O
7 O
weeks O
. O
[]

In O
a O
randomized O
double-blind O
crossover O
trial O
with O
sequential O
analysis O
, O
the O
effects O
of O
oral O
diuretics O
were O
compared O
with O
the O
effects O
of O
placebo O
on O
pulmonary O
mechanics O
in O
ten O
infants O
with O
bronchopulmonary O
dysplasia O
( O
BPD O
) O
. O
[]

Children O
receiving O
vitamin O
C O
had O
fewer O
throat B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
yielding O
beta-hemolytic B-outcome ['Physiological-Clinical']
streptococcus I-outcome ['Physiological-Clinical']
( O
six O
versus O
13 O
, O
P O
less O
than O
0.10 O
) O
, O
but O
no O
difference O
in O
overall O
complicated B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
rate O
( O
24 O
versus O
25 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
participants O
were O
weighed O
at O
the O
outset O
of O
the O
study O
, O
directly O
after O
treatment O
and O
at O
a O
6- O
, O
12- O
and O
18-month O
post-treatment O
follow-up O
without O
any O
booster O
treatment O
after O
the O
10-week O
program O
. O
[]

Journal-Name:Lancet O
(London, O
England) O
[]

RESULTS O
Neither O
captopril O
nor O
enalapril O
influenced O
EEG B-outcome ['Resource-use']
and O
cognitive B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
compared O
with O
placebo O
. O
['Resource-use', 'Life-Impact']

The O
pain B-outcome ['Physiological-Clinical']
score O
was O
lower O
two O
hours O
after O
surgery O
and O
on O
postoperative O
day O
1 O
in O
Group O
IT0.5 O
than O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

DESIGN O
Double-blind O
, O
randomized O
, O
controlled O
study O
. O
[]

Frequently O
, O
gastro-oesophageal O
symptoms O
are O
associated O
with O
these O
drugs O
. O
[]

RESULTS O
Overall O
, O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
> O
or O
= O
3 O
mm O
were O
observed O
in O
18 O
( O
6.0 O
% O
) O
of O
300 O
evaluable O
subjects O
in O
the O
risedronate O
group O
and O
36 O
( O
12.1 O
% O
) O
of O
297 O
in O
the O
alendronate O
group O
during O
treatment O
( O
p O
= O
0.013 O
) O
. O
['Physiological-Clinical']

This O
trial O
is O
registered O
with O
the O
Iranian O
Clinical O
Trials O
Registry O
( O
IRCT1138901151556N10 O
; O
www.irct.ir O
) O
. O
[]

BCG O
( O
RIVM O
) O
versus O
mitomycin O
intravesical O
therapy O
in O
superficial O
bladder O
cancer O
. O
[]

All O
summary O
scores O
and O
therapist B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
frequency O
['Life-Impact']

METHODS O
Eighteen O
subjects O
, O
six O
males O
and O
12 O
females O
, O
mean O
age O
: O
32.2 O
years O
, O
were O
evaluated O
. O
[]

Motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
was O
significantly O
more O
common O
( O
30 O
vs. O
0 O
% O
) O
and O
more O
intense O
with O
the O
0.2 O
% O
ropivacaine-4 O
microg O
fentanyl O
solution O
. O
['Physiological-Clinical']

UNLABELLED O
The O
school O
dental O
screening O
programme O
has O
been O
in O
existence O
from O
the O
beginning O
of O
the O
20th O
century O
yet O
its O
value O
in O
encouraging O
attendance O
among O
children O
with O
a O
dental O
health O
need O
is O
not O
fully O
established O
. O
[]

Major O
, O
minor O
, O
and O
minimal O
bleedings O
( O
Thrombolysis O
In O
Myocardial O
Infarction O
criteria O
) O
occurred O
in O
2.7 O
% O
, O
4.7 O
% O
, O
and O
15.1 O
% O
of O
enrolled O
patients O
. O
[]

A O
total O
of O
34 O
patients O
have O
been O
included O
( O
with O
glutamine O
: O
n O
= O
18 O
; O
without O
glutamine O
: O
n O
= O
16 O
) O
. O
[]

Journal O
ID: O
101213819 O
[]

In O
the O
late-pregnancy O
group O
, O
3-HIA B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
( O
P O
< O
0.002 O
) O
by O
7.1 O
+/- O
1.2 O
mmol/mol O
creatinine O
in O
the O
8 O
women O
who O
received O
biotin O
supplements O
, O
whereas O
3-HIA B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
increased O
by O
0.9 O
+/- O
1.8 O
mmol/mol O
creatinine O
in O
the O
8 O
women O
who O
received O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intensive O
induction O
chemotherapy O
for O
small O
cell O
anaplastic O
carcinoma O
of O
the O
lung O
. O
[]

Early-stage O
squamous O
cell O
carcinoma O
of O
the O
oropharynx O
: O
radiotherapy O
vs. O
trans-oral O
robotic O
surgery O
( O
ORATOR O
) O
-- O
study O
protocol O
for O
a O
randomized O
phase O
II O
trial O
. O
[]

Single-dose O
antibiotic O
prophylaxis O
proved O
to O
be O
useful O
in O
the O
prevention O
of O
serious B-outcome ['Physiological-Clinical']
infectious I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
after O
transurethral O
prostatectomy O
. O
['Physiological-Clinical']

In O
a O
subgroup O
( O
N O
= O
23 O
) O
, O
manual O
motor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
was O
tested O
with O
tasks O
of O
graded O
dexterous O
demand O
. O
['Life-Impact']

Multiple O
risk O
factor O
intervention O
reduces O
cardiovascular O
risk O
in O
hypertensive O
patients O
with O
echolucent O
plaques O
in O
the O
carotid O
artery O
. O
[]

A O
transient B-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
was O
observed O
despite O
unchanged O
levels O
of O
insulin B-outcome ['Resource-use']
after O
treatment O
with O
both O
compounds O
for O
3 O
months O
. O
['Physiological-Clinical', 'Resource-use']

Vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
its O
cellular O
receptor O
VEGFR-2 O
have O
been O
implicated O
as O
the O
main O
endothelial O
pathway O
required O
for O
tumor O
neovascularization O
. O
[]

Absence O
of O
central B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
in O
man O
of O
the O
benzodiazepine O
antagonist O
Ro O
15-1788 O
. O
['Physiological-Clinical']

Among O
groups O
A O
and O
B O
, O
there O
was O
no O
statistical O
difference O
in O
clinicopathological O
profiles O
. O
[]

We O
examined O
the O
prophylactic O
effect O
of O
granisetron O
on O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
120 O
female O
patients O
( O
ASA O
physical O
status O
I O
) O
undergoing O
gynecologic O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

's O
finding O
that O
autistic O
adults O
did O
not O
donate O
more O
to O
charity O
when O
observed O
. O
[]

The O
authors O
' O
objective O
was O
to O
document O
the O
dynamic O
changes O
in O
systolic O
function O
of O
both O
ventricles O
during O
acute O
HF O
and O
after O
a O
3-month O
follow-up O
period O
, O
and O
to O
identify O
factors O
associated O
with O
ventricular O
improvement O
. O
[]

Randomized O
, O
placebo-controlled O
, O
phase O
III O
trial O
of O
sunitinib O
plus O
prednisone O
versus O
prednisone O
alone O
in O
progressive O
, O
metastatic O
, O
castration-resistant O
prostate O
cancer O
. O
[]

CONCLUSIONS O
Conscious O
sedation O
with O
midazolam O
does O
not O
reduce O
the O
cardiac O
stress O
during O
UGIE O
. O
[]

The O
OSTAP O
group O
showed O
a O
statistically O
significant O
reduction O
at O
the O
postoperative O
24th O
hour O
tramadol B-outcome ['Resource-use']
consumption O
(mean O
difference O
22 O
mg, O
95% O
confidence O
interval O
-38.4 O
to O
-5.6 O
mL; O
P O
= O
.009). O
[['Resource-use']]

Title: O
Use O
of O
a O
robotic O
walking O
aid O
in O
rehabilitation O
to O
reduce O
fear B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
falling I-outcome ['Life-Impact']
is O
feasible B-outcome ['Life-Impact']
and O
acceptable B-outcome ['Life-Impact']
from O
the O
end O
user's O
perspective: O
A O
randomised O
comparative O
study. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Nevertheless O
not O
even O
a O
small O
difference O
could O
be O
demonstrated O
in O
the O
presence O
of O
the O
anti O
CD O
20 O
monoclonal O
antibody O
. O
[]

This O
study O
sought O
to O
evaluate O
bleeding B-outcome ['Physiological-Clinical']
rates O
and O
adherence O
to O
treatment O
in O
real-world O
patients O
treated O
with O
prasugrel O
. O
['Physiological-Clinical']

5 O
alpha-metabolism O
in O
finasteride-treated O
subjects O
and O
male O
pseudohermaphrodites O
with O
inherited O
5 O
alpha-reductase O
deficiency O
. O
[]

METHODS O
Participants O
were O
enrolled O
in O
a O
controlled O
, O
randomised O
clinical O
trial O
in O
Barcelona O
, O
Spain O
, O
from O
April O
2001 O
to O
April O
2005 O
. O
[]

METHODS O
Eighty O
patients O
suffering O
from O
pityriasis O
versicolor O
were O
randomly O
divided O
into O
two O
groups O
; O
one O
group O
were O
treated O
with O
2 O
% O
ketoconazole O
cream O
topically O
twice O
daily O
for O
2 O
weeks O
, O
adapalene O
gel O
was O
used O
for O
the O
other O
group O
in O
a O
similar O
fashion O
. O
[]

The O
secondary O
aim O
was O
to O
assess O
the O
non-inferiority O
of O
the O
reduction O
of O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of O
the O
short O
protocol O
versus O
the O
long O
protocol. O
[['Physiological-Clinical']]

METHODS O
This O
study O
was O
a O
prospective O
randomized O
clinical O
trial O
. O
[]

It O
was O
a O
randomized O
controlled O
study O
employing O
a O
single O
subject O
comparison O
design O
in O
two O
different O
conditions O
, O
improvisational O
music O
therapy O
and O
play O
sessions O
with O
toys O
, O
and O
using O
standardized O
tools O
and O
DVD O
analysis O
of O
sessions O
to O
evaluate O
behavioral O
changes O
in O
children O
with O
autism O
. O
[]

There O
were O
no O
differences O
in O
the O
healing B-outcome ['Physiological-Clinical']
rate O
of O
the O
duodenal O
ulcer O
after O
four O
weeks O
, O
86.7 O
% O
being O
achieved O
for O
both O
groups O
. O
['Physiological-Clinical']

DESIGN O
An O
observational O
substudy O
of O
an O
open-label O
randomized O
controlled O
trial O
of O
two O
alternative O
therapeutic O
regimens O
for O
MAC O
. O
[]

Successful O
treatment O
of O
depressed O
, O
distensible O
acne O
scars O
using O
autologous O
fibroblasts O
: O
a O
multi-site O
, O
prospective O
, O
double O
blind O
, O
placebo-controlled O
clinical O
trial O
. O
[]

Randomization O
was O
performed O
before O
LT O
. O
[]

TeachTown O
: O
Basics O
, O
a O
CAI O
program O
which O
also O
includes O
supplementary O
off-computer O
activities O
, O
was O
implemented O
over O
3 O
months O
for O
approximately O
20 O
minutes O
per O
day O
on O
the O
computer O
and O
20 O
minutes O
per O
day O
in O
supplementary O
TeachTown O
: O
Basics O
activities O
. O
[]

Isometric O
back O
extensor O
strength O
, O
spinal O
range O
of O
motion O
, O
and O
scores O
for O
quality O
of O
life O
were O
evaluated O
at O
baseline O
and O
4 O
months O
. O
[]

Patients O
received O
adjuvant O
treatment O
with O
MSL-109 O
, O
60 O
mg O
intravenously O
every O
2 O
weeks O
, O
or O
placebo O
. O
[]

Whereas O
rigid O
and O
Kinesio O
taping O
are O
recommended O
for O
preventing O
these O
injuries, O
high-level O
evidence O
from O
clinical O
trials O
is O
still O
needed. O
[]

After O
equilibration O
between O
the O
blood O
and O
effect-site O
for O
15 O
min O
, O
a O
verbal O
command O
to O
open O
their O
eyes O
was O
given O
two O
times O
to O
the O
patients O
. O
[]

The O
subjects O
were O
randomly O
assigned O
to O
the O
supplemented O
group O
(n O
= O
10), O
receiving O
150 O
mg O
of O
L-theanine O
extract O
for O
6 O
weeks, O
or O
to O
the O
placebo O
group O
(n O
= O
10). O
[]

The O
vaccine O
Zostavax O
has O
been O
shown O
to O
prevent O
herpes O
zoster O
( O
HZ O
) O
and O
postherpetic O
neuralgia O
and O
is O
recommended O
for O
individuals O
> O
or O
=60 O
years O
of O
age O
. O
[]

Music O
or O
guided O
imagery O
for O
women O
undergoing O
colposcopy O
: O
a O
randomized O
controlled O
study O
of O
effects O
on O
anxiety B-outcome ['Life-Impact']
, O
perceived B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Although O
psychosocial O
therapy O
has O
been O
shown O
to O
reduce O
mortality B-outcome ['Mortality']
after O
myocardial O
infarction O
, O
it O
is O
unknown O
whether O
the O
benefits O
of O
psychosocial O
therapy O
on O
mortality O
reduction O
extend O
to O
out-of-hospital O
sudden O
cardiac O
arrest O
, O
a O
main O
cause O
of O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Caffeine O
had O
only O
modest O
effects O
on O
nap B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
plasma O
IL-8 O
, O
TNF-? O
, O
CRP O
, O
lipase O
, O
LDH O
at O
14 O
days O
after O
intervention O
of O
nutrition O
in O
P+EN O
group O
were O
significantly O
lower O
than O
those O
in O
PN O
group O
and O
EN O
group O
( O
IL-8 O
: O
21.00 O
? O
[]

At O
the O
last O
assessment O
, O
41 O
% O
of O
the O
patients O
had O
recovered O
their O
previous O
autonomy O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
a O
whey-predominant O
, O
50 O
% O
medium O
chain O
triglyceride O
formula O
with O
relatively O
high O
concentrations O
of O
zinc O
and O
copper O
would O
promote O
the O
achievement O
of O
the O
in O
utero B-outcome ['Physiological-Clinical']
accretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
zinc I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
copper I-outcome ['Physiological-Clinical']
in O
the O
preterm O
infant O
. O
['Physiological-Clinical']

BACKGROUND O
Consumption O
of O
soluble O
dietary O
fibre O
is O
correlated O
with O
decreased O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
hence O
has O
beneficial O
effects O
on O
the O
metabolic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Biochemical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
tended O
to O
be O
a O
late O
event O
with O
a O
median O
time O
to O
occurrence O
of O
5 O
years. O
[['Physiological-Clinical']]

In O
terms O
of O
open O
infrarenal O
aneurysm O
repair O
, O
no O
randomized O
controlled O
trials O
exist O
to O
introduce O
and O
evaluate O
such O
patient O
care O
programs O
. O
[]

METHODS O
This O
multicenter O
, O
randomized O
, O
controlled O
clinical O
trial O
on O
PER O
will O
be O
conducted O
at O
three O
institutions O
in O
China O
. O
[]

METHODS O
Sixty-eight O
patients O
with O
peripheral O
obstructive O
arterial O
disease O
and O
intermittent O
claudication O
( O
Fontaine O
stage O
II O
) O
were O
randomly O
assigned O
into O
the O
treadmill O
training O
( O
repetitive O
intervals O
to O
onset O
of O
claudication O
pain O
, O
three O
times O
a O
week O
) O
or O
a O
control O
group O
( O
no O
change O
in O
physical O
activity O
) O
over O
3 O
months O
. O
[]

In O
this O
study O
, O
we O
evaluate O
the O
effect O
of O
milrinone O
on O
patients O
with O
ventricular O
dysfunction O
undergoing O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
. O
[]

Comparative O
study O
of O
the O
efficacy O
of O
eprinomectin O
versus O
ivermectin O
, O
and O
field B-outcome ['Physiological-Clinical']
efficacy O
of O
eprinomectin O
only O
, O
for O
the O
treatment O
of O
chorioptic O
mange O
in O
alpacas O
. O
['Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Before O
and O
10 O
minutes O
after O
administration O
of O
each O
desired O
end-expiratory O
anesthetic O
concentration O
, O
the O
following O
parameters O
were O
determined O
: O
hemodynamic B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

SUBJECTS/SETTING O
Data O
from O
13,277 O
postmenopausal O
women O
randomly O
assigned O
to O
the O
low-fat O
intervention O
arm O
of O
the O
Women O
's O
Health O
Initiative O
Dietary O
Modification O
Trial O
. O
[]

In O
addition O
, O
students O
who O
used O
TeachTown O
: O
Basics O
demonstrated O
significant O
progress B-outcome ['Physiological-Clinical']
overall I-outcome ['Physiological-Clinical']
in O
the O
['Physiological-Clinical']

This O
has O
implications O
for O
e-learning O
design O
in O
medicine O
and O
other O
disciplines O
. O
[]

Effects O
of O
oral O
brovincamine O
on O
visual O
field O
damage O
in O
patients O
with O
normal-tension O
glaucoma O
with O
low-normal O
intraocular O
pressure O
. O
[]

Prognostic O
significance O
of O
the O
dobutamine O
echocardiography O
test O
in O
idiopathic B-outcome ['Physiological-Clinical']
dilated I-outcome ['Physiological-Clinical']
cardiomyopathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Exercise O
for O
methamphetamine O
dependence O
: O
rationale O
, O
design O
, O
and O
methodology O
. O
[]

This O
suggests O
a O
role O
for O
the O
use O
of O
errors O
in O
surgical O
technical O
skill O
instruction O
. O
[]

IOP B-outcome ['Physiological-Clinical']
rises I-outcome ['Physiological-Clinical']
of O
> O
6 O
mm O
Hg O
were O
seen O
in O
7 O
% O
of O
patients O
( O
one O
of O
15 O
) O
in O
the O
combined O
treatment O
group O
, O
45 O
% O
( O
five O
of O
11 O
) O
of O
the O
acetylcholine O
group O
, O
and O
70 O
% O
( O
seven O
of O
10 O
) O
of O
the O
acetazolamide O
group O
. O
['Physiological-Clinical']

No O
difference O
in O
[]

Response O
to O
ezetimibe O
was O
generally O
consistent O
across O
all O
subgroups O
analyzed O
. O
[]

The O
results O
reveal O
variability O
in O
the O
prolactin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
the O
artificial O
pumping O
methods O
, O
with O
the O
greatest O
responses O
found O
with O
an O
electric O
pulsatile O
pump O
; O
these O
responses O
compare O
favorably O
with O
those O
of O
natural O
infant O
suckling O
. O
['Physiological-Clinical']

However O
, O
no O
significant O
changes O
in O
resting O
and O
exercise-induced O
mobilizations O
of O
various O
T-lymphocyte O
subsets O
and O
productions O
of O
cytokines O
and O
MPO O
occurred O
following O
the O
N-C O
, O
H-C O
, O
N-T O
, O
and O
H-RT O
interventions O
. O
[]

Sixteen O
subjects O
were O
deemed O
ineligible O
, O
and O
7 O
failed O
to O
attend O
or O
withdrew O
. O
[]

The O
OR O
Study O
intervention O
was O
delayed O
because O
of O
interruptions O
in O
finalizing O
the O
national O
CHW O
policy, O
two O
separate O
cholera O
epidemics, O
and O
the O
Ebola O
epidemic O
lasting O
more O
than O
2 O
years. O
[]

Participants O
allocated O
to O
the O
control O
group O
will O
receive O
arm O
therapy O
in O
accordance O
with O
usual O
care O
. O
[]

The O
primary O
endpoint O
was O
first B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
after O
transurethral O
resection O
. O
['Physiological-Clinical']

As O
for O
cyclophosphamide O
versus O
radiotherapy O
, O
the O
differences O
are O
to O
uncertain O
for O
any O
conclusion O
to O
be O
drawn O
. O
[]

In O
order O
to O
study O
the O
plasma O
levels O
of O
factor O
XaI O
and O
IIaI O
activity O
an O
enzymatically O
depolymerized O
low O
molecular O
weight O
heparin O
( O
LMW-heparin O
; O
Logiparin O
) O
was O
given O
s.c. O
in O
a O
dose O
of O
35 O
XaI O
mu/kg O
b.w O
. O
[]

Treatment O
acceptability B-outcome ['Life-Impact']
was O
high O
for O
both O
support O
persons O
and O
smokers O
. O
['Life-Impact']

RESULTS O
No O
significant O
improvement O
in O
objective O
outcome O
variables O
was O
observed O
in O
the O
population O
treated O
with O
ES O
compared O
with O
the O
population O
treated O
with O
KE O
( O
with O
29.2 O
% O
vs. O
36.4 O
% O
of O
the O
women O
showing O
objective O
improvement O
in O
measured O
urinary B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical']

The O
likelihood O
for O
cost-effectiveness, O
based O
on O
a O
willingness O
to O
pay O
50,000 O
USD O
per O
QALY, O
was O
0.77-1.00. O
[]

Group O
3 O
received O
propofol O
2 O
mg/kg O
i.v. O
, O
followed O
by O
propofol O
50 O
to O
160 O
micrograms/kg/min O
i.v O
. O
[]

The O
results O
did O
not O
show O
any O
significant O
differences O
among O
the O
groups O
regarding O
the O
main O
parameters O
like O
pH-value B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
different I-outcome ['Physiological-Clinical']
insufflation I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
etc O
. O
['Physiological-Clinical']

A O
total O
of O
37 O
patients O
(36%) O
in O
the O
hybrid-procedure O
group O
had O
a O
major O
intraoperative O
or O
postoperative O
complication B-outcome ['Adverse-effects']
, O
as O
compared O
with O
67 O
(64%) O
in O
the O
open-procedure O
group O
(odds O
ratio, O
0.31; O
95% O
confidence O
interval O
[CI], O
0.18 O
to O
0.55; O
P<0.001). O
[['Adverse-effects']]

Prostamol O
Uno O
( O
PU O
) O
efficacy O
and O
safety O
were O
studied O
in O
a O
multicenter O
, O
open-population O
, O
randomized O
and O
comparative O
trial O
. O
[]

Lithium O
and O
granulocytopenia O
during O
induction O
therapy O
of O
acute O
myelogenous O
leukemia O
. O
[]

The O
hazard O
ratio O
for O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
the O
addition O
of O
MTP O
was O
0.71 O
( O
95 O
% O
CI O
, O
0.52 O
to O
0.96 O
) O
. O
['Mortality']

Sham B-outcome ['Physiological-Clinical']
rTMS B-outcome ['Physiological-Clinical']
showed O
a O
trend O
for O
improvement O
over O
time O
on O
positive O
and O
negative O
subscales O
of O
PANSS O
and O
MADRS B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Until O
now O
no O
studies O
have O
been O
performed O
to O
investigate O
whether O
Nordic O
Walking O
has O
beneficial O
effects O
in O
relation O
to O
low O
back O
pain O
. O
[]

Mean O
changes O
tended O
toward O
faster O
transit O
times O
in O
the O
left O
colon O
and O
the O
rectum O
, O
although O
the O
differences O
were O
not O
statistically O
significant O
. O
[]

7 O
. O
[]

Bone B-outcome ['Physiological-Clinical']
levels O
were O
recorded O
on O
radiographs O
taken O
prior O
to O
the O
start O
of O
the O
study O
, O
and O
after O
6 O
months O
. O
['Physiological-Clinical']

CONCLUSION O
Cyclosporin O
bioavailability O
was O
not O
clearly O
modified O
by O
a O
half O
dosage O
of O
ticlopidine O
in O
this O
study O
. O
[]

RESULTS O
Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
data O
were O
recorded O
for O
all O
the O
patients O
during O
the O
operation O
, O
and O
visual O
analogue O
scale O
( O
VAS O
) O
was O
used O
to O
assess O
the O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
at O
4 O
, O
8 O
, O
16 O
, O
24 O
, O
48 O
and O
72 O
h O
after O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
D53 O
immunostimulant O
in O
vivo O
primes O
AM O
to O
produce O
IL-1 B-outcome ['Physiological-Clinical']
following O
low B-outcome ['Physiological-Clinical']
LPS I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
stimulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Funded O
by O
the O
Health O
Research O
Council O
of O
New O
Zealand; O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
number, O
ACTRN12609000593235 O
.). O
[]

Obesity O
and O
mortality O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
: O
analysis O
of O
RTOG O
85-31 O
. O
[]

RESULTS: O
In O
PBMCs, O
LF O
decreased O
ICAM1 O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
(P O
< O
0.05), O
which O
was O
different O
(P O
= O
0.06, O
Bonferroni O
correction) O
from O
the O
observed O
increase O
in O
the O
FF O
group O
(P O
< O
0.05). O
[['Physiological-Clinical']]

Drug O
effects O
were O
evaluated O
on O
children O
's O
attention B-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
game I-outcome ['Life-Impact']
, O
as O
indicated O
by O
their O
on-task O
behavior O
on O
the O
field O
and O
their O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
answer I-outcome ['Life-Impact']
questions I-outcome ['Life-Impact']
about O
the O
status O
of O
the O
game O
at O
all O
times O
. O
['Life-Impact', 'Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Children O
on O
placebo O
did O
not O
show O
statistically O
significant O
changes O
. O
[]

CONCLUSIONS: O
Amongst O
patients O
undergoing O
surgical O
repair O
of O
open O
extremity O
fractures, O
high O
SPOC O
questionnaire O
scores O
at O
6 O
weeks O
post-surgery O
were O
predictive O
of O
persistent B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
reduced O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
and O
pain B-outcome ['Physiological-Clinical']
interference I-outcome ['Physiological-Clinical']
at O
1 O
yr. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
improved O
by O
20 O
% O
in O
patients O
using O
MF-DPI O
once-daily O
in O
the O
evening O
and O
by O
14 O
% O
in O
patients O
using O
MF-DPI O
twice-daily O
. O
['Life-Impact']

Patients O
were O
evaluated O
at O
study O
initiation O
( O
visit O
1 O
) O
and O
at O
end O
of O
treatment O
( O
visit O
2 O
) O
for O
the O
severity O
of O
five O
clinical O
signs O
: O
eyelid B-outcome ['Physiological-Clinical']
debris I-outcome ['Physiological-Clinical']
, O
eyelid B-outcome ['Physiological-Clinical']
redness I-outcome ['Physiological-Clinical']
, O
eyelid B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
, O
meibomian B-outcome ['Physiological-Clinical']
gland I-outcome ['Physiological-Clinical']
( O
MG B-outcome ['Physiological-Clinical']
) O
plugging B-outcome ['Physiological-Clinical']
, O
and O
the O
quality O
of O
MG B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:Clinical O
interventions O
in O
aging O
[]

Parameters O
were O
determined O
before O
the O
treatment O
, O
at O
the O
end O
of O
the O
eighth O
week O
course O
of O
treatment O
( O
week O
8 O
) O
, O
and O
eighth O
( O
week O
8 O
) O
after O
the O
end O
of O
treatment O
. O
[]

However O
, O
research O
has O
failed O
to O
consistently O
demonstrate O
faster O
discharge O
times O
from O
the O
postanesthesia O
care O
unit O
following O
the O
use O
of O
desflurane O
. O
[]

In O
Experiment O
1 O
, O
16 O
healthy O
volunteers O
rated O
the O
pain B-outcome ['Physiological-Clinical']
evoked O
by O
noxious O
heat O
stimuli O
( O
5 O
s O
duration O
; O
interstimulus O
interval O
25 O
s O
) O
of O
set O
temperatures O
( O
47? O
, O
48? O
and O
49?C O
) O
during O
the O
rubber O
hand O
illusion O
or O
during O
a O
control O
condition O
. O
['Physiological-Clinical']

A O
double-blind O
controlled O
study O
comparing O
the O
effects O
of O
bupropion O
to O
doxepin O
in O
outpatients O
with O
primary O
depression O
was O
conducted O
to O
evaluate O
efficacy O
and O
safety O
differences O
between O
the O
two O
drugs O
. O
[]

In O
part O
I O
the O
patients O
received O
omeprazole O
, O
80 O
mg O
+ O
8 O
mg/h O
, O
during O
24 O
h O
followed O
by O
8 O
, O
4 O
or O
2 O
mg/h O
. O
[]

Several O
reports O
indicate O
that O
children O
with O
ASD O
show O
reduced O
error O
processing B-outcome ['Life-Impact']
and O
deficient O
behavioral B-outcome ['Life-Impact']
correction I-outcome ['Life-Impact']
after O
an O
error O
is O
committed O
. O
['Life-Impact', 'Life-Impact']

Glutamine O
did O
not O
affect O
psychometric B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
TIPS O
patients O
with O
or O
without O
LOLA O
. O
['Life-Impact']

CSA B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
were O
predictable O
and O
manageable O
but O
required O
close O
monitoring O
. O
['Adverse-effects']

Plasma O
norepinephrine O
and O
mortality O
. O
[]

Forty-six O
patients O
with O
advanced O
gastric O
carcinoma O
( O
Stage O
IV O
) O
were O
evaluated O
in O
a O
prospective O
randomized O
comparison O
of O
two O
chemotherapy O
regimens O
( O
FAM O
versus O
5-FU O
plus O
BCNU O
) O
to O
identify O
therapeutic O
activity O
. O
[]

Theophylline B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
3-MX I-outcome ['Physiological-Clinical']
as O
well O
as O
to O
1-MU O
decreased O
with O
increasing O
dose O
but O
clearance O
to O
DMU O
remained O
unnaffected O
by O
the O
size O
of O
dose O
. O
['Physiological-Clinical']

Efficacy O
of O
treatment O
on O
clinical O
condition O
and O
some O
immune B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
IgA B-outcome ['Physiological-Clinical']
, O
IgG B-outcome ['Physiological-Clinical']
, O
CD3 B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
) O
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
a O
home-based O
programme O
provided O
over O
12 O
months O
resulted O
in O
sustained O
improvement O
in O
development B-outcome ['Life-Impact']
and O
behaviour B-outcome ['Life-Impact']
12 O
months O
after O
the O
intervention O
ceased O
. O
['Life-Impact', 'Life-Impact']

At O
24 O
h O
and O
7 O
d O
after O
irradiation O
with O
erythemogenic O
doses O
of O
UVB O
to O
the O
backs O
of O
16 O
Japanese O
subjects O
, O
the O
degree O
of O
induced B-outcome ['Physiological-Clinical']
erythema I-outcome ['Physiological-Clinical']
( O
delta O
erythema I-outcome ['Physiological-Clinical']
index O
) O
and O
that O
of O
pigmentation B-outcome ['Physiological-Clinical']
( O
delta O
melanin B-outcome ['Physiological-Clinical']
index O
) O
were O
examined O
by O
an O
image O
analytic O
method O
using O
a O
videomicroscope O
interfaced O
with O
a O
computer O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
A O
randomized O
, O
double-blind O
controlled O
trial O
. O
[]

This O
study O
was O
designed O
to O
investigate O
the O
influence O
of O
a O
lighter O
ball O
( O
Tachikara O
Volley O
Lite O
) O
on O
72 O
seventh-grade O
girls O
' O
tournament O
game O
play O
and O
pretest-to-posttest O
improvement O
for O
a O
16-day O
volleyball O
practice O
period O
. O
[]

These O
results O
suggest O
that O
latanoprost O
stored O
at O
30 O
degrees O
C O
for O
4 O
[]

The O
intervention O
was O
scheduled O
to O
occur O
early O
during O
the O
primary O
PCI O
procedure, O
after O
reperfusion O
of O
the O
infarct-related O
coronary O
artery O
and O
before O
stent O
implant. O
[]

Cholesterol-lowering O
therapy O
may O
retard O
the O
progression O
of O
diabetic O
nephropathy O
. O
[]

Iobitridol O
300 O
compared O
to O
iopromide O
300 O
-- O
a O
double-blind O
randomized O
phase-III O
study O
of O
clinical O
tolerance O
in O
total O
body O
CT. O
UNLABELLED O
PURPOSE O
, O
MATERIAL O
AND O
METHODS O
: O
The O
clinical O
safety O
of O
iobitriodol O
300 O
mg O
I/ml O
and O
iopromide O
300 O
mg O
I/ml O
were O
compared O
in O
a O
randomized O
double O
blind O
phase-III O
study O
conducted O
on O
60 O
patients O
undergoing O
abdominal O
CT O
for O
a O
variety O
of O
indications O
. O
[]

Recombinant O
murine O
GM-CSF O
administration O
to O
neonatal O
rats O
has O
resulted O
in O
neutrophilia O
, O
increased O
neutrophil O
production O
, O
and O
increased O
survival O
of O
pups O
during O
experimental O
Staphylococcus O
aureus O
sepsis O
. O
[]

Five O
of O
the O
11 O
neonates O
with O
gestational O
age O
( O
GA O
) O
< O
or O
= O
28 O
weeks O
and O
three O
of O
the O
seven O
neonates O
in O
GA O
29-30 O
weeks O
died B-outcome ['Mortality']
. O
['Mortality']

5.0 O
) O
, O
( O
50.2 O
? O
[]

BACKGROUND O
Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
accompanied O
by O
a O
number O
of O
adverse O
side O
effects O
including O
reduced O
bone O
mass O
and O
increased O
risk O
for O
fracture O
, O
reduced O
lean O
mass O
and O
muscle O
strength O
, O
mood O
disturbance O
and O
increased O
fat O
mass O
compromising O
physical O
functioning O
, O
independence O
, O
and O
quality O
of O
life O
. O
[]

The O
initial O
cognitive O
therapy O
produced O
a O
significant O
reduction O
in O
panic B-outcome ['Life-Impact']
frequency I-outcome ['Life-Impact']
, O
while O
associative O
therapy O
did O
not O
affect O
panic O
. O
['Life-Impact']

Changes O
of O
gastric B-outcome ['Physiological-Clinical']
drainage I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
therapeutic O
times O
and O
cured O
rate O
were O
investigated O
in O
the O
3 O
groups O
. O
['Physiological-Clinical']

In O
the O
control O
group O
, O
no O
instillation O
was O
performed O
before O
TUR O
. O
[]

OBJECTIVE O
We O
collected O
preliminary O
data O
on O
the O
safety O
and O
efficacy O
of O
supplemental O
arginine O
to O
improve O
natural O
killer O
cell O
cytotoxicity O
in O
a O
sample O
of O
persons O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
and O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
. O
[]

Videotaped O
training O
in O
alcohol O
counseling O
for O
obstetric O
care O
practitioners O
: O
a O
randomized O
controlled O
trial O
. O
[]

To O
date O
, O
most O
of O
these O
risk O
factors O
have O
not O
been O
confirmed O
in O
a O
UK O
population O
. O
[]

CONCLUSION O
Based O
on O
known O
minimum O
inhibitory O
concentration O
data O
, O
the O
uterine B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
moxifloxacin O
achieved O
over O
24 O
hours O
would O
be O
sufficient O
to O
eradicate O
the O
range O
of O
bacterial O
pathogens O
responsible O
for O
PID O
. O
['Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
in O
time O
to O
the O
development O
of O
progressive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
or O
survival B-outcome ['Mortality']
between O
the O
ER O
positive O
and O
ER O
unknown O
patients O
or O
between O
the O
tamoxifen O
and O
tamoxifen O
plus O
CMF O
groups O
. O
['Physiological-Clinical', 'Mortality']

The O
Km O
values O
for O
the O
N-demethylation O
pathways O
( O
3MX O
and O
1-MU O
) O
were O
lower O
corresponding O
to O
therapeutic O
serum O
concentrations O
of O
drug O
. O
[]

A O
double O
blind O
trial O
of O
terfenadine O
and O
placebo O
in O
hay O
fever O
using O
a O
substitution O
technique O
for O
non-responders O
. O
[]

An O
observational O
study O
. O
[]

CONCLUSION O
The O
preliminary O
results O
of O
this O
trial O
suggest O
that O
brachytherapy O
in O
addition O
to O
laser O
therapy O
prolongs O
the O
first O
therapeutic B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
control O
group O
consisted O
of O
40 O
specimens O
from O
normal O
gastric O
mucosa O
. O
[]

DESIGN O
A O
prospective O
, O
investigator-masked O
, O
randomized O
, O
controlled O
comparative O
study O
involving O
36 O
eyes O
of O
34 O
patients O
with O
functioning O
filtering O
blebs O
who O
were O
to O
undergo O
cataract O
surgery O
. O
[]

The O
intervention O
will O
be O
conducted O
by O
specially O
trained O
oncology O
nurses O
and O
includes O
components O
of O
patient O
education O
, O
skills O
training O
and O
counseling O
to O
improve O
self O
care O
regarding O
pain O
management O
beginning O
with O
admission O
followed O
by O
booster O
session O
every O
3rd O
day O
and O
one O
follow O
up O
telephone O
counseling O
within O
2 O
to O
3 O
days O
after O
discharge O
. O
[]

Funded O
by O
Johnson O
& O
Johnson O
and O
Bayer O
; O
ROCKET O
AF O
ClinicalTrials.gov O
number O
, O
NCT00403767 O
. O
) O
. O
[]

Substantial O
safety O
benefits O
were O
observed O
in O
patients O
treated O
with O
UFT/LV O
. O
[]

The O
main O
intervention O
strategies O
were O
: O
information O
about O
the O
risk O
factor O
concept O
to O
participant O
and O
spouse O
( O
in O
groups O
) O
individual O
diet O
and O
anti-smoking O
counselling O
after O
finishing O
an O
extensive O
clinical O
and O
electrocardiographic O
examination O
, O
including O
exercise-ECG O
basis O
and O
background O
for O
the O
counselling O
strategy O
: O
the O
total O
situation O
of O
the O
participant O
. O
[]

Journal O
ID: O
100968562 O
[]

DESIGN O
Randomised O
clinical O
trial O
. O
[]

Ca/Mg O
infusions O
did O
not O
affect O
the O
clinical O
efficacy O
of O
treatment O
. O
[]

Comparison O
of O
participants O
who O
remained O
on O
placebo O
continued O
beyond O
the O
run-in O
period O
to O
the O
end O
of O
the O
study O
. O
[]

These O
results O
overall O
suggested O
that O
Re-PUVA O
is O
the O
most O
effective O
treatment O
for O
PPP O
. O
[]

RESULTS O
Women O
in O
the O
educational O
book O
group O
had O
fewer O
risks O
in O
their O
homes O
and O
exercised O
more O
safety O
[]

The O
periprosthetic B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
was O
evaluated O
in O
5 O
ROIs O
positioned O
around O
the O
acetabular O
component O
. O
['Physiological-Clinical']

CONCLUSIONS O
Our O
findings O
suggest O
that O
dialysis O
with O
polyamide O
membranes O
with O
different O
flux O
characteristics O
did O
not O
modify O
the O
inflammatory O
indices O
and O
lipid O
profile O
in O
stable O
HD O
patients O
; O
however O
, O
a O
seemingly O
beneficial O
effect O
on O
aortic O
stiffness O
was O
noted O
for O
patients O
who O
were O
maintained O
on O
high-flux O
polyamide O
membrane O
. O
[]

In O
this O
study O
, O
we O
compared O
the O
effect O
of O
epidural O
analgesia O
and O
IV O
morphine O
patient-controlled O
analgesia O
( O
PCA O
) O
on O
pain O
relief O
, O
duration O
of O
hospitalization O
, O
oral O
nutrition O
, O
ambulation O
, O
and O
side O
effects O
in O
patients O
undergoing O
a O
major O
surgical O
procedure O
( O
i.e. O
, O
unilateral O
mastectomy O
with O
immediate O
transverse O
rectus O
abdominis O
musculocutaneous O
flap O
reconstruction O
) O
. O
[]

FINDINGS: O
Between O
Feb O
1, O
2014, O
and O
Aug O
31, O
2016, O
2772 O
couples O
were O
randomly O
assigned O
to O
receive O
PICSI O
(n=1387) O
or O
ICSI O
(n=1385), O
of O
whom O
2752 O
(1381 O
in O
the O
PICSI O
group O
and O
1371 O
in O
the O
ICSI O
group) O
were O
included O
in O
the O
primary O
analysis. O
[]

The O
results O
suggest O
that O
intravesical O
seeding O
of O
upper O
urinary O
tract O
urothelial O
carcinoma O
occurs O
during O
nephroureterectomy O
. O
[]

A O
subset O
of O
42 O
women O
at O
one O
site O
underwent O
colposcopy O
. O
[]

Journal-Name:Yonsei O
medical O
journal O
[]

There O
did O
appear O
to O
be O
a O
relative O
increase O
in O
mobilization B-outcome ['Life-Impact']
in O
the O
neighborhood O
with O
the O
highest O
level O
of O
intervention B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

One O
hundred O
patients O
were O
randomized O
to O
receive O
standard O
( O
CDA O
0.14 O
mg/kg/day O
day O
1-5 O
[ O
Arm O
A O
] O
) O
or O
experimental O
treatment O
( O
CDA O
0.14 O
mg/kg/day O
once O
weekly O
for O
5 O
weeks O
[ O
Arm O
B O
] O
) O
. O
[]

RESULTS O
Incidence O
of O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
was O
47.8 O
% O
in O
the O
7 O
Gy O
preoperative O
group O
( O
Brooker O
Score O
I O
: O
36.9 O
% O
; O
II O
: O
8.7 O
% O
; O
III O
: O
2.2 O
% O
; O
IV O
: O
0 O
% O
) O
and O
11.1 O
% O
in O
the O
NSAID O
group O
( O
Brooker O
Score O
I O
: O
9.3 O
% O
; O
II O
: O
1.8 O
% O
; O
III O
: O
0 O
% O
; O
IV O
: O
0 O
% O
) O
. O
['Physiological-Clinical']

The O
proportion O
of O
participants O
who O
took O
at O
least O
90 O
% O
of O
the O
prescribed O
study O
drug O
during O
the O
first O
4 O
weeks O
after O
hematopoietic O
cell O
transplantation O
was O
54 O
% O
overall O
. O
[]

[ O
Effect O
of O
Selaginella O
combined O
with O
radiotherapy O
on O
nasopharyngeal O
carcinoma O
] O
. O
[]

They O
reported O
a O
decrease O
in O
hyperactivity B-outcome ['Life-Impact']
and O
irritability B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Image O
noise O
was O
22.7 O
? O
[]

On O
the O
basis O
of O
these O
examinations O
, O
the O
authors O
identified O
64 O
women O
who O
had O
at O
least O
one O
ruptured O
implant O
at O
the O
first O
magnetic O
resonance O
imaging O
examination O
and O
, O
for O
comparison O
, O
all O
women O
who O
had O
intact O
implants O
at O
both O
examinations O
( O
n O
= O
98 O
) O
. O
[]

They O
assisted O
in O
the O
management O
of O
a O
simulated O
patient O
with O
septic O
shock O
. O
[]

Experiments O
2 O
and O
3 O
demonstrate O
that O
attitude B-outcome ['Life-Impact']
clarity I-outcome ['Life-Impact']
and O
attitude B-outcome ['Life-Impact']
correctness I-outcome ['Life-Impact']
can O
have O
distinct O
antecedents O
( O
repeated O
expression O
and O
consensus O
feedback O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

Levobunolol O
and O
timolol O
were O
equally O
effective O
in O
reducing O
overall O
mean O
IOP B-outcome ['Physiological-Clinical']
; O
reductions O
were O
greater O
than O
8.8 O
mmHg O
in O
all O
three O
treatment O
groups O
. O
['Physiological-Clinical']

METHODS O
Seventy-nine O
patients O
with O
acute O
exacerbated O
COPD O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
39 O
cases O
) O
and O
the O
control O
group O
( O
40 O
cases O
) O
. O
[]

BACKGROUND O
Neuropathic O
pain O
is O
a O
complex O
state O
of O
chronic O
pain O
that O
is O
usually O
accompanied O
by O
peripheral O
and O
central O
nervous O
system O
damage O
or O
dysfunction O
. O
[]

BACKGROUND O
Myocardial O
dysfunction O
needing O
inotropic O
support O
is O
a O
typical O
complication O
after O
on-pump O
cardiac O
surgery O
. O
[]

Addition O
of O
a O
thiazide O
diuretic O
will O
reduce O
pressure O
further O
. O
[]

OBJECTIVE O
Our O
purpose O
was O
to O
compare O
the O
effect O
of O
vaginal O
administration O
of O
misoprostol O
( O
Cytotec O
) O
with O
that O
of O
dinoprostone O
( O
Cervidil O
) O
on O
cervical B-outcome ['Physiological-Clinical']
ripening I-outcome ['Physiological-Clinical']
and O
labor B-outcome ['Physiological-Clinical']
induction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

2019; O
90(1):12-17. O
[]

OBJECTIVE O
To O
examine O
the O
adhesion B-outcome ['Physiological-Clinical']
prevention I-outcome ['Physiological-Clinical']
effects O
of O
2 O
types O
of O
fibrin O
sealant O
after O
laparoscopic O
myomectomy O
( O
LM O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Skills O
acquired O
using O
the O
AccuTouch O
simulator O
transfer O
well O
into O
the O
clinical O
colonoscopy O
environment O
. O
[]

Pacing O
converted O
2 O
of O
11 O
patients O
( O
18 O
% O
) O
who O
received O
placebo O
, O
13 O
of O
15 O
patients O
( O
87 O
% O
) O
who O
received O
ibutilide O
, O
and O
29 O
of O
33 O
patients O
( O
88 O
% O
) O
who O
received O
procainamide O
to O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
significant O
changes O
in O
lipids B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
were O
observed O
. O
['Physiological-Clinical']

Mass O
inoculation O
in O
a O
community O
: O
the O
effect O
of O
primary O
prevention O
of O
stress O
reactions B-outcome ['Life-Impact']
. O
['Life-Impact']

15 O
vs. O
126 O
? O
[]

For O
phase O
2 O
, O
all O
subjects O
were O
then O
treated O
with O
full O
orthodontic O
appliances O
. O
[]

1.7 O
mg O
; O
p O
= O
0.01 O
) O
than O
3-port O
laparoscopy O
. O
[]

Hence O
, O
previous O
trials O
on O
therapy O
with O
inhaled O
NO O
in O
ARDS O
should O
be O
carefully O
interpreted O
, O
as O
they O
used O
constant O
NO O
concentrations O
, O
which O
may O
have O
become O
overdoses O
leading O
to O
deterioration O
of O
oxygenation B-outcome ['Physiological-Clinical']
after O
several O
days O
. O
['Physiological-Clinical']

Orlistat O
can O
promote O
significant O
weight O
loss B-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
obese O
patients O
with O
heart O
failure O
, O
as O
measured O
by O
6-minute O
walk O
test O
and O
functional O
capacity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
experimental O
group O
had O
significant O
gains O
in O
knowledge B-outcome ['Life-Impact']
related I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
anatomy I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
physiology I-outcome ['Life-Impact']
, O
diet B-outcome ['Life-Impact']
, O
and O
lifestyle B-outcome ['Life-Impact']
risk O
factors O
associated O
with O
the O
development O
of O
heart B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

AIM O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
impact O
on O
pain O
and O
anxiety O
of O
the O
combination O
of O
an O
anxiolytic O
and O
an O
analgesic O
as O
compared O
with O
an O
analgesic O
alone O
in O
the O
prehospital O
setting O
of O
suspected O
ACS O
. O
[]

BACKGROUND O
It O
has O
been O
suggested O
that O
the O
use O
of O
adjunctive O
hyperbaric O
oxygen O
therapy O
improves O
the O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
, O
and O
decreases O
the O
risk O
of O
lower B-outcome ['Resource-use']
extremity I-outcome ['Resource-use']
amputations I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Journal-Name:Indian O
heart O
journal O
[]

Fifty-two O
patients O
with O
severe O
rheumatoid O
arthritis O
( O
RA O
) O
from O
four O
Australian O
centres O
were O
randomised O
to O
receive O
cyclosporin O
A O
( O
CSA O
) O
( O
n O
= O
25 O
) O
or O
azathioprine O
( O
AZA O
) O
( O
n O
= O
27 O
) O
for O
six O
months O
. O
[]

was O
given O
on O
all O
study O
days O
and O
each O
volunteer O
was O
randomised O
to O
receive O
45 O
min O
infusion O
of O
either O
5 O
% O
D-glucose O
( O
placebo O
) O
or O
ANF O
( O
99-126 O
) O
3 O
or O
15 O
pmol O
kg-1 O
min-1 O
. O
[]

OBJECTIVES O
To O
assess O
cervical B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
among O
underserved O
women O
participating O
in O
an O
intervention O
designed O
to O
increase O
mammography O
use O
. O
['Life-Impact']

Interactions O
between O
morphine O
and O
methotrimeprazine O
have O
been O
studied O
in O
mice O
and O
man O
with O
respect O
to O
analgesia B-outcome ['Resource-use']
or I-outcome ['Resource-use']
antinociceptive I-outcome ['Resource-use']
activity I-outcome ['Resource-use']
, O
respiratory B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
in O
the O
control O
group O
received O
no O
additional O
treatment O
. O
[]

OBJECTIVES O
To O
examine O
the O
relationships O
between O
changes O
from O
baseline O
to O
post-Resources O
for O
Enhancing O
Alzheimer O
's O
Caregiver O
Health O
( O
REACH O
) O
intervention O
in O
caregiver O
( O
CG O
) O
self-reported O
health O
, O
burden O
, O
and O
bother O
. O
[]

Average O
visual O
analog O
scale O
reading O
for O
GLX O
was O
4.6 O
, O
whereas O
that O
for O
PASCAL O
was O
0.33 O
. O
[]

CONCLUSIONS O
Left O
internal O
thoracic O
artery-radial O
artery O
composite O
grafts O
proved O
to O
be O
a O
safe O
procedure O
in O
elderly O
patients O
. O
[]

The O
primary O
endpoint O
was O
the O
number O
of O
patients O
with O
detectable B-outcome ['Physiological-Clinical']
DTCs I-outcome ['Physiological-Clinical']
at O
3 O
months O
. O
['Physiological-Clinical']

The O
presence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
mean O
of O
physiological O
parameters O
such O
as O
Hba1c B-outcome ['Physiological-Clinical']
, O
P-glucose B-outcome ['Physiological-Clinical']
, O
P-insulin B-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
physical B-outcome ['Physiological-Clinical']
working I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
body O
mass O
index O
, O
Heart B-outcome ['Physiological-Clinical']
Score O
were O
investigated O
and O
participants O
' O
satisfaction B-outcome ['Life-Impact']
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

We O
used O
this O
situation O
to O
determine O
the O
antiplatelet B-outcome ['Physiological-Clinical']
efficacy O
of O
L-arginine O
and O
S-nitrosoglutathione O
( O
GSNO O
) O
, O
a O
physiological O
nitric O
oxide O
donor O
with O
possible O
platelet O
specificity O
. O
['Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
outcomes O
within O
6 O
months O
were O
assessed O
. O
['Physiological-Clinical']

CONCLUSIONS O
Although O
probably O
not O
arrhythmogenic O
in O
normal O
subjects O
, O
moderate O
caffeine O
ingestion O
does O
produce O
a O
small O
but O
statistically O
significant O
prolongation O
of O
signal-averaged B-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Participants O
included O
112 O
families O
of O
a O
child O
who O
had O
Autism O
Spectrum O
Disorder O
who O
met O
criteria O
for O
being O
low-resourced O
and O
who O
were O
randomly O
assigned O
to O
1 O
of O
2 O
3-month O
interventions O
, O
group O
caregiver O
education O
or O
individualized O
caregiver-mediated O
intervention O
( O
CMM O
) O
. O
[]

RESULTS O
Remifentanil O
had O
prototypic O
micro-like O
opioid O
subjective O
effects O
, O
impaired B-outcome ['Life-Impact']
psychomotor I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
and O
produced O
['Life-Impact']

OBJECTIVE O
Obsessive-compulsive O
disorder O
is O
a O
common O
neuropsychiatric O
condition O
. O
[]

Wind-up O
to O
the O
2 O
Hz O
train O
increased O
in O
the O
UO B-outcome ['Physiological-Clinical']
( O
wind-up O
ratio O
1.4 O
( O
0.1 O
) O
to O
1.6 O
( O
0.1 O
) O
; O
p=0.03 O
) O
but O
not O
in O
the O
hand O
( O
wind-up O
ratio O
1.3 O
( O
0.1 O
) O
and O
1.3 O
( O
0.1 O
) O
; O
p=0.3 O
) O
CONCLUSION O
Enhanced O
wind-up O
after O
secondary O
oesophageal O
hyperalgesia O
suggests O
that O
visceral O
pain O
hypersensitivity O
induced O
by O
central O
sensitisation O
results O
from O
increased O
central O
neuronal O
excitability O
. O
['Physiological-Clinical']

In O
a O
randomized O
order O
, O
one O
test O
was O
performed O
with O
preinduced O
quadriceps O
fatigue O
and O
the O
other O
in O
a O
fresh O
state O
. O
[]

More O
than O
50 O
% O
of O
the O
wound B-outcome ['Physiological-Clinical']
area O
had O
closed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Three O
hundred O
twenty-five O
women O
with O
metastatic O
adenocarcinoma O
of O
the O
breast O
who O
had O
failed O
one O
prior O
chemotherapeutic O
regimen O
for O
advanced O
disease O
were O
randomized O
to O
receive O
14 O
mg/m2 O
of O
mitoxantrone O
or O
75 O
mg/m2 O
of O
doxorubicin O
intravenously O
( O
IV O
) O
every O
3 O
weeks O
. O
[]

Comparison O
was O
made O
against O
conventional O
insulin O
therapy O
using O
a O
randomized O
trial O
design O
. O
[]

Participants O
were O
interviewed O
at O
baseline O
, O
post-intervention O
and O
at O
6-month O
follow-up O
with O
a O
structured O
questionnaire O
including O
information O
on O
sociodemographics O
, O
sexual O
and O
drug-using O
behavior O
, O
and O
psychosocial O
characteristics O
. O
[]

Effects O
on O
tyrosine B-outcome ['Physiological-Clinical']
and O
phenylalanine B-outcome ['Physiological-Clinical']
in O
plasma O
and O
urine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Almost O
all O
of O
the O
456 O
participants O
( O
96 O
% O
) O
who O
were O
offered O
the O
opportunity O
of O
discussing O
their O
health O
with O
their O
general O
practitioner O
took O
up O
the O
offer O
; O
64 O
% O
of O
the O
456 O
participants O
reported O
that O
they O
had O
decided O
to O
undertake B-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
. O
['Life-Impact']

General O
anaesthesia O
for O
caesarean O
section O
in O
severe O
pre-eclampsia O
. O
[]

In O
self-assessments O
, O
95 O
% O
of O
patients O
( O
55/58 O
) O
reported O
improved O
angina B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
91 O
% O
( O
53/58 O
) O
felt O
their O
ability B-outcome ['Life-Impact']
to O
perform B-outcome ['Physiological-Clinical']
usual B-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
had O
improved O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

RESULTS O
Among O
the O
children O
who O
received O
amoxicillin-clavulanate O
, O
35 O
% O
had O
initial B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
by O
day O
2 O
, O
61 O
% O
by O
day O
4 O
, O
and O
80 O
% O
by O
day O
7 O
; O
among O
children O
who O
received O
placebo O
, O
28 O
% O
had O
initial O
resolution O
of O
symptoms O
by O
day O
2 O
, O
54 O
% O
by O
day O
4 O
, O
and O
74 O
% O
by O
day O
7 O
( O
P=0.14 O
for O
the O
overall O
comparison O
) O
. O
['Physiological-Clinical']

RESULTS O
MPH O
improved O
parent-rated B-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
of O
the O
preschoolers O
; O
50 O
% O
were O
rated O
as O
responders O
. O
['Life-Impact', 'Life-Impact']

[ O
Pleural O
tent O
after O
upper O
lobectomy O
-- O
randomized O
study O
of O
it O
's O
efficacy O
and O
duration O
of O
the O
effect O
] O
. O
[]

I O
. O
[]

The O
median O
follow-up O
was O
18 O
months O
. O
[]

The O
convergence O
of O
cervical O
and O
trigeminal O
afferents O
on O
second-order O
neurons O
in O
the O
trigeminocervical O
nucleus O
may O
refer O
pain O
from O
the O
upper O
cervical O
spine O
into O
the O
head O
and O
face O
. O
[]

RESULTS: O
A O
statistically O
significant O
difference O
was O
observed O
between O
the O
mean O
self-efficacy B-outcome ['Life-Impact']
indices O
in O
the O
experimental O
group O
(p=0.001). O
[['Life-Impact']]

We O
tested O
the O
efficacy O
of O
polydioxanone O
( O
PDS O
) O
suture O
in O
sternal B-outcome ['Physiological-Clinical']
closure I-outcome ['Physiological-Clinical']
and O
in O
prevention O
of O
complications B-outcome ['Adverse-effects']
in O
comparison O
to O
steel O
wires O
in O
high-risk O
individuals O
. O
['Physiological-Clinical', 'Adverse-effects']

This O
study O
evaluated O
a O
tailored O
intervention O
to O
promote O
sun O
protection O
in O
parents O
and O
their O
children O
, O
hypothesizing O
that O
the O
tailored O
intervention O
would O
lead O
to O
improved O
skin B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
prevention I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
compared O
to O
generic O
materials O
. O
['Life-Impact']

The O
lag O
time O
was O
significantly O
longer O
at O
01.00 O
hours O
than O
at O
13.00 O
hours O
( O
p O
less O
than O
0.01 O
) O
. O
[]

Secondary O
outcomes O
were O
the O
incidence O
of O
positive O
blood B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
, O
necrotising B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
( O
NEC B-outcome ['Physiological-Clinical']
) O
stage B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
or O
III B-outcome ['Physiological-Clinical']
, O
or O
death B-outcome ['Mortality']
, O
and O
the O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Resource-use']

Patients O
were O
randomly O
assigned O
to O
receive O
7, O
9, O
11, O
13 O
or O
15 O
mg O
intrathecal O
hyperbaric O
ropivacaine O
respectively. O
[]

All O
available O
baseline O
and O
6-month O
echocardiograms O
from O
Pediatric O
Carvedilol O
Trial O
( O
PCT O
) O
participants O
( O
carvedilol O
n O
= O
161 O
; O
placebo O
n O
= O
55 O
) O
were O
reviewed O
. O
[]

After O
PBSCT O
, O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
achieve I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ANC O
) O
of O
> O
0.5 O
x O
10 O
( O
9 O
) O
/L O
in O
the O
treatment O
group O
was O
less O
than O
that O
in O
the O
control O
group O
( O
median O
, O
11 O
v O
12 O
days O
; O
the O
log-rank O
test O
, O
P O
=.046 O
) O
, O
although O
the O
last O
day O
of O
red O
blood O
cell O
( O
RBC O
) O
transfusion O
( O
day O
11 O
v O
day O
10 O
) O
and O
the O
duration O
of O
febrile B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
( O
> O
38 O
degrees O
C O
) O
after O
PBSCT O
( O
4 O
v O
4 O
days O
) O
were O
identical O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
flexion O
group O
had O
the O
knee O
flexed O
to O
30? O
during O
this O
period O
. O
[]

The O
role O
of O
glucose-insulin-potassium O
( O
GIK O
) O
infusion O
in O
the O
management O
of O
acute B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
is O
not O
well O
established O
. O
['Physiological-Clinical']

MEASUREMENTS O
Following O
a O
2-week O
screening O
period O
, O
69 O
obese O
healthy O
adults O
received O
a O
hypocaloric O
diet O
and O
were O
randomized O
to O
diethylpropion O
50 O
mg O
BID O
( O
n=37 O
) O
or O
placebo O
( O
n=32 O
) O
for O
6 O
months O
. O
[]

Little O
change O
in O
eGFR B-outcome ['Physiological-Clinical']
occurred O
over O
1 O
year O
in O
the O
atorvastatin O
10-mg O
group O
, O
whereas O
eGFR O
improved O
in O
the O
80-mg O
group O
by O
1.48 O
ml/min/1.73 O
m O
( O
2 O
) O
( O
95 O
% O
confidence O
interval O
1.29 O
to O
1.67 O
, O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

At O
baseline O
, O
no O
difference O
was O
observed O
between O
the O
two O
groups O
. O
[]

Genital B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
in O
healthy O
women O
with O
and O
without O
sexual O
arousal O
disorder O
. O
['Physiological-Clinical']

METHODS O
In O
this O
single-center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
, O
two-arm O
study O
, O
40 O
patients O
with O
persistent O
AR O
were O
randomized O
to O
receive O
either O
montelukast O
and/or O
levocetirizine O
or O
placebo O
( O
n O
= O
20 O
) O
or O
to O
receive O
treatment O
with O
montelukast O
and/or O
desloratadine O
or O
placebo O
( O
n O
= O
20 O
) O
. O
[]

Sigmoidoscopy O
was O
performed O
4 O
wk O
after O
treatment O
to O
determine O
the O
adequacy O
of O
polyp O
eradication O
. O
[]

Heart O
rate O
variability O
characteristics O
in O
sedentary O
postmenopausal O
women O
following O
six O
months O
of O
exercise O
training O
: O
the O
DREW O
study O
. O
[]

Pretreatment O
and O
co-administration O
of O
oral O
anti-diabetic O
agent O
with O
clomiphene O
citrate O
or O
rFSH O
for O
ovulation O
induction O
in O
clomiphene-citrate-resistant O
polycystic O
ovary O
syndrome O
. O
[]

Functional B-outcome ['Life-Impact']
and O
neuropsychologic B-outcome ['Physiological-Clinical']
outcomes O
were O
assessed O
3 O
months O
postoperatively O
. O
['Life-Impact', 'Physiological-Clinical']

FMD B-outcome ['Physiological-Clinical']
remained O
unchanged O
in O
weight O
maintainers O
. O
['Physiological-Clinical']

The O
outcome O
measure O
was O
a O
mammogram B-outcome ['Resource-use']
received O
after O
the O
intervention O
period O
and O
within O
2 O
years O
of O
the O
initial O
mammogram O
date O
. O
['Resource-use']

Patients O
treated O
with O
ferric O
carboxymaltose O
compared O
to O
those O
prescribed O
ferrous O
sulfate O
reported O
greater O
gains O
in O
vitality B-outcome ['Physiological-Clinical']
and O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
and O
experienced O
greater O
improvement B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of O
fatigue B-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
was O
undertaken O
in O
a O
similar O
way O
to O
compare O
capsular O
contracture O
around O
smooth O
and O
textured O
saline-filled O
prostheses O
with O
pores O
of O
small O
size O
. O
[]

Participants O
attended O
their O
local O
practice O
and O
H. O
pylori O
status O
was O
determined O
by O
13C-urea O
breath O
test O
. O
[]

In O
comparison O
, O
a O
schedule O
of O
immunization O
on O
days O
0 O
, O
28 O
and O
56 O
ultimately O
evoked O
the O
highest O
titres O
21 O
days O
after O
the O
final O
injection O
, O
but O
antibody O
persisted O
equally O
well O
over O
two O
years O
with O
either O
schedule O
. O
[]

Students O
spent O
an O
average O
of O
59.1 O
minutes O
per O
week O
outdoors O
while O
attending O
school O
and O
35.5 O
minutes O
during O
peak O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
. O
['Life-Impact']

Brief O
high-impact O
exercise O
may O
have O
a O
role O
in O
reducing O
hip B-outcome ['Physiological-Clinical']
fragility I-outcome ['Physiological-Clinical']
, O
but O
may O
need O
to O
be O
performed O
frequently O
for O
optimal O
response O
. O
['Physiological-Clinical']

Recruitment O
was O
stopped O
after O
inclusion O
of O
19 O
and O
39 O
patients O
in O
monotherapy O
and O
combination O
arms O
respectively, O
as O
per O
pre-specified O
stopping O
rules. O
[]

RESULTS O
Both O
parameters O
were O
reduced O
in O
all O
five O
regimens O
as O
against O
the O
control O
. O
[]

The O
re-enrollment B-outcome ['Life-Impact']
rate O
was O
3.3 O
% O
for O
the O
control O
group O
and O
28.2 O
% O
for O
the O
intervention O
group O
( O
p O
< O
.001 O
) O
. O
['Life-Impact']

Participants O
in O
the O
experimental O
arm O
received O
the O
BCEI O
consisting O
of O
3 O
face-to-face O
education O
and O
support O
sessions O
and O
2 O
face-to-face O
and O
3 O
telephone O
follow-up O
sessions O
, O
along O
with O
supplemental O
written O
and O
audiotape O
materials O
over O
a O
6-month O
period O
. O
[]

First-generation O
trainees O
scored O
significantly O
higher O
than O
second-generation O
trainees O
on O
both O
skills B-outcome ['Life-Impact']
and O
knowledge B-outcome ['Life-Impact']
assessments I-outcome ['Life-Impact']
( O
p O
= O
0.003 O
) O
. O
['Life-Impact', 'Life-Impact']

In O
conclusion O
, O
recombinant O
human O
TSH O
administration O
is O
a O
safe O
and O
effective O
means O
of O
stimulating O
radioiodine O
uptake O
and O
serum O
Tg O
levels O
in O
patients O
undergoing O
evaluation O
for O
thyroid O
cancer O
persistence O
and O
recurrence O
. O
[]

Journal-Name:Journal O
of O
physiology O
and O
pharmacology O
: O
an O
official O
journal O
of O
the O
Polish O
Physiological O
Society O
[]

There O
were O
no O
significant O
differences O
between O
LDL B-outcome ['Physiological-Clinical']
from O
the O
beta-carotene O
and O
placebo O
groups O
, O
as O
assessed O
by O
measuring O
the O
lag O
time B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
conjugated I-outcome ['Physiological-Clinical']
dienes I-outcome ['Physiological-Clinical']
; O
the O
rate O
of O
formation B-outcome ['Physiological-Clinical']
and O
the O
amount O
of O
conjugated B-outcome ['Physiological-Clinical']
dienes I-outcome ['Physiological-Clinical']
formed I-outcome ['Physiological-Clinical']
; O
the O
amount O
of O
lipid B-outcome ['Physiological-Clinical']
peroxides I-outcome ['Physiological-Clinical']
generated I-outcome ['Physiological-Clinical']
; O
and O
the O
relative O
electrophoretic B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
, O
at O
baseline O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
We O
sought O
to O
determine O
the O
safety O
and O
preliminary O
efficacy O
of O
transcatheter O
intramyocardial O
administration O
of O
myoblasts O
in O
patients O
with O
heart O
failure O
( O
HF O
) O
. O
[]

RESULTS O
No O
differences O
in O
effects O
were O
detected O
in O
the O
between-group O
comparisons O
at O
any O
of O
the O
follow-up O
assessments O
. O
[]

There O
was O
no O
association O
of O
nutrient O
intake O
to O
changes O
in O
stool O
consistency O
. O
[]

INTERVENTIONS O
Mastectomy O
group O
received O
wedge O
mastectomy O
plus O
excision O
of O
symptomatic O
axillary O
lymph O
nodes O
. O
[]

Bepotastine O
besilate O
ophthalmic O
solution O
( O
BBOS O
) O
1.5 O
% O
, O
a O
dual-acting O
histamine O
( O
H O
( O
1 O
) O
) O
receptor O
antagonist O
and O
mast O
cell O
stabilizer O
, O
is O
indicated O
for O
itching O
associated O
with O
AC O
. O
[]

Assessment O
of O
airway O
responsiveness O
by O
bronchoprovocation O
and O
bronchodilatation O
tests O
is O
important O
in O
the O
diagnostic O
work-up O
protocol O
of O
bronchial O
asthma O
and O
it O
would O
be O
convenient O
to O
undertake O
both O
tests O
on O
the O
same O
occasion O
. O
[]

The O
degree O
of O
drug-induced O
neutropenia B-outcome ['Physiological-Clinical']
resulting O
from O
a O
controlled O
trial O
( O
UKALL O
I O
) O
of O
treatment O
in O
acute O
lymphoblastic O
leukaemia O
was O
analysed O
. O
['Physiological-Clinical']

It O
may O
be O
used O
as O
an O
alternative O
drug O
for O
fentanyl O
in O
pain O
control O
after O
orthopedic O
surgery. O
[]

In O
addition, O
they O
also O
underwent O
verum O
or O
sham O
TENS O
30 O
min O
daily, O
3 O
times O
weekly O
for O
4 O
weeks. O
[]

[ O
Effects O
of O
shuxuening O
injection O
on O
the O
levels O
of O
serum B-outcome ['Physiological-Clinical']
matrix I-outcome ['Physiological-Clinical']
metalloproteinase-9 I-outcome ['Physiological-Clinical']
and O
tissue B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metalloproteinase-1 I-outcome ['Physiological-Clinical']
in O
acute O
exacerbated O
chronic O
obstructive O
pulmonary O
disease O
patients O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
suggest O
the O
intervention O
improves O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
children O
with O
ASD O
. O
['Life-Impact']

On O
D14 O
, O
100 O
% O
of O
the O
subjects O
had O
protective B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
titers O
( O
anti-rabies O
antibodies O
> O
or O
= O
0.5 O
IU O
ml O
( O
-1 O
) O
, O
which O
is O
the O
WHO-recommended O
level O
of O
seroconversion O
) O
, O
and O
Erig O
PMC O
and O
PHT-Erig O
were O
indistinguishable O
according O
to O
the O
clinical O
definition O
chosen O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effects O
of O
presacral O
irrigation O
and O
simple O
drainage O
on O
the O
perineal O
wound O
healing O
in O
patients O
after O
abdominoperineal O
resection O
( O
APR O
) O
. O
[]

CONCLUSION O
This O
study O
will O
provide O
unique O
and O
comprehensive O
nutritional O
data O
and O
its O
results O
will O
guide O
nutritional O
therapy O
for O
children O
undergoing O
HSCT O
and O
possibly O
other O
catabolic O
patients O
. O
[]

Selection O
criteria O
were O
: O
infertility O
> O
1 O
year O
, O
subnormal O
semen O
, O
sonographic O
diameter O
of O
veins O
> O
3 O
mm O
and O
time O
of O
regurge O
> O
2 O
s. O
Patients O
were O
randomly O
assigned O
to O
the O
groups O
of O
treatment O
, O
with O
follow-up O
every O
3 O
months O
for O
1 O
year O
. O
[]

Tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
decreased O
significantly O
( O
p O
< O
0.01 O
) O
only O
in O
the O
metformin O
group O
, O
but O
this O
was O
not O
significantly O
different O
from O
the O
placebo O
group O
( O
p O
< O
0.12 O
) O
; O
further O
, O
there O
were O
no O
significant O
differences O
in O
the O
change O
in O
plasminogen O
activator O
inhibitor O
1 O
. O
['Physiological-Clinical']

Thus O
the O
potassium-retaining O
diuretic O
amiloride O
, O
like O
the O
aldosterone O
antagonist O
spironolactone O
, O
markedly O
reduces O
both O
the O
ulcer-healing B-outcome ['Physiological-Clinical']
and O
the O
metabolic B-outcome ['Physiological-Clinical']
side-effects I-outcome ['Physiological-Clinical']
of O
carbenoxolone O
sodium O
, O
and O
should O
not O
be O
used O
together O
with O
it O
in O
the O
treatment O
of O
peptic O
ulcer O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
sera O
were O
collected O
from O
a O
randomized O
sample O
of O
subjects O
in O
each O
vaccine O
group O
at O
approximately O
3-month O
intervals O
from O
which O
antibody O
kinetic O
curves O
were O
constructed O
, O
which O
allowed O
us O
to O
estimate O
specific O
antibody O
values O
to O
pertussis O
toxin O
( O
PT O
) O
, O
filamentous O
hemagglutinin O
( O
FHA O
) O
, O
pertactin O
and O
fimbriae-2 O
at O
the O
time O
of O
exposure O
in O
the O
household O
setting O
. O
[]

AIM O
The O
aim O
of O
study O
was O
test O
efficacy O
of O
accelerated O
postoperative O
radiotherapy O
-- O
concomitant O
boost O
in O
patients O
with O
advanced O
larynx O
cancer O
. O
[]

In O
subjects O
with O
impaired O
glucose O
tolerance O
a O
PUFA-rich O
diet O
with O
a O
moderate O
amount O
of O
fat O
tended O
to O
increase O
the O
susceptibility O
of O
[]

METHODS/DESIGN O
The O
RESPECT O
study O
is O
a O
nationwide O
population-based O
prospective O
, O
controlled O
, O
mixed-methods O
intervention O
study O
looking O
at O
children O
aged O
6-18 O
years O
newly O
diagnosed O
with O
cancer O
in O
eastern O
Denmark O
( O
n=120 O
) O
and O
a O
matched O
control O
group O
in O
western O
Denmark O
( O
n=120 O
) O
. O
[]

Most O
men O
randomised O
to O
conservative O
management O
were O
willing O
to O
undertake O
it O
as O
part O
of O
a O
trial O
but O
at O
the O
end O
of O
the O
trial O
they O
were O
divided O
between O
those O
who O
wanted O
to O
continue O
with O
it O
and O
those O
who O
expected O
surgery O
. O
[]

The O
median O
follow-up O
period O
was O
15 O
years O
. O
[]

Participants O
were O
randomly O
allocated O
to O
Study O
and O
Control O
groups O
. O
[]

METHODS O
Accordingly O
, O
we O
evaluated O
26,466 O
NSTE O
ACS O
patients O
from O
the O
Global O
Use O
of O
Strategies O
to O
Open O
Occluded O
Arteries O
in O
Acute O
Coronary O
Syndromes O
( O
GUSTO-IIb O
) O
, O
Platelet O
Glycoprotein O
IIb/IIIa O
in O
Unstable O
Angina O
: O
Receptor O
Suppression O
Using O
Integrilin O
Therapy O
( O
PURSUIT O
) O
, O
and O
Platelet O
IIb/IIIa O
Antagonism O
for O
the O
Reduction O
of O
Acute O
Coronary O
Syndrome O
Events O
in O
a O
Global O
Organization O
Network O
( O
PARAGON O
) O
A O
and O
B O
trials O
to O
ascertain O
the O
timing O
of O
adverse O
events O
. O
[]

The O
fall B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
tcPCO2 I-outcome ['Physiological-Clinical']
was O
predicted O
rather O
by O
the O
frequency O
of O
occurrence O
of O
anxiety-related B-outcome ['Life-Impact']
somatic I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
than O
by O
the O
fear O
of O
these O
symptoms O
. O
['Physiological-Clinical', 'Life-Impact']

Four O
healthy O
volunteers O
with O
significant O
erythema O
and O
telangiectasia O
on O
the O
face O
applied O
EGCG O
cream O
to O
one O
side O
of O
the O
face O
, O
and O
vehicle O
control O
cream O
to O
the O
other O
, O
twice O
daily O
for O
six O
weeks O
. O
[]

Patients O
were O
followed O
up O
for O
outcomes O
of O
death B-outcome ['Mortality']
, O
hepatocellular B-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
and O
hepatic B-outcome ['Physiological-Clinical']
decompensation I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

The O
sources O
of O
dietary B-outcome ['Life-Impact']
CP I-outcome ['Life-Impact']
were O
soybean O
meal O
( O
SBM O
) O
or O
SBM O
and O
urea O
( O
SBM-U O
) O
. O
['Life-Impact']

The O
study O
was O
placebo-controlled O
, O
randomized O
, O
and O
double-blinded O
. O
[]

One O
patient O
in O
each O
arm O
had O
fatal O
pneumonitis O
. O
[]

Protein O
ingestion O
further O
augments O
S6K1 O
phosphorylation O
in O
skeletal O
muscle O
following O
resistance O
type O
exercise O
in O
males O
. O
[]

Risperidone O
dosing O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Histological O
evaluation O
of O
human O
atherosclerosis O
showed O
minimal O
AP-1 O
activation O
in O
non-diseased O
arterial O
wall O
( O
i.e O
. O
[]

Rosiglitazone O
and O
cognitive O
function O
in O
clozapine-treated O
patients O
with O
schizophrenia O
: O
a O
pilot O
study O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
an O
intramammary O
infusion O
, O
containing O
tilmicosin O
phosphate O
, O
to O
an O
infusion O
of O
a O
negative O
control O
intramammary O
placebo O
for O
preventing O
new O
intramammary B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
IMI O
) O
during O
the O
dry O
period O
. O
['Physiological-Clinical']

Confocal O
microscopy O
assessments O
correlated O
well O
with O
the O
histologic O
diagnosis O
. O
[]

Right O
ventricular O
function O
was O
assessed O
using O
transesophageal O
echocardiography O
. O
[]

Publication O
date: O
2019/01/20 O
06:00 O
[entrez] O
[]

METHODS O
The O
effects O
of O
captopril O
( O
12.5 O
mg O
and O
25 O
mg O
) O
and O
enalapril O
( O
5 O
mg O
and O
10 O
mg O
) O
administered O
during O
7-day O
periods O
on O
electroencephalogram B-outcome ['Resource-use']
( I-outcome ['Resource-use']
EEG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
, O
cognitive B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
, O
and O
subjective O
assessments O
were O
investigated O
in O
healthy O
males O
. O
['Resource-use', 'Life-Impact']

Hypertension O
is O
associated O
with O
impaired O
fibrinolysis O
. O
[]

The O
mean O
improvement O
rate O
from O
baseline O
at O
month O
12 O
in O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
and O
the O
maximal B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
2 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
significant O
difference O
in O
the O
Fbg O
level O
was O
obtained O
between O
the O
2 O
groups O
. O
[]

Rye O
bran O
bread O
intake O
elevates O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ferulic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
in O
humans O
, O
but O
does O
not O
affect O
the O
susceptibility O
of O
LDL B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
ex O
vivo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Three O
patients O
showed O
liver B-outcome ['Physiological-Clinical']
involvement I-outcome ['Physiological-Clinical']
secondary O
to O
cryoglobulinemia O
and O
an O
improvement O
of O
histological B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
after O
the O
induction O
with O
combined O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
cases O
of O
intolerable B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
the O
patients O
were O
authorized O
to O
reactivate O
their O
SCS O
. O
['Physiological-Clinical']

On O
the O
basis O
of O
diet O
intervention O
, O
the O
observation O
group O
was O
treated O
with O
electroacupuncture O
at O
local O
points O
combined O
with O
blood-letting O
puncture O
and O
cupping O
, O
and O
the O
control O
group O
with O
oral O
administration O
of O
Probenecid O
. O
[]

Pharmacokinetic O
and O
safety O
evaluation O
of O
high-dose O
combinations O
of O
fosamprenavir O
and O
ritonavir O
. O
[]

This O
analysis O
assessed O
the O
impact O
of O
clindamycin O
phosphate O
1.2 O
% O
-benzoyl O
peroxide O
2.5 O
% O
( O
clindamycin-BPO O
2.5 O
% O
) O
gel O
on O
HRQL O
in O
a O
combined O
study O
population O
( O
N O
= O
2813 O
) O
of O
participants O
with O
moderate O
to O
severe O
acne O
vulgaris O
. O
[]

The O
anthracycline-treated O
cohort O
consisted O
of O
21 O
men O
and O
21 O
women O
with O
a O
mean O
age O
of O
55 O
? O
[]

The O
incidence O
of O
secondary B-outcome ['Physiological-Clinical']
pneumonia I-outcome ['Physiological-Clinical']
was O
reduced O
from O
42 O
% O
to O
17.5 O
% O
( O
not O
significant O
) O
. O
['Physiological-Clinical']

The O
development O
of O
anaesthesia O
was O
fastest O
following O
the O
largest O
dose O
, O
but O
the O
large O
number O
of O
central O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
makes O
that O
dosage O
less O
suitable O
for O
clinical O
work O
. O
['Adverse-effects']

After O
recent O
publicity O
about O
a O
child O
with O
autism O
whose O
condition O
markedly O
improved O
after O
a O
single O
dose O
of O
secretin O
, O
thousands O
of O
children O
with O
autistic O
disorders O
may O
have O
received O
secretin O
injections O
. O
[]

Primary O
endpoints O
of O
abstinence B-outcome ['Life-Impact']
were O
previously O
reported O
. O
['Life-Impact']

Participants O
were O
tested O
at O
baseline O
and O
again O
with O
weights O
placed O
according O
to O
group O
membership O
. O
[]

route O
; O
half O
of O
the O
dose O
was O
injected O
into O
the O
deltoid O
area O
and O
the O
other O
half O
into O
the O
buttocks O
. O
[]

Radiation-induced O
xerostomia O
can O
result O
in O
the O
rapid O
onset O
and O
progression O
of O
dental O
caries O
in O
head O
and O
neck O
cancer O
patients O
. O
[]

Twenty-two O
children O
with O
autism O
spectrum O
disorders O
who O
had O
not O
responded O
to O
supported O
behaviour O
management O
strategies O
for O
severe O
dysomnias O
entered O
a O
double O
blind O
, O
randomised O
, O
controlled O
crossover O
trial O
involving O
3 O
months O
of O
placebo O
versus O
3 O
months O
of O
melatonin O
to O
a O
maximum O
dose O
of O
10 O
mg. O
17 O
children O
completed O
the O
study O
. O
[]

The O
study O
was O
conducted O
in O
the O
neonatal O
intensive O
units O
for O
infants O
undergoing O
routine O
ROP O
screening O
exams O
. O
[]

Complications B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
therapy I-outcome ['Adverse-effects']
occurred O
in O
only O
4 O
patients O
, O
3 O
of O
whom O
had O
transient O
incontinence B-outcome ['Physiological-Clinical']
of O
flatus O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
effectiveness O
of O
the O
Cignolini O
methodology O
, O
an O
original O
Qigong O
massage O
methodology O
, O
in O
treating O
sensory O
impairment O
in O
young O
children O
with O
autism O
was O
evaluated O
in O
a O
small O
, O
controlled O
study O
. O
[]

The O
lavender O
and O
control O
conditions O
showed O
higher O
mean O
vigor-activity B-outcome ['Life-Impact']
ratings O
relative O
to O
the O
rosemary O
group O
, O
while O
both O
rosemary O
and O
lavender O
scents O
were O
associated O
with O
lower O
mean O
ratings O
on O
the O
fatigue-inertia B-outcome ['Life-Impact']
subscale O
, O
relative O
to O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

Median O
FFS B-outcome ['Mortality']
for O
FM O
patients O
was O
36 O
months O
, O
compared O
with O
19 O
months O
for O
CHVP O
patients O
, O
and O
has O
not O
yet O
been O
reached O
for O
early O
CR O
patients O
at O
53 O
months O
. O
['Mortality']

Non-evaporative B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
, O
-14.0 O
and O
-10.6 O
W.m-2 O
( O
p O
less O
than O
0.03 O
) O
, O
for O
the O
pyridostigmine-treated O
subjects O
. O
['Physiological-Clinical']

Three O
models O
of O
eye-lens O
dosemeters O
(Dosilab, O
Landauer O
and O
IRSN) O
were O
assessed O
in O
term O
of O
ergonomics B-outcome ['Life-Impact']
. O
The O
annual O
estimation O
of O
eye-lens B-outcome ['Physiological-Clinical']
doses I-outcome ['Physiological-Clinical']
did O
not O
reach O
the O
annual O
dose O
limit O
of O
20 O
mSv O
revised O
by O
the O
ICRP, O
ranged O
from O
0.00 O
to O
18.12 O
mSv O
with O
a O
mean O
of O
0.96 O
+/- O
2.28 O
mSv. O
[['Life-Impact'], ['Physiological-Clinical']]

Comparison O
of O
0.25 O
% O
S O
( O
- O
) O
-bupivacaine O
with O
0.25 O
% O
RS-bupivacaine O
for O
epidural O
analgesia B-outcome ['Resource-use']
in O
labour O
. O
['Resource-use']

RESULTS O
Men O
in O
the O
CBSM O
group O
maintained O
previously O
observed O
effects O
on O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
perceived B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
was O
eradicated O
in O
all O
CYP2C19 O
PMs O
except O
in O
one O
patient O
infected O
by O
a O
resistant O
strain O
. O
['Physiological-Clinical']

compared O
to O
a O
combination O
of O
slow-release O
theophylline O
and O
ketotifen O
p.o O
. O
( O
[]

Recovery B-outcome ['Physiological-Clinical']
after O
a O
predetermined O
AMP O
PC20 O
challenge O
was O
measured O
( O
primary O
outcome O
) O
, O
along O
with O
exhaled B-outcome ['Physiological-Clinical']
nitric I-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
levels O
, O
plasma B-outcome ['Physiological-Clinical']
eosinophil I-outcome ['Physiological-Clinical']
cationic I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
, O
peripheral B-outcome ['Physiological-Clinical']
eosinophil I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
diary O
card O
outcomes O
, O
and O
quality O
of O
life O
( O
all O
secondary O
outcomes O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
No O
differences O
in O
rocuronium B-outcome ['Physiological-Clinical']
PK I-outcome ['Physiological-Clinical']
parameters O
were O
observed O
between O
study O
groups O
. O
['Physiological-Clinical']

Children O
with O
autism O
's O
response O
to O
novel B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
while O
participating O
in O
interventions O
targeting O
joint O
attention O
or O
symbolic O
play O
skills O
. O
['Physiological-Clinical']

Whether O
either O
scope O
may O
be O
more O
efficient O
in O
any O
subgroups O
was O
also O
investigated O
. O
[]

The O
overall O
response O
rate O
was O
34.6 O
% O
. O
[]

Mean O
differences O
were O
2.6 O
( O
95 O
% O
CI O
, O
0.93-4.22 O
; O
P O
= O
0.002 O
) O
on O
the O
HAM-D?? O
and O
2.1 O
( O
95 O
% O
CI O
, O
0.36-3.76 O
; O
P O
= O
0.017 O
) O
on O
the O
SDS O
. O
[]

The O
purpose O
of O
this O
trial O
was O
to O
determine O
whether O
adjuvant O
AT O
improved O
disease-free O
survival O
compared O
with O
AC O
in O
operable O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
observed O
no O
between-group O
differences O
in O
four O
predefined O
quality-of-life B-outcome ['Life-Impact']
subscales O
( O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
dyspnoea B-outcome ['Physiological-Clinical']
, O
and O
global B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
) O
at O
any O
of O
the O
assessments O
in O
the O
first O
6 O
months O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:Cellular O
physiology O
and O
biochemistry O
: O
international O
journal O
of O
experimental O
cellular O
physiology, O
biochemistry, O
and O
pharmacology O
[]

Post-hoc O
analysis O
indicated O
more O
than O
87 O
% O
of O
children O
receiving O
CFT O
showed O
reliable O
change O
on O
at O
least O
one O
measure O
at O
post-test O
and O
66.7 O
% O
after O
3 O
months O
follow-up O
. O
[]

CONCLUSIONS O
Warfarin O
was O
associated O
with O
significantly O
higher O
rates O
of O
adverse O
events O
and O
provided O
no O
benefit O
over O
aspirin O
in O
this O
trial O
. O
[]

Other O
side O
effects O
were O
equivalent O
between O
solutions O
and O
mild O
in O
severity O
. O
[]

Periods O
of O
unilateral O
strength O
training O
should O
be O
implemented O
into O
periodized O
RT O
programs O
in O
this O
cohort. O
[]

single O
doses O
of O
tegaserod O
( O
0.8 O
mg O
to O
20 O
mg O
) O
or O
placebo O
. O
[]

Does O
surface O
preparation O
alter O
ALA B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
in O
superficial O
non-melanoma O
skin O
cancer O
in O
vivo O
? O
['Physiological-Clinical']

A O
major O
issue O
was O
that O
of O
adapting O
international O
best O
practice O
recommendations O
with O
regard O
to O
home-visiting O
programs O
to O
the O
particularities O
of O
the O
existing O
French O
social O
and O
health O
care O
system O
. O
[]

These O
data O
should O
be O
considered O
in O
treatment O
decision-making O
for O
pts O
with O
advanced O
non-small-cell O
lung O
cancer O
and O
for O
the O
design O
of O
future O
trials O
with O
chemotherapy O
plus O
biologics O
. O
[]

SETTING O
N/A O
. O
[]

RESULTS O
There O
was O
significantly O
less O
blood B-outcome ['Physiological-Clinical']
lost I-outcome ['Physiological-Clinical']
in O
the O
tourniquet O
group O
than O
in O
the O
control O
group O
( O
difference O
between O
means O
1870 O
mL O
, O
95 O
% O
CI O
1159-2580 O
mL O
, O
P O
< O
0.0001 O
; O
transfusion O
rates O
of O
7 O
% O
and O
79 O
% O
, O
P= O
0.0003 O
) O
. O
['Physiological-Clinical']

A O
lens-solution O
interaction O
was O
identified O
, O
with O
LR O
being O
the O
most O
tolerated B-outcome ['Life-Impact']
when O
administered O
with O
the O
MTL O
. O
['Life-Impact']

Caffeine O
attenuated O
this O
power O
gradient O
in O
caffeine O
sensitive O
subjects O
. O
[]

Plasma O
IGF-I O
( O
RIA O
after O
acid-ethanol O
extraction O
) O
was O
measured O
in O
a O
morning O
sample O
. O
[]

Sensory O
side O
effects O
from O
this O
low O
dose O
and O
from O
the O
standard O
MEG-X O
test O
were O
compared O
in O
a O
double-blind O
, O
randomized O
, O
cross-over O
study O
( O
study O
II O
) O
comprising O
15 O
individuals O
with O
normal O
liver O
function O
and O
45 O
patients O
with O
cirrhosis O
( O
15 O
Child O
A O
, O
15 O
Child O
B O
, O
and O
15 O
Child O
C O
) O
. O
[]

APC O
was O
closely O
associated O
with O
response O
to O
interferon B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
randomized O
controlled O
trial O
of O
COMPASS O
web-based O
and O
face-to-face O
teacher O
coaching O
in O
autism O
. O
[]

At O
28-35 O
days O
post-therapy O
, O
the O
continued O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
in O
the O
faropenem O
daloxate O
group O
was O
92.6 O
% O
and O
that O
for O
the O
cefuroxime O
axetil O
group O
was O
94.9 O
% O
( O
95 O
% O
CI O
: O
-6.8 O
% O
; O
+1.2 O
% O
) O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Patients O
were O
randomized O
to O
21-day O
cycles O
of O
oral O
capecitabine O
1,250 O
mg/m O
( O
2 O
) O
twice O
daily O
on O
days O
1 O
to O
14 O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
( O
n O
= O
255 O
) O
or O
to O
docetaxel O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
( O
n O
= O
256 O
) O
. O
[]

A O
comparison O
between O
the O
effect O
of O
oxytocin O
only O
and O
oxytocin O
plus O
propranolol O
on O
the O
labor B-outcome ['Physiological-Clinical']
( O
a O
double O
blind O
randomized O
trial O
) O
. O
['Physiological-Clinical']

Sixty-six O
PNES O
patients O
were O
randomized O
to O
either O
CBT O
( O
plus O
SMC O
) O
or O
SMC O
alone O
, O
scheduled O
to O
occur O
over O
4 O
months O
. O
[]

Anthropometric B-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
biochemical I-outcome ['Physiological-Clinical']
parameters O
were O
measured O
when O
the O
study O
was O
initiated O
and O
completed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Methods: O
Post O
hoc O
analysis O
of O
two O
multicenter, O
randomized, O
double-blind, O
vehicle-controlled O
Phase O
3 O
studies O
in O
moderate O
or O
severe O
acne. O
[]

It O
is O
unknown O
whether O
ST O
, O
with O
or O
without O
concurrent O
endurance O
training O
, O
would O
have O
a O
similar O
effect O
in O
older O
adults O
with O
reduced O
baseline O
arterial B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
microbiologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
follow-up O
, O
safety O
, O
and O
compliance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

At O
D29, O
intention-to-treat O
efficacy O
in O
the O
AmBisome O
arm O
was O
70% O
(95% O
CI O
45-87%) O
in O
the O
unadjusted O
analysis, O
and O
50% O
(95% O
CI O
27-73%) O
in O
the O
adjusted O
analysis, O
while O
in O
the O
combination O
arm, O
it O
was O
81% O
(95% O
CI O
67-90%) O
and O
67% O
(95% O
CI O
48-82%) O
respectively. O
[]

Follow-on O
oral O
antibiotics O
were O
permitted O
in O
both O
groups. O
[]

Concern O
about O
the O
possible O
adverse B-outcome ['Adverse-effects']
health I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
acid O
fog O
has O
been O
fed O
by O
two O
observations O
: O
air O
pollution O
disasters O
earlier O
in O
this O
century O
were O
typically O
associated O
with O
fog O
, O
and O
current O
samples O
of O
fog O
water O
can O
be O
strongly O
acid O
. O
['Adverse-effects']

STUDY O
OBJECTIVE O
To O
examine O
the O
effects O
of O
fructose-1,6-diphosphate O
on O
myocardial B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
using O
nuclear O
scintigraphy O
. O
['Physiological-Clinical']

Twelve O
subjects O
received O
150 O
mg O
YM17E O
in O
both O
the O
fasted O
and O
post-prandial O
states O
. O
[]

17 O
years O
, O
who O
presented O
a O
median O
of O
84 O
months O
after O
chemotherapy O
with O
a O
cumulative O
anthracycline O
exposure O
of O
282 O
? O
[]

The O
treatment O
group O
consisted O
of O
13 O
patients O
who O
were O
given O
5 O
mg O
finasteride O
daily O
for O
4 O
weeks O
before O
surgery O
. O
[]

The O
pre-pPCI B-outcome ['Physiological-Clinical']
ST-segment I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
( O
55+/-21.4 O
% O
vs O
42.4+/-18.2 O
% O
, O
p=0.005 O
) O
, O
TIMI B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
grade O
3 O
( O
29 O
% O
vs O
7 O
% O
, O
p=0.042 O
) O
, O
corrected O
TIMI B-outcome ['Physiological-Clinical']
frame O
count O
( O
58.4+/-32.7 O
vs O
78.9+/-28.4 O
frame O
, O
p=0.018 O
) O
% B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
( O
76.3 O
/63.5-100/ O
vs O
100 O
/73.5-100/ O
; O
median O
/interquartile O
range/ O
, O
p=0.023 O
) O
, O
were O
significantly O
higher O
in O
Group O
1 O
vs O
Group O
2 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
article O
, O
we O
describe O
the O
design O
and O
rationale O
of O
a O
phase O
2 O
, O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
LX4211 B-outcome ['Physiological-Clinical']
in O
subjects O
with O
type O
2 O
diabetes O
mellitus O
who O
have O
inadequate O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
on O
metformin O
monotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Skin O
biopsies O
were O
obtained O
from O
randomized O
subjects O
for O
fibroblast O
production O
. O
[]

Fibroadenomas O
are O
the O
most O
common O
benign O
breast O
condition O
among O
women O
and O
account O
for O
up O
to O
50 O
% O
of O
all O
breast O
biopsies O
being O
performed O
. O
[]

The O
15-year O
actuarial O
rate O
of O
severe B-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
RT I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
did O
not O
differ O
between O
the O
two O
arms O
( O
6 O
% O
for O
q.d O
. O
['Adverse-effects']

The O
postoperative O
analgesic O
requirement O
was O
assessed O
by O
the O
total O
dose O
of O
metamizol B-outcome ['Physiological-Clinical']
administered O
by O
an O
i.v O
. O
['Physiological-Clinical']

Cardiovascular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate O
and O
arterial B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2019/01/22 O
06:00 O
[entrez] O
[]

Journal-Name:Cellular O
physiology O
and O
biochemistry O
: O
international O
journal O
of O
experimental O
cellular O
physiology, O
biochemistry, O
and O
pharmacology O
[]

This O
study O
will O
assess O
whether O
yoga O
is O
effective O
for O
treating O
chronic B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
compared O
with O
self O
care O
and O
exercise O
and O
will O
explore O
the O
mechanisms O
responsible O
for O
any O
observed O
benefits O
. O
['Physiological-Clinical']

Patients O
in O
both O
treatment O
groups O
with O
controlled O
intraocular O
pressures O
were O
more O
likely O
to O
maintain O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Treatment O
of O
recurrent O
chronic O
hyperplastic O
sinusitis O
with O
nasal O
polyposis O
. O
[]

PURPOSE: O
Trachoma, O
caused O
by O
repeated O
ocular O
infection O
with O
Chlamydia O
trachomatis, O
is O
the O
leading O
infectious O
cause O
of O
blindness O
worldwide O
and O
is O
targeted O
for O
elimination O
as O
a O
public O
health O
problem. O
[]

METHODS O
Data O
from O
an O
RCT O
( O
Trial O
of O
Etanercept O
and O
Methotrexate O
with O
Radiographic O
Patient O
Outcomes O
[ O
TEMPO O
] O
; O
n=682 O
) O
and O
an O
observational O
registry O
( O
Rheumatoid O
Arthritis O
DMARD O
Intervention O
and O
Utilization O
Study O
[ O
RADIUS O
II O
] O
; O
n=4341 O
) O
were O
used O
to O
evaluate O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
Clinical O
Disease O
Activity O
Index O
[ O
CDAI O
] O
score O
) O
over O
time O
in O
patients O
initiating O
etanercept O
( O
monotherapy O
or O
with O
methotrexate O
) O
. O
['Physiological-Clinical']

Factor O
VIIa O
was O
increased O
in O
the O
DYDR O
group O
only O
. O
[]

This O
study O
sought O
to O
examine O
the O
efficacy O
of O
a O
calendar/notebook O
rehabilitation O
intervention O
, O
the O
memory B-outcome ['Life-Impact']
support O
system O
( O
MSS O
) O
, O
for O
individuals O
with O
amnestic O
MCI O
. O
['Life-Impact']

Combination O
treatment O
decreased O
the O
TC B-outcome ['Physiological-Clinical']
, O
LDL-C B-outcome ['Physiological-Clinical']
, O
and O
TG B-outcome ['Physiological-Clinical']
levels O
by O
28 O
% O
, O
38 O
% O
, O
and O
39 O
% O
respectively O
, O
and O
increased O
the O
HDL-C B-outcome ['Physiological-Clinical']
level O
by O
23 O
% O
( O
all O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
collected O
ERP B-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
familiar I-outcome ['Life-Impact']
repeated I-outcome ['Life-Impact']
face I-outcome ['Life-Impact']
( O
Familiar B-outcome ['Life-Impact']
) O
, O
an O
unfamiliar B-outcome ['Life-Impact']
repeated I-outcome ['Life-Impact']
face I-outcome ['Life-Impact']
( O
Other O
) O
and O
novel B-outcome ['Life-Impact']
faces I-outcome ['Life-Impact']
( O
Novels B-outcome ['Life-Impact']
) O
in O
29 O
high-functioning O
adults O
with O
ASD O
and O
matched O
controls O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
effects O
of O
ezetimibe/simvastatin O
versus O
simvastatin O
monotherapy O
on O
platelet B-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
in O
patients O
with O
metabolic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Comparative O
analysis O
of O
the O
first O
conducted O
and O
randomly O
assigned O
55 O
cases O
revealed O
a O
significantly O
higher O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
for O
cryobiopsy B-outcome ['Resource-use']
compared O
with O
forceps O
biopsy O
( O
89.1 O
% O
vs O
65.5 O
% O
, O
P O
< O
.05 O
) O
. O
['Life-Impact', 'Resource-use']

At O
the O
3-week O
follow O
up O
, O
the O
resolution B-outcome ['Physiological-Clinical']
rates O
in O
the O
triamcinolone O
acetonide O
injection O
and O
surgical O
treatment O
groups O
were O
not O
significantly O
different O
from O
each O
other O
at O
84 O
% O
( O
47/56 O
) O
and O
87 O
% O
( O
39/45 O
) O
, O
respectively O
( O
P O
< O
0.001 O
) O
, O
but O
was O
significantly O
lower O
in O
the O
conservative O
treatment O
group O
at O
46 O
% O
( O
16/35 O
) O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Importantly O
, O
adjusting O
for O
age O
did O
not O
change O
the O
magnitude O
of O
these O
effects O
. O
[]

Ginger O
also O
seemed O
to O
be O
tolerable B-outcome ['Life-Impact']
and O
safe O
. O
['Life-Impact']

The O
effects O
of O
piracetam O
( O
Nootropil O
, O
UCB6215 O
) O
on O
mental B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
and O
on O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
rCBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
investigated O
in O
eight O
patients O
in O
the O
presenile O
age O
who O
displayed O
symptoms O
of O
moderate O
dementia O
. O
['Life-Impact', 'Physiological-Clinical']

Six O
treatment O
groups O
were O
P10T26 O
( O
10 O
mg O
PN O
+ O
ambient O
temperature O
( O
26 O
?C O
) O
, O
P0T33 O
( O
0 O
mg O
PN O
+ O
ET O
) O
, O
P10T33 O
( O
10 O
mg O
PN O
+ O
ET O
) O
, O
P50T33 O
( O
50 O
mg O
PN O
+ O
ET O
) O
, O
P100T33 O
( O
100 O
mg O
PN O
+ O
ET O
) O
and O
P200T33 O
( O
200 O
mg O
PN O
+ O
ET O
) O
. O
[]

Saline O
or O
granisetron O
was O
given O
intravenously O
( O
IV O
) O
over O
5 O
min O
approximately O
30 O
min O
before O
the O
end O
of O
anesthesia O
. O
[]

This O
study O
was O
designed O
to O
determine O
the O
bioavailability O
of O
GCV O
and O
to O
test O
a O
dosing O
algorithm O
in O
transplant O
and O
dialysis O
patients O
with O
different O
levels O
of O
renal O
function O
. O
[]

The O
groups O
were O
comparable O
with O
regard O
to O
age O
, O
sex O
and O
prednisone O
dose O
. O
[]

After O
these O
trials O
, O
a O
resting O
hypoxia O
trial O
was O
conducted O
without O
handgrip O
or O
PECO O
. O
[]

Whether O
medical O
therapy O
for O
silent O
ischemia O
improves O
prognosis O
is O
not O
known O
. O
[]

These O
visits O
were O
carried O
out O
by O
fieldworkers O
who O
counseled O
the O
mothers O
about O
the O
Ten O
Steps O
for O
Healthy O
Feeding O
from O
Birth O
to O
Two O
Years O
of O
Age O
, O
based O
on O
the O
WHO O
guidelines O
. O
[]

At O
last O
follow-up O
these O
figures O
were O
respectively O
9 O
, O
12 O
, O
and O
17 O
vs O
19 O
, O
2 O
, O
and O
18 O
( O
p=0.004 O
) O
. O
[]

METHODS O
In O
a O
prospective O
randomised O
trial O
, O
254 O
patients O
with O
colon O
cancer O
were O
randomly O
assigned O
postoperative O
ASI O
or O
no O
adjuvant O
treatment O
. O
[]

CONCLUSIONS O
In O
patients O
with O
AIDS O
who O
are O
receiving O
zidovudine O
, O
trimethoprim-sulfamethoxazole O
is O
more O
effective O
than O
aerosolized O
pentamidine O
in O
conventional O
doses O
for O
the O
prevention O
of O
recurrent B-outcome ['Physiological-Clinical']
pneumocystis I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
Two O
hundred O
eighteen O
children O
and O
adolescents O
( O
aged O
6-17 O
years O
) O
with O
a O
diagnosis O
of O
autistic O
disorder O
, O
and O
with O
behaviors O
such O
as O
tantrums O
, O
aggression O
, O
self-injurious O
behavior O
, O
or O
a O
combination O
of O
these O
symptoms O
, O
were O
randomized O
1:1:1:1 O
to O
aripiprazole O
( O
5 O
, O
10 O
, O
or O
15 O
mg/day O
) O
or O
placebo O
in O
this O
8-week O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
parallel-group O
study O
. O
[]

Clonidine O
in O
patients O
undergoing O
noncardiac O
surgery O
. O
[]

The O
FemCap O
was O
believed O
to O
be O
safe O
and O
was O
associated O
with O
significantly O
fewer O
[]

Operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
difficulty B-outcome ['Life-Impact']
of O
finding O
the O
specimen O
was O
significantly O
lower O
in O
the O
modified O
localization O
group O
than O
in O
the O
methylene O
blue O
localization O
group O
(P O
< O
.05). O
[['Life-Impact'], ['Life-Impact']]

Furthermore O
, O
Latino O
health O
care O
professionals O
have O
been O
absent O
from O
these O
intervention O
efforts O
even O
though O
the O
epidemic O
has O
affected O
this O
population O
disproportionately O
. O
[]

6.6 O
yr O
, O
body O
mass O
[ O
BM O
] O
= O
72.9 O
? O
[]

Following O
randomization O
and O
prior O
to O
any O
intervention O
, O
baseline O
discomfort B-outcome ['Physiological-Clinical']
scores O
were O
obtained O
by O
means O
of O
a O
verbally O
administered O
, O
horizontal O
, O
100-mm O
, O
unnumbered O
analog O
discomfort O
scale O
. O
['Physiological-Clinical']

PURPOSE O
To O
characterize O
the O
maximum-tolerated O
dose O
, O
recommended O
dose O
, O
dose-limiting O
toxicities O
( O
DLT O
) O
, O
pharmacokinetic O
profile O
, O
and O
food O
effect O
of O
orally O
administered O
irinotecan O
formulated O
as O
new O
semisolid O
matrix O
capsules O
. O
[]

Patients O
who O
received O
MOF-Strep O
experienced O
substantially O
greater O
vomiting B-outcome ['Physiological-Clinical']
and O
hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
than O
patients O
who O
received O
FU O
+ O
HU O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Alive B-outcome ['Mortality']
at O
30 O
days O
for O
HSD O
and O
NS O
, O
respectively O
, O
was O
70 O
% O
( O
35/50 O
) O
and O
75 O
% O
( O
42/56 O
) O
and O
at O
discharge O
was O
68 O
% O
( O
34/50 O
) O
and O
73 O
% O
( O
41/56 O
) O
. O
['Mortality']

Changes O
in O
the O
hormonal O
milieu O
were O
not O
associated O
with O
recurrence O
. O
[]

Both O
of O
these O
components O
were O
administered O
during O
a O
10-week O
period O
. O
[]

The O
Discharge O
Preparation O
Program O
( O
DPP O
) O
was O
the O
intervention O
condition O
( O
n O
= O
26 O
) O
, O
and O
the O
usual O
rehabilitation O
program O
was O
the O
control O
condition O
( O
n O
= O
23 O
) O
. O
[]

Hampshire O
lambs O
( O
initial O
BW O
29.4 O
? O
[]

Relaxing O
retinotomy O
with O
silicone O
oil O
or O
long-acting O
gas O
in O
eyes O
with O
severe O
proliferative O
vitreoretinopathy O
. O
[]

Local O
injection O
of O
bupivacaine O
after O
rubber O
band O
ligation O
of O
hemorrhoids O
: O
prospective O
, O
randomized O
study O
. O
[]

METHODS O
Patients O
12 O
years O
of O
age O
and O
older O
with O
acne O
vulgaris O
( O
N O
= O
3010 O
) O
participated O
in O
two O
identically-designed O
12-week O
, O
randomized O
, O
double-blind O
studies O
of O
twice-daily O
monotherapy O
with O
dapsone O
gel O
, O
5 O
% O
, O
versus O
a O
vehicle O
gel O
. O
[]

In O
addition O
, O
single-task O
random-interval O
repetition O
performance O
was O
sampled O
and O
compared O
to O
performance O
in O
the O
dual-task O
conditions O
of O
all O
four O
experiments O
. O
[]

Marginal O
biotin O
deficiency O
during O
normal O
pregnancy O
. O
[]

Terbinafine O
, O
250 O
mg O
daily O
for O
3 O
months O
( O
continuous O
) O
or O
terbinafine O
, O
500 O
mg O
daily O
for O
1 O
week O
per O
month O
for O
3 O
months O
( O
pulse O
) O
was O
administered O
. O
[]

All O
the O
subjects O
had O
baseline O
studies O
, O
including O
medical O
history O
, O
physical O
examination O
, O
blood O
and O
urine O
analysis O
. O
[]

CONCLUSION O
The O
combination O
of O
ALVAC-CEA/B7.1 O
vaccine O
and O
systemic O
chemotherapy O
has O
an O
acceptable O
safety O
profile O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

The O
apoptotic B-outcome ['Physiological-Clinical']
index O
( O
AI B-outcome ['Physiological-Clinical']
) O
and O
an O
MIB-1 B-outcome ['Physiological-Clinical']
index O
( O
MI B-outcome ['Physiological-Clinical']
) O
were O
also O
calculated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
used O
baseline O
data O
collected O
in O
the O
Fall O
of O
2006 O
for O
the O
Sun O
Protection O
for O
Florida O
's O
Children O
( O
SPF O
) O
project O
. O
[]

RESULTS O
There O
was O
no O
mortality B-outcome ['Mortality']
in O
either O
group O
. O
['Mortality']

RESULTS O
Of O
the O
95 O
randomized O
patients O
, O
88 O
( O
93 O
% O
) O
completed O
the O
study O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
best O
clinical O
responders O
exhibited O
the O
clearest O
normalization O
of O
the O
elevated O
plasma B-outcome ['Physiological-Clinical']
chemistries I-outcome ['Physiological-Clinical']
, O
especially O
in O
C-terminal-beta-endorphin O
and O
serotonin O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS O
One O
in O
four O
eligible O
primary O
care O
patients O
enrolled O
in O
the O
study O
. O
[]

We O
evaluated O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
low-dose O
etoposide O
in O
relapsed O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
. O
['Physiological-Clinical']

We O
evaluated O
a O
strategy O
of O
balloon O
dissection O
, O
subfascial O
endoscopic O
perforating O
vein O
surgery O
( O
SEPS O
) O
with O
routine O
posterior O
deep O
compartment O
fasciotomy O
, O
including O
ligation O
and O
stripping O
of O
the O
superficial O
system O
, O
for O
use O
when O
reflux O
is O
documented O
at O
duplex O
ultrasound O
( O
US O
) O
scanning O
. O
[]

In O
23 O
research O
centers O
in O
Spain, O
6874 O
men O
and O
women O
aged O
55 O
to O
75 O
years O
with O
metabolic O
syndrome O
and O
no O
cardiovascular O
disease O
were O
enrolled O
in O
the O
trial O
between O
September O
2013 O
and O
December O
2016, O
with O
final O
data O
collection O
in O
March O
2019. O
[]

Comparison O
of O
budesonide O
Turbuhaler O
with O
budesonide O
aqua O
in O
the O
treatment O
of O
seasonal O
allergic O
rhinitis O
. O
[]

We O
randomized O
299 O
older O
men O
to O
treatment O
with O
2mg O
of O
folate O
, O
plus O
25mg O
of O
B6 O
and O
400 O
microg O
of O
B12 O
, O
or O
placebo O
. O
[]

Of O
the O
patients O
making O
a O
telephone O
appointment O
, O
88 O
% O
recieved O
immunisation B-outcome ['Resource-use']
, O
while O
22 O
% O
of O
those O
not O
wanting O
an O
appointment O
went O
on O
to O
be O
immunised O
. O
['Resource-use']

Signal-averaged B-outcome ['Physiological-Clinical']
P-wave I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complex I-outcome ['Physiological-Clinical']
durations I-outcome ['Physiological-Clinical']
did O
not O
significantly O
change O
after O
placebo O
ingestion O
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
of O
the O
present O
study O
on O
the O
administration O
of O
GnRH O
analogue O
to O
females O
with O
myomas O
suggest O
that O
no O
direct O
or O
immediate O
inter-relationship O
exists O
between O
expression O
of O
leptin B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
in O
uterine O
myomas O
on O
one O
hand O
and O
estrogen O
, O
progesterone O
and O
leptin O
levels O
in O
the O
blood O
on O
the O
other O
. O
['Physiological-Clinical']

METHODS: O
We O
randomly O
assigned O
695 O
men O
with O
localized O
prostate O
cancer O
to O
watchful O
waiting O
or O
radical O
prostatectomy O
from O
October O
1989 O
through O
February O
1999 O
and O
collected O
follow-up O
data O
through O
2017. O
[]

In O
20 O
operations O
, O
19 O
children O
were O
randomized O
to O
heparin-coated O
( O
group O
HC O
, O
n O
= O
10 O
) O
or O
standard O
( O
group O
C O
, O
n O
= O
10 O
) O
bypass O
circuits O
. O
[]

It O
is O
known O
that O
cervicogenic O
headache O
sufferers O
present O
with O
several O
musculoskeletal O
changes O
including O
poor O
endurance O
of O
the O
deep O
cervical O
flexor O
muscles O
. O
[]

Effects O
of O
propranolol O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
the O
rat O
. O
['Physiological-Clinical']

Absence O
of O
cervical B-outcome ['Physiological-Clinical']
radiation I-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
after O
hyperfractionated O
radiation O
therapy O
with O
and O
without O
concurrent O
chemotherapy O
for O
locally O
advanced O
, O
unresectable O
, O
nonmetastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
. O
['Physiological-Clinical']

Title: O
Precooling, O
Exertional O
Heatstroke O
Risk O
Factors, O
and O
Postexercise O
Cooling O
Rates. O
[]

Ten O
monozygotic O
twin O
pairs O
of O
pregnant O
cows O
( O
five O
pairs O
of O
parity O
1 O
or O
2 O
, O
and O
five O
pairs O
of O
parity O
3 O
or O
more O
) O
were O
allocated O
to O
two O
diets O
which O
were O
formulated O
to O
provide O
either O
-4 O
meq O
( O
anion O
diet O
) O
or O
+572.5 O
meq O
( O
cation O
diet O
) O
of O
[ O
( O
Na+ O
+ O
K+ O
) O
- O
( O
Cl- O
+ O
SO4= O
) O
] O
kg-1 O
dietary O
dry O
matter O
( O
DM O
) O
. O
[]

Wilcoxon O
rank O
sum O
test O
was O
used O
for O
continuous O
variables O
. O
[]

A O
Roy O
adaptation O
model-based O
support O
and O
education O
intervention O
for O
women O
with O
early-stage O
breast O
cancer O
was O
tested O
in O
a O
three-group O
, O
three-phase O
randomized O
clinical O
trial O
of O
a O
sample O
of O
125 O
women O
. O
[]

This O
randomized O
, O
double-blind O
, O
double-dummy O
, O
multicenter O
, O
parallel-group O
study O
aimed O
at O
comparing O
the O
efficacy O
and O
safety O
of O
calcium O
carbasalate O
( O
equivalent O
to O
900 O
mg O
aspirin O
) O
plus O
metoclopramide O
10 O
mg O
( O
CM O
) O
with O
ergotamine O
tartrate O
1 O
mg O
plus O
caffeine O
100 O
mg O
( O
EC O
) O
administered O
in O
the O
treatment O
of O
2 O
acute O
migraine O
attacks O
. O
[]

Diverting B-outcome ['Physiological-Clinical']
stoma I-outcome ['Physiological-Clinical']
after O
low O
anterior O
resection O
: O
more O
arguments O
in O
favor O
. O
['Physiological-Clinical']

CONCLUSIONS O
Tumor O
budding O
independently O
predicted O
patient O
outcome O
in O
patients O
with O
AJCC/UICC O
stage O
II O
colorectal O
cancer O
and O
may O
therefore O
be O
used O
for O
accurate O
prognostication O
, O
patient O
counseling O
, O
and O
design O
of O
clinical O
trials O
by O
using O
integrated O
multimodal O
therapy O
. O
[]

Fifteen O
low-scoring O
individuals O
and O
14 O
high-scoring O
individuals O
derived O
from O
a O
normal O
population O
participated O
in O
the O
study O
. O
[]

RESULTS O
A O
dose-dependent O
change O
in O
exhaled B-outcome ['Physiological-Clinical']
NO O
during O
graded B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
was O
observed O
( O
p O
= O
0.0012 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Analysis O
of O
prognostic O
factors O
using O
optimized O
statistical O
models O
was O
based O
on O
data O
from O
patients O
in O
E1684 O
, O
E1690 O
, O
E1694 O
, O
and O
E2696 O
. O
[]

In O
both O
tasks O
, O
the O
obtained O
psychometric O
functions O
revealed O
higher O
pitch B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
for O
subjects O
with O
autism O
, O
with O
a O
more O
pronounced O
advantage O
over O
control O
participants O
in O
the O
categorization B-outcome ['Life-Impact']
task O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
Although O
a O
diet O
that O
is O
rich O
in O
fiber O
is O
widely O
recommended O
for O
preventing O
and O
treating O
constipation O
, O
the O
efficacy O
of O
fiber O
supplements O
have O
not O
been O
tested O
sufficiently O
in O
children O
. O
[]

RESULTS O
The O
study O
involved O
42 O
males O
and O
28 O
females O
( O
median O
age O
, O
7.7 O
years O
) O
with O
a O
median O
follow-up O
of O
10.4 O
years O
. O
[]

Despite O
blinding O
, O
subjects O
' O
VAS O
scores O
improved O
from O
baseline O
to O
post-intervention O
for O
stress O
( O
5.5 O
vs. O
2.2 O
) O
, O
relaxation B-outcome ['Life-Impact']
( O
3.8 O
vs. O
8.8 O
) O
and O
peacefulness B-outcome ['Life-Impact']
( O
3.8 O
vs. O
9.0 O
, O
P O
< O
0.05 O
for O
all O
comparisons O
) O
. O
['Life-Impact', 'Life-Impact']

Data O
collection O
occurred O
in O
a O
simulated O
situation O
. O
[]

Few O
reports O
on O
barriers O
, O
however O
, O
have O
focused O
on O
the O
young O
black O
man O
with O
HBP O
, O
the O
age/sex/race O
group O
with O
the O
highest O
rates O
of O
early O
severe O
and O
complicated O
HBP O
and O
the O
lowest O
rates O
of O
awareness O
, O
treatment O
, O
and O
control O
. O
[]

This O
is O
considered O
from O
the O
perspective O
of O
clinical O
assessment O
and O
intervention O
in O
school O
contexts O
. O
[]

The O
SST-GP O
had O
higher O
efficacy O
than O
the O
LA-GP O
. O
[]

METHODS O
Participants O
( O
n O
= O
80 O
) O
were O
recruited O
from O
a O
hospital O
clinic O
in O
Chandigarh O
, O
India O
, O
and O
randomized O
to O
a O
3-month O
group O
intervention O
or O
individual O
enhanced O
standard O
of O
care O
followed O
by O
crossover O
of O
condition O
and O
assessed O
over O
6 O
months O
. O
[]

AIMS O
To O
investigate O
whether O
metoprolol O
controlled O
release/extended O
release O
( O
CR/XL O
) O
once O
daily O
would O
improve O
diastolic B-outcome ['Physiological-Clinical']
and O
systolic B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
heart O
failure O
and O
decreased O
ejection O
fraction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
shear-induced B-outcome ['Physiological-Clinical']
hemostasis I-outcome ['Physiological-Clinical']
was O
monitored O
by O
the O
in O
vitro O
bleeding O
test O
( O
Thrombostat O
) O
, O
which O
mimics O
bleeding O
through O
an O
injured O
arteriole O
. O
['Physiological-Clinical']

Mean O
ratings O
at O
endpoint O
were O
2.8 O
+/- O
1.2 O
on O
risperidone O
and O
4.5 O
+/- O
1.3 O
on O
placebo O
( O
p O
< O
.001 O
) O
. O
[]

Pretreatment O
and O
day-of-debond O
digital O
photographic O
images O
were O
taken O
of O
the O
teeth O
and O
assessed O
by O
up O
to O
5 O
clinical O
and O
3 O
lay O
assessors O
for O
the O
presence O
or O
absence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
the O
esthetic B-outcome ['Life-Impact']
impact. O
[['Physiological-Clinical'], ['Life-Impact']]

table O
: O
see O
text O
] O
Overall O
, O
side O
effects O
from O
adenosine O
were O
not O
different O
between O
men O
and O
women O
. O
[]

Before O
and O
three O
months O
after O
AVF O
creation O
patients O
underwent O
an O
echocardiographic O
examination O
. O
[]

It O
was O
possible O
to O
define O
good O
, O
intermediate O
and O
poor O
renal-function O
groups O
which O
were O
highly O
correlated O
with O
prognosis O
( O
X2 O
for O
trend O
= O
62.6 O
) O
. O
[]

An O
exploratory O
, O
pragmatic O
, O
cluster O
randomised O
trial O
of O
practice O
nurse O
training O
in O
the O
use O
of O
asthma O
action O
plans O
. O
[]

These O
patients O
were O
randomly O
divided O
into O
2 O
groups: O
methylene O
blue O
localization O
group O
(n O
= O
47), O
and O
modified O
localization O
group O
(n O
= O
32), O
where O
the O
patients O
received O
preoperative O
localization O
of O
the O
small O
nodules O
by O
CT-guided O
placing O
wire O
and O
intrapleural O
fibrin O
glue O
near O
the O
nodule O
at O
3 O
days O
before O
the O
operation. O
[]

Energy B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
was O
measured O
by O
indirect O
calorimetry O
and O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
by O
an O
automated O
food-selection O
system O
. O
['Physiological-Clinical', 'Life-Impact']

5-fluorouracil/leucovorin O
) O
. O
[]

LAVH O
, O
when O
compared O
with O
TAH O
in O
the O
two O
weight O
subgroups O
, O
required O
a O
significantly O
longer O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
only O
in O
Group O
2 O
, O
significantly O
reduced O
analgesics B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
only O
in O
Group O
1 O
, O
and O
significantly O
reduced O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
both O
groups O
. O
['Life-Impact', 'Resource-use', 'Resource-use']

But O
, O
there O
was O
no O
significant O
difference O
in O
HBV B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rates O
between O
vaccine O
group O
and O
placebo-controlled O
group O
( O
7.89 O
% O
vs. O
13.25 O
% O
, O
P O
> O
0.1 O
) O
nine O
to O
11 O
years O
following O
immunization O
. O
['Physiological-Clinical']

A O
set O
of O
five O
factors O
were O
found O
to O
consistently O
predict O
depression B-outcome ['Life-Impact']
at O
the O
following O
assessment O
. O
['Life-Impact']

METHODS: O
In O
this O
randomized, O
single-blinded, O
and O
controlled O
study, O
total O
75 O
patients O
were O
randomly O
allocated O
to O
TPI O
group O
(n O
= O
25), O
EMLA O
group O
(n O
= O
25), O
and O
control O
group O
(n O
= O
25). O
[]

METHODS: O
CD80 O
was O
used O
to O
trap O
belatacept O
onto O
streptavidin-coated O
wells. O
[]

However O
, O
cross-sectional O
observations O
at O
7 O
years O
showed O
negative O
correlations O
between O
all O
OPs B-outcome ['Physiological-Clinical']
and O
age O
( O
p O
< O
0.0001-0.003 O
) O
, O
and O
between O
OP-3 B-outcome ['Physiological-Clinical']
and O
duration O
( O
p O
= O
0.003 O
) O
and O
counts O
of O
microaneurysms B-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
mean O
increase O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
associated O
with O
CSA O
; O
no O
persons O
were O
withdrawn O
from O
the O
study O
for O
this O
reason O
. O
['Physiological-Clinical']

Cilomilast O
( O
Ariflo O
) O
, O
a O
new O
oral O
phosphodiesterase-4 O
selective O
inhibitor O
, O
improves O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical']

CONCLUSION: O
Pre-administration O
of O
remifentanil O
in O
target-controlled O
propofol O
and O
remifentanil O
anesthesia O
prolongs O
total O
induction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
about O
35% O
compared O
to O
co-administration O
of O
remifentanil O
and O
propofol O
by O
decreased O
CO. O
[['Life-Impact']]

Potential O
explanations O
for O
the O
pattern O
of O
results O
are O
evaluated O
, O
and O
implications O
for O
theories O
of O
mental O
imagery O
and O
memory O
are O
considered O
. O
[]

In O
a O
prospective O
controlled O
study O
, O
involving O
42 O
patients O
subdivided O
into O
four O
groups O
namely O
, O
higher O
or O
lower O
insufflation O
pressures O
, O
chemically O
inert O
insufflation O
gas O
and O
control O
groups O
; O
the O
use O
of O
analgetics B-outcome ['Resource-use']
, O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
operation B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
amount O
of O
insufflated B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
, O
intraperitoneal B-outcome ['Physiological-Clinical']
pH-values I-outcome ['Physiological-Clinical']
and O
post-operative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
in O
the O
various O
subgroups O
were O
compared O
to O
each O
other O
with O
regard O
to O
post-operative O
pain O
perception O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Failure O
for O
PFS B-outcome ['Mortality']
was O
defined O
as O
the O
first O
occurrence O
of O
local B-outcome ['Physiological-Clinical']
, O
regional B-outcome ['Physiological-Clinical']
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(2.1%) O
in O
intervention O
group O
was O
significantly O
lower O
than O
that O
in O
control O
group O
(4.2%) O
at O
year O
2 O
(chi O
= O
22.138, O
P O
<.001). O
[['Physiological-Clinical']]

Significant O
treatment O
differences O
( O
p O
< O
.01 O
) O
in O
favor O
of O
nefazodone O
were O
also O
seen O
in O
the O
Montgomery-Asberg O
Depression O
Rating O
Scale O
; O
the O
HAM-D O
retardation O
, O
anxiety O
, O
and O
sleep O
disturbance O
factors O
; O
and O
HAM-D O
item O
1 O
( O
depressed O
mood O
) O
. O
[]

Perioperative O
blood O
transfusions O
, O
with O
or O
without O
allogeneic O
leucocytes O
, O
relate O
to O
survival B-outcome ['Mortality']
, O
not O
to O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

The O
children O
in O
both O
groups O
were O
treated O
for O
a O
total O
of O
6 O
weeks. O
[]

An O
SRE O
was O
defined O
as O
pathologic O
fracture O
, O
spinal O
cord O
compression O
, O
and O
radiation O
or O
surgery O
to O
bone O
. O
[]

Allergic O
mothers O
had O
significantly O
lower O
amounts O
of O
bifidobacteria B-outcome ['Physiological-Clinical']
in O
breast-milk O
compared O
with O
non-allergic O
mothers O
[ O
median O
1.3 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
( O
IQR O
22.4-3.0 O
x O
10 O
( O
3 O
) O
) O
vs. O
5.6 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
( O
1.8 O
x O
10 O
( O
3 O
) O
-1.8 O
x O
10 O
( O
4 O
) O
) O
, O
respectively O
, O
( O
P=0.004 O
) O
] O
, O
and O
their O
infants O
had O
concurrently O
lower O
counts O
of O
bifidobacteria B-outcome ['Physiological-Clinical']
in O
feces O
[ O
3.9 O
x O
10 O
( O
8 O
) O
bacterial O
cells/g O
( O
IQR O
6.5 O
x O
10 O
( O
6 O
) O
-1.5 O
x O
10 O
( O
9 O
) O
) O
in O
infants O
of O
allergic O
mothers O
, O
vs. O
2.5 O
x O
10 O
( O
9 O
) O
bacterial O
cells/g O
( O
6.5 O
x O
10 O
( O
8 O
) O
-3.2 O
x O
10 O
( O
10 O
) O
) O
in O
infants O
of O
non-allergic O
mothers O
, O
P=0.013 O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Pregnancy B-outcome ['Physiological-Clinical']
rate O
was O
23.4 O
% O
in O
group O
1 O
, O
27.5 O
% O
in O
group O
2 O
, O
and O
28.1 O
% O
in O
group O
3 O
. O
['Physiological-Clinical']

We O
randomly O
assigned O
101 O
patients O
with O
cirrhosis O
of O
the O
liver O
and O
bleeding O
esophageal O
varices O
to O
undergo O
either O
emergency O
sclerotherapy O
( O
n O
= O
50 O
) O
or O
staple O
transection O
of O
the O
esophagus O
( O
n O
= O
51 O
) O
. O
[]

Efficacy O
was O
determined O
based O
on O
daytime O
intraocular O
pressure O
curve O
and O
safety O
by O
examining O
visual O
fields O
, O
visual O
acuity O
, O
optic O
discs O
, O
by O
determining O
blood O
pressure O
and O
pulse O
rate O
, O
and O
by O
performing O
Schirmer O
and O
fluorescein O
tests O
. O
[]

Because O
bacterial O
populations O
develop O
during O
the O
first O
day O
of O
life O
, O
the O
authors O
examined O
whether O
the O
early O
administration O
of O
bifidobacteria O
has O
a O
positive O
effect O
on O
the O
health B-outcome ['Physiological-Clinical']
of O
low O
birth O
weight O
infants O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
found O
that O
interviewer O
body O
mass O
index O
had O
no O
impact O
on O
self-reported O
energy O
intake O
during O
an O
in-person O
MP24R O
, O
and O
that O
telephone O
recall O
data O
were O
comparable O
with O
in-person O
recalls O
. O
[]

Unique O
identifier O
: O
NCT00282711 O
. O
[]

Vanderbilt O
University O
Medical O
Center, O
Nashville, O
TN. O
[]

Eight O
volunteers O
were O
enrolled O
in O
this O
four-arm O
, O
double-blind O
, O
cross-over O
, O
randomized O
study O
. O
[]

GMFRs O
after O
LAIV O
in O
years O
1 O
and O
2 O
ranged O
from O
1.2 O
to O
6.2 O
, O
compared O
with O
0.5-2.2 O
among O
placebo O
recipients O
. O
[]

CONCLUSIONS O
Retapamulin O
ointment O
1 O
% O
( O
bid O
) O
for O
5 O
days O
was O
as O
effective O
as O
oral O
cephalexin O
( O
bid O
) O
for O
10 O
days O
in O
treatment O
of O
patients O
with O
SID O
, O
and O
was O
well O
tolerated O
. O
[]

METHODS O
The O
randomized O
trial O
involved O
777 O
volunteers O
from O
the O
U.S. O
Army O
Airborne O
School O
, O
Fort O
Benning O
, O
Ga. O
Of O
this O
group O
, O
745 O
completed O
all O
study O
requirements O
( O
369 O
brace-wearers O
and O
376 O
non-brace-wearers O
) O
. O
[]

No O
robotic O
rehabilitation O
session O
had O
to O
be O
replaced B-outcome ['Life-Impact']
by O
conventional O
rehabilitation. O
[['Life-Impact']]

Treatment O
was O
associated O
with O
32 O
days O
longer B-outcome ['Physiological-Clinical']
gestation I-outcome ['Physiological-Clinical']
for O
the O
23 O
participants O
who O
had O
late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
spontaneous I-outcome ['Physiological-Clinical']
preterm I-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
( O
P= O
0.024 O
, O
Mann-Whitney O
U O
test O
) O
and O
significantly O
fewer O
infants O
had O
a O
birthweight O
below O
2,500 O
g B-outcome ['Physiological-Clinical']
( O
secondary O
outcome O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Chemotherapy O
treatments O
are O
intensive O
and O
difficult O
to O
endure O
. O
[]

After O
ulnar O
artery O
compression O
, O
the O
final O
incidence O
of O
RAO O
was O
4.1 O
% O
in O
the O
2,000-IU O
group O
and O
0.8 O
% O
in O
the O
5,000-IU O
group O
( O
p O
= O
0.03 O
) O
. O
[]

No O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
or O
toxicities B-outcome ['Adverse-effects']
were O
documented O
in O
any O
of O
the O
subjects O
during O
the O
administration O
period O
. O
['Adverse-effects', 'Adverse-effects']

Mild B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
to O
7vPnC O
were O
more O
common O
in O
the O
experimental O
group O
than O
the O
control O
group O
( O
100 O
% O
vs O
81.3 O
% O
; O
P O
= O
.002 O
) O
. O
['Physiological-Clinical']

Mean O
increases O
in O
erythrocyte O
riboflavin O
( O
P O
< O
0.0001 O
) O
and O
plasma B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
( O
P=0.01 O
) O
were O
greater O
in O
the O
FeR O
+ O
VA O
group O
than O
in O
the O
VA O
only O
group O
. O
['Physiological-Clinical']

BACKGROUND O
We O
compared O
the O
safety O
and O
immunogenicity O
of O
two O
combined O
diphtheria-tetanus-pertussis-inactivated O
poliovirus O
vaccines O
containing O
either O
acellular O
( O
Pa O
, O
SmithKline O
Beecham O
Biologicals O
) O
or O
whole O
cell O
( O
Pw O
, O
Pasteur O
Merieux O
Connaught O
) O
pertussis O
components O
, O
mixed O
with O
a O
Haemophilus O
influenzae O
type O
b O
polysaccharide O
polyribosylribitol O
phosphate-tetanus O
conjugate O
vaccine O
in O
an O
open O
, O
randomized O
study O
in O
healthy O
infants O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
extracorporeal O
shock O
wave O
therapy O
can O
safely O
and O
effectively O
relieve O
the O
pain B-outcome ['Physiological-Clinical']
associated O
with O
chronic O
plantar O
fasciitis O
compared O
to O
placebo O
treatment O
, O
as O
demonstrated O
by O
pain O
with O
walking O
in O
the O
morning O
. O
['Physiological-Clinical']

This O
could O
be O
observed O
in O
patients O
during O
exercise O
and O
in O
those O
in O
whom O
the O
ischemia B-outcome ['Physiological-Clinical']
was O
provoked O
by O
rapid O
cardiac O
stimulation O
. O
['Physiological-Clinical']

Quantitative O
measurements O
of O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
. O
['Life-Impact']

Low-dose O
aspirin O
increases O
gastrointestinal B-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
of O
transfused O
radiolabeled B-outcome ['Physiological-Clinical']
autologous I-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
the O
present O
randomized O
, O
double-blind O
study O
was O
to O
evaluate O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
proximal O
furcations O
treated O
with O
enamel O
matrix O
derivative O
proteins O
( O
EMD O
) O
. O
['Physiological-Clinical']

Those O
patients O
not O
surgically O
staged O
with O
only O
LAG O
for O
lymph O
node O
evaluation O
were O
less O
accurately O
staged O
, O
as O
reflected O
by O
a O
statistically O
significant O
reduced O
survival O
and O
earlier O
metastases O
. O
[]

of O
4.6 O
Gy O
. O
[]

Side O
effects O
, O
compliance B-outcome ['Life-Impact']
and O
treatment O
response O
were O
evaluated O
by O
questionnaire O
. O
['Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
data O
suggest O
that O
a O
5 O
alpha-reductase O
gene O
codes O
for O
an O
enzyme O
with O
affinity O
for O
multiple B-outcome ['Physiological-Clinical']
steroid I-outcome ['Physiological-Clinical']
substrates I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
relation O
was O
independent O
of O
treatment O
effect O
or O
change O
in O
low-density O
lipoprotein O
cholesterol O
level O
at O
1 O
year O
. O
[]

Interventions O
were O
conducted O
30 O
minutes O
daily O
for O
5-6 O
weeks O
. O
[]

TRIAL O
REGISTRATION O
umin.ac.jp/ctr O
Identifier O
: O
UMIN000002241 O
and O
UMIN000004393 O
. O
[]

The O
median O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
95 O
% O
confidence O
interval O
) O
for O
the O
placebo O
group O
was O
48 O
( O
42 O
, O
54 O
) O
hours O
compared O
with O
57 O
( O
38 O
, O
76 O
) O
hours O
in O
the O
dexamethasone O
group O
( O
p O
= O
0.19 O
) O
. O
['Resource-use']

0.1 O
kg O
) O
were O
used O
in O
a O
randomized O
complete O
block O
experiment O
to O
determine O
the O
effects O
of O
Aspergillus O
oryzae O
extract O
, O
Amaferm O
( O
AMF O
) O
supplementation O
( O
1 O
g/d O
) O
in O
an O
85 O
% O
concentrate O
diet O
on O
growth O
and O
carcass O
characteristics O
. O
[]

A O
5?C O
change O
in O
the O
4-day O
moving O
average O
of O
apparent O
temperature O
was O
associated O
with O
21.6 O
% O
( O
95 O
% O
CI O
: O
2.5 O
, O
44.2 O
; O
p O
= O
0.03 O
) O
higher O
CRP O
. O
[]

A O
treatment O
effect O
for O
haloperidol O
was O
detected O
only O
on O
live B-outcome ['Physiological-Clinical']
ratings I-outcome ['Physiological-Clinical']
and O
not O
on O
ratings O
of O
videotapes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
correlation O
with O
a O
concomitant O
decrease O
of O
triglyceride B-outcome ['Physiological-Clinical']
and O
cholesterol B-outcome ['Physiological-Clinical']
also O
induced O
by O
bezafibrate O
could O
not O
be O
proven O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
individual O
responsiveness O
to O
growth O
hormone O
( O
GH O
) O
treatment O
in O
GH-deficient O
adults O
is O
dependent O
on O
the O
level O
of O
GH-binding O
protein O
, O
body O
mass O
index O
, O
age O
, O
and O
gender O
. O
[]

DNA O
samples O
for O
the O
analysis O
of O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
pattern O
were O
prepared O
from O
primary O
tumors O
and O
matched O
synchronous O
lymph O
node O
metastases O
by O
tissue O
microdissection O
. O
['Physiological-Clinical']

The O
other O
two O
underwent O
a O
Nissen O
fundoplication O
. O
[]

DESIGN O
A O
single-site O
, O
unblinded O
randomized O
trial O
in O
New O
York O
City O
with O
3-month O
follow-up O
. O
[]

Iron O
and O
riboflavin O
supplements O
significantly O
reduced O
the O
prevalences O
of O
riboflavin B-outcome ['Physiological-Clinical']
deficiency I-outcome ['Physiological-Clinical']
( O
from O
60 O
% O
to O
6 O
% O
; O
P O
< O
0.0001 O
) O
, O
iron B-outcome ['Physiological-Clinical']
deficiency I-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
( O
from O
35 O
% O
to O
15 O
% O
; O
P O
< O
0.007 O
) O
, O
and O
abnormal B-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
( O
from O
87 O
% O
to O
30 O
% O
; O
P O
< O
0.05 O
) O
from O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

JET O
remains O
a O
relatively O
common O
postoperative B-outcome ['Physiological-Clinical']
arrhythmia I-outcome ['Physiological-Clinical']
, O
but O
it O
is O
less O
frequent O
than O
previously O
reported O
. O
['Physiological-Clinical']

Single O
nucleotide O
polymorphism O
in O
the O
hypoxia-inducible O
factor-1alpha O
gene O
in O
colorectal O
carcinoma O
. O
[]

Moreover O
, O
enalapril O
is O
more O
effective O
in O
reducing O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
augmentation I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
than O
indapamide O
. O
['Physiological-Clinical']

In O
two O
separate O
studies O
, O
eight O
GHD O
women O
randomly O
received O
either O
oral O
or O
transdermal O
estrogen O
for O
8 O
wk O
before O
crossing O
over O
to O
the O
alternate O
route O
of O
administration O
. O
[]

The O
study O
did O
not O
identify O
any O
subgroup O
of O
patients O
likely O
to O
derive O
a O
significant O
survival O
benefit O
from O
the O
addition O
of O
ATRA O
to O
chemotherapy O
. O
[]

Eighty O
patients O
treated O
all O
migraine O
attacks O
for O
6 O
months O
at O
home O
with O
a O
subcutaneous O
injection O
of O
sumatriptan O
6 O
mg. O
A O
second O
injection O
could O
be O
taken O
after O
1 O
to O
24 O
hours O
if O
relief O
was O
inadequate O
, O
or O
if O
the O
headache B-outcome ['Physiological-Clinical']
recurred O
, O
and O
rescue O
medication O
could O
be O
taken O
1 O
hour O
after O
the O
second O
injection O
. O
['Physiological-Clinical']

Two O
parallel O
prospective O
randomized O
studies O
have O
been O
undertaken O
by O
the O
EORTC O
Urological O
Group O
in O
previously O
untreated O
patients O
with O
prostatic O
cancer O
in O
order O
to O
compare O
low O
dose O
Stilboestrol O
versus O
Cyproterone O
acetate O
versus O
Medroxyprogesterone O
acetate O
in O
the O
first O
trial O
, O
and O
Stilboestrol O
versus O
Estracyt O
in O
the O
second O
trial O
. O
[]

The O
accuracy O
of O
the O
system O
is O
usually O
sufficient O
for O
clinical O
purposes O
, O
provided O
the O
calibration O
is O
checked O
every O
4 O
h O
. O
[]

Such O
findings O
suggest O
that O
self-disclosure O
by O
the O
therapist O
may O
improve O
both O
the O
quality O
of O
the O
therapeutic B-outcome ['Physiological-Clinical']
relationship I-outcome ['Physiological-Clinical']
and O
the O
outcome O
of O
treatment O
. O
['Physiological-Clinical']

Continuous O
intraoperative O
monitoring O
( O
CIM O
) O
for O
systemic O
leak O
from O
the O
perfusion O
circuit O
was O
performed O
using O
radioactive O
iodine-131 O
albumin O
. O
[]

Of O
251 O
evaluable O
patients O
, O
three O
induction O
regimens O
achieved O
similar O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Stool B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
Shigella I-outcome ['Physiological-Clinical']
, O
Salmonella B-outcome ['Physiological-Clinical']
, O
Campylobacter B-outcome ['Physiological-Clinical']
spp I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
had O
complete O
resection O
of O
gross O
tumor O
and O
underwent O
postoperative O
radiotherapy O
( O
6000-6300 O
rads O
over O
7-8 O
weeks O
) O
. O
[]

METHODS O
A O
total O
of O
379 O
patients O
undergoing O
the O
procedure O
were O
randomly O
enrolled O
in O
1 O
of O
3 O
groups O
. O
[]

Safety O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
immunogenicity B-outcome ['Physiological-Clinical']
after O
1 O
and O
2 O
doses O
of O
zoster O
vaccine O
in O
healthy O
adults O
?60 O
years O
of O
age O
. O
['Life-Impact', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Thirty-four O
were O
willing O
to O
make O
behavioural O
changes O
. O
[]

Vaccination O
coverage O
will O
be O
assessed O
at O
3-years O
of O
age, O
thus O
the O
trial O
is O
expected O
to O
be O
completed O
in O
March O
2019. O
[]

A O
transesophageal O
approach O
using O
light O
sedation O
has O
been O
proposed O
as O
a O
means O
of O
augmenting O
the O
success O
rate O
and O
avoiding O
the O
need O
for O
general O
anesthesia O
. O
[]

Both O
techniques O
provided O
good O
operating B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
, O
stable O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
mild O
to O
moderate O
sedation O
, O
without O
loss O
of O
verbal B-outcome ['Life-Impact']
contact I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Randomized O
study O
of O
six O
umbilical O
cord O
care O
regimens O
. O
[]

The O
study O
was O
undertaken O
in O
order O
to O
evaluate O
the O
effect O
of O
prednisone- O
and O
triple-treatment O
upon O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
is O
still O
unresolved O
whether O
survival B-outcome ['Mortality']
is O
prolonged O
by O
adjuvant O
treatment O
of O
the O
liver O
following O
curative O
resection O
of O
colorectal O
liver O
metastases O
. O
['Mortality']

Behavioral B-outcome ['Life-Impact']
rating O
scales O
( O
Clinical O
Global O
Impression O
Scale O
[ O
CGI-I O
] O
, O
Ritvo-Freeman O
Real O
Life O
Rating O
Scale O
[ O
RF-RLRS O
] O
) O
, O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
[ O
ABC O
] O
, O
Turgay O
DSM-IV O
Pervasive B-outcome ['Life-Impact']
Developmental I-outcome ['Life-Impact']
Disorder I-outcome ['Life-Impact']
Rating O
Scale O
[ O
TPDDRS O
] O
) O
and O
safety O
assessment O
scales O
( O
Extrapyramidal O
Symptoms O
Rating O
Scale O
[ O
ESRS O
] O
, O
UKU-Side O
Effect O
Rating O
Scale O
) O
were O
performed O
at O
12 O
, O
16 O
, O
20 O
and O
24 O
weeks O
, O
following O
the O
12 O
week O
double-blind O
phase O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Descriptive O
statistics O
, O
paired O
t-tests O
and O
general O
linear O
models O
adjusted O
for O
baseline O
dietary O
intake O
, O
age O
and O
gender O
were O
used O
to O
examine O
the O
effectiveness O
of O
different O
nutrition O
interventions O
. O
[]

CONCLUSIONS O
Omeprazole O
given O
as O
a O
continuous O
infusion O
of O
80 O
mg O
+ O
8 O
mg/h O
for O
72 O
h O
followed O
by O
omeprazole O
20 O
mg O
once O
daily O
raised O
the O
[]

Journal O
ID: O
101153627 O
[]

This O
information O
is O
not O
available O
for O
many O
early O
measurements O
. O
[]

Comparison O
of O
the O
therapeutic O
efficacy O
of O
phonophoresis O
and O
iontophoresis O
using O
dexamethasone O
sodium O
phosphate O
in O
the O
management O
of O
patients O
with O
knee O
osteoarthritis O
. O
[]

INTERVENTION O
( O
S O
) O
Performing O
IVF O
and O
ICSI O
on O
sibling O
oocytes O
. O
[]

A O
multicentre O
study O
. O
[]

Patients O
received O
either O
nicotinic O
acid O
( O
1.5 O
g O
three O
times O
daily O
) O
or O
no O
therapy O
( O
control O
period O
) O
for O
8 O
weeks O
each O
. O
[]

Both O
women O
with O
a O
history O
of O
PMS O
and O
women O
without O
responded O
with O
more O
negative O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
with O
the O
lower O
dose O
of O
MPA O
. O
['Life-Impact']

Onset O
of O
action O
following O
formoterol O
Turbuhaler O
and O
salbutamol O
pMDI O
in O
reversible O
chronic O
airway O
obstruction O
. O
[]

In O
38 O
patients O
who O
completed O
Phase O
1 O
, O
significant O
delay O
in O
pain B-outcome ['Physiological-Clinical']
increase O
was O
observed O
in O
the O
CMZ O
group O
as O
compared O
with O
placebo O
( O
P O
= O
0.038 O
) O
. O
['Physiological-Clinical']

Eyes O
treated O
with O
latanoprost O
, O
stored O
both O
at O
4 O
degrees O
C O
and O
30 O
degrees O
C O
, O
achieved O
statistically O
significantly O
lower O
mean O
IOPs B-outcome ['Physiological-Clinical']
than O
untreated O
eyes O
at O
all O
time O
points O
, O
except O
at O
21 O
hours O
treated O
by O
the O
drug O
stored O
at O
30 O
degrees O
C. O
We O
subtracted O
the O
IOP O
of O
eyes O
receiving O
latanoprost O
from O
the O
IOP O
of O
untreated O
eyes O
for O
each O
time O
point O
to O
evaluate O
the O
efficacy O
of O
the O
eye O
drops O
( O
delta O
IOP O
) O
. O
['Physiological-Clinical']

INTRODUCTION O
Fasciculations B-outcome ['Physiological-Clinical']
during O
rapid-sequence O
intubation O
may O
lead O
to O
increased O
intracranial O
pressure O
and O
emesis B-outcome ['Physiological-Clinical']
with O
aspiration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
was O
measured O
weekly O
with O
the O
mean O
values O
of O
weeks O
3 O
and O
4 O
of O
each O
phase O
used O
for O
analysis O
. O
['Physiological-Clinical']

Aripiprazole O
treatment O
of O
irritability O
associated O
with O
autistic O
disorder O
and O
the O
relationship O
between O
prior O
antipsychotic O
exposure O
, O
adverse O
events O
, O
and O
weight O
change O
. O
[]

After O
baseline O
competency O
assessment, O
parents O
received O
instruction O
according O
to O
their O
group. O
[]

DESIGN O
, O
SETTING O
, O
PARTICIPANTS O
, O
& O
MEASUREMENTS O
Forty O
patients O
who O
had O
diabetes O
with O
nephropathy O
and O
arteriosclerosis O
obliterans O
and O
had O
already O
been O
treated O
with O
angiotensin O
II O
receptor O
blocker O
( O
n O
= O
40 O
) O
were O
randomly O
assigned O
to O
sarpogrelate O
( O
300 O
mg/d O
; O
n O
= O
20 O
) O
or O
aspirin O
group O
( O
100 O
mg/d O
; O
n O
= O
20 O
) O
. O
[]

No O
relevant O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
with O
any O
of O
the O
induction O
regimens O
. O
['Adverse-effects']

BACKGROUND O
Aspirin O
has O
been O
found O
to O
prevent O
angiotensin O
II-induced O
hypertension O
and O
to O
induce O
nitric O
oxide O
( O
NO O
) O
release O
from O
vascular O
endothelium O
. O
[]

CONCLUSIONS O
The O
use O
of O
intraoperative O
mitomycin O
C O
during O
deep O
sclerectomy O
significantly O
reduced O
the O
postoperative O
IOP O
and O
increased O
the O
success O
rate O
of O
the O
procedure O
. O
[]

RESULTS O
After O
2 O
and O
4 O
months O
of O
treatment O
with O
the O
drug O
regimen O
, O
hs-CRP B-outcome ['Physiological-Clinical']
and O
TA B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
decreased O
and O
consequently O
increased O
among O
the O
E O
( O
+ O
) O
L O
( O
+ O
) O
, O
L O
( O
+ O
) O
and O
E O
( O
+ O
) O
groups O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
the O
occlusal B-outcome ['Physiological-Clinical']
fissure I-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
was O
easy O
to O
apply O
, O
repeatable O
and O
sufficiently O
sensitive O
to O
detect O
plaque O
removed O
by O
brushing O
. O
['Physiological-Clinical']

BACKGROUND O
There O
are O
few O
published O
placebo-controlled O
clinical O
trials O
demonstrating O
the O
efficacy O
of O
the O
newer O
antidepressants O
in O
markedly O
or O
severely O
depressed O
hospitalized O
patients O
. O
[]

In O
pregnant O
women O
neither O
approach O
was O
beneficial O
, O
with O
some O
evidence O
of O
post-partum O
relapse O
. O
[]

RESULTS O
The O
area O
under O
the O
curve O
for O
N-acetylcysteine O
was O
significantly O
higher O
for O
phase O
II O
than O
phase O
I O
( O
P O
< O
.05 O
, O
two-tailed O
paired O
t-test O
) O
. O
[]

Unfortunately O
, O
enrollment O
was O
terminated O
because O
of O
low O
accrual O
of O
women O
with O
cervicitis O
of O
unknown O
etiology O
, O
but O
important O
prevalence O
and O
outcome O
data O
were O
obtained O
. O
[]

RESULTS O
Suture B-outcome ['Physiological-Clinical']
line I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
minutes I-outcome ['Physiological-Clinical']
was O
present O
in O
7 O
( O
14 O
% O
) O
of O
51 O
patients O
in O
the O
BP O
group O
and O
24 O
( O
55 O
% O
) O
of O
44 O
patients O
in O
the O
Dacron O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

A O
proof O
of O
concept O
study O
to O
evaluate O
putative O
benefits O
of O
montelukast O
in O
moderate O
persistent O
asthmatics O
. O
[]

METHODS O
Open O
, O
randomised O
, O
2-way O
crossover O
, O
clinical O
pharmacology O
study O
. O
[]

Treatment O
efficacy O
was O
based O
on O
improving O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
and O
EOG B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
( O
amplitude O
or O
frequency O
of O
nystagmus B-outcome ['Physiological-Clinical']
, O
or O
both O
) O
by O
at O
least O
50 O
% O
of O
pretreatment O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Gonorrhea O
Treatment O
Study O
Group O
. O
[]

Glucocorticoid O
receptor O
( O
GR O
) O
binding O
and O
neurotransmitter O
concentrations O
were O
measured O
in O
stress-related O
brain O
regions O
, O
and O
histological O
analyses O
of O
the O
adrenal O
were O
performed O
. O
[]

Compared O
with O
those O
in O
the O
rhodiola O
treatment O
group, O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
scores O
of O
patients O
in O
the O
rhodiola+non-invasive O
breathing O
group O
decreased O
after O
treatment O
P<0.05. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

ERN O
in O
TMS O
treatment O
group O
became O
significantly O
more O
negative O
. O
[]

Data O
analysis O
methods O
used O
would O
include O
Kaplan-Meier O
plots O
, O
log-rank O
test O
and O
Cox O
modeling O
. O
[]

Total O
platelet B-outcome ['Physiological-Clinical']
and O
fibrin B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
was O
determined O
by O
immunoenzymatic O
methods O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
lack O
of O
relationship O
between O
ability B-outcome ['Life-Impact']
and O
attention B-outcome ['Life-Impact']
to O
familiar O
faces O
may O
indicate O
that O
children O
across O
the O
autism O
spectrum O
are O
able O
to O
fixate O
these O
faces O
in O
a O
similar O
way O
. O
['Life-Impact', 'Life-Impact']

PURPOSE: O
To O
evaluate O
3-dimensional O
epithelial O
remodeling O
in O
patients O
undergoing O
myopic O
laser O
in O
situ O
keratomileusis O
(LASIK) O
versus O
small O
incision O
lenticule O
extraction O
(SMILE). O
[]

Baseline O
characteristics O
differed O
between O
genders, O
with O
women O
being O
younger, O
having O
better O
lung O
function O
and O
more O
often O
experiencing O
>/=2 O
exacerbations O
in O
the O
previous O
year. O
[]

PURPOSE O
The O
goal O
of O
the O
study O
was O
to O
test O
( O
1 O
) O
whether O
individuals O
in O
an O
RCT O
of O
pharmacotherapy O
and O
counseling O
for O
smoking O
cessation O
differed O
in O
their O
healthcare O
costs O
around O
the O
cessation O
period O
, O
and O
( O
2 O
) O
whether O
the O
healthcare O
costs O
of O
those O
in O
the O
trial O
who O
successfully O
quit O
were O
different O
from O
a O
matched O
sample O
of O
smokers O
in O
the O
community O
. O
[]

This O
study O
's O
objective O
was O
to O
determine O
the O
efficacy O
of O
FloSeal O
hemostatic O
matrix O
( O
Baxter O
Healthcare O
Corporation O
, O
Hayward O
, O
CA O
) O
in O
epistaxis O
refractory O
to O
nasal O
packing O
. O
[]

[ O
Physical O
performance O
and O
sedation O
: O
comparative O
study O
of O
the O
effects O
of O
a O
benzodiazepine O
( O
temazepam O
) O
and O
of O
a O
non-benzodiazepine O
hypnotic O
( O
zolpidem O
) O
] O
. O
[]

Effects O
of O
nifedipine O
and O
nitrendipine O
on O
insulin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
obese O
patients O
. O
['Physiological-Clinical']

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Further O
studies O
are O
indicated O
to O
evaluate O
whether O
montelukast O
exhibits O
additive O
effects O
to O
ICS/long-acting O
beta2-adrenoceptor O
agonist O
combination O
inhalers O
upon O
clinically O
[]

Dogs O
and O
cats O
with O
naturally O
occurring O
flea O
infestations O
, O
some O
of O
which O
also O
had O
signs O
associated O
with O
FAD O
, O
were O
assigned O
randomly O
to O
receive O
three O
months O
of O
topical O
treatment O
with O
selamectin O
( O
220 O
dogs O
, O
189 O
cats O
) O
or O
a O
positive-control O
product O
( O
dogs O
: O
fenthion O
, O
n=81 O
; O
cats O
: O
pyrethrins O
, O
n=66 O
) O
. O
[]

All O
had O
prolonged O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
confirmed O
by O
actigraphy O
showing O
a O
mean O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
of O
30 O
minutes O
or O
more O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
2985213R O
[]

Aripiprazole-treated O
AN O
subjects O
were O
more O
likely O
than O
PAE O
subjects O
to O
report O
somnolence O
( O
11.9 O
% O
vs. O
2.8 O
% O
) O
, O
sedation O
( O
22.7 O
% O
vs. O
11.1 O
% O
) O
, O
or O
fatigue O
( O
17.0 O
% O
vs. O
13.9 O
% O
) O
. O
[]

Total O
dose B-outcome ['Life-Impact']
and O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
propofol O
were O
similar O
in O
all O
groups O
. O
['Life-Impact', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Ninety-two O
patients O
with O
advanced O
breast O
cancer O
received O
arzoxifene O
20 O
or O
50 O
mg/day O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
assess O
any O
inconsistency O
with O
the O
protocol O
guidelines O
for O
preoperative O
radiotherapy O
for O
rectal O
cancer O
among O
radiotherapy O
institutions O
participating O
in O
the O
framework O
of O
a O
multicentre O
phase-III O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
clinical O
trial O
. O
[]

Four O
of O
the O
six O
patients O
who O
had O
a O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
during O
a O
reactivation O
of O
their O
disease O
were O
in O
the O
heparin O
group O
. O
['Physiological-Clinical']

The O
result O
was O
robust O
in O
the O
sensitivity O
analysis O
. O
[]

Hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
longer O
for O
overweight O
patients O
than O
for O
normal-weight O
patients O
undergoing O
OA O
( O
3.0 O
vs O
2.0 O
, O
p O
< O
0.01 O
) O
. O
['Resource-use']

Following O
maintenance O
evaluations O
, O
the O
drug O
was O
tapered O
down O
over O
2 O
weeks O
. O
[]

PURPOSE O
Special-effect O
contact O
lenses O
( O
opaque O
, O
tinted O
soft O
contact O
lenses O
that O
incorporate O
decorative O
images O
such O
as O
cateyes O
, O
stars O
, O
or O
hearts O
to O
alter O
eye O
color O
and O
structure O
) O
have O
become O
increasingly O
popular O
. O
[]

However, O
there O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
for O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
(5.0 O
vs. O
4.0 O
months; O
HR O
= O
1.03; O
95% O
CI, O
0.56-1.90; O
P O
= O
.914). O
[['Mortality']]

They O
are O
proposed O
as O
being O
an O
optimal O
method O
for O
teaching O
clinical O
reasoning O
skills O
. O
[]

The O
mean O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
scores O
2 O
hours O
after O
pain B-outcome ['Physiological-Clinical']
medications O
were O
taken O
were O
3.9 O
NRS O
units O
in O
the O
hydrocodone/acetaminophen O
group O
versus O
3.5 O
NRS O
units O
in O
the O
codeine/acetaminophen O
group O
, O
for O
a O
difference O
of O
0.4 O
NRS O
units O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
-0.3 O
to O
1.2 O
NRS O
units O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

and O
AUCtablet O
were O
4,049 O
and O
3,334 O
ng.h/ml O
, O
respectively O
. O
[]

Low-fluence O
photodynamic O
therapy O
versus O
ranibizumab O
for O
chronic O
central O
serous O
chorioretinopathy O
: O
one-year O
results O
of O
a O
randomized O
trial O
. O
[]

One O
group O
of O
25 O
men O
received O
injection O
papaverine O
initially O
followed O
by O
oral O
sildenafil O
, O
and O
another O
25 O
received O
oral O
sildenafil O
followed O
by O
injection O
papaverine O
. O
[]

This O
was O
a O
12-month O
randomized O
, O
prospective O
, O
multicenter O
, O
double-masked O
, O
placebo-controlled O
, O
Food O
and O
Drug O
Administration O
approved O
clinical O
trial O
designed O
to O
compare O
rheopheresis O
treatment O
with O
placebo-control O
treatment O
. O
[]

Cone O
biopsy O
: O
has O
endocervical O
sampling O
a O
role O
? O
[]

Publication O
Type: O
Journal O
Article O
[]

Prior O
focal O
( O
n O
= O
31 O
) O
or O
panretinal O
( O
n O
= O
25 O
) O
laser O
coagulation O
was O
permitted O
. O
[]

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
efficacy O
of O
neridronate O
, O
a O
relatively O
new O
bisphosphonate O
, O
to O
prevent O
bone O
loss O
during O
androgen O
ablation O
. O
[]

KEY O
RESULTS O
Throughout O
extended O
wakefulness O
, O
the O
carriers O
of O
haplotype O
HT4 O
performed O
faster O
on O
the O
PVT O
than O
carriers O
of O
non-HT4 O
haplotype O
alleles O
. O
[]

Previous O
research O
strongly O
suggests O
that O
positioning O
with O
the O
healthy O
( O
unaffected O
) O
lung O
in O
the O
dependent O
lateral O
( O
down O
) O
position O
is O
related O
to O
improved O
oxygenation O
, O
but O
knowledge O
about O
whether O
this O
effect O
is O
maintained O
over O
time O
is O
lacking O
. O
[]

After O
3 O
months O
, O
11/19 O
( O
57.9 O
% O
) O
PPI-treated O
patients O
had O
a O
complete O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
; O
6/8 O
nonresponders O
were O
treated O
with O
PPI O
for O
another O
3 O
months O
and O
became O
all O
symptom-free B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
controlled O
trial O
to O
improve O
colon O
cancer O
screening O
in O
rural O
family O
medicine O
: O
an O
Iowa O
Research O
Network O
( O
IRENE O
) O
study O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
between O
treatment O
groups O
for O
mean O
change O
in O
Fridericia O
's O
correction O
of O
QT O
during O
the O
trial O
. O
[]

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
( O
ii O
) O
ease B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
swallowing I-outcome ['Physiological-Clinical']
, O
( O
iii O
) O
satisfaction O
of O
daily B-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
, O
( O
iv O
) O
dependence O
on O
medications B-outcome ['Resource-use']
, O
( O
v O
) O
working B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
, O
( O
vi O
) O
fatigue B-outcome ['Physiological-Clinical']
, O
( O
vii O
) O
appetite B-outcome ['Physiological-Clinical']
, O
( O
viii O
) O
sociality B-outcome ['Life-Impact']
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Study O
2 O
included O
49 O
subjects O
assigned O
to O
risperidone O
only O
and O
75 O
subjects O
assigned O
to O
risperidone O
plus O
parent O
training O
. O
[]

The O
prevalence O
of O
atelectasis O
was O
10% O
for O
the O
PAR-G O
and O
30% O
for O
the O
1PO-G O
(p=0.0027). O
[]

Long-term O
anticoagulant O
treatment O
after O
acute O
myocardial O
infarction O
. O
[]

The O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
rate O
was O
1.7 O
% O
( O
7/424 O
) O
in O
the O
fondaparinux-treated O
patients O
and O
5.3 O
% O
( O
22/418 O
) O
in O
the O
placebo-treated O
patients O
( O
odds O
ratio O
reduction O
69.8 O
% O
; O
95 O
% O
confidence O
interval O
27.9-87.3 O
; O
P O
= O
0.004 O
) O
. O
['Physiological-Clinical']

Blood O
was O
obtained O
hourly O
. O
[]

Sixty O
women O
were O
qualified O
to O
participate O
in O
the O
study O
. O
[]

Four O
studies O
( O
N O
= O
665 O
) O
demonstrate O
that O
the O
mere O
presence O
of O
highly O
dissimilar O
fillers O
inflates O
witnesses O
' O
confidence B-outcome ['Life-Impact']
in O
a O
mistaken O
identification O
( O
Studies O
1-4 O
) O
, O
provides O
evidence O
that O
this O
['Life-Impact']

For O
plasma O
glucose O
, O
insulin O
and O
leptin O
levels O
and O
BChE O
activity O
fasting O
blood O
was O
used O
. O
[]

During O
the O
study O
, O
56.2 O
percent O
of O
patients O
in O
the O
etanercept O
group O
and O
57.1 O
percent O
of O
those O
in O
the O
control O
group O
had O
at O
least O
one O
severe B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
life-threatening I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
or O
died B-outcome ['Mortality']
( O
P=0.90 O
) O
. O
['Adverse-effects', 'Mortality']

AIM O
To O
follow-up O
, O
one O
year O
later O
, O
a O
double-blind O
, O
randomised O
study O
, O
which O
investigated O
the O
effect O
of O
regular O
brushing O
with O
dentifrices O
on O
the O
oral O
health O
of O
an O
economically O
disadvantaged O
rural O
population O
in O
Andhra O
Pradesh O
, O
India O
who O
were O
primarily O
users O
of O
traditional O
materials O
. O
[]

Multicenter O
trial O
of O
cryotherapy O
for O
retinopathy O
of O
prematurity O
: O
preliminary O
results O
. O
[]

OBJECTIVE O
To O
investigate O
the O
optimum O
conduit O
for O
coronary O
targets O
other O
than O
the O
left O
anterior O
descending O
artery O
, O
we O
evaluated O
long-term O
patencies O
and O
clinical O
outcomes O
of O
the O
radial O
artery O
, O
right O
internal O
thoracic O
artery O
, O
and O
saphenous O
vein O
through O
the O
Radial O
Artery O
Patency O
and O
Clinical O
Outcomes O
trial O
. O
[]

There O
is O
no O
consistently O
safe O
, O
effective O
treatment O
for O
the O
maintenance O
of O
remission O
. O
[]

Botulinum O
toxin O
a O
has O
antinociceptive B-outcome ['Physiological-Clinical']
effects O
in O
treating O
interstitial O
cystitis O
. O
['Physiological-Clinical']

[ O
Intra-uterine O
insemination O
with O
controlled O
ovarian O
hyperstimulation O
compared O
to O
an O
expectant O
management O
in O
couples O
with O
unexplained O
subfertility B-outcome ['Physiological-Clinical']
and O
an O
intermediate O
prognosis O
: O
a O
randomised O
study O
] O
. O
['Physiological-Clinical']

An O
estimated O
15 O
% O
of O
patients O
with O
diabetes O
will O
develop O
a O
foot B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
sometime O
in O
their O
life O
, O
making O
them O
30 O
to O
40 O
times O
more O
likely O
to O
undergo O
amputation O
due O
to O
a O
non-healing O
foot O
ulcer O
than O
the O
non-diabetic O
population O
. O
['Physiological-Clinical']

We O
conclude O
that O
effective O
normalisation O
of O
hypercholesterolaemia B-outcome ['Physiological-Clinical']
may O
retard O
the O
progression O
of O
diabetic B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

SUBJECTS O
n O
= O
81 O
; O
mean O
age O
11 O
months O
; O
79 O
contribute O
longitudinal O
data O
; O
44 O
every O
measurement O
. O
[]

As O
a O
result O
of O
our O
study O
, O
caution O
seems O
to O
be O
necessary O
if O
acylaminopenicillins O
are O
administered O
in O
the O
early O
postoperative O
period O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
monolateral O
postmastectomy O
lymphedema O
were O
randomized O
to O
receive O
two O
cycles O
of O
intermittent O
pneumatic O
compression O
( O
PC O
group O
) O
, O
i.e. O
, O
five O
two-hour O
sessions O
per O
week O
for O
two O
weeks O
, O
to O
be O
repeated O
after O
a O
five-week O
interval O
, O
or O
to O
no O
treatment O
( O
control O
group O
) O
. O
[]

Early O
after O
surgery O
, O
the O
No O
Pres O
group O
had O
lower B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
and O
stroke B-outcome ['Physiological-Clinical']
work I-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
( O
P O
< O
.05 O
by O
repeated-measures O
[ O
rm O
] O
ANOVA O
) O
than O
the O
Pres O
group O
did O
at O
similar O
end-diastolic O
volume O
indexes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
significantly O
higher O
proportion O
of O
ICS O
than O
placebo O
participants O
who O
complied O
with O
using O
their O
inhaler O
reported O
easy B-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
( O
11.2 O
% O
vs O
3.5 O
% O
, O
respectively O
) O
and O
the O
slow B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
cuts I-outcome ['Physiological-Clinical']
or O
sores B-outcome ['Physiological-Clinical']
( O
2.4 O
% O
vs O
0.5 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOMES O
AND O
MEASURES O
Primary O
outcomes O
were O
parental B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
and O
maternal B-outcome ['Life-Impact']
depressive I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

1.3 O
mSv O
; O
amount O
of O
contrast O
agent:57.1 O
? O
[]

A O
randomized O
field O
trial O
was O
conducted O
with O
500 O
mother-child O
pairs O
from O
a O
low-income O
area O
of O
S?o O
Leopoldo O
, O
State O
of O
Rio O
Grande O
do O
Sul O
, O
Brazil O
, O
to O
evaluate O
the O
impact O
of O
a O
nutritional O
intervention O
in O
the O
first O
year O
of O
life O
on O
the O
dietary O
quality O
of O
3- O
to O
4-y-old O
children O
. O
[]

BACKGROUND: O
Endometriosis O
is O
the O
major O
cause O
of O
progressive O
pelvic O
pain O
and O
subfertility. O
[]

Results: O
19 O
patients O
were O
randomly O
distributed O
in O
57.89% O
in O
the O
G2 O
and O
42.11% O
in O
the O
G1. O
[]

Strength O
of O
hand O
grip O
was O
the O
best O
predictor O
of O
volume O
delivered O
and O
was O
more O
strongly O
correlated O
with O
volumes O
delivered O
by O
one O
rather O
than O
two O
hands O
. O
[]

This O
study O
demonstrates O
that O
ketorolac O
relieves O
pain B-outcome ['Physiological-Clinical']
when O
delivered O
by O
EMDA O
and O
offers O
longer-lasting O
pain B-outcome ['Physiological-Clinical']
relief O
than O
does O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
controlled O
study O
of O
customized O
preventive O
medicine O
reminder O
letters O
in O
a O
community O
practice O
. O
[]

at O
250 O
mg O
m-2 O
per O
day O
X O
V O
every O
4 O
weeks O
. O
[]

RESULTS O
In O
total O
, O
155 O
patients O
were O
randomized O
. O
[]

Infant B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
increases O
with O
both O
smoking O
cessation O
and O
smoking O
reduction O
, O
suggesting O
that O
peer O
counseling O
intervention O
programs O
may O
improve O
newborn B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
despite O
their O
failure O
to O
affect O
smoking O
cessation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effect O
of O
trandolapril O
( O
T O
) O
and O
its O
fixed-dose O
combination O
with O
verapamil O
( O
FDTV O
) O
on O
SAM O
levels O
in O
hypertensive O
type-2 O
diabetic O
patients O
. O
[]

CONCLUSIONS O
Rationing O
by O
delay O
was O
not O
detrimental O
to O
either O
mental O
or O
physical O
health O
and O
patients O
in O
both O
arms O
of O
the O
study O
showed O
significant O
and O
similar O
improvement O
in O
health O
by O
15 O
months O
. O
[]

Effects O
of O
antihypertensive O
drugs O
on O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
adolescents O
. O
['Life-Impact']

BACKGROUND: O
This O
study O
assessed O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
two O
common O
types O
of O
exercise O
training-high-intensity O
interval O
training O
(HIIT) O
and O
moderate-intensity O
continuous O
training O
(MICT)-in O
adults O
with O
Crohn's O
disease O
(CD). O
[['Life-Impact'], ['Life-Impact']]

CONCLUSION O
The O
use O
of O
vaginal O
misoprostol O
for O
second O
trimester O
medical O
abortion O
resulted O
in O
a O
higher O
success B-outcome ['Physiological-Clinical']
rate O
than O
sublingual O
misoprostol O
at O
24 O
hours O
but O
the O
abortion B-outcome ['Mortality']
rate O
was O
similar O
at O
48 O
hours O
. O
['Physiological-Clinical', 'Mortality']

Journal O
ID: O
7501160 O
[]

RESULTS: O
Sixty-five O
patients O
completed O
the O
study, O
including O
33 O
in O
the O
control O
group O
and O
32 O
in O
the O
treatment O
group. O
[]

A O
limited O
sampling O
method O
for O
the O
estimation O
of O
flunarizine O
area O
under O
the O
curve O
( O
AUC O
) O
and O
maximum B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sodium O
cromoglycate O
formulated O
as O
a O
pressurized O
aerosol O
( O
2 O
mg O
4-times O
daily O
) O
and O
placebo O
were O
compared O
in O
31 O
adult O
asthmatic O
patients O
in O
a O
double-blind O
crossover O
trial O
lasting O
12 O
weeks O
. O
[]

The O
effects O
of O
a O
multi-component O
higher-functioning O
autism O
anti-stigma O
program O
on O
adolescent O
boys O
. O
[]

A O
similar O
number O
of O
double-blinded B-outcome ['Resource-use']
Pap I-outcome ['Resource-use']
smears I-outcome ['Resource-use']
and O
colposcopies B-outcome ['Resource-use']
with I-outcome ['Resource-use']
biopsy I-outcome ['Resource-use']
were O
performed O
in O
randomly O
selected O
women O
in O
the O
control O
group O
. O
['Resource-use', 'Resource-use']

However, O
there O
is O
a O
paucity O
of O
research O
exploring O
the O
potential O
benefit O
of O
FODMAP O
strategies O
to O
support O
healthy, O
recreational O
athletes O
who O
experience O
GI O
issues O
during O
training. O
[]

A O
sample O
of O
301 O
volunteer O
subjects O
recruited O
from O
the O
waiting O
list O
for O
treatment O
in O
the O
Beth O
Israel O
methadone O
program O
were O
randomly O
assigned O
to O
immediate O
entry O
into O
the O
interim O
clinic O
or O
a O
control O
group O
. O
[]

Title: O
Effect O
of O
hand O
washing O
and O
personal O
hygiene O
on O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
: O
A O
community O
intervention O
study. O
[['Physiological-Clinical']]

Nothing O
was O
administered O
to O
the O
Control O
group O
. O
[]

In O
the O
control O
group O
, O
antibiotic O
therapy O
was O
administrated O
for O
2 O
weeks O
, O
or O
antibiotic O
therapy O
was O
continued O
because O
of O
confirmed O
infection O
until O
clinical O
signs O
and O
symptoms O
of O
infection O
disappeared O
over O
3 O
days O
. O
[]

The O
incidence O
of O
tremor B-outcome ['Physiological-Clinical']
was O
similar O
with O
the O
two O
medications O
. O
['Physiological-Clinical']

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
was O
higher O
in O
the O
vilazodone O
group O
( O
57.6 O
% O
) O
than O
in O
the O
moxifloxacin O
( O
37.0 O
% O
) O
and O
placebo O
( O
35.6 O
% O
) O
groups O
, O
though O
AEs B-outcome ['Adverse-effects']
were O
generally O
mild O
to O
moderate O
in O
severity O
and O
resulted O
in O
few O
discontinuations O
. O
['Adverse-effects', 'Adverse-effects']

MATERIALS O
AND O
METHODS O
We O
used O
100 O
ml O
of O
iopamidol O
300 O
at O
an O
injection O
rate O
of O
3.0 O
ml/s O
, O
100 O
ml O
of O
iopamidol O
300 O
at O
an O
injection O
rate O
of O
3.7 O
ml/s O
, O
and O
80 O
ml O
of O
iopamidol O
370 O
at O
an O
injection O
rate O
of O
3.0 O
ml/s O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
in O
the O
treatment O
of O
myofascial O
pain O
dysfunction O
. O
[]

Height O
and O
weight O
data O
were O
available O
at O
baseline O
for O
788 O
( O
83 O
% O
) O
subjects O
. O
[]

Most O
placebo O
patients O
discontinued O
by O
taking O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
( O
ibuprofen O
200 O
mg O
) O
on O
the O
first O
day O
. O
['Resource-use']

CONCLUSIONS: O
L-Methylfolate O
was O
associated O
with O
no O
change O
in O
efficacy O
on O
measures O
relevant O
to O
neuropsychiatric B-outcome ['Life-Impact', 'Life-Impact']
function I-outcome ['Life-Impact', 'Life-Impact']
in O
adults O
with O
ADHD, O
other O
than O
suggestion O
of O
reduced O
efficacy O
of O
methylphenidate. O
[['Life-Impact', 'Life-Impact']]

This O
study O
reports O
on O
the O
results O
of O
a O
randomized O
controlled O
trial O
that O
evaluated O
a O
caregiver-based O
intervention O
program O
for O
children O
with O
autism O
in O
community O
day-care O
centers O
. O
[]

In O
this O
study O
, O
we O
tested O
the O
hypothesis O
that O
delusional O
schizophrenia O
patients O
are O
more O
likely O
than O
non-delusional O
schizophrenia O
patients O
and O
healthy O
participants O
to O
assign O
affective O
meanings O
to O
neutral O
stimuli O
. O
[]

CONCLUSIONS O
Patterns O
of O
antenatal O
care O
involving O
fewer O
routine O
visits O
for O
women O
at O
low O
risk O
may O
lead O
to O
reduced O
psychosocial B-outcome ['Life-Impact']
effectiveness O
and O
dissatisfaction B-outcome ['Life-Impact']
with O
frequency O
of O
visits O
. O
['Life-Impact', 'Life-Impact']

Title: O
[Clinical O
observation O
of O
LOP O
chemotherapy O
combined O
with O
radiotherapy O
in O
the O
treatment O
of O
early O
nasal O
NK/T O
cell O
lymphoma]. O
[]

AIDS O
Clinical O
Trials O
Group O
Protocol O
021 O
. O
[]

Parenteral O
analgesia O
with O
Tramal O
was O
performed O
in O
23 O
normal O
deliveries O
. O
[]

Fourty-four O
DES-exposed O
offspring O
had O
their O
vaginal O
adenosis O
treated O
with O
the O
carbon O
dioxide O
laser O
( O
group O
I O
) O
, O
and O
the O
remaining O
35 O
DES-exposed O
offspring O
( O
group O
II O
) O
did O
not O
receive O
any O
specific O
treatment O
for O
this O
condition O
. O
[]

The O
outcome O
was O
assessed O
by O
means O
of O
direct O
observations O
( O
n O
= O
11 O
) O
and O
on O
the O
basis O
of O
scores O
on O
a O
list O
of O
target B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
, O
and O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

T O
Kujala O
score O
increased O
from O
70.77 O
points O
preoperatively O
to O
94.32 O
postoperatively O
(P O
< O
.001). O
[]

In O
the O
combination O
regimen O
vindesine O
given O
at O
3 O
mg O
m-2 O
per O
week O
was O
included O
. O
[]

Following O
cessation O
of O
raloxifene O
( O
group O
2 O
) O
, O
bone B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
returned O
to O
baseline O
levels O
( O
by O
120 O
weeks O
) O
. O
['Physiological-Clinical']

The O
daily O
administration O
of O
60 O
mg O
of O
the O
beta-carotene O
preparation O
( O
30 O
mg O
of O
all-trans O
beta-carotene O
and O
30 O
mg O
of O
9-cis O
beta-carotene O
) O
was O
performed O
and O
beta-carotene O
concentrations O
were O
determined O
in O
the O
plasma B-outcome ['Physiological-Clinical']
, O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
platelets O
( O
PLT O
) O
, O
and O
mononuclear B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Of O
57 O
patients O
for O
whom O
we O
thought O
an O
operative O
intervention O
was O
necessary O
, O
30 O
cases O
in O
the O
first O
group O
had O
a O
TURP O
and O
24 O
cases O
in O
the O
second O
group O
had O
a O
PKRP O
. O
[]

Changes O
in O
organ O
function O
and O
outcome O
were O
also O
recorded O
at O
the O
same O
time O
points O
. O
[]

These O
results O
provide O
direct O
evidence O
for O
spinal O
inhibition O
as O
one O
mechanism O
of O
placebo O
analgesia O
and O
highlight O
that O
psychological O
factors O
can O
act O
on O
the O
earliest O
stages O
of O
pain O
processing O
in O
the O
central O
nervous O
system O
. O
[]

To O
gain O
more O
insight O
into O
the O
consequences O
of O
curing O
contraction O
within O
the O
tooth O
cavity O
, O
we O
assessed O
the O
margin O
behavior O
of O
12 O
contemporary O
restorative O
systems O
in O
class O
V O
restorations O
with O
margins O
located O
on O
enamel O
and O
dentin O
after O
mechanical O
loading O
and O
water O
storage O
. O
[]

Eleven O
patients O
were O
treated O
in O
each O
group O
. O
[]

After O
four O
weeks O
of O
treatment O
and O
24 O
hours O
since O
the O
patient O
's O
last O
dose O
, O
both O
cetamolol O
groups O
showed O
a O
significantly O
greater O
( O
P O
less O
than O
or O
equal O
to O
.05 O
) O
reduction O
in O
supine B-outcome ['Physiological-Clinical']
systolic/diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
-18.1 O
+/- O
2.3/-9.2 O
+/- O
1.5 O
mm O
Hg O
[ O
low O
dose O
] O
and O
-17.3 O
+/- O
2.3/-8.3 O
+/- O
1.6 O
mm O
Hg O
[ O
high O
dose O
] O
) O
than O
the O
placebo O
group O
( O
-9.9 O
+/- O
2.5/-3.5 O
+/- O
1.7 O
mm O
Hg O
) O
. O
['Physiological-Clinical']

The O
economics O
of O
behavioural O
approaches O
to O
improving O
health O
must O
be O
made O
explicit O
if O
decision O
makers O
are O
to O
be O
convinced O
that O
allocating O
resources O
toward O
such O
programs O
is O
worthwhile O
. O
[]

BACKGROUND O
Adding O
clonidine O
to O
weak O
ropivacaine O
solutions O
( O
< O
0.2 O
% O
) O
could O
potentially O
enhance B-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
as O
well O
as O
further O
reduce O
the O
risk O
for O
unwanted O
motor O
blockade O
. O
['Life-Impact']

There O
were O
no O
significant O
differences O
in O
generated O
power B-outcome ['Physiological-Clinical']
and O
velocity B-outcome ['Physiological-Clinical']
in O
the O
CON O
phase O
of O
the O
movement O
between O
the O
GCAF O
and O
GCON. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

However O
, O
the O
benefits O
of O
such O
a O
strategy O
remain O
uncertain O
. O
[]

Comparison O
of O
dual-axis O
rotational O
coronary O
angiography O
( O
XPERSWING O
) O
versus O
conventional O
technique O
in O
routine O
practice O
. O
[]

During O
1 O
y O
of O
follow-up O
the O
rate O
of O
diarrhea B-outcome ['Physiological-Clinical']
( O
per O
100 O
wk O
) O
in O
children O
less O
than O
6 O
y O
in O
the O
intervention O
group O
was O
5.89 O
episodes O
whereas O
that O
in O
the O
nonintervention O
group O
was O
7.55 O
episodes O
( O
protective O
efficacy O
22 O
% O
; O
p O
less O
than O
0.0001 O
) O
. O
['Physiological-Clinical']

Results O
indicate O
that O
aquatic O
exercise O
may O
positively O
impact O
the O
primary B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
secondary I-outcome ['Physiological-Clinical']
physical I-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
caused O
by O
a O
brain O
injury O
. O
['Physiological-Clinical']

We O
conclude O
that O
regular O
consumption O
of O
commercially O
prepared O
Fe-fortified O
beikost O
with O
meat O
prevents O
most O
healthy O
term O
infants O
from O
Fe O
deficiency O
even O
if O
Fe O
intake O
is O
substantially O
below O
the O
recommended O
intake O
. O
[]

Positive O
effects O
of O
methylphenidate O
on O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulation I-outcome ['Life-Impact']
in O
children O
with O
pervasive O
developmental O
disorders O
and O
hyperactivity O
. O
['Life-Impact']

Recovery B-outcome ['Life-Impact']
was O
assessed O
by O
a O
research O
nurse O
blinded O
to O
the O
agent O
used O
. O
['Life-Impact']

In O
contrast O
, O
there O
were O
no O
improvements O
in O
the O
control O
group O
. O
[]

These O
results O
were O
consistent O
with O
a O
hypothesized O
dopaminergic O
mechanism O
of O
action O
of O
ascorbic O
acid O
. O
[]

Antimigraine B-outcome ['Resource-use']
efficacy O
of O
telcagepant O
based O
on O
patient O
's O
historical O
triptan O
response O
. O
['Resource-use']

CONCLUSIONS O
The O
results O
confirm O
the O
importance O
of O
psychological O
factors O
in O
early O
RA O
and O
their O
relative O
independence O
from O
physical O
findings O
. O
[]

Patients O
in O
the O
experimental O
group O
received O
a O
brief O
note O
in O
which O
they O
were O
explicitly O
asked O
to O
increase O
both O
their O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
level O
and O
time B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sun I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
, O
while O
control O
group O
patients O
did O
not O
receive O
these O
explicit O
recommendations O
. O
['Life-Impact', 'Life-Impact']

Heart O
failure O
is O
the O
leading O
cause O
of O
hospitalization O
. O
[]

As O
a O
result O
, O
ischemic O
postconditioning O
reduced O
postoperative O
peak O
[]

MAIN O
OUTCOME O
MEASURES O
Positive O
response O
was O
defined O
by O
a O
score O
of O
much O
improved O
or O
very O
much O
improved O
on O
the O
Clinical O
Global O
Impressions O
, O
Improvement O
subscale O
. O
[]

This O
report O
describes O
a O
secondary O
outcome O
measurement O
from O
this O
trial O
, O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Prot. O
[]

78 O
U/L O
; O
LDH O
: O
21.8 O
? O
[]

Adverse O
events O
were O
documented O
. O
[]

Journal O
ID: O
0255562 O
[]

The O
quantified O
version O
of O
the O
Romberg O
test O
performed O
with O
eyes O
open O
or O
closed O
was O
not O
impaired O
after O
anaesthesia O
, O
compared O
with O
the O
control O
values O
, O
indicating O
that O
in O
children O
poor O
equilibrium O
is O
not O
compensated O
by O
vision O
. O
[]

In O
Experiment O
1 O
, O
the O
embryos O
vitrified O
by O
the O
MVAC O
or O
CT O
and O
fresh O
embryos O
without O
vitrification O
( O
Control O
) O
were O
used O
. O
[]

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
determine O
atheroma B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
patients O
with O
spotty O
calcification O
. O
['Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
primary O
end O
point O
was O
a O
composite O
of O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
ischemia-driven B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
48 I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

The O
11-beta-hydroxysteroid O
dehydrogenase O
type O
1 O
inhibitor O
INCB13739 O
improves O
hyperglycemia B-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
inadequately O
controlled O
by O
metformin O
monotherapy O
. O
['Physiological-Clinical']

The O
interval O
from O
calving O
to O
first O
ovulation O
tended O
( O
p=0.10 O
) O
to O
be O
lower O
and O
the O
diameter O
of O
the O
dominant B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
of O
the O
oestrous I-outcome ['Physiological-Clinical']
cycle O
at O
which O
cows O
conceived B-outcome ['Physiological-Clinical']
was O
greater O
( O
p=0.02 O
) O
in O
Control O
than O
High-N O
cows O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
use O
of O
autologous O
blood O
is O
a O
well O
established O
and O
extremely O
popular O
technique O
to O
decrease O
the O
necessity O
for O
homologous O
transfusions O
and O
the O
attendant O
risks O
of O
hepatitis O
, O
HIV O
, O
and O
HTLV O
-- O
I/II O
infections O
. O
[]

BACKGROUND O
The O
proportion O
of O
mothers O
who O
exclusively O
breastfeed O
their O
babies O
up O
to O
6 O
months O
remains O
low O
. O
[]

The O
aim O
of O
this O
trial O
was O
to O
investigate O
whether O
pre-operative O
chemotherapy O
leads O
to O
a O
15 O
% O
higher O
curative B-outcome ['Physiological-Clinical']
resectability I-outcome ['Physiological-Clinical']
rate O
in O
patients O
with O
operable O
gastric O
cancer O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
increase O
in O
peak O
VO2 O
( O
p O
< O
0.05 O
) O
and O
anaerobic O
threshold O
( O
p O
< O
0.01 O
) O
with O
denopamine O
, O
whereas O
no O
significant O
change O
was O
observed O
in O
peak O
work O
rate O
or O
exercise O
time O
. O
[]

For O
that O
highly O
selected O
subgroup, O
surgery O
was O
superior O
to O
medical O
treatment. O
( O
[]

rhTPO O
given O
after O
transplantation O
did O
not O
speed O
platelet B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVES O
We O
tested O
the O
hypotheses O
that O
the O
stove O
intervention O
, O
compared O
with O
open O
fire O
use O
, O
would O
reduce O
ST-segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
and O
increase O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
( O
HRV B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
study O
group O
, O
there O
was O
a O
significant O
improvement O
in O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
and O
an O
improvement O
in O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.06 O
) O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Life-Impact']

Taking O
effective O
preventive O
measures O
is O
particularly O
important O
for O
control O
of O
HFMD O
infection. O
[]

In O
both O
of O
these O
groups O
of O
patients O
the O
diagnostic O
or O
therapeutic O
radioiodine O
application O
was O
done O
after O
withdrawal O
of O
thyroid O
hormone O
treatment O
. O
[]

13 O
, O
age O
71+/-2 O
yr O
) O
groups O
. O
[]

Couple-responsible O
process O
consists O
of O
enactments O
, O
accommodation O
, O
and O
inductive O
process O
. O
[]

BACKGROUND O
Pioglitazone O
and O
glimepiride O
improve O
glycemic O
control O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
by O
different O
mechanisms O
. O
[]

The O
sample O
consists O
of O
225 O
anaemic O
pregnant O
women O
randomly O
allocated O
in O
experimental O
( O
n=75 O
) O
, O
control O
group O
A O
( O
n=75 O
) O
and O
control O
group O
B O
( O
n=75 O
) O
. O
[]

CONCLUSION O
Prophylactic O
preoperative O
IABP O
insertion O
in O
EuroSCORE-stratified O
high-risk O
patients O
is O
not O
associated O
with O
decreased O
30-day O
mortality O
. O
[]

We O
hypothesized O
that O
higher O
amounts O
of O
wear O
particles O
result O
in O
increased O
release O
of O
metal B-outcome ['Physiological-Clinical']
ions I-outcome ['Physiological-Clinical']
and O
ultimately O
lead O
to O
an O
increased O
incidence O
of O
metal B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Applied O
with O
open-labeled O
, O
randomized O
, O
and O
clinical O
trial O
design O
, O
136 O
postmenopausal O
women O
were O
assigned O
into O
four O
groups O
: O
group O
A O
: O
estradiol O
valerate O
( O
E2 O
V O
) O
1 O
mg/d O
+ O
medroxyprogesterone O
acetate O
( O
MPA O
) O
2 O
mg/d O
; O
group O
B O
: O
conjugated O
equine O
estrogen O
0.45 O
mg/d O
+ O
MPA O
2 O
mg/d O
; O
group O
C O
: O
tibolone O
1.25 O
mg/d O
; O
group O
D O
: O
a O
Chinese O
formulated O
herbs O
product O
( O
Kuntai O
) O
4 O
# O
tid O
. O
[]

Despite O
being O
widely O
available O
, O
outpatient O
detoxification O
has O
limited O
efficacy O
as O
a O
stand-alone O
treatment O
. O
[]

Each O
quadrant O
was O
categorized O
into O
control O
group O
(SRP O
alone; O
two O
quadrants O
per O
patient), O
test O
group O
1 O
(SRP O
+ O
PDT), O
and O
test O
group O
2 O
(SRP O
+ O
LLLT. O
[]

PATIENTS O
AND O
METHODS O
From O
December O
1993 O
to O
April O
1999 O
, O
284 O
patients O
with O
1992 O
American O
Joint O
Committee O
on O
Cancer O
stage O
III O
to O
IV O
( O
M0 O
) O
NPC O
were O
randomly O
allocated O
into O
two O
arms O
. O
[]

This O
study O
compared O
oral O
mucositis O
pain O
levels O
in O
4 O
groups O
of O
cancer O
patients O
receiving O
bone O
marrow O
transplants O
( O
BMT O
) O
: O
( O
1 O
) O
treatment O
as O
usual O
control O
, O
( O
2 O
) O
therapist O
support O
, O
( O
3 O
) O
relaxation O
and O
imagery O
training O
, O
and O
( O
4 O
) O
training O
in O
a O
package O
of O
cognitive-behavioral O
coping O
skills O
which O
included O
relaxation O
and O
imagery O
. O
[]

Of O
the O
98 O
patients O
who O
did O
not O
have O
type O
I O
or O
II O
diabetes O
at O
the O
time O
of O
transplantation O
, O
17 O
developed O
posttransplantation B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
or O
an O
abnormal B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance O
test O
within O
2 O
years O
posttransplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHOD O
The O
authors O
conducted O
a O
multisite O
, O
two-part O
study O
of O
risperidone O
in O
children O
ages O
5 O
to O
17 O
years O
with O
autism O
accompanied O
by O
severe O
tantrums O
, O
aggression O
, O
and/or O
self-injurious O
behavior O
who O
showed O
a O
positive O
response O
in O
an O
earlier O
8-week O
trial O
. O
[]

At O
the O
18-month O
follow-up O
, O
two O
patients O
in O
group O
A O
and O
only O
one O
in O
groups O
B O
and O
C O
maintained O
the O
response O
. O
[]

Furthermore O
, O
the O
plasma O
and O
follicular O
fluid O
concentrations O
of O
arginine O
, O
citrulline O
, O
nitrite/nitrate O
( O
NO2-/NO3- O
) O
, O
and O
insulin-like O
growth O
factor-1 O
( O
IGF-1 O
) O
were O
assayed O
. O
[]

After O
at O
least O
14 O
days O
, O
subjects O
were O
randomized O
to O
receive O
either O
olopatadine O
in O
one O
eye O
and O
placebo O
in O
the O
contralateral O
eye O
, O
or O
ketorolac O
in O
one O
eye O
and O
placebo O
in O
the O
contralateral O
eye O
. O
[]

CONCLUSION O
Our O
findings O
indicate O
that O
Autism O
Spectrum O
Disorder O
manifests O
as O
a O
distinct O
behavioral B-outcome ['Life-Impact']
phenomenon I-outcome ['Life-Impact']
in O
Down O
syndrome O
. O
['Life-Impact']

Relative O
decreases O
occurred O
in O
cerebellum O
and O
right O
parahippocampal O
gyrus O
following O
the O
higher O
dose O
. O
[]

In O
the O
ropivacaine O
and O
bupivacaine O
groups O
sensory O
anesthesia O
was O
considered O
adequate O
for O
surgery O
in O
all O
cases O
but O
one O
in O
each O
group O
; O
in O
the O
etidocaine O
group O
, O
however O
60 O
% O
of O
the O
patients O
showed O
[]

The O
use O
of O
cadaver O
allograft O
spares O
the O
hamstring B-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
and O
reduces O
the O
time B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
surgery I-outcome ['Life-Impact']
. O
Therefore, O
such O
study O
appears O
to O
be O
useful O
because O
it O
provides O
valuable O
information O
that O
would O
help O
to O
guide O
treatment O
of O
this O
condition O
in O
children. O
[['Physiological-Clinical'], ['Life-Impact']]

MEASUREMENTS O
Main O
outcomes O
were O
12-month O
changes O
from O
baseline O
in O
bone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
resorption B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
measured O
according O
to O
quantitative O
ultrasound O
scanning O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
UTC O
can O
quantitatively O
evaluate O
tendon O
structure O
and O
thereby O
discriminate O
symptomatic O
and O
asymptomatic O
tendons O
. O
[]

The O
2 O
techniques O
were O
evaluated O
with O
respect O
to O
the O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
scores O
, O
complications B-outcome ['Adverse-effects']
, O
day B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
, O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
, O
and O
level O
of O
satisfaction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Service O
variation O
in O
baseline O
variables O
and O
prediction O
of O
risk O
in O
a O
randomised O
controlled O
trial O
of O
psychological O
treatment O
in O
repeated O
parasuicide O
: O
the O
POPMACT O
Study O
. O
[]

In O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
, O
the O
factors O
and O
total O
scores O
of O
PANSS O
in O
study O
group O
[ O
( O
12.0 O
? O
[]

Intraperitoneal O
irrigation O
of O
the O
diaphragmatic O
surface O
and O
gallbladder O
fossa O
using O
normal O
saline O
, O
bupivacaine O
, O
or O
lignocaine O
may O
effectively O
control O
visceral B-outcome ['Physiological-Clinical']
abdominal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
an O
LC O
. O
['Physiological-Clinical']

The O
overall O
results O
indicated O
that O
dietary O
PN O
supplementation O
at O
100 O
mg/kg O
diet O
may O
reverse O
the O
negative O
effects O
caused O
by O
ET O
and O
may O
protect O
the O
haemato-immunological O
status O
of O
L. O
rohita O
fingerlings O
reared O
at O
higher O
water O
temperature O
. O
[]

Journal O
ID: O
2985248R O
[]

Nicorandil O
( O
30 O
mg O
) O
prevents O
ergometrine-induced B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
numbers O
of O
patients O
demonstrating O
these O
changes O
for O
each O
test O
were O
compared O
using O
the O
McNemar O
test O
for O
each O
time O
point O
. O
[]

[ O
4 O
years O
' O
experience O
with O
a O
balloon-expandable O
endoprosthesis O
. O
[]

Fourteen O
of O
the O
20 O
subjects O
had O
less O
gastric B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
during O
cotherapy O
with O
omeprazole O
. O
['Physiological-Clinical']

There O
are O
, O
however O
, O
signs O
of O
minor O
and O
perhaps O
chronic O
renal O
injury O
. O
[]

Days B-outcome ['Life-Impact']
lost I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
per O
patient O
per O
month O
was O
zero O
on O
three O
times O
12 O
U/kg O
, O
0.4 O
day O
on O
twice O
18 O
U/kg O
and O
once O
36 O
U/kg O
, O
while O
it O
had O
been O
five O
days O
in O
the O
pre-trial O
period O
. O
['Life-Impact']

Acetabular B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
measured O
with O
dual-energy O
X-ray O
absorptiometry O
( O
DXA O
) O
1 O
week O
postoperatively O
, O
and O
after O
12 O
and O
24 O
months O
. O
['Physiological-Clinical']

Internal O
consistency O
reliability O
was O
analyzed O
by O
Cronbach O
's O
alpha O
. O
[]

Abnormalities O
in O
gastrointestinal O
motility O
have O
been O
reported O
in O
a O
substantial O
proportion O
of O
patients O
with O
functional O
dyspepsia O
, O
supporting O
the O
use O
of O
prokinetic O
drugs O
for O
treatment O
of O
dyspeptic O
symptoms O
. O
[]

Effect O
of O
negative O
air O
ionization O
on O
hyperactive O
and O
autistic O
children O
. O
[]

Chronology O
of O
panic O
and O
avoidance O
, O
age O
of O
onset O
in O
panic O
disorder O
, O
and O
prediction O
of O
treatment O
response O
. O
[]

The O
therapeutic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
esmolol O
during O
the O
initial O
treatment O
period O
( O
72 O
% O
) O
was O
similar O
to O
that O
obtained O
when O
esmolol O
was O
given O
as O
a O
second O
agent O
. O
['Physiological-Clinical']

Because O
of O
the O
absence O
of O
differences O
in O
outcome O
among O
the O
four O
randomization O
groups O
, O
cost B-outcome ['Resource-use']
data O
for O
all O
patients O
were O
pooled O
. O
['Resource-use']

Three O
of O
11 O
subjects O
improved O
in O
two O
or O
more O
settings O
. O
[]

All O
patients O
completed O
a O
postprocedure O
questionnaire O
. O
[]

CONCLUSION: O
Longitudinal O
profiling O
is O
an O
essential O
tool O
for O
improving O
our O
understanding O
of O
the O
microbiology O
of O
chronic O
wounds, O
as O
community O
dynamics O
associated O
with O
clinical O
events O
can O
only O
be O
identified O
by O
examining O
changes O
over O
multiple O
time O
points. O
[]

RESULTS O
There O
were O
no O
statistically O
significant O
differences O
between O
the O
two O
groups O
at O
baseline O
. O
[]

These O
findings O
do O
not O
support O
the O
hypothesis O
that O
insulin O
resistance-associated O
hyperinsulinemia O
preferentially O
drives O
endothelin-mediated B-outcome ['Physiological-Clinical']
vasoconstriction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
Thirty-four O
children O
and O
adolescents O
with O
ASD O
( O
age O
range O
8-17 O
years O
; O
IQ O
> O
75 O
) O
were O
enrolled O
in O
a O
10-week O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
donepezil O
( O
doses O
of O
5 O
and O
10 O
mg O
) O
, O
followed O
by O
a O
10-week O
open O
label O
trial O
for O
placebo O
nonresponders O
. O
[]

1.63 O
?g/mL O
immediately O
after O
aortic O
unclamping O
and O
6.59 O
? O
[]

150 O
patients O
will O
be O
included O
and O
randomized O
intraoperatively O
after O
surgical O
exploration O
just O
prior O
to O
resection O
. O
[]

DISCUSSION: O
The O
evidence O
provided O
will O
inform O
program O
investment O
and O
design, O
and O
contribute O
to O
the O
literature O
on O
the O
effect O
of O
menstrual O
health-based O
interventions O
on O
girls' O
agency B-outcome ['Life-Impact']
, O
safety O
and O
life B-outcome ['Life-Impact']
outcomes. O
[['Life-Impact'], ['Life-Impact']]

A O
study O
in O
Kerman O
, O
Islamic O
Republic O
of O
Iran O
in O
2002 O
compared O
the O
effectiveness O
of O
fennel O
and O
mefenamic B-outcome ['Resource-use']
acid I-outcome ['Resource-use']
on O
pain O
relief O
in O
primary O
dysmenorrhoea O
. O
['Resource-use']

During O
the O
study O
, O
the O
horses O
were O
monitored O
for O
general O
health O
, O
lameness O
, O
and O
swelling O
around O
the O
injection O
area O
. O
[]

OBJECTIVE O
Our O
study O
was O
designed O
to O
examine O
the O
efficacy O
of O
stepwise O
hook O
extension O
technique O
for O
radiofrequency O
ablation O
( O
RFA O
) O
therapy O
of O
hepatocellular O
carcinoma O
in O
a O
randomized O
controlled O
study O
. O
[]

Patients O
with O
post-thrombotic O
venous O
disease O
have O
a O
compromised O
hemodynamic O
response O
to O
all O
IPC O
devices O
. O
[]

kg-1 O
) O
was O
also O
significantly O
lower O
( O
P O
< O
0.005 O
) O
than O
that O
for O
AmB O
in O
lipid O
emulsion O
( O
1.47 O
+/- O
0.77 O
liter O
. O
[]

These O
findings O
do O
not O
support O
the O
use O
of O
this O
psychological O
intervention. O
[]

No O
changes O
in O
[]

Publication O
Type: O
Journal O
Article O
[]

PURPOSE: O
To O
evaluate O
corneal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
density I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(ECD) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
morphology S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
2 O
years O
after O
phacoemulsification O
in O
subjects O
from O
the O
COMPASS O
trial O
(ClinicalTrials.gov, O
NCT01085357) O
who O
had O
mild-to-moderate O
primary O
open-angle O
glaucoma O
and O
visually O
significant O
cataracts. O
[['Physiological-Clinical', 'Physiological-Clinical']]

RESULTS O
Diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
of O
TBLB O
using O
Jumbo O
forceps O
was O
significantly O
higher O
than O
using O
normal O
flexible O
forceps O
via O
rigid O
bronchoscopy O
in O
patients O
with O
DPLD O
( O
p O
= O
0.001 O
) O
. O
['Life-Impact']

All O
17 O
subjects O
were O
given O
nicotine O
or O
placebo O
solution O
on O
two O
separate O
occasions O
in O
a O
randomized O
sequence O
. O
[]

The O
groups O
received O
intrathecal O
0.5 O
mg O
morphine O
( O
Group O
IT0.5 O
) O
, O
intrathecal O
0.1 O
mg O
morphine O
( O
Group O
IT0.1 O
) O
or O
10 O
mg O
morphine O
i.v O
. O
( O
[]

RESULTS: O
A O
total O
of O
1773 O
adult O
patients O
with O
episodic O
migraine O
(n O
= O
444 O
for O
galcanezumab O
120 O
mg; O
n O
= O
435 O
for O
galcanezumab O
240 O
mg; O
n O
= O
894 O
for O
placebo O
for O
2 O
studies O
pooled) O
and O
1113 O
patients O
with O
chronic O
migraine O
(n O
= O
278 O
for O
galcanezumab O
120 O
mg; O
n O
= O
277 O
for O
galcanezumab O
240 O
mg; O
n O
= O
558 O
for O
placebo) O
were O
evaluated. O
[]

Increased O
concentrations O
of O
hsCRP B-outcome ['Physiological-Clinical']
were O
strongly O
associated O
with O
the O
development O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
at O
30 O
days O
( O
adjHR O
8.2 O
, O
P O
= O
0.001 O
) O
and O
10 O
months O
( O
adjHR O
2.6 O
, O
P O
= O
0.014 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS: O
A O
total O
of O
60 O
patients O
were O
randomly O
assigned O
to O
1 O
of O
2 O
groups: O
Pre-administered O
with O
remifentanil O
before O
propofol O
infusion O
(Group O
R, O
n O
= O
30) O
and O
co-administered O
with O
remifentanil O
with O
propofol O
(Group O
N, O
n O
= O
30). O
[]

RESULTS O
Rizatriptan O
5 O
mg O
was O
well O
tolerated O
. O
[]

The O
most O
frequently O
reported O
post-vaccination O
symptoms O
were O
irritability B-outcome ['Life-Impact']
in O
the O
DTPa-IPV-Hib O
plus O
separate O
HBV O
group O
( O
49 O
% O
of O
vaccinees O
) O
and O
fever B-outcome ['Physiological-Clinical']
, O
defined O
as O
axillary O
temperature O
> O
or O
=37.5 O
degrees O
C O
, O
in O
the O
DTPa O
HBV- O
IPV-Hib O
group O
( O
50 O
% O
of O
vaccinees O
) O
. O
['Life-Impact', 'Physiological-Clinical']

The O
ET-1 B-outcome ['Physiological-Clinical']
and O
its O
receptor B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
were O
expressed O
in O
the O
right O
and O
left O
ventricles O
of O
control O
and O
T O
( O
3 O
) O
-treated O
broilers O
at O
12 O
, O
28 O
and O
49 O
days O
of O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twenty O
healthy O
volunteers O
were O
randomized O
to O
a O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
to O
determine O
if O
omeprazole O
, O
40 O
mg/day O
prevents O
gastroduodenal O
injury O
due O
to O
two O
weeks O
of O
aspirin O
administration O
( O
650 O
mg O
four O
times O
a O
day O
) O
. O
[]

Pain B-outcome ['Physiological-Clinical']
detection O
and O
tolerance O
thresholds O
for O
pressure O
and O
electric B-outcome ['Resource-use']
stimuli I-outcome ['Resource-use']
were O
measured O
in O
six O
selected O
dermatomes O
( O
C5 O
, O
T4 O
, O
T10 O
, O
L1 O
, O
L4 O
and O
T10BACK O
) O
. O
['Physiological-Clinical', 'Resource-use']

A O
prospective O
randomized O
study O
concerning O
the O
point O
A O
dose O
in O
high-dose O
rate O
intracavitary O
therapy O
for O
carcinoma O
of O
the O
uterine O
cervix O
. O
[]

In O
addition O
, O
the O
patients O
in O
Regimen O
B O
had O
a O
much O
higher O
incidence O
of O
infections B-outcome ['Physiological-Clinical']
than O
Regimen O
A O
. O
['Physiological-Clinical']

The O
mean O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
complete I-outcome ['Life-Impact']
test-1 I-outcome ['Life-Impact']
was O
84.6 O
+/- O
26.6 O
seconds O
in O
training O
group O
and O
90.7 O
+/- O
43.9 O
seconds O
in O
the O
control O
group O
(95% O
CI O
-34.0 O
to O
21.7; O
P O
= O
.653); O
in O
test-2, O
the O
time B-outcome ['Life-Impact']
required O
was O
56.6 O
+/- O
27.9 O
and O
91.2 O
+/- O
43.8 O
seconds O
(95% O
CI O
-63.0 O
to O
-6.2; O
P O
= O
.019), O
respectively. O
[['Life-Impact'], ['Life-Impact']]

The O
primary O
outcome O
was O
pain-specific O
brain O
activity O
evoked O
by O
one O
time-locked O
heel O
lance O
, O
recorded O
with O
electroencephalography O
and O
identified O
by O
principal O
component O
analysis O
. O
[]

In O
addition O
, O
37 O
placebo O
nonresponders O
received O
open-label O
risperidone O
for O
another O
8 O
weeks O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
hsCRP O
across O
the O
spectrum O
of O
ACS O
. O
[]

Patients O
who O
were O
VKA-naive O
and O
experienced O
are O
included O
in O
balanced O
proportions O
. O
[]

LEGO O
therapy O
and O
the O
Social O
Use O
of O
Language O
Programme O
( O
SULP O
) O
were O
evaluated O
as O
social O
skills O
interventions O
for O
6-11 O
year O
olds O
with O
high O
functioning O
autism O
and O
Asperger O
Syndrome O
. O
[]

During O
the O
early O
postoperative O
period O
, O
1 O
, O
2 O
and O
24 O
h O
after O
surgery O
, O
only O
cortisol B-outcome ['Physiological-Clinical']
was O
measured O
. O
['Physiological-Clinical']

The O
trial O
is O
registered O
with O
the O
International O
Standard O
Randomised O
Controlled O
Trial O
Number O
88261002. O
[]

In O
the O
placebo O
group O
, O
none O
of O
the O
patients O
showed O
undetectable B-outcome ['Physiological-Clinical']
HBV I-outcome ['Physiological-Clinical']
DNA B-outcome ['Physiological-Clinical']
, O
HBeAg/Anti-HBe B-outcome ['Physiological-Clinical']
seroconversion B-outcome ['Physiological-Clinical']
or O
HBeAg B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
examiner O
, O
blinded O
to O
the O
treatment O
sequence O
, O
performed O
all O
clinical O
measurements O
. O
[]

Locomoting-to-reach O
: O
information O
variables O
and O
control O
strategies O
for O
nested O
actions O
. O
[]

In O
spite O
of O
the O
ability O
to O
tell O
whether O
a O
subject O
has O
normal O
or O
abnormal O
values O
, O
because O
of O
the O
lack O
of O
prospective O
mortality/morbidity O
data O
, O
home O
blood O
pressure O
monitoring O
can O
not O
be O
used O
to O
decide O
whether O
treatment O
is O
indicated O
. O
[]

CONCLUSIONS O
A O
significant O
decline O
in O
GSH-glutathione B-outcome ['Physiological-Clinical']
disulfide I-outcome ['Physiological-Clinical']
, O
cysteine-cystine B-outcome ['Physiological-Clinical']
, O
and O
vitamin B-outcome ['Physiological-Clinical']
E I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
occurs O
after O
chemotherapy O
and O
BMT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
cyclical O
exacerbations O
of O
epilepsy O
( O
catamenial O
epilepsy O
) O
were O
used O
to O
assess O
the O
antiepileptic O
effect O
of O
a O
benzodiazepine O
, O
clobazam O
. O
[]

OBJECTIVE O
The O
goal O
of O
this O
study O
has O
been O
to O
determine O
whether O
hyaluronic O
acid O
( O
HA O
) O
or O
exercise O
therapy O
can O
improve O
functional O
parameters O
in O
patients O
with O
osteoarthritis O
( O
OA O
) O
of O
the O
ankle O
. O
[]

Liquid O
fluoxetine O
was O
only O
slightly O
, O
and O
not O
significantly O
, O
superior O
to O
placebo O
on O
CGI O
autism B-outcome ['Life-Impact']
score O
partially O
due O
to O
a O
phase O
order O
effect O
. O
['Life-Impact']

4 O
. O
[]

CONCLUSIONS O
The O
economic O
analysis O
demonstrated O
that O
clopidogrel O
combination O
therapy O
is O
not O
only O
cost-effective O
as O
antiplatelet O
therapy O
compared O
with O
ASA O
alone O
, O
but O
it O
is O
also O
cost-effective O
compared O
with O
other O
commonly O
used O
and O
openly O
reimbursed O
cardiovascular O
therapies O
in O
the O
Canadian O
health O
care O
system O
. O
[]

UNLABELLED O
Although O
effective O
in O
neuropathic O
pain O
, O
the O
efficacy O
of O
systemic O
lidocaine O
in O
non-neuropathic O
pain O
remains O
uncertain O
. O
[]

BACKGROUND O
Symptoms O
of O
allergic O
rhinitis O
are O
mediated O
in O
part O
by O
cysteinyl O
leukotrienes O
. O
[]

BACKGROUND O
The O
subjective B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
psychomotor I-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
of O
remifentanil O
have O
not O
been O
evaluated O
. O
['Life-Impact']

BACKGROUND: O
Endometrial O
scratching O
(with O
the O
use O
of O
a O
pipelle O
biopsy) O
is O
a O
technique O
proposed O
to O
facilitate O
embryo B-outcome ['Physiological-Clinical']
implantation I-outcome ['Physiological-Clinical']
and O
increase O
the O
probability O
of O
pregnancy B-outcome ['Physiological-Clinical']
in O
women O
undergoing O
in O
vitro O
fertilization O
(IVF). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS O
ERPs O
were O
recorded O
during O
an O
auditory O
selective O
attention O
task O
( O
SAT O
) O
that O
involved O
detecting O
infrequent O
long-duration O
target O
tones O
presented O
among O
short-duration O
tones O
that O
varied O
in O
location O
( O
left O
vs. O
right O
ear O
) O
and O
pitch O
( O
low O
vs. O
high O
) O
. O
[]

We O
report O
a O
12 O
month O
double-blind O
randomized O
crossover O
trial O
of O
fenfluramine O
in O
20 O
children O
with O
the O
syndrome O
of O
autism O
. O
[]

injection O
of O
depot O
MPA O
500 O
mg O
on O
days O
1 O
, O
14 O
and O
28 O
, O
or O
oral O
megestrol O
acetate O
40 O
mg O
daily O
for O
6 O
weeks O
. O
[]

This O
study O
is O
registered O
, O
number O
ISRCTN54469112 O
. O
[]

3 O
. O
[]

Patients O
?75 O
years O
old O
and O
with O
body O
weight O
?60 O
kg O
received O
a O
maintenance O
dose O
of O
5 O
mg/day O
( O
10 O
mg/day O
for O
all O
the O
other O
patients O
) O
. O
[]

Groups O
from O
the O
sample O
of O
the O
cross-national O
collaborative O
panic O
study O
( O
CNCPS O
) O
were O
compared O
for O
differences O
in O
basic O
characteristics O
and O
for O
the O
ability O
to O
predict O
treatment O
response O
. O
[]

Despite O
the O
shortened B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
, O
the O
incidence O
of O
infections O
and O
the O
rate O
of O
remission O
were O
not O
affected O
. O
['Physiological-Clinical']

METHODS O
Ninety O
patients O
with O
VBIV O
were O
randomly O
divided O
into O
two O
groups O
; O
45 O
patients O
( O
the O
treated O
group O
) O
were O
treated O
with O
YXDM O
and O
BHI O
intravenous O
dripping O
, O
once O
a O
day O
for O
14 O
days O
. O
[]

Microalbuminuria O
is O
an O
important O
risk O
factor O
for O
cardiovascular O
mortality O
in O
non-insulin-dependent O
diabetic O
patients O
as O
well O
as O
in O
the O
general O
population O
. O
[]

Antibiotic O
therapy O
of O
acute O
exacerbations O
of O
chronic O
bronchitis O
. O
[]

Steers O
were O
blocked O
by O
arrival O
at O
the O
feed O
yard O
, O
genotyped O
for O
the O
leptin O
SNP O
, O
allotted O
to O
genotype-specific O
pens O
( O
90 O
steers/pen O
) O
, O
and O
assigned O
randomly O
within O
genotype O
and O
block O
to O
0 O
or O
21 O
d O
of O
dietary O
ZH O
. O
[]

Only O
10 O
% O
of O
patients O
treated O
with O
imiquimod O
were O
clinically O
diagnosed O
with O
recurrence O
1 O
year O
after O
treatment O
. O
[]

BACKGROUND: O
Registered O
healthcare O
workers O
worldwide O
have O
a O
high O
prevalence O
of O
work-related O
musculoskeletal O
disorders, O
particularly O
of O
the O
back. O
[]

Thus O
, O
the O
higher O
concentration O
of O
glycerol O
required O
to O
provide O
equal O
ultrafiltration O
may O
offset O
any O
calorific O
advantage O
. O
[]

CONCLUSION O
Proparacaine O
eye O
drops O
offer O
significant O
relief O
of O
pain O
that O
is O
apparently O
short O
lived O
. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

METHODS: O
This O
randomized O
controlled O
study O
included O
409 O
subjects O
(496 O
eyes) O
older O
than O
1-year-old O
with O
persistent O
CNLDO O
in O
southwest O
China, O
and O
classified O
into O
3 O
groups: O
96 O
cases O
(123 O
eyes) O
were O
the O
tobramycin/dexamethasone O
eye O
drops O
group O
(drops O
group), O
88 O
cases O
(104 O
eyes) O
were O
the O
tobramycin/dexamethasone O
ointment O
group O
(ointment O
group), O
and O
225 O
cases O
(269 O
eyes) O
were O
control O
group O
which O
probing O
with O
normal O
saline O
(NS O
group). O
[]

Compared O
with O
group O
C, O
serum O
norepinephrines B-outcome ['Physiological-Clinical']
in O
group O
D O
was O
significantly O
less O
(t=13.276, O
16.027, O
14.319, O
12.771, O
12.296, O
respectively; O
all O
P<0.05) O
at O
T(1), O
T(2), O
T(3), O
T(4), O
T(5).And O
there O
were O
no O
difference O
between O
these O
two O
groups O
at O
T(0), O
T(6), O
T(7), O
T(8)(all O
P>0.05). O
[['Physiological-Clinical']]

Outcome O
at O
7 O
years O
of O
children O
diagnosed O
with O
autism O
at O
age O
2 O
: O
predictive O
validity O
of O
assessments O
conducted O
at O
2 O
and O
3 O
years O
of O
age O
and O
pattern O
of O
symptom O
change O
over O
time O
. O
[]

The O
modalities O
of O
definitive O
treatment O
( O
radiotherapy O
+/- O
surgery O
) O
were O
chosen O
prior O
to O
randomization O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Two-eighth-grade O
classes O
were O
randomly O
allocated O
to O
the O
intervention O
condition O
and O
all O
remaining O
students O
were O
either O
allocated O
to O
the O
no-intervention O
peer O
or O
no-intervention O
non-peer O
condition O
. O
[]

METHODS O
Year O
1 O
medical O
students O
( O
n O
= O
37 O
) O
were O
randomly O
assigned O
to O
practise O
identifying O
seven O
cardiac O
murmurs O
using O
a O
simulator O
and O
video O
only O
( O
SRL O
group O
) O
or O
a O
simulator O
and O
video O
plus O
the O
booklet O
( O
DSRL O
group O
) O
. O
[]

CONCLUSIONS O
The O
data O
demonstrate O
a O
high O
risk O
for O
patients O
undergoing O
low O
anterior O
resection O
without O
diverting O
ileostomy O
. O
[]

METHODS O
One O
hundred O
and O
twenty-six O
patients O
fulfilled O
the O
eligibility O
criteria O
( O
type O
1 O
diabetes O
for O
> O
1 O
year O
; O
on O
conventional O
insulin O
therapy O
( O
CIT O
) O
; O
aged O
between O
8 O
and O
18 O
years O
) O
, O
of O
whom O
92 O
enrolled O
. O
[]

5 O
. O
[]

Circulating O
concentrations O
of O
pro- O
and O
anti-inflammatory O
mediators O
were O
measured O
before O
and O
after O
the O
1-year O
intervention O
. O
[]

All O
children O
were O
assessed O
before O
and O
after O
treatment O
on O
two O
behavioral O
measures O
, O
the O
Vineland O
Maladaptive B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Domain O
and O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
. O
['Life-Impact', 'Life-Impact']

AIMS: O
Cementless O
primary O
total O
hip O
arthroplasty O
(THA) O
is O
associated O
with O
risks O
of O
bleeding O
and O
thromboembolism. O
[]

Fentanyl O
supplementation O
to O
inhalation O
anaesthesia O
. O
[]

At O
start O
, O
the O
pulsatility B-outcome ['Physiological-Clinical']
and O
resistance B-outcome ['Physiological-Clinical']
indices O
of O
ovarian O
arteries O
were O
elevated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
of O
eight O
patients O
in O
group O
A O
and O
seven O
of O
nine O
in O
group O
B O
had O
a O
history O
of O
Pneumocystis O
carinii O
pneumonia O
( O
PCP O
) O
. O
[]

Qualitative O
information O
gathered O
from O
parents O
and O
teachers O
indicated O
some O
generalization O
of O
strategies O
learned O
in O
the O
clinic O
setting O
to O
both O
home O
and O
school O
settings O
. O
[]

As O
the O
strength B-outcome ['Life-Impact']
increased O
, O
so O
did O
the O
depth O
of O
peel O
. O
['Life-Impact']

A O
statistically O
higher O
ocular B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
was O
seen O
between O
the O
pre- O
and O
postirrigation O
readings O
for O
the O
control O
eye O
in O
volunteers O
irrigated O
with O
MTL O
( O
p O
= O
0.046 O
) O
. O
['Physiological-Clinical']

There O
were O
data O
on O
FLT3 O
internal O
tandem O
duplications O
and O
NPM1 O
mutations O
( O
n O
= O
592 O
) O
, O
CEBPA O
mutations O
( O
n O
= O
423 O
) O
, O
and O
MN1 O
expression O
( O
n O
= O
195 O
) O
. O
[]

It O
is O
characterised O
by O
acute O
, O
potentially O
life-threatening O
neurological O
attacks O
that O
are O
precipitated O
by O
various O
drugs O
, O
reproductive O
hormones O
and O
other O
factors O
. O
[]

The O
changes O
in O
lipid B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
induced O
by O
fasting O
alone O
or O
pegvisomant O
were O
not O
different O
from O
those O
induced O
by O
pegvisomant O
alone O
. O
['Physiological-Clinical']

One O
participant O
was O
unable O
to O
tolerate O
persistent O
GI O
discomfort O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
treatment O
with O
the O
antiherpes O
drug O
valacyclovir O
on O
MRI-evident O
lesions B-outcome ['Physiological-Clinical']
in O
patients O
with O
relapsing-remitting O
MS O
in O
a O
phase O
2 O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Physiological-Clinical']

More O
studies O
are O
required O
to O
establish O
the O
bioavailability O
and O
pharmacokinetic O
effects O
of O
purple O
carrot O
anthocyanins O
and O
phenolic O
acids O
prior O
to O
further O
trials O
of O
efficacy O
with O
respect O
to O
treating O
inflammation O
and O
metabolic O
alterations O
. O
[]

Forty-seven O
patients O
completed O
the O
study O
. O
[]

Baseline O
values O
showed O
that O
the O
7 O
patients O
who O
received O
placebo O
had O
more O
severe O
CHF B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Tumors B-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
or O
the O
target O
tumor O
area O
was O
reduced O
in O
subjects O
in O
the O
4- O
and O
6-week O
dosing O
regimens O
. O
['Physiological-Clinical']

Randomized O
, O
controlled O
study O
of O
various O
agents O
for O
endoscopic O
injection O
sclerotherapy O
of O
bleeding O
canine O
gastric O
varices O
. O
[]

Considering O
patients O
on O
treatment O
or O
within O
28 O
days O
after O
discontinuing O
the O
test O
medication O
, O
92 O
in O
the O
placebo O
group O
died B-outcome ['Mortality']
, O
as O
compared O
with O
60 O
of O
the O
warfarin-treated O
patients O
, O
a O
risk O
reduction O
of O
35 O
% O
( O
P O
= O
0.005 O
) O
. O
['Mortality']

METHODS O
This O
was O
a O
multicenter O
, O
8-week O
, O
parallel-group O
, O
randomized O
, O
double-blind O
, O
double-dummy O
, O
Phase O
III O
clinical O
trial O
. O
[]

Aerobic O
and O
strength O
training O
reduces O
adiposity B-outcome ['Physiological-Clinical']
in O
overweight O
Latina O
adolescents O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
whether O
hysteroscopic O
morcellation O
or O
bipolar O
electrosurgical O
resection O
is O
more O
favorable O
for O
removing O
endometrial B-outcome ['Physiological-Clinical']
polyps I-outcome ['Physiological-Clinical']
in O
an O
office O
setting O
in O
terms O
of O
feasibility B-outcome ['Life-Impact']
, O
speed B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
acceptability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
isolated O
animal O
lungs O
the O
amount O
of O
exhaled O
NO O
is O
decreased O
during O
hypoxia O
. O
[]

RESULTS O
Carbohydrate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
were O
higher O
in O
the O
LF O
and O
HF O
groups O
than O
in O
the O
MUFA O
group O
( O
54 O
% O
compared O
with O
43 O
% O
) O
, O
and O
more O
fiber O
was O
consumed O
by O
the O
HF O
group O
( O
approximately O
50 O
g/d O
) O
than O
by O
the O
LF O
or O
MUFA O
group O
( O
approximately O
23 O
g/d O
) O
. O
['Life-Impact']

After O
7 O
days O
' O
treatment O
( O
400 O
mg O
b.i.d O
. O
) O
, O
[]

A O
double-blind O
, O
double-dummy O
, O
crossover O
study O
was O
carried O
out O
in O
8 O
centres O
to O
compare O
the O
efficacy O
and O
tolerability O
of O
'controlled-release O
' O
ketoprofen O
tablets O
( O
200 O
mg O
) O
with O
that O
of O
indomethacin O
suppositories O
( O
100 O
mg O
) O
in O
out-patients O
with O
definite O
or O
classical O
rheumatoid O
arthritis O
. O
[]

Both O
effects O
remained O
significant O
after O
controlling O
for O
preferred O
meeting O
method O
(p<0.0001 O
and O
p=0.0003, O
respectively) O
and O
among O
EM-bound O
students O
(p=.0423 O
and O
p<0.0110, O
respectively). O
[]

Median O
OS B-outcome ['Mortality']
time I-outcome ['Mortality']
exceeds O
84 O
months O
in O
arm O
1 O
and O
is O
83 O
months O
in O
arm O
2 O
( O
P O
= O
.56 O
) O
. O
['Mortality']

Infant O
attention O
was O
defined O
as O
duration O
of O
time O
spent O
examining O
objects O
. O
[]

Serial O
measurements O
of O
these O
neurohormones O
may O
serve O
as O
useful O
surrogate O
markers O
of O
ventricular B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
and O
prognosticators O
for O
clinical O
risk O
stratification O
. O
['Physiological-Clinical']

The O
injection O
of O
normal O
saline O
solution O
at O
a O
rate O
of O
5 O
mL/sec O
through O
an O
18-gauge O
needle O
was O
continued O
while O
the O
knee O
was O
moved O
through O
a O
range O
of O
motion O
until O
fluid O
extravasated O
from O
the O
iatrogenic O
laceration O
. O
[]

Journal-Name:Taiwanese O
journal O
of O
obstetrics O
& O
gynecology O
[]

We O
compared O
three O
practice O
conditions O
, O
one O
with O
reading O
and O
two O
with O
spelling O
, O
in O
order O
to O
test O
whether O
computer-based O
reading O
and O
spelling O
practice O
has O
an O
influence O
on O
the O
development O
of O
reading O
and O
spelling O
ability O
in O
children O
with O
LD O
. O
[]

There O
were O
922 O
( O
59 O
% O
) O
injury O
visits O
and O
653 O
( O
41 O
% O
) O
noninjury O
visits O
. O
[]

Four O
pramipexole O
doses O
were O
evaluated O
: O
0.125 O
, O
0.25 O
, O
0.50 O
, O
and O
0.75mg/d O
. O
[]

Gene O
expression O
of O
endothelin-1 O
and O
its O
receptors O
in O
the O
heart O
of O
broiler O
chickens O
with O
T O
( O
3 O
) O
-induced O
pulmonary O
hypertension O
. O
[]

CONTEXT O
GnRH O
agonist O
( O
GnRHa O
) O
monthly O
injections O
are O
frequently O
used O
in O
the O
treatment O
of O
central O
precocious O
puberty O
( O
CPP O
) O
. O
[]

The O
risk O
of O
nonvertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
was O
reduced O
by O
33 O
% O
compared O
with O
control O
over O
3 O
years O
( O
p O
= O
0.06 O
) O
. O
['Physiological-Clinical']

Low O
body O
mass O
index O
and O
dyslipidemia O
in O
dialysis O
patients O
linked O
to O
elevated O
plasma O
fibroblast O
growth O
factor O
23 O
. O
[]

Most O
modern O
defibrillators O
used O
for O
the O
cardioversion O
of O
atrial O
fibrillation O
( O
AF O
) O
employ O
high-tilt O
, O
capacitor-based O
biphasic O
waveforms O
. O
[]

The O
therapeutic O
course O
was O
8 O
weeks O
. O
[]

Whereas O
imitation B-outcome ['Life-Impact']
levels O
were O
higher O
for O
pro-socially O
primed O
relative O
to O
non-socially O
primed O
control O
participants O
, O
there O
was O
no O
difference O
between O
pro- O
and O
non- O
socially O
primed O
individuals O
with O
ASC O
. O
['Life-Impact']

The O
ability O
of O
sucrose O
to O
reduce O
clinical O
observational O
scores O
after O
noxious O
events O
in O
newborn O
infants O
should O
not O
be O
interpreted O
as O
pain O
relief O
. O
[]

No O
significant O
differences O
in O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
values O
were O
observed O
between O
group O
A O
( O
P=0.704 O
) O
or O
group O
B O
( O
P=0.270 O
) O
at O
baseline O
, O
or O
at O
5 O
( O
Group O
A O
: O
P=0.340 O
; O
Group O
B O
: O
P=0.559 O
) O
and O
15 O
min O
( O
Group O
A O
: O
P=0.526 O
; O
Group O
B O
: O
P=0.818 O
) O
post O
dose O
. O
['Physiological-Clinical']

These O
data O
are O
in O
agreement O
with O
current O
knowledge O
on O
skeletal O
muscle O
physiology O
and O
show O
the O
reliability O
of O
the O
proposed O
method O
. O
[]

Hematologic B-outcome ['Physiological-Clinical']
and O
nonhematologic O
toxicities I-outcome ['Physiological-Clinical']
were O
mild O
to O
moderate O
. O
['Physiological-Clinical']

BCG O
+ O
FAM O
significantly O
improved O
the O
survival B-outcome ['Mortality']
of I-outcome ['Mortality']
patients I-outcome ['Mortality']
with O
intestinal-type O
but O
not O
diffuse-type O
cancer O
. O
['Mortality']

Non-contrast-enhanced O
4D O
MR O
angiography O
with O
STAR O
spin O
labeling O
and O
variable O
flip O
angle O
sampling O
: O
a O
feasibility O
study O
for O
the O
assessment O
of O
Dural O
Arteriovenous O
Fistula O
. O
[]

The O
physiotherapy O
group O
were O
treated O
with O
ultra-short O
wave O
, O
modulated O
medium O
frequency O
current O
, O
massage O
and O
functional O
training O
. O
[]

There O
were O
also O
no O
statistical O
differences O
between O
the O
two O
groups O
for O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
weaning I-outcome ['Physiological-Clinical']
[ O
IMVG O
: O
1 O
day O
( O
1-6 O
) O
vs. O
SIMVG O
: O
1 O
day O
( O
1-6 O
) O
; O
p O
= O
0.262 O
] O
or O
length O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
[ O
IMVG O
: O
8 O
days O
( O
2-22 O
) O
vs. O
SIMVG O
: O
6 O
days O
( O
3-20 O
) O
; O
p O
= O
0.113 O
] O
. O
['Physiological-Clinical', 'Resource-use']

Intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
complication B-outcome ['Adverse-effects']
rates O
, O
and O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
normal I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
were O
evaluated O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Life-Impact']

METHODS O
A O
controlled O
, O
multiple O
indexes O
study O
was O
conducted O
in O
56 O
old O
subjects O
randomized O
into O
3 O
groups O
. O
[]

AIM O
OF O
THE O
STUDY O
The O
aim O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
fatty O
fish O
and O
lean O
( O
white O
) O
fish O
on O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
factors O
in O
subjects O
with O
CHD O
using O
multiple O
drugs O
for O
this O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinical O
inertia O
, O
the O
tendency O
of O
physicians O
not O
to O
intensify O
treatment O
, O
is O
a O
common O
barrier O
in O
controlling O
chronic O
diseases O
. O
[]

RESULTS O
Using O
a O
serum O
PSA O
cut-off O
of O
4 O
ng/ml O
, O
the O
mean O
lead-time B-outcome ['Physiological-Clinical']
in O
the O
whole O
study O
population O
was O
estimated O
as O
6.8 O
years O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
7.9-8.4 O
) O
. O
['Physiological-Clinical']

Do O
physicians O
' O
implicit O
views O
of O
African O
Americans O
affect O
clinical O
decision O
making O
? O
[]

BACKGROUND O
It O
is O
known O
that O
the O
bifidobacteria O
flora O
play O
important O
roles O
in O
mucosal O
host O
defense O
and O
can O
prevent O
infectious O
diseases O
. O
[]

The O
European O
Myocardial O
Infarction O
Project O
was O
a O
European O
Economic O
Community-supported O
double-blind O
study O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
pre-hospital O
early O
thrombolytic O
treatment O
in O
patients O
with O
suspected O
myocardial O
infarction O
compared O
with O
the O
same O
treatment O
given O
later O
in O
a O
hospital O
setting O
. O
[]

Subjects O
chewed O
nicotine O
gum O
( O
4 O
mg O
) O
or O
placebo O
. O
[]

OT O
seems O
to O
modulate O
this O
effect O
by O
enhancing O
activation B-outcome ['Life-Impact']
differences O
between O
allele O
groups O
, O
which O
suggests O
an O
interaction O
between O
genetic B-outcome ['Physiological-Clinical']
makeup I-outcome ['Physiological-Clinical']
and O
OT B-outcome ['Physiological-Clinical']
availability I-outcome ['Physiological-Clinical']
on O
fusiform B-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
expectant O
management O
group O
one O
twin B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
occurred O
and O
in O
the O
intervention O
group O
one O
woman O
conceived O
twins B-outcome ['Physiological-Clinical']
and O
one O
a O
triplet B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
change O
over O
time O
occurred O
for O
any O
of O
the O
centres O
for O
risk O
perception B-outcome ['Life-Impact']
or O
general B-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

SETTING O
Third-level O
referral O
academic O
centers O
, O
including O
reproductive O
biology O
and O
genetics O
laboratories O
. O
[]

CONCLUSIONS O
Topical O
administration O
of O
diclofenac O
was O
effective O
in O
maintaining B-outcome ['Physiological-Clinical']
mydriasis I-outcome ['Physiological-Clinical']
during O
vitrectomy O
and O
in O
reducing O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
flare I-outcome ['Physiological-Clinical']
as O
determined O
by O
slit-lamp O
evaluations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
cooking O
plant O
oils O
on O
recurrent O
aphthous O
stomatitis O
: O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
[]

Marginal O
benefit/disadvantage O
of O
granulocyte O
colony-stimulating O
factor O
therapy O
after O
autologous O
blood O
stem O
cell O
transplantation O
in O
children O
: O
results O
of O
a O
prospective O
randomized O
trial O
. O
[]

With O
respect O
to O
angiographic B-outcome ['Physiological-Clinical']
new I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
, O
in O
the O
pravastatin O
group O
there O
were O
50 O
% O
less O
patients O
with O
new O
angiographic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
if O
cotreated O
with O
CCBs O
as O
compared O
with O
no O
CCB O
cotreatment O
, O
whereas O
in O
the O
placebo O
( O
no O
pravastatin O
) O
group O
, O
again O
, O
no O
significant O
effect O
of O
CCB O
treatment O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Double-blind O
randomised O
controlled O
trial O
. O
[]

Further O
increase O
of O
the O
dose O
will O
not O
increase O
the O
duration O
. O
[]

treatment O
with O
no O
statistical O
benefit O
regarding O
survival B-outcome ['Mortality']
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

Comparison O
of O
yoga O
versus O
stretching O
for O
chronic B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
: O
protocol O
for O
the O
Yoga O
Exercise O
Self-care O
( O
YES O
) O
trial O
. O
['Physiological-Clinical']

Hypericum O
treatment O
of O
mild O
depressions O
with O
somatic O
symptoms O
. O
[]

The O
mean O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
was O
lower O
( O
p O
< O
0.001 O
) O
in O
both O
groups O
at O
36 O
weeks O
' O
gestation O
than O
at O
presentation O
but O
higher O
( O
p O
= O
0.04 O
) O
in O
the O
hematinic O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

METHOD O
Thirteen O
patients O
received O
early O
conventional O
therapy O
, O
and O
13 O
received O
therapy O
combined O
with O
standing O
balance O
training O
by O
biofeedback O
( O
BPM O
Monitor O
) O
. O
[]

Enhanced O
inotropic O
state O
of O
the O
failing O
left O
ventricle O
by O
cardiac O
contractility O
modulation O
electrical O
signals O
is O
not O
associated O
with O
increased O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESPECT-PTSD O
: O
re-engineering O
systems O
for O
the O
primary O
care O
treatment O
of O
PTSD O
, O
a O
randomized O
controlled O
trial O
. O
[]

RESULTS O
61 O
women O
( O
age O
33.6+/-11.1 O
years O
) O
completed O
the O
intervention O
. O
[]

Selenium O
sulfide O
( O
2.5 O
% O
) O
lotion O
applied O
daily O
for O
10 O
minutes O
for O
7 O
consecutive O
days O
was O
found O
to O
be O
an O
effective O
therapeutic O
agent O
, O
significantly O
superior O
to O
the O
vehicle O
, O
in O
a O
double-blind O
study O
in O
the O
treatment O
of O
tinea O
versicolor O
. O
[]

The O
exercise O
protocol O
consisted O
of O
performing O
the O
bench O
press O
movement O
with O
a O
load O
equal O
to O
70%1RM O
with O
maximal O
possible O
velocity O
(X/0/X/0). O
[]

Forty O
children O
with O
ASD O
( O
7-11 O
years O
) O
and O
their O
primary O
caregiver O
were O
randomly O
assigned O
to O
an O
immediate O
treatment O
( O
IT O
; O
n O
= O
17 O
) O
or O
3-month O
waitlist O
( O
WL O
; O
n O
= O
23 O
) O
condition O
. O
[]

The O
median O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
at O
14 O
days O
was O
significantly O
higher O
in O
the O
GM O
CSF O
group O
( O
1.90 O
vs. O
0.46 O
x O
10 O
( O
9 O
) O
/l O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
use O
structural O
equation O
modeling O
( O
SEM O
) O
to O
re-analyze O
a O
RCT O
, O
comparing O
the O
effects O
of O
pre-curved O
interdental O
brushes O
and O
flossing O
on O
probing O
pocket O
depth O
( O
PPD O
) O
, O
plaque O
indices O
, O
and O
bleeding O
on O
probing O
( O
BOP O
) O
measured O
at O
baseline O
, O
intermediate O
, O
and O
final O
examinations O
. O
[]

The O
accuracy O
of O
clinical B-outcome ['Physiological-Clinical']
neurosensory I-outcome ['Physiological-Clinical']
testing O
for O
nerve O
injury O
diagnosis O
. O
['Physiological-Clinical']

Summing O
scores O
across O
heterogeneous O
symptom O
items O
without O
consideration O
of O
their O
differing O
psychopathological O
significance O
has O
been O
criticized O
as O
producing O
an O
inadequate O
picture O
of O
an O
individual O
's O
clinical O
status O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
NCT01476631 O
. O
[]

Addition O
of O
azathioprine O
and O
prednisone O
to O
ursodeoxycholic O
acid O
resulted O
in O
a O
further O
reduction O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
levels O
by O
a O
median O
of O
25 O
% O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Additionally O
mean O
radiation B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
per O
shoot O
of O
recorded O
Left O
anterior O
oblique O
(LAO) O
oriented O
projections O
was O
34.4+/-15.7mGyvs O
24.9+/-12.9 O
mGy O
for O
a O
non O
LAO O
oriented O
projection. O
( O
[['Life-Impact']]

Subjects O
received O
in O
random O
order O
, O
enalapril O
( O
20 O
mg O
) O
or O
matched O
placebo O
daily O
for O
2 O
weeks O
. O
[]

OBJECTIVE O
To O
observe O
the O
effects O
of O
Shuxuening O
Injection O
( O
SI O
) O
on O
the O
levels O
of O
serum B-outcome ['Physiological-Clinical']
matrix I-outcome ['Physiological-Clinical']
metalloproteinase-9 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MMP-9 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
tissue B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metalloproteinase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TIMP-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
acute O
exacerbated O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
differences O
were O
found O
between O
the O
control O
and O
the O
treatment O
group O
with O
respect O
to O
all O
clinical O
parameters O
of O
cardiac O
performance O
after O
cardiopulmonary O
bypass O
. O
[]

The O
effect O
of O
posture O
on O
Cheyne-Stokes O
respirations O
and O
hemodynamics O
in O
patients O
with O
heart O
failure O
. O
[]

OBJECTIVE O
A O
randomized O
, O
controlled O
trial O
of O
screening O
, O
brief O
intervention O
, O
and O
referral O
to O
treatment O
( O
SBIRT O
) O
for O
drinking O
and O
related O
problems O
among O
at-risk O
and O
dependent O
drinkers O
was O
conducted O
in O
an O
emergency O
department O
( O
ED O
) O
in O
Sosnowiec O
, O
Poland O
, O
among O
patients O
ages O
18 O
years O
and O
older O
. O
[]

No O
significant O
differences O
between O
the O
two O
treatment O
methods O
were O
found O
in O
primary O
or O
any O
of O
the O
secondary O
endpoints O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
percentage O
returning B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
school I-outcome ['Life-Impact']
. O
['Life-Impact']

Participants O
(55% O
female) O
consumed O
50 O
g O
whey O
(WPI; O
active) O
or O
soy O
protein O
isolate O
(SPI; O
control) O
for O
eight O
weeks. O
[]

Primary O
outcome O
was O
incidence O
of O
active O
bleeding B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
secondary O
outcomes O
were O
incidence O
of O
six O
weeks O
rebleeding B-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
and O
mortality B-outcome ['Mortality']
among O
the O
studied O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Mortality']]

Overall O
response O
rate O
was O
42 O
% O
( O
E=44 O
% O
, O
S=44 O
% O
, O
CC=32 O
% O
) O
. O
[]

BACKGROUND O
A O
new O
aqueous O
gel O
formulation O
of O
dapsone O
has O
been O
developed O
that O
allows O
clinically-effective O
doses O
of O
dapsone O
to O
be O
administered O
topically O
with O
minimal O
systemic O
absorption O
. O
[]

METHODS O
The O
effects O
of O
oral O
administration O
of O
Bifidobacterium O
breve O
( O
B. O
breve O
) O
supplements O
were O
studied O
in O
a O
controlled O
trial O
with O
low O
birth O
weight O
infants O
( O
average O
birth O
weight O
1489 O
g O
) O
. O
[]

Does O
a O
first O
trimester O
dating O
scan O
using O
crown O
rump O
length O
measurement O
reduce O
the O
rate O
of O
induction O
of O
labour B-outcome ['Physiological-Clinical']
for O
prolonged B-outcome ['Physiological-Clinical']
pregnancy B-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

Randomised O
controlled O
trial O
( O
RCT O
) O
studies O
in O
this O
area O
have O
been O
rare O
but O
are O
essential O
because O
of O
the O
developmental O
heterogeneity O
of O
the O
disorder O
. O
[]

There O
was O
a O
significant O
difference O
at O
Week O
6 O
in O
model-adjusted B-outcome ['Physiological-Clinical']
CD40-ligand I-outcome ['Physiological-Clinical']
levels O
in O
favor O
of O
clopidogrel O
plus O
aspirin O
compared O
with O
placebo O
plus O
aspirin O
in O
both O
the O
intent-to-treat O
population O
( O
difference O
between O
least-squares O
means O
= O
-186.5 O
; O
95 O
% O
confidence O
interval O
, O
-342.3 O
to O
-30.8 O
; O
P O
= O
0.02 O
) O
and O
the O
per-protocol O
population O
( O
P O
= O
0.05 O
) O
. O
['Physiological-Clinical']

In O
the O
respiration O
chamber O
subjects O
were O
randomly O
assigned O
to O
a O
high-fat O
( O
Hi.F O
) O
diet O
( O
60 O
% O
of O
energy O
( O
En O
% O
) O
fat O
) O
or O
a O
reduced-fat O
( O
Red.F O
) O
diet O
( O
30 O
En O
% O
fat O
) O
. O
[]

RESULTS O
Under O
placebo O
, O
the O
AS O
group O
showed O
decreased O
activity O
in O
the O
right B-outcome ['Physiological-Clinical']
amygdala I-outcome ['Physiological-Clinical']
, O
fusiform B-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
, O
and O
inferior B-outcome ['Physiological-Clinical']
occipital I-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
compared O
with O
the O
control O
group O
during O
face O
processing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

STUDY O
OBJECTIVES O
This O
study O
sought O
to O
establish O
the O
effects O
of O
caffeine O
on O
sleep B-outcome ['Physiological-Clinical']
inertia I-outcome ['Physiological-Clinical']
, O
which O
is O
the O
ubiquitous O
phenomenon O
of O
cognitive O
performance O
impairment O
, O
grogginess O
and O
tendency O
to O
return O
to O
sleep O
immediately O
after O
awakening O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
effect O
of O
nonlinear O
frequency O
compression O
( O
NLFC O
) O
on O
children O
's O
development O
of O
speech O
and O
language O
at O
three O
years O
of O
age O
. O
[]

CONCLUSION O
Although O
a O
rhythm O
control O
strategy O
was O
used O
in O
most O
of O
the O
patients O
in O
this O
trial O
and O
the O
overall O
rate O
of O
use O
of O
warfarin O
was O
low O
, O
the O
significance O
of O
these O
findings O
is O
uncertain O
because O
of O
the O
lack O
of O
data O
from O
randomized O
clinical O
trials O
. O
[]

0.23 O
( O
SD O
) O
IU/mL O
for O
tinzaparin O
and O
0.62 O
? O
[]

A O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
was O
designed O
to O
compare O
steroid B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
between O
placebo O
and O
methotrexate O
( O
MTX O
) O
treatment O
in O
subjects O
with O
corticosteroid-requiring O
asthma O
. O
['Resource-use']

Carpal O
tunnel O
release O
by O
limited O
palmar O
incision O
vs O
traditional O
open O
technique O
: O
randomized O
controlled O
trial O
. O
[]

CONCLUSIONS O
Amoxicillin B-outcome ['Resource-use']
was O
as O
efficacious O
as O
erythromycin O
in O
the O
treatment O
of O
severe B-outcome ['Physiological-Clinical']
pyoderma I-outcome ['Physiological-Clinical']
in O
Mali O
. O
['Resource-use', 'Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
Subnormal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
increased O
fracture B-outcome ['Physiological-Clinical']
risk O
are O
described O
in O
patients O
with O
growth O
hormone O
deficiency O
( O
GHD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
There O
were O
no O
differences O
in O
arch B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
after O
1-phase O
or O
2-phase O
treatment O
of O
Class O
II O
malocclusion O
. O
['Physiological-Clinical']

Such O
alterations O
were O
not O
observed O
in O
group O
C. O
It O
appears O
that O
dietetic O
supplementation O
with O
coconut O
oil O
does O
not O
cause O
dyslipidemia O
and O
seems O
to O
promote O
a O
reduction O
in O
[]

CONCLUSION O
Acupuncture O
combined O
with O
Yizhi O
Jiannao O
Granules O
has O
a O
significant O
therapeutic O
effect O
on O
Alzheimer O
's O
disease O
, O
which O
is O
better O
than O
that O
of O
Yizhi O
Jiannao O
Granules O
or O
Aricept O
. O
[]

Therefore O
, O
we O
studied O
in O
a O
randomized O
clinical O
trial O
the O
relationship O
between O
the O
comminution O
of O
an O
artificial O
test O
food O
, O
i.e O
. O
[]

Changes O
in O
beta-carotene O
levels O
by O
long-term O
administration O
of O
natural O
beta-carotene O
derived O
from O
Dunaliella O
bardawil O
in O
humans O
. O
[]

METHODS O
AND O
RESULTS O
Two O
hundred O
thirty-seven O
consecutive O
women O
patients O
, O
aged O
75 O
years O
or O
younger O
, O
hospitalized O
for O
acute O
myocardial O
infarction O
, O
coronary O
artery O
bypass O
grafting O
, O
or O
percutaneous O
coronary O
intervention O
were O
randomized O
to O
a O
group-based O
psychosocial O
intervention O
program O
or O
usual O
care O
. O
[]

Short-term O
effects O
of O
denopamine O
on O
anaerobic B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
and O
related O
parameters O
in O
patients O
with O
chronic O
heart O
failure O
: O
a O
double-blind O
crossover O
study O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
ascorbic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
were O
higher O
in O
the O
vitamin O
group O
24 O
to O
26 O
hours O
after O
supplementation O
( O
1.28 O
versus O
1.04 O
mg O
per O
100 O
ml O
, O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

The O
reason O
for O
this O
has O
remained O
unclear O
. O
[]

RESULTS O
After O
infusion O
of O
histamine O
pulsatile B-outcome ['Physiological-Clinical']
choroidal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
increased O
by O
5 O
+/- O
3 O
% O
, O
9 O
+/- O
8 O
% O
, O
and O
14 O
+/- O
7 O
% O
( O
P O
= O
0.001 O
, O
ANOVA O
) O
and O
subfoveolar B-outcome ['Physiological-Clinical']
choroidal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
by O
8 O
+/- O
11 O
% O
, O
13 O
+/- O
11 O
% O
, O
and O
13 O
+/- O
12 O
% O
( O
P O
= O
0.003 O
, O
ANOVA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Intervention-group O
participants O
who O
attended O
over O
half O
of O
the O
Working O
Well O
sessions O
reported O
significantly O
lower O
rates O
of O
limitation B-outcome ['Life-Impact']
from O
secondary O
conditions O
over O
the O
1-year O
study O
span O
, O
F O
( O
1 O
, O
124 O
) O
= O
4.11 O
, O
p O
= O
.004 O
. O
['Life-Impact']

This O
study O
compared O
the O
safety O
and O
the O
immunogenicity B-outcome ['Physiological-Clinical']
of O
a O
refrigerator-stable O
formulation O
( O
Zostavax O
refrigerated O
) O
with O
those O
of O
the O
current O
formulation O
( O
Zostavax O
frozen O
) O
in O
subjects O
> O
or O
=50 O
years O
of O
age O
. O
['Physiological-Clinical']

Pilot O
study O
of O
Panax O
quinquefolius O
( O
American O
ginseng O
) O
to O
improve O
cancer-related O
fatigue O
: O
a O
randomized O
, O
double-blind O
, O
dose-finding O
evaluation O
: O
NCCTG O
trial O
N03CA O
. O
[]

RESULTS O
ORR B-outcome ['Physiological-Clinical']
for O
patients O
randomly O
assigned O
to O
receive O
EC O
and O
ED O
were O
42 O
% O
and O
47 O
% O
, O
respectively O
( O
P O
= O
0.63 O
) O
. O
['Physiological-Clinical']

A O
family-based O
, O
cognitive O
behavioural O
treatment O
for O
anxiety O
in O
47 O
children O
with O
comorbid O
anxiety O
disorders O
and O
High O
Functioning O
Autism O
Spectrum O
Disorder O
( O
HFA O
) O
was O
evaluated O
. O
[]

Relatives O
of O
the O
project O
group O
patients O
were O
significantly O
more O
satisfied B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
than O
control O
group O
relatives O
. O
['Life-Impact']

Patients O
underwent O
concealed O
random O
allocation O
to O
a O
target O
glucose O
range O
of O
5 O
to O
7 O
or O
8 O
to O
10 O
mmol/L O
using O
pretested O
algorithms O
of O
insulin O
infusions O
. O
[]

The O
diamorphine O
group O
had O
better O
analgesia B-outcome ['Resource-use']
than O
the O
control O
group O
for O
the O
first O
24 O
hours O
postoperatively O
. O
['Resource-use']

PCA O
morphine O
for O
postoperative O
pain O
. O
[]

Eighteen O
children O
were O
also O
receiving O
nifedipine O
( O
also O
known O
to O
cause O
gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
) O
and O
were O
considered O
separately O
. O
['Physiological-Clinical']

Supplementary O
electrocardiography B-outcome ['Resource-use']
( I-outcome ['Resource-use']
ECG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
was O
performed O
before O
and O
after O
6-month O
treatment O
. O
['Resource-use']

After O
treatment O
with O
chlorhexidine O
varnish O
, O
significantly O
more O
initial B-outcome ['Physiological-Clinical']
root-surface I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
had I-outcome ['Physiological-Clinical']
hardened I-outcome ['Physiological-Clinical']
than O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

A O
total O
of O
452 O
consecutive O
patients O
( O
240 O
with O
kidney O
disease O
and O
212 O
without O
kidney O
disease O
) O
were O
randomly O
assigned O
to O
a O
diagnostic O
strategy O
with O
( O
BNP O
group O
) O
or O
without O
( O
control O
group O
) O
the O
use O
of O
BNP O
levels O
provided O
by O
a O
rapid O
bedside O
assay O
. O
[]

A O
randomized O
, O
controlled O
trial O
of O
wax-matrix O
sustained-release O
niacin O
in O
hypercholesterolemia O
. O
[]

Evaluation O
of O
reducing O
postoperative O
hip O
precautions O
in O
total O
hip O
replacement O
: O
a O
randomized O
prospective O
study O
. O
[]

Results: O
There O
was O
no O
significant O
difference O
in O
general O
data O
and O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
scale O
scores O
between O
the O
two O
groups O
of O
patients O
(all O
P>0.05). O
[['Physiological-Clinical']]

Journal-Name:Indian O
heart O
journal O
[]

The O
effect O
of O
the O
combined O
intervention O
exceeded O
that O
of O
CBT O
or O
Baduanjin O
alone. O
[]

The O
Ca/Mg O
( O
+ O
) O
group O
consisted O
of O
551 O
patients O
, O
the O
Ca/Mg O
( O
- O
) O
group O
consisted O
of O
181 O
patients O
. O
[]

CONCLUSIONS: O
QCA O
has O
potential O
for O
an O
in-depth O
analysis O
of O
complex O
interventions O
as O
it O
can O
rely O
on O
small O
to O
medium O
sample O
sizes O
and O
analyze O
pathways O
to O
success O
and O
non-success O
separately. O
[]

Follow-up O
over O
12 O
months O
will O
enhance O
understanding O
of O
the O
natural O
history O
of O
depression O
in O
cardiac O
patients O
, O
while O
the O
nested O
trial O
will O
inform O
on O
effectiveness O
of O
an O
intervention O
involving O
tailored O
advice O
and O
support O
to O
general O
practitioners O
. O
[]

Enalapril O
and O
eprosartan O
, O
alone O
and O
in O
combination O
, O
were O
used O
to O
determine O
their O
short-term O
effects O
on O
the O
renal O
nitric O
oxide O
system O
and O
renal O
hemodynamics O
of O
human O
subjects O
with O
essential O
hypertension O
. O
[]

Oxytocin B-outcome ['Resource-use']
augmentation I-outcome ['Resource-use']
of O
labor B-outcome ['Physiological-Clinical']
was O
used O
in O
50 O
( O
50.5 O
% O
) O
misoprostol-treated O
patients O
and O
43 O
( O
43.5 O
% O
) O
dinoprostone-treated O
patients O
( O
relative O
risk O
1.14 O
, O
95 O
% O
confidence O
interval O
0.86 O
to O
1.51 O
, O
p O
= O
0.35 O
) O
. O
['Resource-use', 'Physiological-Clinical']

Patients O
were O
examined O
every O
6 O
months O
during O
follow-up O
( O
range O
, O
1-9 O
years O
) O
. O
[]

In O
light O
of O
recent O
data O
on O
the O
mutagenicity O
of O
DNCB O
to O
bacteria O
, O
other O
contact O
allergens O
for O
topical O
immunotherapy O
are O
being O
sought O
. O
[]

The O
median O
time B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
crossover I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Groups I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
Group O
3 O
) O
was O
163 O
, O
99 O
, O
and O
220 O
days O
, O
and O
the O
mean O
time O
was O
172 O
, O
108 O
, O
and O
231 O
days O
. O
['Physiological-Clinical']

After O
2 O
weeks O
on O
placebo O
the O
patients O
were O
assigned O
at O
random O
to O
4 O
groups O
: O
group O
P O
-- O
placebo O
, O
group O
L O
-- O
0.1 O
mg. O
, O
group O
M O
-- O
0.2 O
mg. O
and O
group O
H O
-- O
0.4 O
mg. O
of O
YM617 O
. O
[]

The O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
during O
the O
study O
was O
similar O
in O
conventional O
and O
intensive O
therapy O
groups O
( O
34 O
of O
119 O
, O
28.6 O
% O
vs. O
35 O
of O
121 O
, O
28.9 O
% O
in O
the O
conventional O
and O
intensive O
insulin O
therapy O
groups O
; O
P=0.85 O
) O
. O
['Mortality']

added O
to O
images O
of O
thin/attractive O
models O
would O
affect O
body B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
and O
intent O
to O
diet O
in O
female O
undergraduate O
students O
( O
n=342 O
) O
. O
['Life-Impact']

The O
results O
showed O
that O
there O
were O
no O
statistically O
significant O
differences O
between O
the O
2 O
treatment O
modalities O
regarding O
BOP B-outcome ['Physiological-Clinical']
and O
PPD B-outcome ['Physiological-Clinical']
at O
any O
observation O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Serum O
APN O
levels O
were O
positively O
correlated O
with O
FINS O
and O
TG O
(r O
= O
0.412, O
0.316, O
respectively; O
both O
P<0.05), O
and O
negatively O
correlated O
with O
SBP, O
DBP O
and O
LDL-C O
(r O
= O
-0.292, O
-0.383, O
-0.334, O
respectively; O
all O
P<0.05). O
[]

Overall O
, O
the O
therapy O
improved O
the O
sleep B-outcome ['Physiological-Clinical']
of O
47 O
children O
and O
was O
effective O
in O
reducing O
family B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

No O
statistically O
significant O
relationships O
between O
stool O
consistency O
and O
dietary O
intake O
were O
observed O
. O
[]

Findings O
show O
that O
computer-delivered O
tailored O
interventions O
are O
an O
effective O
adjunct O
to O
the O
clinical O
encounter O
that O
can O
improve O
knowledge O
and O
health O
beliefs O
about O
CRC O
screening O
, O
necessary O
precursors O
to O
behavior O
change O
. O
[]

Journal O
ID: O
0374675 O
[]

RESULTS O
The O
noradrenaline O
spillover O
rate O
, O
indicative O
of O
whole O
body O
sympathetic O
activity O
, O
was O
reduced O
35 O
% O
by O
rilmenidine O
at O
rest O
( O
p O
< O
0.01 O
) O
and O
remained O
significantly O
lower O
during O
mental O
stress O
and O
tilting O
, O
although O
the O
increases O
in O
noradrenaline B-outcome ['Physiological-Clinical']
spillover I-outcome ['Physiological-Clinical']
with O
both O
stimuli O
were O
preserved O
. O
['Physiological-Clinical']

When O
baseline O
scores O
were O
controlled O
, O
there O
were O
no O
significant O
differences O
in O
change O
scores O
of O
cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
over O
eight O
weeks O
between O
the O
two O
groups O
. O
['Life-Impact']

A O
convenience O
sample O
of O
96 O
subjects O
was O
randomly O
assigned O
. O
[]

The O
MI B-outcome ['Physiological-Clinical']
of O
Group O
FC B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
than O
in O
the O
other O
groups O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Synthetic O
serum O
substitute O
( O
SSS O
) O
: O
a O
globulin-enriched O
protein O
supplement O
for O
human O
embryo O
culture O
. O
[]

Only O
standing O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
showed O
a O
dose-dependent O
inhibition O
both O
in O
the O
supine O
and O
upright O
position O
. O
['Physiological-Clinical']

METHODS O
Patients O
with O
autism O
( O
N O
= O
101 O
, O
5-17 O
years O
of O
age O
) O
were O
randomized O
to O
an O
8-week O
trial O
of O
risperidone O
or O
placebo O
and O
63 O
then O
took O
part O
in O
a O
4-month O
open-label O
follow-up O
phase O
. O
[]

The O
stage O
IIc O
and O
III O
shows O
an O
evident O
enhancement O
in O
contrast O
media O
in O
MRI O
. O
[]

This O
suggests O
that O
IL-2 B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
IL-4 I-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
AD I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
is O
less O
sensitive O
to O
regulation O
by O
glucocorticoids O
. O
['Physiological-Clinical']

CONCLUSION O
Efforts O
to O
counsel O
women O
about O
their O
breast O
cancer O
risks O
are O
not O
likely O
to O
be O
effective O
unless O
their O
breast O
cancer O
anxieties O
are O
also O
addressed O
. O
[]

IFN-beta O
was O
injected O
intramuscularly O
three O
times O
weekly O
at O
9 O
M O
IU O
. O
[]

Epidural O
analgesia O
compared O
with O
intravenous O
morphine O
patient-controlled O
analgesia O
: O
postoperative O
outcome O
measures O
after O
mastectomy O
with O
immediate O
TRAM O
flap O
breast O
reconstruction O
. O
[]

[ O
A O
clinical O
study O
on O
the O
effect O
of O
Yinxing O
Damo O
combined O
with O
betahistine O
hydrochloride O
injection O
on O
vertebral B-outcome ['Physiological-Clinical']
basilar I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
vertigo I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effect O
of O
weight O
loss O
on O
inflammation O
in O
patients O
with O
mild O
obstructive O
sleep O
apnea O
. O
[]

After O
suitable O
training, O
patients O
performed O
daily O
spirometry O
at O
home O
using O
a O
portable, O
battery-operated O
spirometer. O
[]

These O
reductions O
were O
associated O
with O
a O
79% O
lower O
mean O
annualized O
attack B-outcome ['Physiological-Clinical']
rate O
than O
that O
observed O
with O
placebo O
(exploratory O
efficacy O
end O
point). O
[['Physiological-Clinical']]

Evidence O
suggests O
that O
the O
elevation O
in O
plasma O
norepinephrine O
levels O
can O
be O
at O
least O
partly O
attributed O
to O
an O
increase O
in O
sympathetic O
nervous O
system O
activity O
. O
[]

Anal O
wall O
DVHs O
were O
used O
for O
fecal O
incontinence O
, O
whereas O
anorectal O
wall O
dose O
best O
described O
the O
other O
two O
endpoints O
. O
[]

Therefore O
, O
abnormalities O
in O
5-HT O
regulation O
in O
autism O
may O
be O
related O
to O
increased O
sensitivity O
of O
the O
5-HT1d O
inhibitory O
receptor O
in O
autism O
. O
[]

Preliminary O
findings O
from O
a O
prospective O
, O
randomized O
trial O
of O
two O
palatal O
operations O
for O
sleep-disordered O
breathing O
. O
[]

Statistical O
analysis O
was O
performed O
by O
linear O
models O
and O
standard O
F O
tests O
. O
[]

The O
effectiveness O
of O
ES O
of O
the O
pelvic O
floor O
in O
urinary O
incontinent O
elderly O
women O
is O
low O
. O
[]

Thirty-three O
patients O
received O
mitoxantrone O
, O
whereas O
30 O
patients O
used O
doxorubicin O
. O
[]

Urine O
samples O
were O
collected O
at O
intake O
, O
on O
Wednesday O
, O
Friday O
( O
the O
last O
day O
of O
detoxification O
) O
, O
and O
the O
following O
Monday O
. O
[]

Unit O
costs O
were O
derived O
from O
the O
DCCT O
, O
manufacturers O
, O
and O
Medicare O
and O
chosen O
to O
reflect O
what O
an O
item O
would O
cost O
to O
a O
single-payer O
national O
health O
system O
. O
[]

Twenty O
children O
were O
included O
in O
the O
study O
but O
four O
( O
two O
in O
each O
group O
) O
had O
to O
be O
excluded O
; O
three O
because O
the O
entry O
criteria O
turned O
out O
not O
to O
be O
fulfilled O
and O
one O
because O
of O
lack O
of O
data O
. O
[]

A O
separate O
Cox O
proportional O
hazards O
model O
was O
run O
using O
IOP O
adjusted O
for O
CCT O
by O
each O
of O
the O
5 O
formulae O
published O
to O
date O
. O
[]

These O
10 O
patients O
experienced O
a O
significantly O
greater O
benefit O
from O
the O
metronidazole B-outcome ['Resource-use']
than O
did O
the O
8 O
patients O
who O
were O
considered O
noncompliant O
, O
i.e. O
, O
a O
reduction O
of O
['Resource-use']

Initial O
bolus O
dose O
of O
rocuronium O
, O
0.6 O
mg O
x O
kg O
( O
-1 O
) O
was O
followed O
by O
continuous O
infusion O
, O
targeting O
at O
steady-state O
95 O
% O
T1 O
depression O
. O
[]

MEASUREMENTS O
After O
4 O
days O
of O
ambulatory O
treatment O
, O
patients O
were O
hospitalized O
, O
and O
IOP B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
were O
obtained O
in O
the O
supine O
and O
sitting O
positions O
with O
a O
handheld O
electronic O
tonometer O
( O
Tono-Pen O
XL O
, O
Bio-Rad O
, O
Glendale O
, O
Calif O
) O
and O
a O
Goldmann O
's O
applanation O
tonometer O
, O
covering O
every O
2-hour O
interval O
, O
around O
the O
clock O
, O
but O
not O
more O
than O
at O
four O
time O
points O
per O
day O
during O
a O
5-day O
period O
. O
['Physiological-Clinical']

Publication O
date: O
2018/12/23 O
06:00 O
[entrez] O
[]

However O
, O
at O
the O
end O
of O
the O
study O
, O
patients O
treated O
with O
cyclical O
clodronate O
had O
higher O
spinal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
compared O
with O
those O
treated O
continuously O
( O
3.32 O
+/- O
0.71 O
versus O
0.43 O
+/- O
0.89 O
% O
, O
P O
< O
.02 O
) O
. O
['Physiological-Clinical']

Total O
mortality B-outcome ['Mortality']
did O
not O
differ O
significantly O
between O
the O
two O
groups O
; O
the O
relative O
risk O
of O
death B-outcome ['Mortality']
for O
staple O
transection O
as O
compared O
with O
sclerotherapy O
was O
0.88 O
( O
95 O
percent O
confidence O
interval O
, O
0.51 O
to O
1.54 O
) O
. O
['Mortality', 'Mortality']

In O
the O
EC O
, O
using O
the O
EC O
machine O
( O
Wieda O
, O
China O
) O
, O
direct O
current O
of O
10-20 O
mA O
was O
applied O
in O
the O
submucosal O
plane O
of O
each O
pile O
core O
for O
5-7 O
minutes O
. O
[]

Regarding O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
when O
anesthesia O
wore O
off O
on O
the O
day O
of O
the O
injection O
, O
20 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
14 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
steps/day B-outcome ['Life-Impact']
were O
significantly O
lower O
in O
the O
intervention O
vs O
control O
group O
(adjusted O
mean O
difference O
= O
- O
336, O
95% O
CI: O
-612 O
to O
- O
60, O
p O
= O
0.02) O
at O
6 O
months. O
[['Life-Impact']]

The O
airway B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
measured O
by O
FEV1 O
, O
followed O
by O
sputum O
induction O
with O
4.5 O
% O
NaCl O
, O
4 O
h O
postchallenge O
. O
['Physiological-Clinical']

Both O
products O
were O
safe O
, O
with O
no O
serious O
adverse O
events O
, O
and O
in O
particular O
, O
no O
anaphylactic O
reactions O
or O
serum O
sickness O
was O
reported O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rate O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adverse O
events O
leading O
to O
withdrawal O
were O
few O
( O
n O
= O
0 O
perindopril O
, O
n O
= O
4 O
placebo O
) O
. O
[]

MATERIAL O
AND O
METHOD O
Thirty O
six O
patients O
were O
randomized O
in O
both O
branches O
: O
diet O
I O
with O
lunch O
and O
dinner O
substituted O
by O
two O
Optisource O
( O
1109,3 O
kcal/day O
, O
166,4g O
of O
carbohydrates O
( O
60 O
% O
) O
, O
63g O
of O
proteins O
( O
23 O
% O
) O
, O
21,3g O
of O
lipids O
17 O
% O
) O
and O
diet O
II O
with O
nutritional O
counselling O
with O
a O
decrease O
of O
500 O
cal/day O
from O
the O
previous O
dietary O
intake O
. O
[]

The O
effect O
of O
intravenous O
lidocaine O
on O
QT B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
during O
tracheal O
intubation O
. O
['Physiological-Clinical']

BACKGROUND O
Hypothermia O
may O
be O
an O
effective O
treatment O
for O
stroke O
or O
acute O
myocardial O
infarction O
; O
however O
, O
it O
provokes O
vigorous O
shivering O
, O
which O
causes O
potentially O
dangerous O
haemodynamic O
responses O
and O
prevents O
further O
hypothermia O
. O
[]

OBJECTIVE O
Cellulose O
sulfate O
( O
CS O
) O
is O
a O
promising O
vaginal O
microbicide O
. O
[]

RESULTS O
From O
pre- O
to O
post-treatment O
, O
all O
children O
had O
less O
parent O
reported O
negativity/lability B-outcome ['Life-Impact']
, O
better O
parent O
reported O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
, O
and O
shorter O
outbursts B-outcome ['Life-Impact']
, O
and O
also O
generated B-outcome ['Life-Impact']
more I-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
in O
response O
to O
vignettes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Funded O
by O
the O
British O
Heath O
Foundation O
and O
others; O
Current O
Controlled O
Trials O
number, O
ISRCTN46552265 O
.). O
[]

Children O
in O
the O
joint O
attention O
intervention O
initiated O
significantly O
more O
showing B-outcome ['Life-Impact']
and O
responsiveness B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
on O
the O
structured O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
assessment O
and O
more O
child-initiated B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
attention I-outcome ['Physiological-Clinical']
in O
the O
mother-child O
interaction O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Clinical O
parameters O
were O
assessed O
to O
determine O
potential O
sources O
of O
bias O
. O
[]

Adjustment O
for O
LDL- B-outcome ['Physiological-Clinical']
and O
HDL-cholesterol B-outcome ['Physiological-Clinical']
did O
not O
affect O
these O
results O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
case O
of O
CYP2D6 O
, O
the O
dextromethorphan B-outcome ['Physiological-Clinical']
to O
dextrorphan B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
not O
['Physiological-Clinical', 'Physiological-Clinical']

Prospective O
, O
blinded O
exploratory O
evaluation O
of O
the O
PlayWisely O
program O
in O
children O
with O
autism O
spectrum O
disorder O
. O
[]

Survival O
rates O
were O
also O
compared O
. O
[]

Compared O
with O
placebo O
, O
NAC O
resulted O
in O
significant O
improvements O
on O
ABC O
irritability B-outcome ['Life-Impact']
subscale O
( O
F O
= O
6.80 O
; O
p O
< O
.001 O
; O
d O
= O
.96 O
) O
. O
['Life-Impact']

We O
present O
secondary O
analyses O
to O
better O
define O
the O
scope O
of O
effects O
of O
methylphenidate O
on O
symptoms O
that O
define O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
and O
oppositional O
defiant O
disorder O
( O
ODD O
) O
, O
as O
well O
as O
the O
core O
autistic O
symptom O
domain O
of O
repetitive O
behavior O
. O
[]

We O
investigated O
the O
benefit O
of O
adding O
all-trans O
retinoic O
acid O
( O
ATRA O
) O
to O
chemotherapy O
for O
younger O
patients O
with O
nonacute O
promyelocytic O
acute O
myeloid O
leukemia O
and O
high-risk O
myelodysplastic O
syndrome O
, O
and O
considered O
interactions O
between O
treatment O
and O
molecular O
markers O
. O
[]

Patients O
were O
followed O
up O
at O
4 O
, O
12 O
, O
and O
24 O
months O
. O
[]

Many O
athletes O
arrive O
at O
training O
sessions O
and O
competitions O
in O
a O
mildly O
hypohydrated O
( O
HYPO O
) O
state O
and O
are O
instructed O
to O
drink O
fluids O
before O
exercise O
to O
reach O
a O
euhydrated O
( O
HYD O
) O
state O
. O
[]

For O
each O
specific O
documentation O
element O
, O
a O
GEE O
model O
gave O
p-values O
of O
> O
0.2 O
in O
independent O
tests O
, O
indicating O
no O
evidence O
of O
significant O
change O
in O
documentation O
after O
the O
intervention O
. O
[]

Standardized O
preoperative O
corticosteroid O
treatment O
in O
neonates O
undergoing O
cardiac O
surgery O
: O
results O
from O
a O
randomized O
trial O
. O
[]

The O
geometric O
means O
of O
AUCi.v O
. O
[]

PURPOSE O
Nearly O
2000 O
patients O
with O
stage O
IIB O
and O
III O
melanoma O
have O
participated O
in O
four O
multicenter O
, O
randomized O
trials O
, O
conducted O
by O
the O
Eastern O
Cooperative O
Oncology O
Group O
and O
the O
Intergroup O
, O
investigating O
adjuvant O
high-dose O
IFN-alpha O
2b O
therapy O
. O
[]

Our O
results O
do O
not O
support O
further O
study O
of O
ganitumab O
in O
this O
subgroup O
of O
patients O
. O
[]

Breakdown O
of O
disease B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
was O
7.8 O
% O
stage O
III O
, O
22.8 O
% O
stage O
IV O
, O
and O
69.4 O
% O
recurrent O
disease O
. O
['Physiological-Clinical']

Comparison O
of O
neurocognitive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
children O
previously O
randomly O
assigned O
to O
intrathecal O
methotrexate O
compared O
with O
triple O
intrathecal O
therapy O
for O
the O
treatment O
of O
childhood O
acute O
lymphoblastic O
leukemia O
. O
['Life-Impact']

Title: O
Preventive O
effects O
of O
galcanezumab O
in O
adult O
patients O
with O
episodic O
or O
chronic O
migraine O
are O
persistent: O
data O
from O
the O
phase O
3, O
randomized, O
double-blind, O
placebo-controlled O
EVOLVE-1, O
EVOLVE-2, O
and O
REGAIN O
studies. O
[]

We O
performed O
the O
following O
interventions O
: O
( O
1 O
) O
weekly O
90-minute O
yoga O
classes O
with O
daily O
at-home O
practice O
, O
( O
2 O
) O
individualized O
facility-based O
aerobic O
exercise O
training O
3 O
times/week O
, O
and O
( O
3 O
) O
0.615 O
g O
omega-3 O
supplement O
, O
3 O
times/day O
. O
[]

These O
include O
first-order O
cues O
such O
as O
luminance O
modulations O
and O
second-order O
cues O
involving O
modulations O
of O
orientation O
and O
contrast O
. O
[]

Alternatively O
, O
the O
distinctiveness O
heuristic O
assumes O
that O
critical B-outcome ['Physiological-Clinical']
lures I-outcome ['Physiological-Clinical']
are O
actively O
withheld O
by O
the O
use O
of O
a O
retrieval O
strategy O
. O
['Physiological-Clinical']

RESULTS O
The O
effects O
of O
5 O
g/day O
of O
MF101 O
did O
not O
differ O
from O
those O
of O
placebo O
. O
[]

This O
prospective O
, O
randomized O
, O
double-blind O
study O
compares O
the O
digital O
block O
results O
following O
the O
administration O
of O
2.5 O
ml O
of O
0.75 O
% O
ropivacaine O
solution O
and O
2.5 O
ml O
of O
2 O
% O
lidocaine O
solution O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
two O
treatment O
groups O
. O
['Adverse-effects']

However O
, O
there O
was O
no O
evidence O
either O
during O
the O
trial O
or O
subsequently O
when O
Senokot O
was O
employed O
to O
supplement O
behavioural O
treatment O
in O
every O
child O
who O
continued O
with O
therapy O
that O
this O
laxative O
contributed O
in O
any O
way O
to O
relieving B-outcome ['Physiological-Clinical']
the O
problem O
in O
this O
group O
of O
cases O
. O
['Physiological-Clinical']

A O
randomised O
controlled O
trial O
comparing O
two O
schedules O
of O
antenatal O
visits O
: O
the O
antenatal O
care O
project O
. O
[]

METHODS O
A O
cluster O
randomized O
field O
trial O
was O
conducted O
among O
2968 O
Bangladeshi O
rural O
children O
6-36 O
months O
old O
. O
[]

Journal-Name:Indian O
heart O
journal O
[]

No O
statistically O
significant O
difference O
in O
fasciculations B-outcome ['Physiological-Clinical']
was O
detected O
between O
the O
two O
groups O
using O
chi O
2 O
analysis O
. O
['Physiological-Clinical']

From O
2,834 O
single O
pregnancies O
, O
1,415 O
were O
selected O
at O
random O
to O
receive O
ultrasound O
imaging O
and O
continuous O
wave O
Doppler O
flow O
studies O
at O
five O
points O
throughout O
pregnancy O
( O
Intensive O
) O
and O
1,419 O
to O
receive O
a O
single O
imaging O
scan O
at O
18 O
weeks O
( O
Regular O
) O
, O
with O
further O
scans O
only O
as O
indicated O
on O
clinical O
grounds O
. O
[]

Doubling O
the O
dose O
of O
valsartan O
to O
320 O
mg O
incrementally O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
by O
-3.8/-3.3 O
mm O
Hg O
( O
P O
= O
not O
significant O
) O
. O
['Physiological-Clinical']

The O
difference O
was O
significant O
in O
the O
proximal O
region O
as O
compared O
to O
the O
control O
group O
( O
Palacos O
) O
. O
[]

Adverse O
events O
and O
Arizona O
Sexual O
Experience O
Scale O
scores O
were O
comparable O
between O
groups O
. O
[]

Group O
B O
patients O
continued O
on O
full-dose O
( O
1,200 O
mg/d O
) O
zidovudine O
therapy O
while O
beginning O
GM-CSF O
therapy O
. O
[]

BACKGROUND O
Malaria O
infections O
are O
the O
leading O
cause O
of O
death O
for O
children O
in O
Madagascar O
. O
[]

A O
number O
of O
preventive O
methods O
have O
been O
tried. O
[]

CLINICAL O
TRIAL O
REGISTRATION O
http O
: O
//www.clinicaltrials.gov O
. O
[]

Samples O
from O
saliva O
, O
dental O
plaque O
and O
faeces O
and O
biopsies O
from O
antrum O
and O
corpus O
were O
analysed O
in O
order O
to O
determine O
the O
ecological O
changes O
in O
the O
normal O
microflora O
. O
[]

Twenty-three O
survivors O
of O
BC O
were O
included O
in O
this O
analysis. O
[]

METHODS O
We O
carried O
out O
clinical O
and O
parasitological O
surveys O
in O
14 O
communities O
in O
matched O
pairs O
. O
[]

RESULTS: O
The O
preoperative O
MDCT O
images O
for O
standard-dose O
protocol O
had O
better O
quality B-outcome ['Life-Impact']
than O
low-dose O
protocol O
(P O
< O
.001, O
q O
= O
4.57). O
[['Life-Impact']]

Bronchodilator B-outcome ['Physiological-Clinical']
efficacy O
was O
evaluated O
by O
serial B-outcome ['Physiological-Clinical']
spirometry I-outcome ['Physiological-Clinical']
for O
6 O
hr O
after O
the O
patients O
self-administered O
the O
study O
drug O
in O
the O
clinic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
8102988 O
[]

Side-effects B-outcome ['Adverse-effects']
mainly O
consisted O
of O
constipation B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
early O
rehabilitation O
protocol O
increases O
the O
pace O
of O
recovery O
compared O
to O
a O
pathway O
with O
hip O
precautions O
without O
increasing O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Patients O
in O
group O
A O
had O
a O
more O
rapid O
increase O
in O
WBC B-outcome ['Physiological-Clinical']
than O
those O
in O
group O
B O
; O
however O
, O
by O
week O
8 O
, O
the O
WBC B-outcome ['Physiological-Clinical']
in O
each O
group O
was O
essentially O
equal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Roland O
adaptation O
of O
the O
Sickness O
Impact O
Profile O
, O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scale O
, O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
scale O
, O
EuroQol O
, O
use O
of O
primary O
and O
secondary B-outcome ['Resource-use']
care I-outcome ['Resource-use']
services I-outcome ['Resource-use']
, O
and O
physical B-outcome ['Resource-use']
and I-outcome ['Resource-use']
complementary I-outcome ['Resource-use']
therapies I-outcome ['Resource-use']
, O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
medication B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
reassurance B-outcome ['Life-Impact']
and O
belief O
in O
value O
of O
radiography O
at O
3 O
and O
9 O
months O
post-randomisation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact']

Five O
( O
16 O
% O
) O
patients O
in O
the O
LC O
group O
required O
conversion O
to O
OC O
, O
in O
most O
because O
severe B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
distorted O
the O
anatomy O
of O
Calot O
's O
triangle O
. O
['Physiological-Clinical']

The O
GPs O
of O
the O
intervention O
patients O
were O
telephoned O
during O
the O
admission O
. O
[]

Title: O
Comparison O
of O
Corneal O
Epithelial O
Remodeling O
Over O
2 O
Years O
in O
LASIK O
Versus O
SMILE: O
A O
Contralateral O
Eye O
Study. O
[]

INTERVENTIONS O
Volunteers O
received O
a O
single O
200-mg O
oral O
dose O
of O
itraconazole O
or O
itraconazole O
with O
concomitant O
oral O
ddI O
300 O
mg O
( O
two O
150-mg O
tablets O
) O
dispersed O
in O
240 O
ml O
water O
. O
[]

The O
basic O
intervention O
was O
a O
one-time O
e-mail O
reminder O
highlighting O
six O
HF-specific O
clinical O
recommendations O
. O
[]

Significantly O
fewer O
patients O
( O
seven O
per O
cent O
versus O
29 O
per O
cent O
, O
p O
= O
0.04 O
) O
in O
the O
ofloxacin O
group O
had O
active O
disease B-outcome ['Physiological-Clinical']
at O
the O
end O
of O
the O
two-week O
treatment O
. O
['Physiological-Clinical']

Quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
was O
also O
improved O
with O
desmopressin O
versus O
placebo O
( O
statistically O
significant O
for O
one O
of O
the O
two O
parameters O
evaluated O
) O
. O
['Physiological-Clinical']

Within-program O
data O
showed O
a O
significant O
reduction O
in O
errors O
made O
from O
first O
to O
last O
use O
. O
[]

Scoring O
of O
neurologic B-outcome ['Physiological-Clinical']
disability I-outcome ['Physiological-Clinical']
was O
performed O
at O
the O
start O
and O
end O
of O
the O
treatment O
period O
. O
['Physiological-Clinical']

The O
study O
shows O
that O
in O
infants O
with O
atopic O
dermatitis O
, O
raised O
serum B-outcome ['Physiological-Clinical']
total O
IgE B-outcome ['Physiological-Clinical']
has O
significantly O
different O
determinants O
from O
that O
a O
specific O
allergen B-outcome ['Physiological-Clinical']
sensitization I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Three O
patients O
in O
each O
treatment O
group O
experienced O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
two O
in O
each O
group O
requiring O
blood O
transfusions O
. O
['Physiological-Clinical']

RESULTS O
Infants O
in O
the O
liberal-transfusion O
group O
received O
more O
RBC B-outcome ['Physiological-Clinical']
transfusions I-outcome ['Physiological-Clinical']
( O
5.2 O
+/- O
4.5 O
[ O
mean O
+/- O
SD O
] O
vs O
3.3 O
+/- O
2.9 O
in O
the O
restrictive-transfusion O
group O
) O
. O
['Physiological-Clinical']

BACKGROUND O
A O
pooled O
post O
hoc O
responder O
analysis O
was O
performed O
to O
assess O
the O
clinical O
benefit O
of O
alvimopan O
, O
a O
peripherally O
acting O
mu-opioid O
receptor O
( O
PAM-OR O
) O
antagonist O
, O
for O
the O
management O
of O
postoperative O
ileus O
after O
bowel O
resection O
. O
[]

RESULTS O
Mean O
concentrations O
of O
CP O
in O
pasture O
and O
urea B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
High-N O
than O
the O
Control O
group O
( O
25.2 O
vs O
21.6 O
and O
8.3 O
vs O
5.4 O
mmol/L O
for O
CP O
and O
urea O
, O
respectively O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
Caregivers O
in O
the O
IOL O
group O
reported O
higher O
levels O
of O
stress O
than O
those O
in O
the O
CL O
group O
3 O
months O
after O
surgery O
, O
but O
there O
were O
no O
group O
differences O
in O
stress O
scores O
at O
the O
post-VA O
assessment O
. O
[]

RESULTS O
Omega-3 O
fatty O
acids O
therapy O
decreased O
triglycerides B-outcome ['Physiological-Clinical']
by O
21 O
% O
and O
triglycerides/HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
improved O
flow-mediated B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
, O
however O
, O
did O
not O
significantly O
change O
insulin B-outcome ['Resource-use']
, O
plasma B-outcome ['Physiological-Clinical']
adiponectin I-outcome ['Physiological-Clinical']
levels O
, O
and O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
determined O
by O
QUICKI O
) O
relative O
to O
baseline O
measurements O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

We O
intend O
to O
build O
on O
our O
work O
by O
using O
the O
survey O
platform O
in O
other O
modalities O
while O
ensuring O
that O
the O
patient O
's O
preferences O
are O
considered O
at O
all O
times O
. O
[]

BK O
caused O
cough B-outcome ['Physiological-Clinical']
at O
13.4 O
+/- O
1.2 O
( O
-log O
M O
) O
in O
5 O
patients O
with O
cough O
associated O
with O
ACE O
inhibitors O
, O
but O
it O
did O
not O
cause O
cough B-outcome ['Physiological-Clinical']
at O
concentrations O
up O
to O
10 O
( O
-5 O
) O
M O
in O
other O
5 O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subthreshold O
TENS O
did O
not O
increase O
the O
symptom O
relief O
produced O
by O
conservative O
treatment O
with O
the O
protocol O
used O
. O
[]

Overall O
our O
data O
seem O
to O
suggest O
that O
for O
most O
BCC O
and O
BD O
lesions O
, O
surface O
preparation O
did O
not O
increase O
ALA B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERPRETATION O
A O
low-intensity O
, O
7-week O
training O
protocol O
has O
a O
beneficial O
effect O
on O
the O
mechanical O
efficiency O
and O
metabolic B-outcome ['Physiological-Clinical']
cost I-outcome ['Physiological-Clinical']
of O
wheelchair O
propulsion O
in O
able-bodied O
participants O
. O
['Physiological-Clinical']

AIM O
To O
compare O
a O
limited O
palmar O
incision O
for O
carpal O
tunnel O
release O
( O
CTR O
) O
with O
a O
traditional O
open O
technique O
, O
which O
is O
still O
considered O
the O
gold O
standard O
. O
[]

This O
was O
not O
statistically O
significant O
( O
P O
= O
.977 O
) O
. O
[]

Stool O
samples O
were O
cultured O
for O
Clostridium O
difficile O
the O
day O
before O
the O
operation O
and O
later O
on O
postoperative O
days O
4 O
, O
7 O
, O
and O
14 O
. O
[]

METHODS: O
A O
total O
of O
98 O
dyslipidemic O
patients O
were O
enrolled O
and O
divided O
into O
amla O
and O
placebo O
groups. O
[]

The O
haemoglobin B-outcome ['Physiological-Clinical']
level O
at O
presentation O
was O
strongly O
correlated O
with O
prognosis O
among O
patients O
in O
the O
good O
renal-function O
group O
. O
['Physiological-Clinical']

Face O
processing O
in O
adolescents O
with O
autistic O
disorder O
: O
The O
inversion O
and O
composite O
effects O
. O
[]

Included O
were O
869 O
children O
who O
were O
6 O
to O
16 O
y O
of O
age O
in O
grades O
1 O
to O
10 O
. O
[]

This O
may O
reflect O
improved O
availability O
of O
cognitive O
processing O
resources O
in O
the O
parietal O
cortex O
, O
an O
area O
that O
on O
the O
one O
hand O
plays O
an O
important O
role O
in O
fundamental O
aspects O
of O
attention O
and O
on O
the O
other O
hand O
has O
been O
found O
to O
be O
functionally O
impaired O
in O
dementia O
. O
[]

The O
cephalad O
dermatome O
level O
of O
the O
block O
and O
degree O
of O
motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
was O
comparable O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

Nasal O
sprays O
of O
recombinant O
alfa-2b O
interferon O
were O
not O
an O
effective O
treatment O
for O
natural O
colds B-outcome ['Physiological-Clinical']
and O
were O
associated O
with O
['Physiological-Clinical']

The O
predischarge O
angiogram O
showed O
the O
presence O
of O
TIMI B-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
in O
96 O
% O
of O
patients O
who O
received O
PCI O
and O
65 O
% O
of O
patients O
who O
received O
SK O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
49 O
patients O
were O
treated O
with O
cryotherapy O
plus O
subcutaneously O
administered O
interferon O
alpha-2a O
, O
and O
48 O
received O
cryotherapy O
plus O
placebo O
. O
[]

Changes O
in O
skin B-outcome ['Physiological-Clinical']
microcirculatory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
flux B-outcome ['Physiological-Clinical']
were O
measured O
bilaterally O
by O
infrared O
photoplethysmography O
and O
laser O
doppler O
fluxmetry O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lidocaine O
had O
the O
quickest O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
anesthesia I-outcome ['Physiological-Clinical']
, O
with O
a O
mean O
time O
of O
1.3 O
minutes O
( O
range O
, O
1 O
to O
2.7 O
minutes O
) O
. O
['Physiological-Clinical']

At O
endpoint O
, O
subjects O
assigned O
to O
ZNS O
were O
taking O
a O
mean O
dosage O
of O
160 O
+/- O
50 O
mg/day O
. O
[]

The O
BMD B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lumbar I-outcome ['Physiological-Clinical']
vertebrae I-outcome ['Physiological-Clinical']
was O
measured O
by O
dual-energy B-outcome ['Resource-use']
X-ray I-outcome ['Resource-use']
absorptiometry I-outcome ['Resource-use']
at O
least O
twice O
, O
12-57 O
months O
apart O
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
This O
community-based O
, O
randomized O
trial O
compared O
the O
exercise O
intervention O
with O
a O
no-intervention O
control O
. O
[]

A O
prospective O
randomised O
comparison O
of O
the O
dynamic O
hip O
screw O
and O
the O
gamma O
locking O
nail O
. O
[]

Secondary O
outcome O
was O
time B-outcome ['Resource-use']
to I-outcome ['Resource-use']
emergency I-outcome ['Resource-use']
medical I-outcome ['Resource-use']
services I-outcome ['Resource-use']
(EMS) I-outcome ['Resource-use']
activation I-outcome ['Resource-use']
. O
We O
analyzed O
data O
via O
Kruskal-Wallis O
rank O
sum O
test. O
[['Resource-use']]

OBJECTIVE: O
To O
determine O
and O
compare O
the O
short-term O
effects O
of O
rigid O
and O
Kinesio O
taping O
on O
scapular B-outcome ['Physiological-Clinical']
dyskinesis I-outcome ['Physiological-Clinical']
, O
scapular B-outcome ['Physiological-Clinical']
upward I-outcome ['Physiological-Clinical']
rotation I-outcome ['Physiological-Clinical']
, O
and O
pectoralis B-outcome ['Physiological-Clinical']
minor I-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
in O
asymptomatic O
overhead O
athletes. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

There O
was O
no O
difference O
in O
number O
becoming O
ill B-outcome ['Physiological-Clinical']
( O
133 O
versus O
129 O
) O
, O
number O
of O
episodes B-outcome ['Physiological-Clinical']
( O
166 O
versus O
159 O
) O
or O
mean O
illness B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
( O
5.5 O
versus O
5.8 O
days O
) O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
aged O
18-55 O
years O
with O
relapsing-remitting O
multiple O
sclerosis O
were O
randomly O
assigned O
( O
1:1:1 O
) O
, O
via O
a O
central O
interactive O
voice O
response O
system O
, O
to O
subcutaneous O
injections O
of O
daclizumab O
HYP O
150 O
mg O
or O
300 O
mg O
, O
or O
placebo O
, O
every O
4 O
weeks O
for O
52 O
weeks O
. O
[]

Short-course O
nitrofurantoin O
for O
the O
treatment O
of O
acute O
uncomplicated O
cystitis O
in O
women O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
etanercept O
and O
control O
groups O
in O
the O
rates O
of O
sustained B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
69.7 O
percent O
vs. O
75.3 O
percent O
, O
P=0.39 O
) O
, O
sustained O
periods O
of O
low-level O
disease I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
86.5 O
percent O
vs. O
90.6 O
percent O
, O
P=0.32 O
) O
, O
or O
the O
time O
required O
to O
achieve O
those O
measures O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
This O
study O
was O
designed O
to O
determine O
whether O
reductions O
in O
morning B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
elicited O
by O
treatment O
of O
moderate O
to O
severe O
obstructive B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
apnea I-outcome ['Physiological-Clinical']
( O
OSA O
) O
in O
heart O
failure O
( O
HF O
) O
patients O
are O
associated O
with O
a O
reduction O
in O
sympathetic B-outcome ['Physiological-Clinical']
vasoconstrictor I-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
the O
end O
of O
the O
intervention O
, O
JASP/ER O
teachers O
used O
more O
JASP/ER O
strategies O
than O
the O
control O
teachers O
, O
and O
JASP/ER O
preschoolers O
used O
more O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
in O
their O
classroom O
than O
control O
children O
. O
['Life-Impact']

CONCLUSIONS O
Mode O
of O
ventilation O
during O
CPB O
did O
not O
affect O
immediate O
postbypass O
oxygenation O
. O
[]

the O
action O
performed O
by O
the O
human O
body O
segment O
specifically O
affected O
by O
writer O
's O
cramp O
) O
or O
inanimate O
object O
motion O
( O
a O
moving O
circle O
reaching O
a O
spatial O
target O
) O
. O
[]

The O
plasma O
half-life O
of O
LY450139 O
was O
approximately O
2.5 O
hours O
. O
[]

METHODS O
We O
studied O
the O
distribution O
of O
a O
Web-based O
and O
a O
print-delivered O
version O
of O
the O
Active O
Plus O
intervention O
in O
a O
clustered O
randomized O
controlled O
trial O
( O
RCT O
) O
. O
[]

Diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
significantly O
in O
group O
L O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

A O
total O
of O
213 O
eligible O
patients O
were O
enrolled O
. O
[]

Effects O
of O
guided O
imagery O
with O
relaxation O
training O
on O
anxiety B-outcome ['Life-Impact']
and O
quality O
of O
life O
among O
patients O
with O
inflammatory O
bowel O
disease O
. O
['Life-Impact']

The O
study O
also O
demonstrated O
the O
potential O
for O
consents O
to O
aid O
the O
student O
provider O
in O
better O
communicating B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
patients I-outcome ['Life-Impact']
. O
['Life-Impact']

Compared O
to O
placebo-treated O
patients O
, O
delta O
power B-outcome ['Physiological-Clinical']
was O
significantly O
increased O
in O
all O
dose O
groups O
. O
['Physiological-Clinical']

A O
significant O
reduction O
in O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
seen O
in O
the O
POIO O
, O
IOPO O
, O
and O
POIOPO O
groups O
whereas O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
the O
POIO O
, O
POIOPO O
, O
and O
LA O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
QoL B-outcome ['Life-Impact']
questionnaires O
were O
completed O
by O
37 O
pts O
( O
88 O
% O
) O
in O
the O
DCT/CDDP O
arm O
and O
39 O
pts O
( O
87 O
% O
) O
in O
the O
VNR/CDDP O
one O
. O
['Life-Impact']

Pre- O
and O
post-course O
tests O
were O
administered O
at O
the O
start O
and O
the O
end O
of O
the O
attachment O
; O
129 O
students O
sat O
both O
tests O
. O
[]

BACKGROUND O
Although O
precordial O
contrast O
echocardiography O
is O
widely O
used O
to O
diagnose O
patent O
foramen O
ovale O
, O
this O
method O
is O
limited O
by O
poor O
sensitivity O
. O
[]

RESULTS O
Glucagon O
elicited O
hyperglycemia B-outcome ['Physiological-Clinical']
whereas O
hyoscine O
N-butyl O
bromide O
manifested O
an O
anticholinergic B-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Naltrexone O
was O
superior O
to O
placebo O
according O
to O
blind O
Clinical O
Global B-outcome ['Physiological-Clinical']
Consensus I-outcome ['Physiological-Clinical']
Ratings O
( O
unpublished O
scale O
) O
. O
['Physiological-Clinical']

Three O
individuals O
with O
mental O
retardation O
exhibited O
stimulus B-outcome ['Life-Impact']
overselectivity I-outcome ['Life-Impact']
in O
a O
delayed O
matching-to-sample O
task O
in O
which O
two O
sample O
stimuli O
were O
displayed O
on O
each O
trial O
. O
['Life-Impact']

Study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
[]

Evidence O
from O
brain-damaged O
patients O
suggests O
that O
regions O
in O
the O
temporal O
lobes O
, O
distinct O
from O
those O
engaged O
in O
lower-level O
auditory O
analysis O
, O
process O
the O
pitch O
and O
rhythmic O
structure O
in O
music O
. O
[]

Each O
patient O
was O
randomly O
assigned O
to O
a O
normal O
or O
lower O
compression O
class O
treatment O
, O
with O
respectively O
mean O
values O
of O
15 O
and O
10 O
mmHg O
pressure O
after O
wearing O
the O
garment O
for O
1 O
month O
. O
[]

The O
COF O
chemotherapy O
consisted O
of O
Vincristine O
1 O
mg O
, O
cyclophosphamide O
600 O
mg O
and O
5-fluorouracil O
500 O
mg O
IV O
on O
days O
1 O
and O
8 O
with O
or O
without O
the O
addition O
of O
Pingyangmycin O
, O
a O
drug O
equivalent O
to O
Bleomycin O
A5 O
, O
at O
the O
dose O
of O
10 O
mg O
IM O
on O
days O
1 O
, O
3 O
, O
6 O
and O
8 O
. O
[]

We O
varied O
the O
direction O
and O
magnitude O
of O
the O
perturbations O
, O
as O
well O
as O
the O
prior O
knowledge O
of O
perturbation O
direction O
. O
[]

The O
duration O
of O
inotropic B-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
was O
shorter O
in O
group O
II O
than O
in O
group O
I O
, O
but O
the O
difference O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

CONCLUSION O
Disease O
activity O
in O
RA O
is O
reduced O
by O
tocilizumab O
treatment O
, O
irrespective O
of O
the O
type O
of O
composite O
measure O
used O
to O
evaluate O
disease O
activity O
. O
[]

Patients O
who O
had O
metabolic O
syndrome O
were O
randomized O
to O
receive O
clopidogrel O
75 O
mg/day O
plus O
aspirin O
81 O
mg/day O
( O
n O
= O
89 O
) O
or O
placebo O
plus O
aspirin O
81 O
mg/day O
( O
n O
= O
92 O
) O
for O
9 O
weeks O
to O
assess O
the O
efficacy O
of O
each O
treatment O
in O
suppression O
of O
inflammatory O
markers O
. O
[]

Quantitative O
sensory O
measurements O
taken O
from O
the O
affected O
area O
before O
and O
after O
the O
drug O
treatment O
included O
pin-prick O
hyperalgesia O
, O
allodynia O
, O
detection O
and O
pain O
thresholds O
to O
electrical O
and O
heat O
stimuli O
, O
temporal O
summation O
of O
repetitive O
electrical O
and O
heat O
stimuli O
. O
[]

Assessments O
were O
conducted O
pre-intervention O
, O
immediately O
post-intervention O
, O
and O
, O
to O
assess O
maintenance O
, O
at O
six-month O
follow-up O
. O
[]

Sham O
device O
v O
inert O
pill O
: O
randomised O
controlled O
trial O
of O
two O
placebo O
treatments O
. O
[]

CONCLUSION O
These O
results O
indicate O
that O
the O
relation O
between O
DA O
and O
treatment O
response O
in O
chronic O
depression O
is O
complex O
, O
but O
suggest O
that O
greater O
DA O
may O
be O
associated O
with O
a O
steeper O
reduction O
and/or O
better O
response O
to O
pharmacotherapy O
. O
[]

Endoscopic O
versus O
operative O
gastrostomy O
: O
final O
results O
of O
a O
prospective O
randomized O
trial O
. O
[]

Pain O
relief O
was O
evaluated O
in O
81 O
patients O
with O
acute O
ureteral O
colic O
and O
the O
confirmed O
presence O
of O
a O
calculus O
. O
[]

A O
total O
of O
24 O
patients O
were O
recruited O
to O
the O
study O
; O
ten O
received O
cyclosporin O
with O
blood O
transfusions O
( O
BT O
) O
( O
group O
1 O
) O
, O
14 O
received O
BT O
alone O
( O
group O
2 O
) O
. O
[]

Plasma O
AT O
, O
lipid-standardized O
AT O
, O
and O
LDL O
AT O
levels O
rose O
in O
a O
dose-dependent O
fashion O
in O
both O
the O
RRR-AT O
and O
all-rac-AT O
groups O
compared O
with O
baseline O
. O
[]

Conclusion O
PRAM O
provides O
meaningful O
and O
direct O
monitoring O
of O
hemodynamics O
and O
cardiac O
efficiency O
during O
the O
dynamic O
period O
of O
anesthetic O
induction O
in O
children O
undergoing O
cardiac O
surgery. O
[]

These O
findings O
support O
further O
evaluation O
of O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
in O
infants O
< O
6 O
months O
of O
age O
. O
[]

Post-CABG B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
was O
treated O
with O
a O
rhythm O
control O
strategy O
in O
81 O
% O
of O
patients O
and O
with O
warfarin O
in O
23 O
% O
of O
patients O
. O
['Physiological-Clinical']

Although O
the O
flexible O
cryoprobe O
has O
been O
established O
for O
bronchoscopic O
interventions O
in O
malignant O
stenosis O
, O
the O
obtained O
biopsies O
, O
called O
cryobiopsies O
, O
have O
not O
been O
investigated O
in O
a O
large O
cohort O
of O
patients O
. O
[]

Experiments O
1 O
and O
2 O
exposed O
groups O
of O
participants O
either O
to O
DTkid O
training O
or O
to O
a O
control O
task O
. O
[]

Baseline O
tone B-outcome ['Physiological-Clinical']
and O
activity B-outcome ['Life-Impact']
were O
measured O
for O
15 O
min O
prior O
to O
instillation O
of O
20 O
ml O
of O
saline O
alone O
or O
with O
nicotine O
, O
1.2 O
mg O
, O
at O
pH O
4.5 O
. O
['Physiological-Clinical', 'Life-Impact']

SETTING O
Urban O
teaching O
hospital O
clinical O
research O
center O
. O
[]

The O
clinical O
study O
shows O
that O
the O
polymer O
complex O
( O
Polym O
) O
produced O
a O
prolonged B-outcome ['Physiological-Clinical']
therapeutic I-outcome ['Physiological-Clinical']
effect O
, O
this O
being O
consistant O
with O
a O
slow O
release O
pattern O
and O
maintained O
a O
more O
effective O
around-the-clock O
control O
than O
pilocarpine O
solution O
. O
['Physiological-Clinical']

The O
difference O
in O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
between O
transfused O
and O
non-transfused O
patients O
was O
not O
statistically O
significant O
( O
29.8 O
versus O
24.3 O
per O
cent O
; O
P O
= O
0.13 O
) O
. O
['Physiological-Clinical']

It O
can O
cause O
nausea O
, O
vomiting O
and O
dysphoria O
in O
mothers O
and O
can O
cause O
reduced O
fetal O
heart O
rate O
variability O
and O
accelerations O
. O
[]

The O
aortic O
and O
hepatic O
equivalence O
margins O
were O
100 O
and O
20 O
Hounsfield O
units, O
respectively. O
[]

Twenty-six O
subjects O
returned O
to O
have O
the O
second O
ankle O
tested O
, O
resulting O
in O
60 O
ankles O
for O
the O
analyses O
. O
[]

Breast O
cancer O
can O
be O
subdivided O
according O
to O
standard O
pathological O
parameters O
including O
histological O
type O
, O
grade O
, O
and O
assessment O
of O
proliferation O
. O
[]

Approximately O
50 O
% O
of O
patients O
with O
migraine O
could O
be O
recommended O
for O
preventive O
therapies O
, O
yet O
only O
3 O
% O
to O
5 O
% O
of O
patients O
receive O
them O
. O
[]

A O
randomized O
controlled O
trial O
. O
[]

The O
same O
group O
of O
30 O
senior O
medical O
students O
used O
in O
the O
first O
study O
was O
used O
as O
novice O
raters O
. O
[]

Only O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
end-diastolic I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
tended O
to O
be O
of O
significance O
. O
['Physiological-Clinical']

14 O
( O
11.0 O
% O
) O
patients O
in O
the O
hydrotalcite O
group O
and O
six O
( O
4.8 O
% O
) O
in O
the O
esomeprazole O
group O
[]

The O
weight O
difference O
between O
the O
treatment O
and O
control O
group O
at O
the O
18-month O
follow-up O
was O
highly O
significant O
( O
p O
< O
0.001 O
) O
. O
[]

The O
space-analysis O
showed O
excessive O
dental-arch B-outcome ['Physiological-Clinical']
space I-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
palatally-displaced O
canine O
. O
['Physiological-Clinical']

In O
both O
groups O
, O
goiter-related B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
effectively O
relieved O
in O
the O
majority O
of O
patients O
. O
['Physiological-Clinical']

BACKGROUND/AIM: O
Our O
hypothesis O
was O
that O
rectus O
sheath O
block O
(RSB) O
analgesia O
could O
enhance O
satisfaction B-outcome ['Life-Impact']
following O
midline O
laparotomy O
in O
patients O
with O
benign O
disease O
and O
cancer O
patients. O
[['Life-Impact']]

DISCUSSION O
Individual O
counselling O
promotes O
regular O
exercise O
with O
subsequent O
improvements O
in O
[]

Renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
during O
the O
hypotensive O
period O
was O
well O
maintained O
. O
['Physiological-Clinical']

Publication O
Type: O
Multicenter O
Study O
[]

Their O
improvemments O
were O
significantly O
greater O
on O
methandienone O
than O
on O
placebo O
; O
their O
body B-outcome ['Physiological-Clinical']
weights I-outcome ['Physiological-Clinical']
rose I-outcome ['Physiological-Clinical']
( O
though O
this O
seemed O
to O
be O
associated O
with O
water O
retention O
) O
; O
and O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
rose I-outcome ['Physiological-Clinical']
significantly O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Sixty-three O
patients O
were O
randomized O
into O
mitoxantrone O
and O
doxorubicin O
groups O
. O
[]

Fifty-two O
practices O
recruited O
participants O
to O
the O
trial O
. O
[]

The O
primary O
outcome O
measure O
is O
severity O
of O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
according O
to O
the O
PHQ9 B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
Genital O
arousal O
was O
assessed O
as O
vaginal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
amplitude O
( O
VPA O
) O
using O
vaginal B-outcome ['Physiological-Clinical']
photoplethysmography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
significantly O
longer O
with O
ASI O
( O
42 O
% O
risk O
reduction O
for O
recurrence O
or O
death O
[ O
0-68 O
] O
, O
p=0.032 O
) O
and O
there O
was O
a O
trend O
towards O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

After O
this O
period O
, O
the O
teeth O
were O
sectioned O
longitudinally O
and O
apical O
leakage O
measurements O
made O
. O
[]

The O
appointment O
of O
the O
oral O
form O
of O
nicorandil O
(Cordinic, O
PIQ-FHARMA O
LLC) O
for O
2 O
days O
and O
1 O
day O
before O
PCI O
30 O
mg/day, O
then O
20 O
mg O
2 O
hours O
before O
the O
PCI O
and O
10 O
mg O
after O
6 O
hours O
after O
the O
surgery O
reduces O
the O
risk O
of O
intraoperative O
myocardial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
The O
obtained O
data O
give O
an O
opportunity O
to O
extend O
the O
indications O
for O
nicorandil's O
appointment O
in O
the O
drug O
support O
during O
PCI O
in O
patients O
with O
stable O
coronary O
artery O
disease. O
[['Physiological-Clinical']]

CONCLUSIONS: O
Under O
the O
VCV O
mode, O
the O
oxygen O
flow O
outside O
the O
atomization O
could O
lead O
to O
the O
increase O
in O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
the O
patient O
side, O
while O
under O
the O
PCV O
mode, O
the O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
the O
patient O
side O
had O
no O
significant O
change. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Approved O
by O
the O
Ethics O
Committee O
of O
Lower O
Austria O
(GS4-EK-4/107-2010). O
[]

CONCLUSION: O
While O
methohexital O
was O
shown O
to O
confer O
greater O
hemodynamic B-outcome ['Physiological-Clinical']
stability O
in O
patients O
taking O
ACEi/ARB, O
the O
measured O
hormone B-outcome ['Physiological-Clinical']
levels O
could O
not O
explain O
the O
mechanism O
for O
this O
effect. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
75 O
patients O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
group O
exercise O
class O
, O
individual O
physiotherapy O
, O
and O
home O
exercises O
alone O
. O
[]

Following O
completion O
of O
a O
2-week O
baseline O
period O
, O
435 O
adults O
with O
stable O
, O
symptomatic O
, O
smoking-related O
COPD O
were O
randomized O
to O
receive O
either O
500 O
microg O
sibenadet O
or O
placebo O
delivered O
via O
pressurized O
metered O
dose O
inhaler O
( O
pMDI O
) O
, O
three O
times O
daily O
for O
52 O
weeks O
. O
[]

The O
patients O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

These O
findings O
suggest O
clinically O
significant O
benefits O
of O
actively O
treating O
JA O
and O
SP O
skills O
in O
young O
children O
with O
autism O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
to O
recommend O
no O
snacks O
vs O
three O
snacks O
per O
day O
on O
1-year O
weight O
loss O
. O
[]

These O
two O
methods O
, O
as O
well O
as O
other O
considerations O
led O
to O
the O
recommendation O
to O
discontinue O
the O
trial O
. O
[]

This O
study O
examined O
the O
effect O
of O
pairing O
inpatient O
alcoholics O
with O
nursing O
home O
residents O
( O
NHRs O
) O
on O
the O
alcoholics B-outcome ['Life-Impact']
' O
self-esteem B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

METHODS: O
This O
was O
a O
post-hoc O
analysis O
of O
a O
cluster-randomized O
trial O
as O
a O
cohort O
study; O
including O
patients O
with O
a O
working O
diagnosis O
of O
CAP O
admitted O
to O
non-ICU O
wards O
without O
a O
cardiac O
event O
on O
admission. O
[]

Cyclo-oxygenase O
2 O
inhibitors O
such O
as O
parecoxib O
are O
not O
associated O
with O
a O
bleeding O
risk O
and O
would O
be O
welcome O
analgesics O
if O
shown O
to O
be O
effective O
. O
[]

The O
effects O
of O
physical O
and O
emotional O
status O
on O
adherence O
to O
a O
low-fat O
dietary O
pattern O
in O
the O
Women O
's O
Health O
Initiative O
. O
[]

Both O
MRI O
sequences O
scored O
significantly O
higher O
compared O
to O
CT O
for O
image O
quality O
and O
confidence O
in O
contouring, O
particularly O
T2*W. O
This O
was O
also O
reflected O
in O
the O
shorter O
time O
for O
contouring, O
measuring O
15.4, O
9.6 O
and O
9.8 O
min O
for O
CT, O
T2W O
and O
T2*W O
MRI O
respectively. O
[]

There O
is O
evidence O
that O
abnormalities O
exist O
in O
the O
serotonin O
( O
5-HT O
) O
system O
in O
autism O
spectrum O
patients O
. O
[]

Altered O
accuracy O
of O
saccadic O
eye O
movements O
in O
children O
with O
fetal O
alcohol O
spectrum O
disorder O
. O
[]

Patients O
were O
randomly O
assigned O
to O
begin O
with O
gabapentin O
( O
1200 O
mg O
daily O
) O
or O
vigabatrin O
( O
2000 O
mg O
daily O
) O
. O
[]

The O
follow-up O
time O
is O
11-20 O
years O
. O
[]

RESULTS O
There O
was O
no O
effect O
of O
group O
assignment O
on O
parent-child O
interaction O
characteristics O
or O
on O
any O
child O
outcomes O
. O
[]

The O
volume O
of O
irrigation B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
used O
and O
its O
hemoglobin O
concentration O
as O
well O
as O
resected O
prostate O
weight O
were O
recorded O
. O
['Physiological-Clinical']

Children O
with O
a O
positive O
MII/pH O
were O
randomly O
treated O
with O
proton O
pump O
inhibitors O
( O
PPIs O
) O
or O
histamine O
H O
( O
2 O
) O
-receptor O
antagonists O
( O
H O
( O
2 O
) O
RAs O
) O
during O
3 O
months O
. O
[]

Randomised O
trial O
of O
efficacy O
and O
safety O
of O
oral O
ganciclovir O
in O
the O
prevention O
of O
cytomegalovirus O
disease O
in O
liver-transplant O
recipients O
. O
[]

This O
procedure O
prompted O
participants O
to O
make O
simultaneous O
identity-matching O
responses O
that O
required O
observation O
and O
discrimination O
of O
both O
sample O
stimuli O
. O
[]

The O
success B-outcome ['Physiological-Clinical']
rate O
of O
second-line O
levofloxacin-based O
triple O
therapy O
is O
decreasing O
. O
['Physiological-Clinical']

We O
studied O
101 O
adult O
patients O
with O
newly O
detected O
bronchial O
asthma O
who O
were O
without O
inhaled O
steroid O
or O
any O
regular O
pharmacological O
treatment O
for O
their O
asthma O
. O
[]

METHODS O
Thirty O
patients O
from O
the O
Heart O
Failure O
Clinic O
of O
the O
Instituto O
Nacional O
de O
Ciencias O
M?dicas O
y O
Nutrici?n O
Salvador O
Zubir?n O
underwent O
photoplethysmography O
using O
the O
hyperemia O
technique O
. O
[]

Alpha O
interferon O
clinical O
trial O
for O
multiple O
sclerosis O
: O
design O
considerations O
. O
[]

Efficacy O
measurements O
were O
comparable O
between O
the O
three O
treatment O
groups O
, O
although O
the O
higher O
lamotrigine O
dose O
was O
possibly O
most O
effective O
, O
with O
60.4 O
% O
completing O
seizure O
free O
compared O
with O
51.3 O
% O
( O
LTG O
100 O
) O
and O
54.7 O
% O
( O
CBZ O
600 O
) O
. O
[]

STUDY O
DESIGN O
Thirty O
patients O
with O
gynecologic O
malignancy O
, O
who O
had O
laparoscopic O
pelvic O
lymphadenectomy O
were O
randomly O
assigned O
for O
lymphadenectomy O
in O
1 O
side O
of O
the O
pelvis O
using O
the O
Ligaclip O
, O
whereas O
, O
in O
the O
other O
side O
, O
the O
bipolar O
coagulation O
to O
seal O
lymphatic O
vessels O
was O
used O
. O
[]

Glucosamine B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
of O
patients O
after O
myocardial O
infarction O
subjected O
to O
rehabilitation O
training O
. O
['Physiological-Clinical']

Journal O
ID: O
101225531 O
[]

A O
high O
Gleason O
score O
and O
the O
presence O
of O
extracapsular O
extension O
in O
the O
radical O
prostatectomy O
specimens O
were O
highly O
predictive O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
. O
(Funded O
by O
the O
Swedish O
Cancer O
Society O
and O
others.). O
[['Mortality']]

This O
study O
examined O
whether O
abstinence-contingent O
incentives O
would O
improve O
outcomes O
for O
patients O
entering O
outpatient O
opiate B-outcome ['Physiological-Clinical']
detoxification I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE: O
There O
is O
a O
need O
to O
investigate O
the O
effects O
of O
pilates O
exercises O
on O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
patients O
with O
chronic O
kidney O
diseases O
(CKD). O
[['Life-Impact']]

METHOD O
Comprehensive O
cognitive-behavioural O
therapy O
has O
been O
developed O
for O
patients O
in O
the O
early O
initial O
prodromal O
state O
. O
[]

CONCLUSION O
Both O
spinal O
and O
general O
anesthesia O
induced O
a O
significant O
decrease O
in O
intraabdominal O
pressure O
. O
[]

METHODS O
AND O
RESULTS O
A O
total O
of O
143 O
patients O
at O
30 O
centers O
were O
randomized O
to O
receive O
25 O
, O
50 O
, O
or O
100 O
mg O
of O
flecainide O
or O
placebo O
twice O
daily O
( O
BID O
) O
. O
[]

The O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sensory I-outcome ['Life-Impact']
block I-outcome ['Life-Impact']
was O
120.5 O
+/- O
37.0 O
minutes O
in O
Dex O
group O
and O
70.5 O
+/- O
34.5 O
minutes O
in O
Control O
group, O
respectively O
(P O
< O
.05). O
[['Life-Impact']]

Fasting B-outcome ['Physiological-Clinical']
and O
post-prandial B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
glycosylated B-outcome ['Physiological-Clinical']
haemoglobin I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
appeared O
to O
be O
unaffected O
by O
either O
agent O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
determine O
whether O
dronabinol O
administered O
alone O
or O
with O
megestrol O
acetate O
was O
more O
, O
less O
, O
or O
equal O
in O
efficacy O
to O
single-agent O
megestrol O
acetate O
for O
palliating O
cancer-associated O
anorexia O
. O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
Non-U.S. O
Gov't, O
[]

Moreover O
, O
this O
effect O
was O
clearly O
seen O
in O
329 O
patients O
with O
a O
mutated O
NPM1 O
gene O
( O
NPM1+ O
) O
, O
but O
not O
in O
319 O
patients O
without O
a O
NPM1 O
mutation O
( O
wtNPM1 O
) O
. O
[]

Twenty-eight O
patients O
undergoing O
painless O
fiberbronchoscopy O
in O
Hangzhou O
First O
People's O
Hospital O
were O
randomly O
divided O
into O
2 O
groups(n=14): O
supraglottic O
tracheal O
tube O
ventilation(group O
A) O
and O
modified O
laryngeal O
mask O
airway(group O
B). O
[]

Autism O
is O
a O
chronic O
pervasive O
neurodevelopmental O
disorder O
characterized O
by O
the O
early O
onset O
of O
social O
and O
communicative O
impairments O
as O
well O
as O
restricted O
, O
ritualized O
, O
stereotypic O
behavior O
. O
[]

The O
fixed O
combination O
between O
troxerutin O
150 O
mg O
and O
carbazochrome O
1.5 O
mg O
( O
Fleboside O
ampoules O
) O
was O
previously O
shown O
to O
have O
a O
good O
efficacy O
and O
safety O
profile O
in O
non-surgical O
patients O
with O
acute O
uncomplicated O
hemorrhoids O
. O
[]

Median O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
was O
reduced O
by O
-5.00 O
to O
-11.75min O
in O
the O
pramipexole O
groups O
, O
vs. O
-2.00 O
for O
placebo O
( O
p O
< O
0.05 O
for O
all O
groups O
except O
0.25mg/d O
) O
. O
['Physiological-Clinical']

Of O
the O
total O
cycles O
in O
the O
NETA/EE O
group O
, O
10 O
% O
were O
amenorrheic B-outcome ['Physiological-Clinical']
, O
compared O
with O
1.1 O
% O
in O
the O
LNG/EE O
group O
. O
['Physiological-Clinical']

Patients O
in O
both O
groups O
improved O
significantly O
after O
treatment O
in O
Barthel O
index O
(BI)], O
elbow B-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
(ROM) I-outcome ['Physiological-Clinical']
, O
and O
elbow B-outcome ['Life-Impact']
muscles I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
. O
However, O
muscle B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
in O
elbow O
joint O
of O
the O
hemiplegic O
upper O
extremity O
improved O
significantly O
after O
SMV O
only O
in O
the O
experimental O
group O
(SPT-SMV). O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Predictive O
and O
prognostic O
roles O
of O
BRAF O
mutation O
in O
stage O
III O
colon O
cancer O
: O
results O
from O
intergroup O
trial O
CALGB O
89803 O
. O
[]

In O
order O
to O
prove O
it O
, O
40 O
patients O
admitted O
in O
a O
five-year O
period O
, O
with O
a O
SP O
, O
were O
randomly O
assigned O
to O
be O
treated O
by O
ICT O
or O
VATS O
. O
[]

To O
assess O
the O
antiviral O
efficacy O
, O
HIV-1 O
RNA O
was O
determined O
at O
baseline O
, O
day O
3 O
, O
day O
7 O
and O
weekly O
thereafter O
. O
[]

Conclusion: O
Foot O
and O
ankle O
characteristics O
were O
different O
in O
individuals O
with O
PFOA O
compared O
to O
control O
participants, O
however O
there O
was O
no O
difference O
in O
dynamic O
knee O
valgus O
during O
single O
leg O
squat. O
[]

This O
study O
examined O
the O
effects O
of O
MCT O
oil O
consumption O
, O
as O
part O
of O
a O
weight O
loss O
diet O
, O
on O
metabolic O
risk O
profile O
compared O
to O
olive O
oil O
. O
[]

A O
double-blind O
placebo-controlled O
study O
. O
[]

CONCLUSION O
The O
quality O
of O
bitewing O
films O
taken O
by O
the O
loop O
and O
holder O
techniques O
was O
not O
significantly O
different O
. O
[]

Changes O
in O
the O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
esters I-outcome ['Physiological-Clinical']
during O
lipid-lowering O
treatment O
with O
diet O
, O
clofibrate O
and O
niceritrol O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
functional B-outcome ['Life-Impact']
outcome O
or O
death B-outcome ['Mortality']
at O
14 O
days O
or O
3 O
months O
. O
['Life-Impact', 'Mortality']

Lateral O
spinal O
radiographs O
were O
taken O
annually O
for O
assessment O
of O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
at O
6-month O
intervals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
included O
adults O
with O
GERD-associated B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
and O
moderate-to-severe B-outcome ['Physiological-Clinical']
nighttime I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
( O
recorded O
by O
patient O
diary O
during O
screening O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ten O
regression O
algorithms O
were O
generated O
designed O
to O
estimate O
GAI O
. O
[]

At O
baseline O
and O
endline, O
knowledge, O
practice O
and O
coverage O
(KPC) O
surveys O
measured O
household O
health-related O
behaviors O
and O
care-seeking O
behaviors. O
[]

During O
phase O
II O
( O
charcoal O
) O
, O
subjects O
ingested O
3 O
g O
acetaminophen O
, O
followed O
one O
hour O
later O
by O
60 O
g O
activated O
charcoal O
and O
a O
supranormal O
loading O
dose O
of O
N-acetylcysteine O
( O
235 O
mg/kg O
) O
. O
[]

The O
rates O
of O
MACEs O
[ O
5.9 O
% O
( O
n O
= O
5 O
) O
in O
the O
SES O
vs. O
9.5 O
% O
( O
n O
= O
8 O
) O
in O
the O
PES O
Group O
, O
P O
= O
0.374 O
] O
and O
definite B-outcome ['Physiological-Clinical']
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
[ O
1.2 O
% O
( O
n O
= O
1 O
) O
in O
the O
SES O
vs. O
3.6 O
% O
( O
n O
= O
3 O
) O
in O
the O
PES O
Group O
, O
P O
= O
0.368 O
] O
were O
similar O
in O
the O
two O
groups O
during O
the O
three-year O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
average O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
was O
about O
5 O
weeks O
. O
['Life-Impact']

The O
children O
have O
good O
recovery B-outcome ['Physiological-Clinical', 'Life-Impact']
conditions I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
no O
obvious O
postoperative O
agitation B-outcome ['Life-Impact']
and O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
after O
DEX O
administration. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Based O
on O
these O
criteria O
, O
nephrotoxicity B-outcome ['Physiological-Clinical']
was O
seen O
in O
2/27 O
( O
7.4 O
% O
) O
patients O
treated O
with O
G-C O
and O
in O
3/19 O
( O
15.8 O
% O
) O
patients O
treated O
with O
N-C. O
Ototoxicity B-outcome ['Physiological-Clinical']
was O
defined O
as O
a O
greater O
than O
20 O
dB O
loss O
at O
any O
frequency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Between-group O
differences O
in O
glycosylated O
hemoglobin O
( O
HbA1c O
) O
, O
continuous O
glucose O
sensor O
data O
, O
insulin O
utilization O
, O
anthropometric O
measures O
, O
and O
patient O
satisfaction O
with O
therapy O
were O
also O
compared O
at O
multiple O
time O
points O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
groups O
when O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bacteremia I-outcome ['Physiological-Clinical']
attributable O
to O
luminal O
colonization O
with O
a O
vancomycin-susceptible O
organism O
was O
compared O
by O
means O
of O
Kaplan-Meier O
survival O
estimates O
. O
['Physiological-Clinical']

Recurrence O
was O
determined O
by O
two O
consecutive O
21-item O
Hamilton O
Rating O
Scale O
for O
Depression O
( O
HRSD O
) O
scores?15 O
and O
clinician O
interview O
. O
[]

The O
interactions O
of O
testing O
conditions O
, O
adhesive-composite O
combination O
and O
tooth O
substrate O
with O
marginal O
adaptation O
were O
evaluated O
by O
two-way O
ANOVA O
. O
[]

REGISTRATION: O
NCT02190630. O
[]

Determination O
of O
vital O
status O
at O
the O
end O
of O
the O
DIG O
trial O
. O
[]

Our O
findings O
provide O
a O
clear O
demonstration O
in O
man O
of O
the O
important O
homeostatic B-outcome ['Physiological-Clinical']
role I-outcome ['Physiological-Clinical']
of O
renal O
prostaglandins O
in O
preserving O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
particularly O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
, O
under O
conditions O
of O
elevated O
circulating O
angiotensin O
II O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Somatostatin O
has O
no O
additional O
benefit O
in O
those O
with O
Forrest O
II O
bleeding O
activity O
. O
[]

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
effectiveness O
of O
combination O
hydrocodone O
7.5 O
mg O
and O
ibuprofen O
200 O
mg O
with O
that O
of O
combination O
codeine O
30 O
mg O
and O
acetaminophen O
300 O
mg O
for O
the O
treatment O
of O
chronic O
pain O
. O
[]

The O
first O
vaccinations O
contained O
10 O
( O
7 O
) O
BCG O
organisms O
. O
[]

METHODS O
After O
refraining O
from O
all O
oral O
hygiene O
procedures O
for O
23-25 O
hours O
, O
subjects O
received O
an O
oral O
tissue O
examination O
and O
those O
with O
pre-brushing O
whole O
mouth O
mean O
plaque O
scores O
> O
or O
= O
0.6 O
based O
on O
the O
Rustogi O
et O
al O
. O
[]

Modified O
Boyarsky O
score O
decreased O
significantly O
with O
a O
mean O
of O
-6.7 O
( O
SD O
4.0 O
) O
points O
in O
the O
beta-sitosterol-treated O
group O
versus O
-2.1 O
( O
3.2 O
) O
points O
in O
the O
placebo O
group O
p O
< O
0.01 O
. O
[]

CONCLUSIONS O
These O
overall O
findings O
suggest O
that O
a O
limited O
bias O
is O
introduced O
by O
drug O
administration O
instructions O
. O
[]

Cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
users O
of O
ecstasy O
. O
['Life-Impact', 'Physiological-Clinical']

Its O
use O
seems O
not O
to O
be O
indicated O
in O
systematic O
gynecologic O
pelvic O
or O
pelvic O
and O
paraaortic O
lymphadenectomy O
. O
[]

Importance O
of O
preventive O
pharmacological O
strategies O
in O
elderly O
patients O
and O
associated O
costs B-outcome ['Resource-use']
. O
['Resource-use']

[ O
Complication B-outcome ['Adverse-effects']
rate O
after O
gastrectomy O
and O
pouch O
reconstruction O
with O
Longmire O
interposition O
] O
. O
['Adverse-effects']

Red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
major I-outcome ['Physiological-Clinical']
retinal I-outcome ['Physiological-Clinical']
veins I-outcome ['Physiological-Clinical']
tended O
to O
decrease O
by O
-9 O
+/- O
12 O
% O
, O
-9 O
+/- O
20 O
% O
, O
and O
-13 O
+/- O
12 O
% O
, O
but O
this O
effect O
did O
not O
reach O
levels O
of O
significance O
. O
['Physiological-Clinical']

Effects O
of O
amlodipine O
and O
enalapril O
on O
platelet B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
['Physiological-Clinical']

The O
results O
showed O
that O
the O
complexity O
of O
emitted B-outcome ['Physiological-Clinical']
messages I-outcome ['Physiological-Clinical']
had O
improved O
statistically O
significantly O
in O
the O
trained O
group O
as O
an O
effect O
of O
training O
. O
['Physiological-Clinical']

To O
test O
these O
competing O
positions O
, O
therapists O
at O
a O
university O
counseling O
center O
were O
instructed O
to O
increase O
the O
number O
of O
self-disclosures O
they O
made O
during O
treatment O
of O
one O
client O
and O
refrain O
from O
making O
self-disclosures O
during O
treatment O
of O
another O
client O
. O
[]

However O
, O
the O
clinical O
relevance O
of O
these O
findings O
await O
results O
of O
the O
IMPROVE-IT O
trial O
( O
Improved O
Reduction O
of O
Outcomes O
: O
Vytorin O
Efficacy O
International O
Trial O
) O
. O
[]

Groups O
receiving O
paromomycin O
or O
placebo O
were O
similar O
for O
clinical O
and O
biological O
items O
collected O
initially O
. O
[]

These O
parameters O
were O
also O
examined O
in O
20 O
healthy O
volunteers. O
[]

Subjects O
in O
Group O
I O
replaced O
lenses O
every O
3 O
months O
, O
whereas O
those O
in O
Group O
II O
were O
not O
scheduled O
to O
replace O
their O
lenses O
. O
[]

This O
study O
aims O
to O
determine O
the O
efficacy O
of O
repeated O
PZQ O
treatments O
against O
Schistosoma B-outcome ['Physiological-Clinical']
mansoni I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
school-aged O
children O
in O
Cote O
d'Ivoire O
using O
the O
traditional O
KK O
technique, O
as O
well O
as O
more O
sensitive O
antigen- O
and O
DNA-detection O
methods. O
[['Physiological-Clinical']]

The O
most O
commonly O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
all O
with O
incidence O
of O
5 O
% O
or O
less O
) O
among O
patients O
receiving O
rizatriptan O
were O
dry B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
, O
asthenia/fatigue B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
PRIMARY O
MEASUREMENTS O
3-monthly O
HbA1c B-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
waist-hip B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
yearly B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
and O
bi-yearly O
assessment O
of I-outcome ['Life-Impact']
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
diabetes I-outcome ['Life-Impact']
, O
health B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
and O
quality O
of O
life O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

There O
still O
existed O
immune B-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
11 O
years O
after O
immunization O
, O
but O
it O
was O
significantly O
weaker O
than O
that O
within O
the O
first O
10 O
years O
after O
immunization O
. O
['Physiological-Clinical']

The O
blood O
levels O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
, O
sVCAM-1 B-outcome ['Physiological-Clinical']
, O
endothelin-1 B-outcome ['Physiological-Clinical']
, O
and O
sE-selectin B-outcome ['Physiological-Clinical']
were O
quantified; O
the O
activities O
of O
catalase B-outcome ['Physiological-Clinical']
, O
superoxide B-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
, O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
, O
glutathione B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
and O
concentrations O
of O
reduced O
glutathione B-outcome ['Physiological-Clinical']
, O
oxidized B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
, O
and O
thiobarbituric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
reactive O
substances, O
were O
also O
quantified O
before O
and O
after O
the O
treatment O
period. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
study O
sought O
to O
determine O
whether O
early O
treatment O
with O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibitors O
in O
patients O
with O
acute O
myocardial O
infarction O
( O
AMI O
) O
is O
useful O
for O
the O
improvement O
of O
fibrinolytic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
this O
trial O
supports O
the O
hypothesis O
that O
acupuncture O
is O
more O
effective O
than O
advice O
and O
exercises O
in O
the O
symptomatic O
treatment O
of O
OA O
of O
the O
hip O
. O
[]

OBJECTIVES O
To O
determine O
the O
effect O
of O
long O
term O
inhaled O
corticosteroids O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
exacerbations B-outcome ['Physiological-Clinical']
, O
and O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
moderate O
to O
severe O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Whether O
by O
telemedicine O
or O
telephone O
consultative O
modalities O
, O
there O
were O
appropriate O
treatment O
decisions B-outcome ['Life-Impact']
, O
high O
rates O
of O
thrombolysis B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
improved O
data O
collection B-outcome ['Physiological-Clinical']
, O
low O
rates O
of O
intracerebral B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
, O
and O
equally O
favorable O
time B-outcome ['Life-Impact']
requirements I-outcome ['Life-Impact']
. O
['Life-Impact', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Each O
dose O
and O
placebo O
was O
given O
three O
times O
in O
a O
randomized O
block O
sequence O
. O
[]

N-acetylcysteine O
had O
no O
effect O
on O
nitroglycerin-induced B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
( O
p O
> O
0.05 O
) O
but O
significantly O
increased O
microcirculatory B-outcome ['Physiological-Clinical']
subcutaneous I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
after O
1 O
h O
( O
nitroglycerin O
plus O
N-acetylcysteine O
: O
6.3 O
+/- O
1.3 O
ml/100 O
g O
per O
min O
vs. O
nitroglycerin O
plus O
placebo O
: O
3.5 O
+/- O
0.3 O
ml/100 O
g O
per O
min O
, O
p O
< O
0.05 O
) O
and O
after O
23 O
h O
( O
4.4 O
+/- O
0.6 O
vs. O
3.1 O
+/- O
0.5 O
ml/100 O
g O
per O
min O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
MATERIALS O
Toxicity O
data O
of O
512 O
patients O
( O
conformally O
treated O
to O
68 O
Gy O
[ O
n O
= O
284 O
] O
and O
78 O
Gy O
[ O
n O
= O
228 O
] O
) O
with O
complete O
follow-up O
at O
3 O
years O
after O
radiotherapy O
were O
studied O
. O
[]

After O
this O
, O
subjects O
randomly O
received O
either O
CLO O
or O
YHO O
, O
and O
3 O
h O
later O
another O
tilt O
was O
performed O
. O
[]

METHODS O
Two O
hundred O
nine O
patients O
with O
acquired O
immunodeficiency O
syndrome O
and O
active O
CMV O
retinitis O
were O
enrolled O
in O
a O
multicenter O
, O
phase O
2/3 O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
. O
[]

Bisphosphonate O
infusions O
: O
patient B-outcome ['Life-Impact']
preference I-outcome ['Life-Impact']
, O
safety O
and O
clinic B-outcome ['Resource-use']
use I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Measurements O
for O
both O
parameters O
were O
taken O
at O
0 O
, O
1 O
, O
2 O
and O
3 O
months O
of O
treatment O
. O
[]

Maximal B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
questionnaire O
scores O
also O
reflected O
decreased O
anticholinergic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
presence O
of O
pyridostigmine O
compared O
with O
placebo O
: O
101.9 O
+/- O
2.2 O
versus O
104.6 O
+/- O
2.8 O
, O
respectively O
( O
p O
less O
than O
0.005 O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

Significant O
errors O
of O
recalibration B-outcome ['Physiological-Clinical']
occur O
in O
6 O
% O
of O
calibrations O
. O
['Physiological-Clinical']

p16 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INK4a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
detected O
in O
68.9 O
% O
of O
the O
patients O
. O
['Physiological-Clinical']

METHODS O
We O
prospectively O
studied O
five O
regimens O
( O
four O
intravenous O
, O
one O
local O
; O
40 O
patients O
each O
) O
with O
a O
control O
group O
( O
no O
tranexamic O
acid O
) O
. O
[]

Independent O
and O
paired O
t-tests O
, O
chi-squared O
tests O
and O
covariance O
analysis O
were O
used O
to O
analysing O
data O
. O
[]

METHODS: O
This O
parallel, O
two-group, O
randomised O
trial O
included O
couples O
undergoing O
an O
ICSI O
procedure O
with O
fresh O
embryo O
transfer O
at O
16 O
assisted O
conception O
units O
in O
the O
UK. O
[]

Pulse B-outcome ['Physiological-Clinical']
oximetry I-outcome ['Physiological-Clinical']
, O
noninvasive B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Validation O
of O
a O
novel O
satisfaction O
questionnaire O
for O
patients O
with O
rheumatoid O
arthritis O
receiving O
outpatient O
clinical O
nurse O
specialist O
care O
, O
inpatient O
care O
, O
or O
day O
patient O
team O
care O
. O
[]

Thirty-two O
patients O
with O
impingement O
syndrome O
underwent O
subacromial O
decompression O
in O
the O
course O
of O
arthroscopic O
shoulder O
surgery O
. O
[]

A O
comparison O
of O
a O
non-ionic O
dimer O
, O
iodixanol O
with O
a O
non-ionic O
monomer O
, O
iohexol O
in O
low O
dose O
intravenous O
urography O
. O
[]

The O
repeatability O
of O
a O
single O
examiner O
in O
scoring O
the O
index O
was O
performed O
using O
4 O
groups O
of O
10 O
subjects O
. O
[]

Publication O
date: O
2019/02/01 O
06:01 O
[medline] O
[]

The O
precision O
of O
maximum O
strength O
assessments O
( O
1 O
repetition O
maximum O
; O
1RM O
) O
is O
important O
to O
evaluate O
the O
functional O
capacity O
and O
to O
prescribe O
and O
monitor O
the O
training O
load O
. O
[]

IQ B-outcome ['Life-Impact']
and O
ACRT B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
improved O
. O
['Life-Impact', 'Life-Impact']

Beneficial O
recovery O
of O
microvascular O
organ O
perfusion O
could O
partly O
explain O
the O
perioperative O
advantages O
reported O
for O
MECC O
. O
[]

Using O
a O
random O
cross-over O
design O
the O
patients O
were O
submitted O
to O
48 O
hr O
. O
[]

A O
large O
randomized O
controlled O
trial O
is O
warranted O
to O
further O
evaluate O
the O
efficacy O
of O
this O
regimen O
. O
[]

Chemotherapy O
of O
advanced O
gastric O
carcinoma O
( O
stage O
IV O
) O
: O
a O
randomized O
study O
of O
FAM O
versus O
5-FU O
plus O
BCNU O
. O
[]

Peri-implant B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
response O
and O
papilla B-outcome ['Physiological-Clinical']
index O
were O
recorded O
4 O
weeks O
after O
definitive O
crown O
placement O
to O
allow O
for O
mucosal O
maturation O
and O
at O
1 O
year O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
dose-dependent O
increase O
in O
dietary O
and O
urinary O
flavonoids O
in O
the O
HF O
group O
, O
with O
no O
change O
in O
other O
groups O
( O
P O
= O
0.0001 O
) O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
high-density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
non-HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
were O
increased O
by O
5 O
% O
and O
7 O
% O
, O
respectively O
, O
in O
the O
FO O
group O
, O
and O
by O
2 O
% O
and O
0 O
% O
in O
the O
control O
group O
( O
P O
< O
.01-.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Children O
younger O
than O
16 O
years O
and O
experiencing O
moderate O
to O
severe O
blunt O
head O
injury O
were O
randomized O
to O
receive O
phenytoin O
or O
placebo O
within O
60 O
minutes O
of O
presentation O
at O
3 O
pediatric O
trauma O
centers O
. O
[]

[ O
Specific B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
chronic O
hepatitis O
B O
patients O
treated O
with O
different O
doses O
of O
recombinant O
hepatitis O
B O
vaccine O
] O
. O
['Physiological-Clinical']

Analgesia O
was O
initiated O
with O
10 O
ml O
of O
the O
study O
solution O
and O
maintained O
with O
10-ml O
top-ups O
. O
[]

A O
significant O
increase O
in O
the O
number O
of O
[]

All O
teeth O
were O
fully O
covered O
with O
polycarbonate O
resin O
crowns O
. O
[]

Primary O
variables O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS O
; O
stratum O
1 O
) O
and O
clinical O
benefit O
rate O
( O
CBR O
; O
stratum O
2 O
) O
. O
['Mortality']

Patients O
were O
adaptively O
randomized O
as O
follows O
: O
Arm O
I-Clo O
: O
Flu O
10:30 O
mg/m O
( O
2 O
) O
, O
Arm O
II-20:20 O
mg/m O
( O
2 O
) O
, O
Arm O
III-30:10 O
mg/m O
( O
2 O
) O
, O
and O
Arm O
IV-single-agent O
Clo O
at O
40 O
mg/m O
( O
2 O
) O
. O
[]

Web-based O
contraception O
satisfaction O
questionnaires O
, O
clinical O
records O
, O
and O
government-linked O
health O
administrative O
databases O
will O
be O
used O
to O
assess O
primary O
and O
secondary O
outcomes O
. O
[]

INTERVENTION O
( O
S O
) O
Mature O
oocytes O
obtained O
from O
a O
single O
cohort O
of O
oocytes O
were O
randomly O
divided O
into O
two O
groups O
; O
one O
was O
cultured O
at O
37?C O
and O
the O
other O
at O
36?C O
from O
the O
time O
of O
ICSI O
to O
the O
time O
of O
embryo O
transfer O
or O
vitrification O
. O
[]

Recurrence B-outcome ['Physiological-Clinical']
rates O
by I-outcome ['Physiological-Clinical']
Gram-stained I-outcome ['Physiological-Clinical']
smear I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
between O
patient O
and O
partner O
treatment O
groups O
at O
five O
and O
eight O
weeks O
after O
initiation O
of O
treatment O
were O
also O
not O
significantly O
different O
between O
the O
two O
patient O
regimens O
. O
['Physiological-Clinical']

Patients O
with O
short-term O
successful O
and O
unsuccessful O
GHQ O
outcomes O
were O
compared O
for O
mid-term O
maintenance O
of O
success O
, O
1-year O
death O
and O
readmission O
rates O
, O
and O
1-year O
depression O
and O
anxiety O
symptoms O
. O
[]

The O
longest O
individual O
treatment O
was O
8.2 O
years O
, O
with O
3139 O
total O
patient-years O
of O
etanercept O
exposure O
. O
[]

A O
controlled O
trial O
with O
diclofensine O
, O
a O
new O
psychoactive O
drug O
, O
in O
the O
treatment O
of O
depression O
. O
[]

All O
patients O
were O
randomly O
assigned O
to O
receive O
2 O
years O
of O
goserelin O
, O
goserelin O
plus O
tamoxifen O
, O
tamoxifen O
alone O
or O
no O
endocrine O
treatment O
. O
[]

A O
study O
with O
non-invasive O
automated O
cardiac O
flow O
measurement O
by O
color O
Doppler O
echocardiography O
. O
[]

BACKGROUND O
The O
primary O
aim O
and O
central O
hypothesis O
of O
the O
study O
are O
that O
a O
designated O
syncope O
unit O
in O
the O
emergency O
department O
improves O
diagnostic O
yield O
and O
reduces O
hospital O
admission O
for O
patients O
with O
syncope O
who O
are O
at O
intermediate O
risk O
for O
an O
adverse O
cardiovascular O
outcome O
. O
[]

The O
subgroup O
of O
patients O
with O
sarcomas O
of O
the O
trunk O
( O
39 O
patients O
) O
demonstrated O
the O
greatest O
benefit O
from O
chemotherapy O
, O
with O
regard O
to O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
less O
than O
or O
equal O
to O
0.001 O
) O
. O
['Mortality']

An O
open-label O
, O
randomized O
controlled O
study O
was O
conducted O
at O
a O
tertiary O
care O
teaching O
hospital O
to O
compare O
efficacy O
and O
safety O
of O
intravenous O
sodium O
valproate O
versus O
diazepam O
infusion O
for O
control O
of O
refractory O
status O
epilepticus O
. O
[]

Effects O
of O
vitamin O
A O
or O
beta O
carotene O
supplementation O
on O
pregnancy-related B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
infant B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
rural O
Bangladesh O
: O
a O
cluster O
randomized O
trial O
. O
['Mortality', 'Mortality']

Forty O
children O
with O
refractory O
status O
epilepticus O
were O
randomized O
to O
receive O
either O
intravenous O
sodium O
valproate O
or O
diazepam O
infusion O
. O
[]

BACKGROUND O
The O
study O
aimed O
to O
investigate O
the O
effectiveness O
of O
a O
new O
multi-component O
social O
skills O
intervention O
for O
children O
with O
Asperger O
syndrome O
( O
AS O
) O
: O
The O
Junior O
Detective O
Training O
Program O
. O
[]

Twelve O
percent O
of O
caudal O
block O
patients O
and O
20 O
% O
of O
diclofenac O
patients O
needed O
rescue B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
, O
a O
statistically O
insignificant O
difference O
. O
['Resource-use']

We O
compared O
'unguided O
' O
SRL O
with O
'directed O
' O
SRL O
( O
DSRL O
) O
, O
wherein O
learners O
followed O
an O
expert-designed O
booklet O
. O
[]

The O
follow O
up O
period O
was O
6 O
months. O
[]

METHODS O
During O
phase O
1 O
treatment O
, O
86 O
subjects O
were O
treated O
with O
a O
bionator O
, O
93 O
were O
treated O
with O
headgear/biteplane O
, O
and O
81 O
served O
as O
the O
observation O
group O
. O
[]

Pharmacogenetic O
interaction O
analysis O
for O
the O
efficacy O
of O
systemic O
treatment O
in O
metastatic O
colorectal O
cancer O
. O
[]

A O
20-min O
set O
of O
audiotaped O
instructions O
on O
progressive O
muscle O
relaxation O
training O
( O
PMRT O
) O
was O
given O
to O
the O
patients O
in O
the O
experimental O
group O
for O
home O
practice O
. O
[]

DESIGN: O
Randomized O
controlled O
trial. O
[]

Effects O
of O
short-term O
isotonic O
& O
isometric O
training O
on O
cardiovascular B-outcome ['Physiological-Clinical']
& O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
Either O
the O
centrifugation O
or O
multiple-pass O
hemoconcentration O
method O
was O
used O
to O
process O
the O
residual O
blood O
from O
the O
cardiopulmonary O
bypass O
circuit O
. O
[]

Patients O
with O
impaired O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
also O
had O
significantly O
reduced O
osteocalcin B-outcome ['Physiological-Clinical']
levels O
( O
p O
< O
0.01 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Of O
the O
initial O
120 O
cases O
, O
11 O
cases O
were O
disqualified O
( O
3 O
cases O
of O
double O
cancer O
and O
8 O
of O
incomplete O
primary O
therapy O
) O
and O
the O
remaining O
109 O
were O
used O
for O
evaluation O
. O
[]

We O
conclude O
that O
, O
in O
elderly O
patients O
undergoing O
elective O
procedures O
, O
withholding O
prehydration O
is O
not O
associated O
with O
any O
greater O
degree O
of O
[]

Title: O
Role O
Of O
0.2% O
Bio-Adhesive O
Chlorhexidine O
Gel O
In O
Reducing O
Incidence O
Of O
Alveolar B-outcome ['Physiological-Clinical']
Osteitis I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

METHODS: O
In O
this O
experimental O
human O
laboratory O
study, O
participants O
(n O
= O
128) O
were O
randomised O
to O
a O
self-affirmation O
or O
control O
group. O
[]

OBJECTIVE O
Determine O
the O
effect O
of O
a O
moderate O
dose O
multivitamin/mineral O
supplement O
on O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

Given O
the O
potential O
barrier O
that O
anxiety O
can O
pose O
for O
patient O
learning O
, O
nurses O
need O
to O
adapt O
their O
interventions O
to O
deal O
with O
the O
patients O
' O
feelings O
of O
anxiety B-outcome ['Life-Impact']
that O
accompany O
cardiac O
surgery O
to O
make O
the O
learning O
process O
effective O
. O
['Life-Impact']

The O
present O
study O
was O
undertaken O
to O
determine O
the O
optimal O
timing O
of O
autologous O
blood O
reinfusion O
in O
elective O
spinal O
surgery O
. O
[]

Reducing O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
at O
open O
myomectomy O
using O
triple O
tourniquets O
: O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical']

No O
significant O
difference O
was O
found O
between O
the O
in-person O
and O
telephone O
recalls O
for O
rEI B-outcome ['Physiological-Clinical']
and O
misreporting O
. O
['Physiological-Clinical']

RESULTS O
From O
December O
2007 O
to O
October O
2008 O
, O
54 O
patients O
were O
assessed O
, O
27 O
of O
whom O
were O
randomized O
to O
each O
arm O
. O
[]

METHODS O
The O
authors O
randomly O
selected O
subjects O
for O
cavity O
preparation O
with O
conventional O
air O
turbine/bur O
dental O
surgery O
or O
an O
Er O
, O
Cr O
: O
YSGG O
laser-powered O
system O
using O
a O
split-mouth O
design O
. O
[]

The O
study O
fills O
a O
critical O
gap O
in O
our O
understanding O
of O
the O
role O
of O
depressive O
symptoms O
during O
pregnancy O
in O
shaping O
mothers O
' O
early O
attachment O
to O
their O
infants O
. O
[]

Journal-Name: O
BMJ O
(Clinical O
research O
ed.) O
[]

Equilibration O
of O
creatinine B-outcome ['Physiological-Clinical']
and O
urea B-outcome ['Physiological-Clinical']
was O
slower O
and O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
lower O
with O
glycerol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
On O
postoperative O
day O
( O
POD O
) O
1 O
, O
there O
were O
no O
significant O
differences O
between O
the O
parameters O
of O
the O
two O
groups O
, O
but O
on O
PODs O
2 O
and O
3 O
, O
both O
the O
pain B-outcome ['Physiological-Clinical']
score O
( O
P O
= O
0.033 O
and O
P O
= O
0.011 O
, O
respectively O
) O
and O
the O
number O
of O
patients O
who O
required O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
injections I-outcome ['Resource-use']
were O
significantly O
less O
in O
group O
1 O
( O
P O
= O
0.022 O
and O
P O
= O
0.007 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Resource-use']

Both O
preparations O
produced O
mean O
serum B-outcome ['Physiological-Clinical']
theophylline I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
within O
the O
10 O
-- O
20 O
mcg/ml O
range O
, O
the O
sustained-release O
tablet O
giving O
higher O
monitoring O
through O
values O
and O
smaller O
through O
to O
peak O
variation O
. O
['Physiological-Clinical']

EEGs O
were O
reviewed O
for O
clinical O
abnormalities O
, O
including O
IEDs O
, O
by O
readers O
blinded O
to O
participants O
' O
behavioral O
symptoms O
. O
[]

Adjusting O
for O
baseline O
and O
age O
, O
the O
peroxide O
strip O
group O
had O
-2.45 O
Deltab* O
, O
2.39 O
DeltaL* O
, O
and O
-0.96 O
Deltaa* O
at O
Week O
2 O
. O
[]

Parent-based O
sleep O
education O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

Indeed O
, O
it O
is O
not O
uncommon O
for O
such O
studies O
to O
conclude O
with O
uninterpretable O
results O
, O
due O
in O
part O
to O
such O
methodological O
pitfalls O
. O
[]

CONCLUSION O
The O
treatment O
with O
rhGH O
of O
adult O
chronic O
hemodialysis O
patients O
for O
6 O
months O
increased O
the O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
significantly O
, O
but O
without O
any O
effect O
on O
ejection O
fraction O
or O
maximal O
working O
capacity O
. O
['Physiological-Clinical']

In O
a O
double-blind O
, O
prospective O
, O
randomly O
allocated O
trial O
, O
the O
patients O
were O
given O
increasing O
doses O
of O
captopril O
at O
25-100 O
mg O
twice O
a O
day O
or O
lisinopril O
at O
10-40 O
mg O
once O
a O
day O
until O
a O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
achieved O
or O
the O
highest O
dose O
was O
reached O
. O
['Physiological-Clinical']

Higher O
weekly B-outcome ['Physiological-Clinical']
contact I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
and O
patient O
ratings O
of O
expressed O
emotion B-outcome ['Life-Impact']
( O
EE O
) O
predicted O
a O
negative O
experience O
of O
caregiving O
. O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Interim O
methadone O
maintenance O
has O
been O
proposed O
as O
a O
method O
of O
providing O
clinically O
effective O
services O
to O
heroin O
addicts O
waiting O
for O
treatment O
in O
standard O
comprehensive O
methadone O
maintenance O
programs O
. O
[]

The O
primary O
outcomes O
are O
implantation B-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rates. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Groups O
II O
, O
III O
and O
IV O
were O
comparable O
with O
regards O
to O
duration O
of O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
and O
total O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
P O
> O
0.05 O
) O
. O
['Resource-use', 'Resource-use']

The O
efficacy O
of O
short- O
and O
long-TXA O
protocols O
in O
the O
reduction O
of O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL) O
was O
compared O
with O
a O
placebo O
group. O
[['Physiological-Clinical']]

Participants O
included O
91 O
physicians O
, O
62 O
men O
and O
29 O
women O
; O
median O
age O
was O
38.7 O
years O
. O
[]

In O
a O
subset O
of O
acute O
respiratory O
distress O
syndrome O
patients O
from O
this O
trial O
, O
we O
performed O
a O
preliminary O
examination O
of O
the O
potential O
mechanisms O
underlying O
these O
clinical O
improvements O
by O
retrospectively O
testing O
the O
hypothesis O
that O
enteral O
feeding O
with O
EPA+GLA O
could O
reduce O
alveolar-capillary O
membrane O
protein O
permeability O
and O
the O
production O
of O
interleukin O
( O
IL O
) O
-8 O
, O
IL-6 O
, O
tumor O
necrosis O
factor-alpha O
, O
and O
leukotriene O
B4 O
that O
are O
responsible O
, O
in O
part O
, O
for O
pulmonary O
inflammation O
. O
[]

Sixteen O
subjects O
with O
well-controlled O
T2DM O
(median O
HbA1c O
47 O
mmol/mol, O
(37-67 O
mmol/mol) O
and O
BMI O
30 O
+/- O
4.4 O
kg/m(2)) O
participated O
in O
the O
study. O
[]

Secondary O
end O
points O
were O
change O
from O
baseline O
in O
sitting O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
SiSBP O
) O
at O
week O
8 O
in O
the O
total O
population O
and O
in O
the O
subgroup O
of O
patients O
who O
had O
previously O
received O
antihypertensive O
treatment O
versus O
those O
who O
had O
not O
. O
['Physiological-Clinical']

Our O
results O
indicate O
that O
short-term O
strength O
training O
increases O
basal O
femoral O
blood O
flow O
and O
vascular O
conductance O
in O
healthy O
middle-aged O
and O
older O
adults O
. O
[]

Both O
the O
antacid O
and O
placebo O
groups O
showed O
improvement O
in O
the O
degree O
of O
esophagitis B-outcome ['Physiological-Clinical']
as O
assessed O
endoscopically O
. O
['Physiological-Clinical']

110 O
patients O
were O
randomly O
allocated O
in O
a O
1:1 O
ratio O
to O
receive O
catheter O
ablation O
and O
an O
ICD O
( O
ablation O
group O
, O
n=54 O
) O
or O
ICD O
alone O
( O
control O
group O
, O
n=56 O
) O
. O
[]

Results: O
At O
week O
12, O
mean O
percent O
reduction O
in O
inflammatory O
and O
noninflammatory O
lesion B-outcome ['Physiological-Clinical']
counts O
were O
60.1% O
and O
53.0%, O
respectively, O
compared O
with O
51.1% O
and O
38.7% O
with O
vehicle O
(P</=0.001) O
in O
the O
Hispanic O
population. O
[['Physiological-Clinical']]

We O
compared O
a O
standard O
diagnostic O
strategy O
( O
culture O
and O
histology O
) O
with O
a O
rapid O
biomarker-based O
diagnostic O
strategy O
( O
aspergillus O
galactomannan O
and O
PCR O
) O
for O
directing O
the O
use O
of O
antifungal O
treatment O
in O
this O
group O
of O
patients O
. O
[]

CONCLUSIONS O
These O
results O
support O
the O
acceptability O
of O
snowshoeing O
as O
a O
valid O
means O
to O
improve O
or O
maintain O
cardiovascular B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
The O
information O
on O
the O
anxiolytic O
techniques O
, O
loco-regional O
anesthesia O
, O
treatment O
of O
perioperative O
pain O
and O
postoperative O
distress O
was O
enthusiastically O
accepted O
and O
albeit O
initially O
induced O
feelings O
of O
astonishment O
resulted O
to O
be O
appreciated B-outcome ['Life-Impact']
and O
preferred B-outcome ['Life-Impact']
in O
the O
whole O
of O
the O
patients O
. O
['Life-Impact', 'Life-Impact']

INTRODUCTION O
AND O
OBJECTIVES O
Coronary O
angiography O
is O
the O
gold O
standard O
for O
the O
study O
of O
coronary O
artery O
disease O
. O
[]

0.28 O
mm O
) O
and O
least O
( O
P O
= O
0.003 O
) O
for O
CC O
steers O
( O
11.0 O
? O
[]

RESULTS O
Patients O
with O
SH O
showed O
higher O
QT B-outcome ['Physiological-Clinical']
dispersion I-outcome ['Physiological-Clinical']
and O
lower B-outcome ['Physiological-Clinical']
HRV I-outcome ['Physiological-Clinical']
measures O
than O
healthy O
controls O
( O
P O
< O
0.01 O
for O
all O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
investigated O
the O
effect O
of O
a O
crown-lengthening O
ferrule O
on O
the O
fracture O
resistance O
of O
endodontically-treated O
teeth O
restored O
with O
two O
dowel-core O
systems O
. O
[]

METHOD O
Ten O
healthy O
volunteers O
were O
enrolled O
into O
an O
open-label O
, O
randomised O
, O
intra-individual O
comparison O
pilot O
study O
. O
[]

However O
, O
there O
was O
a O
high O
drop-out O
rate O
and O
intention O
to O
treat O
analysis O
failed O
to O
demonstrate O
statistically O
significant O
differences O
between O
the O
groups O
. O
[]

BACKGROUND O
In O
1998 O
, O
mandatory O
folic O
acid O
fortification O
of O
white O
flour O
and O
select O
cereal O
grain O
products O
was O
implemented O
in O
Canada O
with O
the O
intention O
to O
increase O
dietary O
folate O
intakes O
of O
reproducing O
women O
. O
[]

A O
total O
of O
106 O
patients O
were O
treated O
with O
PTCA O
. O
[]

Success O
rate O
, O
onset O
, O
and O
duration O
of O
profound O
pulpal O
anesthesia O
were O
evaluated O
by O
the O
electrical O
pulp O
tester O
, O
while O
the O
width O
of O
the O
anesthetic O
field O
and O
duration O
of O
soft O
tissue O
anesthesia O
were O
recorded O
using O
the O
pinprick O
testing O
. O
[]

Nonallergic B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
was O
observed O
in O
less O
than O
3 O
% O
of O
all O
applications O
. O
['Physiological-Clinical']

METHOD O
AND O
MATERIALS O
Ninety-seven O
CP O
and O
AP O
subjects O
underwent O
full-mouth O
SRP O
on O
2 O
consecutive O
days O
. O
[]

The O
overall O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
obtained O
was O
63 O
p. O
100 O
( O
51 O
patients O
) O
with O
17 O
patients O
in O
relapse B-outcome ['Physiological-Clinical']
within O
6 O
to O
40 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
were O
randomly O
assigned O
to O
two O
groups O
of O
five O
each O
. O
[]

Despite O
intriguing O
results O
from O
laboratory O
studies O
, O
previous O
epidemiological O
studies O
showed O
inconsistent O
associations O
of O
circulating O
levels O
of O
25 O
( O
OH O
) O
D O
, O
1,25 O
( O
OH O
) O
2D O
, O
and O
several O
VDR O
polymorphisms O
with O
prostate O
cancer O
risk O
. O
[]

A O
numerical O
plaque O
index O
( O
0-5 O
) O
is O
described O
based O
on O
the O
presence O
and O
distribution O
of O
plaque O
in O
the O
fissures O
and O
over O
the O
occlusal O
surfaces O
of O
permanent O
molar O
and O
premolar O
teeth O
. O
[]

There O
were O
thus O
10 O
pairs O
available O
for O
the O
study O
. O
[]

antibiotic O
monotherapy O
with O
intravenous O
(i.v.) O
[]

When O
the O
results O
obtained O
with O
a O
particularly O
promising O
new O
drug O
or O
procedure O
are O
presented O
early O
in O
the O
course O
of O
study O
( O
within O
1-2 O
years O
) O
, O
the O
investigators O
should O
strongly O
consider O
a O
repeat O
evaluation O
after O
an O
additional O
3-5 O
years O
of O
follow-up O
. O
[]

mTOR B-outcome ['Physiological-Clinical']
signaling I-outcome ['Physiological-Clinical']
was O
assessed O
by O
immunoblotting O
from O
repeated O
muscle O
biopsy O
samples O
. O
['Physiological-Clinical']

The O
results O
support O
treatment O
with O
progesterone O
caproate O
for O
the O
prevention O
of O
premature O
labor O
. O
[]

The O
research O
obtained O
the O
approval O
of O
the O
Hospital O
Research O
Ethics O
committee O
and O
parents O
signed O
informed O
consent O
. O
[]

High O
levels O
of O
acceptance B-outcome ['Life-Impact']
and O
compliance B-outcome ['Life-Impact']
by O
subjects/caregivers O
were O
maintained O
. O
['Life-Impact', 'Life-Impact']

18 O
years O
, O
56 O
% O
female O
, O
active O
drug O
: O
vehicle O
= O
97:100 O
) O
over O
2 O
weeks O
treatment O
with O
bibrocathol O
2 O
% O
eye O
ointment O
was O
evaluated O
. O
[]

CONCLUSIONS O
These O
results O
are O
consistent O
with O
studies O
linking O
oxytocin O
to O
social B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
in O
rodents O
as O
well O
as O
studies O
linking O
oxytocin O
to O
['Life-Impact']

Mean O
baseline O
vasomotor O
symptoms O
frequency O
was O
7.6/day O
, O
and O
the O
mean O
baseline O
total O
MENQOL O
score O
was O
3.8 O
( O
range O
, O
1-8 O
from O
better O
to O
worse O
) O
with O
no O
between-group O
differences O
. O
[]

The O
amblyopia O
was O
defined O
as O
severe/moderate O
( O
< O
0.250 O
logMAR O
) O
, O
n=41 O
or O
mild O
( O
> O
or O
= O
0.250 O
logMAR O
) O
, O
n=10 O
. O
[]

There O
was O
a O
significant O
correlation O
between O
the O
decrease O
in O
FMD B-outcome ['Physiological-Clinical']
and O
the O
increase O
in O
visceral B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
gain O
( O
rho=-0.42 O
, O
p=0.004 O
) O
, O
but O
not O
with O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
gain O
( O
rho=-0.22 O
, O
p=0.15 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
this O
study O
indicate O
that O
propranolol O
treatment O
can O
significantly O
affect O
bone B-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

High-pressure O
, O
rapid-inflation O
pneumatic O
compression O
may O
offer O
additional O
protection O
from O
thrombotic O
complications O
on O
the O
basis O
of O
an O
improved O
hemodynamic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
both O
in O
healthy O
volunteers O
and O
in O
patients O
who O
were O
post-thrombotic O
. O
['Physiological-Clinical']

As O
a O
marker O
of O
oxidative O
stress O
, O
allopurinol O
significantly O
reduced O
malondialdehyde B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Infants O
born O
to O
mothers O
with O
hemoglobin O
( O
Hb O
) O
< O
100 O
g/L O
were O
randomized O
at O
delivery O
to O
either O
immediate O
cord O
clamping O
( O
early O
group O
) O
or O
cord O
clamping O
delayed O
till O
descent O
of O
placenta O
into O
vagina O
( O
delayed O
group O
) O
. O
[]

[ O
Effect O
of O
Yufeining O
on O
induced O
sputum B-outcome ['Physiological-Clinical']
interleukin-8 I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
at O
the O
stable O
phase O
] O
. O
['Physiological-Clinical']

CONCLUSION O
Preemptive O
epidural O
analgesia O
combined O
with O
postoperative O
epidural O
analgesia O
provides O
more O
satisfactory O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
more O
effectively O
prevents O
IL-6 B-outcome ['Physiological-Clinical']
increment I-outcome ['Physiological-Clinical']
than O
exclusive O
epidural O
analgesia O
or O
intravenous O
analgesia O
after O
gastrectomy O
for O
gastric O
carcinoma O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Of O
98 O
randomized O
patients O
, O
61 O
% O
were O
WHO O
functional O
class O
II O
at O
baseline O
. O
[]

Alertness B-outcome ['Life-Impact']
and O
cognitive B-outcome ['Life-Impact']
performance B-outcome ['Life-Impact']
amongst O
the O
chewing O
condition O
did O
not O
differ O
or O
were O
in O
fact O
worse O
when O
compared O
with O
placebo O
. O
['Life-Impact', 'Life-Impact']

Moreover O
, O
the O
intervention O
effect O
on O
inflammation B-outcome ['Physiological-Clinical']
was O
mediated O
by O
its O
effect O
on O
depressive O
symptoms O
. O
['Physiological-Clinical']

Thus O
, O
188 O
patients O
were O
treated O
and O
included O
in O
the O
ITT O
analysis O
( O
94 O
patients O
per O
treatment O
group O
; O
ITT O
analysis O
) O
; O
161 O
patients O
were O
included O
in O
the O
perprotocol O
( O
PP O
) O
analysis O
( O
n O
= O
80 O
for O
amlodipine O
camsylate O
, O
n O
= O
81 O
for O
amlodipine O
besylate O
) O
( O
14 O
patients O
in O
the O
amlodipine O
camsylate O
group O
and O
13 O
patients O
in O
the O
amlodipine O
besylate O
group O
were O
excluded O
from O
the O
PP O
analysis O
due O
to O
consistent O
withdrawal O
or O
protocol O
violation O
) O
. O
[]

RESULTS O
Local O
and O
systemic O
safety O
profiles O
were O
equivalent O
between O
the O
two O
groups O
. O
[]

Central O
nervous O
system O
serotonin O
function O
and O
cardiovascular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
stress O
. O
['Physiological-Clinical']

Control-group O
participants O
also O
experienced O
significantly O
lower O
rates O
of O
limitation B-outcome ['Life-Impact']
, O
but O
pre- O
to O
postdifferences O
were O
less O
dramatic O
, O
F O
( O
1 O
, O
308 O
) O
= O
4.19 O
, O
p O
= O
.006 O
. O
['Life-Impact']

METHOD O
A O
parallel O
group O
design O
was O
employed O
. O
[]

Twenty-two O
children O
with O
severe O
CF O
and O
signs O
of O
acute O
lower O
respiratory O
infection O
were O
randomly O
assigned O
to O
receive O
either O
cloxacillin O
or O
carbenicillin O
plus O
gentamicin O
administered O
intravenously O
for O
ten O
days O
. O
[]

The O
study O
consisted O
of O
a O
pre-screening, O
screening, O
day O
0 O
baseline O
(randomization O
visit) O
and O
three O
follow-up O
visits O
on O
days O
14, O
28 O
and O
56. O
[]

Six O
months O
later O
, O
the O
children O
in O
group O
A O
were O
re-treated O
with O
the O
same O
dose O
of O
praziquantel O
, O
while O
the O
children O
in O
group O
B O
were O
given O
placebos O
. O
[]

Irrigation O
with O
bupivacaine O
at O
the O
surgical O
bed O
for O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

A O
liquid O
chromatography O
mass O
spectrometry O
method O
was O
used O
to O
determine O
eicosanoid B-outcome ['Physiological-Clinical']
levels O
in O
the O
biopsies O
, O
and O
levels O
were O
expressed O
per O
protein O
or O
per O
free O
arachidonic O
acid O
. O
['Physiological-Clinical']

CONCLUSIONS O
Erosion O
increases O
the O
susceptibility B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
enamel I-outcome ['Physiological-Clinical']
to O
toothpaste B-outcome ['Physiological-Clinical']
abrasion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Warfarin O
versus O
aspirin O
for O
prevention O
of O
thromboembolism O
in O
atrial O
fibrillation O
: O
Stroke O
Prevention O
in O
Atrial O
Fibrillation O
II O
Study O
. O
[]

The O
behaviour O
of O
the O
two O
treatments O
was O
not O
homogeneous O
across O
time O
( O
groups-by-time O
interaction O
, O
Greenhouse-Geisser O
correction O
; O
F O
= O
7.30 O
, O
d.f O
. O
[]

Overjets B-outcome ['Physiological-Clinical']
were O
reduced O
by O
7 O
mm O
(SD, O
2.92) O
in O
the O
PT O
group O
and O
6.5 O
mm O
(SD, O
2.62) O
in O
the O
FT O
group, O
with O
no O
statistical O
difference O
between O
the O
groups O
(P O
= O
0.587; O
95% O
CI, O
-1.01, O
1.78). O
[['Physiological-Clinical']]

Tacrolimus O
ointment O
0.03 O
% O
is O
approved O
for O
moderate O
to O
severe O
atopic O
dermatitis O
in O
the O
patient O
population O
between O
two O
to O
seventeen O
years O
of O
age O
and O
Tacrolimus O
0.1 O
% O
ointment O
for O
moderate O
to O
severe O
atopic O
dermatitis O
in O
patients O
18 O
years O
of O
age O
and O
older O
. O
[]

Uncomplicated O
moderate O
coronary O
artery O
dissections O
after O
balloon O
angioplasty O
: O
good O
outcome O
without O
stenting O
. O
[]

METHODS: O
This O
prospective, O
interventional, O
randomized O
clinical O
study O
was O
done O
at O
Alpha O
Vision O
Center, O
Zagazig, O
Egypt. O
[]

CONCLUSIONS:: O
We O
suggest O
that O
after O
reposition O
exercises, O
the O
pelvis O
was O
more O
symmetrically O
aligned O
in O
relation O
to O
body O
axis; O
therefore, O
the O
muscles O
of O
the O
pelvic O
floor O
have O
functional O
length O
and O
did O
not O
shorten O
or O
lengthen O
due O
to O
pelvis O
rotation. O
[]

The O
outcomes O
were O
patients O
' O
disease-related B-outcome ['Physiological-Clinical']
knowledge B-outcome ['Life-Impact']
, O
active B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
with O
illness B-outcome ['Physiological-Clinical']
, O
and O
quality O
of O
life O
( O
QoL B-outcome ['Life-Impact']
) O
at O
the O
end O
of O
their O
stay O
and O
6 O
and O
12 O
months O
thereafter O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

METHODS O
Ten O
healthy O
volunteers O
were O
enrolled O
in O
a O
randomized O
, O
double-blinded O
, O
placebo-controlled O
, O
crossover O
trial O
in O
which O
they O
received O
an O
infusion O
of O
saline O
, O
remifentanil O
, O
or O
alfentanil O
for O
120 O
min O
. O
[]

Limitations O
of O
the O
study O
and O
suggestions O
for O
future O
research O
are O
also O
discussed O
. O
[]

The O
tolerability O
of O
lactated O
Ringer O
's O
solution O
and O
BSS O
plus O
for O
ocular O
irrigation O
with O
and O
without O
the O
Morgan O
therapeutic O
lens O
. O
[]

BACKGROUND/AIM: O
The O
analysis O
of O
prognostic O
factors O
is O
important O
to O
identify O
determinants O
of O
disease-free O
survival O
(DFS) O
and O
overall O
survival O
(OS) O
in O
resected O
non-small-cell O
lung O
cancer O
(NSCLC). O
[]

In O
group O
I O
, O
the O
[]

However O
, O
the O
median O
[]

METHODS O
Outdoor O
workers O
were O
randomly O
allocated O
to O
an O
intervention O
( O
n O
= O
65 O
) O
or O
control O
group O
( O
n O
= O
77 O
) O
. O
[]

Components O
of O
working O
memory O
and O
visual O
selective O
attention O
. O
[]

Terazosin O
and O
enalapril O
had O
a O
comparable O
effect O
on O
resting B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
reducing O
systolic O
( O
SBP B-outcome ['Physiological-Clinical']
) O
and O
diastolic O
( O
DBP B-outcome ['Physiological-Clinical']
) O
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
from O
159.5 O
+/- O
13.9/101.6 O
+/- O
8.8 O
mm O
Hg O
during O
placebo O
by O
7.8 O
% O
/6.7 O
% O
and O
by O
11.3 O
% O
/10.2 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
Nine O
patients O
with O
CSX O
and O
14 O
control O
subjects O
underwent O
a O
continuous O
infusion O
of O
L-arginine O
( O
0.125 O
g/min O
) O
or O
saline O
for O
120 O
minutes O
. O
[]

Determinants O
of O
serum O
creatinine O
trajectory O
in O
acute O
contrast O
nephropathy O
. O
[]

Effect O
of O
different O
rates O
of O
infusion O
of O
propofol O
for O
induction O
of O
anaesthesia B-outcome ['Resource-use']
in O
elderly O
patients O
. O
['Resource-use']

Neither O
was O
subjective O
improvement O
significant O
, O
with O
29.2 O
% O
vs. O
27.3 O
% O
of O
the O
women O
reporting O
improvement O
in O
the O
amount O
of O
urinary B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Chemical B-outcome ['Physiological-Clinical']
cystitis I-outcome ['Physiological-Clinical']
is O
occasionally O
observed O
, O
especially O
if O
multiple O
instillations O
are O
started O
immediately O
after O
TUR O
, O
or O
in O
the O
presence O
of O
additional O
inflammatory O
conditions O
, O
such O
as O
previous O
irradiation O
or O
bacterial O
cystitis O
. O
['Physiological-Clinical']

ACE O
inhibitor O
administration O
does O
not O
modify O
the O
physical O
performance O
of O
nonathletic O
subjects O
; O
AII O
is O
significantly O
increased O
with O
exercise O
despite O
captopril O
treatment O
; O
ACE O
inhibitor O
decreases O
GFR B-outcome ['Physiological-Clinical']
significantly O
but O
does O
not O
influence O
MA O
with O
prolonged O
physical O
effort O
. O
['Physiological-Clinical']

In O
1984 O
a O
multicentre O
, O
prospective O
, O
randomised O
, O
double-blind O
trial O
of O
coumarin O
, O
given O
as O
a O
daily O
50-mg O
dose O
for O
2 O
years O
after O
surgery O
in O
patients O
with O
high-risk O
melanoma O
, O
was O
started O
. O
[]

No O
differences O
between O
the O
2 O
groups O
were O
noted O
in O
the O
rates O
of O
increase O
in O
retinal B-outcome ['Physiological-Clinical']
area O
involved O
by O
CMV B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Blood O
samples O
were O
taken O
prior O
to O
operation O
as O
well O
as O
on O
days O
1 O
, O
3 O
, O
and O
5 O
after O
operation O
. O
[]

Rates O
of O
drug B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
self-report I-outcome ['Life-Impact']
were O
highest O
in O
the O
workplace O
interview O
condition O
and O
lowest O
in O
the O
overall O
group O
questionnaire O
condition O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
An O
Ad O
Hoc O
Melanoma O
Working O
Group O
of O
25 O
investigators O
treated O
604 O
patients O
from O
April O
1997 O
to O
January O
2003 O
. O
[]

The O
trial O
was O
registered O
retrospectively O
with O
ISRCTN O
( O
ISRCTN86573140 O
). O
[]

Untreated O
controls O
at O
the O
2 O
intervals O
showed O
a O
mean O
decrease O
in O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
of O
3.6 O
degrees O
C O
and O
4.1 O
degrees O
C. O
Statistical O
analysis O
showed O
type O
of O
composite O
cement O
to O
be O
a O
significant O
factor O
. O
['Physiological-Clinical']

The O
subjects O
were O
randomly O
allocated O
into O
2 O
groups O
according O
to O
activation O
type: O
incremental O
advancement O
(IA) O
and O
maximum O
advancement O
(MA). O
[]

Prophylaxis O
was O
continued O
until O
the O
patient O
achieved O
complete O
remission O
or O
was O
treated O
for O
8 O
weeks O
without O
antileukemic O
response O
. O
[]

The O
EF B-outcome ['Physiological-Clinical']
showed O
no O
significant O
changes O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

Second O
examinations O
showed O
significantly O
lower O
mean O
PIPP O
scores O
after O
examination O
( O
1 O
min O
( O
P=0.003 O
) O
and O
5 O
min O
( O
P=0.025 O
) O
) O
, O
regardless O
of O
the O
type O
of O
drop O
used O
. O
[]

Sodium-glucose O
cotransporters O
1 O
( O
SGLT1 O
) O
and O
2 O
( O
SGLT2 O
) O
are O
the O
major O
cellular O
transporters O
responsible O
for O
gastrointestinal O
( O
GI O
) O
glucose O
absorption O
and O
renal O
glucose O
reabsorption O
, O
respectively O
. O
[]

Subjects O
with O
treatment O
failure O
despite O
a O
full O
8-week O
fourfold O
fexofenadine O
treatment O
were O
included O
in O
the O
resistant O
CIU O
( O
R-CIU O
group O
) O
. O
[]

RESULTS: O
119 O
children O
aged O
5 O
to O
16 O
years, O
with O
symptomatic O
hypermobility O
were O
randomised O
to O
receive O
an O
individualised O
multidisciplinary O
intervention O
(I) O
(n O
= O
59) O
or O
standard O
management O
(S) O
(n O
= O
60). O
[]

Group O
I O
or O
the O
amiodarone O
group O
( O
n=28 O
) O
received O
amiodarone O
( O
3 O
mg/kg O
in O
100 O
ml O
normal O
saline O
) O
and O
group O
II O
or O
the O
control O
group O
received O
same O
volume O
of O
normal O
saline O
. O
[]

Children O
at O
both O
grade O
levels O
showed O
less O
positive O
attitudes B-outcome ['Life-Impact']
toward O
the O
child O
in O
the O
two O
autism O
conditions O
. O
['Life-Impact']

Clinical O
variables O
were O
compared O
by O
ANCOVA O
and O
paired O
t-tests O
after O
each O
treatment O
interval O
. O
[]

INTERVENTION O
All O
patients O
received O
either O
LE O
0.2 O
% O
or O
placebo O
( O
vehicle O
) O
four O
times O
a O
day O
in O
both O
eyes O
for O
42 O
days O
. O
[]

Better O
baseline O
BCVA O
(> O
50 O
ETDRS O
letters/Snellen O
equivalent O
>/= O
20/100), O
greater O
baseline O
total O
macular O
volume O
(> O
9.99 O
mm(3)), O
and O
presence O
of O
subretinal O
fluid O
at O
baseline O
were O
all O
associated O
with O
early O
improvement O
to O
20/40 O
or O
better O
vision B-outcome ['Physiological-Clinical']
( O
Early O
Treatment O
Diabetic B-outcome ['Physiological-Clinical']
Retinopathy I-outcome ['Physiological-Clinical']
Study O
(ETDRS) O
equivalent O
>/= O
69 O
letters; O
P O
< O
.0001, O
P O
= O
.02, O
and O
P O
= O
.03, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

A O
double-blind O
phase O
II O
study O
of O
propionyl-L-carnitine O
( O
CAS O
17298-37-2 O
) O
versus O
placebo O
was O
carried O
out O
on O
a O
group O
of O
60 O
patients O
with O
mild O
to O
moderate O
( O
II O
and O
III O
NYHA O
class O
) O
congestive O
heart O
failure O
. O
[]

Effects O
of O
intravenous O
sodium O
salicylate O
( O
600 O
mg O
) O
were O
studied O
identically O
in O
eight O
subjects O
. O
[]

Furthermore O
, O
the O
dentition O
of O
the O
patients O
in O
the O
two O
experimental O
groups O
was O
treated O
, O
at O
three-month O
intervals O
, O
with O
chlorhexidine O
and O
fluoride O
varnish O
, O
respectively O
. O
[]

Subjects O
were O
given O
the O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation I-outcome ['Life-Impact']
Schedule O
( O
ADOS O
) O
and O
other O
pertinent B-outcome ['Life-Impact']
developmental I-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
at O
baseline O
and O
at O
weeks O
4 O
and O
8 O
to O
assess O
drug O
effects O
. O
['Life-Impact', 'Life-Impact']

METHODS O
A O
single-blinded O
, O
randomized O
controlled O
trial O
was O
conducted O
with O
323 O
eligible O
adult O
participants O
being O
recruited O
into O
one O
of O
six O
genome O
studies O
at O
Baylor O
College O
of O
Medicine O
in O
Houston O
, O
Texas O
, O
between O
January O
2008 O
and O
August O
2009 O
. O
[]

Total O
sleep O
time O
per O
24 O
hours O
increased O
from O
5.5 O
hours O
( O
range O
3 O
to O
8.5 O
hours O
) O
to O
13.0 O
hours O
( O
range O
10 O
to O
14.5 O
hours O
, O
P O
= O
.001 O
) O
. O
[]

In O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
, O
the O
total O
scores O
of O
SDSS O
in O
study O
group O
( O
5.9 O
? O
[]

Captopril O
and O
quinapril O
doses O
were O
titrated O
to O
lower O
pressure O
similarly O
. O
[]

Protrusion B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
proclination B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
incisors E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
were O
greater O
in O
the O
IA O
group O
(95.90 O
degrees O
+/- O
5.34 O
degrees O
) O
compared O
with O
the O
MA O
group O
(92.04 O
degrees O
+/- O
7.92 O
degrees O
). O
[['Physiological-Clinical', 'Physiological-Clinical']]

During O
the O
8-week O
acute O
trial O
, O
the O
most O
common O
AEs O
on O
the O
Side O
Effects O
Review O
, O
scored O
as O
moderate O
or O
higher O
, O
were O
as O
follows O
( O
placebo O
and O
risperidone O
, O
respectively O
) O
: O
Somnolence B-outcome ['Physiological-Clinical']
( O
12 O
% O
and O
37 O
% O
) O
, O
enuresis B-outcome ['Physiological-Clinical']
( O
29 O
% O
and O
33 O
% O
) O
, O
excessive B-outcome ['Physiological-Clinical']
appetite I-outcome ['Physiological-Clinical']
( O
10 O
% O
and O
33 O
% O
) O
, O
rhinitis B-outcome ['Physiological-Clinical']
( O
8 O
% O
and O
16 O
% O
) O
, O
difficulty B-outcome ['Life-Impact']
waking I-outcome ['Life-Impact']
( O
8 O
% O
and O
12 O
% O
) O
, O
and O
constipation B-outcome ['Physiological-Clinical']
( O
12 O
% O
and O
10 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Compared O
with O
the O
control O
condition O
, O
the O
intervention O
was O
associated O
with O
a O
significant O
increase O
in O
support O
person B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
to O
help O
their O
smoker B-outcome ['Life-Impact']
( O
p O
= O
.034 O
) O
and O
outcome O
expectancies B-outcome ['Life-Impact']
( O
p O
= O
.025 O
) O
from O
baseline O
to O
week O
6 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
Both O
ischaemic O
preconditioning O
and O
cardiopulmonary O
bypass O
induced O
free B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
final O
analysis O
digital O
images O
were O
randomised O
( O
in O
time O
order O
) O
and O
a O
panel O
of O
nurses O
who O
were O
not O
otherwise O
involved O
in O
the O
research O
project O
graded O
the O
wound O
's O
progress O
. O
[]

In O
experimental O
study O
, O
monoaminic B-outcome ['Physiological-Clinical']
transmitters I-outcome ['Physiological-Clinical']
activated O
in O
hypothalamus O
; O
weight O
of O
pituitary B-outcome ['Physiological-Clinical']
, O
adrenal B-outcome ['Physiological-Clinical']
and O
thymus B-outcome ['Physiological-Clinical']
decreased O
; O
number O
of O
CRH B-outcome ['Physiological-Clinical']
positive I-outcome ['Physiological-Clinical']
neurons I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
hypothalamic I-outcome ['Physiological-Clinical']
paraventricular I-outcome ['Physiological-Clinical']
nucleus B-outcome ['Physiological-Clinical']
, O
CRH B-outcome ['Physiological-Clinical']
positive I-outcome ['Physiological-Clinical']
neurofibrilin B-outcome ['Physiological-Clinical']
median O
eminence B-outcome ['Physiological-Clinical']
and O
anterior B-outcome ['Physiological-Clinical']
pituitary I-outcome ['Physiological-Clinical']
ACTH B-outcome ['Physiological-Clinical']
positive I-outcome ['Physiological-Clinical']
secretory I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
decreased O
; O
adrenal B-outcome ['Physiological-Clinical']
fasciculate B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS: O
Comparison O
of O
baseline O
and O
12-month O
follow-up O
showed O
no O
significant O
difference O
in O
the O
overall O
TF1-9 B-outcome ['Physiological-Clinical']
prevalence O
by O
balozi O
between O
control O
and O
treatment O
arms. O
[['Physiological-Clinical']]

One O
of O
the O
2 O
controlled O
preventive O
trials O
within O
the O
Oslo O
Study O
was O
a O
non-drug O
trial O
on O
the O
effect O
of O
diet B-outcome ['Life-Impact']
and O
smoking B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
on O
coronary O
heart O
disease O
in O
1232 O
middleaged O
, O
normotensive O
, O
healthy O
men O
. O
['Life-Impact', 'Resource-use']

METHODS O
72 O
patients O
were O
randomized O
to O
either O
ziprasidone O
or O
placebo O
and O
treated O
prospectively O
for O
6 O
weeks O
. O
[]

Results O
were O
analyzed O
overall O
in O
the O
cohort O
of O
893 O
patients O
with O
endocrine-responsive O
disease O
, O
and O
according O
to O
prospectively O
defined O
categories O
of O
ER O
, O
age O
and O
nodal O
status O
. O
[]

Exercise O
has O
been O
recommended O
for O
enhancing O
sleep O
; O
a O
claim O
linked O
to O
the O
belief O
that O
sleep O
need O
- O
defined O
by O
sleep O
duration O
and O
depth O
- O
is O
increased O
post-exercise O
to O
allow O
tissue O
recovery O
. O
[]

These O
patients O
were O
compared O
to O
a O
group O
of O
22 O
children O
with O
similar O
pathologies O
who O
did O
not O
receive O
sildenafil O
( O
control O
group O
) O
. O
[]

METHODS: O
FLAME O
was O
a O
52-week O
randomized O
controlled O
trial O
in O
patients O
with O
severe-to-very-severe O
COPD O
and O
a O
history O
of O
exacerbations. O
[]

However O
, O
systolic O
BP O
remained O
significantly O
lower O
in O
PR-STENT O
than O
in O
NO-STENT O
( O
140.1 O
? O
[]

There O
were O
significantly O
more O
PONV-free B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
in O
group O
C O
compared O
with O
group O
P O
( O
20 O
and O
11 O
of O
30 O
, O
respectively O
; O
P O
< O
0.04 O
) O
. O
['Physiological-Clinical']

PARTICIPANTS O
Thirty-four O
eyes O
of O
32 O
patients O
with O
chronic O
CSC O
with O
> O
6 O
months O
' O
duration O
of O
symptoms O
or O
recurrent O
CSC O
were O
randomly O
placed O
into O
the O
low-fluence O
PDT O
group O
( O
n O
= O
18 O
) O
or O
the O
ranibizumab O
group O
( O
n O
= O
16 O
) O
. O
[]

BACKGROUND: O
Krill O
powder O
is O
rich O
in O
bioactive O
ingredients O
such O
as O
eicosapentaenoic O
acid O
(EPA), O
docosahexaenoic O
acid O
(DHA), O
phospholipids, O
protein O
and O
astaxanthin. O
[]

Nevertheless O
, O
their O
usefulness O
remains O
uncertain O
and O
contradictory O
. O
[]

RESULTS: O
The O
results O
revealed O
that O
there O
was O
a O
statistically O
significant O
reduction O
in O
plaque B-outcome ['Physiological-Clinical']
index O
(PI) O
and O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
in O
the O
test O
group O
when O
compared O
with O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

INTERVENTIONS O
A O
total O
of O
43 O
of O
67 O
evaluable O
patients O
randomly O
received O
either O
EPA+GLA O
or O
an O
isonitrogenous O
, O
isocaloric O
standard O
diet O
that O
was O
tube O
fed O
at O
a O
minimum O
caloric O
delivery O
of O
75 O
% O
of O
basal O
energy O
expenditure O
times O
1.33 O
for O
at O
least O
4 O
to O
7 O
days O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
prothrombin I-outcome ['Physiological-Clinical']
and O
serum O
['Physiological-Clinical']

AIM O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
whether O
oxidized B-outcome ['Physiological-Clinical']
regenerated I-outcome ['Physiological-Clinical']
cellulose I-outcome ['Physiological-Clinical']
( O
ORC B-outcome ['Physiological-Clinical']
) O
, O
applied O
to O
dirty O
surgical O
wounds O
, O
is O
able O
to O
reduce O
the O
microbial O
load O
and O
, O
consequently O
, O
the O
infection B-outcome ['Physiological-Clinical']
rate O
as O
compared O
to O
conventional O
local O
wound O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Matched O
samples O
labelled O
with O
Ber O
EP4 O
were O
separated O
magnetically O
by O
adding O
a O
secondary O
bead-antibody O
conjugate O
for O
confirmation O
of O
tumour O
cell O
identity O
. O
[]

In O
69 O
artificially O
ventilated O
patients O
the O
clinical B-outcome ['Physiological-Clinical']
, O
bacteriological B-outcome ['Physiological-Clinical']
and O
pharmacological B-outcome ['Physiological-Clinical']
effects O
of O
endotracheally O
administered O
tobramycin O
were O
studied O
in O
comparison O
to O
a O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
low O
rate O
of O
recorded O
complications O
showed O
that O
both O
techniques O
cause O
little O
damage O
to O
the O
tonsillar O
bed O
during O
dissection O
, O
thus O
minimising O
complications O
. O
[]

Artesunate O
plus O
primaquine O
( O
group O
IV O
) O
cleared O
parasitemia B-outcome ['Physiological-Clinical']
faster O
than O
the O
other O
3 O
regimens O
. O
['Physiological-Clinical']

Contrast O
enhancement O
is O
demonstrated O
by O
STIR O
, O
FATSAT O
, O
T1-weighted O
and O
dynamic O
screening O
sequence O
. O
[]

Arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
waveforms I-outcome ['Physiological-Clinical']
were O
recorded O
and O
inspected O
for O
dampening O
or O
other O
deformation O
. O
['Physiological-Clinical']

No O
group O
or O
medication O
effects O
were O
observed O
for O
the O
inhibition B-outcome ['Life-Impact']
condition I-outcome ['Life-Impact']
( O
AY O
trials O
) O
. O
['Life-Impact']

The O
difference O
in O
median O
percentage O
change O
between O
D O
and O
C O
was O
statistically O
significant O
[ O
-4.0 O
( O
D O
) O
vs. O
4.7 O
( O
C O
) O
; O
P O
= O
0.005 O
, O
n O
= O
39 O
] O
. O
[]

PM O
presented O
a O
superior O
ICER B-outcome ['Physiological-Clinical']
, O
suggesting O
that O
it O
may O
be O
a O
promising O
treatment O
option O
to O
implement O
in O
EDs O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effect O
of O
400 O
mug O
of O
oral O
misoprostol O
with O
5 O
U O
of O
intravenous O
oxytocin O
in O
the O
reduction O
of O
postpartum B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
prevention O
of O
postpartum O
hemorrhage O
. O
['Physiological-Clinical']

RESULTS O
A O
non-compartmental O
analysis O
resulted O
in O
linear O
kinetics O
of O
bilastine O
in O
the O
dose O
range O
studied O
. O
[]

Effect O
of O
a O
dental O
cream O
containing O
amorphous O
cream O
phosphate O
complexes O
on O
white O
spot O
lesion O
regression O
assessed O
by O
laser O
fluorescence O
. O
[]

The O
Warfarin O
Re-Infarction O
Study O
. O
[]

The O
diagnostic B-outcome ['Life-Impact']
superiority I-outcome ['Life-Impact']
of O
brushings O
obtained O
before O
biopsy O
did O
not O
relate O
to O
the O
site O
or O
endoscopic O
appearance O
of O
the O
tumor O
. O
['Life-Impact']

The O
supported O
housing O
facilities O
with O
residents O
and O
staff O
were O
randomly O
assigned O
to O
either O
a O
health O
intervention O
programme O
or O
a O
control O
programme O
with O
an O
aesthetic O
content O
. O
[]

Children O
with O
ASD O
and O
typically O
developing O
( O
TD O
) O
children O
viewed O
randomly O
presented O
digital O
morphs O
between O
their O
own O
face O
and O
a O
gender-matched O
other O
face O
, O
and O
made O
self/other O
judgments O
. O
[]

A O
response-cost O
program O
was O
applied O
to O
reduce O
problem O
behaviors O
and O
foster O
skills O
acquisition O
. O
[]

Trial O
Registration O
Date: O
August O
22, O
2017. O
[]

A O
multiple O
logistic O
regression O
analysis O
was O
used O
to O
determine O
the O
factors O
associated O
with O
exclusive O
breastfeeding O
at O
8-12 O
weeks O
postpartum O
. O
[]

A O
psychological O
intervention O
reduces O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
by O
alleviating O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
: O
secondary O
analysis O
of O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Life-Impact']

Objective O
parameters O
were O
used O
to O
evaluate O
therapeutical O
effects O
. O
[]

Quality O
of O
life O
was O
not O
influenced O
by O
either O
treatment O
, O
and O
there O
was O
no O
relevant O
change O
in O
flow-mediated O
dilatation O
in O
patients O
treated O
with O
nebivolol O
or O
metoprolol O
( O
P=0.16 O
) O
. O
[]

In O
an O
additional O
study O
, O
36 O
healthy O
male O
subjects O
received O
iv O
. O
[]

Mild B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
was O
observed O
in O
both O
treatment O
groups O
. O
['Physiological-Clinical']

regimen O
of O
3TC O
, O
combined O
with O
zidovudine O
( O
300 O
mg O
b.i.d O
. O
) O
[]

Remifentanil O
was O
used O
intraoperatively O
, O
and O
i.v O
. O
[]

BACKGROUND O
Amantadine O
hydrochloride O
and O
pemoline O
, O
both O
frequently O
used O
to O
treat O
the O
fatigue O
of O
multiple O
sclerosis O
( O
MS O
) O
, O
may O
also O
improve O
attention O
and O
other O
cognitive O
functions O
in O
MS. O
To O
our O
knowledge O
, O
these O
agents O
have O
never O
been O
compared O
in O
a O
placebo-controlled O
trial O
of O
patients O
with O
MS O
. O
[]

Our O
study O
investigated O
the O
effect O
of O
exposure O
to O
whole-body O
mild-cold O
on O
measures O
of O
arterial B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
( O
aortic B-outcome ['Physiological-Clinical']
and O
brachial B-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
on O
central B-outcome ['Physiological-Clinical']
haemodynamics I-outcome ['Physiological-Clinical']
[ O
including O
augmented O
pressure B-outcome ['Physiological-Clinical']
( O
AP B-outcome ['Physiological-Clinical']
) O
, O
AIx O
] O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
were O
observed O
in O
the O
mean O
1-y O
change O
in O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
between O
the O
control O
, O
medium-dairy O
, O
and O
high-dairy O
groups O
( O
-0.5 O
+/- O
2.5 O
, O
0.3 O
+/- O
2.7 O
, O
and O
0.5 O
+/- O
3.5 O
kg O
, O
respectively O
; O
P O
= O
0.26 O
) O
. O
['Physiological-Clinical']

GAS O
is O
a O
promising O
measurement O
approach O
. O
[]

Hunter O
DBT O
project O
: O
randomized O
controlled O
trial O
of O
dialectical O
behaviour O
therapy O
in O
women O
with O
borderline O
personality O
disorder O
. O
[]

Pain B-outcome ['Physiological-Clinical']
intensity O
and O
pain B-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
were O
statistically O
significantly O
lower O
for O
the O
30-second O
injection O
than O
for O
the O
10-second O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
crossover O
study O
comparing O
efficacy O
of O
transnasal O
endoscopy O
with O
that O
of O
standard O
endoscopy O
to O
detect O
Barrett O
's O
esophagus O
. O
[]

Interventions O
Five O
hundred O
ninety-six O
community O
clusters O
( O
study O
sectors O
) O
were O
randomized O
for O
pregnant O
women O
to O
receive O
weekly O
, O
from O
the O
first O
trimester O
through O
12 O
weeks O
postpartum O
, O
7000 O
?g O
of O
retinol O
equivalents O
as O
retinyl O
palmitate O
, O
42 O
mg O
of O
all-trans O
beta O
carotene O
, O
or O
placebo O
. O
[]

MBCT O
as O
an O
evidence-based O
psychotherapeutic O
intervention O
and O
Mindfulness-Based O
Intervention O
(MBI), O
is O
an O
8-week O
course O
developed O
for O
patients O
with O
relapsing O
depression O
that O
integrates O
mindfulness O
meditation O
practices O
and O
cognitive O
therapy. O
[]

There O
was O
no O
significant O
difference O
in O
elevation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
total O
protein B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Three O
individualized O
goals O
( O
social O
, O
communication O
, O
and O
independence O
skills O
) O
were O
selected O
for O
intervention O
for O
each O
child O
. O
[]

This O
suggests O
that O
their O
dependence O
on O
chemotherapy O
to O
control O
parasite O
infections O
had O
failed O
. O
[]

PURPOSE O
To O
measure O
changes O
and O
predictors O
of O
change O
in O
mammograms O
obtained O
in O
postmenopausal O
women O
undergoing O
continuous O
combined O
hormonal O
replacement O
therapy O
( O
HRT O
) O
. O
[]

As O
compared O
to O
inhalational O
sevoflurane, O
intravenous O
sufentanil-midazolam O
exerts O
more O
favorable O
effects O
on O
systemic B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
efficiency O
during O
anesthetic O
induction O
in O
this O
group O
of O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Complications B-outcome ['Adverse-effects']
occurred O
in O
25 O
% O
of O
PEG O
patients O
and O
12 O
% O
died B-outcome ['Mortality']
. O
['Adverse-effects', 'Mortality']

The O
low-SF O
grating O
was O
a O
more O
effective O
adapter O
than O
the O
high-SF O
grating O
, O
incompatible O
with O
the O
FRF O
model O
. O
[]

A O
total O
of O
360 O
films O
were O
taken O
and O
assessed O
by O
an O
experienced O
practitioner O
not O
apprised O
of O
the O
bitewing O
technique O
used O
. O
[]

Limited O
data O
characterize O
pharmacokinetic O
interactions O
between O
cephalexin O
and O
ranitidine O
, O
and O
no O
data O
exist O
for O
an O
interaction O
with O
proton O
pump O
inhibitors O
. O
[]

Bilateral O
venography O
was O
performed O
in O
all O
patients O
on O
day O
seven O
after O
operation O
, O
and O
showed O
an O
overall O
deep O
vein O
thrombosis O
incidence O
of O
16 O
% O
. O
[]

The O
specimens O
were O
stored O
in O
distilled O
water O
at O
room O
temperature O
for O
24 O
hours O
and O
subsequently O
tested O
in O
shear O
mode O
with O
a O
universal O
testing O
machine O
. O
[]

Comparison O
of O
the O
therapeutic O
effects O
of O
epoetin O
zeta O
to O
epoetin O
alfa O
in O
the O
maintenance O
phase O
of O
renal O
anaemia O
treatment O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

CONCLUSIONS O
Intravesical O
instillation O
of O
pirarubicin O
immediately O
after O
nephroureterectomy O
significantly O
reduced O
the O
bladder B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
in O
patients O
with O
positive O
voided O
urine O
cytology O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
randomized O
double-blinded O
control O
trial O
was O
conducted O
to O
compare O
the O
effectiveness O
of O
tramodol O
and O
placebo O
rectal O
suppository O
for O
the O
management O
of O
postpartum B-outcome ['Physiological-Clinical']
perineal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
perineorrhaphy O
. O
['Physiological-Clinical']

Parenteral O
amino O
acid O
and O
metabolic O
acidosis O
in O
premature O
infants O
. O
[]

injection O
5 O
min O
before O
surgery O
and O
isotonic O
saline O
5 O
mL O
i.v O
. O
[]

Among O
the O
70 O
patients O
, O
24 O
had O
angina O
only O
at O
rest O
. O
[]

CONCLUSION O
These O
results O
indicate O
that O
eye O
gaze O
attracted O
attention B-outcome ['Life-Impact']
more O
effectively O
than O
the O
arrow O
in O
typically O
developed O
children O
, O
while O
children O
with O
autism O
shifted O
their O
attention O
equally O
in O
response O
to O
eye O
gaze O
and O
arrow O
direction O
, O
failing O
to O
show O
preferential O
['Life-Impact']

CONCLUSIONS O
In O
moderate O
persistent O
asthmatics O
switched O
from O
taking O
ICS O
to O
salmeterol O
alone O
, O
adding O
montelukast O
conferred O
significant O
benefits O
on O
all O
parameters O
of O
asthma O
control O
. O
[]

Publication O
date: O
2018/10/31 O
00:00 O
[accepted] O
[]

No O
time O
x O
training O
group O
effect O
was O
found O
for O
any O
of O
the O
vertical B-outcome ['Life-Impact']
jump I-outcome ['Life-Impact']
and O
Agility-15m O
variables O
( O
p B-outcome ['Physiological-Clinical']
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

II O
. O
[]

Specimens O
were O
sectioned O
longitudinally O
in O
the O
bucco-lingual O
direction O
, O
in O
slices O
of O
1 O
mm O
thick O
. O
[]

Multiple O
measures O
of O
cigarette O
smoking O
, O
subjective O
effect O
and O
physiological O
effect O
were O
collected O
during O
90-min O
test O
sessions O
in O
normal O
volunteers O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
1 O
) O
describe O
dietary O
intake O
of O
a O
cohort O
of O
children O
with O
ASD O
compared O
with O
normative O
data O
and O
2 O
) O
determine O
whether O
GI O
symptoms O
and O
stool O
consistency O
are O
related O
to O
dietary O
intake O
. O
[]

Acute O
intervention O
studies O
in O
patients O
with O
myocardial O
infarction O
using O
atenolol O
, O
propranolol O
, O
oxprenolol O
and O
disopyramide O
phosphate O
. O
[]

CONCLUSIONS O
Treatment O
of O
hirsute O
women O
with O
third O
generation O
OCs O
containing O
desogestrel O
results O
in O
a O
significant O
increase O
in O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
and O
decrease O
in O
free B-outcome ['Physiological-Clinical']
testosterone I-outcome ['Physiological-Clinical']
and O
3alpha-androstanediol B-outcome ['Physiological-Clinical']
glucuronide I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
In O
cemented O
THA O
, O
aseptic O
loosening O
of O
the O
cup O
is O
more O
common O
than O
loosening O
of O
the O
stem O
, O
while O
periprosthetic O
osteolysis O
of O
the O
socket O
resulting O
in O
difficult O
reconstruction O
problems O
has O
emerged O
as O
the O
most O
significant O
problem O
with O
cementless O
cup O
fixation O
. O
[]

No O
other O
complications B-outcome ['Adverse-effects']
, O
such O
as O
infection B-outcome ['Physiological-Clinical']
or O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
occurred O
in O
both O
groups. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:BMC O
ophthalmology O
[]

Deterioration O
in O
morphological B-outcome ['Physiological-Clinical']
parameters O
observed O
in O
earlier O
studies O
of O
our O
patients O
did O
not O
become O
worse O
during O
treatment O
with O
candesartan O
or O
placebo O
. O
['Physiological-Clinical']

3 O
. O
[]

Actual O
uptake O
of O
BRCA1 B-outcome ['Physiological-Clinical']
testing O
is O
reported O
with O
a O
six O
year O
follow-up O
. O
['Physiological-Clinical']

Medical O
treatments O
have O
become O
available O
for O
benign O
hypertrophy O
of O
the O
prostate O
, O
including O
alpha-receptor O
blocking O
agents O
and O
5-alpha-reductase O
inhibitors O
. O
[]

Mechanisms O
underlying O
the O
lack O
of O
effect O
of O
implantable O
cardioverter-defibrillator O
therapy O
on O
mortality B-outcome ['Mortality']
in O
high-risk O
patients O
with O
recent O
myocardial O
infarction O
: O
insights O
from O
the O
Defibrillation O
in O
Acute O
Myocardial O
Infarction O
Trial O
( O
DINAMIT O
) O
. O
['Mortality']

Title: O
Does O
all O
single O
infarction O
have O
lower O
risk O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
than O
multiple O
infarctions O
in O
minor O
stroke? O
[['Physiological-Clinical']]

Despite O
this O
reduced O
saliency O
and O
processing O
of O
other O
faces O
, O
recognition O
of O
their O
own O
face O
is O
reported O
to O
be O
more O
typical O
in O
nature O
. O
[]

Significant O
survival O
benefit O
from O
adjuvant O
chemotherapy O
was O
observed O
by O
SPC-Prediction O
in O
MSS O
and O
EBV-negative O
gastric O
cancer. O
[]

The O
incidence O
rate O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
viral B-outcome ['Physiological-Clinical']
infections O
and O
fungal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
was O
similar O
across O
groups O
during O
the O
LTE O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
normal O
men O
, O
saline O
or O
continuous O
( O
0.8 O
mU O
kg-1 O
min-1 O
) O
or O
pulsatile O
( O
5.2 O
mU O
kg-1 O
min-1 O
, O
with O
a O
switching O
on/off O
length O
of O
2/11 O
min O
) O
human O
insulin O
were O
delivered O
on O
different O
days O
and O
in O
random O
order O
. O
[]

Effects O
of O
fenoterol O
on O
inspiratory O
effort O
sensation O
and O
fatigue O
during O
inspiratory O
threshold O
loading O
. O
[]

Sitting B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
were O
reduced O
6 O
and O
5 O
mmHg O
more O
by O
lisinopril O
than O
by O
nifedipine O
over O
12 O
weeks O
monotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Low-intensity O
exercise O
and O
reduction O
of O
the O
risk O
for O
falls B-outcome ['Life-Impact']
among O
at-risk O
elders O
. O
['Life-Impact']

The O
authors O
do O
not O
recommend O
adding O
INB O
for O
patients O
undergoing O
lateral O
thoracotomy O
who O
receive O
0.5 O
mg O
SM O
. O
[]

The O
study O
was O
aimed O
to O
observe O
the O
curative O
effect O
of O
device-guided O
rehabilitation O
on O
respiratory O
functions O
in O
stable O
COPD O
patients. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

About O
70 O
% O
in O
each O
active O
treatment O
group O
considered O
the O
overall O
pain B-outcome ['Physiological-Clinical']
relief O
to O
be O
some O
, O
a O
lot O
, O
or O
complete O
compared O
to O
only O
15 O
% O
on O
placebo O
. O
['Physiological-Clinical']

Further O
research O
could O
assess O
whether O
these O
gains O
generalized O
into O
real O
life O
or O
improved O
performance O
on O
theory O
of O
mind O
measures O
. O
[]

Similarly O
, O
Steri-Strip O
S O
versus O
suture O
for O
the O
abdomen O
was O
faster O
( O
p O
< O
0.001 O
; O
4.9 O
minutes O
, O
SD O
= O
2.3 O
versus O
10.1 O
minutes O
, O
SD O
= O
3.4 O
) O
. O
[]

No O
significant O
differences O
were O
observed O
between O
trimetazidine O
and O
propranolol O
as O
regards O
anginal B-outcome ['Physiological-Clinical']
attack O
rate O
per O
week O
( O
mean O
difference O
P-TMZ O
: O
2 O
; O
95 O
% O
CI O
: O
-4.4 O
, O
0.5 O
) O
and O
exercise B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
( O
mean O
difference O
P-TMZ O
: O
0 O
s O
; O
95 O
% O
CI O
: O
-33 O
, O
34 O
) O
or O
time O
to O
1 O
mm O
ST B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
( O
mean O
difference O
P-TMZ O
: O
13 O
s O
; O
95 O
% O
CI O
: O
-24 O
, O
51 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
The O
number O
of O
patients O
who O
delivered B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
day I-outcome ['Physiological-Clinical']
showed O
no O
difference O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Accordingly O
, O
we O
investigated O
the O
effects O
on O
ambulatory B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
of O
aspirin O
administered O
at O
different O
times O
of O
the O
day O
in O
prehypertension O
. O
['Physiological-Clinical']

FINDINGS O
100 O
patients O
were O
assigned O
the O
high-dose O
regimen O
, O
and O
100 O
the O
control O
regimen O
. O
[]

A O
secondary O
objective O
was O
to O
identify O
molecular O
biomarkers O
correlating O
with O
response O
and O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

METHODS O
Long-term O
intraindividual O
BP O
variability O
was O
defined O
as O
the O
coefficient O
of O
variation O
of O
the O
average O
systolic O
or O
diastolic O
values O
of O
clinic O
and O
24-h O
BP O
measured O
at O
each O
visit O
throughout O
the O
treatment O
period O
. O
[]

CONCLUSION O
AT O
did O
not O
improve O
DFS O
or O
overall O
survival O
in O
this O
population O
, O
and O
was O
associated O
with O
more O
toxicity O
. O
[]

Blood O
and O
sputum O
eosinophils O
and O
serum O
levels O
of O
eosinophil O
cationic O
protein O
( O
ECP O
) O
and O
intercellular O
adhesion O
molecule-1 O
( O
ICAM-1 O
) O
were O
measured O
. O
[]

The O
present O
study O
was O
designed O
to O
assess O
the O
antithrombotic O
effect O
of O
both O
dual O
antiplatelet O
regimens O
using O
a O
human O
ex O
vivo O
model O
of O
arterial O
thrombosis O
. O
[]

Serotonergic O
control O
of O
TSH B-outcome ['Physiological-Clinical']
and O
PRL B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
obese O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
distance O
walked B-outcome ['Life-Impact']
was O
significantly O
higher O
in O
atrioventricular O
synchronous O
than O
in O
ventricular O
pacing O
( O
360 O
+/- O
65 O
m O
vs. O
327 O
+/- O
69 O
m O
; O
P O
< O
0.01 O
) O
. O
['Life-Impact']

The O
most O
important O
methods O
of O
regional O
chemotherapy O
are O
exemplified O
by O
657 O
cases O
of O
primary O
and O
secondary O
liver O
only O
malignancies O
. O
[]

Antiinflammatory B-outcome ['Physiological-Clinical']
effects O
of O
the O
phosphodiesterase-4 O
inhibitor O
cilomilast O
( O
Ariflo O
) O
in O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical']

Multiple O
n-of-1 O
randomized O
, O
crossover O
trials O
. O
[]

Patients O
expressing O
high O
levels O
of O
OPN B-outcome ['Physiological-Clinical']
within I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
BM I-outcome ['Physiological-Clinical']
( O
IHC O
) O
experienced O
shortened O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS O
; O
P O
= O
.025 O
) O
. O
['Physiological-Clinical', 'Mortality']

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameters O
of O
zolmitriptan O
and O
its O
metabolites O
were O
not O
significantly O
affected O
by O
fluoxetine O
pretreatment O
. O
['Physiological-Clinical']

Evidence O
supports O
a O
connection O
among O
dietary O
sodium O
, O
the O
rennin-angiotensin O
system O
, O
and O
myocardial O
function O
. O
[]

The O
primary O
outcome O
was O
microbiologically O
confirmed O
or O
clinically O
suspected O
late-onset O
infection B-outcome ['Physiological-Clinical']
(occurring O
>72 O
h O
after O
birth), O
which O
was O
assessed O
in O
all O
participants O
for O
whom O
primary O
outcome O
data O
was O
available O
by O
calculating O
the O
relative O
risk O
ratio O
with O
95% O
CI O
between O
the O
two O
groups. O
[['Physiological-Clinical']]

The O
frequency O
of O
pathologic B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
, O
hypercalcemia B-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
regularly O
assessed O
, O
as O
well O
as O
size O
and O
number O
of O
osteolytic O
lesions O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
randomized O
study O
, O
biliary O
and O
serum O
bile O
acid O
analyses O
were O
performed O
at O
entry O
and O
after O
2 O
yr O
of O
UDCA O
or O
placebo O
. O
[]

Journal O
ID: O
8900488 O
[]

BACKGROUND: O
Dexmedetomidine O
(Dex), O
as O
an O
adjuvant, O
has O
been O
reported O
to O
prolong O
the O
duration O
of O
spinal O
analgesia O
when O
adding O
to O
local O
anesthetic. O
[]

[ O
Using O
gaviscon O
preparation O
for O
relief O
of O
esophageal O
, O
extraesophageal O
syndromes O
and O
functional O
dyspepsia O
in O
elderly O
patients O
with O
GERD O
] O
. O
[]

Future O
therapeutic O
directions O
for O
factor O
Xa O
inhibition O
in O
the O
prophylaxis O
and O
treatment O
of O
thrombotic O
disorders O
. O
[]

METHODS: O
In O
a O
prospective O
randomized O
contralateral O
eye O
study O
of O
LASIK O
versus O
SMILE O
procedures, O
21 O
consecutive O
patients O
(42 O
eyes) O
were O
evaluated O
with O
corneal O
epithelial O
mapping O
by O
anterior O
segment O
optical O
coherence O
tomography O
for O
up O
to O
2 O
years. O
[]

OBJECTIVES O
To O
explore O
associations O
between O
histology B-outcome ['Physiological-Clinical']
and O
outcome O
in O
advanced O
or O
recurrent O
endometrial O
cancer O
patients O
participating O
in O
Gynecologic O
Oncology O
Group O
chemotherapy O
trials O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

PATIENTS O
AND O
OTHER O
PARTICIPANTS O
Smokers O
recruited O
from O
among O
the O
health O
centre O
users O
through O
the O
preventive O
activities O
and O
health O
promotion O
programme O
. O
[]

It O
may O
significantly O
lower O
the O
risk O
of O
refractory O
angina O
pectoris O
compared O
with O
intravenous O
nitroglycerin O
. O
[]

At O
intervals O
6 O
, O
24 O
, O
and O
48 O
hours O
postbanding O
, O
the O
patient O
recorded O
[]

Title: O
Oral O
versus O
Intravenous O
Antibiotics O
for O
Bone O
and O
Joint O
Infection. O
[]

METHODOLOGY O
One O
hundred O
and O
ninety-three O
( O
193 O
) O
H. O
pylori-positive O
patients O
were O
randomly O
assigned O
to O
one O
of O
the O
following O
7-day O
treatments O
: O
Group O
A O
( O
N O
= O
64 O
) O
: O
amoxicillin O
, O
clarithromycin O
and O
rabeprazole O
; O
Group O
B O
( O
N O
= O
64 O
) O
: O
tinidazole O
, O
clarithromycin O
and O
ranitidine O
bismuth O
citrate O
; O
Group O
C O
( O
N O
= O
65 O
) O
: O
tinidazole O
, O
clarithromycin O
and O
rabeprazole O
Eradication O
was O
assessed O
by O
13C-Urea O
Breath O
Test O
6-8 O
weeks O
after O
the O
end O
of O
the O
therapy O
. O
[]

CONCLUSION O
These O
data O
indicate O
that O
the O
computerized O
WOMAC O
OA O
index O
3.0 O
is O
comparable O
to O
the O
paper O
WOMAC O
in O
all O
three O
dimensions O
. O
[]

Prosthesis O
orientation O
crucially O
affects O
the O
rate O
of O
success B-outcome ['Physiological-Clinical']
of O
the O
fluoroscopic O
evaluation O
. O
['Physiological-Clinical']

Immunotherapy O
maintenance O
in O
acute O
non-lymphocytic O
leukaemia O
. O
[]

METHODS O
Patients O
were O
randomly O
assigned O
to O
undergo O
serial O
testing O
of O
the O
efficacy O
of O
the O
seven O
antiarrhythmic O
drugs O
by O
one O
of O
two O
strategies O
: O
electrophysiologic O
study O
or O
Holter O
monitoring O
together O
with O
exercise O
testing O
. O
[]

Twenty O
adult O
patients O
with O
asthma O
were O
studied O
. O
[]

Functional B-outcome ['Life-Impact']
outcome O
was O
significantly O
improved O
compared O
to O
baseline O
in O
both O
the O
groups O
until O
six O
weeks O
however, O
in O
the O
triamcinolone O
group, O
it O
was O
significant O
until O
twelve O
weeks. O
[['Life-Impact']]

Ang O
II O
may O
play O
a O
role O
in O
the O
interaction O
between O
dietary O
sodium O
and O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
findings O
suggest O
that O
PTF O
may O
have O
beneficial O
effects O
on O
tubulointerstitial O
damage O
in O
diabetic O
kidney O
disease O
. O
[]

Using O
more O
ecologically O
valid O
stimulus O
situations O
than O
the O
traditional O
LED O
in O
the O
dark O
, O
we O
performed O
two O
experiments O
. O
[]

Anaesthesia O
and O
postoperative O
analgesia O
were O
standardized O
and O
the O
same O
surgeon O
performed O
all O
the O
operations O
. O
[]

Granisetron O
revealed O
an O
excellent O
inhibitory B-outcome ['Physiological-Clinical']
effect O
on O
vomiting B-outcome ['Physiological-Clinical']
induced O
by O
remission O
induction O
chemotherapy O
for O
acute O
myeloid O
leukemia O
, O
but O
combination O
with O
granisetron O
and O
methylprednisolone O
was O
considered O
useful O
for O
nausea B-outcome ['Physiological-Clinical']
in O
the O
latter O
half O
of O
the O
treatment O
period O
and O
for O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
revealed O
that O
treated O
young O
adults O
reported O
significantly O
less O
loneliness B-outcome ['Life-Impact']
and O
improved O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
while O
caregivers O
reported O
significant O
improvements O
in O
young O
adults O
' O
overall B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
, O
empathy B-outcome ['Life-Impact']
, O
and O
frequency O
of O
get-togethers B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
bupivacaine O
group O
had O
better O
analgesia B-outcome ['Resource-use']
than O
the O
control O
group O
for O
the O
first O
8 O
hours O
, O
after O
which O
there O
was O
no O
difference O
. O
['Resource-use']

This O
study O
presents O
the O
preliminary O
results O
of O
a O
randomized O
prospective O
two-arm O
study O
in O
which O
bacillus O
Calmette-Gu?rin O
( O
BCG O
) O
RIVM O
, O
a O
Dutch O
BCG O
preparation O
, O
is O
compared O
with O
mitomycin O
C O
( O
MMC O
) O
in O
patients O
with O
primary O
or O
recurrent O
superficial O
bladder O
tumors O
, O
including O
carcinoma O
in O
situ O
( O
CIS O
) O
. O
[]

We O
profiled O
the O
microbiome O
of O
a O
longitudinal O
sample O
series O
of O
28 O
people O
with O
diabetes O
and O
DFUs O
of O
the O
heel O
in O
an O
attempt O
to O
better O
characterize O
the O
relationship O
between O
healing, O
infection O
and O
the O
microbiome. O
[]

The O
mean O
apical B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
of O
six O
groups O
was O
as O
follows O
: O
I O
= O
0.45 O
mm O
, O
II O
= O
0.277 O
mm O
, O
III O
= O
0.343 O
mm O
, O
IV O
= O
0.263 O
mm O
, O
V O
= O
0.336 O
mm O
, O
and O
VI O
= O
2.310 O
mm O
. O
['Physiological-Clinical']

Tachycardia B-outcome ['Physiological-Clinical']
and O
palpitations B-outcome ['Physiological-Clinical']
were O
more O
frequent O
following O
isoproterenol O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
173 O
with O
complete O
before-and O
after-digital O
images O
of O
the O
teeth. O
[]

In O
48 O
instances O
, O
parents O
based O
their O
guess O
on O
perceived O
improvement O
; O
in O
six O
cases O
, O
parents O
based O
their O
guess O
on O
perceived O
deterioration B-outcome ['Life-Impact']
. O
['Life-Impact']

To O
evaluate O
the O
influence O
of O
body O
temperature O
during O
cardiopulmonary O
bypass O
( O
CPB O
) O
on O
postoperative B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
, O
32 O
patients O
undergoing O
elective O
cardiac O
surgery O
were O
randomly O
assigned O
to O
either O
hypothermia O
( O
n O
= O
16 O
) O
or O
normothermia O
( O
n O
= O
16 O
) O
. O
['Physiological-Clinical']

Fourteen O
subjects O
( O
three O
females O
and O
11 O
males O
) O
, O
who O
met O
the O
criteria O
for O
pathological O
gambling O
in O
accordance O
with O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
IV O
, O
were O
randomly O
assigned O
to O
a O
Treatment O
Group O
( O
n=7 O
) O
or O
a O
waiting O
list O
Control O
Group O
( O
n=7 O
) O
. O
[]

At O
entry O
into O
the O
study O
, O
all O
participants O
had O
sterile O
cultures O
of O
cerebrospinal O
fluid O
, O
blood O
, O
and O
urine O
after O
following O
a O
standardized O
course O
of O
therapy O
for O
culture-proved O
cryptococcal O
meningitis O
. O
[]

A O
randomized O
double-blind O
trial O
was O
used O
to O
assess O
endurance B-outcome ['Life-Impact']
, O
resistance B-outcome ['Life-Impact']
, O
strength B-outcome ['Life-Impact']
and O
coordination B-outcome ['Life-Impact']
in O
26 O
athletes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
Inclusion O
of O
1-10 O
microM O
FF-MAS O
in O
a O
30-hour O
IVM O
protocol O
is O
safe O
. O
[]

Intervals B-outcome ['Life-Impact']
between I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
return I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
( O
median O
5 O
days O
, O
range O
2-15 O
) O
were O
shorter O
in O
the O
trial O
group O
than O
in O
the O
control O
group O
( O
median O
10 O
days O
, O
range O
2-21 O
; O
p O
< O
0.001 O
) O
, O
as O
well O
as O
the O
intervals O
between O
the O
['Life-Impact']

One O
epileptic O
woman O
delivered O
a O
newborn O
with O
cleft O
lip O
and O
palate O
. O
[]

Topical O
imiquimod O
5 O
% O
cream O
as O
an O
effective O
treatment O
for O
external O
genital B-outcome ['Physiological-Clinical']
and O
perianal B-outcome ['Physiological-Clinical']
warts O
in O
different O
patient O
populations O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lead-time B-outcome ['Physiological-Clinical']
based O
on O
advanced O
['Physiological-Clinical']

Bone O
marrow-derived O
endothelial O
progenitor O
cells O
( O
EPCs O
) O
improve O
vascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
predict O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nearly O
61.2 O
% O
of O
the O
subjects O
in O
experimental O
group O
became O
non-anaemic B-outcome ['Physiological-Clinical']
after O
the O
intervention O
when O
compared O
to O
control O
group O
A O
. O
['Physiological-Clinical']

In O
the O
future O
, O
surgical O
devices O
may O
have O
to O
prove O
superiority O
in O
randomised O
trials O
or O
be O
monitored O
in O
quality O
registers O
before O
they O
can O
be O
introduced O
into O
day O
to O
day O
surgical O
practice O
. O
[]

Consequently O
, O
various O
adjunctive O
therapies O
have O
been O
investigated O
to O
improve O
clinical O
outcome O
. O
[]

CONCLUSIONS O
The O
nonlinear O
PK O
of O
linagliptin O
and O
its O
plasma O
DPP-4 O
inhibition O
in O
patients O
were O
well O
characterized O
by O
a O
target-mediated O
drug O
disposition O
model O
relating O
DPP-4 O
occupancy O
with O
linagliptin O
to O
DPP-4 O
inhibition O
. O
[]

Fentanyl O
( O
1 O
mcg/kg O
iv O
) O
and O
ketorolac O
( O
30 O
mg O
im O
) O
were O
administered O
immediately O
following O
induction O
of O
anaesthesia O
. O
[]

Effect O
of O
protein O
ingestion O
on O
the O
glucose B-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
people O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

Increasing O
the O
dialysate O
Na+ O
concentration O
decreases O
hypotensive O
episodes O
. O
[]

Research O
questions O
for O
aim O
2 O
were O
as O
follows O
: O
( O
a O
) O
do O
participants O
who O
received O
the O
BCEI O
show O
improvement O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
, O
and O
( O
b O
) O
is O
the O
QOL O
improvement O
sustained O
over O
time O
. O
['Life-Impact', 'Life-Impact']

The O
most O
common O
nasal B-outcome ['Physiological-Clinical']
and O
non-nasal B-outcome ['Physiological-Clinical']
adverse B-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

The O
mean O
rate O
of O
substitutions O
of O
calcium O
by O
strontium O
ions O
was O
4.5 O
% O
. O
[]

BACKGROUND O
Breast O
cancer O
patients O
with O
prior O
response O
to O
endocrine O
therapy O
achieve O
subsequent O
benefit O
from O
additional O
endocrine O
therapies O
. O
[]

CONCLUSIONS: O
The O
traditional O
respiratory O
training O
combined O
with O
device-guided O
pulmonary O
rehabilitation O
can O
improve O
the O
respiratory B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
athletic B-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
in O
stable O
COPD O
patients. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Before O
and O
after O
comparisons O
in O
the O
larger O
sample O
of O
women O
showed O
that O
serial O
CE O
discernibly O
reduced O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP O
) O
( O
-8.7 O
% O
and O
-14.0 O
% O
, O
respectively O
) O
, O
increased O
estimated O
[ O
latin O
capital O
V O
with O
dot O
above O
] O
o2max B-outcome ['Physiological-Clinical']
( O
18.9 O
% O
) O
, O
and O
produced O
a O
trend O
( O
0.10 O
> O
p O
> O
0.05 O
) O
toward O
reduced O
resting B-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
( O
-4.9 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Baseline O
clinical O
characteristics O
of O
the O
allopurinol O
and O
placebo O
groups O
demonstrated O
no O
differences O
in O
terms O
of O
clinical B-outcome ['Physiological-Clinical']
characteristics O
, O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
markers B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Forty-six O
patients O
with O
systemic O
poisoning O
by O
this O
snake O
were O
given O
echis O
antivenom O
made O
either O
by O
the O
South O
African O
Institute O
for O
Medical O
Research O
( O
S.A.I.M.R O
. O
) O
[]

The O
parent O
training O
group O
( O
7 O
with O
autism O
, O
6 O
with O
pervasive O
developmental O
disorder O
NOS O
) O
received O
3 O
to O
9 O
months O
of O
parent O
training O
. O
[]

No O
change O
occurred O
in O
HDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
, O
apo B-outcome ['Physiological-Clinical']
B100/apo B-outcome ['Physiological-Clinical']
A1 B-outcome ['Physiological-Clinical']
ratio O
, O
plasminogen B-outcome ['Physiological-Clinical']
activator B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Pretreatment O
with O
minidose O
succinylcholine O
causes O
no O
greater O
incidence O
of O
fasciculations B-outcome ['Physiological-Clinical']
than O
pancuronium O
in O
rapid-sequence O
intubation O
of O
head O
trauma O
patients O
in O
an O
ED O
setting O
. O
['Physiological-Clinical']

RESULTS O
We O
isolated O
127 O
pathogens O
from O
121 O
( O
60 O
% O
) O
patients O
: O
73 O
( O
57 O
% O
) O
Shigella B-outcome ['Physiological-Clinical']
; O
23 O
( O
18 O
% O
) O
Salmonella B-outcome ['Physiological-Clinical']
; O
18 O
( O
14 O
% O
) O
E. O
coli B-outcome ['Physiological-Clinical']
; O
and O
13 O
( O
10 O
% O
) O
Campylobacter B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
changes O
were O
observed O
in O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
or O
carotid-femoral B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
following O
ST B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
ST+aerobic I-outcome ['Physiological-Clinical']
exercise B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Statistical O
analyses O
were O
performed O
separately O
for O
days O
1 O
and O
4 O
by O
using O
analysis O
of O
variance O
. O
[]

PATIENTS O
AND O
METHODS O
End O
points O
were O
remission B-outcome ['Physiological-Clinical']
rates O
[ O
overall O
response O
( O
OR O
) O
and O
complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
] O
, O
failure-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
( O
FFS B-outcome ['Mortality']
) O
, O
survival B-outcome ['Mortality']
and O
toxicity B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality', 'Mortality', 'Adverse-effects']

CONCLUSIONS O
These O
results O
indicate O
that O
cardiac O
output O
measurements O
are O
affected O
by O
alterations O
in O
patient O
position O
. O
[]

However O
, O
few O
attempts O
have O
been O
made O
to O
define O
and O
measure O
this O
symptom O
. O
[]

However O
, O
a O
recent O
randomized O
trial O
showed O
that O
sulindac O
, O
when O
compared O
with O
placebo O
, O
failed O
to O
prevent O
the O
development O
of O
adenomatous O
polyps O
in O
genotypically O
positive O
but O
phenotypically O
negative O
FAP O
patients O
. O
[]

Of O
18 O
patients O
12 O
were O
evaluable O
for O
their O
response O
to O
therapy O
. O
[]

Journal O
ID: O
2985248R O
[]

A O
series O
of O
multivariable O
analyses O
will O
also O
be O
carried O
out O
to O
identify O
and O
control O
for O
several O
possible O
confounders O
of O
the O
major O
pregnancy B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
and O
HIV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
Statistical O
significance O
will O
be O
defined O
as O
P O
< O
.05. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS O
Of O
the O
1603 O
patients O
with O
PRO O
data O
, O
105 O
had O
a O
recurrence O
and O
342 O
had O
a O
complication O
at O
2 O
years O
. O
[]

[ O
The O
prognostic O
value O
of O
gastric O
metaplasia O
in O
the O
duodenal O
mucosa O
in O
patients O
with O
Helicobacter O
pylori O
positive O
duodenal O
bulb O
ulcer O
] O
. O
[]

Orlistat O
and O
diet O
counseling O
were O
compared O
with O
diet O
counseling O
alone O
. O
[]

TRIAL O
REGISTRATION: O
Netherlands O
Trial O
Register O
NTR4367. O
[]

Mean O
bactericidal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
ceftriaxone O
than O
in O
the O
conventional O
treatment O
group O
at O
the O
beginning O
and O
end O
of O
therapy O
. O
['Physiological-Clinical']

Biventricular O
pacing O
improves O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
prevents O
further O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
in O
patients O
with O
symptomatic O
atrial O
fibrillation O
after O
atrioventricular O
node O
ablation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
example O
, O
the O
[]

Between-group O
differences O
in O
baseline O
characteristics O
of O
participants O
with O
and O
without O
IEDs O
were O
analyzed O
. O
[]

Intravenous O
adenosine O
activates O
pulmonary O
C O
fibers O
and O
induces O
dyspnea O
. O
[]

In O
the O
intent-to-treat O
sample O
, O
pioglitazone O
and O
glimepirede O
produced O
comparable O
reductions O
in O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
end O
of O
the O
study O
( O
-0.78 O
% O
and O
-0.68 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical']

SETTING O
Community-based O
supervised O
intervention O
. O
[]

Children O
were O
randomly O
assigned O
to O
an O
intervention O
( O
n O
= O
28 O
) O
or O
control O
group O
( O
n O
= O
27 O
) O
. O
[]

At O
6 O
months, O
only O
one O
of O
116 O
patients O
(1%) O
assigned O
to O
carvedilol O
had O
an O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
(LVEF) I-outcome ['Physiological-Clinical']
<50% O
compared O
to O
four O
of O
the O
38 O
assigned O
to O
placebo O
(11%), O
(p=0.013). O
[['Physiological-Clinical']]

CONCLUSIONS: O
Systematic O
pelvic O
and O
paraaortic O
lymphadenectomy O
in O
patients O
with O
advanced O
ovarian O
cancer O
who O
had O
undergone O
intraabdominal O
macroscopically O
complete O
resection O
and O
had O
normal O
lymph O
nodes O
both O
before O
and O
during O
surgery O
was O
not O
associated O
with O
longer O
overall B-outcome ['Mortality', 'Physiological-Clinical']
or Seperator ['Mortality', 'Physiological-Clinical']
progression-free B-outcome ['Mortality', 'Physiological-Clinical']
survival E1-outcome ['Mortality', 'Physiological-Clinical']
than O
no O
lymphadenectomy O
and O
was O
associated O
with O
a O
higher O
incidence O
of O
postoperative O
complications B-outcome ['Adverse-effects']
. O
(Funded O
by O
Deutsche O
Forschungsgemeinschaft O
and O
the O
Austrian O
Science O
Fund; O
LION O
ClinicalTrials.gov O
number, O
NCT00712218.). O
[['Mortality', 'Physiological-Clinical'], ['Adverse-effects']]

In O
view O
of O
increasing O
debate O
over O
possible O
benefit O
of O
more O
complete O
surgery O
compared O
to O
conservative O
procedures O
, O
a O
randomized O
controlled O
trial O
contrasting O
the O
then O
standard O
Halsted O
radical O
( O
RDL O
) O
operation O
with O
the O
more O
complete O
extended O
radical O
( O
EXT O
) O
mastectomy O
was O
initiated O
in O
1973 O
. O
[]

The O
ventilatory O
and O
MSNA O
responses O
to O
hypoxic O
PECO O
were O
not O
greater O
than O
the O
sum O
of O
the O
responses O
to O
hypoxia O
and O
PECO O
individually O
, O
indicating O
that O
the O
CC O
are O
not O
sensitized O
during O
metaboreflex O
activation O
. O
[]

METHODS O
Some O
204 O
patients O
with O
mid O
and O
low O
rectal O
adenocarcinomas O
were O
allocated O
randomly O
to O
open O
( O
103 O
) O
or O
laparoscopic O
( O
101 O
) O
surgery O
. O
[]

Thirty-eight O
women O
with O
benign O
ovarian O
dermoid O
cyst O
were O
allocated O
for O
either O
laparoscopy O
( O
18 O
patients O
) O
or O
laparotomy O
( O
20 O
patients O
) O
. O
[]

Analysis O
of O
drainage O
fluids O
showed O
a O
higher B-outcome ['Physiological-Clinical']
contamination I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
15/18 O
= O
83 O
% O
) O
in O
the O
control O
group O
as O
compared O
to O
the O
prophylaxis O
arm O
( O
2/20 O
= O
10 O
% O
) O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
duration O
of O
diarrhoea B-outcome ['Physiological-Clinical']
significantly O
reduced O
in O
the O
S. O
boulardii O
group O
compared O
with O
the O
placebo O
group O
( O
4.7 O
vs O
5.5 O
d O
, O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical']

Mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
in O
both O
the O
experimental O
acupuncture O
treatment O
group O
and O
the O
comparison O
acupuncture O
treatment O
group O
showed O
a O
significant O
difference O
between O
the O
baseline O
and O
the O
third O
month O
of O
the O
study O
. O
['Life-Impact']

Mood B-outcome ['Life-Impact']
remained O
unchanged O
after O
rTMS O
. O
['Life-Impact']

TLA O
was O
comparable O
to O
RLA O
in O
terms O
of O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
130 O
vs O
126.5 O
minutes O
, O
p O
= O
0.64 O
) O
, O
estimated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
p O
= O
0.92 O
) O
, O
specimen B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
p O
= O
0.81 O
) O
, O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
( O
p O
= O
0.25 O
) O
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
p O
= O
0.56 O
) O
and O
the O
complication B-outcome ['Adverse-effects']
rate O
( O
p O
= O
0.58 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Adverse-effects']

Clearance B-outcome ['Physiological-Clinical']
was O
histologically O
confirmed O
2 O
weeks O
after O
the O
last O
application O
of O
imiquimod O
in O
all O
patients O
clinically O
diagnosed O
as O
lesion O
free O
. O
['Physiological-Clinical']

19.2 O
vs. O
42.24 O
? O
[]

Clinical B-outcome ['Physiological-Clinical']
efficacy O
was O
determined O
by O
pneumatic O
otoscopy O
and O
tympanometric O
testing O
3 O
to O
5 O
, O
11 O
to O
14 O
, O
and O
22 O
to O
26 O
days O
after O
the O
initiation O
of O
therapy O
. O
['Physiological-Clinical']

CONCLUSION O
Pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
endometriosis B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
are O
comparable O
among O
the O
3 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Central O
side O
effects O
or O
a O
worsening O
of O
Parkinsonian B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
not O
found O
. O
['Physiological-Clinical']

Ambulatory O
activity O
was O
corrected O
for O
body O
height O
. O
[]

Both O
the O
RET O
and O
REI O
groups O
yielded O
greater O
reductions O
in O
irrational B-outcome ['Life-Impact']
thinking I-outcome ['Life-Impact']
than O
did O
the O
ROC O
and O
WLC O
groups O
. O
['Life-Impact']

This O
study O
raises O
doubts O
about O
the O
clinical O
effectiveness O
of O
HDPM O
in O
autistic O
disorder O
. O
[]

Measurements O
were O
made O
12 O
hours O
after O
the O
last O
twice O
daily O
dose O
and O
24 O
hours O
after O
the O
last O
once O
daily O
dose O
. O
[]

Asthma O
and O
the O
home O
environment O
of O
low-income O
urban O
children O
: O
preliminary O
findings O
from O
the O
Seattle-King O
County O
healthy O
homes O
project O
. O
[]

Hospital O
programs O
will O
follow O
the O
traditional O
outpatient O
model O
consisting O
of O
twice O
weekly O
supervised O
exercise O
training O
and O
education O
for O
eight O
weeks O
. O
[]

Palo O
Alto, O
CA, O
USA. O
[]

Previous O
intervention O
studies O
have O
been O
limited O
by O
size O
or O
design O
and O
have O
shown O
mixed O
results O
. O
[]

Tissue O
samples O
from O
93 O
de O
novo O
diffuse O
large O
B-cell O
lymphoma O
patients O
seen O
between O
1995 O
and O
2009 O
randomly O
receiving O
either O
standard O
combination O
chemotherapy O
( O
CHOP O
, O
n=48 O
) O
or O
the O
identical O
program O
with O
rituximab O
( O
n=45 O
) O
were O
subtyped O
using O
an O
investigational O
immunohistochemical O
( O
IHC O
) O
based O
tissue O
microarray O
( O
TMA O
) O
and O
contrasted O
to O
the O
approximately O
corresponding O
categories O
as O
defined O
either O
by O
Hans O
and O
associates O
using O
a O
three O
marker O
panel O
into O
germinal O
or O
non-germinal O
centre O
subtypes O
or O
by O
Choi O
and O
colleagues O
with O
two O
additional O
antibodies O
into O
germinal O
centre O
( O
GCB O
) O
or O
activated O
B-cells O
( O
ABC O
) O
. O
[]

At O
the O
end O
of O
the O
first O
hour O
of O
infusion O
, O
compared O
with O
saline O
, O
L-arginine O
infusion O
increased O
basal B-outcome ['Physiological-Clinical']
forearm I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
nitrite B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nitrate I-outcome ['Physiological-Clinical']
( O
NOx B-outcome ['Physiological-Clinical']
) O
, O
and O
forearm B-outcome ['Physiological-Clinical']
cGMP I-outcome ['Physiological-Clinical']
release O
and O
decreased O
endothelin-1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
oral O
misoprostol O
400 O
mug O
with O
intramuscular O
syntometrine O
in O
the O
management O
of O
the O
third O
stage O
of O
labor O
. O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
such O
as O
acute B-outcome ['Physiological-Clinical']
appendicitis I-outcome ['Physiological-Clinical']
and O
acute B-outcome ['Physiological-Clinical']
viral I-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
were O
observed O
in O
the O
BT-11 O
group4 O
and O
the O
placebo O
group, O
respectively. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

5 O
. O
[]

SETTING O
Level O
1 O
trauma O
center O
. O
[]

OBJECTIVE O
This O
study O
aims O
to O
assess O
user O
characteristics O
related O
to O
participation B-outcome ['Life-Impact']
and O
attrition B-outcome ['Life-Impact']
when O
comparing O
Web-based O
and O
print-delivered O
tailored O
interventions O
containing O
similar O
content O
and O
thereby O
to O
provide O
recommendations O
in O
choosing O
the O
appropriate O
delivery O
mode O
for O
a O
particular O
target O
audience O
. O
['Life-Impact']

Prerandomization O
procedures O
excluded O
288 O
patients: O
42 O
had O
relief O
of O
their O
heartburn O
during O
the O
2-week O
omeprazole O
trial, O
70 O
did O
not O
complete O
trial O
procedures, O
54 O
were O
excluded O
for O
other O
reasons, O
23 O
had O
non-GERD O
esophageal O
disorders, O
and O
99 O
had O
functional O
heartburn O
(not O
due O
to O
GERD O
or O
other O
histopathologic, O
motility, O
or O
structural O
abnormality). O
[]

[ O
The O
effect O
of O
indobufen O
on O
aortocoronary O
bypass O
patency O
after O
1 O
week O
and O
after O
1 O
year O
] O
. O
[]

Post-surgery O
, O
the O
retrained O
persons O
exhibited O
less O
impairment B-outcome ['Life-Impact']
, O
on O
average O
, O
than O
non-retrained O
persons O
only O
in O
two-point O
perception O
( O
P O
< O
0.025 O
) O
, O
suggesting O
that O
retrained O
persons O
experienced O
or O
interpreted O
the O
tactile B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
differently O
than O
did O
non-retrained O
persons O
. O
['Life-Impact', 'Physiological-Clinical']

By O
the O
sixth O
quarter O
post-quit O
, O
sustained O
quitters O
were O
less O
costly O
than O
trial O
participants O
who O
continued O
smoking O
. O
[]

RESULTS: O
Analysis O
identified O
different O
views O
and O
considerations O
for O
engaging O
in O
a O
weight O
loss O
intervention O
at O
the O
workplace. O
[]

Enhancing O
caregiver O
health O
: O
findings O
from O
the O
resources O
for O
enhancing O
Alzheimer O
's O
caregiver O
health O
II O
intervention O
. O
[]

The O
mechanisms O
of O
FZ O
in O
the O
treatment O
of O
peptic O
ulcer O
disease O
are O
not O
fully O
understood O
, O
perhaps O
partly O
due O
to O
the O
monoamine B-outcome ['Physiological-Clinical']
oxidase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MAO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
inhibitory I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
and O
partly O
to O
the O
antibacterial B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Helicobacter I-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
( O
HP O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
success B-outcome ['Physiological-Clinical']
of O
masking O
study O
participants O
to O
treatment O
allocation O
using O
sham O
intravitreal O
injections O
. O
['Physiological-Clinical']

METHODS O
After O
hemorrhoidal O
banding O
, O
patients O
were O
randomly O
assigned O
to O
receive O
a O
local O
injection O
of O
bupivacaine O
with O
1:200,000 O
epinephrine O
, O
an O
injection O
of O
normal O
saline O
, O
or O
no O
injection O
, O
just O
superior O
to O
each O
band O
. O
[]

RESULTS O
Only O
a O
small O
number O
of O
patients O
met O
the O
predefined O
criteria O
for O
a O
proarrhythmic B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
( O
4 O
formoterol O
and O
2 O
placebo O
patients O
) O
. O
['Physiological-Clinical']

When O
adjusted O
for O
other O
important O
factors O
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
rates O
were O
similar O
( O
P O
=.5 O
) O
and O
although O
there O
was O
less O
resistant O
disease O
in O
younger O
children O
( O
P O
=.003 O
) O
, O
this O
was O
partially O
balanced O
by O
a O
slight O
increase O
in O
deaths B-outcome ['Mortality']
during O
induction O
therapy O
in O
younger O
patients O
( O
P O
=.06 O
) O
. O
['Physiological-Clinical', 'Mortality']

Concurrent O
doxorubicin O
plus O
docetaxel O
is O
not O
more O
effective O
than O
concurrent O
doxorubicin O
plus O
cyclophosphamide O
in O
operable O
breast O
cancer O
with O
0 O
to O
3 O
positive O
axillary O
nodes O
: O
North O
American O
Breast O
Cancer O
Intergroup O
Trial O
E O
2197 O
. O
[]

For O
each O
patient O
, O
the O
teeth O
were O
randomized O
to O
three O
groups O
. O
[]

Patients O
with O
platinum-sensitive O
tumours O
survived O
longer O
when O
they O
were O
treated O
with O
platinum-containing O
chemotherapy O
( O
P O
= O
0.005 O
) O
. O
[]

We O
compared O
TTI O
with O
the O
apical O
paddle O
in O
both O
a O
transverse O
and O
longitudinal O
orientation O
. O
[]

TRIAL O
REGISTRATION O
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html O
Identifier O
: O
UKF001272 O
. O
[]

Eleven O
patients O
with O
a O
diagnosis O
of O
either O
autism O
, O
Asperger O
's O
syndrome O
, O
or O
PDD O
not O
otherwise O
specified O
( O
PDD-NOS O
) O
and O
aged O
6-14 O
years O
were O
randomized O
into O
an O
8-week O
double-blind O
, O
placebo-controlled O
, O
parallel O
treatment O
study O
with O
olanzapine O
. O
[]

After O
the O
intervention, O
only O
the O
exercise O
group O
had O
a O
significantly O
lower O
BMI B-outcome ['Physiological-Clinical']
z-score O
than O
the O
baseline O
score O
by O
about O
0.1 O
(p O
= O
0.03), O
but O
no O
significant O
group O
by O
time O
interaction O
effects O
were O
observed. O
[['Physiological-Clinical']]

Overall, O
the O
103 O
enrolled O
participants O
were O
>/=85th O
percentile O
of O
age O
and O
sex-specific O
body O
mass O
index O
(BMI). O
[]

RESULTS O
For O
needle O
insertion O
, O
30 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
43 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Group O
B O
patients O
showed O
a O
significant O
improvement O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
: O
serum B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
nitrogen B-outcome ['Physiological-Clinical']
48.9 O
+/- O
10.3 O
to O
32.1 O
+/- O
14.4 O
mg/dl O
( O
p O
< O
0.05 O
) O
; O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
1.97 O
+/- O
0.24 O
to O
1.49 O
+/- O
0.39 O
mg/dl O
( O
p O
< O
0.05 O
) O
; O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
35.6 O
+/- O
11.6 O
to O
48.8 O
+/- O
12.3 O
ml/min O
( O
p O
< O
0.05 O
) O
; O
and O
indexed B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
0.56 O
+/- O
0.16 O
to O
2.02 O
+/- O
0.72 O
ml/kg/h O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Biochemical O
progression O
prompted O
a O
change O
of O
chemotherapy O
. O
[]

We O
studied O
if O
H. O
pylori O
eradication O
would O
alter O
the O
course O
of O
premalignant O
histologic O
changes O
in O
the O
stomach O
. O
[]

Screening O
, O
brief O
intervention O
, O
and O
referral O
to O
treatment O
( O
SBIRT O
) O
in O
a O
Polish O
emergency O
department O
: O
three-month O
outcomes O
of O
a O
randomized O
, O
controlled O
clinical O
trial O
. O
[]

Among O
the O
many O
factors O
that O
may O
contribute O
to O
problematic O
clinical O
trial O
results O
, O
error O
in O
measuring O
the O
phenomena O
being O
studied O
is O
of O
particular O
concern O
. O
[]

The O
main O
interest O
of O
this O
study O
, O
however O
, O
lies O
in O
its O
methodology O
( O
video O
analysis O
) O
. O
[]

BACKGROUND O
Yes-associated B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
YAP1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
frequently O
reported O
to O
function O
as O
an O
oncogene O
in O
many O
types O
of O
cancer O
, O
but O
in O
breast O
cancer O
results O
remain O
controversial O
. O
['Physiological-Clinical']

After O
both O
sham O
and O
exercise O
, O
subjects O
received O
, O
in O
sequence O
, O
systemic O
alpha-adrenergic O
blockade O
( O
phentolamine O
) O
and O
L-NMMA O
. O
[]

OBJECTIVE O
To O
determine O
whether O
adding O
vancomycin O
to O
central O
venous O
catheter O
( O
CVC O
) O
flush O
solution O
would O
significantly O
reduce O
the O
incidence O
of O
bacteremia O
attributable O
to O
luminal O
colonization O
with O
vancomycin-susceptible O
organisms O
. O
[]

We O
compared O
two O
procedures O
for O
the O
emergency O
treatment O
of O
bleeding B-outcome ['Physiological-Clinical']
esophageal O
varices O
in O
patients O
who O
did O
not O
respond O
to O
blood O
transfusion O
and O
vasoactive O
drugs O
. O
['Physiological-Clinical']

BACKGROUND O
Clomethiazole O
( O
CLO O
) O
has O
been O
shown O
to O
be O
effective O
in O
treating O
alcohol B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
( O
AWS B-outcome ['Physiological-Clinical']
) O
. O
['Life-Impact', 'Physiological-Clinical']

There O
were O
no O
significant O
improvements O
in O
the O
FTM O
total O
score O
or O
its O
subsections O
. O
[]

Pentoxifylline O
therapy O
in O
HIV O
seropositive O
subjects O
with O
elevated O
TNF O
. O
[]

Wound O
infiltration O
of O
iliac O
crest O
harvest O
site O
with O
local O
anaesthetic O
is O
an O
easy O
technique O
for O
postoperative O
analgesia O
. O
[]

Parent-implemented O
enhanced O
milieu O
teaching O
with O
preschool O
children O
who O
have O
intellectual O
disabilities O
. O
[]

Multivariate O
regression O
was O
used O
to O
calculate O
rates O
of O
decline O
in O
estimated O
GFR O
for O
individuals O
administered O
gemfibrozil O
or O
placebo O
, O
controlling O
for O
prospectively O
determined O
potential O
confounders O
. O
[]

Moreover O
, O
histological O
grading O
would O
be O
clinically O
useful O
in O
defining O
the O
tumor O
characteristics O
and O
behavior O
of O
carcinoma O
in O
situ O
of O
the O
bladder O
. O
[]

Non-Hodgkin O
's O
malignant O
lymphomas O
: O
treatment O
of O
localized O
relapses O
with O
chemo O
+ O
radio O
+ O
BCG-therapy O
. O
[]

Little O
covariation O
was O
detected O
within O
or O
between O
other O
diet B-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
sedentary B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
domains O
suggesting O
that O
interventions O
to O
improve O
these O
behaviors O
in O
adolescents O
need O
to O
include O
specific O
program O
components O
for O
each O
target O
behavior O
of O
interest O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
exercise O
physiology O
, O
it O
has O
been O
traditionally O
assumed O
that O
high-intensity O
aerobic O
exercise O
stops O
at O
the O
point O
commonly O
called O
exhaustion O
because O
fatigued O
subjects O
are O
no O
longer O
able O
to O
generate O
the O
power O
output O
required O
by O
the O
task O
despite O
their O
maximal O
voluntary O
effort O
. O
[]

In O
the O
intervention O
group O
, O
plasma O
levels O
of O
vitamin O
E O
, O
selenium O
and O
coenzyme O
Q10 O
increased O
significantly O
over O
the O
21 O
weeks O
study O
period O
. O
[]

Length O
of O
procedure O
times O
and O
adolescent O
reactions O
were O
also O
recorded O
to O
inform O
clinical O
utility O
. O
[]

However O
, O
expenses O
and O
side O
effects O
of O
these O
agents O
have O
also O
been O
a O
concern O
for O
clinical O
doctors O
. O
[]

Efficacy O
and O
safety O
of O
sildenafil O
in O
Asian O
males O
with O
erectile O
dysfunction O
and O
cardiovascular O
risk O
. O
[]

Title: O
Effectiveness O
and O
cost-effectiveness O
of O
neuromuscular O
exercise O
and O
back O
care O
counseling O
in O
female O
healthcare O
workers O
with O
recurrent O
non-specific O
low O
back O
pain: O
a O
blinded O
four-arm O
randomized O
controlled O
trial. O
[]

There O
was O
significantly O
less O
severe O
and O
less O
frequent O
toxicity B-outcome ['Adverse-effects']
with O
mitoxantrone O
administration O
. O
['Adverse-effects']

The O
sessions O
consisted O
of O
four O
phases O
, O
with O
each O
phase O
lasting O
3 O
minutes O
. O
[]

OBJECTIVE O
To O
assess O
the O
effect O
of O
a O
high-calcium O
, O
fortified O
, O
low-fat O
milk O
drink O
with O
added O
vitamin O
D O
versus O
a O
low-calcium O
placebo O
drink O
on O
anthropometric O
measurements O
of O
postmenopausal O
women O
. O
[]

A O
second O
group O
received O
a O
form O
letter O
listing O
recommendations O
for O
all O
preventive O
procedures O
for O
all O
age O
and O
sex O
groups O
. O
[]

Determinants O
of O
breastfeeding O
practices O
have O
been O
largely O
documented O
in O
high-income O
countries O
. O
[]

at O
the O
dose O
of O
200 O
mg/week O
for O
1 O
year O
. O
[]

We O
observed O
a O
substantial O
downward O
trend O
in O
antibiotic B-outcome ['Resource-use']
prescribing I-outcome ['Resource-use']
, O
even O
in O
the O
absence O
of O
intervention O
. O
['Resource-use']

OBJECTIVE O
To O
measure O
the O
effects O
of O
case O
management O
on O
an O
older O
population O
's O
costs O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
. O
['Resource-use']

CONCLUSIONS O
The O
two O
premedications O
appear O
equally O
effective O
in O
the O
performance B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ERCP I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
prospective O
randomized O
trial O
. O
[]

FINDINGS O
The O
5.3 O
year O
median O
follow-up O
( O
range O
8 O
months O
to O
8 O
years O
11 O
months O
) O
showed O
44 O
% O
( O
95 O
% O
CI O
7-66 O
) O
risk O
reduction O
for O
recurrence O
in O
the O
recurrence-free O
period O
in O
all O
patients O
receiving O
ASI O
( O
p=0.023 O
) O
. O
[]

At O
baseline O
, O
higher O
scores O
on O
alexithymia O
were O
associated O
poorer O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
fewer O
percent O
days B-outcome ['Life-Impact']
abstinent I-outcome ['Life-Impact']
, O
greater O
alcohol B-outcome ['Life-Impact']
dependence O
severity O
, O
and O
several O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Effect O
of O
betamethasone O
valerate O
on O
the O
normal O
human B-outcome ['Physiological-Clinical']
facial I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
flora I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
rate O
of O
definite B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
engraftment I-outcome ['Physiological-Clinical']
was O
1.7-fold O
higher O
in O
marrow O
recipients O
( O
P O
=.001 O
) O
. O
['Physiological-Clinical']

These O
discrepancies O
could O
be O
largely O
resolved O
by O
the O
instructional O
variable O
, O
in O
conjunction O
with O
different O
tone B-outcome ['Physiological-Clinical']
intensities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

They O
consumed O
less O
vitamin B-outcome ['Life-Impact']
D I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
supplements I-outcome ['Life-Impact']
( O
2.15 O
( O
sd O
5.24 O
) O
?g/d O
( O
86 O
( O
sd O
210 O
) O
IU/d O
) O
v. O
4.55 O
( O
sd O
8.48 O
) O
?g/d O
( O
188 O
( O
sd O
344 O
) O
IU/d O
) O
, O
P O
= O
0.003 O
) O
. O
['Life-Impact']

Two O
out O
of O
three O
of O
those O
offered O
a O
health O
talk O
with O
the O
general O
practitioner O
appeared O
willing O
to O
make O
relevant O
lifestyle O
changes O
. O
[]

RESULTS O
The O
mean O
hospital B-outcome ['Resource-use']
stays I-outcome ['Resource-use']
in O
groups O
1 O
and O
2 O
were O
3.1 O
and O
1.6 O
days O
, O
respectively O
( O
P O
= O
0.003 O
) O
. O
['Resource-use']

RESULTS O
Eighty-four O
patients O
were O
randomized O
. O
[]

This O
response O
is O
therefore O
unlikely O
to O
be O
due O
to O
removal O
of O
myocardial B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
angiotensin I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during O
the O
first O
24 O
h O
post-treatment O
was O
similar O
in O
the O
desmopressin O
and O
placebo O
groups O
( O
582 O
vs O
465 O
ml O
, O
respectively O
; O
p O
= O
0.15 O
) O
. O
['Physiological-Clinical']

In O
addition O
, O
cognitive O
behavior O
interventions O
have O
been O
shown O
to O
lower O
the O
risk O
of O
recurrence O
of O
LBP B-outcome ['Physiological-Clinical']
and O
long-term B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
This O
study O
had O
a O
statewide O
group-randomized O
prospective O
trial O
design O
. O
[]

PROCEDURES O
Each O
dog O
was O
randomly O
allocated O
to O
receive O
2 O
of O
3 O
treatments O
( O
1-week O
interval O
) O
. O
[]

All O
methods O
of O
the O
treatment O
of O
severe O
sepsis O
are O
discussed O
with O
reference O
to O
treatment O
indications B-outcome ['Physiological-Clinical']
, O
efficacy O
, O
and O
outcome O
parameters O
. O
['Physiological-Clinical']

AIMS O
Diuretic O
therapy O
is O
conventionally O
used O
to O
treat O
oedema O
in O
patients O
with O
hypoxic O
cor O
pulmonale O
. O
[]

In O
the O
randomly O
selected O
cases O
presence O
of O
leptin O
protein O
and O
of O
leptin O
receptor O
proteins O
was O
examined O
also O
by O
Western O
blotting O
. O
[]

Both O
drugs O
were O
equally O
effective O
as O
measured O
by O
the O
Hamilton O
Rating O
Scale O
for O
Depression O
, O
the O
overall O
assessment O
of O
efficacy O
and O
the O
Zung O
Self-rating O
Scale O
, O
and O
clearly O
superior O
to O
placebo O
; O
there O
were O
no O
significant O
differences O
between O
the O
2 O
active O
drugs O
. O
[]

No O
concomitant O
anti-inflammatory O
or O
antirheumatic O
drug O
therapy O
was O
permitted O
during O
the O
study O
. O
[]

Efficacy O
did O
not O
occur O
until O
after O
several O
months O
of O
leuprolide O
treatment O
, O
but O
there O
was O
no O
evidence O
that O
PMS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
worsened O
with O
the O
onset O
of O
treatment O
. O
['Physiological-Clinical']

Single-agent O
irinotecan O
or O
FOLFIRI O
as O
second-line O
chemotherapy O
for O
advanced B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
; O
results O
of O
a O
randomised O
phase O
II O
study O
( O
DaVINCI O
) O
and O
meta-analysis O
[ O
corrected O
] O
. O
['Physiological-Clinical']

Results O
may O
be O
used O
to O
tailor O
structural, O
organizational, O
provider, O
patient, O
and O
innovation O
factors O
prior O
to O
future O
implementations O
of O
the O
mhGAP-based O
training O
in O
Tunisia. O
[]

A O
combination O
of O
radioiodine O
WBS O
and O
serum O
Tg O
after O
recombinant O
human O
TSH O
stimulation O
detected O
thyroid B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
or O
cancer B-outcome ['Physiological-Clinical']
in O
93 O
% O
of O
patients O
with O
disease O
or O
tissue O
limited O
to O
the O
thyroid O
bed O
and O
100 O
% O
of O
patients O
with O
metastatic O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
oral O
treatment O
group O
showed O
significant O
increases O
in O
plasma B-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
glutathione B-outcome ['Physiological-Clinical']
, O
but O
not O
whole-blood O
glutathione B-outcome ['Physiological-Clinical']
levels O
following O
supplementation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
study O
of O
retinopathy O
during O
one O
year O
of O
tight O
blood O
glucose O
control O
45 O
type O
I O
( O
insulin O
dependent O
) O
diabetics O
without O
proliferative O
retinopathy O
were O
randomised O
to O
receive O
either O
continuous O
subcutaneous O
insulin O
infusion O
, O
multiple O
insulin O
injections O
, O
or O
conventional O
insulin O
treatment O
( O
controls O
) O
. O
[]

The O
current O
study O
asked O
: O
does O
regular O
antacid O
therapy O
have O
a O
favorable O
influence O
on O
the O
natural O
history O
of O
symptomatic B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
esophagitis I-outcome ['Physiological-Clinical']
, O
ie O
, O
does O
therapy O
heal O
or O
otherwise O
change O
esophagitis O
so O
that O
painful O
episodes O
are O
either O
less O
frequent O
, O
less O
severe O
, O
or O
both O
? O
['Physiological-Clinical']

Endoscopic B-outcome ['Resource-use']
, O
clinical B-outcome ['Physiological-Clinical']
, O
and O
['Resource-use', 'Physiological-Clinical']

4 O
out O
of O
10 O
on O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
were O
randomly O
assigned O
to O
one O
of O
the O
following O
four O
groups O
: O
MP+NTI O
, O
PL+NTI O
, O
MP O
+ O
control O
telephone O
intervention O
( O
CTI O
) O
, O
and O
PL+CTI O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
One O
hundred O
forty O
opioid-addicted O
IDUs O
were O
referred O
to O
the O
medical O
clinic O
for O
AOD O
. O
[]

This O
study O
evaluated O
the O
effectiveness O
of O
two-dose O
versus O
three-dose O
of O
SP O
for O
IPTp-SP O
in O
the O
prevention O
of O
low B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
(LBW) I-outcome ['Physiological-Clinical']
and O
malaria B-outcome ['Physiological-Clinical']
parasitaemia I-outcome ['Physiological-Clinical']
. O
Methods: O
: O
An O
open, O
randomized, O
controlled, O
longitudinal O
trial O
was O
conducted O
in O
a O
secondary O
level O
hospital O
in O
Nsukka O
region O
of O
Enugu O
State, O
Nigeria. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Of O
the O
409 O
patients O
enrolled O
, O
323 O
were O
evaluable O
for O
their O
clinical O
and O
bacteriological O
responses O
; O
of O
these O
323 O
children O
, O
172 O
received O
cefprozil O
and O
151 O
received O
penicillin O
V. O
The O
clinical B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
patients O
treated O
with O
cefprozil O
were O
significantly O
better O
than O
those O
in O
patients O
who O
received O
penicillin O
( O
95.3 O
versus O
88.1 O
% O
; O
P O
= O
0.023 O
) O
. O
['Physiological-Clinical']

Our O
findings O
suggest O
one O
potential O
source O
of O
these O
results O
was O
a O
divergence O
between O
student O
and O
educator O
conceptions O
for O
structuring O
the O
practice O
of O
cardiac O
auscultation O
skills O
. O
[]

It O
has O
been O
suggested O
that O
for O
children O
with O
autism O
, O
imitation O
may O
be O
a O
prerequisite O
skill O
that O
can O
assist O
in O
the O
development O
of O
various O
skills O
. O
[]

Double-blind O
comparison O
of O
the O
efficacy O
and O
safety O
of O
trandolapril O
2 O
mg O
and O
hydrochlorothiazide O
25 O
mg O
in O
patients O
with O
mild-to-moderate O
essential O
hypertension O
. O
[]

One O
hundred O
and O
thirty-two O
patients O
were O
included O
in O
the O
cost-effectiveness O
study O
. O
[]

From O
the O
above O
results O
, O
PEB O
seems O
to O
be O
a O
better O
induction O
chemotherapy O
than O
the O
conventional O
one O
for O
advanced O
testicular O
tumors O
. O
[]

An O
unpaired O
two-tailed O
t O
test O
was O
carried O
out O
for O
both O
studies O
to O
compare O
the O
average O
weight O
loss O
of O
root B-outcome ['Physiological-Clinical']
substance I-outcome ['Physiological-Clinical']
with O
the O
modes O
of O
instrumentation O
. O
['Physiological-Clinical']

Plasma O
samples O
were O
obtained O
over O
a O
72-h O
interval O
and O
analyzed O
for O
diflunisal B-outcome ['Physiological-Clinical']
and O
naproxen B-outcome ['Physiological-Clinical']
by O
reversed O
phase O
liquid O
chromatography O
with O
UV O
detection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
analysis O
of O
the O
population O
for O
survival B-outcome ['Mortality']
was O
by O
intention O
to O
treat O
. O
['Mortality']

Due O
to O
easy O
handling O
of O
the O
nasal-spray O
a O
good O
compliance B-outcome ['Life-Impact']
was O
confirmed O
. O
['Life-Impact']

A O
predefined O
subset O
of O
women O
( O
n=1,455 O
) O
had O
extended O
follow-up O
with O
colposcopy/biopsy O
at O
12 O
months O
. O
[]

